new orleans - society of toxicology · new orleans, louisiana from march 6–10, 2005 for our 44th...

44th Annual Meeting & ToxExpoTM

Program

M a r c h 6 – 1 0 , 2 0 0 5

New Orleans

The Society of Toxicology invites you to join us inNew Orleans, Louisiana from March 6–10, 2005 for our 44th Annual Meeting. An outstanding slate of symposia, workshops, roundtables, and continuing education courses that cover a wide range of topics have been selected by the Program and Continuing Education Committees.

New Orleans offers the opportunity to combine cutting-edge science and comradery in a city known for its rich culture, hospitality, and fabulous food. We can't wait to see you there.

Linda S. Birnbaum SOT President


March 6–10, 2005

All text and graphics are © by the Society of Toxicology unless noted. All New Orleans photos are courtesy of the New Orleans Metropolitan Convention & Visitors Bureau, Inc.

New Orleans

Society of Toxicology

Louisiana

SOT President

Program Overview ....................................Inside Front Cover

Events Calendar ........................................................................2

New Orleans Restaurants ........................................................7

Ernest N. Morial Convention Center Map ............................8

Hilton Riverside Hotel Map ..................................................10

Sheraton Hotel Map ............................................................... 11

New Orleans Hotel Accommodations .................................12

ToxExpo™ Exhibit Hall Floorplan .......................................13

2005 Exhibitors ........................................................................14

ToxExpo™ and Informational Sessions ...............................16

General Information ...............................................................21

Award Winners2005 Award Winners ...............................................................27

2004 SOT Fellowship Winners Making Presentations ..........................................................................31

Social FunctionsSocial Events ............................................................................32

SponsorshipDiamond and Platinum Sponsors ...........Inside Front Cover

Gold, Silver, and Contributor Sponsors .....................................................Inside Back Cover

Sessions IndexScientific Sessions Index ........................................................33

Continuing EducationContinuing Education Courses .............................................39

ProgramProgram Description ..............................................................47

SOT ReferencesAuthor Index .........................................................................225SOT Affiliates for 2005 .........................................................2452004–2005 Council .................................................................246Officers and Councilors .......................................................248Past Presidents .......................................................................248Headquarters Staff ...............................................................249Elected Committees ..............................................................250Appointed Committees ........................................................250Officers—Specialty Sections ................................................253Officers—Regional Chapters ...............................................254SOT Award Descriptions .....................................................255Toxicology Specialists ...........................................................264

Contents44th Annual Meeting & ToxExpo™

March 6–10, 2005

New Orleans, Louisiana

EVEN

TS CA

LEND

AR

SOT's 44th Annual Meeting2

Saturday March 5, 2005Events are listed alphabetically by the event start time.8:00 AM to 1:30 PM Council Meeting Hilton Riverside Jasperwood

2:00 PM to 5:00 PM Committee Chair Orientation Ernest N. Morial Convention Center 211

4:00 PM to 7:00 PM Message Center/Lodging Information Booth Ernest N. Morial Convention Center Hall A Lobby

4:00 PM to 7:00 PM Registration Ernest N. Morial Convention Center Hall A Lobby

4:00 PM to 7:00 PM Speaker Ready Room Ernest N. Morial Convention Center 202

5:00 PM to 5:45 PM Continuing Education Walk-Through Ernest N. Morial Convention Center 206

5:00 PM to 7:00 PM CRAD Seminar (First Come, First Served) Sheraton Hotel Napoleon D1

5:30 PM to 8:30 PM Education Fellowship Interviews Sheraton Hotel Edgewood B

5:30 PM to 6:00 PM Undergraduate Education Program Orientation for SOT Hosts, Peer Mentors and Advisors Sheraton Hotel Nottoway

6:15 PM to 9:00 PM Undergraduate Education Program for Minority Students—Lecture & Reception Sheraton Hotel Oak Alley

Sunday March 6, 2005Events are listed alphabetically by the event start time.7:00 AM to 8:30 PM Coat Check Ernest N. Morial Convention Center Hall A Lobby

7:00 AM to 7:45 AM Continuing Education Sunrise Mini-Course (Ticket Required) Ernest N. Morial Convention Center R01

7:00 AM to 5:00 PM Message Center/Lodging Information Booth Ernest N. Morial Convention Center Hall A Lobby

7:00 AM to 8:00 PM Registration Ernest N. Morial Convention Center Hall A Lobby

7:00 AM to 5:00 PM SOT Office Ernest N. Morial Convention Center 205

7:00 AM to 5:30 PM Speaker Ready Room Ernest N. Morial Convention Center 202

7:30 AM to 2:30 PM Concession Stands Ernest N. Morial Convention Center Hall A Lobby

8:00 AM to 5:00 PM Childcare Services (Contingent on Enrollment) Hilton Riverside Windsor

8:00 AM to 10:00 AM CRAD Committee Meeting I Ernest N. Morial Convention Center 216

8:00 AM to 4:30 PM Guest Hospitality Center Hilton Riverside Compass

8:00 AM to 5:00 PM ToxExpo™ Set Up Ernest N. Morial Convention Center Exhibit Hall A

8:00 AM to 5:00 PM Undergraduate Education Program Session Ernest N. Morial Convention Center 213

8:15 AM to 12:00 NOON Continuing Education Courses (Ticket Required) Ernest N. Morial Convention Center (See Signage for Room Locations)

10:00 AM to 3:30 PM CRAD Office (Registration Only) Ernest N. Morial Convention Center 217

11:00 AM to 12:00 NOON IUTOX Enhancement of the Appreciation and Image of Toxicology Task Force Meeting Hilton Riverside Newberry

11:45 AM to 1:15 PM CE Luncheon for Speakers, Committee and Student Volunteers (By Invitation Only) Ernest N. Morial Convention Center 226

12:00 NOON to 1:00 PM IUTOX Education and Career Development Commission Meeting Hilton Riverside Ascot

12:00 NOON to 3:00 PM Toxicological Sciences Associate Editors Meeting Hilton Riverside Jasperwood

1:00 PM to 5:00 PM IUTOX Executive Committee Meeting I Hilton Riverside Newberry

1:15 PM to 5:00 PM Continuing Education Courses (Ticket Required) Ernest N. Morial Convention Center (See Signage for Room Locations)

4:30 PM to 5:15 PM Awards Recipients Photographed Ernest N. Morial Convention Center 220

5:15 PM to 6:30 PM Award Presentation (All Attendees Welcome) Ernest N. Morial Convention Center 220

6:30 PM to 7:30 PM Welcoming Reception (All Attendees Welcome) Ernest N. Morial Convention Center La Louisiane Ballroom

6:45 PM to 7:15 PM Student Advisory Committee Meeting I Hilton Riverside Durham

7:00 PM to 8:00 PM 25–Year Member (or More) Reception (By Invitation Only) Ernest N. Morial Convention Center 215

7:30 PM to 9:30 PM Association of Scientists of Indian Origin in America Hilton Riverside Rosedown

7:30 PM to 9:00 PM International Neurotoxicology Association Business Meeting Hilton Riverside Melrose

7:30 PM to 8:30 PM Student/Post-Doctoral Fellow Mixer (All Students and Post-Docs are Invited to Attend) (Ticket Required) Hilton Riverside Grand Ballroom A

8:00 PM to 10:30 PM Arizona Night Hilton Riverside Oak Alley

8:00 PM to 10:00 PM IUTOX Executive Committee Dinner Brennan’s Restaurant

8:00 PM to 10:00 PM LRRI Reception for Current & Former Employees Embassy Suites Atrium

Annual Meeting Events Calendar

EV

ENT

S C

ALE

ND

AR

up-to-date information at www.toxicology.org 3

Monday March 7, 2005Events are listed alphabetically by the event start time.6:30 AM to 8:00 AM Regulatory Affairs and Legislative Assistance Committee Meeting Ernest N. Morial Convention Center 2166:45 AM to 8:00 AM Metals Specialty Section Officers’ Meeting Ernest N. Morial Convention Center 212 7:00 AM to 8:00 AM American Board of Veterinary Toxicology: Executive Board Meeting Hilton Riverside Durham 7:00 AM to 9:15 AM Carcinogenesis Specialty Section Officers’ Meeting Ernest N. Morial Convention Center 2237:00 AM to 8:30 PM Coat Check Ernest N. Morial Convention Center Hall A Lobby 7:00 AM to 8:30 AM Continuing Education Committee Meeting Ernest N. Morial Convention Center 2257:00 AM to 8:00 AM Ethical, Legal, and Social Issues Specialty Section Officers’ Meeting Ernest N. Morial Convention Center 215 7:00 AM to 8:30 AM Mechanisms Specialty Section Officers’ Meeting Ernest N. Morial Convention Center 2277:00 AM to 5:00 PM Message Center/Lodging Information Booth Ernest N. Morial Convention Center Hall A Lobby7:00 AM to 5:00 PM MPI—CardIon Breakfast Breifing Hilton Riverside Grand Salon 137:00 AM to 9:00 AM Neurotoxicology Specialty Section Officers’ Meeting Ernest N. Morial Convention Center 2287:00 AM to 8:30 AM Past Presidents Breakfast Ernest N. Morial Convention Center 211 7:00 AM to 5:00 PM Registration Ernest N. Morial Convention Center Hall A Lobby7:00 AM to 8:30 AM Regulatory & Safety Specialty Section Officers’ Meeting Ernest N. Morial Convention Center 2297:00 AM to 5:00 PM SOT Office Ernest N. Morial Convention Center 2057:00 AM to 5:00 PM Speaker Ready Room Ernest N. Morial Convention Center 202

7:30 AM to 2:30 PM Concession Stands Ernest N. Morial Convention Center Hall A Lobby7:30 AM to 7:00 PM CRAD Services Ernest N. Morial Convention Center 2177:30 AM to 8:30 AM Membership Committee Meeting Ernest N. Morial Convention Center 2137:30 AM to 8:30 AM Program Committee Walk-Through Ernest N. Morial Convention Center 2067:30 AM to 3:00 PM Undergraduate Education Program for Minority Students Ernest N. Morial Convention Center 2148:00 AM to 5:00 PM Childcare Services (Contingent on Enrollment) Hilton Riverside Windsor 8:00 AM to 4:30 PM Guest Hospitality Center Hilton Riverside Compass8:30 AM to 9:15 AM Plenary Lecture: Science, Policy, and Regulation at the White House Office of Information and Regulatory Affairs Dr. John D. Graham Ernest N. Morial Convention Center La Louisiane Ballroom9:30 AM to 10:30 AM Complimentary Coffee in the Exhibit Hall Ernest N. Morial Convention Center Exhibit Hall A9:30 AM to 2:30 PM Concession Stands Ernest N. Morial Convention Center Exhibit Hall A9:30 AM to 11:00 AM IUTOX Certification and Registration Task Force Meeting Hilton Riverside Ascot 9:30 AM to 11:30 AM Poster Session for Visiting Students Ernest N. Morial Convention Center Exhibit Hall A9:30 AM to 12:30 PM Poster Sessions Ernest N. Morial Convention Center Exhibit Hall A9:30 AM to 12:00 NOON Scientific Sessions (See Program Description for Room Locations) Ernest N. Morial Convention Center 9:30 AM to 4:30 PM ToxExpo™ Exhibits Open Ernest N. Morial Convention Center Exhibit Hall A11:45 AM to 1:30 PM Immunotoxicology Specialty Section Officers’ Meeting Ernest N. Morial Convention Center 211

12:15 PM to 1:15 PM MRC Lecture: Novel Uncompetitive Antagonists Protect Neurons from Excitotoxic, Oxidative, and Nitrosative Stress Dr. Stuart A. Lipton Ernest N. Morial Convention Center La Louisiane Ballroom B12:15 PM to 1:15 PM Roundtable Session: Electrocardiography Safety Evaluation Studies—New Techniques and Approaches Ernest N. Morial Convention Center R0112:30 PM to 5:30 PM IUTOX Executive Committee Meeting II Hilton Riverside Newberry1:00 PM to 3:00 PM Undergraduate Education Program Focus Groups Ernest N. Morial Convention Center 2161:30 PM to 2:30 PM VIP ToxExpo™ Exhibit Hall Walk-Through Ernest N. Morial Convention Center Exhibit Hall A1:30 PM to 4:30 PM Poster Sessions Ernest N. Morial Convention Center Exhibit Hall A1:30 PM to 4:30 PM Scientific Sessions Ernest N. Morial Convention Center (See Program Description for Room Locations)2:30 PM to 3:30 PM Complimentary Refreshments in Exhibit Hall Ernest N. Morial Convention Center Exhibit Hall A4:30 PM to 6:00 PM American Board of Toxicology Mixer/Open Meeting Hilton Riverside Melrose4:30 PM to 6:00 PM CRAD Seminar: Consulting as a Career Choice Ernest N. Morial Convention Center 2074:30 PM to 6:00 PM Scientific Sunset Sessions Ernest N. Morial Convention Center (See Program Description for Room Locations)4:30 PM to 6:00 PM Specialty Section Presidents’ and Officers’ Meeting Ernest N. Morial Convention Center 2235:00 PM to 6:30 PM Harmonization: Legislation/Diet/ Rodent Model Hilton Riverside Belle Chase5:00 PM to 7:00 PM Joint Reception of the Mountain West and Southern California Regional Chapters Hilton Riverside Grand Salon 95:00 PM to 7:00 PM Standard for Exchange of Non-Clinical Data: An Industry FDA Partnership Hilton Riverside Elmwood

5:00 PM to 7:00 PM Taylor & Francis Reception Hilton Riverside Grand Salon 155:30 PM to 7:30 PM Roundtable of Toxicology Consultants Meeting Hilton Riverside Oak Alley6:00 PM to 8:00 PM Central States Regional Chapter Reception Hilton Riverside Grand Salon 196:00 PM to 7:30 PM Ethical, Legal, and Social Issues Specialty Section Reception Ernest N. Morial Convention Center 2156:00 PM to 7:30 PM Hispanic Organization Reception Ernest N. Morial Convention Center 2266:00 PM to 7:30 PM Immunotoxicology Specialty Section Reception Ernest N. Morial Convention Center 2256:00 PM to 7:30 PM Mechanisms Specialty Section Reception Ernest N. Morial Convention Center 2316:00 PM to 8:00 PM Northeast Regional Chapter Reception Hilton Riverside Grand Salon 126:00 PM to 7:30 PM Occupational and Public Health Specialty Section Reception Ernest N. Morial Convention Center 2276:00 PM to 7:30 PM Risk Assessment Specialty Section Reception Ernest N. Morial Convention Center 2296:00 PM to 8:00 PM St. John’s University 3rd Annual Toxicology Alumni Dinner Hilton Riverside Grand Salon 136:00 PM to 7:30 PM Toxicologic and Exploratory Pathology Specialty Section Reception Ernest N. Morial Convention Center 2286:00 PM to 6:30 PM Undergraduate Toxicology Teaching Forum Ernest N. Morial Convention Center R026:00 PM to 8:00 PM University of North Carolina Toxicology Students and Alumni Riverside Hilton Grand Salon 166:30 PM to 8:30 PM Inhalation Toxicology Specialty Section 2005 Editorial Board Meeting Hilton Riverside Grand Salon 67:30 PM to 10:00 PM Oxford University Press Dinner Brennan’s Restaurant9:00 PM to 11:00 PM MSU Center for Integrative Toxicology Alumni and Friends Reception Hilton Riverside Grand Salon 18

Annual Meeting Events Calendar (Continued)

EVEN

TS CA

LEND

AR


Tuesday March 8, 2005Events are listed alphabetically by the event start time.7:00 AM to 8:00 PM Coat Check Ernest N. Morial Convention Center Hall A Lobby

7:00 AM to 8:00 AM Cutaneous & Ocular Toxicology 2005 Editorial Board Meeting Hilton Riverside Oak Alley

7:00 AM to 8:00 AM Molecular Biology Section Officers Meeting Ernest N. Morial Convention Center 228

7:00 AM to 8:00 AM MPI Fast Systems Breakfast Briefing on Flow Cytometry and Immunology Hilton Riverside Grand Salon 3

7:00 AM to 8:30 AM Regional Chapter Presidents and Officers Meeting Ernest N. Morial Convention Center 225

7:00 AM to 8:30 AM Reproductive and Development Specialty Section Officers’ Meeting Ernest N. Morial Convention Center 231

7:00 AM to 7:45 AM Scientific Sunrise Session Ernest N. Morial Convention Center R01


7:00 AM to 8:30 AM Student Advisory Committee Meeting Ernest N. Morial Convention Center 216

7:00 AM to 8:15 AM ULM Toxicology Alumni Breakfast Hilton Riverside Elmwood

7:00 AM to 8:00 AM Women in Toxicology Section Officers’ Meeting Ernest N. Morial Convention Center 229

7:15 AM to 8:15 AM Town Hall Meeting: NIH-Mandated Public Access to Sponsored Research Publications: Impact on Toxicological Sciences Presiding: Lois Lehman-McKeeman, Editor of Toxicological Sciences and Richard Peterson, Chair of the Board of Publications Ernest N. Morial Convention Center R06


7:30 AM to 5:30 PM CRAD Services Ernest N. Morial Convention Center 217

7:30 AM to 9:00 AM Food Safety Specialty Section Officers’ Meeting Ernest N. Morial Convention Center 230

7:30 AM to 8:30 AM In Vitro Specialty Section Officers’ Meeting Ernest N. Morial Convention Center 226

8:00 AM to 9:30 AM Board of Publications Meeting Ernest N. Morial Convention Center 201


8:00 AM to 9:30 AM Dermal Specialty Section Officers’ Meeting Ernest N. Morial Convention Center 227

8:00 AM to 4:30 PM Guest Hospitality Center Hilton Riverside Compass

8:00 AM to 4:00 PM Message Center/Lodging Information Booth Ernest N. Morial Convention Center Hall A Foyer

8:00 AM to 4:30 PM Paracelsus Goes to School Teacher Workshop Ernest N. Morial Convention Center 213

8:00 AM to 4:00 PM Registration Ernest N. Morial Convention Center Hall A Foyer


8:30 AM to 3:45 PM Informational Sessions (Consult the ToxExpo™ Directory for Session Times and Descriptions) Ernest N. Morial Convention Center 215 & 223

8:30 AM to 9:30 AM IUTOX Communications Commission Meeting Hilton Riverside Ascot

8:30 AM to 11:30 AM Scientific Sessions Ernest N. Morial Convention Center (See Program Description for Room Locations)

8:30 AM to 4:30 PM ToxExpo™ Exhibits Open Ernest N. Morial Convention Center Exhibit Hall A

9:30 AM to 10:30 AM Complimentary Coffee in the Exhibit Hall Ernest N. Morial Convention Center Exhibit Hall A

9:30 AM to 12:30 PM Poster Sessions Ernest N. Morial Convention Center Exhibit Hall A

12:00 NOON to 1:15 PM Eleventh International Congress on Toxicology Scientific Program Committee Meeting Belle Chase Hilton Riverside

12:00 NOON to 1:15 PM In Vitro Toxicology Lecture & Luncheon for Students (Ticket Required) Ernest N. Morial Convention Center La Louisiane Ballroom A

12:00 NOON to 1:00 PM SOT/EUROTOX Debate Nanoparticles are a Major Threat to Human Health Ernest N. Morial Convention Center La Louisiane Ballroom B

1:00 PM to 2:00 PM IUTOX Developing Countries Committee Meeting Hilton Riverside Ascot

1:30 PM to 3:30 PM Forum on Grantsmanship and Sources for Research Support Ernest N. Morial Convention Center R02

1:30 PM to 4:30 PM Poster Sessions Ernest N. Morial Convention Center Exhibit Hall A

1:30 PM to 4:30 PM Scientific Sessions Ernest N. Morial Convention Center (See Program Description for Room Locations)

2:30 PM to 3:30 PM Complimentary Refreshments in Exhibit Hall Ernest N. Morial Convention Center Exhibit Hall A

4:30 PM to 5:30 PM An Informal Session for Students with the Director, NIEHS Ernest N. Morial Convention Center 214

4:30 PM to 6:00 PM Scientific Sunset Sessions Ernest N. Morial Convention Center (See Program Description for Room Locations)

4:30 PM to 6:00 PM SOT Annual Business Meeting (SOT Members Only) Ernest N. Morial Convention Center 207

4:45 PM to 6:00 PM ToxExpo 2006 Exhibit Space Selection Meeting Ernest N. Morial Convention Center 223

5:30 PM to 8:00 PM Immunotoxicology Specialty Section Student & Post-Doc Mixer Mullates Restaurant (across the street from the Convention Center)

5:30 PM to 6:30 PM Regional Chapter Contacts for K–12 Education Committee Meeting Ernest N. Morial Convention Center 216

6:00 PM to 9:00 PM American Association of Chinese in Toxicology Hilton Riverside Grand Salon 16

6:00 PM to 7:30 PM Biological Modeling Specialty Section Reception Ernest N. Morial Convention Center 226

6:00 PM to 7:30 PM Carcinogenesis Specialty Section Reception Ernest N. Morial Convention Center 228

6:00 PM to 7:30 PM In Vitro Specialty Section Reception Ernest N. Morial Convention Center 225

6:00 PM to 7:30 PM Inhalation Specialty Section Reception Ernest N. Morial Convention Center 215

6:00 PM to 7:30 PM Metals Specialty Section Reception Ernest N. Morial Convention Center 227

6:00 PM to 7:30 PM Neurotoxicology Specialty Section Reception Ernest N. Morial Convention Center 231

6:00 PM to 8:00 PM Northern California Regional Chapter Reception Hilton Riverside Grand Salon 18

6:00 PM to 8:00 PM Pacific Northwest Regional Chapter Meeting Hilton Riverside Grand Salon 6

6:00 PM to 7:30 PM Regulatory and Safety Evaluation Specialty Section Reception Ernest N. Morial Convention Center 229

6:30 PM to 8:00 PM Neurobehavioral Teratology Society Social Hilton Riverside Grand Salon 12

7:00 PM to 8:30 PM South Central Regional Chapter Meeting/Reception Hilton Riverside Grand Salon 13

7:30 PM to 10:00 PM University of Rochester Alumni Reception Hilton Riverside Grand Salon 15


EV

ENT

S C

ALE

ND

AR


Wednesday March 9, 2005Events are listed alphabetically by the event start time.6:30 AM to 8:00 AM Comparative and Veterinary Specialty Section Officers’ Meeting Ernest N. Morial Convention Center 227

7:00 AM to 8:00 PM Coat Check Ernest N. Morial Convention Center Hall A Lobby

7:00 AM to 8:30 AM Education Subcommittee for Minority Initiatives Meeting Ernest N. Morial Convention Center 216

7:00 AM to 8:30 AM Midwest Regional Chapter Members Breakfast Ernest N. Morial Convention Center 226

7:00 AM to 8:00 AM MPI Research Breakfast Briefing on Positron Emission Temography (PST) Hilton Riverside Grand Salon 3


7:00 AM to 9:00 AM Toxicologic and Exploratory Pathology Specialty Section Officers’ Meeting Ernest N. Morial Convention Center 229

7:00 AM to 8:30 AM WWW Advisory Committee Meeting Ernest N. Morial Convention Center 225

7:15 AM to 8:30 AM Animals in Research Committee Meeting Ernest N. Morial Convention Center 211


7:30 AM to 9:30 AM CRAD Committee Meeting Ernest N. Morial Convention Center 213

7:30 AM to 5:30 PM CRAD Services Ernest N. Morial Convention Center 217


8:00 AM to 4:30 PM Guest Hospitality Center Hilton Riverside Steering Room

8:00 AM to 4:00 PM Message Center/Lodging Information Booth Ernest N. Morial Convention Center Hall A Lobby

8:00 AM to 4:00 PM Registration Ernest N. Morial Convention Center Hall A Lobby


8:30 AM to 3:45 PM Informational Sessions (Consult the ToxExpo™ Directory for Session Times and Descriptions) Ernest N. Morial Convention Center 215 & 223

8:30 AM to 11:30 AM Scientific Sessions Ernest N. Morial Convention Center (See Program Descriptions for Room Locations)

8:30 AM to 4:30 PM ToxExpo™ Exhibits Open Ernest N. Morial Convention Center Exhibit Hall A

9:30 AM to 10:30 AM Complimentary Coffee in the Exhibit Hall Ernest N. Morial Convention Center Exhibit Hall A

9:30 AM to 12:30 PM Poster Sessions Ernest N. Morial Convention Center Exhibit Hall A

11:30 AM to 1:00 PM Education Subcommittee for K–12 Education Meeting Ernest N. Morial Convention Center 216

11:30 AM to 1:30 PM Finance Committee Meeting Ernest N. Morial Convention Center 225

11:45 AM to 1:15 PM Immunotoxicology 2005 Editorial Board Meeting Hilton Riverside Belle Chase

12:00 NOON to 1:00 PM Issues Session: Reorganization of the NIH Grant Review Process and its Potential Impact on Toxicology Research and Training Ernest N. Morial Convention Center 208

12:00 PM to 1:00 PM Roundtable Session: Conducting a Comprehensive Toxicological and Safety Evaluation of Nanomaterials: Current and Challenges and Data Needs Ernest N. Morial Convention Center R08

12:00 NOON to 1:00 PM Special Workshop: A Conversation with the Directors Ernest N. Morial Convention Center R01

1:30 PM to 2:00 PM Education Committee Meeting Ernest N. Morial Convention Center 216

1:30 PM to 3:00 PM Poster Sessions Ernest N. Morial Convention Center Exhibit Hall A

1:30 PM to 4:30 PM Scientific Sessions Ernest N. Morial Convention Center (See Program Description for Room Locations)

2:00 PM to 4:00 PM Exhibit Liaison Committee Meeting Ernest N. Morial Convention Center 228

2:30 PM to 3:30 PM Complimentary Refreshments in Exhibit Hall Ernest N. Morial Convention Center Exhibit Hall A

4:30 PM to 6:00 PM Scientific Sunset Sessions Ernest N. Morial Convention Center (See Program Description for Room Locations)

4:45 PM to 5:30 PM SOT Council Meeting with Students/Post-Doctoral Fellows Ernest N. Morial Convention Center 213

5:00 PM to 6:00 PM Drug Discovery Specialty Section Officers’ Meeting Ernest N. Morial Convention Center 231

5:00 PM to 6:30 PM Toxicology Mechanisms and Methods 2005 Editorial Board Meeting Hilton Riverside Oak Alley

5:00 PM to 6:30 PM University of Wisconsin Molecular and Environmental Toxicology Center Reception Hilton Riverside Rosedown

5:30 PM to 6:00 PM Council Meeting with Student Advisory Committee Ernest N. Morial Convention Center 213

6:00 PM to 7:30 PM Comparative and Veterinary Specialty Section Reception Ernest N. Morial Convention Center 228

6:00 PM to 7:30 PM Dermal Specialty Section Reception Ernest N. Morial Convention Center 227

6:00 PM to 7:30 PM Drug Discovery Specialty Section Reception Ernest N. Morial Convention Center 231

6:00 PM to 7:30 PM Food Safety Specialty Section Reception Ernest N. Morial Convention Center 226

6:00 PM to 7:30 PM Molecular Biology Specialty Section Reception Ernest N. Morial Convention Center 225

6:00 PM to 7:30 PM Reproductive and Developmental Specialty Section Reception Ernest N. Morial Convention Center 229

6:00 PM to 7:30 PM Women in Toxicology Specialty Section Reception and Panel Discussion Ernest N. Morial Convention Center 215

7:00 PM to 8:30 PM President’s Reception (By Invitation Only) Hilton Riverside Versailles Ballroom


EVEN

TS CA

LEND

AR


Thursday March 10, 2005Events are listed alphabetically by the event start time.7:00 AM to 1:00 PMCoat CheckErnest N. Morial Convention CenterHall A Lobby

7:00 AM to 11:30 AMSpeaker Ready RoomErnest N. Morial Convention Center202

7:00 AM to 9:00 AMToxicology Education Foundation Board MeetingHilton RiversideTrafalgar Room

7:30 AM to 11:30 AMConcession StandsErnest N. Morial Convention CenterHall A Lobby

7:30 AM to 9:30 AMCRAD Committee Meeting IIErnest N. Morial Convention Center225

7:30 AM to 12:00 NOONCRAD Services(Message Center Only)Ernest N. Morial Convention Center218

7:30 AM to 8:30 AMProgram Committee MeetingErnest N. Morial Convention Center216

8:00 AM to 12:00 NOONChildcare Services(Contingent on Enrollment)Hilton RiversideWindsor

8:00 AM to 11:30 AMGuest Hospitality CenterHilton RiversideSteering Room

8:00 AM to 11:30 AMMessage Center/Lodging Information BoothErnest N. Morial Convention CenterHall A Lobby

8:00 AM to 11:30 AMRegistrationErnest N. Morial Convention CenterHall A Lobby

8:00 AM to 11:30 AMSOT OfficeErnest N. Morial Convention Center205

8:30 AM to 11:30 AMPoster SessionsErnest N. Morial Convention CenterLa Louisiane Ballroom B

8:30 AM to 11:30 AMScientific SessionsErnest N. Morial Convention Center(See Program Description for Room Locations)

SATELLITE MEETING

12:30 PM to 5:30 PMNAS Public Workshop: Public Databases: Sharing of Toxicogenomic DataHilton RiversideBelle Chase(See Full Details on page 224)


SOT 45th Annual MeetingMarch 5–9, 2006

See You Next Year in . . .

Deadline for SOT 2006 Annual Meeting Session

Proposals is April 30, 2005.

Visit the SOT Web site for Session Proposal and

meeting information.

www.toxicology.org

REST

AU

RA

NT

INFO


New Orleans Restaurants44th Annual Meeting

and ToxExpo

Under $10

Deanie’s Annunciation Street (504) 561–9251

Riverwalk Food Court (504) 522–1555

Red Eye Grill 852 S. Peters Street (504) 593–9393

Taqueria Corona 857 Fulton Street (504) 524–9805

True Brew Café 200 Julia Street (504) 524–8441

Ernst Café 600 S. Peters Street (504) 524–8544

Sweet Olive Café 610 Tchoupitoulas Street (504) 299–8188

Embassy Suites 315 Julia Street (504) 525–1993

Mulate’s Cajun Restaurant 201 Julia Street (504) 522–1492

$10–$20

Rock-n-Sake 823 Fulton Street (504) 821–7253

Rio Mar 800 S. Peter Street (504) 525–3474

Lucy’s Restaurant 701 Tchoupitoulas Street (504) 523–8995

The Praline Connection 907 S. Peters Street (504) 523–3973

Le Cote Brassiere 700 Tchoupitoulas Street (504) 613–2350

Tchop-n-Joes 870 Tchoupitoulas Street (504) 581–2858

The Atrium—Holiday Inn Convention Center Boulevard (504) 524–1881

Above $20

Emeril’s 800 Tchoupitoulas Street (504) 528–9393

Café Adelaide—Loews Hotel 300 Poydras Street (504) 595–3305

Wine Loft 752 Tchoupitoulas Street (504) 561–0116

Tommy’s Cuisine 746 Tchoupitoulas Street (504) 581–1103

New Orleans City Restaurants Located within 4 Blocks of the Convention Center:

For a full listing of New Orleans restaurants see the Annual Meeting Web site at www.toxicology.org.

MA

PS


44th Annual Meeting and ToxExpo

Tour

Bus

Loa

ding

and

Dep

artu

re

Ernest N. Morial

Lower Level

Exhi

bit

Hal

l

Entr

ance

Mes

sag

e C

ente

rTo

urs

Regi

stra

tion

Firs

t A

id

Rest

aura

ntBusi

ness

Cen

ter

Rive

r

La L

ouis

iane

Ba

llroo

mC

once

ssio

ns

Con

cess

ions

N

S

E W

MA

PS



Convention Center Map

Upper Level

Rest

room

s

Rest

room

s

Elev

ator

Elev

ator

MA

PS



Hilton Riverside Hotel Map

Second Floor

Riverside Building

(Second Floor)

Fourth Floor

First Floor

Loading Dock

Jazz

French

Gard

en Ro

om

Main Entrance

Elevators to 2 & 3 Floors and to Parking Garage Level 5

Stand

ard

Pelican

Brid

ge

Port

Steering

Co

mp

ass

To Guest Rooms

Business Center

ATRIUM

Warw

ickD

urh

amN

orw

ichTrafalg

ar

NewberryAscot Windsor

Jean Lafitte's Cove

Oak Valley

Jasperwood

Elmwood Magnolia

Belle Chasse Rosedown

Melrose

Versailles Ballroom

Napoleon Ballroom

Jefferson Ballroom Fountain

Room

Elevators to 1 & 2 Floors and to Parking Garage Level 5

To Riverside Building

Eglinton Winton

Chequers

Marlb

oro

ug

hPrince o

f W

ales

Cam

brid

ge

Elevators to 1 &

3 Flo

ors an

d to Parkin

g

Garag

e Level 5

To Riverside Building

N

S

EW

RiverRiver

River

River

MA

PS



Third Floor

Sheraton Hotel Map

Fourth Floor

N

S

E W

Rive

rRi

ver

New Orleans Hotel Accommodations

HO

TEL

INFO



1. Doubletree Hotel 300 Canal Street New Orleans, LA 70130 Phone: (504) 581–1300 Fax: (504) 522–4100 4 Blocks from Convention Center

2. Embassy Suites 315 Julia Street New Orleans, LA 70130 Phone: (504) 525–1993 Fax: (504) 525–3437 1 Block from Convention Center

3. Hampton Inn & Suites 1201 Convention Center Blvd. New Orleans, LA 70130 Phone: (504) 566–9990 Fax: (504) 566–9997 1 Block from Convention Center

4. Hilton Garden Inn 1001 South Peters Street New Orleans, LA 70130 Phone: (504) 525–0044 Fax: (504) 525–0035 1 Block from Convention Center

5. Hilton Riverside 2 Poydras Street New Orleans, LA 70130 Phone: (504) 561–0500 Fax: (504) 568–1721 2 Blocks from Convention Center

6. Holiday Inn Select 881 Convention Center Blvd. New Orleans, LA 70130 Phone: (504) 524–1881 Fax: (504) 528–1005 1 Block from Convention Center

7. Loews New Orleans 300 Poydras Street New Orleans, LA 70130 Phone: (504) 595–3300 Fax: (504) 595–3310 8 Blocks from Convention Center

8. Sheraton New Orleans 500 Canal Street New Orleans, LA 70130 Phone: (504) 525–2500 Fax: (504) 595–5552 10 Blocks from Convention Center

9. W New Orleans 333 Poydras Street New Orleans, LA 70130 Phone: (504) 525–9444 Fax: (504) 581–7179 10 Blocks from Convention Center

å

ç è

ê

ë

î

ì

í

é

ToxE

xpo



ToxExpo™ in the Exhibit Hall

Secu

rity

Show

Off

ice

Entr

ance

Firs

t A

id

Com

put

er

Stat

ions

Rest

room

s

Con

vent

ion

Cen

ter

BlvdRe

stro

oms/

Con

cess

ions

Con

cess

ions

Post

ers

Post

ers

Com

put

er

Stat

ions

Regi

stra

tion

La Louisiane Ballroom

Tour

s

Itin

erar

y Pl

anne

r C

omp

uter

St

atio

ns

ToxExpo



2005 Exhibitors

Company Name ............................................................................Booth NumberAAALAC International .....................................................................................210ACGIH .................................................................................................................855ADInstruments .................................................................................................1030Affymetrix .........................................................................................................1223Agency for Toxic Substances and Disease Registry ....................................1150Agilent Technologies .........................................................................................360Agilent Technologies .........................................................................................361Alabama Research & Development .................................................................446Allentown Caging Equipment Co. Inc. ..........................................................524Alter Analytical Labs .........................................................................................237Althea Technologies .........................................................................................1327ALZET® Osmotic Pumps .................................................................................707American Association for Laboratory Animal Science (AALAS) ...............329American Chemistry Council (ACC) .............................................................. 111Amgen, Inc. ........................................................................................................358Analytical Development Corporation ............................................................940Ani Lytics, Inc. .................................................................................................1231Anilab, Inc. .........................................................................................................307Animal Identification and Marking System, Inc. (AIMS) ............................831Applied Biosystems .........................................................................................1137Applied Preclinical Services .............................................................................323AppTec Laboratory Services ...........................................................................1318Arcturus ...............................................................................................................250BAS Evansville ...................................................................................................830Battelle HHS ........................................................................................................443BBL Sciences ......................................................................................................1227BD Biosciences ..................................................................................................1153Bio Medic Data Systems Inc. ...........................................................................406Bioagri Pharma ...................................................................................................212BioDynamics/KWS ...........................................................................................856Biological Test Center ........................................................................................944Biologics Consulting Group, LLC ....................................................................949BioReliance, invitrogen bioservices™ .............................................................729Bio-Serv Inc. .......................................................................................................422BioStat Consultants Inc. .................................................................................1337Biotechnics, Inc. ..................................................................................................945Biotrin International ..........................................................................................244Brady Corporation .............................................................................................852Bristol-Myers Squibb Company (BMS) ...........................................................859Burdock Group .................................................................................................1406Buxco Research Systems .................................................................................1031Calvert Laboratories, Inc. .................................................................................941Cambrex ..............................................................................................................960Cantox Health Science International .............................................................1329Carl Zeiss Micro Imaging, Inc. .........................................................................132Cayman Chemical ..............................................................................................251CeeTox Inc. .........................................................................................................845Central Toxicology Laboratory—Syngenta (CTL) .......................................1319CEREP ................................................................................................................1340CH Technologies (USA) Inc. .............................................................................743ChanTest, Inc. .....................................................................................................851Charles River Laboratories Clinical Services ...............................................1007Charles River Laboratories Pathology Services .............................................807Charles River Laboratories Preclinical Services ............................................907Charles River Laboratories Research Models & Services .............................806ChemRisk ............................................................................................................338CIIT Centers for Health Research ..................................................................1028Ciphergen Biosystems, Inc. ............................................................................1322

Company Name ............................................................................Booth NumberCIT ......................................................................................................................1106CLEA International Inc. ....................................................................................318Colorado Histo-Prep ........................................................................................1122Comparative Biosciences ................................................................................1217CorDynamics ......................................................................................................309Covance ...............................................................................................................715Covance Research Products Inc. .....................................................................815CRI, Inc. ..............................................................................................................136Data Integrated Scientific Systems (D.I.S.S.) ..................................................827Data Sciences International ..............................................................................930DaVinci Biomedical Research Products, Inc. .................................................311Detroit R & D, Inc. ...........................................................................................1248DIMS Institute of Medical Science, Inc. .........................................................221Dow Corning Corporation ...............................................................................761Ellegaard Gottingen Minipigs ........................................................................1130Elm Hill Breeding Labs, Inc. ............................................................................306Elsevier Science ..................................................................................................915Embryotech Laboratories, Inc. ......................................................................1144Emka Technologies ..........................................................................................1241Environ International ......................................................................................1330Environmental Health Perspectives (EHP) ..................................................1051Enzo Life Sciences, Inc. ...................................................................................1253EPL, Inc. (Experimental Pathology Labs) .......................................................725Exponent, Inc. .................................................................................................. 1115Expression Analysis .........................................................................................1326Exygen Research ................................................................................................217Fraunhofer ITEM ..............................................................................................1214Gene Logic, Inc. ...............................................................................................1206Genedata ............................................................................................................1324Genospectra, Inc. .............................................................................................1128Gentronix Limited ..............................................................................................460GlobalTox ..........................................................................................................1220Gma Industries, Inc. ..........................................................................................548Gould Instrument Systems, Inc. ......................................................................850Gwathmey, Inc. ..................................................................................................312H & T Corporation ...........................................................................................1430Hamilton Thorne Biosciences, Inc. ...............................................................1215Harlan ..................................................................................................................737HemoGenix LLC ................................................................................................950Hill Top Research, Inc. ......................................................................................931Hilltop Lab Animals, Inc. ...............................................................................1022Human Biologics International (HBI) ...........................................................1307Humana Press .....................................................................................................308Huntingdon Life Sciences ...............................................................................1037Hurley Consulting Associates Ltd. .................................................................351IBT Reference Laboratory ...............................................................................1323Icoria, Inc. .........................................................................................................1049IDEXX Contract Research Services ................................................................1109IIT Research Institute .........................................................................................429Illumina ...............................................................................................................225In Vitro Technologies (IVT) .............................................................................1219Ina Research Inc. ................................................................................................240Instech Solomon ...............................................................................................1309Instem LSS ...........................................................................................................459Institute for In Vitro Sciences, Inc ..................................................................1230International Congress of Toxicology-XI (ICT-XI) .......................................1424International Life Sciences Institute (ILSI) ...................................................1149IPS Therapeutique, Inc. ....................................................................................219ISIS BioComp ......................................................................................................554ITR Laboratories Canada, Inc. .........................................................................751IUTOX ................................................................................................................1420Jai Research Foundation (JRF) ........................................................................ 1110John Wiley & Sons, Inc. ....................................................................................211Korea Institute of Toxicology (KIT) .................................................................325LAB Pre-Clinical Research International ........................................................424LAB Products, Inc. ............................................................................................407LABCAT ..............................................................................................................723LabCorp ...............................................................................................................213Leadscope Inc. ...................................................................................................842

Alphabetical Listing(As of January 1, 2005)

Please visit ToxExpo.com or the ToxExpoTM Directory for product/service descriptions, a map of booth locations,

and other information.

ToxE

xpo



2005 Exhibitors (Continued)

Company Name ............................................................................Booth NumberLHASA Limited ..................................................................................................134Lomir Biomedical, Inc. .....................................................................................927Lovelace Respiratory Research Institute (LRRI) ............................................858Marshall Farms USA, Inc. ..............................................................................1129MB Research Labs, Inc. .....................................................................................316MD Biotech ........................................................................................................1040MDS Pharma Services .......................................................................................337Med Associates Inc. ...........................................................................................759Merck Research Laboratories ...........................................................................936Metabometrix Ltd ..............................................................................................220MicaGenix ...........................................................................................................247Midwest BioResearch LLs (MBR) ....................................................................458Midwest Research Institute (MRI) ...................................................................428Molecular Light Technology UK (A GenProbe Company) (MLT) ..............317MPI Research ......................................................................................................415MultiCase Inc. ..................................................................................................1126National Institute of Environmental Health Science (NIEHS) ..................1050National Library of Medicine .........................................................................1121National Toxicology Program (NTP) ............................................................1052Neuroscience Associates (NSA) .......................................................................331Northview Biosciences ....................................................................................1228Notocord Systems ..............................................................................................336NOTOX B.V. .......................................................................................................330NovaScreen Biosciences Corp ..........................................................................340Nucro-Technics Incorporated ...........................................................................822Oxford University Press ..................................................................................1038Partek Incorporated ...........................................................................................938Pathology Data Solutions, Inc. ......................................................................1024Perry Scientific Inc. ...........................................................................................506Pfizer Global Research & Development .........................................................844Pharmalytica Services ......................................................................................1341Phylonix .............................................................................................................1213PJD Publications-Research Communications ..............................................1018Preclinical Research Associates ........................................................................849Primate Products, Inc. (PPI) ..............................................................................929Prime Resources Bio-Services Limited ..........................................................1325Product Safety Labs .........................................................................................1029Promega Corp ...................................................................................................1242Purina Mills LabDiet .........................................................................................709QTest Labs ...........................................................................................................452Quest Pharmaceutical Services, L.L.C. (QPS) ................................................209Quintiles, Inc. .....................................................................................................922RASS (Risk Assessment Summer School) .....................................................1418RCC Ltd. .............................................................................................................836ReCathCo, LLC ...................................................................................................206Research Diets, Inc. ...........................................................................................359Ricerca Biosciences .............................................................................................550Roche Applied Science ......................................................................................350Roche Diagnostics Corporation .......................................................................354Rosetta Biosoftware ...........................................................................................958RTC, Research Toxicology Centre S.p.A. ......................................................1321RTI International ..............................................................................................1123Safepharm Laboratories Ltd. .........................................................................1143San Diego Instruments, Inc. ...........................................................................1107Saronyx, Inc. .....................................................................................................1306SCANTOX A/S ................................................................................................1124Schleicher & Schuell BioScience, Inc. ...........................................................1252Scientists Center for Animal Welfare (SCAW) ...............................................109SCIREQ, Inc. (Scientific Respiratory Equipment) .........................................937Sequani Limited .................................................................................................823SFBC International .............................................................................................450Sinclair Research Center, Inc. (SRC) ..............................................................1245SITEK Research Laboratories ...........................................................................861SkeleTech, Inc. ....................................................................................................236Smiths Medical MD, Inc. ..................................................................................923SNBL USA, LTD. .............................................................................................1015Society of Quality Assurance (SQA) ................................................................451SOT—Animals In Research Booth .................................................................1416SOT—K–12 Resources Booth ..........................................................................1410

Company Name ............................................................................Booth NumberSOT—Membership Booth ....................................... Across from Exhibit Hall A SOT—Write to Congress (RALA) ..................................................................1422Southern Research Institute ..............................................................................416Springborn Laboratories, Inc. ........................................................................1014SRI International ................................................................................................508StemCell Technologies, Inc. .............................................................................310Stillmeadow Inc. ................................................................................................914Strategic Applications Inc. ................................................................................847Suburban Surgical Company ...........................................................................939Taconic .................................................................................................................425Tandem Labs .....................................................................................................1436Taylor & Francis .................................................................................................437TECHSPACE, INC. .........................................................................................1148The Jackson Laboratory .....................................................................................161The Leyden Group ...........................................................................................1328The Toxicology Group, LLC .............................................................................245Thoren Caging Systems, Inc. ...........................................................................207Tissue Transformation Technologies (TTT) ....................................................453TNO ......................................................................................................................824Tox Monitor/BSR, Inc. ....................................................................................1023TOXCEL LLC ......................................................................................................837Toxicology Education Foundation (TEF) ......................................................1414Toxicology Regulatory Services (TRS) ..........................................................1224Toxicology Research Laboratory (TRL) ..........................................................353Toxikon Corporation ..........................................................................................916TSE Systems GmbH ...........................................................................................442Vesta Therapeutics ...........................................................................................1152VisualSonics ........................................................................................................449Vitrocell Systems ................................................................................................745Vitron, Inc. ........................................................................................................1331WIL Research Laboratories, LLC ....................................................................951Wildlife International Ltd. ............................................................................. 1111XCELLON—The AEgis Technologies Group Inc. ......................................1036Xenobiotic Detection Systems ..........................................................................227XenoTech, LLC ....................................................................................................947Xybion Medical Systems ...................................................................................839

Admittance to the Exhibit Hall is limited to attendees with full registration.

Children under the age of 15 years of age are not allowed in the Exhibit Hall.

Please ask Show Management permission before taking pictures in the Exhibit Hall.

ToxExpo



ToxExpo™ & Informational SessionsToxExpoTM/ExhibitsFor many of the science professionals who attend, the focus of the SOT Annual Meeting is the three-day ToxExpo™ Exhibition. Here, state-of-the-art products and services directly relating to the advancement of research within toxicology and associated areas are displayed.

ToxExpoTM is open:

Monday, March 7 ........................................ 9:30 AM–4:30 PM

Tuesday, March 8 ......................................... 8:30 AM–4:30 PM

Wednesday, March 9 ................................... 8:30 AM–4:30 PM

At the ToxExpo™ Exhibition scientists have a first-hand opportunity to talk with the exhibitors, and to examine and learn about the products and services on display by more than 220 companies.

Reminder:

The ToxExpo™ Exhibition is considered to be part of the Annual Meeting scientific sessions. Guests and Children (under 15 years of age) are not allowed in the Exhibit Hall. The Society requires approval of all photographic equip-ment used in the Exhibit Hall. For information or approval, contact Libby Jones at (703) 438-3115 ext. 1454 or e-mail: [email protected].

Food Service in Exhibit Hall Quick food service is available in the Convention Center. Concession stands will be open from 7:00 AM–2:30 PM each day Sunday through Thursday. Breakfast and lunch items as well as coffee, soda, bottled water, and snacks will be available for purchase. The Atrium Restaurant offers an extensive menu and is open each day.

Informational Sessions(All Informational Sessions will be held in Room 215 and 223 at the Ernest N. Morial Convention Center)

The Rosetta Resolver® System: An Enterprise Solution for Gene Expression Analysis and Predictive ToxicologyPresented by Rosetta Biosciences

Tuesday, March 8 8:30 AM–9:30 AM Room 223

The Rosetta Resolver® System, an enterprise gene expression analysis solution, is a cornerstone in drug discovery for routinely processing and managing data from thousands of high-density microarrays. This presentation will focus on the current chal-lenges of toxicogenomics data analysis in drug development, and how the use of the Resolver system addresses those challenges.

Expression Profiling with BeadArray™ Technology: Identification of Genes Induced by Low Level Oxidative Stress Presented by Illumina


We examined variability in bead-based oligonucleotide micro-arrays by evaluation of dispersion characteristics among hybridization and biological replicate samples of lymphocyte RNA. Using a consecutive sampling and coincidence test, we have identified genes whose expression was significantly altered by low level exposure to oxidative stress.

ToxE

xpo



Exhibits & Informational Sessions (Continued)

Toxicity Testing: What Bone Marrow Can Tell UsPresented by StemCell Technologies, Inc.


Over the past three decades, a spectrum of standardized assays has been developed to characterize and measure bone marrow function and assess the multiple cell lineages it contains. In humans, bone marrow is one of the five major organ systems most sensitive to chronic low-dose chemical toxicants, making it an important target to assess in toxicity screening. This session will illustrate the rationale for targeting bone marrow for drug toxicity screening, assays that are employed and importance of using primary human cells in functional cell-based assays.

Searching the NTP DatabasesPresented by NIEHS

Tuesday, March 8 11:00 AM–12:00 NOON Room 215

The National Toxicology Program (NTP) conducts studies on potentially toxic agents to determine their impact on human health. Enhancing public access to these data, this workshop provides information about what is available within the NTP databases, using real examples to demonstrate the search process.

Designing Better Pre-Clinical Studies Using Gene Expression AnalysisPresented by Gene Logic, Inc.

Tuesday, March 8 11:00 AM–12:00 NOON Room 223

Understanding the expression pattern of a target protein in various tissues can help you plan your small molecule and biologics safety studies with more precision by suggesting additional target tissues and potential areas for concern. In this presentation, you will hear case studies on how scientists can use Gene Logic’s web-based ASCENTA™ System to design better pre-clinical studies.

Rapid Generation of Predictive Toxicogenomic AnalysisPresented by Gene Logic, Inc.

Tuesday, March 8 12:15 PM–1:15 PM Room 223

Learn how to facilitate drug candidate selection by characterizing a compound’s toxicity profile using an easy, intuitive toxicoge-nomic-based software application. Several case studies will be discussed that demonstrate how these rapidly generated results can be combined with other data to help make better inform compound decisions.

Leveraging a Multi-Dimensional Cardiovascular Assessment During Lead Optimization

Presented by CorDynamics


CorDynamics is a contract research organization focused on examining the cardiac effects of emerging drug candidates. Our models allow us to optimize these lead candidates early in the drug development process. Focusing on this critical and dynamic phase improves the attrition rates of compounds selected for further testing, thereby reducing the overall costs and timelines associated with your projects.

An Introduction to Microarrays and GeneChip® Technology for ToxicogenomicsPresented by Affymetrix


The Affymetrix GeneChip® System enables toxicologists to reli-ably generate, analyze, and manage large quantities of genetic information for accelerated research and biomarker discovery. This course is an introduction to GeneChip microarray design, performance, and analysis for applications in toxicogenomics.

ToxExpo



Hemotoxicity Testing of Xenobiotics and New Drugs for all Stages of the Drug Development Pipeline The HALO Platform—In Vitro Hemotoxicity Testing for the 21st CenturyPresented by HemoGenix, LLC


HALO (Hemotoxicity Assays via Luminescence Output) is a multifunctional and multiparameter testing platform that can detect and measure the effects of virtually any compound on up to 14 different proliferating cell populations from 5 species simultaneously from the blood-forming system. The test system is rapid, quantitative, highly sensitive and non-subjective with high-throughput capability and is ideal for all phases of drug development, from screening to monitoring the patient’s lympho-hematopoietic system during clinical trials.

Defining Molecular Mechanisms of Toxicity Using Affymetrix GeneChip® ArraysPresented by Affymetrix

Wednesday, March 9 8:30 AM–9:30 AM Room 215

Leaders in the use of Affymetrix microarray technologies will share the techniques and strategies they have used successfully to apply GeneChip products to their research.

Bioluminescent Methods for ADME/ToxPresented by Promega Corporation

Wednesday, March 9 11:00 AM–12:00 NOON Room 215

Bioluminescence offers significant advantages for configuring sensitive, simple to perform, high through-put assays with ADME/Tox applications. Bioluminescent systems will be described that measure the cytotoxicity of test compounds, their capacity to induce apoptosis, their impact on various CYP450 activities and on the multi-drug transporter (MDR1/Pgp).

Introduction to Real-Time PCRPresented by Applied BioSystems

Wednesday, March 9 11:00 AM–12:00 NOON Room 223

An introduction to the fundamentals of real-time PCR technology and applications. This session will include; an overview of abso-lute and relative quantitation methods, chemistry & instrument options, and assay design considerations.

Advances in Real-Time PCRPresented by Applied BioSystems

Wednesday, March 9 12:15 PM–1:15 PM Room 215

An overview of recent advances including; Validated TaqMan® Gene Expression and SNP Assays for quantitation and geno-typing of the Cytochromes P450 and other drug metabolizing enzymes, FAST thermal cycling options, and TaqMan® Assays for microRNA quantitation.


ToxE

xpo




SOT Informational BoothsSOT—Animals in Research Informational Booth ToxExpo™ 1416The Society of Toxicology is committed to research of the highest quality and views the use of laboratory animals as necessary to protect human health and the environment, except where alternative techniques have been validated. Stop by the Animals in Research Committee booth for information supporting that position, including the SOT "Importance of Animals in Research" brochure and SOT position statements. A variety of other mate-rials will be on display.

SOT—K–12 Resources Booth ToxExpo™ 1410Pick up tips for classroom mentors and the SOT career brochure. Investigate other high quality toxicology and environmental health sciences materials for teachers and toxicologists who visit classrooms. Come share with the K–12 Education Subcommittee what YOU are doing in your commu-nity.

SOT—Membership Booth ToxExpo™ (Across from Exhibit Hall A)The Society of Toxicology (SOT) is the largest association of professional toxicologists in the world. 5,200 plus members from all parts of the United States and more than 40 other countries enhance their careers through the benefits of SOT membership. SOT provides the premier venues for toxicology discourse, including meetings, the official (and highly cited) SOT journal Toxicological Sciences, and ToxExpoTM. Visit the SOT Membership booth to learn more about all member benefits and for a guided tour of the excellent and diverse resources available through the SOT Web site. Application for membership is easy at www.toxicology.org.

SOT—Write to Congress (RALA) ToxExpo™ 1422The Society of Toxicology's Regulatory Affairs and Legislative Assistance (RALA) Committee is the focus for activities that aid and support the scientifically related functions of regulatory agencies and judicial bodies. If the regulation of chemicals and the funding of research in toxicology concern you, visit the SOT Write to Congress booth for information and to write to your Congress person.

ToxExpo



Notes:

GEN

ERA

L IN

FO



The Registration Includes:• Saturday, March 5 evening session addressing career

strategies (see program description on page 45).

• Awards Presentation, Sunday, March 6 from 5:15 PM–6:30 PM.

• Welcoming Reception, Sunday, March 6 from 6:30 PM–7:30 PM.

• Plenary Lecture, Monday, March 7 from 8:30 AM–9:15 AM.

• All Scientific Sessions (see program descriptions beginning on page 45) 9:30 AM Monday, March 7 through 11:30 AM Thursday, March 10.

• ToxExpo™ Exhibit Hall, 9:30 AM Monday, March 7 through 4:30 PM Wednesday, March 9.

Participants are also encouraged to register for the Continuing Education Courses. These are available during three time inter-vals on Sunday, March 6: the sunrise mini-course is from 7:00 AM–7:45 AM; morning courses are 8:15 AM–12:00 NOON; and afternoon courses are from 1:15 PM–5:00 PM.

Registration DeskSaturday .................................................................4:00 PM–7:00 PMSunday .................................................................. 7:00 AM–8:00 PMMonday ................................................................. 7:00 AM–5:00 PMTuesday ................................................................. 8:00 AM–4:00 PMWednesday ........................................................... 8:00 AM–4:00 PMThursday ............................................................ 8:00 AM–11:30 AM

Registration MaterialsWhen you arrive at the Ernest N. Morial Convention Center, please go to the registration area to pick up your registration materials (you do not need to stand in line). Your 2005 Annual Meeting registration badge must be presented to obtain the regis-tration materials (i.e., badge holder, the ToxExpoTM Directory and other supplementary materials). If you do not yet have a meeting badge, please go directly to the registration desk.

Receipt of the Program and The Toxicologist 1. SOT Members in the U.S. and Canada will receive the printed

Program and The Toxicologist on CD ROM (with Itinerary Planner) prior to the meeting, as will U.S. and Canadian non-members who pre-register by January 10, 2005. There will be a printed version of The Toxicologist available on-site in the registration area for a fee of $20, while supplies last.

2. Non-members in the U.S. who register after January 10 will receive the Program and The Toxicologist on CD ROM (with Itinerary Planner) at the registration area on-site.

3. The Annual Meeting Itinerary Planner will be available on the SOT Web site January-March.

4. There will be computer kiosks available in the Exhibit Hall to search The Toxicologist on CD ROM at the Annual Meeting.

NOTE: Please bring your copy of the Program with you to the meeting.

Registration Fees: On-SiteSOT Member ................................................................$350Non-Member .............................................................. $600SOT Retired Member ..................................................$145Post-Doctoral SOT Member ......................................$160Post-Doctoral Non-Member ......................................$240Graduate Student SOT Member ...............................$140Graduate Student Non-Member ...............................$200Student Undergraduate .............................................$140SOT Affiliate ................................................................ $ 0Press .............................................................................. $ 0Guest (Non-Scientist) ........................................................$100

Continuing Education Course Fees: (per AM or PM course)

(Only Annual Meeting Registrants may enroll in CE Courses) On-SiteSOT Member/Corp/SOT Affiliate ...........................$150 Retired ...........................................................................$145Non-Member ...............................................................$250Post-Doctoral (SOT Member or Non-Member) .....................$125Graduate or Undergraduate Student (SOT Member or Non-Member) ............................................................ $ 80Press .............................................................................. $ 0

Continuing Education Sunrise Mini-Course Fees: (includes continental breakfast) On-SiteSOT Member/Corp Affiliate .....................................$ 95Post-Doctoral (SOT Member or Non-Member) .....................$ 95 Retired ...........................................................................$ 95Non-Member ...............................................................$115Graduate or Undergraduate Student ....................... $ 65Press .....................................................................................................$0 0

Scientific Sessions and Special Events will be held at the Ernest N. Morial Convention Center unless otherwise listed.

General Information

GEN

ERA

L IN

FO



Air TransportationNew Orleans is serviced by the Louis Armstrong New Orleans International Airport (MSY), which is a 20 minute drive from the Ernest N. Morial Convention Center and hotel area. Thirteen carriers offer daily flights. For more information, visit www.flymsy.com.

SOT has established discounted rates through Delta Airlines for travel originating in the United States, Canada, and Puerto Rico. Be sure to use the following discount reference number when making your reservations.

Delta Airlines

(800) 221-1212

Reference # 208610A

These rates provide savings of 5–10% off the lowest applicable fare or 10–15% off a full coach fare, up to 30 day prior to the Annual Meeting. By staying over a Saturday night, you can take advantage of additional savings with a two-night minimum stay. You can also receive great savings on discounted fares that do not require a Saturday night stay.

How To Make Air ReservationsNAVIGANT INTERNATIONAL is the official travel manage-ment firm for SOT’s 44th Annual Meeting. To take advantage of their services and savings, simply call toll-free (800) 525-6061 or direct (703) 276-2030 or (703) 276-2040 and select the airfare that is right for your plans. You may use the Travel Form and fax your airline request directly to NAVIGANT INTERNATIONAL at (703) 276-2077 (available on the SOT Web site). If you prefer to e-mail your request, you may do so at: [email protected].

To obtain the maximum discounted fares, call NAVIGANT INTERNATIONAL at least 60 days prior to departure. A modi-fied discounted fare is still obtainable up to 14 days in advance. These exceptional offers are available only to SOT attendees and their guests.

A. Complete the travel form (available on the SOT Web site) and fax to NAVIGANT INTERNATIONAL at (703) 276-2077.

B. Or, cal l NAVIGANT INTERNATIONAL toll-free at (800) 525-6061 or direct (703) 276-2030 Monday through Friday, 9:00 AM–5:30 PM (Eastern Standard Time).

Before calling NAVIGANT INTERNATIONAL, please gather the following information:

• The desired dates of arrival to and departure from New Orleans;

• Your home city or originating airport;

• Your approximate time of departure from the originating airport;

• The number of persons traveling (adults/children);

• Your method of payment, either credit card or check; and

• Your airline frequent flyer number(s).

Identify yourself as a Society of Toxicology attendee. NAVIGANT INTERNATIONAL will find the best fare for you. Watch your mail. You will receive a folio containing your computerized itin-erary.

C. Or, call the airline directly using the toll-free numbers listed for Delta. Provide the reservationists with the reference number listed to receive the discounted airfare.

Ground TransportationAirport shuttles and taxis are the best modes of transportation to and from the Louis Armstrong New Orleans International Airport. The convention center area is about 10–12 miles from the airport and is an I-10 freeway ride of about 20 minutes. All airport shuttles and taxis depart the airport from baggage claim area of the airport and will drop attendees at their hotels or at the convention center, if requested. Rental car companies have their desks located inside at baggage claim as well.

TaxiA cab ride costs $28 from the airport to the Central Business District (CBD) for one or two persons and $12 (per passenger) for three or more passengers. Pick-up is on the lower level, outside the baggage claim area. There may be an additional charge for extra baggage.

General Information (Continued)

GEN

ERA

L IN

FO



Airport ShuttleWith Airport Shuttle, getting from the airport to your final desti-nation has never been easier. Airport Shuttle drivers and vans provide convenient, comfortable, safe and efficient service to travelers. Airport Shuttle is the official ground transportation for the Louis Armstrong New Orleans International Airport to and from downtown New Orleans hotels, the French Quarter, and the Convention Center. Shuttles depart every 15 minutes from the airport. Service is provided 24 hours per day or until the last flight arrives at Louis Armstrong Airport. All drivers are uniformed, professional, courteous, and well-trained. The cost of a one-way trip is $13 per person, $25 roundtrip. Tickets are sold at the Airport Shuttle ticket desk in baggage claim or purchased on-line at www.airportshuttleneworleans.com.

Airport Limousine ServiceNon-scheduled walk up limousine and sedan service is available from the airport to the Central Business District (CBD) and the French Quarter. The rate is $35 for one or two people and $10 per additional passenger for up to 8 passengers (total vehicle capacity). Limousine information desks are located on the lower level baggage claim areas.

Car RentalAvis Rent A Car System is the official car rental company for the 44th Annual Meeting. SOT discounted rates, including unlimited mileage, begin at $43.99 per day. Rates do not include state and local surcharges, tax, optional insurance coverage or gas fueling charges. Should a lower qualifying rate become available, Avis is pleased to present a 5% discount on that rate or, if a car size is selected that is not available, Avis will discount the best available rate by 5%. To receive the SOT discount rates, contact Avis at (800) 331-1600 or AVIS on-line (www.avis.com). You must provide the Avis Worldwide Discount (AWD) number T534999 in order to receive the SOT discounted rate.

For more information about how to get around New Orleans please visit: www.neworleansonline.com/guide/citymaps.

ParkingThere are several parking lots around the convention center, including two (one outdoor, one a parking garage) directly in front of the convention center and one directly beside it. Parking starts at $7 per day.

Amtrack TrainThe Amtrak station is located downtown in the Central Business District. There are always taxis ready and waiting at the station.

BusThe New Orleans Regional Transit Authority provides bus service and streetcar service throughout New Orleans. Cost is $1.25 standard fare and $1.50 for express. Discounted all-day or multi-day passes are available at many hotels. For more informa-tion visit www.norta.com.

StreetcarsOther options for just enjoying the city are the Canal, St. Charles and Riverfront streetcars. Rides are $1.25 ($1.50 for Riverfront) exact change and run only within a 4-6 mile radius of the city. The streetcars are a great way to spend free time, to see City Park and the museum, the river, or historic neighborhoods; however the streetcars will not serve as a form of transportation for travel to and from the hotels and the convention center.

Hotel Accommodations and Reservations Make, change, or cancel your housing reservations with our On-Line Housing Service. There you will find full hotel descriptions and reservation instructions. Be sure to scroll to the bottom of the hotel description information to reserve your hotel. The system does accept individual reservations. Upon completing your reser-vation on-line, an e-mail confirmation will be sent to you.

HOUSING RESERVATION DEADLINE: FEBRUARY 1, 2005

Please use one of the following methods to make your reservation:

ON-LINE:www.toxicology.org

TELEPHONE:Toll-Free (USA): (800) 424-5250

International: (847) 940-2153

FAX:USA: (800) 521-6017

International: (847) 940-2386

MAIL:SOT HOUSING BUREAU

108 Wilmot Road, Suite 400Deerfield, IL 60015-0825


GEN

ERA

L IN

FO



Accessibility for Persons with DisabilitiesThe Ernest N. Morial Convention Center and most of the SOT hotels are accessible to persons with special needs. If you require special services, please mark the appropriate box on the Housing Request Form. If you require more information about disabled access, please call SOT Headquarters and ask for Heidi Prange; (703) 438-3115 ext. 1424 or [email protected].

Guest Hospitality Center and ProgramThe SOT Guest Hospitality Center provides guest participants (non-scientists) with a place to meet and socialize with other guests. Guests must register for the Annual Meeting using the same registration form as the person they are accompanying to visit the Hospitality Center. Guests are welcome to attend the Welcoming Reception, but will not have access to the scientific sessions or the Exhibit Hall. Please remember to wear your badge to all SOT events. The Guest Hospitality Center will be located in the Hilton Riverside Hotel in the Compass Room (Sunday–Tuesday) and the Steering Room (Wednesday–Thursday).

Concierge/Restaurant ReservationsA representative from On the Town will be located in the registra-tion area to provide restaurant menus, entertainment guides, and arrange restaurant reservations for individuals and groups.

Meeting Requests: Hospitality Suites and Ancillary MeetingsAll requests for hospitality suites and ancillary meetings must be approved by SOT Headquarters. To reserve a meeting room, please contact Heidi Prange, Meetings Manager. Ancillary func-tions may only be hosted by SOT Affiliates, exhibitors, or organizations affiliated with SOT. Hospitality suites and ancillary meeting space books fast. Please complete the Ancillary Meeting Form at www.toxicology.org and send it to Heidi Prange.

No hospitality functions or ancillary meetings may be scheduled during the following SOT events:

• Sunday 5:00 PM–7:30 PM: SOT Awards Presentation and Welcoming Reception

• Monday–Thursday 8:00 AM–11:30 AM: Morning SOT Scientific Sessions

• Monday–Thursday 1:30 PM–4:30 PM: Afternoon SOT Scientific Sessions

• Tuesday 4:30 PM–6:00 PM: SOT Annual Business Meeting

Ancillary requests received after December 15, 2004 may not be published in the SOT Program.

The hotels are not permitted to book meeting space without the authorized approval from SOT HQ. However, you are welcome to contact the Convention Service Manager to discuss meeting room rental, food and beverage, and audio visual equipment requests. All coordination for your event should be done between the hotel Convention Service Manager and the Ancillary Function Organizer.

Message Center/Lodging Information DeskThe SOT Message Center/Lodging Information Desk will be located in the SOT registration area of the Ernest N. Morial Convention Center and open during registration hours, Saturday through Thursday. Please inform your office and family of the Message Center/Lodging Information Desk number (504) 670-6900. (The Message Center/Lodging Information Desk will not accept facsimiles.)

Convention Center First Aid and Security The Ernest N. Morial Convention Center has an on-site, ACLS-certified registered nurse, stationed in permanent medical rooms located in Lobby B, Lobby E, and Lobby H during move-in, move-out and event hours. Medical facilities are clearly identified with visual and braille signs. Outside each room is an emergency phone directly connected to the Public Safety Department.

To report an emergency:

Pick up the RED emergency telephone in any telephone bank—dial 1911 or 3040 from any non-coin operated telephone. Use the emergency telephone in the GREEN box outside the medical rooms in Lobby B, Lobby E or Lobby H.

About Safety and Security:

The possibility of demonstrators is very real given the nature of our conference. Emergencies of this nature range from verbal confrontations, protests, strikes or riots. We recommend the following procedures in the event of demonstrations:

• Wear your name badge in the convention center. When leaving the facility, remove it so as to blend with other people.

• If you see a demonstration or protest beginning, please contact any member of the SOT Annual Meeting staff and they will initiate SOT response. If you see actions that appear threatening, notify the nearest security officer.

• Do not engage, defend either side, or subdue person(s) in any type of disturbance. Demonstrators are usually trying to attract media attention. Don’t help them!


GEN

ERA

L IN

FO



• SOT Representatives will respond to media inquiries. Do not participate in interviews or other media responses.

• In the unlikely event that outsiders disrupt a scientific session or other event, SOT security officials have developed a contingency plan. Please follow directions from the chairperson and avoid becoming involved in the situation.

Our first priority is safety. The best way to stay safe is to be aware of your surroundings and to avoid situations where you feel uncomfortable.

SOT Headquarters OfficeErnest N. Morial Convention Center, 205

Sunday .................................................................. 7:00 AM–5:00 PMMonday ................................................................. 7:00 AM–5:00 PMTuesday ................................................................. 8:00 AM–4:00 PMWednesday ........................................................... 8:00 AM–4:00 PMThursday ............................................................ 8:00 AM–11:30 AM

Business Center at the Ernest N. Morial Convention CenterA Business Center is conveniently located in the Atrium of the Ernest N. Morial Convention Center.

Saturday–Thursday ............................................ 8:00 AM–6:00 PM

• Copies • Fax Service • International Calls • Office Supplies • Parcel Shipping • Internet Access* *Internet access is only available in the main store, located across the street from Hall C.

Contact Matthew Sylvester at: Tel: (504) 524–0009; Fax; (504) 670–8996 E-mail: [email protected]

Stay Connected While You TravelAs technology advances, SOT realizes how important it is for attendees to learn the latest scientific discoveries and use tech-nology to stay connected to daily responsibilities while attending the meeting. This year SOT will have stations available in ToxExpo™ to check your e-mail and connect to the Internet. In addition, selected lounge areas in the Exhibit Hall offer wire-less Internet access. Additional information and instructions for accessing the wireless connection are available on the Annual Meeting Web site. All computer equipment at the computer stations was graciously supplied by Dell.

Media Representative Registration/Media Workspace (SOT HQ Office)Ernest N. Morial Convention Center, 205

Sunday–Thursday, March 5–10 ..................(See SOT Office Hours)

Registration fees are waived for working reporters and public information officers. Proof of credentials includes a recognized press card, business card, or letter on official letterhead from an editor of a publication or a producer of a program, certi-fying that you are covering the conference for their respective organizations.

There will be working space for the media in the SOT Office.

For more information, contact Lilly Richards, Media Contact, at (703) 438-3115, Ext. 1454, or e-mail: [email protected].

Annual Meeting SponsorshipThe Society would like to invite your organization to be a proud sponsor of the 2005 Annual Meeting. SOT appreciates the generous contributions of sponsors that make the SOT Annual Meeting possible. Sponsor names are prominently displayed on the Annual Meeting and ToxExpo™ Web sites as well as in print materials that are distributed before and during the Annual Meeting. Sponsorship is recognized through signage displayed around the convention center during the Annual Meeting.

There are five levels of sponsorship available: Diamond (over $10,000), Platinum ($5,000–$9,999), Gold ($2,500– $4,999), Silver ($1,000–$2,499) and Contributor ($500–$999). You will find a complete menu of sponsorships designed to assist your organiza-tion in establishing a leadership position at the SOT 2005 Annual Meeting on the Web site at www.toxicology.org and promotional opportunities can be reviewed at www.toxexpo.com.

For detailed information about SOT sponsor and promotional opportunities, please contact Libby Jones; (703) 438-3115 or [email protected].


GEN

ERA

L IN

FO



Speaker Ready RoomErnest N. Morial Convention Center, 202

Saturday .................................................................4:00 PM–7:00 PMSunday .................................................................. 7:00 AM–5:30 PMMonday–Wednesday .......................................... 7:00 AM–5:00 PMThursday ............................................................ 7:00 AM–11:30 AM

Meeting Courtesy PolicyThe use of photographic equipment is prohibited in all scientific sessions. Please contact Show Management, Libby Jones, for permission to take pictures in the Exhibit Hall. In addition, please turn off sound on all cellular phones while attending scien-tific sessions. Note that the entire Ernest N. Morial Convention Center is a smoke-free environment.

SOT MemorabiliaShirts, portfolios and other items customized for SOT are available for ordering on-line for pick-up at the Annual Meeting. Visit the SOT Web site’s 2005 Annual Meeting Section (www.toxicology.org) for full details.

Career Resource and Development ServicesSOT’s on-line job bank makes it easy for candidates and employers alike to access the Career Resource and Development Service from the main SOT Web site at www.toxicology.org throughout the year. Registrations are continuously processed and valid for six months. Once registered, candidates may search the listing of available jobs and employers may browse candidate profiles. During the registration period, users can update their listings or search the database as often as they wish. Communication with a desired employer or candidate can even be made via e-mail messages created within the system.

The Career Resource and Development Center is an important part of the Annual Meeting, providing a coordinated service for information regarding career opportunities and qualified candidates. Please do your job and candidate searches before you arrive at the meeting. Access to the SOT job bank Web site in the Career Resource and Development Center will be limited to the availability of 4 computers at the meeting. Employers and candidates will have access to computers, but computer use will be restricted to short searches for updates or new information.

Although pre-registration is encouraged, registrations will be accepted at the Annual Meeting. SOT Student Members who register for the Career Resource and Development Service before the SOT Annual Meeting will not be charged the $20 on-site registration fee. Please note that you must be a Student Member of SOT to register in this category. All users with current registra-tions at the time of the Annual Meeting will be permitted to use the service.

For additional information contact Nichelle Sankey at SOT Headquarters; (703) 438-3115 or [email protected].


AW

AR

DS


Arnold J. Lehman AwardDr. Rory B. Conolly’s contributions as a leader in the incorporation of good science in risk assessment and regulatory decisions are consistent with the spirit of the Arnold J. Lehman Award. He has had a significant influence on many important risk assessment decisions and documents within the U.S. government and industry. Even more impor-tantly, his knowledge plus his communication skills have created a lasting appreciation by many of his “students” for the importance of computational biology methods in the field of risk assessment.

Dr. Conolly’s experience with physiologically-based pharmaco-kinetic modeling has resulted in his being widely sought by governmental, industrial, and academic organizations to design and interpret studies involving the science of non-cancer risk assessment and cancer risk assessment modeling. He has provided expert testi-mony before Congress, participated in the preparation of several water quality criteria monographs for EPA, and has conducted risk assessment activities on behalf of NIOSH, NIEHS, IPCS, FDA and the SOT. Dr. Conolly stands out among his colleagues as a leader in the inclusion of good science in risk assessment.

Board of Publications Award in Toxicological Sciences

The Board of Publications has unanimously selected the paper entitled Arsenic Stimulates Angiogenesis and Tumorigenesis In Vivo as the best paper published in Toxicological Sciences during the past year. The joint first authors of this paper are Nicole V. Soucy and Michael A. Ihnat. The co-authors are Chandrashekhar D. Kamat, Linda Hess, Mark J. Post, Linda R. Klei, Callie Clark and Aaron Barchowsky (ToxSci. 76, 271–279, 2003).

Although arsenicals have been used for treating a variety of cancers including acute or chronic leukemias and solid tumors, their clinical use and environmental exposures are also associated with signifi-cant adverse effects on the cardiovascular system. One hypothesis for the antitumor effects of trivalent arsenic As (III) is that it inhibits angiogenesis. At the same time, however, there is conflicting evidence that As (III) is also directly angiogenic in cell culture. The significance of the work reported by Soucy et al. is that the paper represents the first report of the effects of As (III) on angiogenesis in vivo. The authors used both avian and mammalian models to test the hypothesis that As (III) stimulated angiogenesis and tumor growth in a dose-dependent manner. The authors showed that

As (III) increased blood vessel density in the chick chorioallantoic membrane and mouse Matrigel models. Additionally, they demon-strated that As (III) increased the size and density of blood vessels of solid tumors growing in a nude mouse model while enhancing tumor growth and metastatic potential. Importantly, the authors’ work revealed a complex, non-linear dose-response relationship, with pro-angiogenic properties observed at levels relevant to envi-ronmental exposure.

Although the work has not fully characterized the mechanisms underlying the angiogenic properties of As (III), the results repre-sent important new data that impact human health. In particular, the work provides new information regarding the scientific under-pinning of the carcinogenicity of As (III) and the potential for adverse health effects of environmental exposure to As (III) while documenting a very narrow therapeutic window when treating solid tumors with arsenic. The paper is an outstanding example of a relevant, hypothesis-driven approach to address an important human health concern.

Contributions to Public Awareness of Animal Welfare Award

This year, the Awards Committee has selected two recipients for Contributions to the Public Awareness of the Importance of Animals in Toxicology Research Award.

The first recipient is the Foundation for Biomedical Research, which has provided valuable educational resources supporting the use of animals systems for providing invalu-able and irreplaceable insights into human systems. These resources include articles elab-orating the contributions of animal research, materials for both teachers and parents of children in primary and secondary schools, and links to other federal agencies and foun-dation web sites that support and address the needs of animals in biomedical research.

The second recipient is Senator Orrin Hatch, a long-time supporter of biomedical research. Senator Hatch, as Chair of the Senate Judiciary Committee has held hearings on the subject of “Animal Rights: Activism vs. Criminality” to call attention to the rising incidence of terrorist like activities associated with some animal rights group. He will hold another committee meeting on the topic of Animal Rights/Activism in late 2004 or early 2005 with the intent of initiating legislation to protect universities and research organiza-tions from such groups’ illegal and violent activities.

Rory Conolly

2005 Award WinnersThe Society of Toxicology presented the following awards for the year 2005:

Orrin G. Hatch

FBR, Frankie L. Trull, President

AW

AR

DS


Nobuyuki Ito

Distinguished Lifetime Toxicology Scholar Award

This year’s recipient of the Distinguished Lifetime Toxicology Scholar Award is Dr. Daniel Nebert, Professor in the Department of Environmental Health, University of Cincinnati School of Medicine. Dr. Nebert received his M.D. degree from the University of Oregon Medical School, completed his residency training and joined the National Institutes of Health where he held several research leadership positions in the National Institute of Child Health and Human Development. In 1989, he joined the faculty at the University of Cincinnati where he holds cross-appointments in several Departments

and Programs.

Dr. Nebert continues to be one of the most productive and influential scientists of our time. He is the author of over 500 publications and his research on cytochrome P450 (CYP) regulation drug and carcin-ogen metabolism has significantly impacted the fields of toxicology, pharmacology, genetics, endocrinology, oncology, biochemistry and molecular biology. He has contributed seminal research publica-tions to all of these fields and his pioneering efforts on organizing and classifying the CYP superfamily are a model for understanding gene relationships in many other gene families. Dr. Nebert has received honors from numerous scientific societies, government, and universities and in his lectures he not only provides historical scientific insights but also cutting-edge pharmacogenetic research results. Not surprisingly, Dr. Nebert is one of the most highly cited scientists in his field.

Research in Dr. Nebert’s laboratory has been carried out by a long list of graduate students, post-doctoral fellows, research associates, and visiting scientists. Many of these individuals are now distin-guished scientists in their own right and their success has been significantly influenced by Dr. Nebert’s mentorship and collabora-tion. This combination of inspired research and mentorship, coupled with insightful new ideas and hypotheses, defines the scientific career of Dr.Nebert and is consistent with the award of the 2005 Distinguished Lifetime Toxicology Scholar Award from the Society of Toxicology.

Education AwardThe recipient of the 2005 Education Award is Dr. Nobuyuki Ito. Dr. Ito began his pioneering efforts in toxicology education 30 years ago when he established an extensive teaching and training program for toxicologists at the Nagoya City University Medical School, Department of Pathology. He has trained two generations of toxicologists and toxico-logic pathologists in Japan, first as Chairman of the Department, then as Dean of the Medical School and lastly as President of the University. Dr. Ito and his students and senior scientists have made major and significant contributions to risk assessment and regu-

lation of chemicals and food additives in Japan, in the U.S. and internationally. His work in the field of histogenesis and modulation of the neoplastic process and his work on the role of antioxidants in anticarcinogenesis have been acknowledged by many learned societies, including the Princess Takamatsu Cancer Research Fund, the Japanese Cancer Association, and the Federation of Societies of Toxicologic Pathology. During his distinguished career at Nagoya City University Medical School, Dr. Ito has authored and co-authored with his numerous students and associates more than 600 peer-reviewed scientific publications. His former students, numbering more than 100, are in very important positions around the world, continuing his task of educating toxicologists in Japan, Korea, Brazil and the U.S. This years’ Education Award celebrates Dr. Ito’s lifelong contributions to education.

2005 Award Winners (Continued)

Daniel Nebert

AW

AR

DS


Enhancement of Animal WelfareDr. Daniel Acosta, Dean of the College of Pharmacy at the University of Cincinnati, is the 2005 recipient of the Enhancement of Animal Welfare Award. This award was insti-tuted in 2000 to honor a member of the Society of Toxicology whose scientific accomplish-ments have led to a marked reduction in the use of experimental animals for research. Dr. Acosta was one of the early pioneers in the development of in vitro cell cultures as models for testing and mechanistic studies on drugs and toxicants. He, his co-workers, and other scientists in this field developed appropriate conditions for culturing cells from various

tissues that mimicked their derived normal tissues, thus greatly reducing the need for experimental animal testing. Dr. Acosta was not only a pioneer in developing alternative in vitro test methods, but he was successful in maintaining viable cultured cells from multiple sites including liver, heart, kidney, and nervous tissues. In addition to his scientific accomplishments in the field of in vitro toxi-cology, Dr. Acosta has been an outstanding mentor teacher/lecturer, and he is also a former President of the Society of Toxicology. Dr. Acosta’s long-term contributions to in vitro toxicology have greatly decreased the use of animals in research, and he is recognized and honored for his accomplishments with the 2005 Enhancement of Animal Welfare Award.

Merit AwardThe Awards Committee is honored to select Roger O. McClellan, DVM, MMS, DABT, DABVT, FATS, as the 2005 Merit Award recipient. Dr. McClellan is well recognized for distinguished accomplishments in several areas: his pioneering and productive research career; a legacy of leadership through both his impact on the development of renowned research institutes and the fostering of educa-tional programs; and for significant service as a scientific advisor to numerous national and international agencies, academic institutions, and professional and private organizations.

Dr. McClellan has had an extensive, productive and influential research career. He has authored or co-authored more than 350 scientific papers and has edited or co-edited 10 books in the fields of inhalation toxicology, comparative medicine, and human health risk analysis. By virtue of his unique vision, he is recognized for pioneering many influential studies that served as the cornerstone for subsequent research and which have had tremendous influence on subsequent regulatory decisions.

In 1966, at an early age, Dr. McClellan assumed leadership of the Lovelace Inhalation Toxicology Research Institute (ITRI) and subse-quently became its President. The ITRI continues today as part of

the Lovelace Respiratory Research Institute. Under his leadership, Lovelace became an internationally recognized institute known for its high-quality studies of the toxicity of radioactive and chemical airborne pollutants. He introduced strategic, innovative, and multi-disciplinary approaches and championed teamwork to advance the analysis of complex environmental and occupational exposures. In 1988, Dr. McClellan became the third President of the Chemical Industry Institute of Toxicology (CIIT, now CIIT Centers for Health Research). During his tenure with CIIT, he enhanced its reputation as a world leader in understanding the human health risks of chem-ical exposures. There he solidified the concept of using all available data, from epidemiological to subcellular studies, to predict health consequences at exposures relevant to people.

Dr. McClellan has been notably generous in service to a number of professional organizations, including presiding as President of the Society of Toxicology, the Toxicology Education Foundation, the American Board of Veterinary Toxicology, and the American Association for Aerosol Research. He serves in an editorial role for several journals and as the Editor of Critical Reviews in Toxicology. He is a diplomate of both the American Board of Toxicology and the American Board of Veterinary Toxicology, and a Fellow of The Academy of Toxicological Sciences, Society for Risk Analysis, Health Physics Society and American Association for Advancement of Science. He has served on the adjunct faculty of eight academic institutions and is a frequent advisor on toxicology and human risk issues to both public agencies and private parties in the U.S. and abroad.

Dr. McClellan’s significant contributions have been previously recognized by a number of honors. Among them are the following: election to membership in the Institute of Medicine of the National Academy of Sciences; two Distinguished Associate Awards from the Department of Energy for outstanding scientific vision and research leadership in inhalation toxicology, radiation biology, and environ-mental health sciences; an International Aerosol Fellow Award from the International Aerosol Research Assembly for outstanding contri-butions to aerosol science and technology; the Thomas T. Mercer Joint Prize from the American Association for Aerosol Research and the International Society for Aerosols in Medicine for excellence in the field of inhalation materials and pharmaceutical aerosols; an International Society of Regulatory Toxicology and Pharmacology award for outstanding contributions to improving the science for risk-based decision making; Distinguished Alumnus Awards from Washington State University and the University of New Mexico; a career achievement award from the Inhalation Specialty Section of the Society of Toxicology; and the Arnold J. Lehman Award from the Society of Toxicology for major contributions to the control of chemical agents.

For his outstanding scientific career, his leadership in directing and advancing key issues in toxicology and human health risk analysis, and for his distinguished service record, the Society of Toxicology is pleased to bestow the 2005 Merit Award to Dr. McClellan as an additional and well-deserved honor. For his outstanding scien-tific career, his leadership in directing and advancing several key issues in toxicology and human health risk analysis, and for his distinguished service record, the Society of Toxicology is pleased to bestow the 2005 Merit Award to Dr. McClellan as an additional and well-deserved honor.


Roger O. McClellan

Daniel Acosta

AW

AR

DS


Public Communications Award Dr. Robert I. Krieger, an Extension Toxicologist, Department of Entomology, at the University of California, Riverside, has been selected to receive the 2005 Public Communications Award. Dr. Krieger is a distinguished research investigator who has contributed over 100 technical articles published in the peer-reviewed literature. He also served as senior editor of the 2nd Edition of the Handbook of Pesticide Toxicology, a text familiar to most toxicology students. Dr. Krieger’s univer-sity lectures are among the best. In addition, his commitment to meeting the challenge of clearly communicating critical concepts of

toxicology to non-technical audiences is exemplary.

Dr. Krieger’s public outreach is across a range of audience and toxicology topics that has spanned from speaking to kinder-garten students on blow gun dart poison, to town-forum meetings discussing the risk of exposure to malathion due to drift from aerial sprayings against Medfly outbreaks. The variety of venues to which he diligently directs his participation is also notably broad, and includes the following: mentoring contestants and judging entries at grade-school science fairs; continuing education lectures to pesticide user groups, migrant laborers, parents, teachers, and consumers; providing expert witness in a number of jury trials where complex toxicological issues had to be explained in under-standable terms; media reports and newspaper or radio interviews; and as a technical advisor to television shows such as CSI Miami. Dr. Krieger also has aided deliberations convened by legislative bodies or advisory committees on health policy. For example, he assisted the Federal Trade Commission in the evaluation of the effi-cacy of vegetable and produce washes. Dr. Krieger’s publication on the use of mosquito coils in Asia and their subsequent withdrawal from use in Indonesia demonstrates an international impact.

His scientific expertise, coupled with unique oral communication skills and enthusiasm, make Dr. Krieger very effective at presenting a balanced, scientific perspective. Such a perspective is absolutely essential to ensuring that the principles, findings, extrapolations, and uncertainties that underlie toxicological assessments, public concerns, and regulatory strategies are all equally understood by citizens, stakeholders, and decision makers alike. In so doing, he has advanced the understanding and acceptance of toxicology as a scientific discipline critically relevant to enhancing human, animal, and environmental health. The Society of Toxicology is pleased to recognize Dr. Krieger for his outstanding efforts both to commu-nicate clearly and to soundly educate a diverse audience on the fundamentals of our profession.

AstraZeneca Traveling Lectureship This year’s recipient of the AstraZeneca Traveling Lectureship Award is Dr. Kevin M. Crofton. Dr. Crofton is a neurotoxicolo-gist with the Neurotoxicology Division of the National Health and Environmental Effects Laboratory, U.S. Environmental Protection Agency, Research Triangle Park, North Carolina. His primary research interest is the effects of thyroid disrupting chemicals on the ontogeny of the nervous system. Dr. Crofton has presented invited lectures in the U.S., Europe, and Canada and currently serves on the Editorial Boards of several scientific jour-nals. Dr. Crofton’s traveling lectureship is in

support of the development of a new program within EPA to imple-ment and validate the use of high-throughput in vitro methods and alternative species as first-tier screening methods for developmental neurotoxicity. His lectureship will include visits with Dr. Sandra Coecke, Development Coordinator Metabolism and Neurotoxicity at ECVAM Institute for Health and Consumer Protection, European Commission, Joint Research Center, Ispra, Italy; Dr. Adrian Percy of Bayer Crop Science, Sophia Antipolis Research Center in France and Dr. David Ray of the MRC Applied Neuroscience Group, Biomedical Sciences at the University of Nottingham, Queens Medical Centre in Nottingham, England.


Robert Kreiger

Kevin Crofton

AW

AR

DS


2004 Student Award Winners

Colgate-Palmolive Post-Doctoral Fellowship in In Vitro ToxicologyAbstract: 1367

Title: BCL-2 Family Members Protect against Methoxychlor-Induced Toxicity of Mouse Ovarian Antral Follices In Vitro

Novartis Corporation Graduate FellowshipAbstract: 1930

Title: Augmentation of Lipopolysaccharide-Induced Gene Expression and Liver Injury by Ranitidine but not Famotidine

Kimberly Miller

James Luyendyk

Visit the SOT Web site for upcoming award details and deadlines at…

www.toxicology.org

Social Events

SOC

IAL

EV

ENT

S



Awards PresentationSunday, March 6, 5:15 PM–6:30 PM

Room 220

Ernest N. Morial Convention Center

Join us as SOT honors our presti-gious award winners at the Award Presentation. Please refer to the Awards and Fellowships section of the SOT Web site for complete details and nominating form for next year.

Welcoming ReceptionSunday, March 6, 6:30 PM–7:30 PM

La Louisiane Ballroom


The Welcoming Reception is a great opportunity to renew old friendships and to make new acquaintances. Please join the Society in this inau-gural event of the Annual Meeting.

25-Year (or More) Member Reception

Sunday, March 6, 7:00 PM–8:00 PM

Room 215


Have you been a member of the Society of Toxicology for 25 years (or more)? If so, please join your colleagues in celebration and recogni-tion of the scientists who established the Society.

Student/Post-Doctoral Fellow MixerSunday, March 6, 7:30 PM–8:30 PM

Grand Ballroom A

Hilton Riverside Hotel

All students and post-docs are invited to attend this fun-filled recep-tion. Refreshments will be provided by SOT and sponsors. A cash bar will also be available. Ticket and Meeting Badges are required.

Specialty Section ReceptionsMonday, March 7 through Wednesday, March 9, 6:00 PM–7:30 PM


(Refer to the Events Calendar for more details.)

Each of the 20 SOT Specialty Sections will hold a meeting/reception during the 2005 SOT Annual Meeting. All current and prospective SOT Specialty Section Members are encouraged to attend. Please check the Program’s Event Calendar for a listing of times for all Specialty Section meetings and receptions.

Regional Chapter ReceptionsMonday, March 7 through Wednesday, March 9,7:00 PM–11:00 PM

Hilton Riverside Hotel

(Refer to the Events Calendar for more details.)

Many of the SOT Regional Chapters meet during the SOT Annual Meeting. A list of Regional Chapter receptions will be listed in the Program’s Event Calendar.

Sunday, March 6, 7:00 PM–8:00 PM

Room 215


Have you been a member of the Society of Toxicology for 25 years (or more)? If so, please join your colleagues in celebration and recogni-tion of the scientists who established the Society.

SESS

ION

IND

EX



Scientific Session IndexContinuing Education CoursesAll courses will be held on Sunday, March 6, 2005, at the Ernest N. Morial Convention Center. Please check the signage in the registration area for room assignments. Note: Your course mate-rials will be available in the room immediately prior to the course (they will not be available at the registration area). If you have your course ticket, go directly to the assigned course room. If you have not received your course ticket or have not registered, please go to the registration area on Saturday afternoon/evening or on Sunday morning. If you have misplaced your ticket, please go to the Continuing Education Booth, Level 2, at the Ernest N. Morial Convention Center on Sunday. The booth will be open from 6:30 AM–5:15 PM. Course descriptions are on pages 39–45.

7:00 AM–7:45 AM, Sunrise Mini–Course:

1. Fundamentals of Nanotechnology: Chemistry, Exposure, Environmental/Health Assessments and Societal Impacts

8:15 AM–12:00 PM, Morning Courses:

2. Dose Considerations for In Vitro Studies of Air Pollutant Toxicity

3. Developmental Toxicology Studies: Design, Interpretation and Risk Assessment

4. Clinical Pathology—The Granddaddy of Biomarkers

5. Immunology for Toxicologists

6. Evaluation of Cardiac Drug Toxicity in Pharmaceutical Discovery and Development

7. International Harmonization of Technical Requirements for Conducting Non–Clinical Safety Studies of Human Pharmaceuticals: Guidelines, Case Studies, and Challenges

1:15 PM–5:00 PM, Afternoon Courses:

8. Male Reproductive Hazard Identification and Risk Assessment in Pharmaceutical Development (What Do You Do Now That You Have A Signal?)

9. Development and Interpretation of Toxicokinetic Data for Risk and Safety Assessment

10. Phototoxicity: Current Concepts, Experimental Designs, and Regulatory Expectations

11. Something Old, Something New; Traditional and Novel Biomarkers of Renal Injury

12. Evaluation of Cardiac Drug Toxicity in Pharmaceutical Discovery and Development

13. International Harmonization of Technical Requirements for Conducting Non-Clinical Safety Studies of Human Pharmaceuticals: Guidelines, Case Studies, and Challenges

General Scientific Sessions(Listed by date and time.)

Monday

SymposiaDate/Time Topic/Abstract # Room Page

Monday The Future of Molecular RO4 49 9:30 AM Genetic Therapeutics #13–17

Monday Inhalation Exposure and Systemic RO8 50 9:30 AM Immunotoxicity: Mechanisms Linking the Lung and Immune System #18–23

WorkshopsDate/Time Topic/Abstract # Room Page

Monday The Development and RO6 50 9:30 AM Application of Biomarkers of Toxicity #24–29

Monday Dose-Additivity of Mixtures: 220 51 9:30 AM Where are We Going with the Science? #30–34

Monday Role of Nutrigenomics in Safety RO2 52 9:30 AM Assessment of Functional Foods #35–40

Platform SessionsDate/Time Topic/Abstract # Room Page

Monday Nano Particles: General #41–45 208 52 9:30 AM

Monday Neurotoxicity: Pharmacological RO1 53 9:30 AM and Environmental Interactions #46–52

Monday Receptors: PPAR #53–59 207 54 9:30 AM

Poster Sessions* Attended 9:30 AM–11:00 AM; otherwise attended 11:00 AM–12:30 PM.

Date/Time Topic/Abstract # Room Page

Monday * Liver I #60–83 Exhibit Hall 54 9:30 AM

Monday Receptor: Ah Receptor II #84–107 Exhibit Hall 56 9:30 AM

Monday * Gene Expression—I #108–130 Exhibit Hall 57 9:30 AM

Monday Arsenic and Uranium Exhibit Hall 59 9:30 AM Toxicology #131–165

SESSIO

N IN

DEX



Scientific Session Index (Continued) Date/Time Topic/Abstract # Room Page

Monday * Immunotoxicology—Methods Exhibit Hall 61 9:30 AM and Safety Evaluation #166–181

Monday Signal Transduction: Kinases Exhibit Hall 62 9:30 AM #182–187

Monday * Methods and Devices #188–203 Exhibit Hall 63 9:30 AM

Monday Oxidative Stress I #204–229 Exhibit Hall 64 9:30 AM

Monday * Methyl Iodide Risk Exhibit Hall 65 9:30 AM Assessment #230–240

Monday Regulatory/Policy #241–247 Exhibit Hall 66 9:30 AM

Monday * Education and Public Exhibit Hall 67 9:30 AM Outreach #248–251

Monday Childrens Health and Juvenile Exhibit Hall 67 9:30 AM Animal Toxicology #252–270

Monday * Developmental Toxicity Exhibit Hall 68 9:30 AM Testing #271–285


Monday Innovations in Toxicological RO8 70 1:30 PM Sciences Session: Alternative RNA Splicing: A Mechanism for Enhancing Diversity of Gene Expresion #286–291

Monday Dietary Acrylamide: New or 208 70 1:30 PM Ancient Risk? #292–296

Monday Environmental Factors Affecting Ballroom B 71 1:30 PM Breast Cancer Susceptibility #297–302

Monday The Multi-Site Ambient Particle RO4 72 1:30 PM Study (MAPS): An Integrated Approach to Studying Health Effects of PM Components #303–308


Monday Environmental Terrorism: 220 72 1:30 PM Development of Evacuation, Re–Entry and Re–Use Guidelines for Chemical, Biological and Radiological Agents #327–332

Monday High Throughput Screening RO6 73 1:30 PM Approaches in Genetic Toxicology #333–338

RoundtableDate/Time Topic/Abstract # Room Page

Monday Electrocardiography Safety RO1 69 12:15 PM Evaluation Studies—New Techniques and Approaches #339–343


Monday Computational Toxicology: RO1 74 1:30 PM Advances and Applications #344–352

Monday Biotransformation/Cytochrome RO3 74 1:30 PM P450 #353–361

Monday Mechanisms of Immunotoxicity RO2 75 1:30 PM #362–369

Poster Sessions* Attended 1:30 PM–3:00 PM; otherwise attended 3:00 PM–4:30 PM.


Monday * Risk Assessment I #370–408 Exhibit Hall 76 1:30 PM

Monday Exposure Assessment/ Exhibit Hall 78 1:30 PM Epidemiology #409–432

Monday * Respiratory Tract I—Pulmonary, Exhibit Hall 80 1:30 PM Cardiovascular, and Immune Effects of PM #433–460

Monday Pharmaceuticals–General #461–475 Exhibit Hall 82 1:30 PM

Monday * Safety Evaluation–Evaluation of Exhibit Hall 83 1:30 PM Methods In Vitro/In Vivo #476–493

Monday Biomarkers #494–540 Exhibit Hall 84 1:30 PM

Monday * Male Reproductive #541–558 Exhibit Hall 87 1:30 PM

Monday Gene Expression–II #559–579 Exhibit Hall 88 1:30 PM

Monday * Receptor: PPAR #580–589 Exhibit Hall 90 1:30 PM

Monday Neurotoxicity of Metals: Exhibit Hall 91 1:30 PM Dosimetry and Effects #590–609

Monday * Neurotoxicity of Metals: Exhibit Hall 92 1:30 PM Mechanisms #610–634

SESS

ION

IND

EX



Scientific Session Index (Continued)Sunset SessionsDate/Time Topic/Abstract # Room Page

Monday Brominated Flame Retardants: RO6 94 4:30 PM New Findings #309–313

Monday Developmental Toxicology RO8 94 4:30 PM Evaluations: Issues with Including Neurotoxicology and Immunotoxicology Assessments #314–314

Monday Interviewing Skills for Graduate RO2 95 4:30 PM Students and Post–Docs #315–320

Monday Teaching Undergraduate 220 95 4:30 PM Toxicology in the 21st Century #321–326

Tuesday

Sunrise SessionDate/Time Topic/Abstract # Room Page

Tuesday Toxic Torts: Toxicologists in RO1 97 7:00 AM the Courtroom #635–635


Tuesday Altered Iron Homeostasis (Aih) RO2 98 8:30 AM As a Basis for Pulmonary Immunotoxicologic Effects of Particulate Matter #636–641

Tuesday Beyond Liver Toxicognomics: 208 98 8:30 AM Gene Expression Based Biomarkers in Non-Hepatic Tissues #642–647

Tuesday Emerging Issues in Risk Ballroom B 99 8:30 AM Assessment and Risk Perception of Nanomaterials #648–653

Tuesday Nucleocytoplasmic Trafficking in RO6 100 8:30 AM Mechanisms of Toxicity #654–659


Tuesday Current Status and Future RO3 100 8:30 AM Considerations for the Development and Validation of In Vitro Alternatives to the Draize Rabbit Eye Test #660–665

Tuesday Mode of Action in Relevance of RO4 101 8:30 AM Rodent Liver Tumors to Human Cancer Risk #666–672

Tuesday Neuroimaging Strategies for RO1 102 8:30 AM Application to Neurotoxicology and Risk Assessment #673–678


Tuesday Developmental Toxicology 207 102 8:30 AM #679–687

Tuesday Metals Toxicology #688–696 RO8 103 8:30 AM

Tuesday Evaluating DNA Damage and 220 104 8:30 AM Repair #697–705



Tuesday * Biotransformation/Cytochrome Exhibit Hall 104 9:30 AM P450 I #706–740

Tuesday Hepatocarcinogenesis #741–765 Exhibit Hall 107 9:30 AM

Tuesday * Chemical & Biological Weapons Exhibit Hall 108 9:30 AM #766–796

Tuesday Safety Evaluation—Biotechnology Exhibit Hall 111 9:30 AM Products and Vaccines #797–812

Tuesday * Signal Transduction: Oxidant Exhibit Hall 112 9:30 AM Stress #813–823

Tuesday Cardiovascular Disease II #824–846 Exhibit Hall 113 9:30 AM

Tuesday * PBPK Models #847–871 Exhibit Hall 114 9:30 AM

Tuesday Immunomodulation #872–913 Exhibit Hall 116 9:30 AM

Tuesday * Respiratory Tract II #914–947 Exhibit Hall 118 9:30 AM

Tuesday Reproduction and Exhibit Hall 121 9:30 AM Development #948–959

Tuesday * Developmental Neurotoxicity I Exhibit Hall 122 9:30 AM #960–989


Tuesday The AhR in Cell Growth and RO1 126 1:30 PM Death #990–995

Tuesday Organophosphates & Carbmates: RO4 126 1:30 PM Cholinergic vs. Noncholinergic Mechanisms #996–1001

Tuesday Protemics and Antibody Ballroom B 127 1:30 PM Microarrays: Applications in Toxicology #1002–1007

Tuesday Update on Mechanisms for RO8 128 1:30 PM Environmental Tobacco Smoke–Induced Health Effects #1008–1014

SESSIO

N IN

DEX



Scientific Session Index (Continued)WorkshopsDate/Time Topic/Abstract # Room Page

Tuesday Current and Future Science-Based 220 128 1:30 PM Approaches to Drug Evaluation: An Assessment of Potential Cancer Risk #1025–1030

Tuesday Molecular Pathways to RO3 129 1:30 PM Toxicant–Induced Osteoporosis #1031–1036


Tuesday Nanoparticle Toxicity 208 130 1:30 PM #1037–1045

Tuesday Liver #1046–1054 RO6 130 1:30 PM



Tuesday * Developmental Neurotoxicity II Exhibit Hall 131 1:30 PM #1055–1089

Tuesday Nervous System: Methods and Exhibit Hall 133 1:30 PM Functional Effects #1090–1107

Tuesday * Female Reproductive #1108–1123 Exhibit Hall 135 1:30 PM

Tuesday Metals Toxicology #1124–1160 Exhibit Hall 136 1:30 PM

Tuesday * Gene Regulation: Metals Exhibit Hall 138 1:30 PM #1161–1169

Tuesday Pharmaceuticals—Methods of Exhibit Hall 139 1:30 PM Evaluation #1170–1178

Tuesday * Safety Evaluation–Non Exhibit Hall 139 1:30 PM Pharmaceutical #1179–1190

Tuesday Hypersensitivity II #1191–1214 Exhibit Hall 140 1:30 PM

Tuesday * Signal Transduction I #1215–1226 Exhibit Hall 142 1:30 PM

Tuesday Disposition/Pharmacokinetics Exhibit Hall 142 1:30 PM #1227–1258

Tuesday * Genetic Polymorphisms Exhibit Hall 144 1:30 PM #1259–1276

Tuesday Biomonitoring #1277–1291 Exhibit Hall 146 1:30 PM

Tuesday * Statistical and Biological Exhibit Hall 147 1:30 PM Models #1292–1306

Tuesday Food Safety and Nutrition Exhibit Hall 149 1:30 PM Toxicology II #1307–1319

Sunset SessionsDate/Time Topic/Abstract # Room Page

Tuesday In Vitro Toxicity Testing of Air 208 150 4:30 PM Pollutants: Pros and Cons #1015–1019

Tuesday Toxicology Information and 220 150 4:30 PM Data Update #1020–1024

Wednesday


Wednesday Biomarkers of Oxidative Stress: RO4 151 8:30 AM New Prospects and Approaches #1320–1325

Wednesday Genetic Susceptibility and RO2 152 8:30 AM Metal Toxicity #1326–1331

Wednesday Pesticide Neurotoxicity in Adults: 208 152 8:30 AM Integrating Contributions from Epidemiology and Toxicology #1332–1337


Wednesday Current Regulatory and Scientific Ballroom B 153 8:30 AM Views Regarding Chemical Hazards to Children #1338–1344

Wednesday Toxicologic Evaluation of 207 153 8:30 AM Inhaled Vaccines #1345–1350

Wednesday Toxicological Research and Testing: RO3 154 8:30 AM Best Practices and Opportunities for Laboratory Animal Refinement, Reduction, and Replacement #1351–1356


Wednesday Receptors: Ah Receptor #1357–1365 220 154 8:30 AM

Wednesday Female and Male Reproductive RO1 155 8:30 AM Systems #1366–1374

Wednesday Toxicogenomics: Role in Predictive RO6 156 8:30 AM Toxicology and Carcinogenicity #1375–1383

SESS

ION

IND

EX





Wednesday * Food Safety and Nutrition Exhibit Hall 157 9:30 AM Toxicology I #1384–1408

Wednesday Natural Products #1409–1440 Exhibit Hall 158 9:30 AM

Wednesday * Respiratory Tract III #1441–1472 Exhibit Hall 161 9:30 AM

Wednesday Risk Assessment for Acute Exhibit Hall 163 9:30 AM Inhalation Exposures #1473–1485

Wednesday * Modulation of Carcinogenesis Exhibit Hall 164 9:30 AM #1486–1503

Wednesday Carcinogenicity Bioassays Exhibit Hall 165 9:30 AM #1504–1521

Wednesday * Nervous System: Mechanisms Exhibit Hall 166 9:30 AM of Toxicity #1522–1553

Wednesday Biotransformation/Cytochrome Exhibit Hall 168 9:30 AM P450 II #1554–1581

Wednesday * Ecotoxicology #1582–1598 Exhibit Hall 170 9:30 AM

Wednesday Cadmium and Metallothionein Exhibit Hall 171 9:30 AM #1599–1619

Wednesday * In Vitro #1620–1635 Exhibit Hall 172 9:30 AM

Wednesday Safety Evaluation—Spontaneous Exhibit Hall 174 9:30 AM Disease and Control Parameters #1636–1642


Wednesday Developmental Toxicology of RO2 175 1:30 PM the Lung #1643–1648

Wednesday Role of Cell–Cell and Cell–Matrix RO3 176 1:30 PM Interactions in Regulation of Toxicant–Mediated Cell Death #1649–1653

Wednesday The Ubiquitin– Proteasome System RO4 176 1:30 PM as a Biological Target in Toxic Responses and Disease #1654–1658

Wednesday What Makes Metals Neurotoxic Ballroom B 177 1:30 PM in Neurodegenerative Disorders? #1659–1663


Wednesday Conflict of Interest #1678–1683 207 178 1:30 PM

Wednesday Dosimetry and Potential Impacts 220 178 1:30 PM on Reproductive/Developmental Study Design and Interpretation for Risk or Safety Assessment #1684–1689

Wednesday Skin Model Selection for Safety RO6 179 1:30 PM Assessment of Topical Drug Products: Regulatory and Industry Perspectives #1690–1694

RoundtableDate/Time Topic/Abstract # Room Page

Wednesday Conducting a Comprehensive RO8 175 12:00 PM Toxicological and Safety Evaluation of Nanomaterials: Current Challenges and Data Needs #1695–1699


Wednesday Bioinformatics: Applications to RO1 179 1:30 PM Toxicology #1700–1709

Wednesday Mechanisms of Hypersensitivity I 208 180 1:30 PM #1710–1717

Wednesday Molecular Mechanisms of RO8 181 1:30 PM Oxidative Stress #1718–1726



Wednesday * Endocrine Disruptors #1727–1759 Exhibit Hall 181 1:30 PM

Wednesday Steroid Receptors #1760–1775 Exhibit Hall 184 1:30 PM

Wednesday * Pharmaceuticals–Metabolic/ Exhibit Hall 185 1:30 PM Cancer #1776–1785

Wednesday Mechanisms of Carcinogenesis Exhibit Hall 186 1:30 PM #1786–1823

Wednesday * Cardiovascular Disease I—Gene Exhibit Hall 188 1:30 PM Expression #1824–1844

Wednesday Oxidative Stress II #1845–1864 Exhibit Hall 190 1:30 PM

Wednesday * Immunotoxicology In Vitro/ Exhibit Hall 191 1:30 PM Mechanisms #1865–1896

Wednesday Liver II #1897–1935 Exhibit Hall 193 1:30 PM

Scientific Session Index (Continued)

SESSIO

N IN

DEX




Wednesday * Neurotoxicity, Pesticides Exhibit Hall 196 1:30 PM #1936–1967

Sunset SessionsDate/Time Topic/Abstract # Room Page

Wednesday Advances in Material Safety Data 207 198 4:30 PM Sheet Communication #1664–1668

Wednesday The Safety Assessment of 208 199 4:30 PM Nutritionally Improved Food and Feed Crops #1669–1673

Wednesday Vinyl Chloride: Legacy and 220 199 4:30 PM Lessons Learned #1674–1677

Thursday


Thursday Cross–Species Toxicology in the RO4 200 8:30 AM Age of Genomics #1968–1973

Thursday Developmental Expression of 208 201 8:30 AM Human Phase I and Phase II Toxicant Metabolizing Enzymes: Impact on Early Life Stage Susceptibility #1978–1984

Thursday Systems Biology: Approaches and 220 201 8:30 AM Applications to Toxicology #1979–1984


Thursday Cellular/Molecular Mechanisms RO8 202 8:30 AM Involved in Environmental Chemicals —Induced Dopaminergic Neurotocivity and the Consequences on Neurodegenerative Diseases #1985–1989

Thursday Safety Assessment of Biological RO6 203 8:30 AM Therapeutic Products—Defining the Scientific and Regulatory Issues #1990–1995

Poster Sessions* Attended 8:30 AM–10:00 AM; otherwise attended 10:00 AM–11:30 AM.


Thursday * Alternatives to Mammalian Ballroom B 203 8:30 AM Models #1996–2023

Thursday Safety Evaluation—Safety Ballroom B 205 8:30 AM Pharmacology #2024–2032

Thursday * Persistent Organic Pollutants Ballroom B 205 8:30 AM #2033–2072

Thursday Risk Assessment II #2073–2112 Ballroom B 208 8:30 AM

Thursday * Renal Toxicology #2113–2142 Ballroom B 211 8:30 AM

Thursday Pesticides #2143–2170 Ballroom B 213 8:30 AM

Thursday * Dermal Toxicology #2171–2203 Ballroom B 215 8:30 AM

Thursday Genotoxicity #2204–2236 Ballroom B 217 8:30 AM

Thursday * Developmental Toxicology Ballroom B 219 8:30 AM Mechanisms #2237–2261

Thursday DNA and Protein Adducts Ballroom B 221 8:30 AM #2262–2275

Thursday * Apoptosis #2276–2303 Ballroom B 222 8:30 AM

Scientific Session Index (Continued)

Continuing Education

44th Annual Meetingand ToxExpo


CE

The Continuing Education Program offers a wide range of courses that coverstate-of-the-art knowledge in toxicology, as well as new developments in toxi-cology and related disciplines. Courses can be applied toward certifying andlicensing board requirements and may also be used for recertification with theAmerican Board of Toxicology (ABT). Both basic and advanced course topicsare offered. The basic course is intended to provide a broad overview of an areaor to assist individuals in learning new techniques or approaches. The advancedcourse is intended to be of interest to individuals with previous knowledge of thesubject or already working in the field.

Please Note: Each Continuing Education Course is offered in one of three timeblocks: Sunrise (7:00 AM–7:45 AM), AM (8:15 AM–12:00 NOON) or PM (1:15 PM–5:00 PM). Check the signage in the SOT registration area forroom assignments.

*The Primary Specialty Section (SS) or Regional Chapter (RC) Endorser

FUNDAMENTALS OF NANOTECHNOLOGY: CHEMISTRY,EXPOSURE, HEALTH/ ENVIRONMENTAL ASSESSMENTS ANDSOCIETAL IMPACTS

SUNRISE MINI-COURSE 1 BASIC

Chairperson(s): David B. Warheit, DuPont Haskell Laboratory, Newark, DE.

Endorsed by:Ethical Legal and Social Issues SSInhalation SS*Occupational and Public Health SSRisk Assessment SS

Nanotechnology is an emerging multidisciplinary science that deals with thecreation and use of molecules a few billionths of a meter in size. Assessing thepotential hazards of the nanomaterials in this technology, and the productsconstructed from nanoparticulates is an emerging area in toxicology and healthrisk assessment. The development of toxicity data sets and exposure assess-ments for various nanoparticles and nanomaterials is ongoing and evolving asnew particles, materials and exposure methodologies are developed. A relatedissue in toxicology and risk assessment is the extent to which nanoparticle toxi-city can be extrapolated from existing toxicology databases for macro andmicroscale particle-types. Additional information needs that are beingaddressed include the environmental and biological fate, transport, persistence,and transformation, as well as the recyclability and overall sustainability ofmanufactured nanoparticles. This sunrise lecture is designed to be a basicprimer on the fundamental chemistry and physics of engineered nanostructures.The understanding of the composition of and source generation of particlesbecomes fundamentally more important when one considers that the surfaces orsurface coatings may comprise > 50% composition of small nanoparticles (< 30nm), and herein will lie the interactions of nanoparticles with cells. Futurestudies likely will demonstrate that method of particle synthesis, surface coat-ings, aggregation potential, surface charge, and shape may be as or moreimportant than particle size in modifying biological/toxicological effects.Methods to form materials such as single-walled carbon nanotubes, fullerenes,quantum dots, nanocrystalline ceramics (e.g., titania), and nanometals will bereviewed. For each material class, the essential properties and applications willbe outlined. The tutorial will conclude with a discussion of the actual applica-tions of these high performance materials and projections for the industrygrowth over the next decade.

• The Basics of Engineered Nanomaterials for Toxicologists or Tutorial:The Fundamental Chemistry and Physics of EngineeredNanostructures, Vicki L. Colvin, Rice University, Houston, TX.

DOSE CONSIDERATIONS FOR IN VITRO STUDIES OF AIRPOLLUTANT TOXICITY

AM 02 BASIC

Chairperson(s): John B. Morris, University of Connecticut, Storrs, CT, andJeanClare Seagrave, Lovelace Respiratory Research Institute, Albuquerque,NM.

Endorsed by:In Vitro SSInhalation SS*Risk Assessment SSStudent Advisory Committee

Technological advances have made possible the investigation of the cellulareffects of air pollutants through variety of in vitro approaches. However, in orderto be relevant to human health effects following ambient exposures, thesemethods must accurately model biologically relevant exposure pathways, dosesand responses. This continuing education course will provide both theoreticaland practical information on appropriate dose selection and dosage techniquesfor in vitro studies of air pollutant toxicity. The first presentation will cover thebasic concepts of vapor dosimetry including the roles of partitioning, chemicalreactivity and local metabolism. Specific information on regional respiratorydeposition in laboratory animals and humans and its relevance to cellular micro-dosimetry will be provided. The second presentation will include specificexamples of in vitro approaches with a focus on microdosimetric considerationsfor reactive gases; in particular the potential biological impacts of surface lininglayers and their constituents will be emphasized. Basic concepts of size specificregional particle deposition and clearance will be covered in the third presenta-tion. Specific information on regional respiratory deposition efficiencies inlaboratory animals and humans and its relevance to cellular microdosimetry willbe provided. The final presentation will describe specific examples of in vitroapproaches on particle toxicity with a cellular dosimetric comparison of effectsobserved in vitro compared to those in vivo. Overall the course is aimed atproviding information not only on the importance of employing in vivo dosi-metric considerations in designing in vitro studies, but also with providing afirm conceptual foundation for the selection of relevant doses for such work.

• Dosimetric Considerations for Vapors and Gases, John B. Morris,University of Connecticut, Storrs, CT.

• In Vitro Systems for Studies of Reactive Gases, Edward Postlethwait,University of Alabama at Birmingham, Birmingham, AL.

• Dosimetric Considerations for Particles, Richard B. Schlesinger, PaceUniversity, Pleasantville, NY.

• In Vitro Systems for Studies of Particles, JeanClare Seagrave, LovelaceRespiratory Research Institute, Albuquerque, NM.



CE

SOT’s 44th Annual Meeting40

DEVELOPMENTAL TOXICOLOGY STUDIES: DESIGN,INTERPRETATION, AND RISK ASSESSMENT

AM 03 BASIC

Chairperson(s): Joseph F. Holson, WIL Research Laboratories, Inc, Ashland,OH and Ronald D. Hood, RD Hood & Associates, Toxicology Consultants,Tuscaloosa, AL.

Endorsed by:Reproductive and Developmental Toxicology SS*Risk Assessment SS

Developmental toxicity studies are among the most complex and challenging inthe field of toxicology. They entail multiple and interrelated endpoints andsystems that are rapidly changing in characteristics and in their responses totoxic insults over time. These studies inherently generate large data sets.However, because of the decline in relevant training programs, data from devel-opmental toxicity studies are often managed or interpreted by individuals withlimited backgrounds in these fields. Although published regulatory agencyguidance is available, this course will extend such guidance by presenting indetail current study designs, procedures for study evaluation, and case studies.Lectures will cover fetal endpoints including mortality, growth, visceral examsand skeletal exams, as well as endpoints of maternal toxicity and their relation-ship to developmental toxicity. Developmental toxicity will be viewed in a broadcontext, including aspects of postnatal development and multigenerationaleffects. Proper analysis of developmental toxicity data requires specific statis-tical considerations, and these will be presented. Finally, putting together all thedata from such studies for human risk assessment will be discussed.Considerations of design flexibility, endpoint sensitivities, and use of mode ofaction analysis and confirmatory studies will be included. Thus, the course willpresent key information required for understanding the biological and toxico-logical bases of findings from developmental toxicity studies and will provideguidance for analysis and interpretation.

• Evaluation of Fetal Weight, External and Visceral Anomalies inDevelopmental Toxicity Studies, Donald G. Stump, WIL ResearchLaboratories, Inc, Ashland, OH.

• Overview of Developmental Toxicity Study Designs, EndpointSensitivities, Statistical Power, Variability, and Use of HistoricalControl Data, Joseph F. Holson, WIL Research Laboratories, Inc, Ashland,OH.

• Evaluation of Skeletal Endpoints in Developmental Toxicity Studies,John M. Rogers, U.S. EPA, Research Triangle Park, NC.

• Use of Developmental Toxicity Data in Risk Assessment, Susan L.Makris, U.S. EPA, Washington, DC.

CLINICAL PATHOLOGY—THE GRANDDADDY OF BIOMARKERS

AM 04 BASIC

Chairperson(s): Thomas Monticello, Sanofi-Aventis, Bridgewater, NJ andGail Walter, Gail Walter Consultants, Kalamazoo, MI.

Endorsed by:Comparative and Veterinary SSRegulatory and Safety Evaluation SSRisk Assessment SSStudent Advisory CommitteeToxicologic & Exploratory Pathology SS*

Research for novel biomarkers of toxicity continues to grow at a rapid pace.While biomarkers of tissue injury have a long history in the discipline of clin-ical pathology, the full value of these preclinical datasets are oftentimes underand/or over interpreted by scientists not extensively trained in this discipline.This basic course will emphasize current practices in clinical pathology utilizedin drug discovery and preclinical safety studies and will also highlight advancesin more novel biomarkers of toxicity. Basic interpretation of clinical pathologyparameters will be presented in addition to factors to consider with respect toanimal model, study design and the assays themselves. Examples of hepaticbiomarkers and more recently identified biomarkers of toxicity will be high-lighted. The applicability and pitfalls of utilizing reference ranges will bediscussed, as will the approach in determining biological relevance of resultsversus statistical significance. Finally, regulatory perspectives on completedatasets and data interpretation will be addressed. This course is intended for thegeneral toxicology community to improve their understanding of clinicalpathology data and the role of clinical pathology in biomarker development.

• Clinical Pathology Techniques in Discovery, Safety Assessment andBiomarker Development, Laurie O’Rourke, Novartis, East Hanover, NJ.

• Coping with Multiple Masters: The Fine Art of Balancing ClinicalPathology and Toxicology in Preclinical Drug Development, Gail Walter,Gail Walter Consultants, Kalamazoo, MI.

• Avoiding Pitfalls in the Interpretation of the Hemogram and otherClinical Pathology Assays Conducted for Toxicology Testing, NancyEverds, Dupont Haskell Laboratory, Newark, DE.

• Regulatory Perspectives on Clinical Pathology Data Analysis, KennethHastings, CDER, U.S. FDA, Rockville, MD.




CE

IMMUNOLOGY FOR TOXICOLOGISTS

AM 05 BASIC

Chairperson(s): Ian Kimber, Syngenta Central Toxicology Laboratory,Macclesfield,Cheshire, United Kingdom and Dori R. Germolec, NationalInstitute for Environmental Health Sciences, Research Triangle Park, NC.

Endorsed by:Immunotoxicology SS*Risk Assessment SS

The adaptive immune system that is found in mammals comprises a dedicatedinteracting system of tissues, cells and molecules that work in concert to providespecific immune responses and host resistance to pathogenic microorganismsand transformed cells. Specific immunity is supplemented by, and works inharmony with, the phylogenetically more ancient innate immune system.Immunotoxicology describes the study of adverse health effects that may resultfrom the interaction of xenobiotics with one or more components of the immunesystem. Such health effects may take a variety of forms. These include frankimmunotoxicity where there is functional impairment of the immune system.The concern here is that compromised immune function may translate into anincreased susceptibility to infectious and/or malignant disease. A second poten-tial consequence of the interaction of chemicals or proteins with the immunesystem is allergy; defined as the adverse health effects that may arise from thestimulation of a specific immune response. Allergic disease may take a varietyof forms, those of greatest significance for toxicologists being skin sensitizationand allergic contact dermatitis, allergic sensitization of the respiratory tract,food allergy and idiosynctratic allergic drug reactions. Finally, xenobiotics havebeen implicated in the induction or exacerbation of autoimmune reactions andautoimmune disease. This course will provide a grounding in fundamental andclinical aspects of immunology, and will describe the basic elements immuno-toxicity, allergy and autoimmunity. The objective is deliver an accessible guideto the immune system and immunotoxicology for general toxicologists.

• An Introduction to Immunology: Fundamental and Clinical Aspects,Ian Kimber, Syngenta Central Toxicology Laboratory, Macclesfield,Cheshire, United Kingdom.

• Elementary Immunotoxicology, Robert House, DynPort VaccineCompany, Frederick, MD.

• Allergy and Allergic Disease, MaryJane Selgrade, U.S. EPA, ResearchTriangle Park, NC.

• Autoimmunity and Autoimmune Disease, Dori R. Germolec, NationalInstitute for Environmental Health Sciences, Research Triangle Park, NC.

EVALUATION OF CARDIAC DRUG TOXICITY INPHARMACEUTICAL DISCOVERY AND DEVELOPMENT

AM 06 (REPEATS AS PM 12) BASIC

Chairperson(s): Brian Short, Allergan, Irvine, CA and Y. J. Kang, Universityof Louisville, Louisville, KY.

Endorsed by:Comparative and Veterinary SSHESI Biomarkers Technical CommitteeMechanisms SSRegulatory and Safety Evaluation SSStudent Advisory CommitteeToxicologic and Exploratory Pathology SS

The heart is an important potential target organ to evaluate in nonclinical andclinical studies during drug development as well as a therapeutic site of actionfor many cardiovascular diseases. There are examples in almost every thera-peutic class of drugs that produced unanticipated cardiotoxicity leading tomarket withdrawal or cessation of development. Toxicologists are an integralpart of an interdisciplinary group, including physiologists, pharmacologists,pathologists, clinicians, and regulators, which assess cardiac safety. As such,toxicologists play a critical role in the screening of pharmaceutical agents forcardiotoxicity as well as in establishing an adequate margin of safety andworking basis for monitoring therapeutic endpoints and clinical safety of trialparticipants. The goal of this continuing education course is to illustrate the inte-gration of physiology, pharmacology, toxicology, and pathology of the heartaddressing both recent scientific advances and practical knowledge in pharma-ceutical company setting. This course will cover in vitro and in vivo models ofdrug-induced cardiac injury and recent advances in biomarkers of cardiac injuryto improve the strategy for detection and nonclinical and clinical monitoring ofdrug-related cardiotoxicity. This CE course will provide current understandingof the physiology of the heart with a focus on normal and drug-induced distur-bances in cardiac electrophysiology and cardiac function, as well as testingstrategies for assessing potential cardioactive drug candidates prior to entry intoclinical trials. It will also cover basic and advanced knowledge of pathology ofthe heart, including a review of cardiac pathological evaluation, and providecase examples of the integration of physiological and pathological parametersand risk assessment to humans. Biochemical, cellular and molecular mecha-nisms of cardiac toxicity, including recent work in experimental animal studiesand novel approaches directed toward understanding mechanisms of drug-induced cardiac injury, cardiomyopathy and cardiac hypertrophy will bepresented. Finally, biomarkers of drug-induced cardiac injury will be discussed.This will include a review of the findings of the Expert Working Group onBiomarkers of Drug-Induced Cardiac Toxicity, an in-depth look at serumtroponins, and related work currently in progress under the ILSI-sponsoredSubcommittee on the Development and Application of Biomarkers of Toxicity.

• Physiological Basis for Cardiac Drug Toxicity and Evaluation, Robyn L.Phelps, Allergan, Irvine, CA.

• Integrating Cardiac Pathology into Drug Discovery and Development,Calvert Louden, AstraZeneca Pharmaceuticals, Wilmington, DE.

• Mechanisms of Drug-Induced Cardiotoxicity, Y. J. Kang, University ofLouisville, Louisville, KY.

• Biomarkers of Drug-Induced Cardiac Toxicity, Malcolm J. York,GlaxoSmithKline, Ware, Hertfordshire, United Kingdom.



CE


INTERNATIONAL HARMONIZATION OF TECHNICALREQUIREMENTS FOR CONDUCTING NON-CLINICAL SAFETY STUDIES OF HUMAN PHARMACEUTICALS: GUIDELINES, CASESTUDIES, AND CHALLENGES

AM 07 (REPEATS AS PM 13) BASIC

Chairperson(s): Rakesh Dixit, Merck Research Laboratories, West Point, PA.

Endorsed by:Carcinogenesis SS*Regulatory & Safety Evaluation SSRisk Assessment SS

The International Conference on Harmonization of Technical Requirements forRegistration of Pharmaceuticals for Human Use (ICH) was established in 1990to standardize and harmonize technical requirements for the world-widemarketing approval of human pharmaceuticals. The six party ICH comprises theregulatory agencies and research-based pharmaceutical industrial organizationsfrom three major geographical areas, the United States, the European Union andthe Japan. The major goals of the ICH process are to minimize unique regionalrequirements, reduce the duplication of non-clinical toxicology and clinicaltesting requirements, and to accelerate the global development, registration andmarketing of human pharmaceuticals in a cost-effective manner. Under Safetytopics (non-clinical safety), 15 major guidelines have been harmonized andimplemented through three major global regulatory agencies. These includeguidelines on technical requirements for genotoxicity, toxicity, carcinogenicity,reproductive and development toxicity, biotechnology safety, toxicokinetics,safety pharmacology and joint safety and efficacy. This course is designed toprovide a thorough understanding of the rationale behind ICH guidelines andthe utility of the ICH guidelines in accelerating and global harmonization ofsafety evaluation of pharmaceuticals. The presentations will also highlight casestudies with detailed examples, and experience in conducting non-clinical ICHsafety studies. The presentations will also discuss the challenges, and problemsencountered due to the differences in the interpretation, and the acceptance ofthe ICH Guidelines by the practicing regulatory organizations, reviewers and thetraditional practices of specific geographical areas.

• Guidelines on Genotoxicity Testing: Case Studies, Study Interpretationand Challenges, Sheila Galloway, Merck Research Laboratories, WestPoint, PA.

• Developmental and Reproductive Toxicology Testing: Case StudiesStudy Interpretation and Challenges, Maureen Fesuton, Sanofi-Synthelabo, PA.

• Chronic Toxicity, Carcinogenicity and Toxicokinetics Guidelines: CaseStudies and Challenges, Rakesh Dixit, Merck Research Laboratories,West Point, PA.

• U.S. FDA’s Experience and Guidance Related to ICH SafetyGuidelines, David Jacobson-Kram, U.S. FDA, Rockville, MD.

MALE REPRODUCTIVE HAZARD IDENTIFICATION AND RISKASSESSMENT IN PHARMACEUTICAL DEVELOPMENT (WHAT DOYOU DO NOW THAT YOU HAVE A SIGNAL?)

PM 08 ADVANCED

Chairperson(s): Michael W. Conner, Theravance, Inc., South San Francisco,CA and Robert E. Chapin, Pfizer, Inc., Groton, CT.

Endorsed by:Reproductive and Developmental Toxicology SSRegulatory and Safety Evaluation SSToxicologic & Exploratory Pathology SS

In the preclinical development of pharmaceuticals, there are numerous opportu-nities to observe effects on the male reproductive system. There are relevantendpoints in both routine repeated-dose toxicity studies and in the develop-mental and reproductive toxicity studies. In recent years methods foridentification of male reproductive injury have expanded well beyond the tradi-tional endpoints of fecundity in rodent fertility studies and routine microscopicexamination of testes in repeated-dose and reproductive toxicity studies. Thereis an expectation, for instance, that pathologists will examine testes with knowl-edge of and reference to the stages of the seminiferous epithelium. Assessmentof number, motility and frequency of morphological abnormalities in epidy-dimal sperm has become routine in rodent fertility studies. Recently, someemphasis has also been placed on identification of biomarkers for testicularinjury. The next steps following identification of a signal are ill defined. Thepurpose of this continuing education course is to address what types of signalsare commonly observed and to present a rationale for interpreting these datawith regard to risk assessment for volunteers and patients. The speakers in thiscourse will place an emphasis on case studies and will provide their proposalsfor subsequent preclinical and/or clinical investigations. We will deal with theissue of reversible vs. irreversible injury, and review the latest data on the differ-ences between these two. We will hear case reports on investigative mechanisticstudies and when they are best pursued, and the course will close with a reviewof the considerations that should be addressed when risk-assessing male repro-ductive findings.

• Early Signal Identification, Dianne Creasy, Huntingdon Life Sciences,East Millstone, NJ.

• Signals in Primates—Reversible and Irreversible Injury, KimBoekelheide, Brown University, Providence, RI.

• Further Characterization of Male Reproductive Injury—Case Studies,Patrick J. Wier, GlaxoSmithKline, King of Prussia, PA.

• Safety Assessment for Male Reproductive Injury, Robert E. Chapin,Pfizer, Groton, CT.




CE

DEVELOPMENT AND INTERPRETATION OF TOXICOKINETICDATA FOR RISK AND SAFETY ASSESSMENT

PM 09 ADVANCED

Chairperson(s): John Lipscomb, U.S. EPA / ORD, Cincinnati, OH and JosBessems, TNO, Zeist, Netherlands.

Endorsed by:Regulatory and Safety Evaluation SSRisk Assessment SS*Student Advisory Committee

Drug development and environmental health risk assessment activities are basedon knowledge of chemical disposition and tissue interactions, that may be sepa-rately considered as toxicokinetics (TK) and toxicodynamics (TD). Eachactivity is initiated with valuation of basic toxicity information, including char-acterizing effective doses and the dose-response relationship identifying criticalorgans, tissues and processes; examining metabolic characteristics and the toxicnature of metabolites. Each activity culminates with the assessment of TK andTD relative to the concentration/dose-response relationship. This basic contin-uing education course is intended for the general toxicologist desiring toincrease the use of TK data to build compound dossiers, and to address theneeds of scientists designing toxicity and pharmacokinetic studies, preclinicaland clinical studies, and conducting safety and/or risk assessments. Fourlectures will be presented; content will address the design, conduct and evalua-tion of studies to inform an understanding of chemical disposition andeffectiveness in the biological system. Instruction will be given on the consider-ations of doses and concentrations used in whole-animal toxicity and ADMEstudies and in in vitro investigations; the biochemical basis of chemical metab-olism and the considerations and assumptions necessary to interpret metabolismfindings; best use of TK data to inform doses intended for use in TD studies;extrapolations of effective doses between and among species through the use ofdefault and chemical-specific uncertainty/adjustment factors; available guid-ance on uncertainty factor derivation for human health risk assessment;overview of PBPK modeling and its application to extrapolations of dose, routeand duration, between and among species; and the basis and results of choice ofclassical or PBPK modeling for drug development and risk assessment.

• Use of ADME Data in Toxicity Study Design, Jos Bessems, TNO, Zeist,Netherlands.

• Combining Toxicokinetic and Toxicodynamic Data for Application inDrug Development, Rakesh Dixit, Merck Research Laboratories, WestPoint, PA.

• Use of Compound Specific and General Kinetic Data in Human RiskAssessment, John Lipscomb, U.S. EPA / ORD, Cincinnati, OH.

• Physiologically Based Pharmacokinetic Modeling, Hugh Barton,Research Triangle Park, NC.

PHOTOTOXICITY: CURRENT CONCEPTS, EXPERIMENTALDESIGNS, AND REGULATORY EXPECTATIONS

PM 10 BASIC

Chairperson(s): Joseph Tigner, Purdue Pharma L.P., Ardsley, NY and VincentA. Murphy, P&G Pharmaceuticals, Inc., Cincinnati, OH.

Endorsed by:Regulatory and Safety Evaluation SS*Risk Assessment SS

Exposure to solar ultraviolet and visible radiation produces acute and chronicskin damage. Chemicals, including pharmaceutical agents, may exacerbate sucheffects following topical or systemic exposure. The aim of phototoxicologicaltesting is to predict the likelihood of such events using various in vivo and invitro models. The purpose of this course is to familiarize toxicologists with thebasic concepts of phototoxicological testing. This is especially important in lightof recent U.S. and European regulatory guidances relating to photosafetytesting. The program will describe the comparative anatomy, physiology, andbasic photobiology of the skin, the basic principles and experimental designsused in phototoxicity testing in nonclinical species and people as well as in vitromodels. The course will also address the most recent regulatory guideline fromthe U.S. FDA regarding phototoxicity testing.

• Effect of Light on the Structure and Function of Skin, J.F. Nash, TheProcter & Gamble Co., Cincinnati, OH.

• Phototoxicity, Photocarcinogenicity, and Photoallergy. Study Designsand Issues, P. Donald Forbes, Argus Research-Charles River, Horsham,PA.

• Drug Phototoxicity in Humans: A Randomized Controlled TrialMethodology, James Ferguson, Dundee, Scotland.

• CDER/FDA Photosafety Guidance for Industry, Abigail Jacobs, U.S.FDA/CDER, Rockville, MD.



CE


SOMETHING OLD, SOMETHING NEW; TRADITIONAL AND NOVELBIOMARKERS OF RENAL INJURY

PM 11 BASIC

Chairperson(s): Susan Emeigh Hart, AstraZeneca Pharmaceuticals,Wilmington, DE and Syril Pettit, ILSI Health and Environmental SciencesInstitute (HESI), Washington, DC.

Endorsed by:Risk Assessment SSToxicologic & Exploratory Pathology SS*

Because the kidney is an important target organ of toxicity, there is a need forsensitive, specific and non-invasive assays that can be used to detect low-level,potentially reversible renal injury in both animal toxicology studies and the clin-ical setting. Most of the available techniques do not allow identification of thesegment(s) of the kidney affected by a toxicant. Better understanding of thepathophysiology of nephrotoxic processes, combined with information arisingfrom genomic, proteomic and molecular biologic assessment of the effects ofnephrotoxic chemicals has led to the identification of several promising newcandidates that might serve as sensitive, segment-selective biomarkers ofnephrotoxicity that can be applied readily in both the preclinical and clinicalsettings with adequate testing and validation. This basic CE course will providean overview of renal structure and function, discuss the appropriate use andlimitations of traditional clinical pathology assessment of renal injury, anddescribe the processes necessary for appropriate validation and subsequentregulatory acceptance of a novel biomarker. The final two speakers will describethe novel biomarker candidates under consideration by the NephrotoxicityWorking Group of the ILSI-HESI Technical Committee on the Development andApplication of Biomarkers of Toxicity. The first of these will provide anoverview of novel biomarkers for proximal tubular injury while the second willdiscuss the pathophysiology of renal papillary necrosis and how it relates to theidentification of novel biomarkers of papillary injury.

• Technical and Regulatory Issues in Biomarker Selection andValidation, James T. MacGregor, Toxicology Consulting Services, Arnold,MD.

• Classical Clinical Pathology Approaches to the Assessment of RenalStructure and Function, Denise Bounous, Bristol-Meyers SquibbCompany, Princeton, NJ.

• Emerging Biomarkers of Renal Proximal Tubular Injury, Ernie Harpur,Sanofi-Synthelabo Research, Malvern, PA.

• Emerging Biomarkers of Renal Papillary Necrosis, Susan Emeigh Hart,AstraZeneca Pharmaceuticals, Wilmington, DE.

EVALUATION OF CARDIAC DRUG TOXICITY INPHARMACEUTICAL DISCOVERY AND DEVELOPMENT

PM 12 (REPEATS AS AM 06) BASIC

Chairperson(s): Brian Short, Allergan, Irvine, CA and Y. J. Kang, Universityof Louisville, Louisville, KY.

Endorsed by:Comparative and Veterinary SSHESI Biomarkers Technical CommitteeMechanisms SSRegulatory and Safety Evaluation SSStudent Advisory Committee

The heart is an important potential target organ to evaluate in nonclinical andclinical studies during drug development as well as a therapeutic site of actionfor many cardiovascular diseases. There are examples in almost every thera-peutic class of drugs that produced unanticipated cardiotoxicity leading tomarket withdrawal or cessation of development. Toxicologists are an integralpart of an interdisciplinary group, including physiologists, pharmacologists,pathologists, clinicians, and regulators, which assess cardiac safety. As such,toxicologists play a critical role in the screening of pharmaceutical agents forcardiotoxicity as well as in establishing an adequate margin of safety andworking basis for monitoring therapeutic endpoints and clinical safety of trialparticipants. The goal of this continuing education course is to illustrate the inte-gration of physiology, pharmacology, toxicology, and pathology of the heartaddressing both recent scientific advances and practical knowledge in pharma-ceutical company setting. This course will cover in vitro and in vivo models ofdrug-induced cardiac injury and recent advances in biomarkers of cardiac injuryto improve the strategy for detection and nonclinical and clinical monitoring ofdrug-related cardiotoxicity. This CE course will provide current understandingof the physiology of the heart with a focus on normal and drug-induced distur-bances in cardiac electrophysiology and cardiac function, as well as testingstrategies for assessing potential cardioactive drug candidates prior to entry intoclinical trials. It will also cover basic and advanced knowledge of pathology ofthe heart, including a review of cardiac pathological evaluation, and providecase examples of the integration of physiological and pathological parametersand risk assessment to humans. Biochemical, cellular and molecular mecha-nisms of cardiac toxicity, including recent work in experimental animal studiesand novel approaches directed toward understanding mechanisms of drug-induced cardiac injury, cardiomyopathy and cardiac hypertrophy will bepresented. Finally, biomarkers of drug-induced cardiac injury will be discussed.This will include a review of the findings of the Expert Working Group onBiomarkers of Drug-Induced Cardiac Toxicity, an in-depth look at serumtroponins, and related work currently in progress under the ILSI-sponsoredSubcommittee on the Development and Application of Biomarkers of Toxicity.

• Physiological Basis for Cardiac Drug Toxicity and Evaluation, Robyn L.Phelps, Allergan, Irvine, CA.

• Integrating Cardiac Pathology into Drug Discovery and Development,Calvert Louden, AstraZeneca Pharmaceuticals, Wilmington, DE.

• Mechanisms of Drug-Induced Cardiotoxicity, University of Louisville,Louisville, KY.

• Biomarkers of Drug-Induced Cardiac Toxicity, Malcolm J. York,GlaxoSmithKline, Ware, Hertfordshire, United Kingdom.




CE

INTERNATIONAL HARMONIZATION OF TECHNICALREQUIREMENTS FOR CONDUCTING NON-CLINICAL SAFETYSTUDIES OF HUMAN PHARMACEUTICALS: GUIDELINES, CASESTUDIES, AND CHALLENGES

PM 13 (REPEATS AS AM 07) BASIC

Chairperson(s): Rakesh Dixit, Merck Research Laboratories, West Point, PA.

The International Conference on Harmonization of Technical Requirements forRegistration of Pharmaceuticals for Human Use (ICH) was established in 1990to standardize and harmonize technical requirements for the world-widemarketing approval of human pharmaceuticals. The six party ICH comprises theregulatory agencies and research-based pharmaceutical industrial organizationsfrom three major geographical areas, the United States, the European Union andthe Japan. The major goals of the ICH process are to minimize unique regionalrequirements, reduce the duplication of non-clinical toxicology and clinicaltesting requirements, and to accelerate the global development, registration andmarketing of human pharmaceuticals in a cost-effective manner. Under Safetytopics (non-clinical safety), 15 major guidelines have been harmonized andimplemented through three major global regulatory agencies. These includeguidelines on technical requirements for genotoxicity, toxicity, carcinogenicity,reproductive and development toxicity, biotechnology safety, toxicokinetics,safety pharmacology and joint safety and efficacy. This course is designed toprovide a thorough understanding of the rationale behind ICH guidelines andthe utility of the ICH guidelines in accelerating and global harmonization ofsafety evaluation of pharmaceuticals. The presentations will also highlight casestudies with detailed examples, and experience in conducting non-clinical ICHsafety studies. The presentations will also discuss the challenges, and problemsencountered due to the differences in the interpretation, and the acceptance ofthe ICH Guidelines by the practicing regulatory organizations, reviewers and thetraditional practices of specific geographical areas.

• Guidelines on Genotoxicity Testing: Case Studies, Study Interpretationand Challenges, Sheila Galloway, Merck Research Laboratories, WestPoint, PA.

• Developmental and Reproductive Toxicology Testing: Case StudiesStudy Interpretation and Challenges, Maureen Fesuton, Sanofi-Synthelabo, PA.

• Chronic Toxicity, Carcinogenicity and Toxicokinetics Guidelines: CaseStudies and Challenges, Rakesh Dixit, Merck Research Laboratories,West Point, PA.

• U.S. FDA’s Experience and Guidance Related to ICH SafetyGuidelines, David Jacobson-Kram, U.S. FDA, Rockville, MD.


CE


Notes:

SATU

RDAY

/ S

UN

DAY



Saturday Afternoon, March 52:00 PM to 5:00 PMRoom 211

COMMITTEE CHAIR ORIENTATION

If you will be a Committee Chairperson in 2005–2006, please make plans toattend the Committee Chairperson Meeting scheduled for 2:00 PM–5:00 PM,Saturday, March, 5. With new committee assignments taking effect on May 1,2005, the meeting is intended to provide new (and current, if desired) chairper-sons with a basic tutorial on the SOT structure, operation, and strategicdirection. For additional information, please contact SOT Headquarters.

Saturday Afternoon, March 55:00 PM to 7:00 PMSheraton Hotel, Napoleon D1

CRAD SEMINAR: CAREER MOVE: AN AMALGAM OFOPPORTUNITIES AND UNCERTAINTIES

Chairperson(s): Mitzi Nagarkatti, Virginia Commonwealth University,Richmond, VA and Julia Kimbell, CIIT Centers for Health Research, ResearchTriangle Park, NC.

Endorsed by:Career Resource and Development Committee (formerly PlacementCommittee)Education CommitteeWomen in Toxicology SS

This workshop is targeted to those seeking career advancement opportunitiesincluding graduate students, post-doctoral trainees as well as entry-level, mid-career and established professionals in all employment sectors for toxicologists.The session will address the major issues that are faced particularly prior to jobseeking such as marketing one-self, critical decision-making and negotiatingoffers. Emphasis will also be placed on the challenges and angst involved inchange of scientific career paths across academia, government, industry,contract jobs and consultancy.

In the first part of the session, the types of post-doctoral opportunities availableand funding resources for such mentored training will be presented. If oneaccepts a job without undertaking post-doctoral training, how to update one’sprofessional skills will also be addressed. The latter part of the session will dealwith the details involved in accepting the first independent investigator positionas well as what is involved in moving from academia to non-academic positionsand vice versa.

• Time of Angst: What to Look for in Seeking Post-Doctoral Training,MaryJane Selgrade, EPA, Research Triangle Park, NC.

• To Be or Not to Be: Is Post-Doctoral Training Essential for Non-Academic Positions?, Justin Teeguarden, Pacific Northwest NationalLaboratories, Richland, WA.

• Welcome to the Academic World: Moving Up the Academic Ladder,Norbert Kaminski, Michigan State University, East Lansing, MI.

• Back to the Grind: Facing Challenges of Transition from Non-Academic to Academic, Raymond Yang, Colorado State University, FortCollins, CO.

• Moving to Different Pastures: Adapting to Job Switch from Academiato a Non-Academic Position, Myrtle Davis, Eli Lilly & Company,Greenfield, IN.

Saturday Afternoon, March, 56:15 PM to 9:00 PMSheraton Hotel, Oak Alley

UNDERGRADUATE EDUCATION PROGRAM FOR MINORITYSTUDENTS

Chairperson(s): Rosita Proteau, SCMI Chair, Oregon State University,Corvallis, OR and Alice Villalobos, University of Rochester, Rochester, NY.

Sponsored by:Education CommitteeEducation Subcommittee for Minority Initiatives

The objective of this program is to introduce minority undergraduate studentsand their advisors to toxicology and to encourage preparation for graduate studyand pursuit of careers in the discipline. The opening session will provide anintroduction to toxicology and promote interaction of the students with theirpeers, students who had participated in the program in the past, and SOT toxi-cologist hosts.

5:30 PM–6:00 PM Orientation for SOT Hosts, Peer Mentors, andAdvisors

6:00 PM–6:15 PM Registration for Students

6:15 PM–7:00 PM Opening Event

7:15 PM Dinner

7:45 PM–8:30 PM Opening Lecture: What is Toxicology?

Craig Marcus, University of New Mexico,Albuquerque, NM.

8:30 PM–9:00 PM Dessert and Networking

Sunday

Sunday Morning, March 68:00 AM to 5:00 PMRoom 213

UNDERGRADUATE EDUCATION PROGRAM

Chairperson(s): Rosita Proteau, SCMI Chair, Oregon State University,Corvallis, OR and Alice Villalobos, University of Rochester, Rochester, NY.


A series of special introductory toxicology lectures will be presented to under-graduate students registered for this program, including the participants in theUndergraduate Minority Education Program for Minority Students. This will befollowed by sessions providing information for successful application to grad-uate school, and the opportunity to meet with directors of academic toxicologyprograms and internship sponsors. The goal is to encourage undergraduatestudents to prepare for graduate study and pursuit of careers in toxicology.

8:00 AM Introductions and Special Toxicology Lectures I

8:15 AM–8:45 AM Nanotechnology and Related Toxicology

Program DescriptionScientific Sessions and Special Events will be held at the Ernest N. Morial Convention Center unless otherwise listed.

SATURD

AY / SUN

DAY

Program Description



Martin Philbert, University of Michigan, AnnArbor, MI.

8:45 AM–9:15 AM Forensic Toxicology

William J. George, Tulane University School ofMedicine, New Orleans, LA.

9:15 AM–9:45 AM Break and Discussion at Poster Boards with FirstSpeakers

Special Toxicology Lectures II

9:45 AM–10:15 AM Contaminants, Endocrine Disruption, andWildlife: Lessons from the Swamp

Lou Guillette, University of Florida, Gainesville,FL.

10:15 AM–10:30 AM TBA

Speaker TBA

Interactive Session

10:30 AM–11:30 AM Effects of TCDD on Mammary Glands andLactation

B. Paige Lawrence, Washington State University,Pullman, WA.

11:30 AM–12:30 PM Lunch and Discussion at Poster Boards

For Students

12:30 PM–2:45 PM Break out Sessions, 40-minute concurrentsessions, each repeated three times (12:30 PM–1:10 PM, 1:15 PM–1:55 PM, 2:00 PM–2:40 PM)

A) What is Graduate School and What Can IExpect?

Damani Parran, Virginia/Maryland RegionalCollege of Veterinary Medicine, Blacksburg, VA.

Adrian Nanez, University of Louisville,Louisville, KY.

B) An Academic Advisor’s Perspective on How toGet into Graduate School

Heather Kleiner, Lousiana State University,Shreveport, LA.

C) What Do I Say? Suggestions for Discussionwith Program Directors, Internship Hosts, PosterPresenters

Vicente Santa Cruz, Chevron Phillips ChemicalCompany LP, Woodlands, TX.

For Advisors

12:30 PM–1:10 PM Tips for Advising Prospective Graduate Students

Rick Schnellmann, Medical University of SouthCarolina, Charleston, SC.

1:15 PM–1:55 PM An Admissions Committee Perspective on StudentDiversity

Mary Ann Smith, University of Texas School ofPublic Health, Houston, TX.

2:00 PM–2:40 PM Mentoring Diverse Undergraduates

Antonio Baines, University of North Carolina-Chapel Hill, NC.

All Participants

3:00 PM–5:00 PM Open Time with Academic Toxicology ProgramDirectors and Internship Sponsors

Sunday Evening, March 65:15 PM to 6:30 PMRoom 220

AWARDS PRESENTATION

Join the Society in recognizing and honoring distinguished toxicologists as theyreceive prestigious awards at the SOT Awards Presentation.

Sunday Evening, March 66:30 PM to 7:30 PMLa Louisiane Ballroom

WELCOMING RECEPTION

Join us on Sunday, March 6, 2005, as SOT kicks-off its 44th Annual Meeting.This will be a memorable evening of reminiscing with friends, good fun, andlooking to the future of SOT. Please join the Society in this inaugural event ofthe Annual Meeting. Enjoy complimentary hors d’oeuvres; a cash bar will beavailable.

Sunday Evening, March 67:00 PM to 8:00 PMRoom 215

25-YEAR (OR MORE) MEMBER RECEPTION

Have you been a member of the Society of Toxicology for 25 years (or more)?If so, please consider joining your colleagues in celebration and recognition ofthe scientists who established the Society.

Sunday Evening, March 67:30 PM to 8:30 PMHilton Riverside, Grand Ballroom A

STUDENT/POST-DOCTORAL FELLOW MIXER

All students and post-docs are invited to network at this fun-filled reception.Refreshments will be provided by SOT and sponsors — a cash bar will also beavailable. Meeting Badges and tickets are required.

Program Description



MO

ND

AY

Monday Morning

Monday Morning, March 77:30 AM to 3:00 PMRoom 214

UNDERGRADUATE EDUCATION PROGRAM FOR MINORITYSTUDENTS

Chairperson(s): Rosita Proteau, SCMI Chair, Oregon State University,Corvallis, OR.

Sponsored by:Education Committee Education Subcommittee for Minority Initiatives

7:30 AM–8:00 AM Breakfast for Students, Advisors, Peer Mentors,and SOT Hosts

8:15 AM–9:15 AM Plenary Lecture: Science, Policy, and Regulationat the White House Office of Information andRegulatory Affairs, John D. Graham, Office ofInformation and Regulatory Affairs, OIRA

9:30 AM–11:30 AM Special Poster Session for Visiting Students

11:45 AM–1:00 PM Closing Session

1:00 PM–3:00 PM Evaluation Focus Groups

Monday Morning, March 78:30 AM to 9:15 AMLa Louisiane Ballroom

PLENARY LECTURE: SCIENCE, POLICY, AND REGULATION ATTHE WHITE HOUSE OFFICE OF INFORMATION ANDREGULATORY AFFAIRS

Lecturer: John D. Graham, Administrator, Office of Management and Budget,OIRA.

John D. Graham, PhD, is Administrator of the Office of Information andRegulatory Affairs within the White House Office of Management and Budget.As OIRA Administrator, Dr. Graham has pursued an agenda of “smarter regu-lation.” This means that the office is neither pro-regulation nor anti-regulation.OIRA seeks to accelerate the adoption of sensible rules, modify existing rulesto make them more effective and less costly, and rescind outdated rules whosebenefits do not justify their costs. Under Dr. Graham’s leadership, OIRA hasmade changes in many areas to increase the reliance on sound science. Theseinitiatives include government-wide Information Quality Guidelines, guidanceon Peer Review, and a revised circular on Regulatory Analysis for benefits andcosts of regulations. Dr. Graham will talk about these initiatives, other OIRAactivities, and also share with SOT ways in which members of the public canconstructively engage in the process of bringing sound science to the policyarena.

Monday Morning, March 79:30 AM to 11:30 AMExhibit Hall A

POSTER SESSION FOR VISITING STUDENTS

Chairperson(s): Rosita Proteau, SCMI Chair, Oregon State University,Corvallis, OR and Javier Avalos, TopTox, Sacramento, CA.


This poster session is part of the Undergraduate Education Program forMinority Students. All are welcome to view the specially selected presentationswhich provide an overview of research in toxicology and demonstrate the diver-sity within the discipline.

Monday Morning, March 79:30 AM to 12:00 NOONRoom RO4

SYMPOSIUM SESSION: THE FUTURE OF MOLECULAR GENETICTHERAPEUTICS

Chairperson(s): David Monteith, Lilly Research Laboratories, Greenfield, INand Vijay Reddy, Lilly Research Laboratories, Greenfield, IN.

Endorsed by:Comparative and Veterinary SSRegulatory and Safety Evaluation SS*Student Advisory Committee

During the last decade the decoding of the human genome has provided excitingpossibilities for the treatment of human disease. The promise of gene therapyand antisense have stirred the imagination to the potential of redirectingabnormal cellular processes. These therapies provide potential advantages inspecificity to gene targets and selectivity for protein intervention in somedisease targets that are often considered ‘undruggable’ with traditionalchemotherapies. To date, these technologies have provided interesting technolo-gies as research tools to gain perspective with respect to effects of varioustargets; in particular antisense strategies using single-strand and siRNA providetools to validate molecular targets in disease pathways. These antisenseapproaches utilize different mechanisms (i.e., RISK complex and RNase H) toreduce a target protein in a manner not achievable with a small moleculeapproach. Gene therapy has posed the potential to treat and possibly cure diseaseby replacing lost function with the insertion of a normal gene. Currently, thereare numerous antisense and gene therapy clinical candidates in development bycorporate sponsors as well as academic centers and investigators. The selectionof disease candidates and targets is complex. The administration, delivery, cellpermeability, and pharmacokinetic and pharmacodynamic attributes haveplayed a critical role in the development of these therapies. This symposium willcover the biologic and safety hurdles these therapies have faced and the solu-tions that have been developed to evaluate these molecules in patients. Thesymposium will consist of an expert panel of presenters involved in the scienceand development issues surrounding molecular genetic therapies.

#13 9:30 THE FUTURE OF MOLECULAR GENETICTHERAPEUTICS. D. Monteith and V. Reddy. Eli Lillyand Company, Greenfield, IN.

#14 9:40 GENE THERAPY: A SIMPLE CONCEPT WITHCOMPLEX CHALLENGES. R. M. Lyons. Self-Employed, Gaithersburg, MD.

Program Description


MO

ND

AY


#15 10:15 DEVELOPMENT OF SHORT INTERFERINGRNAS (SIRNAS) AS POTENTIALTHERAPEUTICS. P. A. Pavco. Development, SirnaTherapeutics, Inc., Boulder, CO. Sponsor: J. Lockridge.

#16 10:50 ANTISENSE THERAPEUTICS: PROGRESS INTHE DEVELOPMENT OF A NOVELTHERAPEUTIC PLATFORM. S. P. Henry and A. A.Levin. Toxicology, Isis Pharmaceuticals, Carlsbad, CA.

#17 11:25 CLINICAL CONSIDERATIONS IN THEDEVELOPMENT OF MOLECULAR THERAPIESFOR CANCER. M. F. Burgess. Lilly Research Centre,Windlesham, Surrey, United Kingdom. Sponsor: D.Monteith.


SYMPOSIUM SESSION: INHALATION EXPOSURE AND SYSTEMICIMMUNOTOXICITY: MECHANISMS LINKING THE LUNG ANDIMMUNE SYSTEM

Chairperson(s): MaryJane Selgrade, U.S. EPA, Research Triangle Park, NCand Judy T. Zelikoff, New York University, Environmental Medicine, New York,NY.

Endorsed by:Immunotoxicology SSInhalation SSRisk Assessment SSStudent Advisory Committee

Although toxicity to the lung and cardiovascular system are the most frequentlystudied targets following inhalation exposure, suppression of systemic immuneresponses has been observed following exposure to a number of diversecompounds. Defects in a variety of immune effector mechanisms have beenobserved. Frequently, these effects are not a direct result of exposure of immunetargets to the chemical or its metabolites, but involve instead the production ofmediators in the lung that circulate widely and/or interactions with the nervoussystem. Often these exposures are to complex mixtures and the active compo-nents as well as pharmacokinetics are uncertain. Many of these issues have beenconsidered in recent studies of JP-8 Jet fuel, Sarin, Tobacco smoke, and differentgasoline formulations, all of which suppress systemic immune response andhave the potential to impact susceptibility to infectious disease and tumor chal-lenge in rodents. These studies have implications for public health, homelandsecurity, industrial hygiene, and indoor environments. This symposium is asequel to a 2004 symposium Modulation of Host Defenses by Ambient andSource Particulate Air pollutants which focused on pulmonary immuneresponses and infections

#18 9:30 OVERVIEW INHALATION EXPOSURE ANDSYSTEMIC IMMUNOTOXICITY:MECHANISMS LINKING THE LUNG ANDIMMUNE SYSTEM. M. Selgrade1 and J. Zelikoff2.1NHEERL, U.S. EPA, Research Triangle Park, NC and2Department of Environmental Medicine, New YorkUniversity School of Medicine, Tuxedo, NY.

#19 9:35 INTRODUCTION: INHALATION EXPOSUREAND SYSTEMIC IMMUNOTOXICITY:MECHANISMS LINKING THE LUNG ANDIMMUNE SYSTEM. M. Selgrade. NHEERL, U.S.EPA, Research Triangle Park, NC.

#20 10:05 IMMUNOTOXICITY OF AEROSOLIZED JP-8JET FUEL EXPOSURE AND ITS PREVENTIONBY SUBSTANCE P. D. T. Harris1 and M. Witten2.1Microbiology & Immunology, University of Arizona,Tucson, AZ and 2Pediatrics, University of Arizona,Tucson, AZ.

#21 10:35 IMMUNOTOXICITY OF SARIN AND OTHERCHOLINERGIC AGENTS. M. Sopori, R. Kalra, R.Langley, S. Razani-Boroujerdi, N. Mishra and R.Henderson. Immunology, Lovelace RespiratoryResearch Institute, Albuquerque, NM.

#22 11:05 PRENATAL EXPOSURE OF MICE TOCIGARETTE SMOKE ALTERS TUMORSURVEILLANCE MECHANISM(S) IN THEJUVENILE AND ADULT OFFSPRING. J. T. Zelikoffand S. P. Ng. Nelson Institute of EnvironmentalMedicine, School of Medicine, New York University,Tuxedo, NY.

#23 11:35 COMPARATIVE INHALATIONIMMUNOTOXICITY OF GASOLINE ANDGASOLINE PLUS OXYGENATE ADDITIVES INRATS. L. Twerdok1, V. L. Peachee2 and K. L. White2.1American Petroleum Institute, Washington, DC and2ImmunoTox, Inc., Richmond, VA.


WORKSHOP SESSION: THE DEVELOPMENT AND APPLICATIONOF BIOMARKERS OF TOXICITY

Chairperson(s): Amy Lavin, International Life Sciences Institute, Washington,DC.

Endorsed by:HESI Biomarkers Technical CommitteeRegulatory and Safety Evaluation SS*Risk Assessment SSToxicologic and Exploratory Pathology SS

A biomarker, or biological marker, is defined as a characteristic that is measuredand evaluated as an indicator of normal biological processes, pathogenicprocesses, or pharmacological responses to a therapeutic intervention(FDA/NIH Definitions Working Group, 1999). Such biomarkers have long beenused in preclinical safety studies during drug development. Nevertheless, manytraditional biomarkers lack the sensitivity and specificity required to extrapolateresults from preclinical studies to human clinical outcomes. As a result, interestin the discovery and validation of new bridging biomarkers of toxicity hasexpanded rapidly in recent years. This increase is due both to the advent of new“-omic” technologies, as well as to a shift in focus within the pharmaceuticalcompanies and regulatory agencies towards finding safety biomarkers that canbe of greater use in the drug discovery and safety assessment processes. Thesedrivers have contributed to formation of the Health and Environmental SciencesInstitute (HESI) Biomarkers Technical Committee, which is conducting acollaborative research program to evaluate possible new biomarkers for use inpreclinical drug development. Biomarkers being explored by the committee foruse in preclinical safety studies include serum cardiac troponins, a panel ofnephrotoxicity biomarkers (the GSTs, PAP-1, KIM-1, and clusterin), andinhibin B as a biomarker of testicular toxicity. The use of such biomarkers willallow for integrated mechanistic and hypothesis-building studies conducted inthe laboratory to be confirmed in man and vice versa.

Program Description



MO

ND

AY

#24 9:30 THE DEVELOPMENT AND APPLICATION OFBIOMARKERS OF TOXICITY. J. Dean2 and A. L.Lavin1. 1ILSI Health and Environmental SciencesInstitute, Washington, DC and 2Sanofi-Synthelabo, Inc.,Malvern, PA.

#25 9:40 NEW BRIDGING BIOMARKERS FOR SAFETYASSESSMENT. J. T. MacGregor. ToxicologyConsulting Services, Arnold, MD.

#26 10:05 SERUM CARDIAC TROPONINS ASBIOMARKERS OF DRUG-INDUCEDCARDIOTOXICITY. M. J. York. Pathology,GlaxoSmithKline, Ware, Hertfordshire, UnitedKingdom. Sponsor: A. Lavin.

#27 10:30 INHIBIN B AS A POTENTIAL BIOMARKER OFTESTICULAR TOXICITY. J. Stewart. SafetyAssessment, AstraZeneca Pharmaceuticals,Macclesfield, Cheshire, United Kingdom. Sponsor: A.Lavin.

#28 10:55 BIOMARKERS OF NEPHROTOXICITY. S.Beushausen1 and A. Lavin2. 1WWSS, Pfizer, Inc., St.Louis, MO and 2Health and Environmental SciencesInstitute, Washington, DC.

#29 11:20 REGULATORY ASPECTS OF NEWBIOMARKERS OF TOXICITY. F. Frueh.FDA/CDER, Rockville, MD. Sponsor: A. Lavin.

Monday Morning, March 79:30 AM to 12:00 NOONRoom 220

WORKSHOP SESSION: DOSE-ADDITIVITY OF MIXTURES:WHERE ARE WE GOING WITH THE SCIENCE?

Chairperson(s): Rory Conolly, CIIT Centers for Health Research, ResearchTriangle Park, NC and William H. Farland, U.S. EPA, Washington, DC.

Endorsed by:Carcinogenesis SSMixtures Task Force*Risk Assessment SSStudent Advisory Committee

A growing challenge in human risk assessment is development of methods toevaluate risks posed by low-level exposures to environmentally relevantmixtures. Development of Relative Potency factors (RPFs), which assumefundamental dose additivity, are currently used as the primary method for eval-uating the risks of mixtures of compounds acting though similar modes ofaction. Examples of these are the RPF schemes for dioxins (Toxic EquivalencyFactors) and organophosphate and carbamate pesticides. The aim of the work-shop is provide a broad overview and discussion of the state of the science forthe use and justification of relative potency factors in environmental and humanhealth risk assessment. The workshop will include presentations describingspecific examples of how RPFs are currently applied to cancer assessments ofdioxin-like compounds and to non-cancer neurotoxicity endpoints such asexemplified by organophosphate and carbamate pesticides. The recentlycompleted National Toxicology Program chronic rodent studies testing criticalRPF hypotheses will be discussed as a specific example of the potential impactof experimental findings on RPF assumptions. In addition, the workshop willdiscuss the central importance of dosimetry and exposure assessments to evalu-ation of the RPF approach, particularly addressing implications forunderstanding potential health risks associated with low-level exposures tochemical mixtures. The Workshop presentations will be designed to engenderboth Panel and Audience discussion focused on defining the scientific justifica-tion and limitations of the use of RPF approaches, and identifying futureresearch needs that will improve risk assessment tools used to assess healthimpacts associated with low-level exposures to a broad spectrum of environ-mental chemicals.

#30 9:30 DOSE-ADDITIVITY OF MIXTURES: WHEREARE WE GOING WITH THE SCIENCE? R.Conolly. CIIT Centers for Health Research, ResearchTriangle Park, NC.

#31 9:40 CAN MODE OF ACTION PREDICT MIXTURETOXICITY FOR RISK ASSESSMENT? C. J.Borgert1,2. 1Applied Pharmacology and Toxicology,Inc., Gainesville, FL and 2Physiological Sciences,University of FL College of Veterinary Medicine,Gainesville, FL.

#32 10:10 THE USE OF TEFS IN ASSESSING MIXTURESOF DIOXINS, FURANS AND DIOXIN-LIKE PCBs.W. H. Farland, M. DeVito and L. Birnbaum. Office ofResearch and Development, U.S. EPA, Washington,DC.

#33 10:40 TESTING THE TOXIC EQUIVALENCY FACTOR(TEF) HYPOTHESIS: THE NTP DIOXIN/PCBCANCER BIOASSAYS. N. J. Walker1, M. E. Wyde1, P.W. Crockett2, A. Nyska1, J. R. Bucher1 and C. J.Portier1. 1NIEHS, Research Triangle Park, NC and2Constella Group, Research Triangle Park, NC.

Program Description


MO

ND

AY


#34 11:10 PHYSIOLOGICALLY BASEDPHARMACOKINETIC (PBPK) MODELING ASAN ALTERNATIVE TO RELATIVE POTENCYFACTORS (RPFS) IN CUMULATIVE RISKASSESSMENT: AN EXAMPLE WITHACETYLCHOLINESTERASE- (ACHE)INHIBITING PESTICIDES. R. Conolly, J. Wang andY. Tan. Center for Computational Systems Biology &Human Health Assessment, CIIT Centers for HealthResearch, Research Triangle Park, NC.


WORKSHOP SESSION: ROLE OF NUTRIGENOMICS IN SAFETYASSESSMENT OF FUNCTIONAL FOODS

Chairperson(s): Madhu Soni, Burdock Group, Vero Beach, FL and TimothyZacharewski, Michigan State University, East Lansing, MI.

Endorsed by:Food Safety SS*Mechanisms SSRisk Assessment SS

The recent completion of human genome (blueprint) has triggered an explosionin research into how drugs might be individualized to capitalize on each patients unique genetic code. The line between food and drug is blurring in the era ofthe genome. It appears that the food industry is on the verge of a new era wherecompanies will design foods and market them to consumers according to theconsumer′s genetic makeup. Increased use of bioactive ingredients (so calledfunctional foods) is challenging toxicologists when making safety determina-tions. This evaluation is different from that of drugs or toxins as efficacy orbenefit analysis of the ingredients has not been factored in the safety determi-nation. The evaluation of absorption, body distribution and metabolism willresult in a realistic assessment of ranges in target tissue concentrations.Biological effects (both desirable and undesirable) can then be determined basedupon genomic and proteomic changes, the result of which will be a bottom upapproach rather than a top down methodology that imposes unrealistic safetyfactors. Thus, data from gene nutrient interaction will open the ways for newconcepts of risk-benefit evaluation. The proposed workshop will cover recentdiscoveries in nutrition, genomics and proteomics and how these developmentswill change currently used methodology for risk assessment of bioactive/func-tional foods. This workshop will focus on applied genomic technologies andtheir impact on nutrition, health sciences and particularly on safety determina-tion of functional foods. The objectives achieved will be: (1) Provide examplesof the impact of genotype (cardiovascular diseases, cancer susceptibility,allergy, etc) on the response to foods and food components; (2) Identify relevantbiomarkers that are applicable for assessing the benefits and risks of selectedfoods; (3) FDA s thinking on use of microarray data in regulatory approvals; and(4) Regulatory and other challenges in determining safety of “nutriomic” foods.

#35 9:30 ROLE OF NUTRIGENOMICS IN SAFETYASSESSMENT OF FUNCTIONAL FOODS. M. G.Soni1 and T. R. Zacharewski2. 1Burdock Group, VeroBeach, FL and 2Biochemistry and Molecular Biology,Michigan State University, East Lansing, MI.

#36 9:40 RISK ASSESSMENT OF FOOD AND FOODCOMPONENTS AT (NEAR) PHYSIOLOGICALCONCENTRATIONS. B. van Ommen. PhysiologicalSciences, TNO Nutrition and Food Research, Zeist,Netherlands. Sponsor: M. Soni.

#37 10:05 GENE AND PROTEIN EXPRESSION CHANGESDURING IMMUNE RESPONSES TO FOODALLERGENS. R. J. Dearman and I. Kimber. SyngentaCTL, Macclesfield, United Kingdom.

#38 10:30 NUTRIGENOMICS AND INFLAMMATION. K.Kornman. Interleukin Genetics, Waltham, MA. Sponsor:M. Soni.

#39 10:55 USE OF MICROARRAY DATA IN REGULATORYAPPROVAL. D. G. Hattan and T. S. Thurmond. Officeof Food Additive Safety, U.S. FDA Center for FoodSafety & Applied Nutrition, College Park, MD.

#40 11:20 IMPACT OF MOLECULAR NUTRITION ON THESAFETY ASSESSMENT OF FUNCTIONALFOODS: A SWOT ANALYSIS. P. Gillies1,2, P. Kris-Etherton2 and J. Vanden Heuvel3. 1Nutrition & Health,DuPont, Newark, DE, 2Department of NutritionalSciences, The Pennsylvania State University, StateCollege, PA and 3Department of Veterinary Medicine,The Pennsylvania State University, State College, PA.


PLATFORM SESSION: NANO PARTICLES

Chairperson(s): Mary Jane Cunningham, Houston Advanced ResearchCenter, The Woodlands, TX and Adrian Nordone, Cabot Corporation, Billerica,MA.

#41 9:30 A NEW GENERATION OF MULTIFUNCTIONALNANOPARTICLES POSSESSING MAGNETICMOTOR EFFECT FOR DRUG OR GENEDELIVERY. K. Yu1, J. Kim1, M. Cho1, B. Kim2, J.Lee2 and T. Yoon2. 1Laboratory of Toxiclogy, College ofVeterinary Medicine, Seoul National University, Seoul,South Korea and 2Materials Chemistry Laboratory,School of Chemistry, Seoul National University, Seoul,South Korea.

#42 10:00 THE AGGREGATION OF SINGLE-WALLEDCARBON NANOTUBES IN FRESH WATER ANDSEA WATER. H. Cheng and J. Cheng. Biology andChemsitry, City University of Hong Kong, Hong Kong,N/A, Hong Kong.

#43 10:30 PROTOCOLS FOR ASSESSING IN VITROTOXICITY OF NANOPARTICULATES. M.Palazuelos1, A. Moraga2, K. Powers1 and B. Moudgil3.1Particle Engineering Research Center, University ofFlorida, Gainesville, FL, 2Interdisciplinary Center forBiotechnology Research, University of Florida,Gainesville, FL and 3Center for Human andEnvironmental Toxicology, University of Florida,Gainesville, FL. Sponsor: S. Roberts.

#44 11:00 ASSESSING THE POTENTIAL HAZARD OFENGINEERED NANOPARTICLES IN THEWORK ENVIRONMENT. A. J. Nordone1, J. Jose2

and C. A. Gray2. 1Cabot Corporation, Leuven, Belgiumand 2Cabot Corporation, Billerica, MA.

Program Description



MO

ND

AY

#45 11:30 GENE EXPRESSION PROFILING OFNANOSCALE MATERIALS USING A SYSTEMSBIOLOGY APPROACH. M. Cunningham1, S. R.Magnuson2 and M. T. Falduto2. 1Life Sciences &Health, Houston Advanced Research Center, TheWoodlands, TX and 2GenUs BioSystems, Inc., St.Charles, IL.


PLATFORM SESSION: NEUROTOXICITY: PHARMACOLOGICALAND ENVIRONMENTAL INTERACTIONS

Chairperson(s): Laurence Fechter, VA Medical Center, Loma Linda, CA andCarey N. Pope, Oklahoma State University, Stillwater, OK.

#46 9:30 IN VITRO AND IN VIVO EXPOSURE TO ORTHO-SUBSTITUTED PCB 95 AND PCB 170 ALTERNEUROPLASTICITY IN THE RATHIPPOCAMPAL SLICES. K. Kim1, I. N. Pessah1 andT. E. Alberston2. 1Molecular Biosciences:VM,U.C.Davis, Davis, CA and 2Internal medicine :Medicalschool, U.C.Davis, Sacramento, CA.

#47 9:50 OVEREXPRESSION OF NQO1 PROTECTSHUMAN DOPAMINERGIC SK-N-MCNEUROBLASTOMA CELLS AGAINSTDOPAMINE INDUCED CELL DEATH. S. H. Inayat-Hussain1,2, K. S. Zafar1, A. Bao1 and D. Ross1.1Pharmacology Sciences, University of Colorado,Denver, CO and 2Biomedical Science, Faculty of AlliedHealth Sciences, Universiti Kebangsaan Malaysia,Kuala Lumpur, WP, Malaysia.

#48 10:10 FORCED EXERCISE ATTENUATES KAINICACID-INDUCED NEUROTOXICITY IN THEHIPPOCAMPUS OF C57BL/6J MICE. S. A.Benkovic, J. P. O’Callaghan and D. B. Miller. TMBB,CDC-NIOSH, Morgantown, WV.

#49 10:30 EVALUATING THE NMDA-GLUTAMATERECEPTOR AS A SITE OF ACTION FORTOLUENE, IN VIVO. A. S. Bale1, Q. T. Krantz2, P. J.Bushnell1, T. J. Shafer1 and W. K. Boyes1.1Neurotoxicology Division, NHEERL, ORD, U.S. EPA,Research Triangle Park, NC and 2ExperimentalToxicology Division, NHEERL, ORD, U.S. EPA,Research Triangle Park, NC.

#50 10:50 INVOLVEMENT OF OXIDATIVE STRESS INPOTENTIATION OF NOISE INDUCED HEARINGLOSS (NIHL) BY CHEMICAL CONTAMINANTS.L. D. fechter, B. Pouyatos and C. A. Gearhart. Research(151), Loma Linda VA Medical Center, Loma Linda,CA.

#51 11:10 MODULATION OF CHOLINERGIC TOXICITYBY CANNABINOIDS. A. Nallapaneni, N. Mirajkar, S.Karanth and C. Pope. Physiological Sciences,Oklahoma State University, Stillwater, OK.

#52 11:30 TEMPORAL PARAMETERS OFENVIRONMENTAL ENRICHMENT-INDUCEDCOGNITIVE ENHANCEMENT IN A RODENTMODEL OF LEAD NEUROTOXICITY. C. D.Toscano, J. L. McGlothan, J. R. Moss and T. R.Guilarte. Environmental Health Sciences, JohnsHopkins University, Baltimore, MD.


PLATFORM SESSION: RECEPTORS: PPAR

Chairperson(s): Jon Corton, Toxicogenomics, Chapel Hill, NC.

#53 9:30 PEROXISOME PROLIFERATOR-ACTIVATEDRECEPTOR αα IS REGULATED BY GSK3. K. A.Burns and J. P. Vanden Heuvel. Center for MolecularToxicology and Carcinogenesis, The Pennsylvania StateUniversity, University Park, PA.

#54 9:50 PEROXISOME PROLIFERATOR-ACTIVATEDRECEPTOR ALPHA- AND P53-RESPONSIVEGENE REGULATION BY RIBOSOMAL PROTEINL11. L. Gopinathan1, J. P. Gray2 and J. P. VandenHeuvel1. 1Center for Molecular Toxicology andCarcinogenesis, Penn State University, State College,PA and 2Department of Pharmacology and Toxicology,Rutgers University, Piscataway, NJ.

#55 10:10 THE PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-ββ(PPARββ) AGONISTGW0742 INHIBITS COLON CARCINOGENESIS.H. E. Marin1, A. N. Billin2, T. M. Willson2 and J. M.Peters3,1. 1Biochemistry, Microbiology, and MolecularBiology, The Pennsylvania State University, UniversityPark, PA, 2Nuclear Receptor Discovery Research,GlaxoSmithKline, Research Triangle Park, NC and3Veterinary Science and the Center of MolecularToxicology and Carcinogenesis, Pennsylvania StateUniversity, University Park, PA.

#56 10:30 UNDERSTANDING GENE EXPRESSIONCHANGES CONTROLLED BY THEPEROXISOME PROLIFERATOR-ACTIVATEDRECEPTORαα IN RATS. P. D. Cornwell1, W. J.Bailey2, A. T. De Souza1 and R. G. Ulrich1. 1PreclinicalMolecular Profiling, Rosetta Inpharmatics LLC (awholly owned subsidiary of Merck & Co. Inc.), Seattle,WA and 2LSIT, Merck Research Laboratories, WestPoint, PA.

#57 10:50 OVERLAPPING TRANSCRIPTIONALPROGRAMS REGULATED BY THE NUCLEARRECEPTORS PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR ALPHA, RETINOID XRECEPTOR AND LIVER X RECEPTOR INMOUSE LIVER. A. Laughter2, S. P. Anderson1, C.Dunn2, L. Yoon1, C. Swanson2, R. Chandraratna3, T. M.Stulnig4, K. R. Steffensen4, J. Gustaffson4 and J. C.Corton5,2. 1GSK, Research Trangle Park, NC, 2CIIT,Research Trangle Park, NC, 3Allergan, Irvine, CA,4Karolinska Institute, Huddinge, Sweden and5ToxicoGenomics, Chapel Hill, NC.

Program Description


MO

ND

AY


#58 11:10 THE TRANSCRIPTIONAL RESPONSE TO APEROXISOME PROLIFERATOR-ACTIVATEDRECEPTOR ALPHA AGONIST INCLUDESINCREASED EXPRESSION OF PROTEOMEMAINTENANCE GENES. S. P. Anderson1, P.Howroyd2,3, J. Liu4, X. Qian4, R. Bahnemann5, C.Swanson3, M. Kwak6, T. W. Kensler6 and J. C.Corton7,3. 1GSK, Research Triangle Park, NC, 2EPL,Research Triangle Park, NC, 3CIIT, Research TrianglePark, NC, 4NCI at NIEHS, Research Triangle Park, NC,5BASF, Ludwigshafen, Germany, 6Johns HopkinsUniversity, Baltimore, MD and 7ToxicoGenomics,Chapel Hill, NC.

#59 11:30 ROLE OF PPARALPHA IN CALORICRESTRICTION EFFECTS IN THE MOUSELIVER. J. C. Corton1,4, U. Apte2, S. P. Anderson3, P.Limaye2, L. Yoon3, J. Latendresse5, J. Everitt4, K. A.Voss6, C. Kimbrough3, J. S. Wong7, S. S. Gill7, R. A.Chandraratna8, M. Kwak9, T. W. Kensler9, T. M.Stulnig10, K. R. Steffensen10, J. Gustafsson10 and H. M.Mehendale2. 1ToxicoGenomics, Chapel Hill, NC,2University of Louisiana, Monroe, LA, 3GSK, ResearchTriangle Park, NC, 4CIIT, Research Triangle Park, NC,5PAI, Jefferson, AR, 6USDA, Athens, GA, 7Universityof California, Riverside, CA, 8Allergan, Irvine, CA,9Johns Hopkins University, Baltimore, MD and10Karolinska Institute, Huddinge, Sweden.

Monday Morning, March 79:30 AM to 12:30 PMExhibit Hall

POSTER SESSION: LIVER I

Chairperson(s): Hartmut Jaeschke, University of Arizona, Tucson, AZ.

Displayed: 9:30 AM–12:30 PM

Attended: 9:30 AM–11:00 AM

#60 TOXICOGENETIC ANALYSIS OFSUSCEPTIBILITY TO ACETAMINOPHEN-INDUCED LIVER INJURY. A. Hege1, C. Lodestro3,D. Lee3, L. D. Balletta3, B. U. Bradford2, A. Maki2, R.Tennant4, M. A. Bogue5, K. Paigen5, D. W. Threadgill1,3

and I. Rusyn1,2. 1Curriculum in Toxicology, UNC,Chapel Hill, NC, 2Department of EnvironmentalSciences and Engineering, UNC, Chapel Hill, NC,3Department of Genetics, UNC, Chapel Hill, NC,4NIEHS, Research Triangle Park, NC and 5The JacksonLaboratory, Bar Harbor, ME.

#61 PARACETAMOL TOXICITY IN RATSPRETREATED WITH CYTOCHROME P450 ORGLUTATHIONE INHIBITORS USING ANINTEGRATED GENOMICS APPROACH. M. F.DeCristofaro1, D. Bodian1, E. Perentes2, I. M.Nicholls2, P. End2, J. Harleman2, S. Chibout3, F.Staedtler3 and H. Firat3. 1Biomarker Development,Novartis Pharmaceuticals Corporation, East Hanover,NY, 2Preclinical Safety, Novartis Pharmacology AG,Basel, Switzerland and 3Biomarker Development,Novartis Pharmacology AG, Basel, Switzerland.

#62 DECREASED ACETAMINOPHEN ANDBROMOBENZENE-INDUCEDHEPATOTOXICITY AND LETHALITY IN TYPE 2DIABETIC MICE. M. S. Mitra1, S. P. Sawant1, A. V.Dnyanmote1, J. R. Latendresse2, A. Warbritton2 and H.M. Mehendale1. 1University of Louisiana at Monroe,Monroe, LA and 2NCTR, Jefferson, AR.

#63 ROLE OF POLY(ADP-RIBOSE) POLYMERASE(PARP) ACTIVATION IN ACETAMINOPHEN-INDUCED LIVER CELL NECROSIS IN MICE. C.Cover1, P. Fickert2, T. Knight1, A. Fuchsbichler2, M.Trauner2 and H. Jaeschke1. 1Liver Research Institute,University of Arizona, Tucson, AZ and 2Department ofMedicine, Medical University of Graz, Graz, Austria.

#64 PROTEOMIC ANALYSIS OF WHOLE LIVERAND SUBCELLULAR FRACTIONS FOLLOWINGACETAMINOPHEN-INDUCEDHEPATOTOXICITY IN MALE RATS. M. E. Bruno1,B. A. Wetmore1, J. H. Madenspacher1, R. Pieper1, A. M.McGrath2, C. L. Gatlin2, A. J. Makusky2, M. Zhao2, J.Zhou2, J. Taylor2, S. Steiner2, J. M. Fostel1, M. D.Waters1, R. W. Tennant1, K. B. Tomer1 and B. A.Merrick1. 1National Ctr Toxicogenomics, NIEHS,Research Triangle Pk, NC and 2Proteomics Division,Large Scale Biology Corporation, Germantown, MD.

#65 ROLE OF THE XENOBIOTIC RECEPTOR PXRIN ACETAMINOPHEN HEPATOTOXICITY. K. K.Wolf2, S. G. Wood1, B. W. Walton-Strong3, K. Yasuda7,L. Lan7, P. R. Sinclair1,3,2, S. A. Wrighton4, E. H.Jeffery5, R. M. Evans6, E. G. Schuetz7 and J. F.Sinclair1,3,2. 1Veterans Administration Medical Center,White River Junction, VT, 2Pharmacology andToxicology, Dartmouth Medical School, Hanover, NH,3Biochemistry, Dartmouth Medical School, Hanover,NH, 4Department of Drug Disposition, Lilly ResearchLaboratories, Indianapolis, IN, 5Department of FoodScience and Human Nutrition, University of Illinois,Urbana, IL, 6Howard Hughes Medical Institute, GeneExpression Laboratory, The Salk Institute for BiologicalStudies, La Jolla, CA and 7Department ofPharmaceutical Sciences, St. Jude Children’s ResearchHospital, Memphis, TN.

#66 THE EFFECT OF S-ADENOSYL-L-METHIONINE(SAME)ON MITOCHONDRIAL GLUTATHIONEAND PROTEIN CARBONYLS FOLLOWINGACETAMINOPHEN (APAP) TREATMENT INMICE. M. Terneus, K. Kiningham and M. Valentovic.Pharmacology, Marshall University School of Medicine,Huntington, WV.

#67 EVIDENCE SUGGESTING A ROLE FORNAD(P)H:QUINONE OXIDOREDUCTASE 1 INTHE PROTECTION AGAINSTACETAMINOPHEN HEPATOTOXICITY BYCLOFIBRATE TREATMENT. J. S. Moffit1, L. M.Aleksunes1, A. M. Slitt2, M. Kardas1, C. D. Klaassen2

and J. E. Manautou1. 1Department of PharmaceuticalSciences, University of Connecticut, Storrs, CT and2Department of Pharmacology, Toxicology andTherapeutics, University of Kansas Medical Center,Kansas City, KS.

Program Description



MO

ND

AY

#68 ROLE OF VASCULAR ENDOTHELIAL GROWTHFACTOR (VEGF) IN ACETAMINOPHENHEPATOTOXICITY. B. Donahower1, S. S.McCullough2 and L. P. James3,2. 1Pharmacology,University of Arkansas For Medical Sciences, LittleRock, AR, 2Toxicology, University of Arkansas ForMedical Sciences, Little Rock, AR and 3ArkansasChildren’s Hospital Research Institute, Little Rock, AR.Sponsor: J. Hinson.

#69 LIPOPOLYSACCHARIDE POTENTIATESACETAMINOPHEN HEPATOTOXICITY. S. W.Newport, C. M. Dugan, X. Deng, P. E. Ganey, R. A.Roth and J. F. Maddox. Pharmacology and Toxicology,National Food Safety and Toxicology Center, MichiganState University, East Lansing, MI.

#70 POTENTIATION OF 3-(3, 5-DICHLOROPHENYL)-2, 4-THIAZOLIDINEDIONE (DCPT)-INDUCEDHEPATOTOXICITY IN RATS BYDEXAMETHASONE (DEX) PRETREATMENT. C.M. Crincoli, N. N. Patel, R. Tchao and P. J. Harvison.Department of Pharmaceutical Sciences, University ofthe Sciences in Philadelphia, Philadelphia, PA.

#71 PROTECTIVE EFFECT OF DIBROMOACETATEIN PRIMARY HEPATOCYTE CULTURES. J. M.McMillan and K. McKelvey. Pharmacology, MedicalUniversity of South Carolina, Charleston, SC.

#72 NICOTINAMIDE ALTERATION OFBROMOBENZENE-INDUCEDHEPATOTOXICITY. K. W. Hall1, P. C. Grivas1, C.Muro-Cacho2 and R. D. Harbison1,2. 1Toxicology,University of South Florida, Tampa, FL and 2Pathology,College of Medicine, University of South Florida,Tampa, FL.

#73 COLCHICINE ANTIMITOSIS ABOLISHESSUBCHRONIC CHLOROFORM-INDUCEDPROTECTION AGAINST LETHAL DOSE OFCHLOROFORM. B. K. Philip1, S. S. Anand2, P. S.Palkar1, M. M. Mumtaz3, J. R. Latendresse4 and H. M.Mehendale1. 1Department of Toxicology, University ofLouisiana at Monroe, Monroe, LA, 2University ofGeorgia, Athens, GA, 3ATSDR, CDC, Chamblee, GAand 4NCTR, Jefferson, AR.

#74 UNDERNUTRITION FAILS TO EXACERBATEALCOHOL-INDUCED LIVER DAMAGEDESPITE EVIDENCE OF INCREASEDOXIDATIVE STRESS. J. N. Baumgardner1,2, B. N.Yarberry2, J. V. Badeaux2, M. Hidestrand1,2, K.Shankar1,2, T. M. Badger2,3 and M. J. Ronis1,2.1Pharmacology and Toxicology, University of Arkansasfor Medical Sciences (UAMS), Little Rock, AR,2Arkansas Children’s Nutrition Center, Little Rock, ARand 3Physiology and Biophysics, UAMS, Little Rock,AR.

#75 RESILIENCY OF AGED FISCHER 344 RATS TOCHLORDECONE-AMPLIFIED CARBONTETRACHLORIDE TOXICITY. H. M. Mehendale,B. Murali and M. C. Korrapati. Toxicology, Universityof Louisiana at Monroe, Monroe, LA.

#76 PENTOXIFYLLINE AND ANTI-TUMORNECROSIS FACTOR αα ANTIBODIES AREUNABLE TO PROTECT MICE FROMFUMONISIN HEPATOTOXICITY. Q. He and R. P.Sharma. The University of Georgia, Athens, GA.

#77 CALPASTATIN OVER-EXPRESSION PROTECTSAGAINST TOXICANT-INDUCED PROGRESSIONOF INJURY ASSOCIATED WITH ACUTE LIVERFAILURE IN MICE. P. B. Limaye1, V. S. Bhave1, P. S.Palkar1, J. R. Latendresse2, S. Yu3, J. K. Reddy3 and H.M. Mehendale1. 1Toxicology, University of Louisiana atMonroe, Monroe, LA, 2NCTR, Jefferson, AR and3Northwestern University, Chicago, IL.

#78 IMPAIRED HEPATIC REGENERATION INMETALLOTHIONEIN KNOCKOUT MICEAFTER PARTIAL HEPATECTOMY. J. R. Oliverand G. Cherian. Pathology, University of WesternOntario, London, ON, Canada.

#79 THE ROLE OF GLUTATHIONE DEPLETIONAND OXIDATIVE STRESS ON CYTOTOXICITYOF CHROMIUM (VI) IN ISOLATED RATHEPATOCYTES. O. S. El-Tawil1, A. M. Mohamadin2

and A. H. Abou-Hadeed3. 1Toxicology and ForensicMedicine, Faculty of Veterinary Medicine, CairoUniversity, Cairo, Egypt, 2Department of Biochemistry,Faculty of Pharmacy, Al-Azhar University, Cairo, Egyptand 3Department of Forensic Medicine and Toxicology,Faculty of Veterinary Medicine, Zagazig University,Zagzig, Egypt.

#80 ANTI-HYPERCHOLESTEROLEMIA DRUGS INTHE STATIN CLASS REDUCE GLUTATHIONELEVELS AND INCREASE CASPASE 3ACTIVATION IN AN IN VITRO CELL MODEL. J.F. Pregenzer, J. M. McKim, Jr., P. C. Wilga and D. K.Petrella. CeeTox, Kalamazoo, MI.

#81 EFFECT OF THIAZOLIDINEDIONE (TZD) RINGMODIFICATION ON 3-(3, 5-DICHLOROPHENYL)-2, 4-THIAZOLIDINEDIONE (DCPT) INDUCEDHEPATOTOXICITY IN RATS. N. N. Patel, C. M.Crincoli, R. Tchao and P. J. Harvison. Department ofPharmaceutical Sciences, University of the Sciences inPhiladelphia, Philadelphia, PA.

#82 ENDOGENOUS FATTY ACID METHYL ESTERSAS A POTENTIAL MARKER OF HUMANHEPATOCELLULAR CARCINOMA. S. H. Khan, B.S. Kaphalia and G. Ansari. Pathology, UTMB,Galveston, TX.

#83 AN INVESTIGATION INTO THERELATIONSHIP OF VITAMIN A LEVELS ANDHEPATITIS, HYPERPLASIA, BENIGN ORMALIGNANT LESIONS IN RODENT LIVERS. C.Bray. Covance Laboratories Ltd., Harrogate, UnitedKingdom. Sponsor: D. Everett.

Program Description


MO

ND

AY



POSTER SESSION: RECEPTOR: AH RECEPTOR II

Chairperson(s): Michael Denison, University of California, Davis, Davis,CA.


Attended: 11:00 AM–12:30 PM

#84 CHARACTERIZATION OF A HIGH-POTENCYENDOGENOUS LIGAND FOR THE ARYLHYDROCARBON RECEPTOR. E. C. Henry1, J. C.Bemis1, A. S. Kende2 and T. A. Gasiewicz1.1Environmental Medicine, University of Rochester,Rochester, NY and 2Chemistry, University of Rochester,Rochester, NY.

#85 NATURALLY OCCURRING ANTAGONISTS OFAHR PATHWAY: A NOVEL APPROACH OFCANCER CHEMOPREVENTION? D. puppala andH. Swanson. Pharmacology, University of Kentucky,Lexington, KY.

#86 IMPACT OF NH-TERMINAL TAGS ON AHRECEPTOR LOCALIZATION ANDDEGRADATION IN CELL CULTURE. J.McQuown2,1, J. Wentworth1, E. Dougherty1 and R. S.Pollenz1. 1Biology, University of South Florida, Tampa,FL and 2Cancer Biology, Moffitt Cancer Center, Tampa,FL.

#87 COMPUTATIONAL APPROACH TOWARDSIDENTIFYING GENES WITH DIOXINRESPONSE ELEMENTS IN HUMAN, MOUSE,AND RAT GENOMES. C. Vezina, H. M. Theobaldand R. E. Peterson. School of Pharmacy, UW-Madison,Madison, WI.

#88 IDENTIFICATION OF ZEBRAFISH ARNT1HOMOLOGS: TCDD DEVELOPMENTALTOXICITY IN ZEBRAFISH REQUIRES ARNT1.A. L. Prasch1, R. L. Tanguay2, W. Heideman1 and R. E.Peterson1. 1University of Wisconsin, Madison, WI and2Environmental & Molecular Toxicology, Oregon StateUniversity, Corvallis, OR.

#89 5, 6-LEUKOTRIENE A4 A IS POTENTACTIVATOR OF THE AH RECEPTOR. C. R.Chiaro1, A. D. Jones2, Y. Cao1, J. Born3, C. Marcus3

and G. H. Perdew1. 1Veterinary Science, Penn StateUniversity, University Park, PA, 2Chemistry, Penn StateUniversity, University Park, PA and 3Toxicology,University of New Mexico, Albuquerque, NM.

#90 ER-αα REPRESSES TCDD-INDUCIBLE CYP1A1GENE TRANSCRIPTION THROUGH A DIRECTPROTEIN-PROTEIN INTERACTION WITHAHR/ARNT. T. Beischlag and G. H. Perdew. Centerfor Molecular Toxicology and Carcinogenesis,Department of Veterinary Sciences, Penn StateUniversity, University Park, PA.

#91 ROLE OF ARNT2 IN NORMAL DEVELOPMENTBUT NOT TCDD DEVELOPMENTAL TOXICITYIN ZEBRAFISH. A. J. HILL1, A. L. Prasch2,1, W.Heideman1,2 and R. E. Peterson1,2. 1School ofPharmacy, University of Wisconsin, Madison, WI and2Molecular and Environmental Toxicology Center,University of Wisconsin, Madison, WI.

#92 ALTERED CELL CYCLE REGULATION IN AHRECEPTOR-NULL MOUSE FIBROBLASTS. X.Chang and A. Puga. Environmental Health, Universityof Cincinnati Medical Center, Cincinnati, OH.

#93 COMPARISONS OF RAT LIVER GENEEXPRESSION PROFILES FOR TCDD, D3T ANDI3C: IMPLICATIONS FOR THE TOXICITYEQUIVALENCE FACTOR (TEF) APPROACH. C.Sutter1, K. Illouz2, A. Possolo2, S. Goodwin1, Y.Huang1, T. Kensler3, J. Silkworth2 and T. Sutter1.1Feinstone Center for Genomic Research, University ofMemphis, Memphis, TN, 2Global Research, GE,Schenectady, NY and 3Environmental Health Sciences,Johns Hopkins Bloomberg School of Public Health,Baltimore, MD.

#94 NATURALLY OCCURRING MARINECOMPOUNDS SHOW A SPECIES-SPECIFICDIFFERENCE IN AHR DRIVEN REPORTERGENE EXPRESSION. D. DeGroot1, M. E. Hahn2, B.K. Carte3, T. Higa4 and M. S. Denison1. 1EnvironmentalToxicology, University of California, Davis, CA,2Woods Hole Oceanographic Institution, Woods Hole,MA, 3Ancile Pharmaceuticals, San Diego, CA and4University of Ryukyus, Okinawa, Japan.

#95 PERSISTENT BINDING OF LIGANDS TO THEHEPATIC AH RECEPTOR FROM VARIOUSSPECIES. J. E. Bohonowych and M. S. Denison.Environmental Toxicology, University of CaliforniaDavis, Davis, CA.

#96 TCDD EXPOSURES ACTIVATE PKC, MAPK ANDNFKB SIGNALING PATHWAYS IN HUMANCANCER CELLS. C. K. Yu, M. H. Wong and C. K.Wong. Biology, Hong Kong Baptist University, HongKong, China.

#97 THE ARYL HYDROCARBON RECEPTOR (AHR)ANTAGONIST EGCG, INHIBITS AHRACTIVATION THROUGH AN INDIRECTMECHANISM INVOLVING BINDING TO HSP90:A NOVEL MECHANISM FOR A REPORTEDANTI-CANCER AGENT. C. M. Palermo and T. A.Gasiewicz. Department of Environmental Medicine,University of Rochester, Rochester, NY.

#98 A NOVEL ARNT-INTERACTING PEPTIDE AINP2ENHANCES THE ARYL HYDROCARBONRECEPTOR SIGNALING. Y. Li, T. C. Luu and W. K.Chan. Thomas J. Long School of Pharmacy & HealthSciences, University of the Pacific, Stockton, CA.

#99 THE ROLE OF THE JUN N-TERMINAL KINASEPATHWAYS IN THE TISSUE-SPECIFIC TCDDTOXICITY. Z. Tan, A. Puga and Y. Xia. EnvironmentalHealth, University of Cincinnati, Cincinnati, OH.

Program Description



MO

ND

AY

#100 ISOLATION AND CHARACTERIZATION OFTHE CYP1A1 PROMOTER REGION FROMZEBRAFISH. J. Wentworth and R. S. Pollenz. Biology,University of South Florida, Tampa, FL.

#101 MICROARRAY EXAMINATION OF TCDDMEDIATED CHANGES IN GENE EXPRESSIONIN HEPA1C1C7 MURINE HEPATOMA CELLS. E.Dere, D. R. Boverhof, L. D. Burgoon and T. R.Zacharewski. Department of Biochemistry & MolecularBiology, Department of Pharmacology & Toxicology,Center for Integrative Toxicology, National Food Safety& Toxicology Center, Michigan State University, EastLansing, MI.

#102 2, 3, 7, 8-TETRACHLORODIBENZO-P-DIOXINALTERS EXPRESSION OF RETINOIC ACIDRECEPTORS IN NORMAL HUMANKERATINOCYTES. K. A. Murphy, C. M. Villano andL. A. White. Biochemistry and Microbiology, RutgersUniversity, New Brunswick, NJ.

#103 HEPATIC GENE EXPRESSION IN AHR-/- ANDC57BL/6J MICE TREATED WITH 7H-DIBENZO[C, G]CARBAZOLE. D. Warshawsky, M.Genter, B. Warner, S. Goins, K. LaDow, A. Puga, M.Sartor and M. Medvedovic. Environmental Health,University of Cincinnati College of Medicine,Cincinnati, OH.

#104 ARYL HYDROCARBON RECEPTORACTIVATION INHIBITS E2F1-INDUCEDAPOPTOSIS. J. L. Marlowe, X. Chang and A. Puga.Environmental Health, University of Cincinnati,Cincinnati, OH.

#105 ARNT1 AND ARNT2 ARE EXPRESSED INHUMAN KERATINOCYTES IN VITRO. K. N. DeAbrew1 and B. Allen-Hoffmann1,2. 1Molecular andEnvironmental Toxicology Center, University ofWisconsin, Madison, WI and 2Department of Pathologyand Laboratory Medicine, University of Wisconsin,Madison, WI.

#106 DETECTION OF AH RECEPTOR LIGANDS INEXTRACTS FROM COMMON COMMERCIALAND CONSUMER PRODUCTS USING AHR-BASED BIOASSAYS. M. S. Denison1, W. J. Rogers1,J. E. Bohonowych1, M. Ziccardi1, T. Pedersen2, K.Dettmer2, B. D. Hammock2 and B. Zhao1.1Environmental Toxicology, University of California,Davis, CA and 2Entomology, University of California,Davis, CA.

#107 INTERACTION BETWEEN THE AH RECEPTORAND NF-KB PATHWAYS: ANTAGONISM ATTHE LEVEL OF HISTONE MODIFICATIONS. T.Z. Yu, S. Ke and Y. Tian. Texas A&M University,College Station, TX.


POSTER SESSION: GENE EXPRESSION-I

Chairperson(s): Lori White, Rutgers University, New Brunswick, NJ.



#108 INTEGRATED ANALYSIS OF GENEEXPRESSION DATA, LITERATURE, ANDBIOLOGICAL PATHWAYS OF MOUSEEMPHYSEMA STUDY. V. L. Burnett1, P. J. Monroe1,K. Lee2 and J. G. Pounds3. 1OmniViz, Inc., Maynard,MA, 2Battelle Toxicology Northwest, Richland, WA and3Pacific Northwest National Laboratory, Richland, WA.

#109 TRANSCRIPTIONPATH, A NOVEL METHODTHAT IDENTIFIES AND QUANTIFIES GENETRANSCRIPTION, DETECTS CHANGESASSOCIATED WITH TOXICOLOGY. M. E.Warren1, V. Alexiadis1, B. Egan1, J. Cashman2 and P.Labhart1. 1Genpathway, Inc., San Diego, CA and2Human BioMolecular Research Institute, San Diego,CA. Sponsor: D. Schlenk.

#110 CELL BASED ASSAYS REVEAL INDIVIDUALAND COOPERATIVE ROLES FOR THE GLITRANSCRIPTION FACTORS IN MEDIATINGTHE HEDGEHOG SIGNAL. R. J. Lipinski2,1 and W.Bushman1,2. 1Surgery, University of Wisconsin-Madison, Madison, WI and 2Molecular andEnvironmental Toxicology Center, University ofWisconsin-Madison, Madison, WI.

#111 TOXICOGENOMIC ANALYSIS OF INTESTINALRESPONSES TO NORMAL OR IMBALANCEDHUMAN MICROFLORA IN GERM-FREE MICEOR HFA MICE EXPOSED TOANTIMICROBIALS. S. jeong, S. Park, H. Kang andJ. Cho. Toxicology Division, National VeterinaryResearch & Quarantine Service, Anyang, South Korea.

#112 INDUCTION OF CYCLOOXYGENASE-2 BYCORTICOSTERONE IN CARDIOMYOCYTES. H.Sun and Q. M. Chen. Pharmacology, University ofArizona, Tucson, AZ.

#113 DEVELOPING AN IN VITRO GENEEXPRESSION ASSAY FOR PREDICTINGHEPATOTOXICITY. S. abel, Y. Yang and J. Waring.Toxicogenomics, Abbott Laboratories, Abbott Park, IL.

#114 ELUCIDATION OF THE MECHANISM OFKINASE INHIBITOR-INDUCED KIDNEY ANDLIVER TOXICITY USING THE “OMICS”TECHNOLOGIES. P. S. Rao1, M. Wojke1, M.Hower1, T. Connolly2, J. Gautier1, J. Leonard1, A.Amberg1, M. Kurz4, H. Juretschke3, M. Valerio1, M.Pino1, K. Morgan1 and Z. Jayyosi1. 1Drug SafetyEvaluation, Aventis, Bridgewater, NJ, 2CambridgeGenomics Center, Aventis, Boston, MA, 3Biomarkers,Aventis, Frankfurt, Germany and 4Chemistry, Aventis,Frankfurt, Germany.

Program Description


MO

ND

AY


#115 CHARACTERIZATION OF FUNCTIONALVARIATION IN HUMAN GSTM3 IN GLIOMACELLS USING RNAI. X. Liu, M. R. Campbell, G. S.Pittman and D. A. Bell. Molecular genetics, NIEHS,Research Triangle Park, NC.

#116 DIFFERENTIAL GENE EXPRESSION IN F344RATS FOLLOWING EXPOSURE TO EITHERPOLYBROMINATED DIPHENYL ETHERS(PBDES) OR PCBs. J. M. Sanders1,2, L. T. Burka1 andM. L. Cunningham1. 1Laboratory of Pharmacology andChemistry, NIEHS, Research Triangle Park, NC and2Department of Toxicology, NC State University,Raleigh, NC.

#117 EXTRACTION OF GENES WITH STABLEEXPRESSION IN RAT LIVER TREATED WITHVARIOUS COMPOUNDS–ANALYSIS OF THEDATA IN THE TOXICOGENOMICS PROJECT INJAPAN -. H. UEDA, T. KASAHARA, H. TOTSUKA,T. MIYAGISHIMA, T. URUSHIDANI and T. NAGAO.Toxicogenomics Project, National Institute of HealthScience, Setagayaku, Tokyo, Japan. Sponsor: T.INOUE.

#118 CHARACTERIZATION OF AN ACUTEMOLECULAR MARKER OF NON-GENOTOXICHEPATOCARCINOGENESIS IN RODENTS BYGENE EXPRESSION PROFILING IN A LONG-TERM CLOFIBRIC ACID STUDY. C. Michel1, C.Desdouets2, R. A. Roberts1,3, K. R. Isaacs4 and E.Boitier1. 1Drug Safety Evaluation, Sanofi Aventis,Vitry-sur-Seine, France, 2INSERM U370, Paris, France,3Safety Assessment, AstraZeneca, Cheshire, UnitedKingdom and 4CITP, Harrogate, United Kingdom.

#119 PROFILES OF GLOBAL GENE EXPRESSION INIONIZING RADIATION-DAMAGED HUMANDIPLOID FIBROBLASTS REVEALSYNCHRONIZATION BEHIND THE G1CHECKPOINT. T. Zhou1, J. W. Chou2, D. A.Simpson1, Y. Zhou1, T. E. Mullen1, M. Medeiros1, P. R.Bushel2, R. S. Paules2, X. Yang1, P. Hurban3, E. K.Lobenhofer3 and W. K. Kaufmann1. 1Pathology & Lab.Medicine, University of North Carolina, Chapel Hill,NC, 2National Institute of Environmental HealthScience, Research Triangle Park, NC and 3ParadigmGenetics, Research Triangle Park, NC.

#120 EXPRESSION OF THE HELIX-LOOP-HELIXINHIBITOR OF DNA BINDING-1 (ID-1) GENE ISREGULATED BY RETINOIC ACID IN NORMALHUMAN KERATINOCYTES. L. A. White and C. M.Villano. Biochemistry and Microbiology, RutgersUniversity, New Brunswick, NJ.

#121 APPLICATION OF A CROSS-PLATFORM RNASTANDARD FOR ASSESSING MICROARRAYDATA COMPARABILITY. P. S. Pine1, B. A.Rosenzweig1, J. C. Fuscoe2, C. A. Afshari3, H. K.Hamadeh3, J. D. Retief4, Y. Turpaz4, E. Blomme5, R.Ciurlionis5, J. F. Waring5, R. S. Paules6, C. J. Tucker6,T. L. Fare7, E. M. Coffey7, Y. He7, J. Collins8, K.Jarnagin9, S. Fujimoto9, G. L. Kiser10, T. Kaysser-Kranich10, F. D. Sistare11, J. Sina11 and K. Thompson1.1CDER, U.S. FDA, Silver Spring, MD, 2NCTR, U.S.FDA, Jefferson, AR, 3Amgen Inc., Thousand Oaks, CA,4Affymetrix Inc., Santa Clara, CA, 5AbbottLaboratories, Abbott Park, IL, 6NIEHS, ResearchTriangle Park, NC, 7Rosetta Inpharmatics, Seattle, WA,8Agilent Technologies, Santa Clara, CA, 9IconixPharmaceuticals, Mountain View, CA, 10GE Healthcare,Chandler, AZ and 11Merck & Co. Inc., West Point, PA.

#122 GENE EXPRESSION MODIFICATIONS IN AMOUSE EMPHYSEMA MODEL INDUCED BYELASTASE. Q. Meng1, K. M. Waters2, J. M. Malard2,K. Lee1 and J. G. Pounds2. 1Battelle ToxicologyNorthwest, Richland, WA and 2Pacific NorthwestNational Laboratories, Richland, WA.

#123 TUMOR SUBTYPE CHEMOTHERAPEUTICRESPONSES IN THE BREAST. K. Hoadley1, M. A.Troester2 and C. M. Perou1,2,3. 1Curriculum in Geneticsand Molecular Biology, University of North Carolina,Chapel Hill, NC, 2Lineberger Comprehensive CancerCenter, University of North Carolina, Chapel Hill, NCand 3Department of Genetics, University of NorthCarolina, Chapel Hill, NC. Sponsor: J. Swenberg.

#124 USE OF GENE EXPRESSION CHANGES INCIRCULATING BLOOD CELLS TO MONITORXENOESTROGEN EXPOSURE IN NEONATALMICE. F. Lim, K. Antrobus, D. J. Moore, H. Tinwell, I.Kimber, J. Ashby, G. Orphanides and J. Moggs.Syngenta CTL, Macclesfield, Cheshire, UnitedKingdom.

#125 COMPARISON OF WHOLE BLOOD GENEEXPRESSION PROFILES FROM THREE NON-HUMAN PRIMATE SPECIES AND HUMANS. C.S. Phillips and J. F. Dillman. Applied Pharmacology,USAMRICD, Aberdeen Proving Ground, MD. Sponsor:A. Sciuto.

#126 THE BIOLOGY OF DRUG SIGNATURES. C.Pearson, R. Brennan, M. Fielden, B. Ganter, W. Hu, S.Tugendreich, A. Vladimirova and K. Kolaja. IconixPharmaceuticals, Inc., Mountain View, CA.

#127 GENE EXPRESSION ANALYSIS OFFERSUNIQUE ADVANTAGES TO HISTOPATHOLOGYIN PREDICTION OF OVERALL LIVERCONDITION. A. N. Heinloth1, G. A. Boorman2 and R.S. Paules1. 1NCT, NIEHS, Research Triangle Park, NCand 2ETP, NIEHS, Research Triangle Park, NC.

Program Description



MO

ND

AY

#128 CHANGES IN GENE EXPRESSION INDUCED BYTECHNICAL CHLORDANE, CIS-NONACHLOR,TRANS-NONACHLOR AND OXYCHLORDANEIN RAT LIVERS MONITORED BYOLIGONUCLEOTIDE MICRO-ARRAYS.CURRAN, I.H.A., HIERLIHY, A., AND BONDY, G.,TOXICOLOGY RESEARCH DIVISION, FOODDIRECTORATE, HPFB, HEALTH CANADA,OTTAWA, ONTARIO, CANADA. I. Curran, A.Hierlihy and G. Bondy. Toxicology Research Division,Food Directorate, Health Canada, Ottawa, ON, Canada.Sponsor: G. Bondy.

#129 EFFECT OF REPRODUCTIVE TOXICANTS ONGENE EXPRESSION IN THE RAT TESTES. T.Fukushima1,2, T. Yamamoto1, R. Kikkawa1, Y.Hamada1, I. Horii1 and C. Mori2. 1Worldwide SafetySciences, Pfizer Global and Research NagoyaLaboratories, Taketoyo, Aichi, Japan and2Bioenvironmental Medicine, Chiba University, Chiba,Japan. Sponsor: M. Kurata.

#130 GENE EXPRESSION CHANGES IN FETALTHYMUS EXPOSED TO ORGANICCOMPOUNDS EXTRACTED FROM DIESELEXHAUST PARTICLES. T. Ito1, H. Nagai1,2, T. Lin3,R. E. Peterson3, C. Tohyama1, T. Kobayashi1 and K.Nohara1. 1National Institute for Environmental Studies,Tsukuba, Japan, 2Science University of Tokyo, Noda,Japan and 3University of Wisconsin, Madison, WI.


POSTER SESSION: ARSENIC AND URANIUM TOXICOLOGY

Chairperson(s): John P. Christopher, CAL-EPA, Sacramento, CA and DavidS. Barber, University of Florida, Gainesville, FL.



#131 MOLECULAR CLONING ANDCHARACTERIZATION OF HUMAN CYT19, ANS-ADENOSYL-L-METHIONINE:AS-METHYLTRANSFERASE FROM HEPG2 CELLS.A. McNally and D. Barber. University of Florida,Gainesville, FL.

#132 GLOBAL CHANGES IN POSTTRANSLATIONALCOVALENT HISTONE MODIFICATIONSMEDIATED BY LOW-DOSE ARSENIC. J. F.Reichard and A. Puga. Environmental Health,University of Cincinnati, Cincinnati, OH.

#133 ARSENIC CAUSES DOSE-DEPENDENTENHANCEMENT AND SUPPRESSION OFRETINOIC ACID RECEPTOR (RAR)-MEDIATEDGENE ACTIVATION. J. C. Davey, L. Ingram, C.Batki, J. Lariviere and J. W. Hamilton. Pharmacology &Toxicology, Dartmouth Medical School, Hanover, NH.

#134 ARSENITE INHIBITS CELL CYCLEPROGRESSION OF U937 MYELOID LEUKEMIACELLS THROUGH INDUCTION OF CDC25ADEGRADATION. G. McCollum Lehmann and M. J.McCabe. University of Rochester, Rochester, NY.

#135 MOLECULAR MECHANISMS UNDERLYINGINHIBITION OF INSULIN-STIMULATEDGLUCOSE UPTAKE IN ADIPOCYTES EXPOSEDTO TRIVALENT ARSENICALS. D. S. Paul, A. W.Harmon and M. Styblo. Department of Nutrition,University of North Carolina, Chapel Hill, NC.

#136 FURTHER STUDIES ON ABERRANT GENEEXPRESSION IN ARSENIC-INDUCEDMALIGNANT TRANSFORMATION OF LIVEREPITHELIAL CELLS. J. Liu1, L. Benbrahim-Tallaa1,Y. Xie1, X. Qian2, W. Qu1, J. Otstot3 and M. Waalkes1.1Laboratory of Comparative Carcinogenesis, NCI atNIEHS, Research Triangle Park, NC, 2LST, NIEHS,Research Triangle Park, NC and 3DNA SequencingCore, NIEHS, Research Triangle Park, NC.

#137 ARSENITE DECREASES CYP3A INDUCTION INCULTURED RAT HEPATOCYTES BY DUALMECHANISMS. T. L. Noreault1, J. M. Jacobs3,4, R. C.Nichols2,3, H. W. Trask4, S. A. Wrighton5, P. R.Sinclair1,2,4, R. M. Evans6 and J. F. Sinclair1,2,4.1Pharmacology & Toxicology, Dartmouth MedicalSchool, Hanover, NH, 2VA Medical Center, White RiverJunction, VT, 3Microbiology/Immunology, DartmouthMedical School, Hanover, NH, 4Biochemistry,Dartmouth Medical School, Hanover, NH, 5LillyResearch Laboratories, Indianapolis, IN and 6HowardHughes Medical Institute, Salk Institute for BiologicalStudies, San Diego, CA.

#138 ANALYSIS OF GLOBAL AND GENE SPECIFICDNA METHYLATION IN LIVERS OF NEWBORNMICE TRANSPLACENTALLY EXPOSED TO ACARCINOGENIC DOSE OF ARSENIC. Y. Xie1, J.Liu1, L. Benbrahim-Tallaa1, B. Diwan2 and M.Waalkes1. 1Laboratory of Comparative Carcinogenesis,NCI at NIEHS, Research Triangle Park, NC and 2BRP,SAIC-Frederick, NCI at Frederick, Frederick, MD.

#139 ARSENITE INDUCES CYTOKERATINEXPRESSION IN MICE LIVER. P. Ramirez1, M.Cerbon2 and M. E. Gonsebatt3. 1Laboratorio deToxicologia Celular, FES Cuautitlan, Cuatitlan, Mexico,2Biologia, Facultad de Quimica, UNAM, Mexico, DF,Mexico and 3Medical Genomics and EnvironmentalToxicology, Instituto de Investigaciones Biomedicas,UNAM, Mexico, DF, Mexico.

#140 REDUCTION OF ARSENATE BY HUMANERYTHROCYTE (RBC) LYSATE AND RATLIVER CYTOSOL (CS) IS LINKED TOGLYCOLYSIS. B. Nemeti and Z. Gregus. DepartmentPharmacology, University Pecs, Med. School, Pecs,Hungary.

#141 THE ROLE OF THE RAS SIGNALING PATHWAYIN ANDROGEN-INDEPENDENCE ACQUIREDDURING ARSENIC-INDUCED MALIGNANTTRANSFORMATION OF HUMAN PROSTATEEPITHELIAL CELLS. L. Benbrahim-Tallaa1, M.Webber2 and M. Waalkes1. 1Laboratory of ComparativeCarcinogenesis, NCI at NIEHS, Research Triangle Park,NC and 2Michigan State University, East Lansing, MI.

#142 ARSENITE BINDING TO SUBSETS OF THEHUMAN ESTROGEN RECEPTOR-αα. K. T. Kitchinand K. A. Wallace. Environmental CarcinogenesisDivision, U.S. EPA, Research Triangle Park, NC.

Program Description


MO

ND

AY


#143 ALTERED PROTEIN EXPRESSIONFOLLOWING IN UTERO EXPOSURE TOARSENIC. C. Lantz, J. S. Petrick and A. M. Hays. CellBiology and Anatomy, University of Arizona, Tucson,AZ.

#144 ABERRANT GENE EXPRESSION IN THENEONATAL MOUSE LUNG FOLLOWING INUTERO EXPOSURE TO INORGANIC ARSENIC.J. Shen1, Y. Xie1, J. Liu1, B. Diwan2 and M. Waalkes1.1Laboratory of Comparative Carcinogenesis, NCI atNIEHS, Research Triangle Park, NC and 2BRP, SAIC-Frederick, NCI at Frederick, Frederick, MD.

#145 ARSENIC INDUCES CHROMOSOMAL ANDCENTROMERIC ABNORMALITIES, IN HUMANLUNG CELLS. J. P. Lynch1,2, S. S. Wise1,2 and J. P.Wise1,2. 1Wise Laboratory of Environmental andGenetic Toxicology, University of Southern Maine,Portland, ME and 2Maine Center for Toxicology andEnvironmental Health, University of Southern Maine,Portland, ME.

#146 CHARACTERIZATION OF HUMAN BLADDERUROTHELIAL CELLS MALIGNANTLYTRANSFORMED BY ARSENITE. K. E. Billings1, T.G. Bredfeldt1, X. H. Zheng1, M. J. Kopplin1, G. S.Watts2, D. A. Sens4, E. A. Mash3 and A. J. Gandolfi1.1Depts of Pharmacology and Toxicology, University ofAZ, Tucson, AZ, 2AZ Cancer Center, University of AZ,Tucson, AZ, 3Department of Chemistry, University ofAZ, Tucson, AZ and 4Depts of Pathology and Surgery,School of Medicine and Health Sciences, University ofND, Grand Forks, ND.

#147 ARSENITE AND MONOMETHYL ARSONOUSACID-INDUCED TOXICITY IN HUMANUROTHELIAL CELLS. T. G. Bredfeldt1, K. E.Billings1, X. H. Zheng1, E. A. Mash2, F. E. Domann3, S.S. Lau1, D. A. Sens4 and A. J. Gandolfi1. 1Pharmacologyand Toxicology, University of AZ, Tucson, AZ,2Chemistry, University of AZ, Tucson, AZ, 3RadiationOncology, University of IA, Iowa City, IA and4Pathology and Surgery, University of ND, GrandForks, ND.

#148 METABOLISM AND TOXICITY OF ARSENIC INHUMAN URINARY BLADDER EPITHELIALCELLS EXPRESSING RAT ARSENIC (+3)-METHYLTRANSFERASE. Z. Drobna1, S. B.Waters2, V. Devesa3, A. W. Harmon1, D. J. Thomas4 andM. Styblo1,3. 1Pediatrics, UNC Chapel Hill, NC, ChapelHill, NC, 2Curriculum in Toxicology, UNC, ChapelHill, NC, 3CEMALB, UNC, Chapel Hill, NC and4NHEERL, U.S. EPA, Triangle Research Park, NC.

#149 GLYCERALDEHYDE 3-PHOSPHATEDEHYDROGENASE (GAPDH) AS AN ARSENATEREDUCTASE IN HUMAN RED BLOOD CELLS(HRBC) AND RAT LIVER CYTOSOL (RLC). Z.Gregus and B. Nemeti. Department Pharmacology,University Pecs, Med. School, Pecs, Hungary.

#150 ARSENITE INDUCES PROCOAGULANTACTIVITY IN HUMAN PLATELETS BYPHOSPHATIDYLSERINE EXPOSURE ANDMICROPARTICLE GENERATION. O. Bae, K. Limand J. Chung. College of Pharmacy, Seoul NationalUniversity, Seoul, South Korea.

#151 ARSENIC METHYLTRANSFERASE CYT19EXPRESSION AND ACTIVITY IN RAT TISSUES.Y. Kobayashi1,2, T. Hayakawa1 and S. Hirano1.1Environmental Health Sciences Division, NationalInstitute for Environmental Studies, Tsukuba, Ibaraki,Japan and 2Japan Foundation for Aging and Health,Chita, Aichi, Japan.

#152 THE ROLE OF VALENCE AND METHYLATIONSTATE ON THE ACTIVITY OF ARSENICDURING MITOSIS. A. D. Kligerman, C. L. Doerr andA. H. Tennant. Environmental Carcinogenesis Division,U.S. EPA, Research Triangle Park, NC. Sponsor: D.Wolf.

#153 INORGANIC ARSENIC BIOTRANSFORMATIONAND MMA(V) REDUCTASE/GSTO1-1KNOCKOUT MICE. U. K. Chowdhury, R. A.Zakharyan, M. D. Avram, M. Wollenberg, A.Hernandez, M. Kopplin and H. V. Aposhian. Molecularand Cellular Biology, University of Arizona, Tucson,AZ.

#154 DETERMINATION OF TRANSCRIPTIONFACTORS IMPORTANT IN ARSENIC-INDUCEDALTERATIONS IN GENE EXPRESSION. A. Hays1,R. Pandey2, R. Ahmed1, A. S. Andrew3, J. W. Hamilton3

and C. Lantz1. 1Cell Biology and Anatomy, Universityof Arizona, Tucson, AZ, 2Arizona Cancer Center,University of Arizona, Tucson, AZ and 3Pharmacology& Toxicology, Dartmouth Medical School, Hanover,NH.

#155 ARSENIC IN SEAFOOD: WHAT PERCENTAGEOF THE TOTAL IS INORGANIC ARSENIC? L. L.Chappell1, J. Colman1, R. M. Lorenzana3, P. McGinnis2,R. Troast4 and A. Yeow4. 1Environ Sciences Ctr,Syracuse Research Corp, Syracuse, NY, 2SyracuseResearch Corp, Philadelphia, PA, 3ORD Region 10,U.S. EPA, Seattle, WA and 4OSRTI, U.S. EPA,Washington, DC.

#156 ASSESSMENT OF EXPOSURE TO ARSENIC ANDLIFE STYLE IN KOREAN. J. Park1, W. Lee1, M.Choi4, E. Park2, K. Park3 and S. Kim3. 1PreventiveMedicine, Chung-Ang University, Seoul, South Korea,2Pathology, Chung-Ang University, Seoul, South Korea,3Advanced Analysis Center, Korea Institute of Scienceand Technology, Seoul, South Korea and 4Chung-UnUniversity, Chung-Un, South Korea.

#157 URANYL ACETATE INDUCED OXIDATIVESTRESS IN CHINESE HAMSTER OVARY AA8CELLS: EFFECT ON DNA OXIDATION. J.Orozco1, A. M. Hays1, M. Yazzie2, D. M. Stearns2 andC. Lantz1. 1Cell Biology and Anatomy, University ofArizona, Tucson, AZ and 2Department of Chemistry andBiochemistry, Northern Arizona University, Flagstaff,AZ.

#158 THE HPRT SPECTRA OF SPONTANEOUS,URANYL-ACETATE- AND HYDROGEN-PEROXIDE-INDUCED HPRT MUTANTS INCHINESE HAMSTER OVARY EM9 CELLS. V. H.Coryell and D. M. Stearns. Chemistry andBiochemistry, Northern Arizona University, Flagstaff,AZ.

Program Description



MO

ND

AY

#159 CYTOTOXICITY, GENOTOXICITYANDMUTAGENICITY OF COMBINED EXPOSURESOF URANYL ACETATE AND SODIUMARSENITE IN CHO CELLS. Y. Monica1, W. H.Johnson1, J. T. Shelley1, H. M. Allison2, R. C. Lantz2

and D. M. Stearns1. 1Chemistry and Biochemistry,Northern Arizona University, Flagstaff, AZ and 2CellBiology and Anatomy, University of Arizona, Tucson,AZ.

#160 GENOTOXICITY OF PARTICULATE URANIUMAND CHROMIUM. S. S. Wise1,2, A. L. Holmes1,2, J.A. Moreland1,2 and J. P. Wise1,2. 1Wise Laboratory ofEnvironmental and Genetic Toxicology, University ofSouthern Maine, Portland, ME and 2Maine Center forToxicology and Environmental Health, University ofSouthern Maine, Portland, ME.

#161 NEPHROTOXIC EFFECTS OF DEPLETEDURANIUM (DU) IN THE RAT. INTERACTIONSWITH STRESS. L. Tobias1, D. Barber2, K.Zimmerman1, S. Hancock1, J. Hinckley1, M. Ehrich1

and B. S. Jortner1. 1Virginia Tech, Blacksburg, VA and2University of Florida, Gainesville, FL.

#162 BIOLOGIC EFFECTS AFTER BRIEFINHALATION EXPOSURE TO URANIUM OXIDEOR DEPLETED URANIUM OXIDE AEROSOLS.F. F. Hahn1, E. B. Barr1, G. Bench2, J. Karlsson3 and J.Lewis3. 1Lovelace Respiratory Research Institute,Albuquerque, NM, 2LLNL, Livermore, CA and3University of New Mexico, Albuquerque, NM.

#163 RENAL BIOMARKER RESULTS IN DEPLETEDURANIUM (DU) EXPOSED GULF WARVETERANS. M. A. McDiarmid1,2 and K. Squibb1,2.1Occupational Health, University of Maryland MedicalCenter, Baltimore, MD and 2Depleted UraniumFollowup Program, VA Maryland Health Care System,Baltimore, MD.

#164 ASSESSING THE RENAL TOXICITY OFDEPLETED URANIUM AND OTHER URANIUMCOMPOUNDS. L. E. Roszell1, F. F. Hahn2 and R. B.Lee1. 1US Army Center for Health Promotion andPreventive Medicine, Aberdeen Proving Ground, MDand 2Lovelace Respiratory Research Institute,Albuquerque, NM.

#165 UTILITY OF PATIENT MAILED URINESPECIMENS FOR RENAL BIOMARKERANALYSIS IN DEPLETED URANIUM (DU)EXPOSED 1991 GULF WAR VETERANS. K. S.Squibb1,2, M. Oliver1,2, P. Gucer1,2, S. Engelhardt2,1 andM. McDiarmid1,2. 1Program in Toxicology, Universityof Maryland School of Medicine, Baltimore, MD and2Depleted Uranium Program, VA Maryland Health CareSystem, Baltimore, MD.


POSTER SESSION: IMMUNOTOXICOLOGY–METHODS ANDSAFETY EVALUATION

Chairperson(s): Danuta Herzyk, GlaxoSmithKline, Safety AssessmentImmunotoxicology, King of Prussia, PA and Kimber White, VirginiaCommonwealth University, Pharmacology and Toxicology, Richmond, VA.



#166 NK CELL CYTOTOXICITY EVALUATION:TECHNICAL AND ANALYTICALALTERNATIVES TO CONVENTIONAL51CHROMIUM RELEASE ASSAY. E. R. Gore1, J.K. Gower1, E. Kurail2 and D. J. Herzyk1. 1SafetyAssessment, GlaxoSmithKline, King of Prussia, PA and2Statistical Sciences, GlaxoSmithKline, King of Prussia,PA.

#167 ANTI-NKP46 IMPROVES DETECTION OFNATURAL KILLER CELLS IN MACAQUEBLOOD. W. Frings and G. Weinbauer. CovanceLaboratories GmbH, 48163 Muenster, Germany.

#168 IMMUNE SYSTEM DEVELOPMENT IN THECYNOMOLGUS MONKEY: LYMPH NODESAND SPLEEN. G. Habermann, S. Friderichs-Gromoll,J. Kaspareit and E. Buse. Covance Laboratories GmbH,48163 Muenster, Germany. Sponsor: G. Weinbauer.

#169 ANALYTICAL VALIDATION OF PERIPHERALBLOOD IMMUNOPHENOTYPING FORCYNOMOLGUS MONKEY. R. Caldwell, J. Fishel,G. Leatherberry and P. Marshall. Covance Laboratories,Madison, WI. Sponsor: P. Thomas.

#170 IMMUNOGENICITY AND IMMUNOTOXICITYASSESSMENTS OF TWO DRUG AFFINITYCOMPLEX COMPOUNDS IN CYNOMOLGUSMONKEYS. S. Wen1, V. Iordanova1, C. N.Papagiannis2, M. Rebelatto2, T. Najarian1 and J.Castaigne1. 1ConjuChem, Inc., Montreal, QC, Canadaand 2MPI Research, Inc., Mattawan, MI. Sponsor: J.Daniels.

#171 DEVELOPMENT AND VALIDATION OF SEMI-QUANTITATIVE ASSAYS FOR TOTAL ANDNEUTRALIZING PRIMATE ANTIBODIESAGAINST A HUMAN THERAPEUTICMONOCLONAL ANTIBODY. X. Guo1, D. Finco-Kent1, C. Soderstrom1, B. Cohen1, H. Wang1 and T.Kawabata1. 1Pfizer Inc., Groton, CT and 2Pfizer Inc.,Groton, CT.

#172 TEMPORAL STABILITY OF WHOLE BLOODAND MONONUCLEAR CELL CULTURES TOSUPPORT LYMPHOCYTE PROLIFERATIONFOLLOWING MITOGEN AND RECALLANTIGEN STIMULATION. M. Wing, S. Wilkins, J.Hubbard and K. Gilbert. Huntingdon Life Sciences Ltd.,Huntingdon, United Kingdom. Sponsor: S. Dean.

Program Description


MO

ND

AY


#173 PERIPHERAL LYMPH NODES: ISSUES WITHTHE COLLECTION AND ANALYSIS FORIMMUNOTOXICITY STUDIES. P. J. Haley1, L.Chouinard2, P. Ciaccio1, D. Ennulat3, L. Gore3, S.Emeigh Hart1 and J. Lapointe4. 1Global SafetyAssessment, AstraZeneca, Wilmington, DE, 2CTBR,Montreal, QC, Canada, 3GlaxoSmithKline, King ofPrussia, PA and 4Pfizer, Groton, CT.

#174 VALIDATION OF A METHOD FOR THEDETECTION OF ANTI-PROTEIN-X IGGANTIBODIES IN RAT AND DOG SERUM BYENZYME LINKED IMMUNOSORBENT ASSAY(ELISA). M. Ionescu, N. Rouleau, G. Desilets, A.Michaux, M. Duchesneau and L. LeSauteur.Immunology, CTBR Bio-Research Inc., Senneville, QC,Canada.

#175 THE REAL TIME MONITOR OF ANTIBODY-CELL BINDING BY BIOSENSOR ASSAY. K.Harada, N. Ohtake, S. Hayashi, E. Furukawa, Y.Kikuchi and J. Kawahara. Pharmaceutical DevelopmentLaboratories, Pharmaceutical Division, Kirin BreweryCo., Ltd.,, Maebashi-shi, Gunma, Japan. Sponsor: E.Weaver.

#176 ADVANTAGE OF USING WHOLE SHEEP REDBLOOD CELLS VERSUS CELL MEMBRANE INELISA ASSAYS TO ASSESSIMMUNOSUPPRESSION IN VIVO. T. Tsuchiya, A.Minakawa, H. Watanabe, E. Ohta, M. Sasaki, T. Ikeda,K. Samura and M. Nishikibe. Tsukuba SafetyAssessment Laboratories, Banyu Pharmaceutical Co.,Ltd.,, Tsukuba, Ibaraki, Japan. Sponsor: N. Imura.

#177 AN ALTERNATIVE KLH-BASED PROTOCOLFOR THE SRBC PLAQUE-FORMING CELLASSAY: DOSE RANGE FINDER STUDY. M. vanZijverden, E. Klein Koerkamp, P. van den Berg and A.Penninks. Toxicology and Applied Pharmacology, TNONutrition and Food Research, Zeist, Netherlands.Sponsor: V. Feron.

#178 SENSITIVITY OF THE KEYHOLE LIMPETHEMOCYANIN (KLH) ELISA MODEL ISDIRECTLY RELATED TO DOSE USED FORSENSITIZATION. V. L. Peachee1,2, C. M. Sheth1, A.M. Halpen2 and K. L. White1,2. 1Pharmacology andToxicology, Virginia Commonwealth University,Richmond, VA and 2ImmunoTox, Inc., Richmond, VA.

#179 EVALUATION OF T CELL RESPONSES TOKEYHOLE LIMPET HEMOCYANIN IN THE RATMODEL. A. E. Hillegas, C. A. Genell, C. C. Maier andD. J. Herzyk. Safety Assessment, GlasxoSmithKline,King of Prussia, PA.

#180 COMPARISON OF ANTIBODY TITER ANDCONCENTRATION IN A RATIMMUNOTOXICITY MODEL. J. R. Piccotti, J. D.Alvey, C. Y. Malinczak and R. M. Slim. WorldwideSafety Sciences, Pfizer Global Research &Development, Ann Arbor, MI. Sponsor: M. Bleavins.

#181 THE UTILITY OF HOST RESISTANCE ASSAYSIN LEAD CANDIDATE SELECTION ANDPHARMACEUTICAL SAFETY ASSESSMENT. S.Groom, C. Thompson and K. Rioux. Toxicology, CTBR,Senneville, QC, Canada.


POSTER SESSION: SIGNAL TRANSDUCTION: KINASES

Chairperson(s): Dennis Petersen, University of Colorado, Denver, CO.



#182 ALTERED SIGNAL TRANSDUCTION IN HUMANKERATINOCYTES FOLLOWING EXPOSURE TOBI-FUNCTIONAL ALKYLATING AGENTS. G. D.Minsavage and J. F. Dillman. Applied PharmacologyBranch Army Medical Research Institute of ChemicalDefense, Aberdeen Proving Ground, MD.

#183 2, 4, 6-TRINITROTOLUENE CAUSESREDUCTION OF ENOS ACTIVITY BUTPHOSPHORYLATES ENOS THROUGHACTIVATION OF PI3K/AKT SIGNALING INENDOTHELIAL CELLS. Y. sun and Y. Kumagai.Social and Environmental Medicine, University ofTsukuba, Tsukuba, Ibaraki, Japan. Sponsor: A.Naganuma.

#184 PROTEIN KINASE Cζζ MEDIATES LPSACTIVATION OF NUCLEAR FACTOR KAPPA B(NF-κκB) IN KIDNEY EPITHELIAL CELLS. W. W.Polk, J. V. Kushleika, M. E. Ellis, P. L. Simmonds and J.S. Woods. Environmental and Occupational HealthSciences, University of Washington, Seattle, WA.

#185 4-HYDROXYNONENAL-MEDIATEDINHIBITION OF ERK-ELK-AP-1 SIGNALING. B.P. Sampey, J. A. Doorn and D. R. Petersen.Pharmaceutical Sciences, University of Colorado HSC,Denver, CO.

#186 INORGANIC PHOSPHATE CONTROLS CELLGROWTH THROUGH AKT/MEK-MEDIATEDERK-DEPENDENT MNK1 TRANSLOCATION INNORMAL HUMAN BRONCHIAL EPITHELIALCELLS. S. Chang1, G. R. Beck2, K. Lee3, D. Cho4 andM. Cho1. 1Laboratory of Toxicology, College ofVeterinary Medicine, Seoul National University, Seoul,South Korea, 2Laboratory of Cancer Prevention,National Cancer Institute, Frederick, MD, 3Laboratoryof MOlecular Oncology, Korea Institute of Radiological& Medical Sciences, Seoul, South Korea and4Reproductive Toxicology, National Institute ofToxicological Research, KFDA, Seoul, South Korea.

#187 ACTIVATION OF THE TRANSCRIPTIONFACTOR AP-1 BY 2, 2’4, 4’-TETRACHLOROBIPHENYL (TCB) INVOLVESEXTRACELLULAR SIGNAL-REGULATEDKINASES (ERKS) ENHANCED EXPRESSION OFC-FOS PROTOONCOGENE AND IN RAT LIVERCELLS. G. Chen, B. V. Madhukar and B. Wood.Pediatrics/Human Development, Michigan StateUniversity, East Lansing, MI.

Program Description



MO

ND

AY


POSTER SESSION: METHODS AND DEVICES

Chairperson(s): James Swenberg, University of North Carolina Chapel Hill,Chapel Hill, NC and Kenneth Cheever, NIOSH, Cincinnati, OH.



#188 EFFECT OF EXTRACTION TECHNIQUE, LONG-TERM STORAGE AND GENDER ON GENEEXPRESSION PROFILES OF HUMAN WHOLEBLOOD. S. Kim1, R. N. Murrell2, J. E. Schmid3, K. E.Thompson3, D. J. Dix3 and J. C. Rockett3. 1Curriculumin Toxicology, University of North Carolina, ChapelHill, NC, 2Environmental and Molecular Toxicology,North Carolina State University, Raleigh, NC and3RTD/NHEERL/ORD, U.S. EPA, Research TrianglePark, NC.

#189 NANBIOTECHNOLOGY: DEVICES TOQUANTIFY CELLS AND THEIR FUNCTIONS. R.T. Emeny, T. J. Zieziulewicz, N. Mishra, J. N. Turnerand D. A. Lawrence. Wadsworth Center, Albany, NY.

#190 A HEADSPACE PROCEDURE FOR THEQUANTIFICATION OF 1- AND 2-BROMOPROPANE IN HUMAN URINE. C.B’Hymer and K. L. Cheever. BHAB, NIOSH,Cincinnati, OH.

#191 EVALUATION OF TEST PROCEDURES FORTHE QUANTIFICATION OF URINARY (2-METHOXYETHOXY)ACETIC ACID. K. L. Cheeverand C. B’Hymer. Molecular and Genetic Monitoring,NIOSH, Cincinnati, OH.

#192 AUTOMATIC BIOSENSOR ANALYZER FORRAPID ASSAY OF NEUROPATHY TARGETESTERASE (NTE) IN BLOOD. V. V. Malygin1, G. F.Makhaeva1, N. N. Strakhova1, L. V. Sigolaeva2, L. G.Sokolovskaya2, A. V. Eremenko2, I. N. Kurochkin2 andR. J. Richardson3. 1Institute of Physiologically ActiveCompounds RAS, Chernogolovka, Russian Federation,2Faculty of Chemistry, M.V. Lomonosov Moscow StateUniversity, Moscow, Russian Federation and 3EHSDepartment, Toxicology Program, University ofMichigan, Ann Arbor, MI.

#193 AN IMPROVED METHOD FOR THEQUANTITATION OF 8-HYDROXY-2’-DEOXYGUANOSINE IN BIOLOGICALSAMPLES. A. M. Luke1, S. Liao2, G. Boysen2 and J.A. Swenberg1,2. 1Curriculum in Toxicology, Universityof North Carolina, Chapel Hill, NC and 2Department ofEnvironmental Sciences and Engineering, University ofNorth Carolina, Chapel Hill, NC.

#194 BIOLOGICAL SAMPLE ANALYSIS METHODSDEVELOPMENT AND VALIDATION FOR ATOXICOKINETIC STUDY OF BIS(2-CHLOROETHOXY)METHANE. B. L. Burback1, S.Hong1, J. D. Johnson1, S. W. Graves1, J. Merrill1 and C.Smith2. 1Chemistry Technical Center, Battelle,Columbus, OH and 2NIEHS, Research Triangle Park,NC.

#195 VALIDATION OF A METHOD FOR THEDETECTION OF ANTI-KEYHOLE LIMPETHEMOCYANIN (KLH) IGM ANTIBODIES INTHE NEONATAL/JUVENILE CD-1 MOUSESERUM BY ENZYME-LINKEDIMMUNOSORBENT ASSAY (ELISA). N. Rouleau,C. Gelinas and L. LeSauteur. Immunology, CTBR,Senneville, QC, Canada.

#196 NANBIOTECHNOLOGY: GRATING-COUPLEDSURFACE PLASMON RESONANCE (GCSPR), ACELL AND PROTEIN MICROARRAYPLATFORM FOR THE ANALYSIS OFTOXICANT EFFECTS. D. Unfricht1, A. Sweatt1, S.Fernandez2, G. Jin1, T. Zieziulewicz3, D. Lawrence3 andM. A. Lynes1. 1Molecular and Cell Biology, Universityof Connecticut, Storrs, CT, CT, 2Ciencia, Inc., E.Hartford, CT and 3Wadsworth Center, Albany, NY.

#197 RAT KIDNEY INJURY MOLECULE-1 (RKIM-1)ELISA: A SENSITIVE ASSAY FOR EARLYDETECTION OF KIDNEY TUBULAR INJURY INPRECLINICAL TOXICITY STUDIES. V. S. Vaidya,T. Ichimura and J. V. Bonventre. Renal, Brigham andWomen’s Hospital, Harvard Medical School, Boston,MA.

#198 ANALYSIS OF HYDROXYMETHYLVINYLKETONE DERIVED 1, N2-PROPANODEOXYGUANOSINE BY LC-MS/MS.M. W. Powley1, V. E. Walker2 and J. A. Swenberg1.1Environmental Sciences and Engineering, Universityof North Carolina, Chapel Hill, NC and 2LovelaceRespiratory Research Institute, Albuquerque, NM.

#199 DEVELOPMENT AND VALIDATION OF ABIOANALYTICAL METHOD FOR TUNGSTEN.D. Kracko1, R. Marr1, R. Arimoto2 and J. McDonald1.1Toxicology, Lovelace Respiratory Research Institute,Albuquerque, NM and 2Carlsbad EnvironmentalMonitoring and Research Center, Carlsbad, NM.Sponsor: J. Mauderly.

#200 N-(2, 3, 4, 5, 6-PENTAFLUOROPHENYL)DITHIOCARBAMATEAS A SENSITIVE DERIVATIZING REAGENTFOR THE ESTIMATION OF EPOXIDES OF 1, 3-BUTADIENE AND OTHER PETROCHEMICALALKENES. R. M. Uppu. Environmental Toxicology,Southern University and A&M College, Baton Rouge,LA.

#201 A LUMINESCENT METHOD FOR MEASURINGDRUG-DEPENDENT CHANGES IN P-GLYCOPROTEIN ATPASE ACTIVITY. J. Cali, R.Bulliet and D. Ma. Promega Corp, Madison, WI.

#202 COMPARISON OF CALUX BIOASSAY ANDHRGC/MS CHEMICAL ANALYSIS FOR THEDIOXIN LEVEL IN ENVIRONMENTALMATRICES. Y. Y. Sheen1, K. E. Joung1, K. N. Min1, J.S. Kim1, M. J. Seo1, S. Y. Yang1 and Y. H. Chung2.1Pharmacy, Ewha Womans University, Seoul, SouthKorea and 2Water Research, National Institute ofEnvironmental Research, Incheon, South Korea.Sponsor: J. Chung.

Program Description


MO

ND

AY


#203 A METHOD FOR REPEATED JUGULAR-VEINTOXICOKINETIC BLOOD SAMPLING INCONSCIOUS, NON-CANNULATED RATS. R. E.Kubaszky, G. Washer, N. Galliard, J. Laliberte and H.M. Moldovan. General Toxicology, ITR LaboratoriesCanada, Baie d’Urfe (Montreal), QC, Canada.


POSTER SESSION: OXIDATIVE STRESS I

Chairperson(s): Bhupendra Kaphalia, University Of Texas, Galveston, TXand Manisha Bagchi, Interhealth Research Center, Benicia, CA.



#204 ELECTROSTATIC SURFACE CHARGE OFNANOPARTICLES ACTIVATES CNSMACROPHAGES (MICROGLIA). M. Pooler1, O.Makwana1, J. Carter2, I. Beck-Speier3, W. Kreyling3

and B. Veronesi2. 1Toxicology Program, NCSU,Raleigh, NC, 2NHEERL, U.S. EPA, Research TrianglePark, NC and 3National Research Center forEnvironment and Health, GSF Research Center,Munich, Germany.

#205 INCREASED REACTIVE OXYGEN SPECIESPRODUCTION AND METABOLICALTERATIONS IN MITOCHONDRIA OFEXPERIMENTAL DIABETIC RAT TISSUES. H.Raza1,2, S. K. Prabu2 and N. G. Avadhani2.1Biochemistry, UAE University, Al Ain, United ArabEmirates and 2Animal Biology, University ofPennsylvania, Philadelphia, PA.

#206 FAILURE OF DIETARY VITAMIN E TOPREVENT DOXORUBICIN-INDUCED CARDIACMITOCHONDRIONOPATHY IN VIVO. J. M.Berthiaume1, P. Oliveira2, M. W. Fariss3 and K. B.Wallace1. 1Biochem. & Mol. Biology, ToxicologyGraduate Program, University of Minnesota, Duluth,MN, 2Center for Neurosciences and Cell Biology,University of Coimbra, Coimbra, Portugal and3Pharmaceutical Sciences and Cancer Center, Universityof Colorado Health Sciences Center, Denver, CO.

#207 PRIMAQUINE-INDUCED HEMOLYTICANEMIA: ROLE OF SPLENIC MACROPHAGES,LIPID PEROXIDATION AND CYTOSKELETALPROTEIN ALTERATIONS IN THEHEMOTOXICITY OF 5-HYDROXYPRIMAQUINE. Z. Bowman1, J. D.Morrow2, D. J. Jollow1 and D. C. McMillan1. 1Cell andMolecular Pharmacology, Medical University of SouthCarolina, Charleston, SC and 2Department of Medicine,Vanderbilt University School of Medicine, Nashville,TN.

#208 OXIDATIVE STRESS CAUSED BYGLUTATHIONE SYNTHESIS INHIBITORBUTHIONINE SULFOXIMINE RESULTS INGENOME REARRANGEMENTS IN MICE. R. H.Schiestl and R. Reliene. Pathology, EnvironmentalHealth and Radiation Oncology, UCLA, Los Angeles,CA.

#209 INHIBITION OF HSP90αα CHAPERONEACTIVITY BY 4-HYDROXY-2-NONENAL. D. R.Petersen1, D. L. Carbone1, J. A. Doorn2 and Z.Kiebler1. 1University of Colorado Health SciencesCenter, Denver, CO and 2University of Iowa, Iowa City,IA.

#210 HIGH FAT DIET DIFFERENTIALLY AND SITE-SPECIFICALLY ALTERS LUNG GLUTATHIONEAND ACUTE CYTOTOXICITY IN MALE ANDFEMALE MICE. L. S. Van Winkle1, R. Stelck1, J.Graham2, K. Sutherland1, C. Brown1, J. Shimizu1, A.Buckpitt3, P. Havel2 and G. Baker1. 1VM:APC, UCDavis, Davis, CA, 2Nutrition, UC Davis, Davis, CA and3VM: Mol Biosci, UC Davis, Davis, CA.

#211 MOLECULAR PATHOLOGICAL ANALYSIS OFHEPATOCARCINOGENESIS IN MICE TREATEDWITH DICYCLANIL. M. moto1, T. Umemura2, M.Okamura1, Y. Kashida1, N. Machida1 and K.Mitsumori1. 1Tokyo University of Agriculture andTechnology, Tokyo, Japan and 2NIHS, Tokyo, Japan.Sponsor: M. takahashi.

#212 ROLE OF NITRIC OXIDE IN DIESEL EXHAUSTPARTICLE-INDUCED GENOTOXIC ANDMUTAGENIC ACTIVITIES IN THE RAT LUNG. J.Y. Ma1, H. W. Zhao1, X. J. Yin2, M. W. Barger1, J. K.Ma2 and V. Catranova1. 1HELD, NIOSH, Morgantown,WV and 2School of Pharmacy, West Virginia University,Morgantown, WV.

#213 CONTRIBUTION OF REACTIVE OXYGENSPECIES TO PARA-AMINOPHENOL-INDUCEDCYTOTOXICITY. B. D. Foreman and J. B. Tarloff.Pharmaceutical Sciences, University of the Sciences inPhiladelphia, Philadelphia, PA.

#214 ENVIRONMENTAL BASIS OFNEURODEGENERATION (ND) AND AGING:DIBROMOACETONITRILE (DBAN) INDUCESPROTEIN OXIDATION, INHIBITSPROTEASOMAL ACTIVITY AND ALTERSCYTOSOLIC PROTEOME IN NEUROGLIALCELLS. A. E. Ahmed1, A. Kurosky2, J. R. Perez-Polo2,B. Kurian1 and S. Jacob1. 1Pathology, University TXMedical Branch, Galveston, TX and 2HBC&G,University TX Medical Branch, Galveston, TX.

#215 AGE-RELATED ALTERATIONS IN KAINICACID-INDUCED NEURONAL OXIDATIVEDAMAGE. D. Milatovic1, S. Zaja-Milatovic1, R. C.Gupta2 and T. J. Montine1. 1Pathology, University ofWashington, Seattle, WA and 2Toxicology, Murray StateUniversity, Hipkinsville, KY.

#216 PROTECTIVE EFFECTS OF TAURINE AGAINSTREACTIVE OXYGEN SPECIES IN ARPE-19CELLS. M. Tsang and R. Tchao. Department ofPharmaceutical Sciences, University of the Sciences inPhiladelphia, Philadelphia, PA. Sponsor: J. Tarloff.

Program Description



MO

ND

AY

#217 INDUCTION OF INFLAMMATORY MEDIATORSAND ANTIOXIDANTS FOLLOWING EXPOSUREOF MACROPHAGES TO PARAQUAT. R.Mukhopadhyay1, J. P. Gray1, D. E. Heck2, A. T. Black1,V. M. Mishin2, M. Thiruchelvam1, D. A. Cory-Slechta1

and J. D. Laskin1. 1Environmental and OccupationalMedicine, UMDNJ-Robert W Johnson Med. School,Piscataway, NJ and 2Pharmacology and Toxicology,Rutgers University, Piscataway, NJ.

#218 ASCORBATE INHIBITS UROPORPHYRIA INASCORBATE-REQUIRING MICE. P. R. Sinclair1,2,N. Gorman1,2, H. W. Trask1,2, A. Zaharia1,2 and J. F.Sinclair1,2. 1Research, VA Med. Ctr, White RiverJunction, VT and 2Biochem/Pharmacol-Toxicol,Dartmouth Med. School, Hanover, NH.

#219 DETERMINATION OF PARAMETERSINDICATIVE FOR OXIDATIVE STRESS INCARBON TETRACHLORIDE TREATED RATS. P.Sagelsdorff1 and Y. Balduchelly2. 1MechanisticToxicology, RCC Ltd., Fuellinsdorf, Switzerland and2Chimie, HEVs, Sion, Switzerland. Sponsor: K.Sachsse.

#220 6-HYDROXYDOPAMINE ACTIVATES THEANTIOXIDANT RESPONSE ELEMENTTHROUGH A COMBINATION OF OXIDATIVE,EXCITOTOXIC, AND STRUCTURAL FACTORS.R. J. Jakel1,2,3, J. T. Kern3, D. A. Johnson3 and J. A.Johnson1,3. 1Neuroscience Training Program, Universityof Wisconsin, Madison, WI, 2Medical Scientist TrainingProgram and UW Medical School, University ofWisconsin, Madison, WI and 3Pharmaceutical Sciences,University of Wisconsin, Madison, WI.

#221 ACTIVATION OF TRANSCRIPTION FACTORAP-1 IN ANILINE-INDUCED SPELENICTOXICITY. S. -. Kannan, J. -. Wang and M. Khan.Pathology, Univesrity of Texas Medical Branch,Galveston, TX.

#222 DOWN-REGULATION OF NITRIC OXIDE ANDANTIOXIDANT SYSTEMS IN ALCOHOL-INDUCED HYPERTENSION. K. Husain, J. Lalla andS. Kazim. Pharmacology and Toxicology, Ponce Schoolof Medicine, Ponce, Puerto Rico.

#223 HO-1 INDUCTION CONTRIBUTES TO PCB-INDUCED OXIDATIVE STRESS INDOPAMINERGIC CELLS. D. W. Lee, R. M. Geleinand L. A. Opanashuk. Department of EnvironmentalMedicine, University of Rochester School of Medicineand Dentistry, Rochester, NY.

#224 REACTIVE OXYGEN/NITROGEN SPECIES INACETAMINOPHEN (APAP) TOXICITY INFRESHLY ISOLATED MOUSE HEPATOCYTES.A. B. Reid and J. A. Hinson. Pharmacology, Universityof Arkansas for Medical Sciences, Little Rock, AR.

#225 ACETAMINOPHEN INDUCED HEPATOXICITYIN A GCLM- NULL MOUSE MODEL. L.McConnachie1, C. Fernandez1, I. Mohar1, R. Pierce2

and T. Kavanagh1. 1Department of Environmental andOccupational Health Sciences, University ofWashington., Seattle, WA and 2Department of Pathologyand Lab. Medicine, University of Rochester, Rochester,NY.

#226 INDUCTION OF METALLOTHIONEINSYNTHESIS MEDIATED THROUGH OXIDATIVESTRESS IN MITOCHONDRIA AND ITSBIOLOGICAL ROLE. M. Sato. Faculty of Pharmacy,Tokushima Bunri University, Tokushima, Japan.

#227 HEPATOCYTE-SPECIFIC DELETION OF GCLCRESULTS IN PROGRESSIVE LOSS OFMITOCHONDRIAL FUNCTION. Y. Chen, D. Shen,H. G. Shertzer, M. L. Miller, S. N. Schneider, D. W.Nebert and T. P. Dalton. Environmental Health,University of Cincinnati Medical Center, Cincinnati,OH.

#228 A NOVEL HALOENOL LACTONE DERIVATIVEINDUCES OXIDATIVE STRESS IN HUMANTUMOR CELLS THROUGH A GLUTATHIONE S-TRANSFERASE MEDIATED MECHANISM. W.Wang and J. Zheng. Pharmaceutical Sciences,Northeastern University, Boston, MA.

#229 IDENTIFICATION AND CHARACTERIZATIONOF BIOACTIVE COMPOUNDS FROM TOBACCOAS INHIBITORS OF NEURONAL NITRIC OXIDESYNTHASE. P. Venkatakrishnan1 and T. R. Miller1.1Graduate Center for Toxicology, University ofKentucky, Lexington, KY and 2Graduate Center forToxicology, University of Kentucky, Lexington, KY.


POSTER SESSION: METHYL IODIDE RISK ASSESSMENT

Chairperson(s): Michael Gargas, Sapphire Group Inc., Dayton, OH and LisaSweeney, The Sapphire Group, Dayton, OH.



#230 DEVELOPMENT AND VALIDATION OF ANASSAY FOR IODIDE IN SERUM USING IONCHROMATOGRAPHY WITH AMPEROMETRICDETECTION. E. Kaiser1, J. M. Flaherty1, M. W.Himmelstein2 and J. H. Kinzell3. 1Exygen Research,Inc., State College, PA, 2DuPont Haskell Laboratory forHealth and Environmental Sciences, Newark, DE and3Arvesta Corporation, San Francisco, CA.

#231 METHYLATION OF HEMOGLOBIN CYSTEINEAS A BIOMARKER OF EXPOSURE TOIODOMETHANE. D. L. Nabb1, M. W. Himmelstein1,M. P. Delorme1, E. Sloter3, M. L. Gargas2, J. H.Kinzell4 and R. A. Kemper1. 1DuPont HaskellLaboratory, Newark, DE, 2The Sapphire Group, Dayton,OH, 3WIL Research Laboratories, Ashland, OH and4Arvesta Corporation, San Fransisco, CA.

#232 UPTAKE OF METHYL IODIDE IN THE NASALCAVITY OF RATS AND RABBITS. K. D. Thrall1, A.D. Woodstock1, J. J. Soelberg1, J. H. Kinzell2 and M. L.Gargas3. 1Battelle, Pacific Northwest Division,Richland, WA, 2Arvesta Corp., San Francisco, CA and3The Sapphire Group, Inc., Beavercreek, OH.

Program Description


MO

ND

AY


#233 SPECIES AND TISSUE COMPARISON OF THEGLUTATHIONE CONJUGATION OF METHYLIODIDE IN RAT, RABBIT, AND HUMANCYTOSOL. T. Poet1, H. Wu1, J. Soelberg1, J. Kinzell2

and M. Gargas3. 1Biological Monitoring and Modeling,Battelle, Richland, WA, 2Arvesta Corp, San Francisco,CA and 3The Sapphire Group, Inc., Beavercreek, OH.

#234 IODOMETHANE: 2-DAY MECHANISTICINHALATION EXPOSURE STUDY IN THE RAT.M. W. Himmelstein1, M. P. DeLorme1, R. A. Kemper1,D. L. Nabb1, J. C. O’Connor1, M. L. Gargas2 and J. H.Kinzell3. 1DuPont Haskell Laboratory for Health andEnvironmental Sciences, Newark, DE, 2The SapphireGroup, Dayton, OH and 3Arvesta Corporation, SanFrancisco, CA.

#235 EVALUATION OF RESPIRATORY PARAMETERSIN RATS AND RABBITS EXPOSED TOIODOMETHANE. M. DeLorme1, M. W. Himmelstein1,M. L. Gargas2 and J. H. Kinzell3. 1DuPont HaskellLaboratory, Newark, DE, 2The Sapphire Group, Dayton,OH and 3Aresta Corporation, San Francisco, CA.

#236 IODOMETHANE PARTITION COEFFICIENTSIN RAT AND RABBIT TISSUES AND HUMANBLOOD. S. Gannon1, M. W. Himmelstein1, L. M.Sweeney2, M. L. Gargas2 and J. H. Kinzell3. 1DupontHaskell Laboratory for Health and EnvironmentalSciences, New Castle, DE, 2The Sapphire Group,Dayton, OH and 3Arvesta Corporation, San Francisco,CA.

#237 DERIVATION OF HUMAN TOXICITYREFERENCE VALUES FOR METHYL IODIDEUSING PBPK MODELING. L. M. Sweeney1, J. H.Kinzell2 and M. L. Gargas1. 1The Sapphire Group,Dayton, OH and 2Arvesta Corporation, San Francisco,CA.

#238 THE DISPOSITION AND PHARMACOKINETICSOF RADIOIODIDE IN PREGNANT RABBITSAND FETUSES. J. E. Morris1, L. B. Sasser1, J. A.Creim1, L. K. Fritz1, K. D. Thrall1, J. H. Kinzell2 andM. L. Gargas3. 1Battelle, Pacific Northwest Division,Richland, WA, 2Arvesta Corp., San Francisco, CA and3The Sapphire Group, Beavercreek, OH.

#239 PRENATAL DEVELOPMENTAL TOXICITYSTUDIES IN RABBITS REVEAL A SUSCEPTIBLEWINDOW OF METHYL IODIDE-INDUCEDFETOTOXICITY LATE IN GESTATION. M. D.Nemec1, E. D. Sloter1, J. F. Holson1, D. G. Stump1 andJ. Kinzell2. 1WIL Research Laboratories, Inc., Ashland,OH and 2Arvesta Corporation, San Francisco, CA.

#240 METHYL IODIDE-INDUCEDHYPOTHYROIDISM IN FETAL RABBITS. E. D.Sloter1, M. D. Nemec1, R. Baumgartner1, J. F. Holson1,M. Gargas2 and J. Kinzell3. 1WIL ResearchLaboratories, Inc., Ashland, OH, 2The Sapphire Group,Inc., Beavercreek, OH and 3Arvesta Corporation, SanFrancisco, CA.


POSTER SESSION: REGULATORY/POLICY

Chairperson(s): Abdel-Razak Kadry, OPHS/USDA/FSIS, Washington, DC andTimothy McMahon, U.S. EPA, Washington, DC.



#241 QUANTITATIVE ASSESSMENT OF DERMALSENSITIZATION RISK FROM TREATEDARTICLES: HEXAVALENT CHROMIUM (CRVI)AS A CASE STUDY. T. McMahon and J. Chen. U.S.EPA, Washington, DC.

#242 THE USE OF RISK ASSESSMENT INEVALUATING FOOD BIOSECURITY OPTIONS.A. M. Kadry1, C. Maczka2, P. Santiago2 and L. Borghi3.1Risk Assessement Division, OPHS/USDA/FSIS,Washington, DC, 2OFSEP/USDA/FSIS, Washington,DC and 3Science Applications InternationalCorporation, Germantown, MD.

#243 MYCOTOXIN RISK ASSESSMENT FOR THEPURPOSE OF SETTING INTERNATIONALREGULATORY STANDARDS. F. Wu. Environmental& Occupational Health, University of Pittsburgh,Pittsburgh, PA. Sponsor: M. Karol.

#244 ASSESSMENT OF THE TOXICOLOGICAL RISKOF CHEMICAL MIXTURES AT WORKPLACE. A.Vyskocil1, D. Drolet2, C. Viau1, F. Lemay2, G.Lapointe3, R. Tardif1, G. Truchon2, M. Baril2, N.Gagnon3, D. Begin1 and M. Gerin1. 1Environmental andOccupational Health, University of Montreal, Montreal,QC, Canada, 2IRSST, Montreal, QC, Canada and3CSST, Montreal, QC, Canada.

#245 SCIENTIFIC PEER REVIEW TO INFORMREGULATORY DECISION-MAKING:LEADERSHIP RESPONSIBILITIES ANDCAUTIONS. D. Patton1,2 and S. Olin1. 1Risk ScienceInstitute, International Life Sciences Institute,Washington, DC and 2Consultant, Washington, DC.Sponsor: P. Fenner-crisp.

#246 A STRATEGY FOR THE SELECTION OF THENON-RODENT IN REGULATORYPHARMACEUTICAL TOXICITY TESTING. J.Burnett and J. Gardner. Covance Laboratories Ltd.,Harrogate, United Kingdom. Sponsor: D. Everett.

#247 CIRCADIAN VARIATION IN FEEDINGBEHAVIOUR OF RODENTS RECEIVINGPOWDERED DIET ON REGULATORYTOXICITY STUDIES: 1) THE MOUSE. D. Everett,R. Jones and F. Halleema. Covance Laboratories Ltd.,Harrogate, United Kingdom.

Program Description



MO

ND

AY


POSTER SESSION: EDUCATION AND PUBLIC OUTREACH

Chairperson(s): Daniel Petersen, U.S. EPA, Cincinnati, OH.



#248 ADDRESSING TOXICOLOGICAL CHALLENGESTO COMMUNITY WATER FLUORIDATION INWASHINGTON STATE. D. Dodge, R. C. Pleus andM. K. Peterson. Intertox, Seattle, WA.

#249 HOW STAFF GROW IN A CRO. L. K. Earl.Toxicology Consultancy, Huntingdon Life Sciences,Cambridgeshire, United Kingdom. Sponsor: C. Hardy.

#250 PERCEPTION OF METHYLMERCURY RISKINFORMATION. D. D. Petersen1,2. 1ORD, U.S. EPA,Cincinnati, OH and 2Biology, University of Cincinnati,Cincinnati, OH.

#251 TOXICOLOGY EDUCATION–TO LEARN OR TOTEACH? T. Malmfors. Malmfors Consulting AB,Johanneshov, Stockholm, Sweden.


POSTER SESSION: CHILDRENS HEALTH AND JUVENILE ANIMALTOXICOLOGY

Chairperson(s): Susan Knadle, CAL-EPA, Sacramento, CA and GonzaloGarcia-Vargas, Universidad Juarez del Estado de Durango, Gomez Palacio,Mexico.



#252 BLOOD LEAD, ANEMIA, AND SHORT STATUREARE INDEPENDENTLY ASSOCIATED WITHCOGNITIVE PERFORMANCE IN MEXICANSCHOOL CHILDREN. G. G. Garcia-Vargas1, K.Kordaz2, M. Rubio-Andrade1, P. Lopez3, J. L. Rosado4,J. Alatorre Rico5, D. Ronquillo4, M. E. Cebrian6 and R.J. Stoltzfus2. 1Facultad de Medicina., UniversidadJuarez de Durango, Gomez Palacio, Durango, Mexico,2Division Nutritional Sciences, Cornell University, NewYork, 3Department Fisiologia Nutricion, Inst. Nal.Ciencias Medicas y Nutricion, Mexico, D. F., Mexico,4Escuela de Ciencias Naturales, UAQ, Queretaro,Mexico, 5Facultad de Psicologia, UNAM, Mexico, D.F., Mexico and 6Depto Toxicologia, CINVESTAV-IPN,Mexico, D. F., Mexico.

#253 LEAD EXPOSURE AS RISK FACTOR BYALLERGY DISEASES IN MEXICANCHILDHOOD. A PILOT STUDY. R. Goytia-Acevedo1, G. Rodriguez1, M. Meza-Velazquez1, E.Calderon-Aranda2, G. Garcia-Arenas1, G. Rosales1, M.Rubio-Andrade1, R. Candelas1 and G. Garcia-Vargas1.1Investigacion, Universidad Juarez Del Estado deDurango, Gomez Palacio, Durango, Mexico and2Toxicologia, Centro de Investigacion y de EstudiosAvanzados, DF, Mexico.

#254 DEVELOPMENT OF CHILD-SPECIFICREFERENCE VALUES FOR SCHOOL SITE RISKASSESSMENT. S. Knadle1, D. W. Chan1, J. C.Carlisle1, K. E. Stewart3, C. A. Poole2, C. Vaughn2, S.Camacho2 and D. M. Siegel1. 1Cal/EPA, Sacramento,CA, 2UC, Davis, CA and 3U.S. EPA, S.F., CA.

#255 ENVIRONMENTAL FACTORS AND PUBERTYTIMING: SUMMARY OF AN EXPERT PANELWORKSHOP. S. Y. Euling1, S. G. Selevan1, O. H.Pescovitz2 and N. E. Skakkebaek3. 1NCEA-W, U.S.EPA, Washington, DC, 2PediatricEndocrinology/Diabetology, Indiana University,Indianapolis, IN and 3University Department of Growthand Reproduction, Rigshospitalet, Copenhagen,Denmark. Sponsor: C. Kimmel.

#256 BISPHENOL A EXPOSURE AND ENDOCRINEDISORDERS IN CHILDREN. M. Yang1, Y. Kim1, C.Shin2, S. Han3 and M. Pyo1. 1Pharmacy, SookmyungWomen’s University, Seoul, South Korea, 2Pediatrics,Seoul National University, Seoul, South Korea and3Urology, Yonsei University, Seoul, South Korea.

#257 AN AGE-DEPENDENT HALF-LIFE MODEL FORESTIMATING CHILDHOOD BODY BURDENSOF DIBENZODIOXINS AND DIBENZOFURANS.B. D. Kerger1, H. W. Leung2, P. Scott3 and D. J.Paustenbach4. 1Health Science Resource Integration,Inc., Tallahassee, FL, 2Private Consultant, Danbury, CT,3ChemRisk, Pittsburgh, PA and 4ChemRisk, SanFrancisco, CA.

#258 ARE THERE AGE RELATED DIFFERENCES INCHILDRENS SUSCEPTIBILITY FORDEVELOPING SECONDARY ACUTEMYELOGENOUS LEUKEMIA? D. Pyatt1,2, S.Hays4 and C. Cushing3. 1ChemRisk, Boulder, CO,2MTEHS, University of Colorado Health SciencesCenter, Denver, CO, 3Exponent, Boulder, CO and4Summit Toxicology, Lyons, CO.

#259 PBPK MODELING OF INTER-CHILDDIFFERENCES IN PHARMACOKINETICS ONTHE BASIS OF SUBJECT-SPECIFIC DATA ONHEPATIC CYP2E1 LEVELS. A. Nong1, D. G.McCarver2, R. Hines2 and K. Krishnan1. 1Occupationaland Environmental Health, Universite de Montreal,Montreal, QC, Canada and 2Medical College ofWisconsin, Milwaukee, WI.

Program Description


MO

ND

AY


#260 DEVELOPMENTAL EXPOSURE TOENVIRONMENTAL ESTROGENS ISASSOCIATED WITH OBESITY LATER IN LIFE.E. Padilla-Banks1, W. Jefferson1,2, R. Snyder2 and R.Newbold1. 1Laboratory of Molecular Toxicology,NIEHS, NIH/DHHS, Research Triangle Park, NC and2Molecular and Evironmental Toxicology Department,NC State University, Raleigh, NC.

#261 PHYSIOLOGICAL PARAMETERS FOR EARLYLIFE STAGES. S. Olin1, H. Clewell2, R. Gentry2 andI. Working Group1. 1Risk Science Institute, InternationalLife Sciences Institute, Washington, DC and2ENVIRON Health Sciences Institute, Ruston, LA.

#262 NON-CLINICAL RODENT PEDIATRIC STUDIESAT CTBR: ASSESSMENT OF MORTALITY ANDGROWTH. L. Pouliot, L. Pinsonneault, M. Adamo andK. Robinson. Toxicology, CTBR, Senneville, QC,Canada. Sponsor: M. Vezina.

#263 AGE-RELATED DIFFERENCES INSUSCEPTIBILITY TO TOXIC EFFECTS OFVALPROIC ACID IN RATS. P. Espandiari, T. Miller,A. Knapton, J. Zhang and J. Hanig. CDER, U.S. FDA,Silver Spring, MD.

#264 ASSESSMENT OF HAZARD POTENTIAL ANDRISK FOR ASTHMATIC RESPONSESFOLLOWING RESIDENTIAL EXPOSURE TOPHTHALATES. R. McKee, R. David, J. H. Butala, R.Parod and L. Navarro. Phthalate Esters Panel,Washington, DC.

#265 BENZYL ALCOHOL: SAFETY ASSESSMENT INJUVENILE RATS. O. Foulon, L. Mungapen, W.Gaoua and R. Forster. CIT, Evreux, France.

#266 LIPID PEROXIDATION PRODUCT INDUCEDGASTRIC GROWTH IN POSTNATAL RATS BYMODULATION OF SELECTED PROTEINKINASES. P. C. Lee1,2. 1Pediatrics, Medical College ofWisconsin, Milwaukee, WI and 2Pharmacology andToxicology, Medical College of Wisconsin, Milwaukee,WI.

#267 GENE EXPRESSION PROFILES OF THEARTICULAR CARTILAGE IN JUVENILE RATSTREATED WITH THE QUINOLONEANTIBACTERIAL AGENT OFLOXACIN. K.Goto1, K. Yabe1, S. Takada1, Y. Yamamoto1, H. Yokota2,T. Jindo1 and K. Furuhama1. 1Drug Safety ResearchLaboratory, Daiichi Pharmaceutical Co., Ltd.,, Tokyo,Japan and 2Proteome Research Laboratory, DaiichiPharmaceutical Co., Ltd.,, Tokyo, Japan.

#268 A NOVEL APPROACH TO GENERATEJUVENILE ANIMAL DATA DURING THEPRE/POSTNATAL RANGE FINDING STUDY INTHE RAT. L. M. De Schaepdrijver1, G. P. Bailey1, L.M. Burns2, J. Monbaliu1, P. Annaert1, T. P. Coogan3 andW. Coussement1. 1Johnson and Johnson PharmaceuticalResearch & Development, Beerse, Belgium, 2SequaniLimited, Ledbury, United Kingdom and 3Johnson andJohnson Pharmaceutical Research and Development,Springhouse, PA.

#269 IMPACT OF DOSE RATE ON NEUROTOXICITYOUTCOME IN CD RAT PUPS GIVEN THE N-METHYL-D-ASPARTATE (NMDA) RECEPTORANTAGONIST, MK-801. M. S. Marty, J. A.Hammond, A. J. Clark, D. Rick, J. Van Fleet, A. K.Andrus and J. P. Maurissen. Toxicology &Environmental Research, The Dow Chemical Company,Midland, MI.

#270 COMPARATIVE DATA OF HAND-REARED ANDMATERNALLY REARED INFANTCYNOMOLGUS MONKEYS FOR TOXICITYSTUDIES. F. P. de Villa1, R. M. Perez1, T. Hayashi1, N.Muto2, M. Nomura2 and H. Nakagawa2. 1Ina ResearchPhilippines, Inc., Binan Laguna, Philippines and 2InaResearch Inc., Nagano, Japan.


POSTER SESSION: DEVELOPMENTAL TOXICITY TESTING

Chairperson(s): Christopher Lau, U.S. EPA, Research Triangle Park, NC andGregg Cappon, Pfizer Global Research & Development, Groton, CT.



#271 INFLUENCE OF MATERNAL TOXICITY INSTUDIES ON DEVELOPMENTAL TOXICITY: AWORKSHOP REPORT. F. Welsch1 and E. C.Hennes2. 1Orbitox, Santa Fe, NM and 2ECETOC,Brussels, Belgium.

#272 TIME-MATED RABBITS WITH VASCULARACCESS PORT (VAP): A NOVEL APPROACH TOTHE VASCULAR SYSTEM FOR SERIALINFUSION OR REPETITIVE BLOODCOLLECTION. D. S. Broughton1, B. Fetter2, S.Fleener1 and N. Frampton2. 1Technical Services, CRP,Denver, PA and 2SAD, CRP, Denver, PA. Sponsor: K.Williams.

#273 EFFECTS OF FEED RESTRICTION ONEMBRYO-FETAL DEVELOPMENT IN RATS ANDRABBITS. T. N. Lawrence, L. Tripp, M. S. Gilman, G.D. Cappon, M. E. Hurtt and T. L. Fleeman. PfizerGlobal Research and Development, Groton, CT.

#274 MICROARRAY-BASED ANALYSIS OFNUTRITION-ETHANOL INTERACTIONSDURING GESTATION. K. Shankar1,3, M.Hidestrand1,3, B. Yarberry3, R. Xiao2,3, F. A. Simmen2,3,T. M. Badger2,3,1 and M. J. Ronis1,3. 1Pharmacology andToxicology, University of Arkansas for MedicalSciences, Little Rock, AR, 2Physiology and Biophysics,University of Arkansas for Medical Sciences, LittleRock, AR and 3Arkansas Children’s Nutrition Center,Little Rock, AR.

Program Description



MO

ND

AY

#275 DEVELOPMENTAL AND REPRODUCTIVETOXICITY OF DI-ISOHEPTYL PHTHALATE INRODENTS. R. H. McKee1, K. L. Pavkov1, G. W.Trimmer1, L. H. Keller2 and D. G. Stump3. 1Toxicology& Environmental Sciences, ExxonMobil BiomedicalSciences, Inc., Annandale, NJ, 2ExxonMobil ChemicalCompany, Houston, TX and 3Wil ResearchLaboratories, Ashland, OH.

#276 ASSESSING THE ROLE OF CYTOSOLICPHOSPHOLIPASE A (CPLA2) INHIBITION INPHTHALATE ESTER TOXICITY. R. A. Clewell, S.M. Ross, K. W. Gaido and M. E. Andersen. CIITCenters for Health Research, Research Triangle Park,NC.

#277 MEDIUM CHAIN CHLORINATEDPARAFFIN(MCCP)-INDUCED HAEMORRHAGICLESIONS IN NEONATAL SPRAGUE-DAWLEYRATS. A ROLE FOR ALTERED VITAMIN KDISPOSITION? C. Elcombe1, B. Elcombe1, R.Powrie1, S. Barton3 and D. Farrar2. 1CXR BiosciencesLtd., Dundee, United Kingdom, 2Ineos Chlor Ltd.,Runcorn, United Kingdom and 3Inveresk Research,Tranent, United Kingdom.

#278 EFFECTS OF EXPOSURE TO 1-BROMOPROPANE IN GESTATION ANDLACTATION PERIOD ON DAMS ANDOFFSPRING IN RATS. K. Furuhashi1, H. Wang1, J.Kitoh1, H. Tsukamura2, K. Maeda2, Y. Takeuchi1 and G.Ichihara1. 1Nagoya University Graduate School ofMedicine, Nagoya, Japan and 2Nagoya UniversityGraduate School of Bioagricultural Sciences, Nagoya,Japan.

#279 L-THREO 3, 4-DIHYDROXYPHENYLSERINE(DOPS) TREATMENT DURING PERINATALDEVELOPMENT DOES NOT ALTER THEIMPACT OF DIETARY COPPER DEFICIENCY INMICE. J. Pyatskowit and J. R. Prohaska. University ofMinnesota-Duluth, Duluth, MN. Sponsor: K. Wallace.

#280 EFFECTS OF PERFLUOROOCTANOIC ACIDEXPOSURE DURING PREGNANCY IN THEMOUSE. J. Thibodeaux, R. G. Hanson, J. M. Rogersand C. Lau. RTD, NHEERL, ORD, U.S. EPA, ResearchTriangle Park, NC.

#281 DEVELOPMENTAL TOXICITY OF 1-BUTANOLGIVEN TO RATS IN DRINKING WATERTHROUGHOUT PREGNANCY. M. EMA1, H. Hara2,M. Matsumoto1, A. Hirose1 and E. KAMATA1. 1RiskAssessment, National Institute of Health Sciences,Tokyo, Japan and 2Ina Research, Inc., Ina, Japan.

#282 ASSESSMENT OF ISOBUTYL HEPTYL KETONE(IBHK) BY ORAL GAVAGE IN AN OECD 422 RATREPRODUCTION/DEVELOPMENTALSCREENING STUDY WITH SYSTEMIC ANDNEUROLOGICAL ENDPOINTS. D. M. Wilson, E.W. Carney, C. L. Zablotny, B. L. Yano and T. J. Cawley.Dow Chemical, Midland, MI.

#283 A REVIEW OF THE ROLE OF GENOTOXICITYIN THE DEVELOPMENTAL/REPRODUCTIVETOXICITY OF AGROCHEMICALS. P. R. IYER1

and D. W. Gammon2. 1OEHHA/RCHAS,CALIFORNIA EPA, SACRAMENTO, CA and 2CDPR,California EPA, Sacramento, CA.

#284 DETERMINATION OF DART REFERENCEDOSES FOR WORKPLACE CHEMICALEXPOSURES. C. J. Fields1, R. J. Parod2, T. A.Lewandowski1, C. A. Bradlee2, S. L. Jasti2 and E. J.Kerfoot2. 1Gradient Corporation, Seattle, WA and2BASF Corporation, Wynadotte, MI.

#285 DEVELOPMENT OF QSAR MODELS TOPREDICT DEVELOPMENTAL ANDREPRODUCTIVE TOXICITY OF CHEMICALS.H. Choudhury1, R. Venkatapathy2 and C. Moudgal1.1NCEA, U.S. EPA, Sodertalje, Sweden and2ORISE/NCEA-U.S. EPA, Cincinnati, OH.

Abstract 286 is located on page 70.

Monday Afternoon

Monday Afternoon, March 712:15 PM to 1:15 PMBallroom B

MEDICAL RESEARCH COUNCIL (MRC) LECTURE: NOVELUNCOMPETITIVE ANTAGONISTS PROTECT NEURONS FROMEXCITOTOXIC, OXIDATIVE, AND NITROSATIVE STRESS

Lecturer: Stuart A. Lipton, MD, PhD, Professor, Burnham/Salk/ScrippsResearch Institutes and UC San Diego.

Monday Afternoon, March 712:15 PM to 1:15 PMRoom RO1

ROUNDTABLE SESSION: ELECTROCARDIOGRAPHY SAFETYEVALUATION STUDIES–NEW TECHNIQUES AND APPROACHES

Chairperson(s): Lewis B. Kinter, AstraZeneca Pharmaceuticals, Wilmington,DE and Dennis J. Murphy, GlaxoSmithKline Pharmaceuticals, King ofPrussia, PA.

#339 12:15 ELECTROCARDIOGRAPHY SAFETYEVALUATION STUDIES: NEW TECHNIQUESAND APPROACHES. L. B. Kinter1 and D. J.Murphy2. 1Safety Assessment, AstraZeneca,Wilmington, DE and 2Drug Safety Assessment,GlaxoSmithKline, King of Prussia, PA.

#340 12:20 CARDIAC ELECTROPHYSIOLOGY FROM THESINGLE CELL TO THE INTACT HEART. R.Hamlin. Veterinary Cardiology, Ohio State University,Columbus, OH. Sponsor: L. Kinter.

#341 12:30 TECHNIQUES AND ELECTROGRAPHIC LEADPLACEMENTS FOR IMPLANTED ECGMONITORS. R. Coatney. Animal Modeling &Imaging, GlaxoSmithKline, King of Prussia, PA.Sponsor: L. Kinter.

Program Description


MO

ND

AY


#342 12:45 INTRACARDIAC AND INTRAVASCULAR LEADUTILIZATION: METHODS FOR IMPROVEDDATA COLLECTION. C. Hassler. SafetyPharmacology, Battelle Memorial Laboratories,Columbus, OH. Sponsor: L. Kinter.

#343 1:00 OBTAINING QUALITY ECG ENDPOINTS INSAFETY PHARMACOLOGY AND GENERALTOXICOLOGY STUDIES. ARE RESTRAINT ANDSURGICAL INTERVENTION NECESSARY? M.Zawada and L. B. Kinter. Safety Assessment,AstraZeneca, Wilmington, DE.

Abstract 344 is located on page74.


INNOVATIONS IN TOXICOLOGICAL SCIENCES SESSION:ALTERNATIVE RNA SPLICING: A MECHANISM FOR ENHANCINGDIVERSITY OF GENE EXPRESSION

Chairperson(s): Curt Omiecinski, Pennsylvania State University, UniversityPark, PA and Craig Marcus, University of New Mexico, Albuquerque, NM.

Endorsed by:Carcinogenesis SS

Alternative RNA splicing is an emerging field of molecular science that hassignificant impact on the toxicological considerations of gene expression andprotein function. The diversity of alternatively spliced transcripts has far-reaching significance in terms of understanding interindividual differences inresponse to xenobiotics, mechanisms of toxicity at the molecular level, tissue-specific toxicity, and the mechanisms for regulating responses to environmentaland chemical challenge. This Symposium will provide an overview of basicmechanisms and toxicological significance of RNA alternative splicing, with afocus on alternatively spliced xenobiotic nuclear receptors. Importantly, thesession will also address bioinformatics-related issues pertaining to the identi-fication of splice variants, including the design of microarray and genomicsplatforms that facilitate variant transcript detection.

#286 1:30 INTRODUCTION TO SYMPOSIUM:ALTERNATIVE RNA SPLICING: AMECHANISM FOR ENHANCING DIVERSITY OFGENE EXPRESSION. C. Omiecinski. Ctr MolecToxicology, Penn State University, University Park, PA.

#287 1:35 DISCOVERY AND TISSUE-SPECIFICMONITORING OF ALTERNATIVE PRE-MNRASPLICING WVENTS USING INK-JETMICROARRAYS. J. M. Johnson, J. Castle, P. Garrett-Engele, Z. Kan, L. Lim, C. Armour, C. Raymond and E.Schadt. Informatics, Rosetta Inpharmatics, Merck &Co., Inc., Seattle, WA. Sponsor: C. Marcus.

#288 2:10 FUNCTIONALLY DISTINCT ISOFORMS OF THEFARNESOID X RECEPTOR (FXR). P. A. Edwards,Y. Zhang and F. Y. Lee. Biological Chemistry, UCLA,Los Angeles, CA. Sponsor: C. Marcus.

#289 2:45 HUMAN PXR: GENERATION OF DIVERSITYTHROUGH ALTERNATIVE SPLICING ANDPOLYMORPHISM. E. G. Schuetz. PharmaceuticalSciences, St. Jude Children’s Research Hospital,Memphis, TN. Sponsor: C. Marcus.

#290 3:20 FUNCTIONALLY DISTINCT ALTERNATIVESPLICE VARIANTS OF THE HUMANXENOBIOTIC RECEPTOR, CAR. C. Omiecinski, S.Auerbach and M. Stoner. Ctr Molec Toxicology, PennState University, University Park, PA.

#291 3:55 STEROID RECEPTOR COACTIVATORSPROMOTE COORDINATE TRANCRIPTION ANDALTERNATIVE SPLICING. B. W. O’Malley.Molecular & Cellular Biology, Baylor College ofMedicine, Houston, TX. Sponsor: C. Marcus.

Monday Afternoon, March 71:30 PM to 4:30 PMRoom 208

SYMPOSIUM SESSION: DIETARY ACRYLAMIDE: NEW ORANCIENT RISK?

Chairperson(s): Philip M. Bolger, U.S. FDA, College Park, MD and DanialDoerge, National Center for Toxicological Research, Jefferson, AR.

Endorsed by:Food Safety SS*Occupational and Public Health SSRegulatory and Safety Evaluation SSRisk Assessment SS

Initial investigations by Swedish researchers of fried and oven-baked foods indi-cated that acrylamide formation is associated with high temperature cookingprocesses for certain carbohydrate-rich foods, such as potatoes and cereals.Since then similar findings have been reported by researchers in other countries.The discovery of acrylamide in food is a concern because acrylamide is a poten-tial carcinogen and genotoxicant, and a known human neurotoxicant. It does notappear to be present in uncooked food and is present in low or undetectablelevels in foods cooked at lower temperatures, such as by boiling. One plausiblemechanism responsible for acrylamide formation in carbohydrate-rich foodscooked at high temperatures is the Mallard reaction between asparagine andcertain sugars. However, not enough is known about acrylamide formation toidentify safe, effective, and practical modifications to food processing tech-niques that will clearly prevent or reduce formation. Identifying majormechanisms of formation is an important step in identifying ways to reduce orprevent acrylamide formation during cooking. There are significant uncertain-ties about the impact of dietary acrylamide exposure on public health, sincefoods reported to contain acrylamide have been consumed for many years.While acrylamide causes cancer in laboratory animals at high doses, it is notclear whether a similar response would occur at the much lower levels found infood. Several epidemiological environmental studies of workplace and dietaryexposures have failed to show an increased cancer risk with acrylamide expo-sure. It is also conceivable that subtle effects can occur on the developingnervous system at acrylamide doses lower than those that have been studied inanimals and humans. To better assess the risk of acrylamide information isneeded on dietary exposure, bioavailability from food, biomarkers of exposure,and the potential to cause cancer and neurotoxic or neurodevelopmental effectswhen consumed in food.

#292 1:30 OVERVIEW OF DIETARY ACRYLAMIDE. P. M.Bolger. Center for Food Safety and Applied Nutrition,US Food and Drug Administration, College Park, MD.

#293 1:35 TOXICOKINETICS OF ACRYLAMIDE ANDGLYCIDAMIDE IN B6C3F1 MICE AND FISCHER344 RATS. D. R. Doerge1, J. F. Young2, L. McDaniel1,N. C. Twaddle1 and M. I. Churchwell1. 1Biochem.Toxicol., NCTR, Jefferson, AR and 2Biometry and RiskAssessment, NCTR, Jefferson, AR. Sponsor: P. Bolger.

Program Description



MO

ND

AY

#294 1:50 REFERENCE VALUES IN THE ACRYLAMIDEIRIS ASSESSMENT DEVELOPED BY THE U.S.EPA. R. S. DeWoskin. ORD/NCEA, U.S. EPA,Research Triangle Park, NC.

#295 2:30 DIETARY ACRYLAMIDE AND RISK OF HUMANCANCER: THE ROLE OF EPIDEMIOLOGY. L.Mucci1 and H. Adami2. 1Channing Laboratory, HarvardMedical School, Boston, MA and 2Department ofMedical Epidemiology and Biostatistics, KarolinskaInstitutet, Stockholm, Sweden. Sponsor: P. Bolger.

#296 3:10 AN INTERNATIONAL SAFETY/RISKASSESSMENT OF ACRYLAMIDE. S. H. Henry.Center for Food Safety & Applied Nutrition (HFS-308),U. S. Food & Drug Admin., College Park, MD.

Monday Afternoon, March 71:30 PM to 4:30 PMLa Louisiane Ballroom B

SYMPOSIUM SESSION: ENVIRONMENTAL FACTORS AFFECTINGBREAST CANCER SUSCEPTIBILITY

Chairperson(s): Suzanne Fenton, U.S. EPA, Research Triangle Park, NC andScott W. Burchiel, University of New Mexico, Albuquerque, NM.

Endorsed by:Carcinogenesis SSReproductive and Development SS*Toxicologic and Exploratory Pathology SSWomen in Toxicology SS

Breast cancer is still the most common malignancy afflicting women in theWestern world. Although substantial progress has been made in elucidatingsome of the genetic contributors to breast cancer (i.e., the highly penetrantsusceptibility genes, BRCA1 and 2), it has been estimated that only 6-12% ofall breast cancer cases are due to heritable factors. Few other specific factorshave been identified that contribute significantly to an individuals lifetime riskof breast cancer. It has become apparent that elements affecting cancer suscep-tibility (genetic or environmental components) cannot be considered separately.Environmental factors (e.g., industrial compounds, pharmaceuticals, diet, occu-pational hazards) have been identified in both epidemiological and rodentstudies that alter breast development and tumor formation. These constituentsmay act as either a mutagen or as a developmental compound able to altersusceptibility to carcinogens. In addition to the contributions of environmentalfactors, a large percentage of cancer cases are due to sporadic mutations thatmay occur as a result of spontaneous genetic events, and the interactionsbetween gene and environmental factors. A relatively recent focus in the breastcancer field is on the interaction between genes and environment as the causalmechanism in the disease. Primary candidates for gene-environment interactionstudies have been genes that encode enzymes involved in the metabolism ofestablished cancer risk factors and those involving oxidative stress response.There are common varying forms of these genes (polymorphisms) that maydirectly result in impacting the risk of cancer by altering normal metabolism,circulating hormone levels, ability to respond correctly to normal stressors, orresponse to environmental factors. We will present data from both epidemiolog-ical and rodent studies demonstrating the importance that environmental factorsplay in breast cancer susceptibility. These studies will elucidate the importanceof evaluating gene-environment interactions and the various environmentalfactors, such as diet and endocrine disrupting chemicals, on breast cancer riskassessment.

#297 1:30 ENVIRONMENTAL FACTORS AFFECTINGBREAST CANCER SUSCEPTIBILITY. S. Fenton.U.S. EPA, Research Triangle Park, NC.

#298 1:45 GENE-ENVIRONMENT INTERACTIONS IN THEETIOLOGY OF BREAST CANCER. C. Ambrosone.Roswell Park Cancer Institute, Buffalo, NY. Sponsor: S.Fenton.

#299 2:15 INFLUENCE OF ENDOCRINE DISRUPTINGCOMPOUNDS (EDCS) ON MAMMARY GLANDDEVELOPMENT AND TUMORSUSCEPTIBILITY. S. Fenton1 and J. L. Rayner2.1Reproductive Toxicology Division, U.S. EPA,Research Triangle Park, NC and 2DESE, UNC, ChapelHill, NC.

#300 2:45 EARLY LIFE DIETARY ESTROGENICEXPOSURES AND LATER SUSCEPTIBILITY TOMAMMARY TUMORIGENESIS. L. A. Hilakivi-Clarke, B. Yu and M. Martin. Oncology, GeorgetownUniversity, Washington, DC. Sponsor: S. Fenton.

#301 3:15 DNA DAMAGE/REPAIR IN HUMAN BREASTCANCER RISK. J. J. Hu. Cancer Biology, WakeForest U. School of Medicine, Winston-Salem, NC.

#302 3:45 ROLE OF OXIDANT STRESS IN THEACTIVATION OF GROWTH FACTORSIGNALING PATHWAYS IN HUMAN BREASTEPITHELIAL CELLS BY ENVIRONMENTALPOLYCYCLIC AROMATIC HYDROCARBONS(PAHS). S. W. Burchiel1, A. D. Burdick2, K. F.Melendez1, F. T. Lauer1 and J. W. Davis3. 1College ofPharmacy, University of New Mexico, Albuquerque,NM, 2Center for Molecular Toxicology, Penn StateUniversity, University Park, PA and 3Worldwide SafetySciences, Pfizer Global Research and Development, St.Louis, MO.

Program Description


MO

ND

AY



SYMPOSIUM SESSION: THE MULTI-SITE AMBIENT PARTICLESTUDY (MAPS): AN INTEGRATED APPROACH TO STUDYINGHEALTH EFFECTS OF PM COMPONENTS

Chairperson(s): Robert Devlin, National Health and Environmental EffectsResearch Laboratory, Research Triangle Park, NC and Terry Gordon, NewYork University, Tuxedo, NY.

Endorsed by:Inhalation SS*Occupational and Public Health SS

The World Health Organization estimates that particulate air pollution (PM) isresponsible for more than 500, 000 deaths worldwide each year. A large numberof epidemiology studies have associated PM mass with increased mortality, andthe EPA currently regulates PM on the basis of mass in different size ranges.However, recent studies suggest that PM derived from different sources maydiffer in toxicity and that specific PM components may serve as markers fordifferent sources, suggesting an alternative, more efficient way of regulatingPM. The overall objective of MAPS was to collect particles from severaldifferent geographical regions, characterize their physical and chemical proper-ties, and make them available to investigators for in vitro and animal instillationhealth studies that can relate health effects with PM components and ultimatelysources. Airborne particles in the ultrafine, fine, and coarse size ranges werecollected in eight different locations in the US and Europe. The sites wereselected to take advantage of regional differences in PM sources and compo-nents. Weekly samples were collected for a period of a month in each location,using a 3 stage particle impactor (developed at Harvard University) which iscapable of collecting several mg of material during a weekly sampling interval.The particles were then assayed for a number of chemical components and madeavailable to investigators in several different laboratories. This symposium willdescribe some of the studies which have characterized health effects associatedwith PM and PM components from each of the different geographical locations.Relating adverse health effects to specific PM size modes and specific PMchemical components is the first step towards relating these effects to PMderived from specific sources. This will ultimately allow the EPA to more effec-tively implement PM standards, thereby reducing not only the health impactsnow associated with PM, but also their substantial impacts on quality of life andthe national economy.

#303 1:30 THE MULTI-SITE AMBIENT PARTICLE STUDY(MAPS): AN INTEGRATED APPROACH TOSTUDYING HEALTH EFFECTS OF PMCOMPONENTS. R. Devlin1 and T. Gordon2. 1U.S.EPA, Research Triangle Park, NC and 2EnvironmentalMedicine, New York University, Tuxedo, NY.

#304 1:45 SAMPLE CHARACTERIZATION AND SOURCEAPPORTIONMENT OF AMBIENTPARTICULATE MATTER: COMBININGATMOSPHERIC SCIENCE AND LUNGTOXICOLOGY. J. M. Veranth1, G. S. Yost1, J. C.Chow2 and J. G. Watson2. 1Pharmacology andToxicology, University of Utah, Salt Lake City, UT and2Atmospheric Sciences, Desert Research Institute, Reno,NV.

#305 2:15 EFFECTS OF AMBIENT PM ON OXIDATIVESTRESS AND SIGNALING PATHWAYS. L. Chen1,X. Jin1, C. Huang1, T. Gordon1 and J. Hwang2.1Environmental Medicine, NYU School of Medicine,Tuxedo, NY and 2Statistics Institute, Academia Sinica,Taipei, Taiwan.

#306 2:45 EFFECTS ON CYTOKINE PRODUCTION BYMACROPHAGES, ENDOTHELIUM ANDEPITHELIAL CELLS. J. N. Finkelstein1,2.1Pediatrics, University of Rochester, Rochester, NY and2Evironmental Medicine, University of Rochester,Rochester, NY.

#307 3:15 HEALTH EFFECTS OF PARTICLES FROMTRAFFIC-RELATED AMBIENT AIRPOLLUTION ON RESPIRATORY ALLERGY ANDINFLAMMATION: A EUROPEAN MULTISITESTUDY. F. Cassee1,3, T. Sandstrom3 and E. Dybing2.1Centre for Environmental Health Research (MGO),National Institute for Public Health and theEnvironment (RIVM), Bilthoven, Netherlands,2Norwegian Institute of Public Health, Oslo, Norwayand 3Medicine and Allergy University Hospital, Umea,Sweden.

#308 3:45 EFFECT OF SIZE FRACTIONATED AMBIENTPM SAMPLES ON INDUCTION OFPULMONARY ALLERGY IN MICE. M. Gilmour.NHEERL, U.S. EPA, Research Triangle Park, NC.



WORKSHOP SESSION: ENVIRONMENTAL TERRORISM:DEVELOPMENT OF EVACUATION, RE-ENTRY AND RE-USEGUIDELINES FOR CHEMICAL, BIOLOGICAL ANDRADIOLOGICAL AGENTS

Chairperson(s): Mark Maddaloni, U.S. EPA, New York, NY and AnnieJarabek, U.S. EPA, Research Triangle Park, NC.

Endorsed by:Risk Assessment SS*

The collapse of the World Trade Center (WTC) presented a host of challengesto the governmental agencies charged with making decisions on evacuation, re-entry and long-term re-habitation for the impacted public in Lower Manhattan.Occupational standards, ranging from immediately dangerous to life and health(IDLH) concentrations to long-term permissible exposure limits (PELs) existedfor many of the building components and combustion by-products released fromthe WTC disaster. However, these standards are generally not well-suited forapplication to the general public (i.e. residents and office workers).Conventional environmental standards and guidelines have focused on estab-lishing long-term exposure limits for chemical contaminants in the ambientenvironment. That leaves a lot of poorly chartered territory for assessing envi-ronmental terrorism incidents that may involve biological or radiological agentswithin indoor settings, as well as in the ambient environment. The anthraxbioterrorism event of October, 2001 made that abundantly clear. The environ-mental response to the WTC disaster involved numerous governmental agenciesalong with the inevitable overlapping of jurisdictions and responsibilities. Afuture environmental terrorism event will likely follow suit. Accordingly, thisworkshop will engage the key governmental agencies involved in protecting thepublic health from environmental terrorism. The workshop will focus oncomparing and contrasting available methods for deriving short term (i.e. evac-uation), subchronic (i.e. re-entry) and long-term (i.e. re-habitation) exposurecriteria a for chemical, biological and radiological agents. Of particular interestwill be the role of background levels, analytical detection limits, social andeconomic disruption, and other miscellaneous factors in the setting of exposurelimits. Risk levels for the different exposure scenarios and agent classes will beevaluated for comparability. Data gaps and methodological shortcomings willbe identified for representative exposure scenarios within each class of agents.

Program Description



MO

ND

AY

#327 1:30 ENVIRONMENTAL TERRORISM:DEVELOPMENT OF EVACUATION, RE-ENTRYAND RE-USE GUIDELINES FOR CHEMICAL,BIOLOGICAL AND RADIOLOGICAL AGENTS.M. A. Maddaloni. U.S. EPA, New York. Sponsor: A.Jarabek.

#328 1:45 AN EPA PERSPECTIVE ON CHEMICALCONTAMINATION CLEAN-UP. S. Sterling, I. P.Baumel and C. Sonich-Mullin. ORD/NHSRC, U.S.EPA, Washington, DC. Sponsor: M. Maddaloni.

#329 2:15 A MILITARY APPROACH TO ASSESSINGHEALTH RISK. V. Hauschild and B. Thran.Directorate of Health Risk Management, US Army Ctrfor Health Promotion and Preventive Medicine,Aberdeen Proving Ground, Edgewood Area, MD.Sponsor: M. Maddaloni.

#330 2:45 BIOTERRORIST THREATS TO THE US FOODSUPPLY SYSTEM: A RISK ASSESSMENTPERSPECTIVE. B. Hope. Air Quality Division,Oregon Department of Environmental Quality, Portland,OR. Sponsor: A. Jarabeck.

#331 3:15 A PRIMER ON RADIATION ISSUES RELATEDTO NUCLEAR TERRORISM. S. L. Simon.Radiation Epidemiology Branch, National CancerInstitutes, Bethesda, MD. Sponsor: M. Maddaloni.

#332 3:45 DEVELOPMENT OF OPERATIONALGUIDELINES FOR CONSEQUENCEMANAGEMENT OF RADIOLOGICALDISPERSAL DEVICE INCIDENTS. S. Domotor1, A.Wallo1, C. YU2, D. LePoire2 and S. Kamboj2. 1USDOE, Washington, DC and 2Argonne NationalLaboratory, Washington, DC. Sponsor: A. Jarabek.


WORKSHOP SESSION: HIGH THROUGHPUT SCREENINGAPPROACHES IN GENETIC TOXICOLOGY

Chairperson(s): Jiri Aubrecht, Pfizer, Inc., Groton, CT and Robert Schiestl,University of California, Los Angeles, Los Angeles, CA.

Endorsed by:In Vitro SS*Risk Assessment SS

Recent progress in combinatorial chemistry, molecular biology, genomics, andautomation has enabled identifying a relatively large number of compoundscapable of reacting with intended pharmacological targets. However, 40% ofdrug candidates ultimately fail during clinical development due to safety relatedissues. The overall attrition of drug candidates due to genetic toxicology issuesalone includes about 12% of drug candidates. This causes delays in the introduc-tion of vital drugs to patients and significant economic losses. Therefore, thedevelopment of relevant mechanism-based high throughput screening technolo-gies to assess genetic toxicity at the early stages of drug discovery withrelatively limited amount of chemical is extremely important. Genetic toxi-cology provides the necessary information for assessment of the genotoxic riskassociated with the use of drugs. Since the beginning of genotoxicity testing inthe early 1970s, many different test systems have been developed and used.Since no single test is capable of detecting all genotoxic agents, the current stan-dard in vitro genotoxicity testing consists of evaluating mutagenicity (bacterialreverse mutation assay) and chromosome damage (lymphocyte aberration assayor mouse lymphoma assay). Unfortunately, these standard in vitro assays are notamenable to high throughput testing and their application in early phases of drugdiscovery is not feasible. Therefore, the research and assay development effortshave been directed to developing alternative approaches, technologies and/orendpoints. The speakers in this session present emerging state-of-the-art tech-nologies under development and/or currently used in the pharmaceuticalindustry. The topics covered in this symposium comprise high throughputversions of the Salmonella assay, assays for DNA deletions, chromosome aber-rations, the comet assay and a gene expression reporter assay. The presentationswill cover exciting developments that may spark further interest in the automa-tion of genotoxicity assays.

#333 1:30 HIGH THROUGHPUT SCREENINGAPPROACHES IN GENETIC TOXICOLOGY. R.H. Schiestl2 and J. Aubrecht1. 1Safety Sciences, Pfizer,Inc., Groton, CT and 2Departments of Pathology andEnvironmental Health, UCLA, Los Angeles, CA.

#334 1:40 BIOLUMINESCENT SALMONELLA REVERSEMUTATION ASSAY: A HIGH THROUGHPUTAPPROACH FOR DETECTION OFMUTAGENICITY. J. Aubrecht. Safety Sciences,Pfizer, Inc., Groton, CT.

#335 2:10 BIOLUMINESCENT YEAST DEL ASSAY TODETECT CARCINOGENS AND CLASTOGENS. R.Schiestl1 and J. Aubrecht2. 1Pathology, UCLA, LosAngeles, CA and 2Safety Sciences, Pfizer, Inc., Groton,CT.

#336 2:40 APPLICATION OF A HIGH THROUGHPUTCOMET ASSAY IN DRUG DISCOVERY. A.Hartmann1 and W. Frieauff2. 1Non Clinical Safety,F.Hoffmann-La Roche Ltd., Basel, Switzerland and2GenSafe / Precinical Safety, Novartis Pharmacology,Basel, Switzerland. Sponsor: J. Aubrecht.

Program Description


MO

ND

AY


#337 3:10 A FLOW CYTOMETRIC PROCESS FORDETECTING ANEUGENIC AGENTS IN VITRO. P.A. Muehlbauer and M. J. Schuler. Genetic Toxicology,Pfizer Global R & D, Groton, CT.

#338 3:40 HIGH-THROUGHPUT SCREENING USINGSTRESS-RESPONSIVE REPORTER GENEASSAYS. R. Brennan1 and J. D. Haley2. 1Toxicology,Iconix Pharmaceuticals Inc., Mountain View, CA and2Cancer Cell Biology, OSI Pharmaceuticals Inc.,Farmingdale, NY.



PLATFORM SESSION: COMPUTATIONAL TOXICOLOGY:ADVANCES AND APPLICATIONS

Chairperson(s): Melvin Andersen, CIIT Centers for Health Research,Research Triangle Park, NC and Kannan Krishnan, Université de Montréal,Montreal, QC, Canada.

#344 1:30 BIOLOGICALLY-BASED MATHEMATICALMODEL FOR GENE EXPRESSION DUE TO JP-8EXPOSURE TO SKIN. J. N. McDougal1, C. M.Garrett1, C. A. Amato1, Y. Zheng2, Q. Zhang3 and R. B.Conolly3. 1Department of Pharmacology & Toxicology,Wright State University School of Medicine, Dayton,OH, 2Department of Biomedical Engineering, PurdueUniversity, West Lafayette, IN and 3Center forComputational Systems Biology and Human HealthAssessment, CIIT Centers for Health Research,Research Triangle Park, NC.

#345 1:50 MODELLING THE RELATIONSHIP BETWEENNICKEL AND CHROMIUM EXPOSURE ANDCONTACT DERMATITIS. S. Franks and A. Jones.Health and Safety Laboratory, Buxton, UnitedKingdom. Sponsor: R. Conolly.

#346 2:10 COMPUTATIONAL MODELS FOR THEACQUISITION OF NEOCORTICAL NEURONS INTHE DEVELOPING HUMAN, MONKEY, ANDMOUSE: CROSS SPECIES COMPARISON OFTOXICODYNAMICS. J. M. Gohlke, W. C. Griffithand E. M. Faustman. Environmental and OccupationalHealth Sciences, University of Washington, Seattle,WA.

#347 2:30 MAGNETIC RESONANCE IMAGING ANDCOMPUTATIONAL FLUID DYNAMICSSIMULATIONS OF RABBIT NASAL AIRFLOWSFOR HYBRID CFD/PBPK MODELING OFMETHYL IODIDE. H. E. Trease1, K. R. Minard1, L.L. Trease1, R. A. Corley1, J. S. Kimbell2, J. R.Harkema3, J. H. Kinzell4 and M. L. Gargas5. 1BattelleNorthwest, Richland, WA, 2CIIT Centers for HealthResearch, Research Triangle Park, NC, 3Michigan StateUniversity, East Lansing, MI, 4Arvesta Corp., SanFrancisco, CA and 5The Sapphire Group, Beavercreek,OH.

#348 2:50 IN SILICO PHARMACOGENETIC ANALYSIS OFR-WARFARIN METABOLISM. Y. Guo1, P. Cheung2,J. Wang1, G. Liao1, J. Usuka1, M. Masjedizadeh3, P.Weller2 and G. Peltz1. 1Genetics & Genomics, RochePalo Alto, Palo Alto, CA, 2DMPK, Roche Palo Alto,Palo Alto, CA and 3Chemical Services, Roche PaloAlto, Palo Alto, CA.

#349 3:10 AN INTEGRATED QSAR-PBPK MODEL FORSIMULATING PHARMACOKINETICS OFCHEMICALS IN MIXTURES. K. Price and K.Krishnan. Occupational and Environmental Health,Universite de Montreal, Montreal, QC, Canada.

#350 3:30 ISSUES IN THE USE OF PBPK MODELING INTHE DEVELOPMENT OF CANCER SLOPEFACTORS FOR PERCHLOROETHYLENE. J. E.Kester, P. Gentry, T. R. Covington and H. J. Clewell.ENVIRON Health Sciences Institute, Ruston, LA.

#351 3:50 NEW APPLICATIONS FOR THE LEAD PBPKMODEL. S. M. Hays. Summit Toxicology, Lyons, CO.Sponsor: D. Pyatt.

#352 4:10 CAN HYDROGEN CYANIDE POISONING BEDETECTED IN EXHALED AIR? G. Johanson, K.Stamyr and P. Nord. Work Environment Toxicology,Karolinska Institute, Stockholm, Sweden.


PLATFORM SESSION: BIOTRANSFORMATION/CYTOCHROMEP450

Chairperson(s): Ernest Hodgson, North Carolina State University, Raleigh,NC and Burhan Ghanayem, NIEHS, Research Triangle Park, NC.

#353 1:30 LARGE-SCALE GENE EXPRESSIONPROFILING IN RATS IDENTIFIES MANYNOVEL CYP1A1 INDUCERS AND AHRECEPTOR LIGANDS. W. Hu1, M. R. Fielden1, D.Baston2, B. Zhao2, Y. Song2, J. Bohonowych2, A.Soshilov2, D. DeGroot2, C. Sorrentino2, M. Denison2

and K. Kolaja1. 1Chemogenomics and Toxicology,Iconix Pharmaceuticals Inc., Mountain View, CA and2Department of Environmental Toxicology, Universityof California Davis, Davis, CA.

#354 1:50 EFFECTS OF FLAVONOIDS ON CYP1EXPRESSION IN RL95-2 ENDOMETRIALCANCER CELLS. Z. R. Master1, T. R. Sutter2 and K.L. Willett1. 1Pharmacology and EnvironmentalToxicology Research Program, University ofMississippi, University, MS and 2W. Harry FeinstoneCenter for Genomic Research, University of Memphis,Memphis, TN.

#355 2:10 REDUCTION OF OBESITY IS ASSOCIATEDWITH INCREASED HEPATIC CYP3AEXPRESSION IN WOMEN. D. Springer1, T. I.Leakey1, R. J. Feuers1, C. Buffington2, G. S. Cowan2

and J. E. Leakey1. 1OSC, NCTR, Jefferson, AR and2Department of Surgery, University of Tennessee,Memphys, TN.

Program Description



MO

ND

AY

#356 2:30 BIPHENYL PROPARGYL ETHERS ASINHIBITORS OF CYP 1A1, CYP 1A2, AND CYP2B1. N. E. Hopkins1, B. Bowman2, T. Smith2,1, C.DeCuir-Charbonnet1, A. Henderson1 and M.Foroozesh2. 1Cell & Molecular Biology, TulaneUniversity, New Orleans, LA and 2Chemistry, XavierUniversity, New Orleans, LA.

#357 2:50 USE OF A HUMAN HEPATOCYTE-DERIVEDCELL LINE TO SIMULTANEOUSLY ASSESSCYP3A4 INDUCTION AND TIME-DEPENDENTINHIBITION. S. L. Ripp1, K. A. Trevena1, D. R.Gibbons2,1 and J. B. Mills1. 1Pharmacokinetics,Dynamics, & Metabolism, Pfizer Global Research &Development, Groton, CT and 2Michigan StateUniversity, East Lansing, MI.

#358 3:10 HUMAN NAPHTHALENE METABOLISM. T. M.Cho, R. L. Rose and E. Hodgson. Environmental &Molecular Toxicology, North Carolina State University,Raleigh, NC.

#359 3:30 ROLE OF PULMONARY CYTOCHROME P4503A1 IN 1-NITRONAPHTHALENEBIOACTIVATION AND INJURY IN ADULT ANDPOSTNATAL RATS. K. C. Day, J. D. Reynolds, D. R.Morin, C. G. Plopper and M. V. Fanucchi. University ofCalifornia, Davis, Davis, CA.

#360 3:50 MODIFICATION OF PULMONARY CYP2B1 ANDINDUCED CYP1A1 ACTIVITIES BYINTRAVENOUS INJECTION OF IRONDEXTRAN. M. M. Ghanem1,2, L. Battelli1, M.Barger1, J. Nath2 and A. F. Hubbs1. 1HELD, NIOSH,CDC, Morgantown, WV and 2Genetics andDevelopmental Biology Program, WVU, Morgantown,WV. Sponsor: V. Castranova.

#361 4:10 ROLE OF CYP2E1 IN THE OXIDATION OFACRYLAMIDE (AA) TO GLYCIDAMIDE (GA)AND FORMATION OF DNA AND HEMOGLOBINADDUCTS. B. I. Ghanayem1, L. McDaniel2, M. I.Churchwell2, N. C. Twaddle2, R. Snyder3, T. R. Fennell3

and D. R. Doerge2. 1Laboratory of Pharmacology andChemistry, NIEHS/NIH, Research Triangle Park, NC,2NCTR, Jefferson, AR and 3RTI International, ResearchTriangle Park, NC.


PLATFORM SESSION: MECHANISMS OF IMMUNOTOXICITY

Chairperson(s): Mitzi Nagarkatti, Virginia Commonwealth University,Richmond, VA and David Shepherd, University of Montana, Missoula, MT.

#362 1:30 GENE EXPRESSION ALTERATIONS INIMMUNE SYSTEM PATHWAYS FOLLOWINGEXPOSURE TO IMMUNOSUPPRESSIVECHEMICALS. R. M. Patterson1, N. Walker1, S.Baker2, T. Dickinson2, K. White3, D. Musgrove3, S.Harrison1 and D. R. Germolec1. 1NIEHS, ResearchTriangle Park, NC, 2Illumina, Inc., San Diego, CA and3VCU, Richmond, VA.

#363 1:52 THE ROLE OF CYCLIN DEPENDENT KINASEINHIBITOR P21 IN TCDD-INDUCED THYMICATROPHY. M. Fisher1, M. Nagarkatti2 and P. S.Nagarkatti1,2. 1Pharmacology and Toxicology, VirginiaCommonwealth University School of Medicine,Richmond, VA and 2Microbiology and Immunology,Virginia Commonwealth University School ofMedicine, Richmond, VA.

#364 2:14 TCDD SUPPRESSES ANTIGEN-SPECIFICINTERACTIONS BETWEEN OTII CD4 T CELLSAND OVA-LOADED DENDRITIC CELLS. S.Navarro1 and D. M. Shepherd1,2. 1CEHS, University ofMontana, Missoula, MT and 2Biomedical &Pharmaceutical Sciences, University of Montana,Missoula, MT.

#365 2:36 SUPERANTIGEN-PRIMED T CELLS EXPOSEDTO 2, 3, 7, 8-TETRACHLORODIBENZO-P-DIOXIN (TCDD) UNDERGO APOPTOSISDURING THE FIRST ENCOUNTER ANDEXHIBIT ANERGY UPON RESTIMULATIONWITH THE ANTIGEN. L. Faulconer2, I. Camacho1,M. Nagarkatti1 and P. Nagarkatti2. 1Microbiology andImmunology, Virginia Commonwealth University,Richmond, VA and 2Pharmacology and Toxicology,Virginia Commonwealth University, Richmond, VA.

#366 2:58 B CELL MATURATION AND TCDD-INDUCEDMODULATION OF THE 3’αα ENHANCER. C. E.Sulentic. Pharmacology&Toxicology, Wright StateUniversity, Dayton, OH.

#367 3:20 SYNTHETIC AND ENDOGENOUS PPARγγAGONISTS, GW7845, 15-DEOXY-∆∆12, 14-PROSTAGLANDIN J2, AND MONO-(2-ETHYLHEXYL) PHTHALATE, ACTIVATECOMPLEX CASPASE CASCADES IN PRO/PRE-BCELLS. J. Schlezinger, J. Emberley and D. Sherr.Environmental Health, Boston University School ofPublic Health, Boston, MA.

#368 3:42 CB2 CANNABINOID RECEPTOR AGONIST,JWH015 TRIGGERS APOPTOSIS IN IMMUNECELLS: POTENTIAL ROLE FOR CB2SELECTIVE LIGANDS ASIMMUNOSUPPRESSIVE AGENTS. C. A. Lombard1,M. Nagarkatti1 and P. S. Nagarkatti2. 1Microbiologyand Immunology, MCV Campus, VirginiaCommonwealth University, Richmond, VA and2Pharmacology and Toxicology, MCV Campus, VirginiaCommonwealth University, Richmond, VA.

#369 4:04 THE ENDOGENOUS CANNABINOID, 2-ARACHIDONYL-GLYCEROL, SUPPRESSES NF-AT NUCLEAR TRANSLOCATION ANDINTERFERON-γγ PRODUCTION. B. L. Kaplan1,2, Y.Ouyang1, C. E. Rockwell1, G. K. Rao1,2 and N. E.Kaminski1,2. 1Pharmacology and Toxicology, MichiganState University, East Lansing, MI and 2Center forIntegrative Toxicology, Michigan State University, EastLansing, MI.

Program Description


MO

ND

AY


Monday Afternoon, March 71:30 PM to 4:30 PMExhibit Hall

POSTER SESSION: RISK ASSESSMENT I

Chairperson(s): Moiz Mumtaz, ATSDR, Chamblee, GA.

Displayed: 1:30 PM–4:30 PM

Attended: 1:30 PM–3:00 PM

#370 CONCEPTUAL PRINCIPLES FOR UTILIZINGOMIC TECHNOLOGIES IN MECHANISTICRISK ASSESSMENT. C. Borgert1,2, P. Guiney3, G.Casella4 and K. Shiverick5. 1Applied PharmacologyToxicology Inc., Gainesville, FL, 2Department ofPhysiological Sciences, University of FL College ofVeterinary Medicine, Gainesville, FL, 3S.C. Johnson &Son, Inc., University of FL College of VeterinaryMedicine, Racine, WI, 4Department of Statistics,University of FL College of Veterinary Medicine,Gainesville, FL and 5University of FL College ofMedicine, Gainesville, FL.

#371 USE OF GENOMICS DATA TO PREDICT MODEOF ACTION IN CHEMICAL HAZARDCHARACTERIZATION. I. Pagan1 and B. Sen2,3.1NCEA/ORD, U.S. EPA, Research Triangle Park, NC,2National Research Council, Washington, DC and3ECD/ORD, U.S. EPA, Research Triangle Park, NC.

#372 ASSIGNING OCCUPATIONAL HAZARDCATEGORIES (OHCS) FOR MATERIALS USEDAND SYNTHESIZED IN THEPHARMACEUTICAL INDUSTRY. F. J. Guerriero1,C. W. Seaman2, M. J. Olson3, M. W. Abromovitz1 andG. L. Sprague1. 1GlaxoSmithKline, King of Prussia, PA,2GlaxoSmithKline, Ware, Herts, United Kingdom and3GlaxoSmithKline, Research Triangle Park, NC.

#373 USING STRUCTURE-ACTIVITYRELATIONSHIPS FOR CHEMICAL HAZARDSCREENING UNDER THE SUSTAINABLEFUTURES PROGRAM. L. T. Haber1, A. Maier1, E.Becker2 and J. Santory3. 1Toxicology Excellence forRisk Assessment (TERA), Cincinnati, OH, 2Consortiumfor Environmental Risk Management (CERM),Evansville, IN and 3CERM, Pittsburgh, PA.

#374 SCIENTIFIC CRITERIA TO TEST INGREDIENTSADDED TO CIGARETTES. D. M. Byrd, A.Brownawell, M. Falk, R. Feldman, K. Lewis and P.Nixon. LSRO, Bethesda, MD.

#375 AN INTEGRATED DECISION TOOL FOREVALUATING CHEMICAL SAFETY INLABORATORY RESEARCH STUDIESINVOLVING ANIMALS. A. Maier1, J. Utrecht2, C.Pittinger4, J. Stewart3 and A. Parker1. 1ToxicologyExcellence for Risk Assessment (TERA), Cincinnati,OH, 2University of Cincinnati, Cincinnati, OH,3Environmental Health and Engineering, Newton, MAand 4Exponent, Inc., Cincinnati, OH.

#376 REAL WORLD TOXICOLOGY: A FRAMEWORKFOR EVALUATING TORT CLAIMS IN THECOURTROOM. S. M. Bobst1, N. Zheng2 and F.Thomas2. 1CERATOX, Houston, TX and 2RAM GroupInc., Houston, TX. Sponsor: J. Jabbour.

#377 A FRAMEWORK/APPROACH FORINCORPORATING PBPK MODELING INTOCUMULATIVE RISK ASSESSMENT OFCHEMICAL MIXTURES. R. S. Yang1, J. E.Dennison1 and J. C. Lipscomb2. 1Quantitative andComputational Toxicology Group, Center forEnvironmental Toxicology and Technology, ColoradoState University, Fort Collins, CO and 2U.S. EPA,ORD/NCEA, Cincinnati, OH.

#378 DEVELOPMENT OF A CHILDREN’S HEALTHRISK ASSESSMENT FRAMEWORK USING ALIFE-STAGE APPROACH. S. Barone1, R. Brown2,1,S. Euling1, E. Cohen-Hubal3, C. A. Kimmel1, S.Makris1, J. Moya1, S. G. Selevan1, B. Sonawane1, T.Thomas4,1 and C. M. Thompson4,1. 1NCEA, U.S. EPA,Washington, DC, 2ASPH, Association of Schools ofPublic Health, Washington, DC, 3NERL, U.S. EPA,Research Triangle park, NC and 4AAAS, AmericanAssociation for Advancement Science, Washington, DC.

#379 CASE STUDIES: DEVELOPING A DECISION-MAKING FRAMEWORK FOR OCCUPATIONALHEALTH AND SAFETY CLEARANCE OF NEWCHEMICALS. S. Kim1, A. Maier2, P. J. Hakkinen2,3,A. Wullenweber2, D. A. Seid1 and L. T. Haber2.1Applied Biosystems, Foster City, CA, 2ToxicologyExcellence for Risk Assessment, Cincinnati, OH and3Institute for Health and Consumer Protection, Physicaland Chemical Exposure Unit, European Commission,Joint Research Centre, Ispra, Italy.

#380 A RETROSPECTIVE REVIEW OF STUDIESUTILIZING GAVAGE DOSING OF PRE-WEANING RATS DEMONSTRATES NOADVERSE CONSEQUENCES OF DOSINGPROCEDURES. S. L. Makris1, E. Mendez2 and K. C.Raffaele3. 1ORD/NCEA, U.S. EPA, Washington, DC,2OPP, U.S. EPA, Washington, DC and 3OPP, U.S. EPA,Washington, DC.

#381 RISK ASSESSMENT IN NEPHROTOXICOLOGY– SENSITIVITY OF RENAL TESTS. P. A. Potnis1,A. Maier1 and T. L. Guidotti1. 1Environmental andOccupational Health, The George WashingtonUniversity, Washington, DC, 2Toxicology, ToxicologyExcellence for Risk Assessment (TERA), Cincinnati,OH and 3Environmental and Occupational Health, TheGeorge Washington University, Washington, DC.

#382 RELEVANCE OF RODENT FORESTOMACHTUMORS IN CANCER RISK ASSESSMENT. D.Proctor and S. Hong. Exponent, Irvine, CA.

#383 APPLICATION OF QSTRS TO SELECT ASURROGATE CHEMICAL FOR A CHEMICALLACKING ORAL TOXICITY DATA. R. M. Bruce1,R. Venkatapathy2, C. Moudgal1 and H. Choudhury1.1NCEA, U.S. EPA, Cincinnati, OH and 2ORISE/NCEA-U.S. EPA, Cincinnati, OH.

#384 A HISTORICAL PERSPECTIVE ON LONG-TERM ANIMAL BIOASSAYS. T. A. Lewandowski1,B. D. Beck2, L. A. Beyer2 and L. R. Rhomberg2.1Gradient Corporation, Seattle, WA and 2GradientCorporation, Cambridge, MA.

Program Description



MO

ND

AY

#385 THE T25 METHOD FOR CANCER HAZARDCHARACTERISATION. COMPARISON WITHHAZARD CHARACTERISATION BASED ONEPIDEMIOLOGY. T. Sanner1 and E. Dybing2.1Institute of Cancer Research, The Norwegian RadiumHospital, Oslo, Norway and 2Division of EnvironmentalMedicine, Norwegian Institute of Public Health, Oslo,Norway.

#386 DOSE-RELATED ISSUES IN THE DESIGN ANDINTERPRETATION OF CHRONIC TOXICITYAND CARCINOGENICITY STUDIES INRODENTS. L. Rhomberg1, S. Olin2 and I. WorkingGroup2. 1Gradient Corporation, Cambridge, MA and2Risk Science Institute, International Life SciencesInstitute, Washington, DC.

#387 STATISTICAL PROPERTIES OF CARCINOGENTHRESHOLD ESTIMATES USING LOG-LINEARREGRESSION. D. A. Dankovic and M. T. Wheeler.Risk Evaluation Branch, CDC/NIOSH, Cincinnati, OH.

#388 AN EMPIRICAL APPROACH TO DOSE-DURATION-RESPONSE MODELING AND TIME-SCALING. K. G. Brown1 and G. L. Foureman2.1KBinc, Chapel Hill, NC and 2NCEA/ORD, U.S. EPA,Research Triangle Park, NC.

#389 STATISTICAL METHODOLOGY FOR THESIMULTANEOUS ANALYSIS OF MULTIPLETYPES OF OUTCOMES IN NONLINEARTHRESHOLD MODELS. T. Coffey1, C. Gennings1

and V. C. Moser2. 1Biostatistics, VirginiaCommonwealth University, Richmond, VA and2ORD/NHEERL, U.S. EPA, Research Triangle Park,NC.

#390 TOXICITY ESTIMATION OF LOW LEVELSHORT-TERM EXPOSURES TO CHEMICALMIXTURES. M. M. Mumtaz1, C. T. De Rosa1, H.Pohl1, D. Moffett1,2, H. A. El-Masri1 and B. A. Fowler1.1Division of Toxicology, ATSDR, Atlanta, GA and 2USPublic Health Service, Atlanta, GA.

#391 PURITY ANALYSES FOR TOXICOLOGYSTUDIES–A CASE STUDY WITHANTHRAQUINONE. S. Graves1, N. South1 and C.Smith2. 1Toxicology Columbus, Battelle, Columbus, OHand 2NIEHS, Research Triangle Park, NC.

#392 THE TCDD TEQ IN HUMAN BLOOD FROMDIETARY VS. ANTHROPOGENIC DIOXINS: ADIETARY STUDY. M. A. harris1 and B. Finley2.1Exponent, Houston, TX and 2Exponent, Santa Rosa,CA. Sponsor: L. Haws.

#393 RELATIVE POTENCIES OF THREE DIOXINCONGENERS BASED ON LIVER FOCIFORMATION ASSAY AND LIVERCONCENTRATIONS IN RAT AND HUMANESTIMATED BY PBPK MODELS. W. Maruyamaand Y. Aoki. Research Center for Environmental Risk,National Institute for Environmental Studies, Tsukuba,Japan.

#394 VARIABILITY AND UNCERTAINTYDISTRIBUTIONS FOR THE CARCINOGENICPOTENCY OF 2, 3, 7, 8-TCDD. E. Crouch.Cambridge Environmental Inc., Cambridge, MA.Sponsor: L. Green.

#395 COMPARING ENVIRONMENTALLY RELEVANTPCBs TO TCDD IN CYP1A2 NULL ANDWILDTYPE MICE. D. E. Burgin1,2, J. J. Diliberto3

and L. S. Birnbaum3. 1National Center forEnvironmental Economics, U.S. EPA, Washington, DC,2Toxicology, University of North Carolina, Chapel Hill,NC and 3ORD/NHEERL/ETD, U.S. EPA, ResearchTriangle Park, NC.

#396 CANCER POTENCY ESTIMATION FORACRYLAMIDE. M. S. Sandy, T. A. McDonald and L.Zeise. Office of Environmental Health HazardAssessment, California EPA, Oakland, CA.

#397 ACRYLAMIDE TOXICITY–IS A REAPPRAISALNECESSARY? C. Siegers1 and J. B. Schulze2.1Institute of Experimental and Clinical Pharmacologyand Toxicology, Luebeck, Germany and 2Office of theDean, Medical Faculty, Frankfurt, Germany.

#398 DOSE-RESPONSE MODELING OF IN VIVOGENOTOXICITY DATA: ITS RELEVANCE TORISK ASSESSMENT ILLUSTRATED BY ANAPPLICATION TO ACRYLAMIDE. B. Allen1, E.Zeiger2, M. Friedman3 and A. Shipp4. 1Environ HealthSciences Institute, Chapel Hill, NC, 2Errol ZeigerConsulting, Chapel Hill, NC, 3UNDMJ, Newark, NJand 4Environ Health Sciences Institute, Ruston, LA.

#399 ISSUES RELATING TO THE DERIVATION OFORAL TOXICITY VALUES FORCHLORDECONE. J. A. Stickney1, M. H. Follansbee1,D. W. Wohlers2, P. R. McClure2, M. Odin2 and P. M.McGinnis3. 1Environmental Science Center, SyracuseResearch Corp, Scarborough, ME, 2EnvironmentalScience Center, Syracuse Research Corp, Syracuse, NYand 3Environmental Science Center, Syracuse ResearchCorp, Philadelphia, PA.

#400 RE-EVALUATION OF THE RISK OF LUNGCANCER FROM DIESEL EXHAUST EXPOSURE.T. W. Hesterberg2, W. B. Bunn2 and C. A. Lapin1. 1Lapinand Associates, Glendale, CA and 2International Truckand Engine Corp, Warrenville, IL.

#401 IMPORTANCE OF PEROXISOMEPROLIFERATION IN UNDERSTANDINGPOTENTIAL MODE(S) OF ACTION FOR TCEAND ITS APPLICATION IN RISK ASSESSMENT.N. Keshava1 and J. C. Caldwell1. 1Office of Researchand Development, U.S. EPA, Washington, DC and2Office of Research and Development, U.S. EPA,Washington, DC.

#402 INCORPORATION OF TRICHLOROACETICACID PLASMA BINDING IN HUMAN ANDMOUSE IN TRICHLOROETHYLENE RISKASSESSMENT. D. A. Keys1, M. H. Lumpkin2, J. V.Bruckner1 and J. W. Fisher1. 1InterdisciplinaryToxicology Program, University of Georgia, Athens,GA and 2Clayton Group Services, Inc., Kennesaw, GA.

Program Description


MO

ND

AY


#403 USE OF A PHYSIOLOGICALLY BASEDPHARMACOKINETIC MODEL FORCHLOROFORM TO EVALAUTEBIOMONITORING DATA. K. H. Liao1, R. B.Conolly1, A. M. Mason2 and Y. Tan1. 1Center forComputational Systems Biology & Human HealthAssessment, CIIT Centers for Health Research,Research Triangle Park, NC and 2Chlorine ChemistryCouncil, Arlington, VA.

#404 MONTE CARLO ANALYSIS OF SOURCES OFVARIABILITY IN CHLOROFORM-INDUCEDHEPATIC CYTOLETHALITY ANDREGENERATIVE PROLIFERATION IN B6C3F1MICE. Y. Tan and R. B. Conolly. Center forComputational Systems Biology & Human HealthAssessment, CIIT Centers for Health Research,Research Triangle Park, NC.

#405 DOSE-RESPONSE MODELING ANDBENCHMARK CALCULATIONS FROMSPONTANEOUS BEHAVIOR DATA ON MICENEONATALLY EXPOSED TO 2, 2′′, 4, 4′′,5–PENTABROMODIPHENYL ETHER. S. Sand1, D.von Rosen2, P. Eriksson3, A. Fredriksson3, H. Viberg3,K. Victorin1 and A. Falk Filipsson1. 1Institute ofEnvironmental Medicine, Karolinska Institutet,Stockholm, Sweden, 2Biometry and Informatics,Swedish University of Agricultural Sciences, Uppsala,Sweden and 3Enviromental Toxicology, UppsalaUniversity, Uppsala, Sweden.

#406 ADVANTAGES AND LIMITATIONS OFBENCHMARK DOSE MODELING AND THENOAEL/LOAEL APPROACH IN PERFORMINGDOSE-RESPONSE ASSESSMENT BASED ONSMALL STUDIES: SUBCHRONIC RFD FORCHLOROBENZENE AS A CASE STUDY. M. Odin,P. McClure and P. McGinnis. Environmental ScienceCenter, Syracuse Research Corp, Syracuse, NY.

#407 BENCHMARK DOSE MODELING OFDEVELOPMENTAL RESPONSES IN OFFSPRINGOF RATS EXPOSED TO TRICHLOROACETICACID. L. H. Moilanen1, P. McClure1, D. Wong2 and P.McGinnis1. 1Environmental Science Center, SyracuseResearch Corp, Syracuse, NY and 2Office of Research& Development NCEA/IRIS Program, U.S. EPA,Washington, DC.

#408 EMPIRICAL EVALUATION OF SUFFICIENTSIMILARITY FOR A MIXTURE OF NINEHALOACETIC ACIDS (HAA’S) ON CHINESEHAMSTER OVARY CELL CHRONICCYTOTOXICITY USING A FIXED-RATIO RAYDESIGN. L. G. Stork1, C. Gennings1, W. Carter, Jr.1, R.Johnson1, D. Mays2, R. Carchman3, J. Simmons4 and M.Plewa5. 1Biostatistics, Virginia CommonwealthUniversity, Richmond, VA, 2Statistical Sciences and O.R., VCU, Richmond, VA, 3Solveritas, LLC, Richmond,VA, 4ORD/NHEERL, U.S. EPA, Research TrianglePark, NC and 5Crop Sciences, University of Illinois atUrbana-Champaign, Urbana, IL.


POSTER SESSION: EXPOSURE ASSESSMENT/EPIDEMIOLOGY

Chairperson(s): Michael Lumpkin, Clayton Group Services Inc., Kennesaw,GA and Robert Krieger, University of California Riverside, Riverside, CA.



#409 EVALUATION OF PROPOSED THRESHOLDDOSES FOR CHRYSOTILE EXPOSURE ANDRESPIRATORY DISEASE. B. Finley1, F. Mowat2, R.Richter3, G. Brorby4, V. Craven1 and P. Sheehan4.1Exponent, Santa Rosa, CA, 2Exponent, Menlo Park,CA, 3Exponent, Irvine, CA and 4Exponent, Oakland,CA.

#410 CHRYSOTILE ASBESTOS EXPOSUREASSOCIATED WITH REMOVAL OFAUTOMOBILE EXHAUST SYSTEMS (CIRCA1946-1970). D. J. Paustenbach1, A. Madl1, K. Clark1,K. Fehling1 and T. Lee2. 1ChemRisk, Inc., SanFrancisco, CA and 2Carolina EHS, Lake Wylie, SC, SC.

#411 EXPOSURE RECONSTRUCTION OFHISTORICAL AIRBORNE BENZENECONCENTRATIONS: CASE STUDY OF A DECKCREWMAN ON BOARD CRUDE OIL ANDCHEMICAL TANKERS. A. Madl1, K. Unice3, P.Scott3, K. Robinson2, P. Scaramella1, D. Pyatt2,4 and D.Paustenbach1. 1ChemRisk, Inc., San Francisco, CA,2ChemRisk, Inc., Boulder, CO, 3ChemRisk, Inc.,Pittsburgh, PA and 4University of Colorado HealthSciences Center, Denver, CO.

#412 DIESEL-RELATED BENZENE EXPOSURESDURING REFUELING OPERATIONS AT TWOGROCERY DISTRIBUTION CENTERS. M. J.Fedoruk1, T. Smalstig1, J. Tran1, M. Shum1, R. O.Richter1, R. Bronstein1 and B. D. Kerger2. 1ExponentInc., Irvine, CA and 2Health Science ResourceIntegration, Inc., Tallahassee, FL.

#413 OCCUPATIONAL PESTICIDE EXPOSUREDURING SEED CORN PRODUCTION INMICHIGAN. B. Hughes1, L. Olsen2, P. Hite3 and P.Bills2. 1PPPM, MI Department Ag., Lansing, MI, 2Ent.,MSU, East Lansing, MI and 3Lab., MI Department Ag.,East Lansing, MI.

#414 PESTICIDE EXPOSURE ASSESSMENT:MOISTURE ENHANCES MALATHIONTRANSFER TO HARVESTER GLOVES ANDCLOTHING, BUT DOES NOT INCREASEABSORBED DOSE. R. I. Krieger, X. Zhang, T. Dinoff,Y. Chou and S. Acevedo. University of CaliforniaRiverside, Riverside, CA.

#415 CHEMICAL EXPOSURE ASSESSMENT:SURFACE DEPOSITION OF ENVIRONMENTALTOBACCO SMOKE (ETS). J. J. Keenan, X. Zhangand R. Krieger. Environmental Toxicology Program andDepartment of Entomology, University of California,Riverside, CA.

Program Description



MO

ND

AY

#416 VALIDATION OF A SURROGATE MIX TODETERMINE CONCENTRATION OFINDIVIDUAL COMPONENTS OF JP-8 INAEROSOL AND VAPOR SAMPLES BY GC/MS. K.Dietzel1, J. Campbell1, M. Bartlett2, M. Witten3 and J.Fisher1. 1Interdisciplinary Toxicology Program,Univeristy of Georgia, Athens, GA, 2Pharmaceuticaland Biomedical Sciences, University of Georgia,Athens, GA and 3Pediatrics, Univeristy of Arizona,Tucson, AZ.

#417 PHYSICOCHEMICAL CHARACTERISATION OFCOMBUSTION PARTICLES FROMRESIDENTIAL WOOD SMOKE AND VEHICLEEXHAUST. A. Kocbach1, K. E. Yttri2, P. E. Schwarze1

and E. Namork1. 1Environmental Medicine, NorwegianInstitute of Public Health, Oslo, Norway and2Department for Chemical Analysis, NorwegianInstitute for Air Research, Kjeller, Norway. Sponsor: E.Dybing.

#418 COMPARISON OF TRACER METHODS USEDTO MEASURE IN-VEHICLECONCENTRATIONS. M. D. Easter1, R. Ireson2, T.Hesterberg3, M. Lakin1 and C. Lapin4. 1EnSIGHT,Walnut Creek, CA, 2AQM Consulting, Greenbrae, CA,3International Truck & Engine Corporation, Chicago, ILand 4Lapin & Associates, Los Angeles, CA.

#419 SIMULATION AND ASSESSMENT OFOCCUPATIONAL EXPOSURES TOISOCYANATES AND VOCS DURINGAPPLICATION OF A URETHANE PRODUCTSUITE UNDER WORST-CASE CONDITIONS. M.H. Lumpkin1, V. Runnion1, R. Lieckfield1, S. D. Paul1

and R. D. Harbison2. 1Clayton Group Services, Inc.,Kennesaw, GA and 2Environmental & OccupationalHealth, College of Public Health, University of SouthFlorida, Tampa, FL.

#420 OCCUPATIONAL EXPOSURE TO ULTRAFINEPARTICLES AND POLYCYCLIC AROMATICHYDROCARBONS FROM CANDLE EMISSIONS.D. Silver and R. D. Harbison. University of SouthFlorida, Tampa, FL.

#421 EXPOSURE ASSESSMENT FOR PERCHLORATEIN MILK. D. Proctor. Exponent, Irvine, CA.

#422 CURRENT ALCOHOL USE IS ASSOCIATEDWITH A REDUCED RISK OF HOT FLASHES INPERI-MENOPAUSAL WOMEN. C. Schilling1, L.Gallicchio2, S. Miller2, J. Babus1, L. Lewis1, H. Zacur2

and J. A. Flaws1. 1University of Maryland, Baltimore,MD and 2Johns Hopkins University, Baltimore, MD.

#423 ENVIRONMENTAL EXPOSURE TO CADMIUMAT A LEVEL INSUFFICIENT TO INDUCERENAL TUBULAR DYSFUNCTION DOES NOTAFFECT BONE DENSITY AMONG FEMALEJAPANESE FARMERS. F. Kayama1,2, H.Horiguchi1,2, E. Oguma1,2, S. Sasaki3, K. Miyamaoto1,Y. Ikeda1 and M. Munehito1. 1Environmental Medicine,Jichi Medical School, Kawachi-Gun, Tochigi, Japan,2CREST, JST, Kawaguchi, Saitama, Japan and3National Institute of Health and Nutrition, Tokyo,Japan. Sponsor: T. Yoshida.

#424 HEALTH EFFECTS REPORTED IN TEXASHOMES WITH VISIBLE MOLD AND/OR WATERDAMAGE. J. Gandy1,2 and A. J. Harris1. 1Center forToxicology and Environmental Health, Little Rock, ARand 2College of Public Health, Department ofPharmacology and Toxicology, University of ArkansasSchool for Medical Sciences, Little Rock, AR.

#425 AN INVESTIGATION OF HOME DAMPNESSAND ADVERSE HEALTH EFFECTS ON ANATIVE AMERICAN RESERVATION. A. L. Stock,K. Davis, C. Brown, J. Sarisky and C. Blanton. NCEH,Centers For Disease Control and Prevention, Atlanta,GA.

#426 UNIVOCAL DECISION RULES FOR THEASSESSMENT OF CHRONIC SOLVENT-INDUCED ENCEPHALOPATHY; A PROPOSAL.M. Verberk1, J. van der Hoek4, E. Wekking3,2, M. vanHout5,2, G. Hageman3,2 and G. van der Laan2. 1CoronelInstitute for Occupational Medicine, Academic MedicalCenter, Amsterdam, Netherlands, 2Netherlands Centerfor Occupational Diseases, Academic Medical Center,Amsterdam, Netherlands, 3Psychiatry, AcademicMedical Center, Amsterdam, Netherlands, 4Neurology,Medical Spectrum Twente Hospital Group, Enschede,Netherlands and 5Clinical Psychology, MedicalSpectrum Twente Hospital Group, Enschede,Netherlands. Sponsor: P. Bogaard.

#427 MATERNAL DDE SERUM LEVELS ANDNEUROLOGICAL DEVELOPMENT IN INFANTS.PRELIMINARY FINDINGS. L. Torres-Sanchez1, L.Lopez-Carrillo1, L. Schnaas2, E. Osorio2, M.Hernandez2, R. Garcia3 and M. Cebrian3. 1INSP,Morelos, Mexico, 2IN Perinatologia, Mexico City,Mexico and 3Toxicology, CINVESTAV-IPN, MexicoCity, Mexico.

#428 ASSESSING THE PUBLIC HEALTH IMPACTSOF THE 1991 GULF WAR IN SAUDI ARABIA: AQUALITATIVE RISK ASSESSMENT APPROACH.H. I. Williams1, A. Wiman1, C. Williams1, C. Stineman2,R. Freeman3, R. V. Lee4, M. Bell5, M. J. Symons6, S.Kim6, R. White6, J. Samet6 and P. Breysse6. 1Ecologyand Environment, Inc., Tallahassee, FL, 2Ecology andEnvironment, Inc., Chicago, IL, 3TERRA, Inc.,Tallahassee, FL, 4School of Medicine and BiomedicalSciences, State University of New York at Buffalo,Buffalo, NY, 5Yale School of Forestry andEnvironmental Studies, New Haven, CT and 6JohnsHopkins Bloomberg School of Public Health,Baltimore, MD.

#429 GETTING THE LEAD DOSE-RESPONSE CURVERIGHT: IMPLICATIONS FOR PUBLIC HEALTHAND POLICY. S. J. Rothenberg1, J. C. Rothenberg2

and D. A. Fox3. 1Instituto Nacional de Salud Publica,Cuernavaca, Morelos, Mexico, 2University of Sydney,Camperdown, NSW, Australia and 3University ofHouston, Houston, TX.

#430 MECHANISMS OF METAL-ASSOCIATEDVASCULAR DISEASE. E. K. Silbergeld, A. Navas-Acien, B. S. Schwartz, R. Sharrett, E. Sharrett and E.Guallar. Johns Hopkins University Bloomberg SchoolPublic Health, Baltimore, MD.

Program Description


MO

ND

AY


#431 CATEGORIZATION OF THE ASSOCIATIONSBETWEEN EXPOSURE TO THE HERBICIDESUSED IN VIETNAM OR THEIRCONTAMINANTS AND HEALTH OUTCOMES. J.Cohen and M. Catlin. The National Academies,Washington, DC.

#432 THE IMPACT OF REDUCTION OF THEOCCUPATIONAL EXPOSURE LIMIT FORFORMALDEHYDE IN QUEBEC: A RE-EVALUATION OF HEALTH RISKS. N. Noisel, M.Bouchard and G. Carrier. Sante Environnementale &Sante Au Travail, Universite de Montreal, Montreal,QC, Canada.


POSTER SESSION: RESPIRATORY TRACT I–PULMONARY,CARDIOVASCULAR, AND IMMUNE EFFECTS OF PMCHAIRPERSON(S): PRAMILA SINGH, U.S. EPA, RESEARCH TRIANGLEPARK, NC AND MICHELLE V. FANUCCHI, UC DAVIS, DAVIS, CA.



#433 EFFECTS OF INHALED COMBUSTION-DERIVED PARTICULATE MATTER ON INDICESOF CARDIAC, PULMONARY, ANDTHERMOREGULATORY FUNCTION INSPONTANEOUSLY HYPERTENSIVE RATS. L. B.Wichers1, W. H. Rowan2, J. P. Nolan2, U. P. Kodavanti2,M. J. Schladweiler2, A. D. Ledbetter2, D. L. Costa2 andW. P. Watkinson2. 1SPH, UNC, Chapel Hill, NC and2ORD/NHEERL/ETD/PTB, U.S. EPA, ResearchTriangle Park, NC.

#434 CARDIOPULMONARY EFFECT OFPARTICULATE MATTERS ON DIABETIC RATS:FROM CAPS TO ULTRAFINE PARTICLES. Y. Leiand T. Cheng. College of Public Health, NationalTaiwan University, Taipei, Taiwan. Sponsor: T. Ueng.

#435 TOXICOGENOMIC EXPRESSION PROFILES OFSPONTANEOUSLY HYPERTENSIVE RATSEXPOSED TO CONCENTRATED AMBIENTPARTICLES. Y. Lei and T. Cheng. Public Health,National Taiwan University, Taipei, Taiwan. Sponsor:T. Ueng.

#436 TIME-COURSE OF INFLAMMATION ANDTISSUE DAMAGE IN THE MOUSE LUNGCAUSED BY FINE PARTICULATE MATTERFROM SIX EUROPEAN CITIES (PAMCHAR). M.S. Happo1,2, R. O. Salonen1, A. I. Halinen1, P. Jalava1,2

and M. Hirvonen1. 1Department of EnvironmentalHealth, National Public Health Institute, Kuopio,Finland and 2University of Kuopio, Kuopio, Finland.Sponsor: M. Viluksela.

#437 EXPOSURE TO CONCENTRATED AMBIENTPARTICLES DOES NOT AFFECTENDOTHELIAL VASOMOTOR FUNCTION INPATIENTS WITH ISCHEMIC HEART DISEASE.N. L. Mills1, D. E. Newby1, S. D. Robinson1, D.Anderson1, E. Freney1, D. Robert1, N. A. Boon1, W.MacNee1, K. Donaldson1 and F. Cassee2. 1Centre forCardiovascular Science, ELEGI Colt ResearchLaboratories or Department of Chemistry, University ofEdinburgh, Edinburgh, United Kingdom and 2Centre forEnvironmental Health Research, National Institute forPublic Health and the Environment, Bilthoven,Netherlands.

#438 EXPOSURE TO CONCENTRATED AMBIENTPARTICLES IN DETROIT ALTERS HEART RATEVARIABILITY IN SPONTANEOUSLYHYPERTENSIVE RATS. J. G. Wagner1, L. B.Wichers2, M. Morishita3, A. C. Rohr4, G. J. Keeler3 andJ. R. Harkema1. 1Michigan State University, EastLansing, MI, 2U.S. EPA -NHEERL, Research TrianglePark, NC, 3University Michigan, Ann Arbor, MI and4Electrical Power Research Inst, Palo Alto, CA.

#439 EXPOSURE TO CONCENTRATED AMBIENTPARTICLES IN DETROIT, MICHIGAN CAUSESHEART RATE AND THERMOREGULATORYCHANGES IN SPONTANEOUSLYHYPERTENSIVE AND WISTAR-KYOTO RATS.A. C. Rohr1, J. G. Wagner2, M. Morishita3, G. J.Keeler3 and J. R. Harkema2. 1EPRI, Palo Alto, CA,2Michigan State University, East Lansing, MI and3University of Michigan, Ann Arbor, MI.

#440 SUBCHRONIC EFFECTS OF CONCENTRATEDAMBIENT PARTICLES (CAPS) IN SENESCENTMICE (AKR). Q. LI and L. Chen. EnvironmentalHealth, NYU School of Medicine, Tuxedo, NY.

#441 CARDIAC INJURY FROM LONG-TERMEPISODIC EXPOSURE TO PARTICULATEMATTER (PM): SOLUBLE COMPONENTS ORSOLID PARTICLES? U. P. Kodavanti1, M. C.Schladweiler1, A. D. Ledbetter1, J. McGee1, P. S.Gilmour2, W. P. Watkinson1, D. C. Christiani3, D. L.Costa1, R. H. Jaskot1, J. H. Richards1 and A. Nyska4.1ETD/NHEERL/ORD, U.S. EPA, Research TrianglePark, NC, 2CEMALB, UNC, Chapel Hill, NC, 3HSPH,Boston, MA and 4NIEHS, Research Triangle Park, NC.

#442 HEART RATE CHANGES IN 24-MONTH OLDFISHER 344 RATS EXPOSED TOCONCENTRATED PARTICULATE MATTER(PM2.5) CLOSE TO A FREEWAY IN DIAMONDBAR, CA. A. K. hamade, T. Lam and M. T. Kleinman.University of California, Irvine, CA. Sponsor: H.Hamadeh.

#443 EFFECTS OF ON-ROAD AEROSOLS IN AGEDRATS. A. Elder1, N. Corson1, P. Mercer1, R. Gelein1, J.Finkelstein2, P. Hopke3, W. Watts4, D. Kittelson4 and G.Oberdorster1. 1Environment Med., University ofRochester, Rochester, NY, 2Ped., University ofRochester, Rochester, NY, 3Chem. Eng., ClarksonUniversity, Potsdam, NY and 4Mech. Eng., Universityof Minnesota, Minneapolis, MN.

Program Description



MO

ND

AY

#444 COLLECTION, AEROSOLIZATION, ANDCHARACTERIZATION OF PAVED ROAD DUSTFOR AN INHALATION TOXICITY STUDY. J.McDonald, E. Barr and J. L. Mauderly. Toxicology,Lovelace Respiratory Research Institute, Albuquerque,NM.

#445 CHEMICAL, MICROBIOLOGICAL ANDTOXICOLOGICAL CHARACTERIZATION OFFINE PARTICULATE MATTER (PM2.5) FROMAN INDOOR ENVIRONMENT IN PUERTO RICO.A. Gioda1, E. Fuentes-Mattei2,1, B. Bolanos2 and B. D.Jimenez-Velez2,1. 1Center of Environmental andToxicological Research-UPR Medical Science Campus,San Juan, PR, Puerto Rico and 2Biochemistry, UPRMedical Science Campus, San Juan, PR, Puerto Rico.

#446 HIGH NO2/NOX RATIO IN DIESEL ENGINEEMISSION AEROSOL MAY REPRESENT AMORE IMPORTANT ACUTE TOXIC TRIGGERTHAN PARTICULATE MATTER (PM) FORLUNG TISSUE. J. MORIN1, A. Bion1,2, V. Keravec2,1

and F. Dionnet2. 1INSERM U644, Rouen, France and2CERTAM, Saint Etienne du Rouvray, France. Sponsor:R. FORSTER.

#447 EFFECTS OF DIESEL EXHAUST ON TLR3SIGNALING IN RESPIRATORY EPITHELIALCELLS. J. M. Ciencewicki1, M. Madden3,1 and I.Jaspers2,1. 1Curriculum of Toxicology, University ofNorth Carolina, Chapel Hill, NC, 2Pediatrics, Universityof North Carolina, Chapel Hill, NC and 3Human StudiesDivision, U.S. EPA, Chapel Hill, NC.

#448 NEUROTROPHIN RECEPTOR BLOCKADEATTENUATES DIESEL EXHAUSTPARTICULATE MATTER (DEP)ENHANCEMENT OF ALLERGIC RESPONSES. A.K. Farraj1,2, N. Haykal-Coates2, A. D. Ledbetter2, P. A.Evansky2 and S. H. Gavett2. 1Molecular and BiomedicalSciences, North Carolina State University, Raleigh, NCand 2Experimental Toxicology Division, NHEERL,ORD, U.S. EPA, Research Triangle Park, NC.

#449 YM1/2 CHITINASE PROTEINS IN MURINENASAL EPITHELIUM AFTER A 13-WEEKINHALATION EXPOSURE TO ULTRAFINECARBON BLACK PARTICLES. J. R. Harkema1, P.Santhanam1, J. G. Wagner1, L. A. Bramble1, A. P.Elder2 and G. Oberdorster2. 1Pathobiology andDiagnostic Invesitgation, Michigan State University,East Lansing, MI and 2Environmental Medicine,University of Rochester, Rochester, NY.

#450 PARTICLE SURFACE AREA AND PARTICLENUMBER, BUT NOT PARTICLE MASS,PREDICT THE ADJUVANT EFFECT OFPARTICLES ON ALLERGIC RESPONSES INMICE. U. C. Nygaard, M. Samuelsen, A. Aase and M.Lovik. Environmental Immunology, Norwegian Instituteof Public Health, Oslo, Norway. Sponsor: E. Dybing.

#451 CHEMICAL CHARACTERISTICS ANDTOXICITY OF POLAR ORGANIC EXTRACT OFDIESEL EXHAUST PARTICLES. T. Kobayashi1, H.Shima1 and E. Koike2. 1Environmental Health SciencesDivision, National Institute for Environmental Studies,Tsukuba, Ibaragi, Japan and 2PM2.5 and DEP ResearchProject, National Institute for Environmental Studies,Tsukuba, Ibaragi, Japan. Sponsor: S. Hirano.

#452 ORGANIC EXTRACT OF DIESEL EXHAUSTPARTICLES STIMULATES EXPRESSION OF IAAND COSTIMULATORY MOLECULESASSOCIATED WITH ANTIGEN PRESENTATIONIN RAT PERIPHERAL BLOOD MONOCYTESBUT NOT ALVEOLAR MACROPHAGES. E.KOIKE1 and T. KOBAYASHI2. 1PM2.5 and DEPResearch Project, National Institute for EnvironmentalStudies, Tsukuba, Ibaraki, Japan and 2EnvironmentalHealth Sciences Division, National Institute forEnvironmental Studies, Tsukuba, Ibaraki, Japan.Sponsor: S. Hirano.

#453 WOOD SMOKE PARTICLES INCREASEALLERGIC RESPONSES IN MICE, BUT LESSTHAN DIESEL EXHAUST PARTICLES (DEP). M.Samuelsen, U. C. Nygaard and M. Lovik. NorwegianInstitute of Public Health, Oslo, Norway. Sponsor: E.Dybing.

#454 COMPARISON OF PULMONARY TOXICITYBETWEEN HEALTHY SPRAGUE-DAWLEY RATSAND SPONTANEOUSLY HYPERTENSIVE RATSEXPOSED TO DIESEL EXHAUST PARTICLES.W. Chang, Y. Lei and T. Cheng. College of PublicHealth, Institute of Occupational Medicine andIndustrial Hygiene, Taipei, Taiwan. Sponsor: T. Ueng.

#455 APOE MOUSE MODEL OF ATHEROSCLEROSISCONFERS SUSCEPTIBILITY TOEXTRAPULMONARY EFFECTS OF DIESELEXHAUST. M. J. Campen, J. Seagrave, L. Blair, S.Lucas, A. Gigliotti, M. Reed and J. McDonald.Toxicology, Lovelace Respiratory Research Institute,Albuquerque, NM.

#456 RELATIVE EFFICACY OF COMBUSTIONEMISSION PARTICULATE MATTER TOADSORB THE NEUTROPHIL-ATTRACTINGCHEMOKINE IL-8. J. Seagrave and C. Knall.Lovelace Respiratory Research Institute, Albuquerque,NM.

#457 DIESEL EXHAUST PARTICLES SUPPRESS LPS-STIMULATED PRODUCTION OF PGE2 INHUMAN ALVEOLAR MACROPHAGES: ROLEOF P38 MAPK AND ERK PATHWAYS. M. C.Madden1, S. Becker1 and S. Mundandhara2. 1ORD,NHEERL, HSD, Clinical Research Branch, U.S. EPA,Chapel Hill, NC and 2CEMALB, University N.Carolina, Chapel Hill, NC.

#458 SULFORAPHANE, A POTENT PHASE 2INDUCER, INHIBITS THE ADJUVANT EFFECTOF AEROSOLIZED DIESEL EXHAUSTPARTICLES IN A MURINE MODEL FOROVALBUMIN SENSITIZATION. M. J. Whitekus, S.A. Ritz and D. Diaz-Sanchez. UCLA School ofMedicine/Division of Clinical Immunology and Allergy,UCLA, Los Angeles, CA.

Program Description


MO

ND

AY


#459 THE INCREASE IN TOTAL IGE IN SERUM OFFEMALE MICE AFTER INTRANASALEXPOSURE OF CARBON BLACK PARTICLESWITH POLLEN. K. Kobayashi1, K. Itoh1, Y. Inoue1,Y. Kudo1, M. Tsunoda1, T. Satoh1, C. Yashiro2, Y.Sugita-Konishi2 and Y. Aizawa1. 1Preventive Medicineand Public Health, Kitasato University School ofMedicine, Sagamihara, Kanagawa, Japan and 2Divisionof Microbiology, National Institute of Health Sciences,Setagaya-ku, Tokyo, Japan.

#460 DIESEL AND HARDWOOD SMOKE EMISSIONSDIFFERENTIALLY AFFECT CLEARANCE ANDINFLAMMATION OF INTRATRACHEALLYINSTILLED PSEUDOMONAS AERUGINOSA. M.Reed1 and K. S. Harrod2. 1Toxicology, LovelaceRespiratory Research Institute, Albuquerque, NM and2Infectious Disease Program, Lovelace RespiratoryResearch Institute, Albuquerque, NM.


POSTER SESSION: PHARMACEUTICALS-GENERAL

Chairperson(s): Mary Moslem, University of Texas, Galveston, TX.



#461 SAFETY EVALUATION OF AEROSOLIZEDCYCLOSPORINE IN RATS AND DOGS. T. Wang1,R. Steigerwalt1, M. Lynch2, R. Kovelesky1, C.Rodriguez1 and K. Sprugel1. 1Drug Assessment andDevelopment, Chiron Corporation, Emeryville, CA and2Toxicology, Battelle, Columbus, OH.

#462 TOXICITY OF A SELECTIVE INHIBITOR OFLCK IS DUE TO INHIBITION OF LCK AND ISNOT CHEMOTYPE-RELATED. R. F. Stachlewitz1,A. J. Schwartz1, B. Bettencourt1, J. Syed1, D. Conlon1,J. E. Erickson1, E. O’Connor1, D. J. Calderwood2 andG. C. Hirst2. 1Discovery Safety, Metabolism &Pharmacokinetics, Abbott Bioresearch Center, AbbottLaboratories, Worcester, MA and 2Chemistry, AbbottBioresearch Center, Abbott Laboratories, Worcester,MA.

#463 THE IMMUNOHISTOCHEMICAL EXPRESSIONOF UROPLAKIN III IN RAT BLADDER TISSUE.S. Grainger. Covance Laboratories Ltd., Harrogate,United Kingdom. Sponsor: D. Everett.

#464 BORTEZOMIB (VELCADE®) DOES NOTINDUCE THE FORMATION OF PROTEINASE K-RESISTANT PRION PROTEIN IN MURINE ANDHUMAN NEURONAL CELL LINES IN VITRO. V.G. Sasseville1, A. Raczynski1, V. Csizmadia1, W.Riordan1, J. Ironside2, M. Rolfe1 and P. Bouchard1.1Millennium Pharmaceuticals, Inc., Cambridge, MA and2University of Edinburgh, Edinburgh, United Kingdom.Sponsor: C. Alden.

#465 PHARMACOLOGY AND TOLERABILITY OFINS50589, A REVERSIBLE P2Y12 RECEPTORANTAGONIST WITH ANTI-PLATELETAGGREGATION ACTIVITY, ADMINISTERED BYCONTINUOUS INTRAVENOUS INFUSION INRATS AND DOGS. M. S. Cowlen, C. S. Crean, R.Krishnamoorthy, P. S. Watson, J. L. Boyer, W. M.Peterson and S. A. Anderson. Inspire, Durham, NC.

#466 RANGE-FINDING TOXICITY STUDIES WITHSQ109, AN ANTI-TUBERCULAR AGENT, INRATS AND DOGS. E. Glaze1, Y. Chen2, L. Alex2, R.Morrissey3, L. Jia1, P. Noker4 and J. Tomaszewski1.1NIH, Rockville, MD, 2University of Illinois, Chicago,IL, 3Pathology Associates, Chicago, IL and 4SouthernResearch Institute, Birmingham, AL.

#467 SAFETY ASSESSMENT OF A NOVEL P38INHIBITOR IN CYNOMOLGUS MONKEYSFOLLOWING DAILY ORAL DOSING. S. L. Wild1,T. Pabst Marra1, G. Jang1, W. Min1, R. House3, A.Mould2 and M. Cosenza1. 1Amgen Inc., Thousand Oaks,CA, 2Covance Laboratories Inc., Madison, WI and3DynPort Vaccine Company LLC, Frederick, MD.

#468 CYTOFLAVINE REDUCES HYPOXIA CAUSEDBY SEVERE ALCOHOLIC INTOXICATION ANDMILD HEAD TRAUMA. A. D. Tsivinsky1,3, B. V.Batotsyrenov2, T. N. Savateeva1, V. E. Marusanov3 andA. L. Kovalenko1. 1Institute of Toxicology,St.Petersburg, Russian Federation, 2Regional PoisonCenter, St.Petersburg, Russian Federation and3Postgraduate Medical Academy, St.Petersburg, RussianFederation. Sponsor: J. Waksman.

#469 TEMPO ATTENUATION OF DICLOFENACADDUCTION AND ENTEROPATHY. L. Kaphalia1,J. F. Aronson1, K. A. Nethery1 and M. TreinenMoslen1,2. 1Pathology, University of Texas MedicalBranch, Galveston, TX and 2Internal Medicine,University of Texas Medical Branch, Galveston, TX.

#470 ENDOSCOPY STUDY OF THEGASTROINTESTINAL TOLERANCE OFSTRONTIUM RANELATE IN CYNOMOLGUSMONKEYS. C. Fisch1, M. Attia1, F. Dargent1, S. deJouffrey1, I. Dupin-Roger2 and J. Claude3. 1CIT,Evreux, France, 2Laboratoires Servier, Courbevoie,France and 3Paris V University, Paris, France.

#471 TC 1734-112: PRECLINICAL SAFETYASSESSMENT OF A SELECTIVE αα4ββ2NICOTINIC ACETYLCHOLINE RECEPTORAGONIST. V. M. Traina, G. J. Gatto and M. Bencherif.Toxicology, Targacept, Inc., Winston-Salem, NC.

#472 OPIOIDS: OCCUPATIONAL CONTACTDERMATITIS AND THE LOCAL LYMPH NODEASSAY (LLNA). M. J. Olson1, F. J. Guerriero2, M.Cunningham-Hill2 and N. Tapscott2. 1GlaxoSmithKline,Research Triangle Park, NC and 2GlaxoSmithKline,Philadelphia, PA.

Program Description



MO

ND

AY

#473 USE OF NALTREXONE TO PREVENT ADVERSEEFFECTS OF SUFENTANIL IN BEAGLE DOGS.M. Soloviev1, M. J. Taylor2, T. R. Edwards1, J.Culwell2, C. R. Rampersand2, J. A. Felice2, D.Argonza2, M. Calimlin2, R. Ordonio2, R. Afan2, T. J.Siacotos2 and G. J. Schaefer1. 1WIL ResearchLaboratories, Ashland, OH and 2Durect Corporation,Cupertino, CA.

#474 FLORIDA RED TIDES: MOLECULARTHERAPEUTICS FROM A SEA OF RED. D.Baden1, A. J. Bourdelais1 and W. Abraham2. 1Center forMarine Science, UNCW, Wilmington, NC and 2Divisionof Research, Mt Sinai Medical Center, Miami Beach,FL.

#475 EFFICACY OF PIROXICAM IN ALLEVIATINGTETRACYCLINE-INDUCED MUSCLE DAMAGE.J. Jahun1 and H. M. Lantum2. 1Faculty of Vet. Medicine,Amadou Bello University, Zaria, Nigeria and 2AfricanSociety for Toxicological Sciences (ASTS), Rochester,NY.


POSTER SESSION: SAFETY EVALUATION-EVALUATION OFMETHODS IN VITRO/IN VIVO

Chairperson(s): Albert Li, Advanced Pharmaceutical Sciences Inc.,Columbia, MD.



#476 THE EFFECTS OF CONTINUOUSINTRAVENOUS INFUSION OF SALINE ONBODY WEIGHT GAIN, FOOD INTAKE ANDCLINICAL PATHOLOGY IN THE GÖTTINGENMINI PIG. M. Mus and C. Copeman. IPN, CTBR Bio-Research Inc., Senneville, QC, Canada. Sponsor: M.Vezina.

#477 BACKGROUND INCIDENCE OFEXPERIMENTAL DESIGN-RELATED EVENTSON INTRAVENOUS INFUSION STUDIES. C.Copeman and M. Vezina. IPN, CTBR Bio-ResearchInc., Senneville, QC, Canada.

#478 VALIDATION OF A NEWLY INVENTED PORTCATHETER SYSTEM FOR CONTINUOUSINFUSION STUDIES. P. Nowak, S. Korte, F. Vogeland W. Mueller. Covance Laboratories GmbH, 48163Muenster, Germany. Sponsor: G. Weinbauer.

#479 CONTINUOUS SUBCUTANEOUS INFUSION INRODENTS AND NON RODENTS. M. Stilianesis, S.Groom and C. Copeman. Toxicology, CTBR,Senneville, QC, Canada. Sponsor: M. Vezina.

#480 A METHOD FOR LONG-TERM CONTINUOUSSUBCUTANEOUS INFUSION IN RATS ANDDOGS. G. Washer, S. Jerat, M. Landry, S. Vachon, N.Galliard, J. Laliberte, P. Ha and J. Hooson. ITRLaboratories Canada Inc., Baie d’Urfe, QC, Canada.

#481 SUCCESSFULL PREVALIDATION OF AN INVITRO RECONSTITUTED HUMAN CORNEAMODEL TO ASSESS THE EYE IRRITATINGPOTENTIAL OF CHEMICALS. B. De Wever1, F.Van Goethem2, F. Straube3, N. Alepee4 and E.Adriaens5. 1SkinEthic Laboratories, Nice, France,2Johnson & Johnson Pharmaceutical R&D, Beerse,Belgium, 3Novartis Pharmacology, Basel, Switzerland,4Pfizer Global R&D, Amboise, France and 5Universityof Ghent, Ghent, Belgium.

#482 IN VITRO SKIN IRRITATION : STRONGREPRODUCIBILITY FOR 50 CHEMICALSTESTED ON THE SKINETHICRECONSTITUTED HUMAN EPIDERMALMODEL. B. De Wever1, C. Tornier1, H. Maibach2, E.Adriaens3 and M. Rosdy1. 1SkinEthic Laboratories,Nice, France, 2University Center of San Francisco, SanFrancisco, CA and 3University of Ghent, Ghent,Belgium.

#483 DETERMINATION OF THE DOSE-RESPONSERELATIONSHIP FOR SURFACTANTS USINGTHE BCOP. S. Yan and E. Choudhury. Limited Brands,Paramus, NJ.

#484 EVALUATION OF A SOLUBILITY PROTOCOLFOR IN VITRO CYTOTOXICITY TESTING. J.Strickland1,2, M. Paris1,2, W. Stokes1, S. Casati3, R.Tice1,2, H. Raabe4, C. Cao5, R. Clothier6, J. Harbell4, G.Mun4, A. Sizemore4, G. Moyer4, J. Madren-Whalley4,C. Krishna5, M. Owen6, N. Borne6, M. Wenk7 and M.Vallant8. 1NICEATM, NIEHS, Research Triangle Park,NC, 2ILS, Inc., Research Triangle Park, NC, 3JRC,ECVAM, Ispra, Italy, 4IIVS, Gaithersburg, MD, 5ECBC,USArmy, Aberdeen Proving Ground, MD, 6Universityof Nottingham, Nottingham, United Kingdom,7BioReliance, Rockville, MD and 8NIEHS, ResearchTriangle Park, NC.

#485 INTEGRATED DISCRETE MULTIPLE ORGANCULTURE: A NOVEL IN VITROEXPERIMENTAL SYSTEM FOR TOXICITYSTUDIES. A. P. LI1,3, Y. Sakai1 and C. Bode2.1Advanced Pharmaceutical Sciences, Inc., Columbia,MD, 2Tissue Transformation Technologies, Inc., Edison,NJ and 3The ADMET Group LLC, Rockville, MD.

#486 EFFECTS OF NANOSPHERES ON THEADHESION AND CELL VIABILITY OFASTROCYTES. C. Au1, L. Mutkus2, A. Dobson2, J.Riffle3, J. Lallli3, R. Claus3 and M. Aschner1.1Pediatrics, Vanderbilt University Medical Center,Nashville, TN, 2Physiology and Pharmacology, WakeForest University School of Medicine, Winston Salem,NC and 3NanoSonic Inc., Blacksburg, VA.

#487 IN VITRO MODEL OF PENETRATION ANDACTIVE DECONTAMINATION OF ACORROSIVE. L. MATHIEU1, C. Godard1, H.Coudouel1 and A. H. Hall2. 1Scientific Researches,Prevor, Talence, France and 2Scientific communications,TCMTS Inc., Elk Mountain, WY.

#488 TESTING CASCADE TO PREDICT THEPOTENTIAL OF DRUG DISCOVERYCOMPOUNDS TO INDUCE MITOCHONDRIALDYSFUNCTION. L. D. Marroquin, G. J. Stevens andY. Will. Safety Sciences, Pfizer, San Diego, CA.

Program Description


MO

ND

AY


#489 PREDICTION OF TOXICITY PARAMETERS OFAMINO- AND NITROBENZENE DERIVATIVES.K. Kabirov and A. Lyubimov. Toxicology ResearchLaboratory, University of Illinois at Chicago, Chicago,IL.

#490 THE USE OF LASER SCANNING CYTOMETRY(LSC) AS A POTENTIAL TOOL FORQUANTITATIVE ANALYSIS OF CYPS IN LIVERTISSUE SECTIONS. V. Kostrubsky1, S. Kulkarni1, A.Shen2, S. Schomaker2, I. Pruimboom-Brees2, D.Amacher2 and D. Brees2. 1WWSS, Pfizer, Ann Arbor,MI and 2WWSS, Pfizer, Groton, CT.

#491 METABONOMICS COMES INTO THE COLD:COMPARISON OF SENSITIVITY ANDREPRODUCIBILITY OF CRYOGENIC PROBESVERSUS INCREASED FIELD STRENGTH. M. J.Santostefano1, B. C. Sweatman2, S. Castellino3, A. W.Nicholls2, S. A. Ringeissen2, B. F. Hamilton1, H. L.Jordan1, T. L. Schehl4 and J. N. Haselden2. 1SA,GlaxoSmithKline, Research Triangle Park, NC, 2IPT,GlaxoSmithKline, Ware, United Kingdom, 3DMPK,GlaxoSmithKline, Research Triangle Park, NC and4Randstad, Research Triangle Park, NC.

#492 EFFECTS OF REPEAT INTRAMUSCULARDOSING OF KETAMINE FOR 14-DAYS INCYNOMOLGUS MONKEYS. K. Moore1, J.Mandsager1, S. Roesch1, P. Franklin1, J. Jabbour1, W.Congdon1, S. Meyer1 and R. Nagata2,1. 1SafetyAssessment, SNBL USA, Ltd.,, Everett, WA and 2ShinNippon Biomedical Laboratories, Ltd., Kagoshima,Japan.

#493 A CANINE MODEL FOR SAFETY EVALUATIONOF PERCUTANEOUS INTRAHEPATICINJECTION OF 10% ROSE BENGAL. R. Jones1, E.Wachter2, D. Griffin1, K. Davis1 and N. Foster1.1Toxicology, Charles River Laboratories– DDS–Arkansas Division, Redfield, AR and 2ProvectusPharmaceuticals, Inc., Knoxville, TN.


POSTER SESSION: BIOMARKERS

Chairperson(s): Timothy Fennell, RTI International, Research Triangle Park,NY and Deirdre Mahle, US Air Force, Wright-Patterson AFB, OH.



#494 CHARACTERIZATION OF NOVELBIOMARKERS OF PERCHLORATE EXPOSUREIN ZEBRAFISH. S. Mukhi1 and R. Patino2.1Department of Environmental Toxicology, Texas TechUniversity, Lubbock, TX and 2Texas Cooperative Fishand Wildlife Research Unit, Lubbock, TX.

#495 CROSS-TISSUE BIOMARKERS THAT PREDICTAND CHARACTERIZE THE ACUTE PHASERESPONSE. S. Tugendreich. Iconix Pharmaceuticals,Mountain View, CA. Sponsor: K. Kolaja.

#496 THE CHANGE IN FINGER OVAL AREA IN ANON-HUMAN PRIMATE COLLAGEN-INDUCEDARTHRITIS MODEL AND ITS CORRELATIONWITH BIOCHEMICAL PARAMETERS. N. Horai,H. Horai, H. Tsusaki, H. Tokado, K. Fukuzaki and R.Nagata. Shin Nippon Biomedical Laboratories, Ltd.,(SNBL), Kagoshima, Japan.

#497 EFFECTS OF BRIEF ENVIRONMENTALTOBACCO SMOKE (ETS) AND PROPIONICACID EXPOSURES. J. C. Walker, D. B. Walker, R.Whitt, J. C. Suarez, K. W. Winship, M. Russo and N. J.Walker. Sensory Research Institute, Florida StateUniversity, Tallahassee, FL. Sponsor: C. Smith.

#498 RESPONSES OF MRP2-DEFICIENT TR RAT TOREPEATED DICLOFENAC EXPOSURE. V.Ramirez-Alcantara1,2, L. Kaphalia1, J. F. Aronson1,3, M.F. Kanz1 and M. Treinen-Moslen1,3. 1Pathology, UTMB,Galveston, TX, 2CINVESTAV-IPN, D.F, Mexico and3Internal Medicine, UTMB, Galveston, TX.

#499 EVALUATION OF THE EFFECTS OFINTRANASAL ADMINISTRATION OF IL-4 TOMICE AND INHIBITION OF THESE EFFECTSBY A MURINE IL-4 RECEPTOR ANTIBODY. M.Horner1, L. L. Carlock1, J. Tocker1, B. He2 and J. L.Bussiere1. 1Amgen Inc., Thousand Oaks, CA and 2GeneLogic Laboratories Inc., Gaithersburg, MD.

#500 CYSTEINYL KERATIN 1 AND 10 PROTEINADDUCTS OF BENZENE OXIDE ANDNAPHTHALENE-1, 2-OXIDE FORQUANTIFICATION OF DERMAL EXPOSURE TOBENZENE AND NAPHTHALENE. L. A. Nylander-French1, D. Fox1, K. Jayara1, D. G. Klapper2, A. Gold1,L. M. Ball1 and J. E. French3. 1Environmental Sciences& Engineering, UNC-CH, Chapel Hill, NC,2Department of Microbiology and Immunology, UNC-CH, Chapel Hill, NC and 3Laboratory of MolecularToxicology, NIEHS, Research Triangle Park, NC.

#501 GLYCOPROTEOMIC ANALYSIS OF RATPLASMA FOLLOWING PROTEINPHOSPHATASE INHIBITION BYMICROCYSTIN-LR. C. R. Wilson1,3, F. E. Regnier2

and S. B. Hooser1,3. 1Animal Disease DiagnosticLaboratory, Purdue University, West Lafayette, IN,2Chemistry, Purdue University, West Lafayette, IN and3Vet. Path, Purdue University, West Lafayette, IN.

#502 FORMATION OF UVA LIGHT INDUCEDOXYPEUCEDANIN DNA ADDUCTS ANDDETECTION USING HPLC 32P-POSTLABELING. L. H. Couch1,2, N. V. Gopee1,2, M.I. Churchwell1, D. R. Doerge1, W. G. Wamer3 and P. C.Howard1,2. 1Division of Biochemical Toxicology,NCTR, U.S. FDA, Jefferson, AR, 2NTP Center forPhototoxicology, NCTR, U.S. FDA, Jefferson, AR and3Office of Cosmetics and Colors, CFSAN, U.S. FDA,College Park, MD.

Program Description



MO

ND

AY

#503 ACTIVATION OF HUMAN AH RECEPTORSIGNALING BY POLYCYCLIC AROMATICHYDROCARBONS AND EXTRACTS OF SOILSFROM THE NEW ORLEANS AREA. C. A. Miller1,G. Wang2, J. Hughes3 and A. Alnafisi1. 1EnvironmentalHealth Sciences, Tulane University, New Orleans, LA,2Chemistry, Xavier University, New Orleans, LA and3Biostatistics, Tulane University, New Orleans, LA.

#504 INDUCTION OF CYCLOOXYGENASE-2 IN THELUNGS OF RATS EXPOSED TO TOBACCOSMOKE. K. R. Smith1, S. T. Owens1, A. W. Goodyear1,U. P. Kodavanti2 and K. E. Pinkerton1. 1Center forHealth and the Environment, University of California,Davis, CA and 2NHEERL, U.S. EPA, Research TrianglePark, NC.

#505 DNA AND HEMOGLOBIN ADDUCTS FROMORAL ADMINISTRATION OF ACRYLAMIDE TOMALE FISCHER 344 RATS. T. Fennell1, R. W.Snyder1 and M. A. Friedman2. 1RTI International,Research Triangle Park, NC and 2UMDNJ, Newark, NJ.

#506 CHARACTERIZATION OF MAINSTREAMCIGARETTE SMOKE-INDUCED CHRONICINFLAMMATION IN ICR AND C57BL/6 MICE. K.C. Hodge-Bell1, K. M. Lee2, A. F. Fuciarelli2, R. A.Renne2, S. J. Harbo2 and W. J. McKinney1. 1Research &Technology, Phillip Morris USA, Richmond, VA and2Battelle Toxicology Northwest, Richland, WA.

#507 NANBIOTECHNOLOGY: AUTOMATED REAL-TIME MEASURES OF TOXICANT INFLUENCEON CELL SPEED IN CHEMOTACTICENVIRONMENTS. X. Yin, N. Hadjout, D. Knecht andM. A. Lynes. Molecular and Cell Biology, University ofConnecticut, Storrs, CT, CT.

#508 MODULATION OF EXTRACELLULAR MATRIXMARKS EARLY DEGENERATION OF KIDNEYPAPILLAE INTERSTITIAL CELLS (IC) OF RATSDOSED WITH INDOMETHACIN (IND). P.Ciaccio1, S. Emeigh Hart1, J. Bartock1, V. Oreffo2, C.Kind2, K. Kenne3, S. Matis1, F. Pognan4 and B.Graham4. 1Safety Assessment, AstrazenecaPharmacology, Wilmington, DE, 2AstrazenecaPharmacology, Leicestershire, United Kingdom,3Astrazeneca Pharmacology, Sodertalje, Sweden and4Astrazeneca Pharmacology, Macclesfield, UnitedKingdom.

#509 A METABONOMICS INVESTIGATION OF THEHEPTOTOXICITY OF VALPROIC ACID. L. K.Schnackenberg1, D. Hansen2 and R. D. Beger1.1Division of Systems Toxicology, National Center forToxicological Research, Jefferson, AR and 2Division ofGenetic and Reproductive Toxicology, National Centerfor Toxicological Research, Jefferson, AR.

#510 POTENTIAL ROLE OF METHYLGUANIDINEFOUND IN METABONOMICS INVESTIGATIONOF NEPHROTOXICITY. A. Amberg1, I.Stammberger1, M. Kurz2, M. Will2, H. Juretschke3 andM. Gerl3. 1Drug Safety Evaluation, Sanofi Aventis,Hattersheim, Germany, 2Chemistry, Sanofi Aventis,Frankfurt, Germany and 3Gobal Experimental Medicine,Sanofi Aventis, Frankfurt, Germany. Sponsor: M.Bonnefoi.

#511 PATTERN RECOGNITION OF NMR SPECTRAOF URINE FROM WISTAR RATS DOSED WITHLIVER AND RENAL TOXICANTS. R. D. Beger1, L.K. Schnackenberg1, Y. P. Dragan1, M. D. Reily2 and D.G. Robertson3. 1Division of Systems Toxicology,National Center for Toxicological Research, Jefferson,AR, 2Discovery Technologies, Pfizer, Ann Arbor, MIand 3World Wide Safety Sciences, Pfizer, Ann Arbor,MI.

#512 DIBUTYLTIN EXPOSURE ALTERSCIRCULATING BLOOD GROWTH FACTORLEVELS. T. Lyons-Darden1, S. Jenkins2, R. Luebke4

and S. Barone3. 1Neurotoxicology, U.S. EPA, ResearchTriangle Park, NC, 2Office of Air Quality Planning andStandards, U.S. EPA, Research Triangle Park, NC,3National Center for Environmental Assessment, U.S.EPA, Washington, DC and 4Environmantal Toxicology,U.S. EPA, Research TRaingle Park, NC.

#513 EVALUATION OF CYTOCHROME P450 1A1 AND1B1 IN HUMAN BLOOD LYMPHOCYTES ASBIOMARKERS OF EXPOSURE TO DIOXIN-LIKECOMPOUNDS. M. van Duursen, T. Sanderson and M.van den Berg. Institute for Risk Assessment Sciences,Utrecht, Netherlands.

#514 MULTI-TISSUE CHARACTERIZATION OFRHABDOMYOLYSIS FOR THE HIGH PROFILEFAILURE CERIVASTATIN. B. Ganter and K. L.Kolaja. Chemogenomics and Toxicology, IconixPharmaceuticals, Mountain View, CA.

#515 EVALUATION OF KIDNEY TOXICITYDETECTION METHODS: URINARY GSTS ANDPROTEIN PROFILING BY SELDI-TOF-MS. K.Okamoto1,2, W. W. Collette2, M. Mondal2, A. dePeyster1 and G. J. Stevens2. 1Graduate School of PublicHealth, San Diego State University, San Diego, CA and2Worldwide Safety Sciences, Pfizer Global Researchand Development, San Diego, CA.

#516 CHARACTERIZATION OF EPOXIDE ADDUCTSOF POLYCYCLIC AROMATICHYDROCARBONS (PAH) WITH HEMOGLOBIN(HB). M. Y. Ali, H. E. Hurst and S. R. Myers.Pharmacology and Toxicology, Center forEnvironmental and Occupational Health Sciences,University of Louisville, Louisville, KY.

#517 EXHALATION OF CYTOKINES BYLABORATORY RODENTS. E. Bermudez and O. R.Moss. CIIT Centers for Health Research, ResearchTriangle Park, NC.

#518 THE INFLUENCE OF DIET ON ENDPOINTSTYPICALLY USED IN 13-WEEK TOXICITYSTUDIES FOR RODENTS. E. Harvey2, L. J. Betz2

and G. Travlos1. 1NIEHS, Durham, NC and 2ConstellaHealth Sciences, Durham, NC. Sponsor: C. Portier.

Program Description


MO

ND

AY


#519 USE OF IN VITRO TECHNOLOGIES ANDMETABONOMICS IN THE STUDY OFPHOSPHOLIPIDOSIS. C. E. Thomas1, J. M. Colet2,A. Meissner2, B. Halstead1, R. Morgan1, K. Kramer2,W. Dewe3 and D. Monteith1. 1Inv. Toxicology., LillyResearch Labs, Greenfield, IN, 2Inv. Toxicology., LillyDevelopment Centre, Mont-Saint-Guibert, Belgium and3Statistics, Lilly Development Centre, Mont-Saint-Guibert, Belgium.

#520 EVALUATION OF VITAMIN K AND VITAMIN KEPOXIDE AS BIOMARKERS OFCOAGULOPATHY IN RAT SERUM UTILIZINGHPLC. K. A. Navetta, P. E. Quintas, M. D. Aleo and J.L. Colangelo. Safety Sciences, Pfizer, Groton, CT.

#521 A MOLECULAR BASIS FOR THE PREDICTIONOF RENAL TUBULAR INJURY BY DRUGSIGNATURES FOLLOWING SHORT-TERMCOMPOUND TREATMENT. M. Fielden, G.Natsoulis and K. Kolaja. Chemogenomics andToxicology, Iconix Pharmaceuticals Inc., MountainView, CA.

#522 BIOMARKERS THAT CHARACTERIZEFIBROSIS AND BILE DUCT HYPERPLASIA. A.Vladimirova, R. Brennan, M. Fielden, K. Kolaja and C.Pearson. Iconix Pharmaceuticals, Inc., Mountain View,CA.

#523 MULTI-ADDUCT ANALYSIS OF GLOBIN FROMMICE AND RATS AFTER INHALATIONEXPOSURE TO 1, 3-BUTADIENE. N. I. Georgieva1,G. Boysen1, P. B. Upton1, Y. Li1, V. Walker2 and J. A.Swenberg1. 1ESE, UNC, Chapel Hill, NC and 2LovelaceRespiratory Research Institute, Albuquerque, NM.

#524 INTERACTIONS OF COMPLEX CHEMICALMIXTURES FROM CONTAMINATEDSEDIMENTS AT A SUPERFUND SITE. A.Gillespie1, T. D. Phillips1, T. J. McDonald2, L. He1, G.Zhou2,1 and K. Donnelly2,1. 1VIBS, Texas A&MUniversity, College Station, TX and 2EOH, Texas A&MUniversity H.S.C., S.R.P.H., College Station, TX.

#525 CORRELATION OF HEXENAL-DERIVED DNABINDING WITH DETOXIFICATION AND DNAREPAIR STATUS IN CULTURED CELLS. M. D.Stout1, J. Nakamura2, G. Boysen2, M. W. Powley2 and J.A. Swenberg1,2. 1Curriculum in Toxicology, Universityof North Carolina, Chapel Hill, NC and 2EnvironmentalSciences and Engineering, University of North Carolina,Chapel Hill, NC.

#526 COMPARISON OF PLASMA AND URINESAMPLES FROM ANIT-EXPOSED F344 RATSUSING NMR SPECTROSCOPY. D. Mahle1, N. J.DelRaso1, S. C. Gustafson2, C. L. Leakeas2, M. P.Westrick1, A. E. Neuforth3 and N. V. Reo3.1AFRL/HEPB, US Air Force, Wright-Patterson AFB,OH, 2AFIT/ENG, US Air Force, Wright-Patterson AFB,OH and 3Wright State University, Fairborn, OH.

#527 USE OF METABOLOMICS TO IDENTIFYBIOMARKERS OF BREVETOXIN EXPOSURE. A.J. bourdelais1, J. Benson2, A. Higgins3, H. Mei3, K.Powell3, K. Wang3, B. Tibbetts2 and D. G. Baden1.1CMS, UNCW, Wilmington, NC, 2Lovelace RespiratoryResearch Institute, Albuquerque, NM and 3Icoria,Research Triangle Park, NC.

#528 CAN LEVELS OF PLASMA TESTOSTERONE BEUSED TO PREDICT MALE SEXUAL MATURITYIN RHESUS MONKEYS (MACACA MULATTA)?M. D. Saunders, R. Davis, S. Fox and L. Earl.Toxicology Operations, Huntingdon Life Sciences,Huntingdon, United Kingdom. Sponsor: C. Hardy.

#529 ADMINISTRATION OF A MEK INHIBITORRESULTS IN TISSUE MINERALIZATION IN THERAT DUE TO DYSREGULATION OFPHOSPHORUS AND CALCIUM HOMEOSTASIS.A. P. Brown, C. Courtney, T. Carlson and M. Graziano.Safety Sciences, Pfizer Global Research andDevelopment, Ann Arbor, MI.

#530 USE OF METABONOMIC ANALYSIS FORBIOMARKERS OF MUSCULOSKELETALSYNDROME IN RATS. F. Grzemski1, L. C. Robosky2,M. D. Reily2, D. Baker2, C. A. Lesch3, M. G. Evans1,D. F. Wells1 and D. G. Robertson3. 1Safety Sciences,Pfizer, Ann Arbor, MI, 2Discovery Technology, Pfizer,Ann Arbor, MI and 3Inflammation Pharmacology,Pfizer, Ann Arbor, MI.

#531 INVESTIGATION OF A HEPATOTOXICITYSCREENING SYSTEM IN PRIMARY CELLCULTURE. R. Kikkawa, T. Yamamoto, T. Fukushima,Y. Hamada, H. Yamada and I. Horii. PGRD NagoyaLab., Pfizer Japan Inc., Taketoyo, Aichi, Japan.Sponsor: K. Masaaki.

#532 THE IDENTIFICATION OF POTENTIALVASCULITIS BIOMARKERS TARGETEDTHROUGH SELDI SCREENING. C. Drupa1, J. L.Colangelo1, R. A. Goldstein1, M. L. Mirsky1, R. M.Leimgruber2, M. Cabonce2, P. W. Brown2 and E.Dalmasso3. 1World Wide Safety Sciences, Pfizer,Groton, CT, 2World Wide Safety Sciences, Pfizer, St.Louis, MO and 3Ciphergen Biosystems, Inc., Fremont,CA. Sponsor: M. Lawton.

#533 ALANINE AMINOTRANSFERASE ACTIVITY INTHE FA2N-4 HEPATOCYTE CLONE. E. R. Jacksonand D. E. Amacher. Safety Sciences, Pfizer, Inc.,Groton, CT.

#534 TOXICOLOGIC AND PATHOLOGICSURVEILLANCE OF SEARCH & RESCUE DOGSDEPLOYED TO THE WORLD TRADE CENTER,THE PENTAGON, AND THE STATEN ISLANDFRESH KILLS LANDFILL SITES. W. K. Rumbeiha1,S. D. Fitzgerald1, E. W. Braselton1, C. M. Otto2 and A.B. Downend2. 1Pathobiology and DiagnosticInvestigagtion, Michigan State University, Lansing, MIand 2Clinical Sciences, School of Veterinary Medicine,University of Pennsyllvania, Philadelphia, PA.

#535 SEQUENCE AND EXPRESSION ANALYSIS OFCANINE ALT1 AND ALT2. L. Nelms, B. Lu and M.Lawton. Pfizer, Groton, CT.

Program Description



MO

ND

AY

#536 AUTOMATED BIOCHEMICALMEASUREMENTS OF ACYL-COA OXIDASEAND CARNITINE PALMITOYLTRANSFERASEFOR ASSESSMENT OF PPAR-INDUCEDPEROXISOME PROLIFERATION INCYNOMOLGUS MONKEYS. D. F. Adams, M. A.Tirmenstein, K. M. Lynch, C. X. Hu, B. E. Maleeff, T.L. Gales, T. S. Sellers, D. Ennulat and L. W. Schwartz.Safety Asssessment, GlaxoSmithKline, King of Prussia,PA.

#537 EVALUATING TOXICOLOGY AT A SYSTEMSLEVEL USING COHERENT ANALYSIS OFLARGE-SCALE DATA STREAMS. I. Shah, Z. Cai,B. Bullard, T. Colatsky, A. Berger, M. Fedor, P. Hurban,G. Yuan and A. Higgins. Icoria, INC, Research TrianglePark, NC. Sponsor: N. Sponsor.

#538 A COMPARISON OF THE SPECIFICITY ANDSENSITIVITY OF TRADITIONAL BIOMARKERSOF NEPHROTOXICITY IN THE RAT WITHMETABONOMIC AND PROTEOMICMETHODOLOGIES. A. C. Gibbs. Scientific andRegulatory Consulting, Covance Laboratories Ltd.,Harrogate, United Kingdom. Sponsor: D. Everett.

#539 THE RELATIONSHIP OF TREATMENT-RELATED DECREASES IN SERUM ALKALINEPHOSPHATASE ACTIVITY WITHALTERATIONS IN BODY WEIGHT FOR RATS IN13-WEEK TOXICITY STUDIES. L. Betz2, E.Harvey2 and G. Travlos1. 1NIEHS, Durham, NC and2Constella Health Sciences, Durham, NC. Sponsor: C.Portier.

#540 IDENTIFYING CANDIDATE BIOMARKERS OFVITAMIN D ANALOG–INDUCED RENALMINERALIZATION USING A SYSTEMSBIOLOGY APPROACH. C. I. Nduaka1, L. Jones2, M.Boren1, N. hanson1, T. Osborne3, K. Herbert1, L.Nelms1, M. Nowakowski1, K. Steever1, C. Edmond1, D.Blackwell1, M. Delnomdedieu1, C. Bagi1, F. Geoly1 andM. Lawton1. 1World Wide Safety Sciences, Pfizer Inc.,Groton, CT, 2University of Maryland, Baltimore, MDand 3University of Illinois, Chicago, IL.


POSTER SESSION: MALE REPRODUCTIVE

Chairperson(s): Sandra Morseth, Morseth Consulting LLC, Jefferson, MDand Darryl Arfsten, US Navy, Wright-Patterson AFB, OH.



#541 EFFECT OF TESTICULAR EDEMA ONSPERMATOGENESIS IN TOXICANT-TREATEDRAT TESTES. K. Porter, C. C. Weng and M. L.Meistrich. Experimental Radiation Oncology, U.T. M.D.Anderson Cancer Center, Houston, TX.

#542 EFFECT OF ETHYLENE GLYCOLMONOETHYL ETHER ON SPERM MOTION INRAT. R. WANG1, K. OHTANI1, N. JIA2, M. SUDA1,X. GAO2 and T. HONMA1. 1National Institute Ind.Health, Kawasaki, Kanagawa, Japan and 2BeijingDiseases Control and Prevention Center, Beijing, China.Sponsor: X. YU.

#543 CHANGES OF GENE EXPRESSION IN THEEPIDIDYMIDES AND SPERM ACROSOMEREACTION IN RATS TREATED WITHSULFASALAZINE FOR SEVERAL DAYS. Y.Hamada1, T. Fukushima1,2, M. Komiyama2, C. Mori2

and I. Horii1. 1Worldwide Safety Sciences, PfizerGlobal and Research Nagoya Laboratories, Taketoyo,Aichi, Japan and 2Bioenvironmental Medicine, ChibaUniversity, Chiba, Japan. Sponsor: M. Kurata.

#544 DEVELOPMENTAL TOXICOLOGY OF CJC-1131,A LONG-ACTING GLP-1 ANALOGUE. B.Lawrence1, S. Wen1, Y. Fukushima1, E. M. Lewis2, S.Morseth3 and J. Castaigne1. 1ConjuChem, Inc.,Montreal, QC, Canada, 2Argus Research, Horsham, PAand 3Morseth Consulting LLC., Jefferson, MD.

#545 EFFECT OF IMPLANTED DEPLETED URANIUM(DU) ON MALE RAT REPRODUCTIVESUCCESS, SPERM CONCENTRATION ANDMOTION. D. P. Arfsten1, E. R. Wilfong1, E. W.Johnson1, D. J. Schaeffer2 and K. R. Still1. 1NHRC EHELab., Wright-Patterson AFB, OH and 2Department ofVeterinary Biosciences, University of Illinois at UrbanaChampaign, Urbana, IL.

#546 THE EFFECTS OF SUBACUTE ORALEXPOSURE TO VINCLOZOLIN ONREPRODUCTIVE PARAMETERS INPERIPUBERTAL AND POST-PUBERTAL BOARS.T. J. Evans1, E. M. Walters1, Y. Agca1, T. J. Fangman2,F. Williams III1, J. K. Critser1 and R. A. Hess3.1Veterinary Pathobiology, University of Missouri,Columbia, MO, 2Veterinary Extension and ContinuingEducation, University of Missouri, Columbia, MO and3Veterinary Biosciences, University of Illinois, Urbana,IL.

#547 DELAYED PREPUTIAL SEPARATION (PPS) ANDSP22 MEASUREMENT IN RATS ADMINISTEREDBROMOCHLOROACETIC ACID (BCA) INDRINKING WATER. C. S. Sloan1, G. R. Klinefelter2,J. M. Goldman2, K. D. Vick1, P. A. Fail1 and R. W. Tyl1.1Life Sciences and Toxicology, RTI International,Research Triangle Park, NC and 2ReproductiveToxicology Division, NHEERL, U.S. EPA, ResearchTriangle Park, NC.

#548 USE OF 5αα-DIHYDROTESTOSTERONE (DHT)-EXPOSED UROGENITAL SINUSES (UGS) FROMFEMALE MICE TO INVESTIGATE INHIBITIONOF PROSTATIC BUDDING CAUSED BY 2, 3, 7, 8-TETRACHLORODIBENZO-P-DIOXIN (TCDD). T.Lin and R. E. Peterson. School of Pharmacy, Universityof Wisconsin, Madison, WI.

Program Description


MO

ND

AY


#549 IN VIVO EXPOSURE OF PREPUBERTAL RATSTO METHOXYCHLOR (M) INHIBITS EX VIVOLEYDIG CELL (LC) BASAL AND HUMANCHORIONIC GONADOTROPIN (HCG)-STIMULATED TESTOSTERONE (T)FORMATION. E. P. Murono and R. C. Derk.Pathology and Physiology Research Branch,CDC/NIOSH, Morgantown, WV. Sponsor: V.Castranova.

#550 IN UTERO EXPOSURE TO 2, 3, 7, 8-TETRACHLORODIBENZO-P-DIOXIN ALTERSSONIC HEDGEHOG AND BONEMORPHOGENIC PROTEIN 4 EXPRESSION INTHE DEVELOPING MOUSE UROGENITALSINUS. W. A. Fritz, W. A. Bushman and R. E. Peterson.University of Wisconsin, Madison, WI.

#551 CRITICAL WINDOW OF MALEREPRODUCTIVE TRACT DEVELOPMENT INRATS FOLLOWING GESTATIONAL EXPOSURETO DI-N-BUTYL PHTHALATE. C. M. Carruthers1

and P. Foster2. 1NIEHS, Research Triangle Park, NCand 2NIEHS, Research Triangle Park, NC.

#552 EFFECT OF DI(N-BUTYL) PHTHALATE ONMALE REPRODUCTIVE ORGANDEVELOPMENT IN HYPOTHYROID RATS. H.Kim, E. Lee, M. Ahn and H. Kim. College of Pharmacy,Pusan National University, PUSAN, South Korea.Sponsor: I. Yu.

#553 EFFECTS OF TCDD ON STEROIDOGENESIS OFRAT LEYDIG CELLS. K. P. Lai, H. Y. Yeung, M. H.Wong and C. K. Wong. Biology, Hong Kong BaptistUniversity, Hong Kong, China.

#554 ESTROGEN RECEPTOR ALPHA IS NOTREQUIRED FOR NORMAL PROSTATIC BUDFORMATION OR FOR INHIBITION OFPROSTATIC BUD FORMATION BY 2, 3, 7, 8-TETRACHLORODIBENZO-P-DIOXIN (TCDD) INMICE. S. M. Hicks2, T. Lin1, M. Mukai3, P. S. Cooke3

and R. E. Peterson1,2. 1School of Pharmacy, Universityof Wisconsin, Madison, WI, 2Molecular andEnvironmental Toxicology Center, University ofWisconsin, Madison, WI and 3Department of VeterinaryBiosciences, University of Illinois, Urbana, IL.

#555 CHARACTERIZATION OF 2, 3, 7, 8-TETRACHLORODIBENZO-P-DIOXIN (TCDD)RESPONSIVENESS IN MOUSE UROGENITALSINUS (UGS) USING ARYL HYDROCARBONRECEPTOR (AHR)-DEPENDENT LACZ MICE. D.R. Kelman1, J. C. Bemis3, T. Lin2, T. A. Gasiewicz3 andR. E. Peterson1,2. 1Molecular and EnvironmentalToxicology Center, University of Wisconsin, Madison,WI, 2Pharmacy, University of Wisconsin, Madison, WIand 3Environmental Medicine, University of Rochester,Rochester, NY.

#556 ANALYSIS OF CORTACTIN EXPRESSION INTHE ECTOPLASMIC SPECIALIZATION OFTESTES IN FLUTAMIDE TREATMENT MOUSE.R. Anahara1, Y. Toyama2, M. Maekawa2, M. Kai3,4, F.Ishino5, K. Toshimori2 and C. Mori1,6.1Bioenvironmental Medicine, Chiba University, Chiba,Japan, 2Anatomy and Developmental Biology, ChibaUniversity, Chiba, Japan, 3Pharmaceutical ResearchLaboratories, Kirin Brewery Co. Ltd., Gunma, Japan,4Division for Gene Research, Center for BiologicalResources and Informatics, Tokyo, Japan, 5MedicalResearch Institute, Tokyo Medical and DentalUniversity, Tokyo, Japan and 6CREST, Japan Scienceand Technology Agency, Kawaguchi, Japan.

#557 CHARACTERIZATION OF THE GENEEXPRESSION PROFILE INDUCED BYETHYLENE GLYCOL MONOMETHYL ETHERIN THE RAT TESTIS WITH DNAMICROARRAYS. E. Blomme1, R. Ciurlionis1, K.Whitney1, I. Milicic1, M. Strakhova1 and J. Waring1.1Abbott Labs, Abbott Park, IL and 2Abbott Labs, AbbottPark, IL.

#558 THE USE OF CD-1 MICE FOR FERTILITY ANDEARLY-EMBRYONIC DEVELOPMENT (ICH-1STUDIES. L. Pinsonneault, A. St-Pierre, C. Tremblay,M. Adamo, L. Pouliot and K. Robinson. ReproductiveToxicology, CTBR Bio-Research Inc., Senneville, QC,Canada. Sponsor: M. Vezina.


POSTER SESSION: GENE EXPRESSION II

Chairperson(s): Curtis Klaassen, Kansas University Medical Center, KansasCity, KS.



#559 UNDERSTANDING HEPATIC VACUOLATION:GENE EXPRESSION ANALYSIS OFPHOSPHOLIPIDOSIS AND STEATOSIS IN RATLIVER. D. Pelletier, B. Lu and M. Lawton. Molecularand Investigative Toxicology, Pfizer Inc., Groton, CT.

#560 TOXICOGENOMIC STUDY OF HYCANTHONE,AN ANTITUMOR AGENT: MOLECULARMECHANISMS OF HEPATOTOXICITY. A. E.Roberts, Y. Wang, X. Luo, R. Khan-Malek, V. Shultz, J.Morsman, N. Bowen, N. Bichet, O. Gillardeaux and V.Baker. Toxicology, Sanofi-aventis, Malvern, PA.

#561 GENE EXPRESSION PROFILING IN RAT LIVERAND HEPATOCYTES TREATED WITH FIBRICACIDS: ANALYSIS OF THE DATA IN THETOXICOGENONMICS PROJECT IN JAPAN. K.Tamura, T. Miyagishima, T. Urushidani and T. Nagao.Toxicogenomics Project, National Institute of HealthSciences, Tokyo, Japan. Sponsor: T. Inoue.

Program Description



MO

ND

AY

#562 GENE EXPRESSION PROFILING IN RAT LIVERAND HEPATOCYTES TREATED WITHETHIONINE–ANALYSIS OF THE DATA IN THETOXICOGENOMICS PROJECT IN JAPAN -. T.Matsushita, T. Miyagishima, T. Urushidani and T.Nagao. Toxicogenomics Progect, National Institute ofHealth Sciences, Tokyo, Japan. Sponsor: T. Inoue.

#563 GENE EXPRESSION ARRAY ANALYSIS OFMALE C3H AND C57BL/6 LIVER. J. C. Fuscoe2,1,A. Naito1, T. Han2,1 and Y. Dragan1. 1SystemsToxicology, National Center for ToxicolologicalResearch, Jefferson, AR and 2Center for FunctionalGenomics, NCTR, Jefferson, AR.

#564 REGULATION OF MOUSE HEPATICTRANSPORTERS BY PERFLUORODECANOICACID (PFDA). X. Cheng, J. M. Maher, M. Z. Dieterand C. D. Klaassen. Pharmacology & Toxicology,KUMC, Kansas City, KS.

#565 ANALYSIS OF BENZO(A)PYRENE-INDUCEDGENE EXPRESSION CHANGES IN FISHER 344RAT LIVER BY QUANTITATIVE REAL-TIMEPCR. A. U. N and J. C. Means.Chemistry/Environmental Institute, Western MichiganUniversity, Kalamazoo, MI.

#566 ALTERATIONS OF GENE EXPRESSION INFEMALE LUNG ADENOCARCINOMA CL5CELLS BY MOTORCYCLE EXHAUSTPARTICULATES AND BENZO(A)PYRENE. T.Ueng and C. Hung. Institute of Toxicology, NationalTaiwan University, Taipei, Taiwan.

#567 EXPRESSION OF GENES INVOLVED INPOLYCYCLIC AROMATIC HYDROCARBONS(PAH) TOXICITY IN HEPG2 CULTURE CELLS.F. Castorena-Torres1, M. Bermudez de Leon2, B.Cisneros2, J. E. Salinas-Moreno3 and A. Albores1.1Toxicology Section., Cinvestav-IPN, Mexico City,Mexico, 2Genetics and Biology Molecular Department,Cinvestav-IPN, Mexico City, Mexico and 3HospitalGeneral de Zona 24, IMSS, Nueva Rosita, Coah.,Mexico.

#568 EFFECTS OF DIETS CONTAINING HIGH SOYPROTEIN AND ISOFLAVONES ON GENEEXPRESSION IN FEMALE RAT LIVERS. A.Hierlihy, G. Cooke and I. Curran. Toxicology ResearchDivision, Health Canada, Ottawa, ON, Canada.

#569 A GENE SIGNATURE FOR BILE DUCT TOXINS.M. K. McMillian1, J. B. Parker1, A. M. Leone1, M.Kemmerer1, A. Y. Nie1, S. Bryant1, J. Herlich1, L.Yieh2, A. Bittner2, X. Liu2, J. Wan2, M. D. Johnson1

and P. G. Lord1. 1Mechanistic Toxicology, Johnson &Johnson PRD, LLC, Raritan, NJ and 2Bioinformatics &Microarrays, Johnson & Johnson PRD, LLC, La Jolla,CA.

#570 CENTRAL ROLE OF LIVER RECEPTORHOMOLOG-1 IN INDUCING LIVER-SPECIFICGENES AND REGULATING LIPIDMETABOLISM IN KIDNEY OF 5/6NEPHRECTOMIZED RATS. H. Lu and C. D.Klaassen. Pharmacology and Toxicology, KU MedicalCenter, Kansas City, KS.

#571 GENE EXPRESSION PROCESS IS A MAJORINTRACELLULAR TARGET ASSOCIATEDWITH A-NAPHTHYLISOTHIOCYANATEHEPATOTOXICITY. V. Chan1, A. R. Stapleton1 andN. DelRaso2. 1ManTech Environmental Technology,Inc., Wright-Patterson AFB, Dayton, OH and 2AppliedBiotechnology Branch, Human EffectivenessDirectorate, Air Force Research Laboratory, Wright-Patterson AFB, Dayton, OH. Sponsor: J. Gearhart.

#572 GESTATIONAL EXPOSURE TO THEPHYTOESTROGEN GENISTEIN INFLUENCESEPIGENETIC GENE REGULATION IN MICE. D.C. Dolinoy1, R. L. Jirtle1 and R. A. Waterland2.1Department of Radiation Oncology, Duke UniversityMedical Center, Durham, NC and 2Departments ofPediatrics and Molecular and Human Genetics, BaylorCollege of Medicine, Houston, TX.

#573 USING RNA INTERFERENCE TO VALIDATEMECHANISMS OF TOXICITY. J. Milano and D.Tran. Safety Assessment, AstraZeneca, Wilmington, DE.Sponsor: P. Ciaccio.

#574 CIGARETTE SMOKE CONDENSATE INHIBITSPROMOTER ACTIVITY OF LYSYL OXIDASE INCULTURED LUNG FIBROBLASTS. S. Gao1, Y.Zhao1, L. Chen1, D. K. Chou1, P. Toselli1, I. Chou2, P.Stone1 and W. Li1. 1Biochemistry, Boston UniversitySchool of Medicine, Boston, MA and 2Microbiology,Boston University School of Medicine, Boston, MA.

#575 REGULATION OF THE STEROIDOGENICACUTE REGULATORY PROTEIN (STAR) BYTRANSFORMING GROWTH FACTOR BETA(TGF-BETA). J. Kocerha1, N. Denslow1 and M.Prucha2. 1Department of Physiological Sciences,University of Florida, Gainesville, FL and 2Departmentof Pharmacology and Therapeutics, University ofFlorida, Gainesville, FL.

#576 COMPENSATORY CHANGES IN PHASE I, II,AND III ENZYMES IN MICE LACKING THEMULTIDRUG RESISTANCE-ASSOCIATEDPROTEIN 1 (MRP1/ABCC1). J. Sivils, L. Bain, R. A.Feldman, A. J. Zimmerman and I. Gonzalez. Biology,University of Texas El Paso, El Paso, TX.

#577 TIME COURSE OF HEPG2 GENE EXPRESSIONFOLLOWING TREATMENT WITHTHIOXANTHONE ANTITUMOR COMPOUNDS.A. E. Roberts, X. Luo, Y. Wang, R. Khan-Malek, V.Shultz, J. Morsman, N. Bowen, N. Bichet, O.Gillardeaux and V. Baker. Sanofi-aventis, Malvern, PA.

#578 ISOLATING (NEURO)TOXIC GENEEXPRESSION SIGNATURES. P. S. Spencer and N.and. Center for Research on Occupational andEnvironmental Toxicology, Oregon Health & ScienceUniversity, Portland, OR.

Program Description


MO

ND

AY


#579 PREDICTION OF TRANSCRIPTION FACTORSCOMMONLY AFFECTED BY GLUTAMATE-CYSTEINE LIGASE EXPRESSION IN MICEEXPOSED TO ACETAMINOPHEN, CARBONTETRACHLORIDE OR TUMOR NECROSISFACTOR. S. Shi, D. Botta, T. Bammler, R. P. Beyerand T. J. Kavanagh. Environmental and OccupationalHealth Sciences, University of Washington, Seattle,WA.

Monday Afternoon, March 7

1:30 PM to 4:30 PMExhibit Hall

POSTER SESSION: RECEPTOR: PPAR

Chairperson(s): Andrew Burdick, Penn State University, University Park, PA.



#580 MOLECULAR MECHANISMS OF PPARA-MEDIATED GENE EXPRESSION OF PXR. S.aouabdi, G. Gibson and N. Plant. school of biologicaland molecular sciences, university of surrey, guildford,surrey, United Kingdom.

#581 DECREASED LONGEVITY ANDENHANCEMENT OF AGE-DEPENDENTLESIONS IN MICE LACKING THE NUCLEARRECEPTOR PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR ALPHA. P. Howroyd1,2,C. Swanson1, C. Dunn1, R. C. Cattley1,3 and J. C.Corton4,1. 1CIIT, Research Triangle Park, NC, 2EPL,Research Triangle Park, NC, 3Amgen, Thousand Oaks,CA and 4ToxicoGenomics, Chapel Hill, NC.

#582 CONSTITUTIVE EXPRESSION OFPEROXISOME PROLIFERATOR-ACTIVATEDRECEPTOR ALPHA-REGULATED GENES INDWARF MICE. A. J. Stauber2, J. Liu4, M. P.Waalkes4, H. Brown-Borg3, K. A. Voss5, J. J.Kopchick6 and J. C. Corton1,2. 1ToxicoGenomics,Chapel Hill, NC, 2CIIT Centers for Health Research,Research Triangle Park, NC, 3University of NorthDakota, Grand Forks, ND, 4NCI at NIEHS, ResearchTriangle Park, NC, 5USDA, Athens, GA and 6OhioUniversity, Athens, OH.

#583 PEROXISOME PROLIFERATOR ACTIVATEDRECEPTOR ββ (PPARββ) REGULATESEXPRESSION OF CANCER-RELATED GENESIN LIVER. W. Shan1,2 and J. M. Peters1. 1Departmentof Veterinary Science and Center for MolecularToxicology and Carcinogenesis, The PennsylvaniaState University, University Park, PA and 2TheIntercollege Graduate Degree Program in Genetics,The Pennsylvania State University, University Park,PA.

#584 GENE EXPRESSION PATTERNS ASSOCIATEDWITH FENOFIBRATE INDUCED MYOPATHY.N. R. Bordelon, B. H. Romach, R. Brown and R. T.Miller. SA, GSK, Research Triangle Park, NC.

#585 EVALUATION OF THE ACTIVITY OF THEPESTICIDE CYHALOFOP-BUTYL IN APEROXISOME-PROLIFERATOR RECEPTOR-ααREPORTER ASSAY. G. D. Charles1, L. Kan1, T. R.Hanley2 and B. B. Gollapudi1. 1The Dow ChemicalCompany, Midland, MI and 2Dow AgroSciences LLC,Indianapolis, IN.

#586 PEROXISOME PROLIFERATOR-ACTIVATEDRECEPTOR ββ (PPARββ) SELECTIVELYREGULATES KERATINOCYTEDIFFERENTIATION AND PROLIFERATION. D.J. Kim1,2, A. N. Billin3, T. M. Willson3 and J. M.Peters1,2. 1Department of Veterinary Science and TheCenter for Molecular Toxicology and Carcinogenesis,The Pennsylvania State University, University Park,PA, 2Graduate Program in Molecular Toxicology, TheHuck Institute for Life Sciences, The PennsylvaniaState University, University Park, PA and 3DiscoveryResearch, GlaxoSmithKline, Research Triangle Park,NC.

#587 THE PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR ββ (PPARββ) AGONISTGW0742 INHIBITS SKIN CARCINOGENESIS.M. K. Devlin1,2, D. J. Kim1, A. N. Billin3, T. M.Willson3 and J. M. Peters1,2. 1Department ofVeterinary Sciences and The Center for MolecularToxicology and Carcinogenesis, Penn State University,University Park, PA, 2Graduate Program in MolecularMedicine, Huck Institute for Life Sciences,Pennsylvania State University, University Park, PA and3Discovery Research, GlaxoSmithKline, ResearchTriangle Park, NC.

#588 TRANSCRIPTIONAL REGULATION OFTISSUE-SPECIFIC INHIBITOR OF MATRIXMETALLOPROTEINASE 1 (TIMP1) BYPEROXISOME PROLIFERATOR-ACTIVATORRECEPTOR ββ (PPARββ). M. T. Bility1,2, D. J. Kim1,2,A. N. Billin3, T. M. Willson3 and J. M. Peters1,2.1Department of Veterinary Science and The Center forMolecular Toxicology and Carcinogenesis, ThePennsylvania State University, University Park, PA,2Graduate Program in Molecular Toxicology, TheHuck Institutes for Life Sciences, The PennsylvaniaState University, University Park, PA and 3DiscoveryResearch, GlaxoSmithKline, Research Triangle Park,NC.

#589 TRANSCRIPTION PROFILING REVEALSHEPATIC HYPERTROPHY TO BEINDISTINGUISHABLE FROM THEPHARMACOLOGY OF PPARαα AGONISM INTHE RAT. A. T. De Souza1, P. D. Cornwell1, X. Dai2,M. J. Caguyong3 and R. G. Ulrich1. 1PreclinicalMolecular Profiling, Rosetta Inpharmatics, a whollyowned subsiduary of Merck & Co. Inc., Seattle, WA,2Informatics, Rosetta Inpharmatics, a wholly ownedsubsiduary of Merck & Co. Inc., Seattle, WA and3Project Management, Rosetta Inpharmatics, a whollyowned subsiduary of Merck & Co. Inc., Seattle, WA.

Program Description



MO

ND

AY


POSTER SESSION: NEUROTOXICITY OF METALS: DOSIMETRYAND EFFECTS

Chairperson(s): Donald Smith, University of California Santa Cruz, SantaCruz, CA and Vanessa Fitsanakis, Vanderbilt University Medical Center,Nashville, TN.



#590 DISTRIBUTION OF COPPER (CU) AND ZINC(ZN) TRANSPORTER IN RAT CHOROIDPLEXUS, BRAIN REGIONAL CAPILLARIES,AND CHOROIDAL Z310 CELLS BY REAL TIMERT-PCR. M. Chigurupati, G. Li, B. Choi, S. X. Wangand W. Zheng. School of Health Sciences, PurdueUniversity, West Lafayette, IN.

#591 COPPER (CU) TRANSPORT ANDTRANSPORTERS IN THE BLOOD-BRAINBARRIER (BBB) AND BLOOD-CSF BARRIER(BCB). B. Choi, J. S. Crossgrove, M. Chigurupati andW. Zheng. School of Health Sciences, PurdueUniversity, West Lafayette, IN.

#592 THE EFFECTS OF COPPERDIMETHYLDITHIOCARBAMATE (CDDC) ONRAT HIPPOCAMPAL ASTROCYTES. L. Passaintand L. D. Trombetta. Pharmaceutical Sciences, St. JohnsUniverstty, Jamaica, NY.

#593 MANGANESE EXPOSURE ALTERS IRONREGULATORY MECHANISMS AT BLOOD-CEREBROSPINAL FLUID BARRIER (BCB) ANDSELECTED REGIONS OF BLOOD-BRAINBARRIER (BBB) IN RATS. G. Li1, J. Liu2, M. P.Waalkes2 and W. Zheng1. 1School of Health Sciences,Purdue University, West Lafayette, IN and 2InorganicCarcinogenesis Section, NCI at NIEHS, ResearchTriangle Park, NC.

#594 OVEREXPRESSION OF DMT1 IN THECHOROID PLEXUS FOLLOWING MANGANESE(MN) EXPOSURE. X. Wang, J. G. Li and W. Zheng.Health Sciences, Purdue University, West Lafayette, IN.Sponsor: W. Zheng.

#595 IRON DEFICIENT AND MANGANESEENHANCED DIETS ALTER METALS ANDTRANSPORTERS IN THE DEVELOPING RATBRAIN. S. J. Garcia1, T. Syversen2, K. Gellein3 and M.Aschner4. 1Physiology/ Pharmacology, Wake ForestUniversity Health Sciences, Winston Salem, NC,2Neuroscience, Norwegian University of Science &Technology, Trondheim, Norway, 3Chemistry,Norwegian University of Science & Technology,Trondheim, Norway and 4Pediatrics, VanderbiltUniversity Medical Center, Nashville, NC.

#596 INFLUENCE OF SUBACUTE MANGANESESULFATE ON DOPAMINE AND N-METHYL-D-ASPARTATE RECEPTORS. H. Komiskey. XavierUniversity of Louisiana, New Orleans, LA.

#597 BIOLOGICAL MARKERS OF MN EXPOSURE:RELATIONSHIPS BETWEEN MN DOSE,PARTITIONING IN BLOOD, ANDACCUMULATION IN BRAIN. C. Kern1, L. Cadena1,R. Gwiazda1, R. Lucchini2 and D. R. Smith1.1Environmental Toxicology, University of California,Santa Cruz, CA and 2Institute of Occupational Health,University of Brescia, Brescia, Italy.

#598 PROGRESSION OF NEUROCHEMICALEFFECTS IN DIFFERENT BRAIN REGIONS AS AFUNCTION OF THE MAGNITUDE ANDDURATION OF MANGANESE EXPOSURE. R.Gwiazda, C. Kern and D. Smith. EnvironmentalToxicology, University of California, Santa Cruz, SantaCruz, CA.

#599 DETERMINATION OF DEPLETED URANIUM(DU) IN RATS FOLLOWING 6-MONTHEXPOSURE TO SURGICALLY IMPLANTED DUPELLETS. V. A. Fitsanakis1, K. M. Erikson2, S. J.Garcia3, T. L. Syversen4 and M. Aschner1. 1Pediatrics,Vanderbilt University Medical Center, Nashville, TN,2Nutrition, UNC-G, Greensboro, NC, 3Physiology &Pharmacology, Wake Forest University Medical School,Winston-Salem, NC and 4Neuroscience, NorwegianUniversity of Science & Technology, Trondheim,Norway.

#600 NEUROLOGICAL EFFECTS OF ACUTEURANIUM EXPOSURE. D. Barber1, S. Hancock, 2,A. McNally1, J. Hinckley2, E. Binder2, M. Ehrich2 andB. Jortner2. 1Center for Environmental and HumanToxicology, University of Florida, Gainesville, FL and2Laboratory for Neurotoxicity Studies, VPI&SU,Blacksburg, VA.

#601 DIFFERENTIAL EFFECT OF LEAD (PB)EXPOSURE ON THE N-METHYL-D-ASPARTATE(NMDA) INDUCED INWARD CURRENT INDOPAMINE (DA)-CONTAINING NEURONS ANDHIPPOCAMPAL CA1 NEURONS. D. K. Pitts and M.W. Lewis. Pharmaceutical Sciences, Wayne StateUniversity, Detroit, MI.

#602 ORAL EXPOSURE TO INORGANIC LEAD (PB)IN RATS: BLOOD CONCENTRATIONS, BRAINCONCENTRATIONS AND EFFECTS ONACOUSTIC STARTLE. R. Commissaris, A. Davis andD. K. Pitts. Pharmaceutical Sciences, Wayne StateUniversity, Detroit, MI.

#603 LIPID PEROXIDATION AND DISTRIBUTION OFINORGANIC ARSENIC AND ITS METABOLITESIN RAT NERVOUS SYSTEM. E. Garcia-Chavez1, I.Jimenez2, B. Segura3, L. C. Sanchez-Pena1, J. C.Guadarrama2 and L. M. Del Razo1. 1Toxicology,Cinvestav-IPN, Mexico D.F., Mexico, 2Physiol.Biophys. & Neurosci., Cinvestav-IPN, Mexico D.F.,Mexico and 3FES-Iztacala, UNAM, Mexico D.F.,Mexico.

Program Description


MO

ND

AY


#604 EFFECT OF INORGANIC ARSENIC EXPOSUREINITIATING FROM IN UTERO THROUGHAFTER BIRTH ON THE NEUROBEHAVIOR ANDNEUROTRANSMITTERS IN THE BRAIN OFMOUSE OFFSPRING. T. Itoh1, Y. Nakagi1, K.Nakai2, H. Sato2, C. Watanabe3, H. Yamauchi4 and T.Yoshida1. 1Asahikawa Medical College, Asahikawa,Japan, 2Tohoku University, Sendai, Japan, 3TokyoUniversity, Tokyo, Japan and 4St. Marianna MedicalCollege, Kawasaki, Japan.

#605 NEUROBEHAVIORAL CHANGES INMETALLOTHIONEIN-NULL MICEPRENATALLY EXPOSED TO MERCURY VAPOR.M. Yoshida1, C. Watanabe2, K. Horie1, M. Satoh3, M.Sawada4 and A. Shimada4. 1Department ofBiochemistry, St. Marianna University School ofMedicine, Kawasaki, Japan, 2Department of HumanEcology, Graduate School of Medicine, University ofTokyo, Tokyo, Japan, 3Department of Hygienics, GifuPharmaceutical University, Gifu, Japan and4Department of Veterinary Pathology, Tottori University,Tottori, Japan.

#606 MERCURY EXPOSURE OF MOTHERS ANDNEWBORNS IN SURINAM: A PILOT STUDY. S.Mohan1, M. Tiller2, G. B. Vandervoet2, H. Kanhai2 andF. A. de Wolff2. 1Department of Obstetrics andGynecology, ‘s Lands Hospital, Gravenstratt,Netherlands and 2Toxicology Laboratory, LeidenUniversity Medical Center, Leiden, Netherlands.

#607 THE EFFECTS OF TRIBUTYLTIN (TBT)CHLORIDE ON DOPAMINE METABOLISM INBRAIN TISSUES OF FEMALE MICE AFTERSUBACUTE ORAL EXPOSURE. M. Tsunoda1, Y.Kudo1, K. Nakano2, N. Konno3, Y. Sugita-Konishi4 andY. Aizawa1. 1Preventive Medicine and Public Health,Kitasato University School of Medicine, Sagamihara,Kanagawa, Japan, 2Fukushima Prefecture Ken-pokuPublic Health and Welfare Office, Fukushima, Japan,3Home Economics, Koriyama Women’s University,Koriyama, Fukushima, Japan and 4Division ofMicrobiology, National Institute of Health Sciences,Setagaya-ku, Tokyo, Japan.

#608 BLOOD BRAIN BARRIER (BBB) DISRUPTIONAFTER VANADIUM INHALATION. M. AVILA-COSTA1,2, A. Zepeda-Rodriguez2, L. Colin-Barenque1,F. Pasos2, P. Aley1, A. Gonzalez-Villalva2, P. Mussali-Galante2, J. Ordonez-Librado1, A. Gutierrez-Valdez1, V.Rodriguez-Lara2, A. Reyes-Olivera1, G. Pinon-Zarate2,M. Rojas-Lemus2, V. Delgado2, B. Chavez2 and T. I.Fortoul2. 1Neurosciencias, UNAM, Mexico, D.F.,Mexico and 2Biologia Celular Y Tisular, UNAM,Mexico, D.F., Mexico.

#609 CYTOTOXIC EFFECTS OF TELLURIUMTETRACHLORIDE AND (4-METHOXYPHENYL)TRICHLOROTELLURIUM ON RATHIPPOCAMPAL ASTROCYTES. M. Aravantinou2

and D. Hardej1. 1Pharmaceutical Sciences, St. John’sUniversity, Jamaica, NY and 2Biological Sciences, St.John’s University, Jamaica, NY.


POSTER SESSION: NEUROTOXICITY OF METALS: MECHANISMS

Chairperson(s): Richard Seegal, New York State Department of Health,Albany, NY and Damani Parran, National Institute of Environmental HealthScience, Raleigh, NC.



#610 TMT-INDUCED NEUROGENESIS IN THE ADULTMOUSE HIPPOCAMPUS. B. C. Weig, K. R. Reuhland H. E. Lowndes. Department of Pharmacology andToxicology, Joint Graduate Program in Toxicology,Rutgers University, Piscataway, NJ.

#611 NEURONAL MICROTUBULE DAMAGE CAUSEDBY IN VITRO EXPOSURE TO LEAD ANDMETHYLMERCURY. J. L. Bisson1 and K. R.Reuhl1,2. 1Joint Graduate Program in Toxicology,Rutgers/UMDNJ, Piscataway, NJ and 2NeurotoxicologyLabs, Department of Pharmacology and Toxicology,Rutgers University, Piscataway, NJ.

#612 THE EFFECTS OF MANCOZEB ON THEMICROTUBULAR ARCHITECTURE OF RATHIPPOCAMPAL ASTROCYTES. M. M. Tsang and L.D. Trombetta. Pharmaceutical Sciences, St. JohnsUniverstty, Jamaica, NY.

#613 NEUROPROTECTIVE EFFECTS OFMELATONIN ON NEUROBLASTOMA CELLSEXPOSED TO LEAD. C. S. Chetty1, A. O. Dennis1, J.Heinz1, M. C. Vemuri2 and C. Suresh1. 1NaturalSciences and Mathematics, Savannah State University,Savannah, GA and 2Surgery, Children’s Hospital ofPhiladelphia, Philadelphia, PA.

#614 BLOCKAGE OF INTERLEUKIN-6 SECRETIONFROM ASTROGLIA BY LEAD: INVOLVEMENTOF GRP78. Y. Qian1, F. Valencia1, Y. Zheng1, K. S.Ramos2 and E. Tiffany-Castiglioni1. 1Texas A&MUniversity, College Station, TX and 2University ofLouisville Health Sciences Center, Louisville, KY.

#615 MANGANESE INDUCED APOPTOSIS IN SH-SY5Y HUMAN NEUROBLASTOMA CELLS. A. P.Stephenson and R. Reams. College of Pharmacy, FloridaA&M University, Tallahassee, FL.

#616 THE MODULATION OF METALLOTHIONEIN-3(MT-3) EXPRESSION IN MOUSE ASTROCYTESIN RESPONSE TO PROINFLAMMATORYMEDIATORS, SECOND MESSENGERACTIVATORS, AND CELL STRESS. S. H. Garrett.Pathology, University of North Dakota, Grand Forks,ND.

#617 MANGANESE-INDUCED ALTERATIONS IN NF-κκB-RELATED GENE EXPRESSION BYACTIVATED MICROGLIA. P. L. Crittenden and N.M. Filipov. Center for Environmental Health Sciences,Basic Sciences, Coll. Vet. Med., Mississippi StateUniversity, Mississippi State, MS.

Program Description



MO

ND

AY

#618 DIFFERENTIAL GENE EXPRESSION AT TWODOSES OF METHYLMERCURY IN MOUSECEREBELLA AS ANALYZED BY APOPTOSIS-SPECIFIC MICROARRAY. K. A. Thuett, S. Bellumand L. C. Abbott. Veterinary Integrative Biosciences,Texas A&M University / College of VeterinaryMedicine & Biomedical Sciences, College Station, TX.

#619 FORMATION OF REACTIVE OXYGEN SPECIESIN CEREBELLAR GRANULE CELLS OF MICEEXPOSED TO METHYLMERCURY. S. Bellum, K.A. Thuett and L. C. Abbott. Veterinary IntegrativeBiosciences, Texas A&M University, College Station,TX.

#620 METHYLMERCURY (MEHG)-INDUCEDREACTIVE OXYGEN SPECIES (ROS) LEVELSARE MODULATED BY INTRACELLULARREDOX. M. Aschner2, G. Shanker1, T. Syversen3, J.Aschner2 and U. Sonnewald3. 1Physiology andPharmacology, Wake Forest University School ofMedicine, Winston Salem, NC, 2Pediatrics, VanderbiltUniversity Medical Center, Nashville, TN and3Neuroscience, University of Trondheim, Trondheim,Norway.

#621 EFFECTS OF METHYLMERCURY ONMITOCHONDRIAL FUNCTION AND REACTIVEOXYGEN SPECIES FORMATION IN STRIATALSYNAPTOSOMES FROM RAT. A. Dreiem1 and R. F.Seegal1,2. 1New York State Department of Health,Wadsworth Center, Albany, NY and 2School of PublicHealth, University at Albany, Albany, NY.

#622 POTENTIATION OF MITOCHONDRIALSUSCEPTIBILITY, OXIDATIVE STRESS ANDNF-KB SIGNALING FOLLOWING CHEMICALMIXTURE (LEAD AND ARSENIC)-INDUCEDNEUROTOXICITY. R. Yasmeen, G. Hashim, O.Ogunmosin, D. Ghosh and P. G. Gunasekar. Biology,Texas Southern University, Houston, TX.

#623 EFFECTS OF GABA-B RECEPTOR ACTIVATION& INHIBITON ON METHYLMERCURY-INDUCED ALTERATIONS OF INTRACELLULARCA IN RAT CEREBELLAR GRANULENEURONS. D. K. Atchison and W. D. Atchison.Department Pharmacology/Toxicology, Mich StateUniversity, East Lansing, MI.

#624 COMPARATIVE EFFECTS OFMETHYLMERCURY (MEHG) ONINTRACELLULAR CA IN RAT CEREBELLARGRANULE & CORTICAL NEURONS INCULTURE. A. Segarra and W. D. Atchison. DepartmentPharmacology/Toxicology, Mich State University, EastLansing, MI.

#625 EFFECTS OF SEMI-CHRONICMETHYLMERCURY EXPOSURE ONINTRACELLULAR CALCIUM LEVELS IN RATUNDIFFERENTIATED PC12 CELLS. S. Baker2,1

and W. D. Atchison1,2. 1DepartmentPharmacology/Toxicology, Mich State University, EastLansing, MI and 2Coll Vet. Med., Mich StateUniversity, East Lansing, MI.

#626 EFFECTS OF THIMEROSAL ON NGF SIGNALTRANSDUCTION AND CELL DEATH INNEUROBLASTOMA CELLS. D. K. Parran, A. M.Barker and M. F. Ehrich. Biomedical Sciences, VirginiaTech, Blacksburg, VA.

#627 METHYL MERCURY (MEHG) ALTERS IL-6SIGNAL TRANSDUCTION IN MOUSECEREBELLAR CELLS IN CULTURE. E. S.Calderon-Aranda1,2, L. C. Acosta-Saavedra2 and E. K.Silbergeld1. 1EHS, BSPH, Johns Hopkins University,Baltimore, MD and 2Toxicologia, Cinvestav, Mexico,DF, Mexico.

#628 ACUTE EXPOSURE TO URANYL ION (UO2) INVITRO DIMINISHES K+-STIMULATEDGLUTAMATE/GABA RELEASE INDEPENDENTOF EXTRACELLULAR CALCIUM. S. M. Lasleyand K. R. Vietti. Biomedical & Therapeutic Sciences,University of Illinois College of Medicine, Peoria, IL.

#629 EFFECTS OF LOW-LEVEL MN EXPOSURE ONTHE METABOLISM OF AMINO ACIDS, GABA,AND CELLULAR RESPIRATION INGABAERGIC AF5 NEURAL CELLS. D. R. Crooks1,N. Welch1, A. F. Rosenthal1, J. Sanchez2, W. J. Freed2

and D. R. Smith1. 1Environmental Toxicology,University of Calif. Santa Cruz, Santa Cruz, CA and2Cellular Neurobiology Branch, National Institute onDrug Abuse, Baltimore, MD.

#630 MN ALTERS CELLULAR COMT-1,SECRETOGRANIN II, AND UCH-LI LEVELS INPC12 CELLS: IMPLICATIONS FOR MNNEUROTOXICITY. D. R. Smith, S. Reaney, S.Whitman, R. Gwiazda and T. Holman. EnvironmentalToxicology, University of California, Santa Cruz, CA.

#631 MANGANESE INHIBITS THE BINDING OF THECOCAINE ANALOG [3H]-WIN 35, 428 TO THEDOPAMINE TRANSPORTER (DAT) FROM RATSTRIATUM. M. Chen, E. Furukawa and T. R. Guilarte.Environmental Health Sciences, Johns HopkinsUniversity Bloomberg School of Public Health,Baltimore, MD.

#632 DIFFERENTIAL EFFECTS OF MANGANESE(MN) AND MPP+ IN DIFFERENTIATED ANDNON-DIFFERENTIATED PC12 CELLS. L. T.Russel, K. S. Squibb and A. M. Elnabawi. Program inToxicology, University of Maryland School ofMedicine, Baltimore, MD.

#633 NEUROTOXIC EFFECT OF MANGANESE ANDNEUROPROTECTIVE EFFECT OF COPPER IN ACELL CULTURE MODEL OF PRION DISEASES.C. J. Choi, V. Anantharam, A. Kanthasamy and A.Kanthasamy. Biomedical Sciences, Iowa StateUniversity, Ames, IA.

#634 MECHANISM OF ARSENIC PERIPHERALNEUROTOXICITY. A. Vahidnia, G. B. Vandervoetand F. A. de Wolff. Toxicology Laboratory, LeidenUniversity Medical Center, Leiden, Netherlands.


Program Description


MO

ND

AY



SUNSET SESSION: BROMINATED FLAME RETARDANTS: NEWFINDINGS

Chairperson(s): Arnold Schecter, University of Texas School of Public Health,Dallas, TX and Linda Birnbaum, U.S. EPA, Research Triangle Park, NC.

Endorsed by:Neurotoxicology SSOccupational and Public Health SS*Reproductive and Development SSRisk Assessment SS

The brominated flame retardants are new potential public health hazards. Theyresemble PCBs and are found worldwide. They can be found in carpets, styro-foam, and in household and office electrical equipment. Brominated flameretardants (BFRs), especially the common polybrominated diphenyl ethers(PBDEs) have recently been reported in humans at markedly increasing levelsin blood and milk. The highest levels in humans and food worldwide have beenreported in US samples. Studies of milk report 10-100 times higher levels in USthan in European women. US food levels are highest in fish, then meat, andfinally dairy. All human and food samples measured to date are contaminatedwith many of the 13 commonly reported PBDE congeners, although thecongener pattern can vary in different specimens. Blood and milk levels in theUSA are currently similar. PBDEs cannot be measured in 1973 blood, and areincreasing markedly in humans in the USA (at the same time dioxins and PCBsare decreasing). No human health studies of these compounds have beenpublished but cell culture and laboratory animal studies suggest certain adversehealth effects, similar to those reported for PCBs which the PBDEs structurallyresemble. New findings will be presented for human tissue levels and foodlevels in the USA and worldwide in the general population and in speciallyexposed workers. The uncertainty regarding toxicity of various congeners willbe reviewed and compared to the dioxin toxic equivalency factor concept. Nosuch toxicity comparison factors are available for the PBDEs at the present timemaking it difficult to decide which congeners should be measured. There iscurrently no consensus on which to be measured; this topic will be reviewed andrecommendations made. Temporal trends in human PBDE levels will bepresented and compared with temporal trend for dioxins, dibenzofurans andPCBs. New toxicological findings with respect to pharmacokinetics, neurolog-ical, reproductive and developmental, endocrine, and cancer endpoints will bepresented. Finally, human risk assessment will be considered.

#309 4:30 BROMINATED FLAME RETARDANTS: NEWFINDINGS. L. Birnbaum1 and A. J. Schecter. 1U.S.EPA, Research Triangle Park, NC and 2EnvironmentalSciences, University of Texas School of Public Health,Dallas, TX.

#310 4:40 PBDES IN US HUMANS, FOOD ANDENVIRONMENTAL SAMPLES. A. J. Schecter1, O.Paepke2, J. Ryan3, L. Birnbaum4, D. Staskal5 and K.Tung1. 1Environmental Sciences, University of TexasSchool of Public Health, Dallas, TX, 2ERGOLaboratory, Hamburg, Germany, 3Health Canada,Ottawa, ON, Canada, 4U.S. EPA, Research TrianglePark, NC and 5UNC, Chapel Hill, NC.

#311 4:55 TOXICOKINETICS OF BDE 47 IN MICE. D.Staskal1, J. J. Diliberto2, M. J. DeVito2 and L. S.Birnbaum2. 1UNC Curriculum in Toxicology, ResearchTriangle Park, NC and 2ETD, NHEERL, ORD, U.S.EPA, Research Triangle Park, NC.

#312 5:10 DEVELOPMENTAL NEUROTOXICITY OFPBDES IN MICE AND RATS. H. Viberg, A.Fredriksson and P. Eriksson. Environmental Toxicology,Uppsala University, Uppsala, Sweden.

#313 5:25 PBDE LEVELS AMONG US WOMEN, DAILYINTAKE AND RISK OF HARM TO THEDEVELOPING BRAIN AND REPRODUCTIVEORGANS. T. A. McDonald. Office of EnvironmentalHealth Hazard Assessment, California EnvironmentalProtection Agency, Oakland, CA. Sponsor: L. Zeise.


SUNSET SESSION: DEVELOPMENTAL TOXICOLOGYEVALUATIONS: ISSUES WITH INCLUDING NEUROTOXICOLOGYAND IMMUNOTOXICOLOGY ASSESSMENTS

Chairperson(s): Gregory S. Ladics, DuPont Co., Newark, DE and Leigh AnnBurns Naas, Pfizer, Inc., San Diego, CA.

Endorsed by:Immunotoxicology SS*Neurotoxicology SSRisk Assessment SS

Evaluation of offspring following maternal exposures during gestation andlactation (i.e. reproductive/developmental toxicology [RDT]) has historicallybeen a routine part of the safety assessment process. Recently, increased atten-tion has focused on the effects of agricultural and industrial chemicals, as wellas pharmaceuticals, on the developing nervous and immune systems of the fetusand newborn. This new focus on developmental neurotoxicology (DNT) anddevelopmental immunotoxicology (DIT) is based on the premise that the devel-oping nervous and immune systems may be qualitatively and/or quantitativelymore susceptible to chemical perturbation compared to the adult and studiesconducted currently may be insufficient to protect the young. DNT studies havebecome common for agricultural chemicals, following the preparation of testguidelines from the U.S. EPA (OPPTS 870.6300, 1998) and OECD (TG 426,draft). With increased DNT testing and the prospect of new DIT test guidelines,there has been considerable interest in both DNT and DIT, with many scientificworkshops, roundtables, symposia, as well as sponsored research devoted to thesubjects. The intent of this session is to highlight and discuss issues that arecommon to RDT, DNT, and DIT, including the consequences of high dose selec-tion and maternal toxicity; the adequacy of pup exposure during lactation;whether a different dosing paradigm should be applied to RDT vs. DNT or DITstudies; whether DIT and DNT endpoints can be incorporated into a single(RDT) study for hazard identification purposes (e.g., for screening purposes,what endpoints have proven their value and should be retained). This sessionwill provide a forum to discuss how assessment of RDT, DIT, and DNT couldbe integrated for hazard identification purposes and to reduce animal usage.

#314 4:30 DEVELOPMENTAL TOXICOLOGYEVALUATIONS: ISSUES WITH INCLUDINGNEUROTOXICOLOGY ANDIMMUNOTOXICOLOGY ASSESSMENTS. G. S.Ladics1 and L. Burns-Naas2. 1DuPont Co., Newark, DEand 2Pfizer, Inc., San Diego, CA.

Program Description



MO

ND

AY


SUNSET SESSION: INTERVIEWING SKILLS FOR GRADUATESTUDENTS AND POST-DOCS

Chairperson(s): Robert J. Mitkus, University of Maryland, Baltimore, MDand Melinda Pomeroy, Virginia-Maryland Regional College of VeterinaryMedicine, Blacksburg, VA.

Endorsed by:Career Resource and Development CommitteeEducation CommitteeNational Capital Area Chapter*Student Advisory Committee

The ability to interview well is a critical career skill, and keeping this skill up-to-date is even more important in a volatile social and economic environment.Moreover, interviewing skills that are considered important in one sector of thejob market may be quite different from those in another. Therefore, it is nosurprise that there are substantial differences in the expectations of employerslooking to fill positions in these two areas of post-graduate employment. Thepurpose of this session is to expand the personal skills sets of graduate studentsand post-docs with regard to interviewing for post-doctoral research positions atan academic institution, faculty positions at a community college or undergrad-uate institution, positions in the federal government, as well as positions in theprivate sector. This goal will be accomplished through formal presentations oninterviewing skills, followed by question-and-answer sessions. An informedpresentation on interview questions that are legally permissible across all hiringsectors is an essential part of this session. Because acquiring and processingknowledge of current interviewing skills and practices is a prerequisite forputting these skills into practice, this workshop is a must for all toxicologistswho are making the transition into the workforce.

#315 4:30 INTERVIEWING SKILLS FOR GRADUATESTUDENTS AND POST-DOCS. R. J. Mitkus1 and M.Pomeroy-Black2. 1Epidemiology and PreventiveMedicine, University of Maryland, Baltimore, MD and2Biomedical Sciences and Pathobiology, Virginia-Maryland Regional College of Veterinary Medicine,Blacksburg, VA.

#316 4:32 INTERVIEWING FOR AN ACADEMIC POST-DOCTORAL POSITION. M. Ehrich. BiomedicalSciences and Pathobiology, Virginia-Maryland RegionalCollege of Veterinary Medicine, Blacksburg, VA.

#317 4:47 INTERVIEWING SKILLS FOR A TEACHINGPOSITION AT AN UNDERGRADUATEINSTITUTION. R. Resau. Biology, McDaniel College,Baltimore, MD. Sponsor: R. Mitkus.

#318 5:02 INTERVIEWING SKILLS FOR A POSITION INTHE FEDERAL GOVERNMENT: ANINTERVIEWER’S PERSPECTIVE. R. J. Mitkus andA. C. Mosby. Office of Communications andGovernment Relations, U.S. EPA Region III,Philadelphia, PA. Sponsor: R. Mitkus.

#319 5:17 INTERVIEWING SKILLS FOR A POSITION INTHE PRIVATE SECTOR. J. C. Lamb. The WeinbergGroup, Washington, DC.

#320 5:32 WHAT INTERVIEWERS CAN AND CANNOTASK BY LAW. A. Mosby. OPM, U.S. EPA Region III,Philadelphia, PA. Sponsor: R. Mitkus.


SUNSET SESSION: TEACHING UNDERGRADUATE TOXICOLOGYIN THE 21ST CENTURY

Chairperson(s): Thomas W. Simmons, Indiana University of Pennsylvania,Indiana, PA and Joan B. Tarloff, University of Sciences in Philadelphia,Philadelphia, PA.

Endorsed by:Allegheny-Erie RCEducation Committee*Mid-Atlantic RCWomen in Toxicology SS

Undergraduate toxicology course offerings and teaching methods for deliveringthese courses have dramatically changed over the last twenty years. Historically,toxicology was a discipline that was more or less restricted to graduate and post-doctoral training. This emphasis was reflected by a symposium on Some SpecialToxicology Education and Training Programs that was sponsored by theNational Institute of Environmental Health Sciences in 1980. The idea of under-graduate toxicology offerings was debated and discussed, and four Bachelor ofScience programs were highlighted at this workshop. In 1992 a follow-up forumon Undergraduate Toxicology Coursework was convened at a Society ofToxicology annual meeting. The objective of this Forum was to reach aconsensus on the content of a one-year course in toxicology to be offered at theundergraduate level by colleges and universities. Interestingly, Dr. Donald Reedstated in his opening remarks that by the 21st century there could be tens ofthousands of undergraduate students taking toxicology. Although the number ofundergraduate students enrolled today in toxicology courses may not number inthe tens of thousands, it is clear that a significant number of students are takingcourses in major, minor and track toxicology programs. In addition, many morestudents are enrolled in courses offered by non-toxicology/pharmacology degreeprograms. Along with this increase in toxicology course offerings; topics,methods and tools for teaching toxicology have also grown. New technologiesincluding software programs and internet resources, current events includingbio-terrorism, television programming such as Crime Scene Investigation, andnew teaching strategies incorporating scientific inquiry, constructivism, andreflective practice are transforming the toxicology classroom. The goal of thisworkshop is to provide a forum to improve teaching and learning in the toxico-logical sciences, by sharing experiences related to these trends.

#321 4:30 TEACHING UNDERGRADUATE TOXICOLOGYIN THE 21ST CENTURY. T. W. Simmons1 and J. B.Tarloff2. 1Department of Biology, Indiana University ofPennsylvania, Indiana, PA and 2Department ofPharmaceutical Sciences, University of the Sciences inPhiladelphia, Philadelphia, PA.

#322 4:35 OVERVIEW OF UNDERGRADUATE COURSEOFFERINGS: TOXICOLOGY TEACHINGPROJECT. T. W. Simmons. Department of Biology,Indiana University of Pennsylvania, Indiana, PA.

#323 4:40 LABORATORY EXPERIENCES IN THECLASSROOM. J. B. Tarloff. Department ofPharmaceutical Sciences, University of the Sciences inPhiladelphia, Philadelphia, PA.

#324 5:00 CURRENT EVENTS IN THE CLASSROOM. S. M.Ford. College of Pharmacy & Allied Health, Saint JohnsUniversity, Jamaica, NY.

#325 5:20 LOBO PHARMACOKINETICS COMPUTERSOFTWARE: INTERACTIVEPHARMACOKINETIC MODELING. C. Marcus1,D. Godwin1, E. Danoff1 and R. Galinsky2. 1College ofPharmacy, University New Mexico, Albuquerque, NMand 2College of Pharmacy and Pharmacal Sciences,Purdue University, W. Lafayette, IN.

#326 5:40 DISTANCE EDUCATION: ONLINE TEACHINGOF TOXICOLOGY. K. L. Willett and A. Bouldin.Department of Pharmacology, University of Mississippi,University, MS.



CAREER RESOURCE AND DEVELOPMENT SEMINAR:CONSULTING AS A CAREER CHOICE

Sponsored by:The Career Resource and Development Committee (formerly thePlacement Committee)

Chairperson(s): Tracy Williams, Eli Lilly & Company, Greenfield, IN andBarbara D. Beck, Gradient Corporation, Cambridge, MA.

Toxicology consulting provides a unique employment option that can be tailoredto an individual scientist’s educational and technical background. Toxicologyconsultants may enjoy certain freedoms with respect to schedule, client relation-ships, and work environment, although client demands, market factors, andother elements can be limitations. Toxicology consultants are employed in everysector of toxicology including, but not limited to, consumer products, environ-mental, agriculture, chemical, and pharmaceutical industries, litigation support,risk assessment and product safety. Prior to embarking on this career path it iswise to appreciate the advantages and disadvantages of consulting and under-stand what consulting is all about. In this session, participants will learn aboutlife as a toxicology consultant, choosing to operate as a sole practitioner versusjoining a company, starting a consulting business, consulting following retire-ment, and Internet-based and other tools to increase your visibility and clientportfolio.

• Consulting Overview, Tracy Williams, Eli Lilly and Company, Greenfield,IN.

• Life of a Consultant, Barbara D. Beck, Gradient Corporation, Cambridge,MA.

• Starting a Consulting Company, Rosalind School, Integral ConsultingInc, Mercer Island, WA.

• Virtual Consulting Tools and Opportunities, Dennis Hoover, Eli Lillyand Company, Greenfield, IN.


SPECIALTY SECTION PRESIDENTS’AND OFFICERS’ MEETING

Monday Evening

Monday Evening, March 76:00 PM to 6:30 PMRoom RO2

UNDERGRADUATE TOXICOLOGY TEACHING FORUM

Chairperson(s): Thomas Simmons, Indiana University of Pennsylvania,Indiana, PA.

Sponsored by:Education Committee Allegheny-Erie Regional Chapter

All those interested in undergraduate education are invited to attend this session.The meeting will continue the discussion from the Sunset Workshop, anddevelop a formal structure for continuing the group. Other future activities willbe discussed as time permits.

Monday Evening, March 76:00 PM to 7:30 PMSee Events Calendar on Pages 2–6 for Room Listings

SPECIALTY SECTION MEETINGS:ETHICAL, LEGAL AND SOCIAL ISSUES, IMMUNOTOXICOLOGY,MECHANISMS, OCCUPATIONAL AND PUBLIC HEALTH, RISKASSESSMENT, TOXICOLOGIC AND EXPLORATORY PATHOLOGY

Monday Evening, March 76:00 PM to 11:00 PMSee Events Calendar on Pages 2–6 for Room Listings

REGIONAL CHAPTER MEETINGS/RECEPTIONS

Many of the Regional Chapters meet during the SOT Annual Meeting. Detailsfor these Regional Chapter receptions and meetings are listed in Program’sEvents Calendar.

Program Description


MO

ND

AY


Tuesday Morning

Tuesday Morning, March 87:00 AM to 8:30 AMRoom 225

REGIONAL CHAPTER PRESIDENTS’AND OFFICERS’ MEETING

Tuesday Morning, March 87:00 AM to 7:45 AMRO1

SUNRISE SESSION: TOXIC TORTS: TOXICOLOGISTS IN THECOURTROOM

Chairperson(s): Richard Parent, Consultox, Ltd.,, Damariscotta, ME andWillie J. McKinney, Philip Morris, USA, Richmond, VA.

Endorsed by:Career Resource and Development Committee*Ethical Legal and Social Issues SSRegulatory and Safety Evaluation SSStudent Advisory Committee

Litigation involving exposure to chemicals is on the rise in the United States.This has created a new role for toxicologists. Toxicologists are often called uponto provide testimony (e.g. expert, fact) in a variety of legal situations (e.g. court,deposition, hearings, state, federal, defense, and plaintiff). However, explainingextremely complex and sometimes controversial scientific concepts and data toa non-scientist (e.g. judges, juries) can be challenging. Therefore, knowledge ofskills necessary for effective clear testimony, attorney/client expectations, andpotential ethical conflicts are critical prior to entering the court room. In addi-tion, a toxicologist called upon to provide litigation support should be aware ofthe potential positive and negative career impacts. This sunrise session willprovide a forum to discuss issues a scientist functioning as an expert witnessmay encounter as well as give information that will be valuable for scientistcalled upon for expert testimony.

#635 7:00 TOXIC TORTS: TOXICOLOGISTS IN THECOURTROOM. W. J. McKinney1, R. Parent2, R. G.Smith3 and A. R. Brody4. 1Philip Morris USA,Richmond, VA, 2Consultox, Damariscotta, ME,3Venable LLP, Baltimore, MD and 4Pathology andLaboratory Medicine, Tulane University HealthSciences Center, New Orleans, LA.

Tuesday Morning, March 87:15 AM to 8:15 AMRoom RO6

TOWN HALL MEETING: NIH-MANDATED PUBLIC ACCESS TOSPONSORED RESEARCH PUBLICATIONS: IMPACT ONTOXICOLOGICAL SCIENCES

Presiding: Lois Lehman-McKeeman, Editor of Toxicological Sciences andRichard Peterson, Chair of the Board of Publications.

Lois Lehman-McKeeman, Editor of Toxicological Sciences, and RichardPeterson, Chair of the Board of Publications, will share their perspectives on thepotential consequences of new policies mandating open access to NIH-sponsored research on the future of our Journal.

Tuesday Morning, March 88:00 AM to 4:30 PMRoom 213

PARACELSUS GOES TO SCHOOL TEACHER WORKSHOP

Chairperson(s): Kenneth McMartin, Louisiana State University HealthScience Center, Shreveport, LA and Mark Reasor, West Virginia University,Morgantown, WV.

Sponsored by:The Education CommitteeThe Education Subcommittee for K–12 Education

This special program will be offered for local educators teaching grades K–12and for interested SOT members. The main goal of the program is to enhancescience education by stimulating ideas for incorporating multidisciplinary toxi-cology and environmental health science concepts and teaching materials intoclassrooms. Lectures and interactive workshops will be tailored to the needs ofdifferent grade levels. New Orleans area toxicologists will serve as SciencePartners to continue the effort in local classrooms.

7:15 AM–7:45 AM Registration

8:00 AM–8:15 AM Opening and WelcomeKenneth McMartin, Local Chair, LSU HealthScience Center, Shreveport, LA.

Linda Birnbaum, SOT President, U.S. EPA,Research Triangle Park, NC.

8:15 AM–8:35 AM The Diversity that is ToxicologyHarihara Mehendale, University of Louisiana atMonroe, Monroe, LA.

8:35 AM–9:05 AM Overview of Local Toxicological Issues inLouisianaCharles Miller, Tulane University, New Orleans,LA.

Steve Pruett, LSU Health Science Center,Shreveport, LA

9:05 AM–9:15 AM Issues Surrounding the Use of Animals inToxicological ResearchJoanne Zurlo, NAS Institute of Laboratory AnimalScience, Washington, DC.

9:15 AM–11: 45 AM Workshops Session I

K–4—My Health My World (Room 211) Barbara Tharp and Nancy Moreno, Baylor Collegeof Medicine, Houston, TX.

4–8—What Students Need to Know About Diet,Sun Exposure, and Tobacco Use (Room 212)Jennifer Gorenstein and Donna Meyer, Universityof Texas MD Anderson Cancer Center, Smithville,TX.

9–12—Risk Assessment Case Study (Room 214)Suzanne Fitzpatrick, U.S. FDA, Rockville, MDand Joseph Rodericks, ENVIRON Corporation,Arlington, VA.

11:45 AM–1:15 PM Lunch for Teachers and Toxicology SciencePartners (break out rooms)Education Poster Session

Program Description



TUES

DAY

Program Description


TUESD

AY


1:15 PM–2:45 PM Workshop Session II (break out rooms)

2:45 PM–3:15 PM Paracelsus in Practice (Room 213)Moderator: David Cragin, Merck and Company,Inc., Whitehouse Station, NJ.

3:15 PM–3:30 PM Program Conclusion and EvaluationKenneth McMartin, LSU Health Science Center,Shreveport, LA.

3:30 PM–4:30 PM Visit ToxExpo


INFORMATIONAL SESSION: THE ROSETTA RESOLVER®SYSTEM: AN ENTERPRISE SOLUTION FOR GENE EXPRESSIONANALYSIS AND PREDICTIVE TOXICOLOGY

The Rosetta Resolver® System, an enterprise gene expression analysis solution,is a cornerstone in drug discovery for routinely processing and managing datafrom thousands of high-density microarrays. This presentation will focus on thecurrent challenges of toxicogenomics data analysis in drug development, andhow the use of the Resolver system addresses those challenges.


SYMPOSIUM SESSION: ALTERED IRON HOMEOSTASIS (AIH) AS ABASIS FOR PULMONARY IMMUNOTOXICOLOGIC EFFECTS OFPARTICULATE MATTER

Chairperson(s): Mitch Cohen, New York University School of Medicine,Tuxedo, NY and Andrew Ghio, National Health & Environmental EffectResearch Laboratory, Chapel Hill, NC.

Endorsed by:Immunotoxicology SS*Inhalation Specialty SectionStudent Advisory Committee

The scientific literature is replete with reports on the pulmonary toxicologic andimmuno-toxicologic effects of particulate matter (PM). Although it has becomeincreasingly accepted that the composition of PM is a major factor influencingbiological effects, mechanisms to describe how composition might induceobserved toxicities are mostly lacking. The altered iron homeostasis (AIH)theory postulates that specific components in PM induce alterations in the levelsof free catalytically-active iron within the lungs as well as in iron availability toboth lung epithelial and immune cells. These changes, in turn, impact upon localresponses to infectious agents and allergens, as well as upon the release of cellproducts that might contribute to cardiopulmonary changes. The AIH theory notonly provides a basis to explain how select PM constituents might induce theseeffects, but also how day-to-day or regional differences in the amounts of thesecomponents (relative to that of iron) may underlie the variability in reportedhealth effects induced with equivalent doses of differing PM samples. Followingintroductory talks about the role of iron homeostasis in maintenance of immunecell functions and how components of PM may be selectively mobilized, thissymposium will highlight specifically how AIH could be the basis for theobserved alterations in allergic, immunologic, and cardiopulmonary responsesafter host exposures to PM.

#636 8:30 ALTERED IRON HOMEOSTASIS (AIH) AS ABASIS FOR PULMONARYIMMUNOTOXICOLOGIC EFFECTS OFPARTICULATE MATTER. M. Cohen. EnvironmentalMedicine, New York University, Tuxedo, NY.

#637 8:35 THE ROLE OF IRON (FE) HOMEOSTASIS INIMMUNE CELL FUNCTIONALITY. C. L. Bowlus.Department of Internal Medicine, University ofCalifornia Davis Medical Center, Sacramento, CA.Sponsor: M. Cohen.

#638 9:10 MOBILIZATION OF METALS FROMPARTICLES: IMMUNOTOXICOLOGICIMPLICATIONS. A. E. Aust. Department ofChemistry and Biochemistry, Utah State University,Logan, UT.

#639 9:45 METALS, PARTICLES AND IMPACT UPONPULMONARY ALLERGIC RESPONSES. M.Gilmour. National Health and Environmental EffectsResearch Laboratory, U.S. EPA, Research TrianglePark, Durham, NC.

#640 10:20 EFFECTS OF PARTICLES ON FE TRANSPORTAND THE IMMUNOTOXICOLOGICOUTCOMES. A. J. Ghio. National Health andEnvironmental Effects Research Laboratory, U.S. EPA,Research Triangle Park, NC.

#641 10:55 DO ALTERED FE STATUS-INDUCED EFFECTSON TRANSCRIPTION FACTORS HAVE A ROLEIN PM-INDUCEDPULMONARY/CARDIOVASCULAR DISEASES?K. Salnikow. Laboratory of ComparativeCarcinogenesis, National Cancer Institute, Frederick,MD.


SYMPOSIUM SESSION: BEYOND LIVER TOXICOGENOMICS:GENE EXPRESSION BASED BIOMARKERS IN NON-HEPATICTISSUES

Chairperson(s): Kyle Kolaja, Iconix, Mountain View, CA and David J. Dix,National Health & Environmental Effects Research Laboratory, ResearchTriangle Park, NC.

Endorsed by:Carcinogenesis SSToxicologic and Exploratory Pathology SS

Toxicogenomics, the genome scale analysis of chemically induced changes incomplex populations of mRNA to understand toxicity, has already dramaticallyimpacted predictive and mechanistic toxicology. Gene expression basedbiomarkers can provide a precise and rapid assessment of toxicity or exposure,but most toxicogenomics efforts to date have been conducted in liver due to toxi-cological interest, technical ease of data creation, relative homogeneity of tissuesample, and historical inertia. Recently analysis of gene expression data in non-hepatic organs and tissues has started to gain momentum, and this session willinclude presentations of significant and promising examples ranging from toxi-cogenomic analyses of vascular, cardiac, kidney, neural and reproductive tissuestreated with various drugs, chemicals, and toxicants. From these burgeoningstudies, researchers are identifying biomarkers predictive of toxicity and indica-tive of various mechanisms and pharmacology in non-hepatic tissues.

#642 8:30 BEYOND LIVER TOXICOGENOMICS: GENEEXPRESSION BASED BIOMARKERS IN NON-HEPATIC TISSUES. K. L. Kolaja. Toxicology, IconixPharmaceuticals, Mountain View, CA.

Program Description



TUES

DAY

#643 8:35 MEASURING GENE EXPRESSION IN BLOODVESSELS: THE CHALLENGES OF APPLYINGTOXICOGENOMICS TO VASCULITIS. M. P.Lawton. Molecular and Investigative Toxicology, Pfizer,Inc., Groton, CT.

#644 9:10 GENE EXPRESSION PROFILING TO IDENTIFYBIOMARKERS OF REPRODUCTIVE TOXICITY.D. J. Dix. Office of Research and Development, U.S.EPA, Research Triangle Park, NC.

#645 9:45 EXPOSURE-INDUCED NEURODEGENERATION:A TOXICOGENOMICS CASE STUDY OFNEURONAL FUNCTION ANDNEURODEGENERATIVE DISEASE. A. Brooks1,2,D. Cory-Slechta3, E. Richfeild3 and M. Thiruchelvam3.1Environmental Medicine, Univeristy of RochesterMedical Center, Rochester, NY, 2Functional GenomicsCenter, Univeristy of Rochester Medical Center,Rochester, NY and 3Environmental and OccupationalMedicine, UMDNJ, Piscataway, NJ.

#646 10:20 GENE EXPRESSION-BASED BIOMARKERS OFCARDIAC AND RENAL PHARMACO- ANDTOXICOGENOMICS. K. L. Kolaja. Chemogenomicsand Toxicology, Iconix Pharmaceuticals, MountainView, CA.

#647 10:55 APPLICATION OF TOXICOGENOMICSBEYOND LIVER. Y. Yang, R. Ciurlionis, S. J. Abel, E.A. Blomme and J. F. Waring. R463, AbbottLaboratories, Abbott Park, IL.

Tuesday Morning, March 88:30 AM to 11:30 AMLa Louisiane Ballroom B

SYMPOSIUM SESSION: EMERGING ISSUES IN RISK ASSESSMENTAND RISK PERCEPTION OF NANOMATERIALS

Chairperson(s): Joyce S. Tsuji, Exponent Environmental Group Inc.,Bellevue, WA and Annette B. Santamaria, Exponent, Houston, TX.

Endorsed by:Inhalation SSRisk Assessment SS*

Nanotechnology has been hailed as the new industrial revolution akin to siliconchip development in the last century. Nanomaterials are generally <100nm insize that potentially involve a variety of chemicals, shapes, and physicochemicalproperties that confer unique electrical, thermal, and imaging characteristics.Such variable characteristics have complex exposure and toxicological implica-tions. Research supporting assessments of the health risks of nanomaterials,however, has greatly lagged technological development and nanomaterials arecurrently being used and proposed for various applications in technology, medi-cine, and consumer products with great potential for exposure, but relativelylimited understanding of health risks. Little health risk information plays intopublic fears of nanotechnology. Like genetically modified organisms, the futureof nanotechnology will depend on public acceptance of the risks versus bene-fits. Toxicity and exposure studies supporting health risk assessments ofdifferent nanomaterials are crucial to fill the current void in the knowledge ofthe potential effects of these products. This symposium presents recent findingsfor the components of characterizing health risks of nanomaterials. In additionto applications of available data for risk assessments of nanomaterials, riskperceptions by the public and by toxicology dogma, along with possible reasonsfor different interpretations of the recently published pulmonary toxicity studieswill be presented. Methodologies and recent findings for characterizing aerosolexposures and the potential for dermal penetration are essential for assessingexposures to nanomaterials. Recent and ongoing research on various types ofcarbon nanotubes in mice indicates a potential for pulmonary toxicity. However,recent studies refute the common belief that inhalation toxicity always increaseswith smaller particle size. These recent toxicity and exposure data are beginningto shape risk assessments and safety evaluations that will be used to regulatenanomaterials in consumer products and provide assurance of health and envi-ronmental protection.

#648 8:30 EMERGING ISSUES IN RISK ASSESSMENT ANDRISK PERCEPTION OF NANOMATERIALS. J. S.Tsuji. Health Risk, Exponent, Bellevue, WA.

#649 8:45 CHARACTERIZING EXPOSURES TONANOMATERIALS. A. D. Maynard. NIOSH,Cincinnati, OH. Sponsor: J. Tsuji.

#650 9:15 PULMONARY TOXICITY OF CARBONNANOTUBES IN MICE AND IMPLICATIONSFOR HUMAN RISK ASSESSMENT. J. T. James andC. Lam. SF23, Johnson Space Center, Houston, TX.

#651 9:45 IMPACT OF EXPOSURES TO NANOPARTICLESON RESPIRATORY HEALTH: PARTICLE SIZEMAY NOT BE MORE IMPORTANT THANSURFACE CHARACTERISTICS. D. B. Warheit.Pulmonary Toxicology, DuPont Haskell Lab., Newark,DE.

#652 10:15 EVALUATION OF THE DERMAL PENETRATIONOF NANOSCALE MATERIALS. P. C. Howard.Jefferson Laboratories, U.S. Food & DrugAdministration, Jefferson, AR.

Program Description


TUESD

AY


#653 10:45 RISK ASSESSMENT AND SAFETY EVALUATIONOF NANOMATERIALS IN CONSUMERPRODUCTS. A. B. Santamaria1 and N. J. Rachman2.1Health Risk, Exponent, Houston, TX and 2Food andChemicals, Exponent, Washington, DC.


SYMPOSIUM SESSION: NUCLEOCYTOPLASMIC TRAFFICKINGIN MECHANISMS OF TOXICITY

Chairperson(s): Walter Watson, Johns Hopkins Bloomberg School of PublicHealth, Baltimore, MD and Richard Pollenz, University of South Florida,Tampa, FL.

Endorsed by:Mechanisms SS*Molecular Biology SSStudent Advisory Committee

Transport of proteins across the nuclear membrane is tightly regulated by thenuclear pore, a multisubunit complex consisting of at least 30 proteins. Thereare few known examples of toxins or toxicants that act directly at the nuclearpore to affect transport. However, import or export of specific proteins is a keycomponent of cellular responses to a variety of toxicants. For example, manytranscription factors are maintained as inactive cytoplasmic pools that canrapidly translocate to the nucleus upon exposure to toxicants and other stimuli.Interactions that anchor proteins in either compartment or target proteins to thenuclear pore may be disrupted (or enhanced) by toxicants or by specific post-translational modifications such as phosphorylation or SUMO modification. Anunderstanding of the factors that control the dynamic localization of proteinsacross the nuclear membrane is necessary for the definition of toxicologicalmechanisms and physiological pathways.

#654 8:30 NUCLEOCYTOPLASMIC TRAFFICKING INMECHANISMS OF TOXICITY. W. H. Watson1 andG. H. Perdew2. 1Environmental Health Sciences, JohnsHopkins Bloomberg School of Public Health,Baltimore, MD and 2Center for Molecular Toxicology,Penn State University, University Park, PA.

#655 8:30 NUCLEOCYTOPLASMIC TRAFFICKING INMECHANISMS OF TOXICITY. W. H. Watson.Environmental Health Sciences, Johns HopkinsBloomberg School of Public Health, Baltimore, MD.

#656 8:35 NUCLEAR PROTEIN TRANSPORT: A ROLE INREGULATING CELLULAR RESPONSES TOSTIMULI. A. H. Corbett, M. T. Harreman, T. M. Klineand A. E. Hodel. Biochemistry, Emory UniversitySchool of Medicine, Atlanta, GA. Sponsor: W. Watson.

#657 9:20 SPECIES-DEPENDENT DIFFERENCES IN AHRECEPTOR NUCLEOCYTOPLASMICSHUTTLING PROPERTIES. G. Perdew, P.Ramadoss and B. D. Hollingshead. Center forMolecular Toxicology and Carcinogenesis andDepartment of Veterinary Science, The PennsylvaniaState University, University Park, PA.

#658 10:05 SUMO MODIFICATION AND REGULATION OFNUCLEAR TRANSPORT. M. J. Matunis and H.Zhang. Biochemistry and Molecular Biology, JohnsHopkins University, Baltimore, MD. Sponsor: W.Watson.

#659 10:50 TOXICANT-INDUCED NUCLEARTRANSLOCATION OF THIOREDOXIN. W. H.Watson. Environmental Health Sciences, Johns HopkinsBloomberg School of Public Health, Baltimore, MD.


WORKSHOP SESSION: CURRENT STATUS AND FUTURECONSIDERATIONS FOR THE DEVELOPMENT AND VALIDATIONOF IN VITRO ALTERNATIVES TO THE DRAIZE RABBIT EYE TEST

Chairperson(s): William Stokes, National Institute of Environmental HealthSciences, Research Triangle Park, NC.

Endorsed by:In Vitro SS*Regulatory and Safety Evaluation SSRisk Assessment SSStudent Advisory Committee

The Draize rabbit eye test has been used as the standard test method forassessing ocular irritation and corrosivity potential of chemicals and productsfor over 60 years. Largely due to the pain and discomfort associated with thistest, there have been extensive efforts to develop and validate alternative testmethods that would partially or fully replace the current regulatory version ofthe Draize rabbit eye test. These efforts are also being driven by the 7thAmendment to the European Union Cosmetics Directive that will ban the use ofanimals for ocular testing by 2009 and pressure to minimize or avoid animal usefor the European Union Chemicals Policy Initiative (REACH). This workshopwill address scientific and regulatory considerations for developing and vali-dating in vitro test methods that will refine, reduce, and replace the Draize rabbiteye test. ICCVAM, NICEATM, and ECVAM have recently initiated collabora-tions to assess the usefulness of currently available in vitro ocular toxicitymethods and to review the state-of-the-science with regard to in vitro testmethods. These efforts include an evaluation of several in vitro test methods fortheir ability to detect severe ocular irritants, an assessment of the performancecharacteristics of the in vivo rabbit eye test, and a review of the current status ofmethods for identifying nonirritants and mild to moderate irritants. Current andfuture challenges in validating alternative methods and approaches to evaluateocular toxicity will be presented including the need for high quality referencedata to assess test method performance.

#660 8:30 CURRENT STATUS AND FUTURECONSIDERATIONS FOR THE DEVELOPMENTOF IN VITRO ALTERNATIVES TO THE DRAIZERABBIT EYE TEST FOR ASSESSING OCULARIRRITANTS. T. Hartung1 and W. S. Stokes2. 1ECVAM,Ispra, Italy and 2NICEATM, NIEHS/NIH/DHHS,Research Triangle Park, NC.

#661 8:40 CURRENT STATUS AND FUTURECONSIDERATIONS FOR ALTERNATIVEMETHODS TO REFINE, REDUCE, ANDREPLACE ANIMAL USE FOR OCULAR SAFETYTESTING. W. S. Stokes. NICEATM,NIEHS/NIH/DHHS, Research Triangle Park, NC.

#662 9:10 THE PERFORMANCE CHARACTERISTICS OFTHE IN VIVO RABBIT EYE TEST. J. H. Haseman1,N. Y. Choksi2,3, C. Inhof2,3, J. Truax2,3, R. R. Tice2,3 andW. S. Stokes3. 1Consultant, NIEHS/NIH/DHHS,Research Triangle Park, NC, 2ILS, Inc., ResearchTriangle Park, NC and 3NICEATM,NIEHS/NIH/DHHS, Research Triangle Park, NC.

Program Description



TUES

DAY

#663 9:40 PERFORMANCE OF BCOP, IRE, ICE, AND HET-CAM IN DETECTING SUBSTANCES THATINDUCE SEVERE IRRITATION ANDIRREVERSIBLE OCULAR DAMAGE. N. Y.Choksi1,2, D. A. Allen1,2, C. Inhof1,2, J. Truax1,2, R. R.Tice1,2 and W. S. Stokes2. 1ILS, Inc., Research TrianglePark, NC and 2NICEATM, NIEHS/NIH/DHHS,Research Triangle Park, NC.

#664 10:10 THE STATE OF THE SCIENCE ON IN VITROTEST METHODS FOR DETECTING MILD TOMODERATE OCULAR IRRITANTS. C. Eskes, T.Hartung and V. Zuang. ECVAM, IHCP, EuropeanCommission–DG JRC, Ispra, Varese, Italy. Sponsor: W.Stokes.

#665 10:40 CHALLENGES IN THE VALIDATION OFALTERNATIVE TEST METHODS TO EVALUATEOCULAR TOXICITY. T. Hartung, C. Eskes and V.Zuang. European Centre for the Validation ofAlternative Methods, European Commission DG JRC,Ispra, Varese, Italy. Sponsor: W. Stokes.


WORKSHOP SESSION: MODE OF ACTION IN RELEVANCE OFRODENT LIVER TUMORS TO HUMAN CANCER RISK

Chairperson(s): Yvonne Dragan, National Center for Toxicological Research,Jefferson, AR and Michael Holsapple, International Life Sciences Institute,Washington, DC.

Endorsed by:Carcinogenesis SS*Regulatory and Safety Evaluation SSRisk Assessment SS

The recent adoption of the IPCS mode of action paradigm (Sonich-Mullin et al.,2001, Regul Toxicol Pharmacol 34:146-152) coupled with the recent ILSIhuman relevance framework (Cohen et al., 2003, Crit Rev Toxicol 33:581-589)have led to an approach for the systematic analysis of data on modes of carcino-genic action of chemicals in experimental animals and its application to theassessment of human cancer risk assessment. Hazard identification and riskassessment paradigms depend on the presumption of similarity of rodents tohumans, yet species-specific responses and high dose to low dose extrapolationplague the development of appropriate risk assessments. The first step in a modeof action analysis is to establish the key biochemical and cellular events,temporal occurrence, and dose response concordance relationships common toeach mode of action of a chemical. The next step is to assess the biological plau-sibility and relevance to human cancer risk of the proposed mode(s) of actiontaking kinetic and dynamic factors into consideration. The identification of keyevents can be used to bridge species and dose differences. These discussionswill be used to generate a minimal dataset necessary to establish selected modesof action. This mode of action framework has been previously applied to rodentliver tumors associated with exposure to peroxisome proliferators mediatedthrough the alpha receptor (Klaunig et al., 2003, Crit Rev Toxicol 33:655-780).More recently, several additional modes of action for rodent liver cancer devel-opment have been described including cytotoxicity, P450 induction, hormonemediated and porphyrogenicity / metal overload. An understanding of the modeof action underlying cancer development in the liver will place rodent livertumors into a more appropriate perspective when human risk assessment isperformed.

#666 8:30 MODE OF ACTION IN RELEVANCE OFRODENT LIVER TUMORS TO HUMAN CANCERRISK. M. P. Holsapple1 and Y. P. Dragan2. 1HESI,Washington, DC and 2NCTR, Jefferson, AR.

#667 8:35 THE PATHOGENESIS OF RODENTHEPATOCARCINOGENESIS: POTENTIALAPPLICATIONS TO HUMAN CANCER RISK. H.C. Pitot. Oncology, McArdle Lab., University ofWisconsin, Madison, WI.

#668 9:05 FRAMEWORK FOR EVALUATING THE HUMANRELEVANCE OF CARCINOGENIC MODES OFACTION IN ANIMALS. S. M. Cohen. Pathology andMicrobiology, University of Nebraska Medical Center,Omaha, NE.

#669 9:35 MODE OF ACTION AND HUMAN RELEVANCEOF PHENOBARBITAL-LIKE RODENT LIVERCARCINOGENS. A. R. Boobis1, B. G. Lake2, E.Harpur3, J. M. Rice4 and J. I. Goodman5. 1ExperimentalMedicine and Toxicology, Imperial College London,London, United Kingdom, 2BIBRA International Ltd.,Carshalton, United Kingdom, 3Sanofi-Synthelabo,Malvern, PA, 4Georgetown University, Washington, DCand 5Michigan State University, East Lansing, MI.

#670 9:55 MODE OF ACTION AND HUMAN RELEVANCEOF METAL OVERLOAD ANDPORPHYRINOGENIC COMPOUNDS. J. E.Klaunig1, A. Nyska2, J. Popp3, A. Smith4, W. Stott5 andG. Williams6. 1Indiana University, Indianapolis, IN,2NIEHS/NTP, Research Triangle Park, NC, 3PurduePharmacology, New York, 4MRC Toxicology,University of Leicester, United Kingdom, 5The DowChemical Company, Midland, MI and 6New YorkMedical College, Valhalla, NY.

#671 10:15 HORMONAL PERTURBATION AS A MODE OFACTION FOR RODENT LIVER TUMORS. T.Pastoor4, Y. Dragan1, M. Cunningham3, I. White7, J.Teeguarden6, H. Pitot, III5 and C. Capen2. 1NCTR,Jefferson, AR, 2Ohio State University, Columbus, OH,3NIH/National Center for Toxicogenomics, ResearchTriangle Park, NC, 4Syngenta CropScience, Greenboro,NC, 5University of Wisconsin, Madison, WI,6ENVIRON Corporation, Collegeville, PA and7University of Leicester, Leicester, United Kingdom.

#672 10:35 RODENT HEPATIC TUMORS: CYTOXICITYMODE OF ACTION. V. L. Dellarco1, S. Cohen2, D.Wolf3, R. Maronpot4 and D. Jacobson-Kram5. 1Office ofPesticide Programs, U.S. EPA, Washington, DC,2University of Nebraska Medical Center, Omaha, NE,3Health and Environmental Effects ResearchLaboratory, U.S. EPA, Research Triangle Park, NC,4NIEHS, National Toxicology Program, ResearchTriangle Park, NC and 5CDER, U.S. FDA, Rockville,MD.

Program Description


TUESD

AY



WORKSHOP SESSION: NEUROIMAGING STRATEGIES FORAPPLICATION TO NEUROTOXICOLOGY AND RISK ASSESSMENT

Chairperson(s): William Slikker, Jr., National Center for ToxicologicalResearch, Jefferson, AR and Tomas Guilarte, Johns Hopkins, Baltimore, MD.

Endorsed by:Comparative and Veterinary SSNeurotoxicology SS*Regulatory and Safety Evaluation SSStudent Advisory Committee

Recent technological innovations now make it possible to apply many in vivoneuroimaging technologies such as positron emission tomography (PET) andmagnetic resonance imaging (MRI) to small animals, including nonhumanprimates, rats and mice. The availability of these new technologies coincideswith progress in developing animal models of various developmental andneurodegenerative diseases and improvements in assessment protocols for iden-tifying deficits in animals that correlate well with human deficits. Theintegration of neuroimaging techniques with traditional neurotoxicologicalassessments has the potential to enhance greatly the ability to relate behavioral,cognitive or motor dysfunction induced by a toxicant to structural and functionalbrain pathology. Changes in anatomy of soft and hard tissue, metabolism andgene expression can now be done in both a preclinical and a clinical settingusing such technologies as Magnetic Resonance Imaging (MRI), MagneticResonance Spectroscopy (MRS), Positron Emission Tomography (PET),Computer Tomography Scanning (CT scan) and Visible and Infrared SpectralImaging. This permits longitudinal studies of the same subject subsequentlyreducing the number of animals required for studies while providing definitiveinformation as a basis of risk assessment. This workshop will be of interest totoxicologists in general and in particular to neurotoxicologists and risk asses-sors.

#673 8:30 NEUROIMAGING STRATEGIES FORAPPLICATION TO NEUROTOXICOLOGY ANDRISK ASSESSMENT. W. Slikker1 and T. R. Guilarte2.1Division of Neurotoxicology, NCTR/FDA, Jefferson,AR and 2Department of Environmental Health Sciences,Johns Hopkins Medical Institutions, Baltimore, MD.

#674 8:35 NEUROIMAGING: NEW APPROACHES FORNEUROTOXICOLOGY. W. Slikker. Division ofNeurotoxicology, NCTR/FDA, Jefferson, AR.

#675 9:10 MAGNETIC RESONANCE IMAGING OFMETALS IN THE BRAIN. D. C. Dorman. CIITCenters for Health Research, Research Triangle Park,NC.

#676 9:45 MOLECULAR IMAGING OF CENTRALNERVOUS SYSTEM BIOLOGY IN SMALLANIMALS. M. G. Pomper. Department of Radiology,Pharmacology, and Molecular Sciences and Oncology,Johns Hopkins University School of Medicine,Baltimore, MD. Sponsor: W. Slikker.

#677 10:20 MRS TO ASSESS DEVELOPMENTALNEUROTOXICITY. C. Cloak. Manoa School ofMedicine, University of Hawai’i, Honolulu, HI.Sponsor: W. Slikkers, Jr.

#678 10:55 EARLY BIOMARKERS OF PARKINSON’SDISEASE AS DEFINED BY POSITRONEMISSION TOMOGRAPHY. T. R. Guilarte1, M. K.Chen1, H. Kuwabara2, J. L. McGlothan1, M.Alexander2, J. R. Brasic2, R. J. Adams3 and D. F.Wong1,2. 1Department Environmental Health Sciences,Johns Hopkins Un, Baltimore, MD, 2DepartmentRadiology, Johns Hopkins University, Baltimore, MDand 3Department Comparative Med., Johns HopkinsUniversity, Baltimore, MD.


PLATFORM SESSION: DEVELOPMENTAL TOXICOLOGY

Chairperson(s): Anne Greenlee, OHSU, LaGrande, OR and Barbara Abbott,U.S. EPA, Research Triangle Park, NC.

#679 8:30 EARLY EXPOSURE TO TCDD IMPAIR RATBONE TISSUE COMPOSITION AND FUNCTION.M. P. Lind1, H. M. Miettinen2, J. Orberg3, M.Backstrom1, I. Pettersson3,1, S. Larsson4 and M.Viluksela2. 1Institute of Environmental Medicine,Karolinska Institutet, Stockholm, Sweden, 2Departmentof Environmental Health, National Public HealthInstitute, Kuopio, Finland, 3Department ofEnvironmental Toxicology, Uppsala University,Uppsala, Sweden and 4Department of Orthopaedics,Uppsala University Hospital, Uppsala, Sweden.Sponsor: G. Johansson.

#680 8:50 EXPRESSION OF EGFR AND ITS LIGANDS INRESPONSE TO TCDD OR RETINOIC ACID INEGF AND TGFαα KO FETAL MOUSE PALATE. B.D. Abbott1, H. Boyd2, C. Wood1 and G. Held1. 1Repro.Toxicology. Division, U.S. EPA/ORD/NHEERL,Research Triangle Park, NC and 2MARC Program,NCCU, Durham, NC.

#681 9:10 A ROBUST EXAMINATION OF EFFECTS OFTCDD ON THE DEVELOPING MALEREPRODUCTIVE SYSTEM. D. R. Bell1, G. Loizou2,S. White3, A. Fernandes3, M. Rose3, B. G. Miller4, L.Tran4, S. Clode5, P. M. Foster6 and A. MacNicoll3.1Biology, Nottingham, Notts, United Kingdom, 2HSL,Sheffield, United Kingdom, 3CSL, York, UnitedKingdom, 4IOM, Edinburgh, United Kingdom,5Covance, Harrogate, United Kingdom and 6NIEHS,Raleigh, NC.

#682 9:30 COMPARISON OF MATRIGEL™ AND GELATINSUBSTRATA FOR FEEDER-FREE CULTURE OFUNDIFFERENTIATED MOUSE EMBRYONICSTEM CELLS FOR TOXICITY TESTING. A. R.Greenlee1,2, T. A. Kronenwetter-Koepel2, S. J. Kaiser2

and K. Liu3. 1School of Nursing and Center forResearch on Occupational and EnvironmentalToxicology, OHSU, La Grande, OR, 2Marshfield ClinicResearch Foundation, Marshfield, WI and 3Departmentof Biostatistics, Forest Research Institute, Jersey City,NJ.

Program Description



TUES

DAY

#683 9:50 ALTERED TRANSCRIPTIONAL RESPONSES INMOUSE EMBRYOS EXPOSED TOBISINDOLYLMALEIMIDE I (BIS I) IN WHOLEEMBRYO CULTURE. E. D. Karoly1,2, J. E. Schmid2,M. R. Blanton2 and E. S. Hunter III2. 1Curriculum inToxicology, UNC Chapel Hill, Chapel Hill, NC and2Reproductive Toxicology Division, NHEERL, ORD,U.S. EPA, Research Triangle Park, NC.

#684 10:10 FOLATE PREVENTION OF OXIDATIVE STRESSIN FUMONISIN-INDUCED NEURAL TUBEDEFECTS. J. B. Gelineau-van Waes, J. Wilberding, F.Aleman, L. Bauer and J. Maddox. Department ofGenetics, Cell Biology & Anatomy, University ofNebraska Medical Center, Omaha, NE. Sponsor: G.Bennett.

#685 10:30 MATERNAL IMMUNE STIMULATIONREDUCES DIABETES INDUCEDCRANIOFACIAL MALFORMATIONS. S. D.Holladay1,2, T. C. Hrubec2,1, R. Prater2,1 and K. Toops1.1Veterinary Medicine, Virginia Tech, Blacksburg, VAand 2Biomedical Sciences, College of OsteopathicMedicine, Blacksburg, VA.

#686 10:50 ARSENIC TOXICITY: MOLECULAR ANDDEVELOPMENTAL MECHANISMS INMISCARRIAGE. J. Coffin1, W. He2, R. J. Greenwell1,J. C. Pfau1, D. Brooks1, M. Bently3, T. J. Poole3 and H.D. Beall1. 1CEHS, University of Montana, Missoula,MT, 2University of Pittsburg, Pittsburg, PA and 3SUNYUpstate Medical University, Syracuse, NY.

#687 11:10 SYNERGISTIC DEVELOPMENTAL TOXICITYOF POLYCYCLIC AROMATICHYDROCARBONS: TOWARDS AMECHANISTIC UNDERSTANDING. R. Di Giulio1,S. Billiard1, J. Meyer3, D. Wassenberg1 and P. Hodson2.1Duke University, Durham, NC, 2Queens University,Kingston, ON, Canada and 3NIEHS, Research TrianglePark, NC.


PLATFORM SESSION: METALS TOXICOLOGY

Chairperson(s): Joyce S. Tsuji, Exponent Environmental Group Inc.,Bellevue, WA and Michael P. Waalkes, NIEHS, Research Triangle Park, NC.

#688 8:30 ARSENIC TRIOXIDE INHIBITS NUCLEAREXPRESSION OF RXR AND BINDING OF RXR-CONTAINING HETERODIMERS. K. K. Mann, A.M. Padovani and W. H. Miller. Lady Davis Institute forMedical Research, McGill University, Montreal, QC,Canada.

#689 8:50 P53 MODULATES ARSENITE-INDUCEDMITOTIC DISRUPTION AND ALTERED GENEEXPRESSION. S. C. McNeely1, B. Taylor1, X. Xu1, W.Zacharias2,1, M. J. McCabe3 and J. States1.1Pharmacology & Toxicology, University of Louisville,Louisville, KY, 2Medicine, University of Louisville,Louisville, KY and 3Environmental Medicine,University of Rochester, Rochester, NY.

#690 9:10 P53 SUPPRESSION OF ARSENITE INDUCEDMITOTIC ARREST IS MEDIATED BY P21. B.Taylor1, S. C. McNeely1, H. L. Miller1, M. J. McCabe2

and J. States1. 1Pharmacology & Toxicology, Universityof Louisville, Louisville, KY and 2EnvironmentalMedicine, University of Rochester, Rochester, NY.

#691 9:30 ARSENIC EXPOSURE ACCELERATESATHEROGENIC CHANGES IN APOE-/- MICE. J.States1, S. Srivastava3, U. Sen2, H. L. Miller1 and S. E.D’Souza2. 1Pharmacology & Toxicology, University ofLouisville, Louisville, KY, 2Physiology & Biophysics,University of Louisville, Louisville, KY and 3Medicine,University of Louisville, Louisville, KY.

#692 9:50 EXAMINING BIOMARKERS OF EXPOSUREAND PREPARATION TECHNIQUES FORARSENIC QUANTITATION IN BIOLOGICALSTUDIES. B. M. Adair1, E. E. Hudgens2, R. L.Calderon2 and D. J. Thomas1. 1ExperimentalToxicology Division/NHEERL, U.S. EPA, ResearchTriangle Park, NC and 2Human SudiesDivision/NHEERL, U.S. EPA, Chapel Hill, NC.

#693 10:10 BIOMONITORING OF A COMMUNITY FORSOIL ARSENIC EXPOSURE. J. S. Tsuji1, M. D. VanKerkhove2, C. G. Scrafford3 and R. S. Kaetzel1.1Exponent, Bellevue, WA, 2Exponent, New York and3Exponent, Washington, DC.

#694 10:30 CARCINOGENIC EFFECTS OF CADMIUMCHLORIDE, CISPLATIN AND NICKELSUBSULFIDE IN METALLOTHIONEIN-I/IIDOUBLE KNOCKOUT MICE. M. Waalkes1, J. Liu1,K. Kasprzak3 and B. Diwan2. 1Laboratory ofComparative Carcinogenesis, NCI at NIEHS, ResearchTriangle Park, NC, 2NCI at Frederick, Frederick, MDand 3BRP, SAIC-Frederick, NCI at Frederick, Frederick,MD.

#695 10:50 LEAD IS A RISK FACTOR FOROSTEOARTHRITIS: MOLECULARMECHANISMS. J. E. Puzas, K. Hochberg, M. Zuscik,T. Sheu, E. Schwarz, R. O’Keefe and R. Rosier.Department of Orthopaedics, University of RochesterSchool of Medicine, Rochester, NY.

#696 11:10 DISSOLUTION RATES OF NANOPARTICULATEMETALLIC SPECIES IN ARTIFICIAL HUMANSWEAT UNDER PHYSIOLOGICALLYRELEVANT CONDITIONS. N. J. Szabo, S. C.Wasdo, G. Brubaker, C. M. Jenkins and S. M. Roberts.University of Florida, Gainesville, FL.

Program Description


TUESD

AY



PLATFORM SESSION: EVALUATING DNADAMAGE AND REPAIR

Chairperson(s): Toby G. Rossman, New York University School of Medicine,Tuxedo, NY and John E. French, NIEHS, Research Triangle Park, NC.

#697 8:30 GENETIC TOXICOLOGY TESTING IN HTS. R.M. Walmsley1,2, P. Cahill2, A. Knight2 and N.Billinton2. 1Biomolecular Sciences, UMIST,Manchester, England, United Kingdom and 2ProductDevelopment, Gentronix Ltd., Manchester, UnitedKingdom. Sponsor: S. Dean.

#698 8:50 AMES II AND DEREK VERSUS THE STANDARDAMES PROTOCOL: A COMPARATIVE STUDY.C. Andreas, K. Braun, I. Stammberger, H. Spirkl and A.Amberg. Sanofi-Aventis, Hattersheim, Germany.Sponsor: M. Bonnefoi.

#699 9:10 STUDY IN VITRO OF THE TUMORIGENICACTION OF ACRYLAMIDE ON THYROIDCELLS. J. DUMONT1, J. Van Sande1, C. Massart1, M.Friedman2 and V. CHICO-GALDEZ1. 1I.R.I.B.H.M.,ULB, Brussels, Belgium and 2Free Consultant, Orlando,FL.

#700 9:30 UNEXPECTED CLASTOGENICITY OF SOMEPHARMACEUTICALS IS DUE TO DNAINTERCALATION. R. D. Snyder1, G. B. Zairov1 andL. B. Hendry2. 1Investigative and MolecularToxicology, Schering-Plough, Lafayette, NJ, 2Schering-Plough, Lafayette, NJ and 3AcceleratedPharmaceuticals, Augusta, GA.

#701 9:50 PHOSPHOTRIESTER ALKYLATION OF DNA BYMNU AND MMS. L. H. Pottenger, F. Zhang, M. J.Bartels, M. R. Schisler and B. B. Gollapudi. Toxicologyand Environmental Research & Consulting, The DowChemical Company, Midland, MI.

#702 10:10 RECOGNITION AND REPAIR OF BUTADIENEEPOXIDE DNA ADDUCTS: INVOLVEMENT OFNUCLEOTIDE EXCISION REPAIR. J. Wickliffe1,O. Masters2, S. Herring1, M. Ammenheuser1, L.Galbert1, J. Xie1, R. S. Lloyd3 and J. Ward1. 1Universityof Texas Medical Branch, Galveston, TX, 2University ofOklahoma, Norman, OK and 3Oregon Health andScience University, Portland, OR.

#703 10:30 BENZO[A]PYRENE-DNA ADDUCTS DERIVEDFROM DIOL-EPOXIDE AND QUINONEPATHWAYS. Q. Ruan1, Q. Dai2, H. Kim1, R. G.Harvey2, T. M. Penning1 and I. A. Blair1. 1Departmentof Pharmacology, University of Pennsylvania,Philadelphia, PA and 2Ben May Institute for CancerResearch, University of Chicago, Chicago, IL. Sponsor:S. Burchiel.

#704 10:50 SIGNALING PATHWAYS FOR DNA DAMAGEAND REPAIR, APOPTOSIS AND LYMPHOIDPROGENITOR CELL SURVIVAL AREDYSREGULATED BY N-ACETYL-L-CYSTEINE.J. E. French1, K. R. Martin2, F. W. Kari1 and J. C.Barrett3. 1Laboratory of Molecular Toxicology, NIEHS,NIH, Research Triangle Park, NC, 2Nutrition andCancer Laboratory, Pennsylvania State University,University Park, PA and 3Laboratory of Biosystems andCancer, NCI, Bethesda, MD.

#705 11:10 PREVENTION OF ARSENIC CO-CARCINOGENESIS BY SELENIUMCOMPOUNDS. T. G. Rossman, A. N. Uddin and F. J.Burns. Environment Med., New York University Schoolof Medicine, Tuxedo, NY.

Tuesday Morning, March 89:30 AM to 12:30 PMExhibit Hall

POSTER SESSION: BIOTRANSFORMATION/CYTOCHROME P450 I

Chairperson(s): Xinxin Ding, New York State Department of Health, Albany,NY.



#706 CELLULAR DISTRIBUTION OF SELECTIVEAGE DEPENDENT TESTICULARCYTOCHROME P450-DEPENDENTALKOXYRESORUFIN O-DEALKYLATION INSPRAGUE-DAWLEY RATS. J. E. Seng1, J. Gandy2,R. Ansari2 and J. Leakey3. 1Charles River Laboratories,Discovery and Developmental Services, Redfield, AR,2Department of Pharmacology & Toxicology, Universityof Arkansas Medical Sciences, Little Rock, AR and3National Center for Toxicological Research, Jefferson,AR.

#707 ORAL ADMINISTRATION OF EGCG IS NON-TOXIC AND MODULATES CYP19 AND CYP2E1IN THE FEMALE BALB/C MOUSE. M. J. Scandlyn,M. G. Goodin and R. J. Rosengren. Pharmacology &Toxicology, University of Otago, Dunedin, NewZealand.

#708 MAJOR DETERMINANTS IN SEX DIFFERENCEON DAILY RHYTHM OF HEPATIC P450MONOOXYGENASE ACTIVITIES IN RATS. J.Hirao1, S. Arakawa1, M. Nishimura2, N. Niino1, K. Ito1,N. Kiyosawa1, K. Muramatsu1 and T. Furukawa1.1Medicinal Safety Research Laboratories, SANKYOCO., LTD., Fukuroi, Shizuoka, Japan and 2BiomedicalResearch Laboratories, SANKYO CO., LTD.,Shinagawa, Tokyo, Japan. Sponsor: N. Matsunuma.

Program Description



TUES

DAY

#709 INTERINDIVIDUAL VARIATION OFEXPRESSION LEVEL OF CYP3A4 AND ITSRELATED PHARMACOGENETIC GENES INJAPANESE LIVER TISSUE. A. Miyajima-Tabata1, S.Ozawa1, J. He1, H. Tanaka2, K. Nakai2, M. Sunouchi1,Y. Kamikawa3, K. Kubota4, H. Ogata2 and Y. Ohno1.1Division of Pharmacology, National Institute of HealthSciences, Setagaya, Tokyo, Japan, 2Department ofBiopharmaceutics, Meiji Pharmaceutical University,Kiyose, Tokyo, Japan, 3Department of Pharmacology,Dokkyo University School of Medicine, Mibu, Tochigi,Japan and 4Second Department of Surgery, DokkyoUniversity School of Medicine, Mibu, Tochigi, Japan.Sponsor: M. Ema.

#710 USE OF NOVEL MULTIPLEXED QPCR ASSAYSTO ACCURATELY QUANTIFY HUMANCYTOCHROME P450 EXPRESSION. R. D.Larsen1, C. Chang1, M. Tan1, C. Patten2 and S. Parikh2.1BD Biosciences Clontech, Palo Alto, CA and 2BDBiosciences Discovery Labware, Billerica, MA.Sponsor: D. Stresser.

#711 USING P450-GLO™ LUMINESCENT ASSAYS TOSCREEN FOR XENOBIOTIC EFFECTS ONCYTOCHROMES P450. J. Cali1, D. Liu1, R. Bulliet1

and D. Ma1. 1Promega Corp, Madison, WI and 2R&D,Promega Biosciences, Sac Louis Obispo, CA.

#712 DIOXIN AND DIET EFFECTS ON GROWTH ANDP450 INDUCTION. M. La Merrill1 and D. W.Threadgill2,1. 1Curriculum in Toxicology, UNC-CH,Chapel Hill, NC and 2Genetics, UNC-CH, Chapel Hill,NC.

#713 DIOXIN INDUCTION OF CYP1A1 EXPRESSIONIS SUPPRESSED IN HEPATITIS C VIRUSREPLICATING CELLS. G. R. Anderson, A. Hasan, I.Qadri and L. C. Quattrochi. Medicine, University ofColorado Health Sciences Ctr, Denver, CO.

#714 DIFFERENTIAL REGULATION OF LIVERMITOCHONDRIAL CYTOCHROME P4501A1(P450MT2) BY 3-METHYLCHOLANTHRENE INMICE DEFICIENT IN THE CYTOCHROMEP4501A2 GENE. B. Moorthy, S. Kondraganti and W.Jiang. Pediatrics, Baylor College of Medicine, Houston,TX.

#715 ENDOGENOUS SUBSTRATES OF CYP1B1WHICH MAY BE ENDOGENOUS LIGANDS OFTHE ARYL HYDROCARBON RECEPTOR. B.Stapleton1, A. Annalora1, C. Chiaro5, M. Doshi3, A.Bailey1, J. Omdahl2, B. Bejjani4, D. Edward3, G.Perdew5 and C. Marcus1. 1Toxicology, University NewMexico, Albuquerque, NM, 2Biochemistry, UniversityNew Mexico, Albuquerque, NM, 3Opthalmology &Visual Sciences., University IL, Chicago, IL, 4Genetics& Pediatrics, WA. St. University, Spokane, WA and5Cell & Molecular Biology, Penn. St. University,University Park, PA.

#716 THE RESPONSE OF THE RAT HEPATIC P450SYSTEM TO FIVE ARCHETYPAL HUMANMICROSOMAL ENZYME INHIBITORS. S. J.Schomaker, S. E. Boldt and D. E. Amacher. SafetySciences Groton, Pfizer Inc., Groton, CT.

#717 EFFECTS OF DIESEL EXHAUST PARTICLES ONCYTOCHROME P450 ACTIVITIES IN PRIMARYCULTURES OF ADULT RAT HEPATOCYTES: AUSEFUL INDICATOR FOR THE STUDY OFHEALTH RISK. T. Jeon1, S. Hyun1, S. Lee1, C. Jin1,D. Lee1, G. Kim1, I. Jun1, K. Chung2, C. Moon3 and T.Jeong1. 1College of Pharmacy, Yeungnam University,Kyungsan, South Korea, 2College of Pharmacy,Sungkyunkwan University, Suwon, South Korea and3College of Pharmacy, Seoul National University, Seoul,South Korea.

#718 IN VITRO EVALUATION OF HISTAMINE ANDITS MAJOR METABOLITES AS INHIBITORS ORINDUCERS OF CYTOCHOME P450EXPRESSION IN HUMAN LIVER. S. A. Tonetta1, F.Nodikum-Moffor2, B. L. Paris2 and B. M. Richard1.1Nonclinical, Maxim Pharmaceuticals, San Diego, CAand 2Metabolism, Xenotech LLC, Lenexa, KS.

#719 COMPARATIVE STUDIES OF CYTOCHROMEP4503A4 INDUCTION RESPONSE IN PRIMARYCULTURES OF CRYOPRESERVED AND FRESHHUMAN HEPATOCYTES. J. Johnson1, C. M.Chandler1, S. Kim2, L. Tarabelsi1, D. M. Stresser1, M.Sinz2 and J. G. Zhang1. 1BD Discovery Labware,woburn, MA and 2Bristol Myers Squibb Co.,Wallingford, CT.

#720 REGULATIONS OF HUMAN CYP3A4PROXIMAL AND XREM PROMOTERACTIVITIES IN HEPA I AND HEPG2 CELLS. Y. Y.Sheen, K. N. Min, J. Y. An, K. E. Joung, Y. W. Kim andD. Kim. Pharmacy, Ewha Womans University, Seoul,seoul, South Korea. Sponsor: J. Chung.

#721 ROLE OF NF-κκB IN REGULATION OF PXRTRANSCRIPTIONAL ACTIVITY: AMECHANISM FOR THE SUPPRESSION OFCYTOCHROME P450 3A4 BY INFLAMMATORYAGENTS. X. Gu1, T. Sheng2, S. Ke1, P. E. Thomas3,M. A. Gallo3, W. Xie4 and Y. Tian1. 1InterdisciplinaryFaculty of Toxicology, College Station, TX, 2TheUniversity of Texas Medical Branch, Galveston, TX,3EOHSI, Rutgers University, Piscataway, NJ and4University of Pittsburgh, Pittsburgh, PA.

#722 DOWN-REGULATION OF HEPATICCYTOCHROME P450S IN ENDOTOXEMICMICE IS INDEPENDENT OF PEROXISOMEPROLIFERATOR ACTIVATED RECEPTORALPHA (PPARαα). T. Richardson and E. T. Morgan.Pharmacology, Emory University, Atlanta, GA.

#723 GENERATION AND CHARACTERIZATION OF ATRANSGENIC MOUSE MODEL WITH HEPATICEXPRESSION OF HUMAN CYP2A6. J. Gu, Q.Zhang, T. Su, H. Cui, X. Zhuo, P. J. Swiatek, L. Zhang,W. Yang and X. Ding. Wadsworth Center, Albany, NY.

Program Description


TUESD

AY


#724 AFFINITY LABELING OF SER-57 IN RATCYTOCHROME P450C24A1 (CYP24A1) OF THEVITAMIN D PATHWAY: MUTATION ANDCHARACTERIZATION. A. J. Annalora1,2, A.Pastusyzn2, R. Ray3, C. B. Marcus1 and J. L. Omdahl2.1College of Pharmacy, University of New Mexico,Albuquerque, NM, 2Department of Biochemistry andMolecular Biology, University of New Mexico,Albuquerque, NM and 3Vitamin D Laboratory, BostonUniversity-SOM, Boston, MA.

#725 THE USE OF THE MECHANISM BASEDINHIBITOR 2-ETHYNYLNAPHTHALENE (2EN)TO PROBE THE ACTIVE SITE OF CYP2B4. D.Cheng, J. R. Reed, R. W. Kelley and W. L. Backes.Pharmacology, LSUHSC, New Orleans, LA.

#726 INHIBITION OF THE HUMAN LIVERMICROSOMAL AND HUMAN CYTOCHROMEP450 1A2 AND 3A4 METABOLISM OFESTRADIOL BY DEPLOYMENT-RELATEDCHEMICALS. K. A. Usmani, R. L. Rose and E.Hodgson. Environmental & Molecular Toxicology,North Carolina State University, Raleigh, NC.

#727 CORRELATIONS BETWEEN ACTIVITIES OFCYPS 2E1/1A2 AND HISTOLOGIC FIBROSIS INHCV PATIENTS. S. I. Shedlofsky1,3, R. T. Tosheva1,C. Hallberg2 and K. E. Anderson2. 1Medicine,University of Kentucky, Lexington, KY, 2University ofTexas Medical Branch, Galveston, TX and 3GeneralClinical Research Center, Lexington, KY.

#728 ROLE OF CYTOCHROME P450 2E1 (CYP2E1) INTRICHLOROETHYLENE (TCE) METABOLISMAND DISPOSITION: COMPARATIVE STUDIESUSING CYP2E1-/- AND WILD-TYPE MICE. D.Kim and B. I. Ghanayem. Laboratory of Pharmacologyand Chemistry, NIEHS/NIH, Research Triangle Park,NC.

#729 CYTOCHROME P450 2E1 (CYP2E1) INDUCTIONBY PYRIDAZINE PRODUCES QUALITATIVEAND QUANTITATIVE CHANGES IN THEMETABOLISM OF TRICHLOROETHYLENE TOPOTENTIALLY CARCINOGENICMETABOLITES. S. Lee, S. Muralidhara, C. A. Whiteand J. V. Bruckner*. Department of PBS, University ofGeorgia, Athens, GA.

#730 PROTECTIVE EFFECT OF DIALLYL SULFONEAGAINST LUNG MUTAGENESIS INDUCED BYVINYL CARBAMATE. L. G. Hernandez and P.Forkert. Department of Anatomy and Cell Biology,Queen’s University, Kingston, ON, Canada.

#731 ROLE OF TOXICOKINETICS IN THEBIOACTIVATION-MEDIATED LIVER INJURYOF THIOACETAMIDE IN AD LIBITUM FED ANDDIET RESTRICTED RATS. J. Chilakapati, M. C.Korrapati and H. M. Mehendale. Toxicology, Universityof Louisiana at Monroe, Monroe, LA.

#732 CYP2E1 OXIDATION MEDIATES THE SPERMTOXICITY OF 1-BROMOPROPANE IN MICE. C.Garner1, J. Davis1, C. Sloan1, J. Burgess1, A. Jeffcoat1,A. Hughes1, A. Parham1, J. Mathews1, L. Burka2 and B.Ghanayem2. 1DMPK, RTI International, ResearchTriangle Park, NC and 2NIEHS, Research TrianglePark, NC.

#733 HEPATIC METABOLISM OF AROMATIC AMINEHAIR DYE COMPONENTS AS COMPAREDWITH THAT OF 2-AMINOFLUORENE. L.Stanley1, J. Skare2, E. Doyle1, R. Powrie1, D. D’Angelo2 and C. Elcombe1. 1CXR Biosciences Ltd.,Dundee, United Kingdom and 2Central Product Safety,Sharon Woods Technical Center, Procter & GambleCompany, Cincinnati, OH.

#734 DECHLORINATION OF PCB IUPAC #101 BYHUMAN CYP 2B6 TRANSFECTED INSECT CELLMICROSOMES. D. P. Waller and J. E. McGraw.Biopharmaceutical Sciences, University of Illinois atChicago College of Pharmacy, Chicago, IL.

#735 REGIO-SPECIFIC (ωω TO ωω-6) FATTY ACID(LAURIC, MYRISTIC AND PALMITIC)HYDROXYLATION IN HUMAN POOLED LIVERAND RECOMBINANT MICROSOMES. M. L.Haasch and J. C. Allgood. National Center for NaturalProducts Research, Environmental Toxicology ResearchProgram, Pharmacology, The University of Mississippi,University, MS.

#736 ROLE OF CYTOCHROME P450 3A INHEPATOTOXICITY OF THECHLOROACETANILIDE HERBICIDEALACHLOR. S. R. Miranda and S. A. Meyer.Toxicology, University of Louisiana at Monroe,Monroe, LA.

#737 INTERINDIVIDUAL VARIABILITY IN P450-MEDIATED METABOLISM OF 4-(METHYLNITROSAMINO)-1-(3-PYRIDYL)-1-BUTANONE(NNK) IN HUMAN WHOLEPERIPHERAL LUNG MICROSOMES. P. J. Brown1,K. R. Reid2, D. Petsikas2 and T. E. Massey1.1Pharmacology and Toxicology, Queen, Kingston, ON,Canada and 2Surgery, Queen’s University, Kingston,ON, Canada.

#738 COMPARATIVE METABOLISM OF AFLATOXINB1 (AFB1) BY ZEBRAFISH, RAINBOW TROUTAND HUMAN CYTOCHROMES P450. C. L.Miranda, W. Chung, J. Wang and D. R. Buhler.Environment & Molec. Toxicology, Oregon StateUniversity, Corvallis, OR.

#739 EXPRESSION AND CHARECTERIZATION OFCHANNEL CATFISH CYP 2X1. S. MOSADEGHI,B. Furnes, C. Wong and D. Schlenk. EnvironmentalToxicology, University of California, Riverside, CA.

#740 CHARACTERIZATION AND COMPARISON OFMETHODS FOR VESICULARRECONSTITUTION OF CYTOCHROME P4502B4 AND NADPH P450 REDUCTASE. J. R. Reed, R.W. Kelley and W. L. Backes. Pharmacology, LouisianaState University Health Science Center, New Orleans,LA.

Program Description



TUES

DAY


POSTER SESSION: HEPATOCARCINOGENESIS

Chairperson(s): Alan M. Jeffrey, New York Medical College, Valhalla, NY andLisa M. Kamendulis, Indiana University School of Medicine, Indianapolis, IN.



#741 QUANTITATIVE DOSE-RESPONSE EFFECTS OFACETYLAMINOFLUORENEHEPATOCARCINOGENESIS IN RATS. A. M.Jeffrey, M. J. Iatropoulos, J. Duan and G. M. Williams.New York Medical College, Valhalla, NY.

#742 INFLUENCE OF STRAIN AND DIET ONHEPATOCARCINOGENICITY OF N-BUTYL-N-(4-HYDROXYBUTYL)NITROSAMINE (BBN) INRATS. A. Hagiwara1, T. Murai2, E. Miyata1, Y. Toda1,M. Sano1, S. Mori2 and S. Fukushima2. 1Daiyu-kaiInstitute of Medical Science, Ichinomiya, Japan and2Department of Pathology, Osaka City UniversityMedical School, Osaka, Japan.

#743 THIAMETHOXAM INDUCED MOUSE LIVERTUMORS AND THEIR RELEVANCE TOHUMANS 1. MODE OF ACTION STUDIES INTHE MOUSE. S. Lloyd2, T. Green2, A. Toghill2, R.Lee2, F. Waechter2, J. Noakes2 and T. P. Pastoor1.1Syngenta Crop Protection, Greensboro, NC and2Syngenta Central Toxicology Laboratory, AlderleyPark, United Kingdom.

#744 THIAMETHOXAM INDUCED MOUSE LIVERTUMORS AND THEIR RELEVANCE TOHUMANS 2. SPECIES DIFFERENCES INRESPONSE. C. Waterfield2, T. Green2, R. Lee2, A.Toghill2, F. Waechter2, R. Peffer1, J. Noakes2, M.Robinson2 and T. P. Pastoor1. 1Syngenta CropProtection, Greensboro, NC and 2Syngenta CTL,Alderley Park, Cheshire, United Kingdom.

#745 THIAMETHOXAM INDUCED MOUSE LIVERTUMORS AND THEIR RELEVANCE TOHUMANS 3. WEIGHT OF EVIDENCEEVALUATION. T. P. Pastoor1, P. Rose2, S. Lloyd2, R.Peffer1 and T. Green2. 1Syngenta Crop Protection,Greensboro, NC and 2Syngenta CTL, Alderley Park,Cheshire, United Kingdom.

#746 ESTIMATION OF A NO OBSERVED EFFECTLEVEL FOR 4, 4′′-OXYDIANILINE, AGENOTOXIC LIVER CARCINOGEN, IN A 16-WEEK FEEDING STUDY USING MALE F344RATS. Y. Doi1, N. Imai1, A. Hagiwara1, H. Yoshino1, S.Tamano1, H. Wanibuchi2, K. Morimura2 and S.Fukushima2. 1Daiyu-Kai Institute of Medical Science,Inc., Ichinomiya, Japan and 2Department of Pathology,Osaka City University Medical School, Osaka, Japan.

#747 MUTAGENICITY OF PYRROLIZIDINEALKALOIDS IN RAT LIVER. T. Chen, N. Mei andR. H. Heflich. Division of Genetic and ReproductiveToxicology, NCTR/FDA, Jefferson, AR.

#748 EXPERIMENTAL STUDY ON CARCINOGENESISINDUCED BY CYANOBACTERIALMICROCYSTINS AND ORGANIC EXTRACTS OFTAP WATER. J. ZHAO1,2, S. Jiang1, W. Qu1 and H.Zhu1. 1EOH, Fudan University, Shanghai, China and2EOH, University of Pitt, Pittsburgh, PA. Sponsor: J.Jiang.

#749 INHIBITION OF GAP JUNCTIONALINTERCELLULAR COMMUNICATION BYCHLOROHYDROXYFURANONES IN WB-F344CELLS. E. Rintala, P. Hakulinen, J. Maki-Paakkanenand H. Komulainen. Department of EnvironmentalHealth, National Public Health Institute, Kuopio,Finland. Sponsor: J. Tuomisto.

#750 αα2-MACROGLOBULIN: A NOVELCYTOCHEMICAL MARKERCHARACTERIZING PRENEOPLASTIC ANDNEOPLASTIC RAT LIVER LESIONS NEGATIVEFOR HITHERTO ESTABLISHEDCYTOCHEMICAL MARKERS. T. Sukata1,2, S.Uwagawa1,2, K. Ozaki1,2, K. Sumida1, M. Kushida1,2,K. Saito1, K. Morimura2, K. Oeda1, N. Mikami1 and S.Fukushima2. 1Environmental Health ScienceLaboratory, Sumitomo Chemical Co., Ltd.,, Osaka,Japan and 2Pathology, Osaka City University MedicalSchool, Osaka, Japan.

#751 MECHANISMS OF 2-BUTOXYETHANOLCARCINOGENESIS. S. M. Corthals, L. M.Kamendulis and J. E. Klaunig. Division of Toxicology,Indiana University School of Medicine, Indianapolis,IN.

#752 EVIDENCE FOR THE INVOLVEMENT OF THEKUPFFER CELL IN HEPATICCARCINOGENESIS. L. M. Kamendulis, S. M.Corthals and J. E. Klaunig. Division of Toxicology,Indiana University School of Medicine, Indianapolis,IN.

#753 MECHANISTIC ANALYSIS OF CARCINOGENICAND NONCARCINOGENIC LIVER TOXICANTSUSING TOXICOGENOMIC DATA DERIVEDFROM RAT LIVER OR PRIMARY RATHEPATOCYTES. M. S. Orr, K. K. Daniels and W. B.Mattes. Toxicogenomics, Gene Logic Inc.,Gaithersburg, MD.

#754 DEVELOPMENT OF A GENE SIGNATURE THATDISCRIMINATES BETWEEN GENOTOXIC ANDNON-GENOTOXIC COMPOUNDS. G. Vansant, P.Pezzoli, C. Duffy and J. Monforte. Althea Technologies,San Diego, CA. Sponsor: F. Ferre.

#755 A GENE EXPRESSION SIGNATURE FOR NON-GENOTOXIC CARCINOGENS. A. Y. Nie, M. K.McMillian, A. M. Leone, J. B. Parker, L. Piechta, S.Bryant, J. Herlich, M. Kemmerer, N. Raghavan, D.Amaratunga, L. Yieh, A. Bittner, J. Wan, M. D. Johnsonand P. G. Lord. Mechanistic Toxicology, Johnson &Johnson PRD, LLC, Raritan, NJ.

#756 EFFECTS OF 3-METHYLCHOLANTHRENE ONHEPATIC GENE EXPRESSION PATTERNS INRATS USING CDNA MICROARRAY ANALYSES.S. Kondraganti, W. Jiang, K. Muthiah and B. Moorthy.Pediatrics, Baylor College of Medicine, Houston, TX.

Program Description


TUESD

AY


#757 GENE EXPRESSION PROFILING IDENTIFIESGENE CHANGES INDICATIVE OF POTENTIALEARLY NEOPLASTIC LIVER LESIONS CAUSEDBY THE RODENT HEPATOCARCINOGENMETHYLEUGENOL. J. T. Auman, J. Foley and R. S.Paules. National Center for Toxicogenomics, NIEHS,Research Triangle Park, NC.

#758 GENE REGULATION PATTERNS IN RAINBOWTROUT AFLATOXIN B1-INDUCEDHEPATOCELLULAR CARCINOMA COMPAREDTO NORMAL ADJACENT LIVER. S. C. Tilton1,2, J.D. Hendricks1, G. S. Bailey1,2 and D. E. Williams1,2.1Environmental & Molecular Toxicology Departmentand Marine & Freshwater Biomedical Sciences Center,Oregon State University, Corvallis, OR and 2LinusPauling Institute, Oregon State University, Corvallis,OR.

#759 TOXICOGENOMIC ANALYSIS OF NUCLEARRECEPTOR-MEDIATED AND -INDEPENDENTRESPONSES TO PEROXISOMEPROLIFERATORS. C. G. Woods1, B. U. Bradford1,M. L. Cunningham2, M. Kadiiska3, R. P. Mason3, A. M.Burns4, J. M. Peters4 and I. Rusyn1. 1EnvironmentalScience and Engineering, UNC, Chapel Hill, NC, 2NCTand NTP, NIEHS, Research Triangle Park, NC,3Laboratory of Pharmacology and Chemistry, NIEHS,Research Triangle Park, NC and 4Veterinary Science,PSU, University Park, PA. Sponsor: I. Rusyn.

#760 COMPARATIVE EEFFECTS OFTRICHLORACETIC ACID ON RODENT ANDHUMAN HEPATOCYTES: ROLE OFPEROXISOME PROLIFERATOR ACTIVATEDRECEPTOR αα (PPARαα). D. J. Smith, X. Pu, L. M.Kamendulis and J. E. Klaunig. Division of Toxicology,Indiana University School of Medicine, Indianapolis,IN.

#761 THE EFFECTS OF AMMONIUMPERFLUOROOCTANOATE (APFO) ON THETRANSCRIPTIONAL PROFILE OF PANCREASAND LIVER OF MALE RATS. S. Plummer, O.Vassieva and C. Elcombe. CXR Biosciences Ltd.,Dundee, United Kingdom.

#762 EFFECT OF 6MONTS ADMINISTRATION OFHEPATIC TUMOR PROMOTERS ON IGFSIGNALING PATHWAY EXPRESSION IN THERAT LIVER. A. Naito, S. Dial and Y. Dragan. Divisionof System Toxicology, NCTR, Jefferson, AR.

#763 DIFFERENTIAL CHANGES OF GENEEXPRESSION PROFILES IN MALE LONG-EVANS CINNAMON AND F344 RATS BY THEADMINISTRATION OF N-NITROSOMORPHOLINE. Y. Kawano1, K.Nakayama1, D. Nakae2, A. Maekawa2, M. Tsuchitani1

and M. Sekijima1. 1Mitsubishi Chemical Safety InstituteLtd.,, Ibaraki, Japan and 2Sasaki Institute, SasakiFoundation, Tokyo, Japan.

#764 DOWN-REGULATION OF E-CADHERIN BY THEINTEGRIN-LINKED KINASE PATHWAY (ILK) INHEPATOCYTES; A POSSIBLE MECHANISMFOR HEXACHLOROBENZENE-INDUCEDTUMOR PROMOTION. I. Plante, D. G. Cyr and M.Charbonneau. INRS-Institut Armand-Frappier,Universite du Quebec, Montreal, QC, Canada.

#765 TOXICOGENOMIC APPROACH FORPREDICTION OF HEPATOCARCINOGENSUSING RAT HEPATOMA CELLS ANDCOMPARISON OF GENE EXPRESSIONPATTERNS WITH CHEMICAL-TREATED RATAND HUMAN HEPATOMA CELLS. K.TSUJIMURA1,2, M. Asamoto1, S. Suzuki1, K. Ogawa1

and T. Shirai1. 1Department of Experimental Pathologyand Tumor Biology, Nagoya City University GraduateSchool of Medical Sciences, Nagoya, Aichi, Japan and2Chemicals Assessment Center, Hita laboratory,Chemicals Evaluation and Research Institute, Hita, Oita,Japan.


POSTER SESSION: CHEMICAL & BIOLOGICAL WEAPONS

Chairperson(s): Alan Brimfield, USAMRICD, Aberdeen Proving Groud, MDand Gary Rosenthal, RxKinetix, Louisville, CO.



#766 EVALUATION OF A VACCINE DELIVERYSYSTEM FOR RECOMBINANT ANTHRAXPROTECTIVE ANTIGEN IN RABBITS. J. M.Blonder1, C. Coeshott1, E. Verderber1, A. Samaniego1,S. Smithson2, M. Westerink2 and G. Rosenthal1.1RxKinetix, Louisville, CO and 2Department Medicine,Medical College of Ohio, Toledo, OH.

#767 HISTOLOGICAL RESPONSE OF RAT ORGANSTO REPEATED BLAST OVERPRESSUREEXPOSURE. EFFECTS OF NUMBER OFEXPOSURES AND TIME AFTER EXPOSURE. N.Elsayed1,2, N. Gorbunov3, A. Januszkiewicz3 and J.Atkins3. 1Hurley Consulting Associates, Chatham, NJ,2SUNY Downstate Medical Center, Brooklyn, NY and3Walter Reed Army Institute of Research, Silver Spring,MD.

#768 DEVELOPMENT OF A MICROBIAL RISKASSESSMENT METHODS COMPENDIUM ANDASSESSMENT OF SECONDARY DATA U. M.Coleman1, P. McClure1, P. McGinnis2, R. Starmer1, P.Rodgers3, I. Baumel4,6, J. Choich4,7 and E. Brady-Roberts4,5. 1Environ Sciences Ctr, Syracuse ResearchCorp, Syracuse, NY, 2Syr Res Corp, Philadelphia, PA,3Battelle Mem Inst, Columbus, OH, 4NHomeland SecRes, U.S. EPA, Washington, DC, 5NHomeland Sec Res,U.S. EPA, Cincinnati, OH, 6U.S. EPA, Washington, DCand 7Amer Assn Adv Sciences, Washington, DC.

Program Description



TUES

DAY

#769 MICROARRAY ANALYSIS OF RAW264.7 CELLSEXPOSED TO BACILLUS ANTHRACIS-EVIDENCE OF VOLLUM 1B-INDUCEDMACROPHAGE APOPTOSIS. B. W. Gutting and R.S. Mackie. NSWC Dahlgren, Dahlgren, VA.

#770 DECONTAMINATION OF BACILLUSANTHRACIS SPORES ON INDOOR BUILDINGSURFACES USING FORMALDEHYDE GAS. W. R.Richter, Y. W. Choi, C. L. Sabourin, M. L. Taylor and J.V. Rogers. Battelle Memorial Institute, Columbus, OH.

#771 DECONTAMINATION OF BACILLUSANTHRACIS SPORES ON INDOOR BUILDINGSURFACES USING HYDROGEN PEROXIDEGAS. Y. W. Choi, W. R. Richter, C. L. Sabourin, M. L.Taylor and J. V. Rogers. Battelle Memorial Institute,Columbus, OH.

#772 A METHOD FOR THE SIMULTANEOUSMEASUREMENT OF SPECIFIC IGGS TO FIVECDC SELECT BIOTERRORISM AGENTS INSERUM. R. E. Biagini1, D. L. Sammons1, J. P. Smith1,B. A. MacKenzie1, C. A. Striley1, S. A. Robertson1, J.E. Snawder1 and C. P. Quinn2. 1CDC/NIOSH,Cincinnati, OH and 2CDC/NCID, Atlanta, GA.

#773 GENERATION, METHODOLOGY ANDANALYSIS OF VX VAPOR. J. S. Anthony1, E. M.Jakubowski1, R. J. Mioduszewski1, S. A. Thomson1, K.L. Matson2, R. A. Evans2, C. L. Crouse2 and J. M.McGuire2. 1Edgewood Chemical Biological Center,Department of the Army, Aberdeen Proving Ground,MD and 2Geo-Centers, Inc., Abingdon, MD.

#774 CORRELATING GENE EXPRESSION PROFILESWITH THERAPEUTIC EFFICACY OFPOTENTIAL VESICANT MEDICALCOUNTERMEASURES. J. F. Dillman1, L. M.Dorsch1, A. I. Hege1, A. J. Sylvester1, C. S. Phillips1, R.C. Kiser2, Y. W. Choi2 and C. L. Sabourin2. 1AppliedPharmacology, USAMRICD, Aberdeen ProvingGround, MD and 2Medical Research and EvaluationFacility, Battelle Memorial Institute, Columbus, OH.

#775 FLUORIDE ION REGENERATION OFCYCLOSARIN (GF) FROM MINIPIG TISSUEAND FLUIDS FOLLOWING WHOLE BODY GFMIOSIS LEVEL VAPOR EXPOSURE. E. M.Jakubowski1, J. M. McGuire2, R. A. Evans2, S. W.Hulet1, D. C. Burnett1, R. A. Way1, B. P. Gaviola1, J. A.Scotto1, W. T. Muse1, D. B. Miller1, R. J.Mioduszewski1 and S. A. Thomson1. 1Toxicology Team,Edgewood Chemical Biological Center, APG-Edgewood, MD and 2Geo-Centers, Inc., Edgewood,MD.

#776 CHOLINESTERASE AND SARIN (GB)REGENERATION PROFILE FOLLOWING LOWLEVEL GB IN GUINEA PIGS: USEFULNESSFOR PBPK MODELING. L. A. Lumley1, C.Whalley2, J. McGuire3, M. O’Malley1, A.D’Ambrozio1, C. Robison1, E. Mason1, C.Krauthauser3, E. Jakubowski2, S. McAvoy1, T.Rowland1, C. Clark1, R. Evans3, D. Miller3, T. Belski3,J. Renner3, J. Scotto2, J. Jarvis2, J. Anthony2, C.Crouse3, J. McDonough1, R. Mioduszewski2, S.Thomson2 and T. Shih1. 1USAMRICD, AberdeenProving Ground, MD, 2ECBC, Aberdeen ProvingGround, MD and 3Geo-Centers, Aberdeen ProvingGround, MD.

#777 PRETREATMENT OF HUMAN EPIDERMALKERATINOCYTES WITH D, L SULFORAPHENEPROTECTS AGAINST SULFUR MUSTARDCYTOTOXICITY. C. L. Gross, E. W. Nealley, M. T.Nipwoda and W. J. Smith. USAMRICD, APG-EA, MD.Sponsor: A. Sciuto.

#778 THE EFFECT OF SULFUR MUSTARDEXPOSURE ON THE PERCENT, SIZE ANDDENSITY OF HUMAN T CELLS (CD3+). H. L.Meier and M. S. Oravitz. Biochemical PharmacologyResearch Institute of Chemical Defense, AberdeenProving Ground, MD. Sponsor: S. Baskin.

#779 EFFECT OF TOPICAL IODINE TREATMENT ONEARLY SULFUR-MUSTARD-INDUCEDCUTANEOUS CHANGES AND EPIDERMAL-CELL PROLIFERATION. S. Trivedi1, U. Wormser2,N. Flagler1, B. Brodsky2, S. Peddada2 and A. Nyska1.1Laboratory of Experimental Pathology, NIEHS,Research Triangle Park, NC and 2School of Pharmacy,Faculty of Medicine, Institute of Life Sciences, TheHebrew University of Jerusalem, Jerusalem, Israel.

#780 THE MATRIX METALLOPROTEINASEINHIBITOR GM 1489 REDUCES MMP-9ACTIVITY AFTER SULFUR MUSTARDEXPOSURE IN VIVO. D. R. Gerecke1, P. Bhatt1, Y.Chang1, C. L. Sabourin2, T. L. Rudge Jr.2, R. C. Kiser2,S. L. Casbohm2, M. K. Gordon1, D. J. Riley3, M. P.Shakarjian3 and R. P. Casillas2. 1Pharmacology &Toxicology, Rutgers University, Piscataway, NJ,2Battelle Memorial Inst., Med. Res. & Eval. Fac.,Columbus, OH and 3Medicine, UMDNJ-Robert WoodJohnson Med. School, Piscataway, NJ.

#781 OBSERVATIONS ON THE INTERACTION OFSULFUR MUSTARD WITH CYTOCHROME P450.A. A. Brimfield1 and E. Hodgson2. 1BiochemicalPharmacology, USAMRICD, Aberdeen ProvingGround, MD and 2Environmental and MolecularToxicology, North Carolina State University, Raleigh,NC.

#782 PUTATIVE ROLE OF PLATELET ACTIVATINGFACTOR (PAF) ANALOGS IN CELL CYCLEABERRATIONS IN HUMAN ENDOTHELIALCELLS IN VITRO. O. E. Clark, E. W. Nealley, K. W.Leiter, K. L. Finke, A. L. Miller and W. J. Smith.Pharmacology, USAMRICD, Aberdeen ProvingGround, MD.

Program Description


TUESD

AY


#783 ORAL DOSING WITH N-ACETYL-L-CYSTEINESIGNIFICANTLY INCREASES GLUTATHIONELEVELS AND GLUTATHIONE-S-TRANSFERASEACTIVITY IN RAT SKIN. E. Wilfong, A. J. Bobb, E.W. Johnson, S. L. Lohrke, R. H. Casavant and D. P.Arfsten. Naval Health Research Center DetachmentEnvironmental Health Effects Laboratory, Wright-Patterson AFB, OH.

#784 TOPICAL IODINE SUPPRESSES SULFUR-MUSTARD-INDUCED TUMOR NECROSISFACTOR-ALPHA INDUCTION IN MOUSE-EARMODEL. U. Wormser1, B. Brodsky1, E. Proscura1, J. F.Foley2, T. Jones2 and A. Nyska2. 1Pharmacology, TheHebrew University, Jerusalem, Israel and 2Laboratory ofExperimental Pathology, NIEHS, Research TrianglePark, NC.

#785 DEVELOPMENT OF INTERSPECIES ANDMULTI-EXPOSURE ROUTE DOSE METRICSFOR SARIN VIA PHYSIOLOGICALLY BASEDPHARMACOKINETIC/PHARMACODYNAMICMODELLING. J. Gearhart1, K. Yu2, P. Robinson1, E.Jakubowski3, R. Mioduszewski3, C. Whalley3, S.Thompson3, T. Shih4, L. Lumley4 and J. McDonough4.1ManTech Environmental Technology, Inc., Wright-Patterson AFB, OH, 2AFRL/HEPB, Wright-PattersonAFB, OH, 3US Army Edgewood Chem Bio Center,Aberdeen Proving Ground, MD and 4US Army MRICD,Aberdeen Proving Ground, MD.

#786 A PBPK REGIONAL MODEL FOR NERVEAGENTS IN THE BRAIN. P. J. Robinson1, J. M.Gearhart1, K. O. Yu1, E. M. Jakubowski2, R. J.Mioduszewski2 and S. A. Thomson2. 1Wright-PattersonAFB, Dayton, OH and 2Edgewood Chemical BiologicalCenter, Aberdeen, MD.

#787 SARIN (GB) REGENERATION ANDCHOLINESTERASE PROFILES FOLLOWINGINHALATION OF GB IN GUINEA PIGS:APPLICATION TO PBPK MODELING. C. E.Whalley1, L. A. Lumley2, E. M. Jakubowski1, J.McGuire3, C. Krauthauser3, D. Miller3, R. Evans3, T.Belski3, J. Renner3, J. Anthony1, C. Crouse3, J. Scotto1,J. Jarvis1, A. Totura3, M. O’Malley2, A. D’Ambrozio2,C. Robison2, E. Mason2, S. McAvoy2, T. Rowland2, C.Clark2, J. H. McDonough2, R. J. Mioduszewski1, T. M.Shih2 and S. A. Thomson1. 1ECBC, Aberdeen ProvingGround, MD, 2USAMRICD, Aberdeen Proving Ground,MD and 3Geo-Centers, Aberdeen Proving Ground, MD.

#788 ESTIMATING LETHAL AND SEVERE TOXICEFFECTS IN MINIPIGS FOLLOWING 10, 60 AND180-MINUTES OF WHOLE-BODY GB VAPOREXPOSURE. S. W. Hulet1, D. R. Sommerville1, P. A.Dabisch2, B. J. Benton1, D. B. Miller2, J. S. Forster1, J.A. Scotto1, R. B. Crosier1, C. L. Krauthauser2, J. R.Jarvis2, J. H. Manthei1, W. T. Muse1, D. C. Burnett1, R.A. Moretz1, B. P. Gaviola1, R. J. Mioduszewski1 and S.A. Thomson1. 1Toxicology, US Army ECBC, AberdeenProving Grounds, MD and 2GEO-Centers, Inc.,Abingdon, MD.

#789 PRETREATMENT WITH CARBOXYESTERASEINHIBITOR CBDP SENSITIZES MICE TOSARIN: POTENTIAL MODEL FOR LOW-DOSEEXPOSURE ASSESSMENT. R. D. Grubbs, W. A.Price, J. B. Lucot and M. Morris. Pharmacology &Toxicology, Wright State University School ofMedicine, Dayton, OH.

#790 GENISTEIN PROTECTS MICE FROMRADIATION-INDUCED WEIGHT LOSS. M. R.Landauer, J. Kramer, C. Pham and V. Srinivasan.AFRRI, Bethesda, MD.

#791 LOW DOSE SARIN PRODUCES LONG LASTINGCHANGES IN CARDIOVASCULAR FUNCTION.V. Farah, S. J. Paton and M. Morris. Pharmacology andToxicology, Wright State University, Dayton, OH.Sponsor: J. McDougal.

#792 EVIDENCE OF CYSTEINE LOADING IN SKINAND OTHER TISSUES IN SPRAGUE-DAWLEYRATS DOSED AT 4-HOUR INTERVALS WITH N-ACETYL-L-CYSTEINE (1, 200 MG/KG). E. W.Johnson, E. R. Wilfong, A. J. Bobb and D. P. Arfsten.NHRC EHE Lab., Wright-Patterson AFB, OH.

#793 LOW-LEVEL INHALATION EXPOSURE TO GB,GF AND VX INDUCES EXPRESSION OFNEURONAL APOPTOSIS AND REGENERATIONGENES IN RAT. J. W. Sekowski1, J. Bucher1, M.Orehek1, M. Horsmon1, J. J. Valdes1, C. Whalley1, B.Benton1, W. Muse1, D. Miller1, J. Scotto1, J. Forster1, J.Manthei1, R. Way1, D. Burnett1, B. Gaviola1, R.Mioduszewski1, S. Thomson1, M. Nau2 and M. Vahey2.1Edgewood Chemical Biological Center, US ArmyRDECOM, APG-EA, MD and 2Walter Reed ArmyInstitute of Research, US Army MRMC, Rockville,MD.

#794 MECHANISM OF THE MIOTIC TOLERANCEOBSERVED FOLLOWING MULTIPLEEXPOSURES TO SARIN VAPOR. P. A. Dabisch2,1,D. B. Miller3, D. C. Burnett1, E. M. Jakubowski1, S. A.Reutter1, R. J. Mioduszewski1 and S. Thomson1.1Operational Toxicology, US Army EdgewoodChemical Biological Center, Aberdeen Proving Ground,MD, 2National Research Council PostdoctoralAssociate, National Academy of Sciences, Washington,DC and 3Geo-Centers, Inc., Aberdeen Proving Ground,MD.

#795 THE URINE CONCENTRATIONS OF 2-AMINO-2-THIAZOLINE-4- CARBOXYLIC ACID AS ABIOMARKER FOR CYANIDE IN SMOKING ANDNON-SMOKING MALE AND FEMALEVOLUNTEERS. B. A. Logue1, S. I. Baskin2, G. A.Rockwood2, N. P. Kirschten2, S. Royster2, M.Keebaugh2 and G. E. Platoff2. 1Drug Assessment,USAMRICD, Aberdeen Proving Ground, MD and2South Dakota State University, Brookings, SD.

#796 INTERACTION OF 2-AMINO-2-THIOZOLINE-4-CARBOXYLIC ACID WITH CYTOCHROME COXIDASE IMMOBILIZED IN AN ELECTRODE-SUPPORTED LIPID BILAYER MEMBRANE. J. B.Kelly2, F. M. Hawkridge2, S. I. Baskin1, G. A.Rockwood1 and G. E. Platoff. 1USAMRICD, AberdeenProving Ground, MD and 2Chemistry, VirginiaCommonwealth University, Richmond, VA.

Program Description



TUES

DAY


POSTER SESSION: SAFETY EVALUATION-BIOTECHNOLOGYPRODUCTS AND VACCINES



#797 VALIDATION OF REAL TIME QUANTITATIVEPCR AND SAMPLE PREPARATIONPROCEDURE IN BIODISTRIBUTION STUDY OFADENOVIRUS VECTORS. B. Tian, S. S. Rentz, G. S.Gregory, R. Tina and J. G. Page. Southern ResearchInstitute, Birmingham, AL.

#798 SINGLE-DOSE TOXICITY STUDY OF ANONCOLYTIC ADENOVIRUS ADMINISTERED BYINTRAVENOUS INFUSION TO CYNOMOLGUSMONKEYS. B. McIntyre1, S. Thibault1, N. Kishnani2,D. Compton1, R. Veneziale1, J. Nelson3, R. Ralston4,2

and R. Morrissey1. 1Schering-Plough Research Institute,Lafayette, NJ, 2Schering-Plough Research Institute,Kenilworth, NJ, 3Charles River Laboratories, SierraDivision, Sparks, NV and 4Canji, San Diego, CA.

#799 FIFTEEN-MONTH REPEATED DOSESUBCUTANEOUS ADMINISTRATION STUDY OFRHFGF-2 IN ATHYMIC NUDE MICE. S. Tsunoda1,T. Nakamura1, T. Sibanushi1, K. Kuzutani1 and M.Takahashi2. 1Safety Research Department, KakenPharmaceutical co., Ltd., Sizuoka, Japan and 2PathologyPeer Review Center, Tokyo, Japan.

#800 PRECLINICAL SAFETY OF RECOMBINANTHUMAN THROMBIN. J. K. Heffernan, R. Ponce, L.A. Zuckerman, J. Visich and M. Rogge. PreclinicalDevelopment, ZymoGenetics, Seattle, WA.

#801 SAFETY ASSESSMENT OF MONOCLONALANTIBODY MAB216 + VINCRISTINE INRABBITS. K. Steinmetz1, D. Fairchild1, N. Teng2, M.Bieber2, K. Schweikart3, J. Tomaszewski3 and J.Mirsalis1. 1SRI International, Menlo Park, CA,2Stanford University, Stanford, CA and 3NationalCancer Institute, Bethesda, MD.

#802 RISING DOSE TOLERABILITY STUDIES OF ACHIMERIC ANTI-PHOSPHATIDYLSERINEMONOCLONAL ANTIBODY (TARVACIN™) INRATS AND CYNOMOLGUS MONKEYS. S.Carpenter1, C. Stewart2, L. Willis2 and P. E. Thorpe3.1Peregrine Pharmaceuticals, Inc., Tustin, CA, 2MPIResearch, Inc., Mattawan, MI and 3The University ofTexas Southwestern, Dallas, TX.

#803 SAFETY EVALUATION OF A CHIMERIC ANTI-PHOSPHATIDYLSERINE MONOCLONALANTIBODY (TARVACIN™) IN MICE USING AFULL-THICKNESS EXCISIONAL DERMALWOUND MODEL. S. Carpenter1, T. Nguyen2 and P.E. Thorpe3. 1Peregrine Pharmaceuticals, Inc., Tustin,CA, 2Explora Biolabs, LLC, La Jolla, CA and 3TheUniversity of Texas Southwestern, Dallas, TX. Sponsor:L. Kamendulis.

#804 REPRODUCTIVE AND DEVELOPMENTALEFFECTS OF AVASTIN™, A MONOCLONALANTIBODY AGAINST VASCULARENDOTHELIAL GROWTH FACTOR. C. L. Zuch1,A. Bricarello2, J. C. Beyer1, P. J. Thomford3, B. J.Christian3 and A. M. Hoberman4. 1Safety Assessment,Genentech, Inc., South San Francisco, CA, 2StudyManagement, Genentech, Inc., South San Francisco,CA, 3Covance Laboratories, Inc., Madison, WI and4Charles River Laboratories, Inc., Argus ResearchDivision, Horsham, PA.

#805 ACUTE TOXICITY STUDIES WITH ATRANSFORMING GROWTH FACTOR-BETAANTAGONIST IN SPRAGUE-DAWLEY RATSAND CYNOMOLGUS MONKEYS. E. R. LaCasse,R. Pawliuk, J. DelCarpini, C. Rogers and L. Andrews.Pharmacology/Toxicology, Genzyme, Framingham,MA.

#806 SAFETY EVALUATION OF A HUMAN FUSIONPROTEIN PRO97796 (BR3-FC). T. R. Gelzleichter1,T. Kamenosono2, D. M. Danilenko1, S. Ren1, A. Song1,S. R. Brignoli1, T. M. Watson1 and Y. Vugmeyster1.1Genentech, South San Francisco, CA and 2SNBL,USA, Seattle, WA.

#807 CJC-1295, A LONG-ACTING GROWTHHORMONE RELEASE FACTOR ANALOGUE, ISWELL TOLERATED IN DOGS UP TO 14 DAYS. V.Iordanova1, S. Wen1, B. Lawrence1, C. N. Papagiannis2,S. Morseth3 and J. Castaigne1. 1ConjuChem, Inc.,Montreal, QC, Canada, 2MPI Research, Inc., Mattawan,MI and 3Morseth Consulting LLC, Jefferson, MD.

#808 RODENT SUBCHRONIC TOXICITY STUDIESWITH THE PEPTIDE ANTIBIOTIC XMP.629. R.Hawks1, S. W. Frantz2, J. T. Secrest2 and K. E. Meyer1.1XOMA LLC, Berkeley, CA and 2MPI Research,Mattawan, MI.

#809 SAFETY AND EFFICACY OF GLYCOSYLATEDUNDENATURED TYPE II COLLAGEN (UC-II) INOBESE-ARTHRITIC DOGS. R. C. Gupta1, L.DeParle1, T. Canerdy1, J. Goad1, M. Bagchi2 and D.Bagchi2. 1Toxicology, Murray State university,Hopkinsville, KY and 2InterHealth Nutraceuticals Inc.,Benicia, CA.

#810 PRECLINICAL SAFETY ASSESSMENT OFRECOMBINANT PLAGUE VACCINE (RF1V)FOLLOWING REPEAT-DOSEADMINISTRATION. R. V. House1, J. Shearer1, S.Manetz2 and S. Morris1. 1DynPort Vaccine CompanyLLC, Frederick, MD and 2Gene Logic Laboratories,Gaithersburg, MD.

#811 PRECLINICAL SAFETY ASSESSMENT OFRECOMBINANT BOTULINUM VACCINE A/B(RBV A/B) FOLLOWING REPEAT-DOSEADMINISTRATION. J. Shearer1, I. Henderson1, S.Manetz2 and R. V. House1. 1DynPort Vaccine CompanyLLC, Frederick, MD and 2Gene Logic Laboratories.Inc., Gaithersburg, MD.

Program Description


TUESD

AY


#812 SPONTANEOUS HEMORRHAGE OF THEPANCREATIC ISLET IN SPRAGUE-DAWLEYRATS. M. Imaoka, T. Suzuki, K. Nozaki, H. Satoh, T.Sugawara and K. Furuhama. Drug Safety ResearchLaboratory, Daiichi Pharmaceutical Co., Ltd., Tokyo,Japan.


POSTER SESSION: SIGNAL TRANSDUCTION: OXIDANT STRESS

Chairperson(s): Dean P. Jones, Emory University SOM, Atlanta, GA.



#813 NRF2 ACTIVATION INVOLVES AN OXIDATIVE-STRESS INDEPENDENT PATHWAY INTETRAFLUOROETHYLCYSTEINE-INDUCEDCYTOTOXICITY. H. Ho1, C. White2, C. Fernandez2,N. Fausto3, T. Kavanagh2, S. Nelson1 and S. Bruschi1.1Medicinal Chemistry, University of Washington,Seattle, WA, 2Environmental and Occupational Health,University of Washington, Seattle, WA and 3Pathology,University of Washington, Seattle, WA.

#814 NRF2-DEPENDENT ARE ACTIVATION IS AGAIN OF FUNCTION ALTERATION SPECIFICTO DIFFERENTIATED AND FUNCTIONALLYACTIVATED ASTROCYTES. J. A. Johnson, J. Li, D.A. Johnson and M. J. Calkins. School of Pharmacy,University of Wisconsin, Madison, WI.

#815 INDUCTION OF NAD(P)H:QUINONEOXIDOREDUCTASE 1 IN MOUSE LIVERDURING EXTRAHEPATIC CHOLESTASIS ISDEPENDENT UPON NRF2 ACTIVATION. A. L.Slitt1, L. M. Aleksunes2, J. M. Maher1, M. Z. Dieter1, N.J. Cherrington3, J. E. Manautou2, J. Y. Chan4 and C. D.Klaassen1. 1Pharmacology, Toxicology, & Therapeutics,University of Kansas Medical Center, Kansas City, KS,2Pharmaceutical Sciences, University of Connecticut,Storrs, CT, 3Pharmacology and Toxicology, Universityof Arizona, Tucson, AZ and 4Pathology, University ofCalifornia Irvine, Irvine, CA.

#816 ALTERATIONS IN GENE EXPRESSION BY 2378-TETRACHLORO-P-DIBENZODIOXIN (TCDD) INLIVERS OF NRF2 KNOCKOUT MICE. M.Matsumoto1, H. Sato2, K. Itoh3, M. Yamamoto3 and Y.Aoki1. 1National Institute for Environmental Studies,Tsukuba, Japan, 2Institute of Medicinal MolecularDesign Inc., Tokyo, Japan and 3University of TsukubaTARA Center, Tsukuba, Japan.

#817 PHOSPHORYLATION OF NRF2 BY CASEINKINASE 2 (CK2) REGULATES ACTIVATION ANDDEGRADATION. J. Pi1,2, Y. Bai2, J. Reece3, J.William4, D. Liu5, M. Freeman6, W. Fahl7, D. Shugar8

and M. Waalkes1. 1Lab. of Comparative Carcinogenesis,NCI at NIEHS, Research Triangle Park, NC, 2Divisionof Biology Sciences, CIIT Centers for Health Research,Research Triangle Park, NC, 3LST, NIEHS, ResearchTriangle Park, NC, 4LSB, NIEHS, Research TrianglePark, NC, 5LRDT, NIEHS, Research Triangle Park, NC,6Vanderbilt University School of Medicine, Nashvile,TN, 7University of Wisconsin, Madison, WI and 8PolishAcademy of Sciences, Warsaw, Poland.

#818 NRF3 NEGATIVELY REGULATES ARE-MEDIATED EXPRESSION AND ANTIOXIDANTINDUCTION OF DETOXIFYING ENZYMEGENES. S. KANNAN and A. K. JAISWAL.Pharmacology, Baylor College of Medicine, Houston,TX. Sponsor: B. Moorthy.

#819 ANTIOXIDANT INDUCED NUCLEAR IMPORTAND EXPORT OF OXIDATIVE STRESS-RESONSE FACTOR NRF2. A. K. Jain and A. K.Jaiswal. Pharmacology, Baylor College of Medicine,Houston, TX. Sponsor: B. Moorthy.

#820 COMPARTMENTAL OXIDATION OFTHIOL/DISULFIDE REDOX COUPLES DURINGEGF SIGNALING. P. J. Halvey1, J. M. Hansen1, W. H.Watson2, Y. Go1 and D. P. Jones1. 1Medicine, EmoryUniversity, Atlanta, GA and 2Environmental HealthSciences, Johns Hopkins University, Baltimore, MD.

#821 UPREGULATION OF MRP3 AND MRP4 BYSULFHYDRYL-MODIFYING COMPOUNDS ISMEDIATED BY THE TRANSCRIPTION FACTORNRF2. J. M. Maher1, M. Z. Dieter1, A. L. Slitt1, J. Y.Chan2 and C. D. Klaassen1. 1University of KansasMedical Center, Kansas City, KS and 2University ofCalifornia Irvine, Irvine, CA.

#822 EPIGENETIC EFFECTS OF OXIDATIVESTRESS. B. Upham1,2 and J. E. Trosko1,2.1Pediatrics/Human Development, Michigan StateUniversity, East Lansing, MI and 2National Food Safety& Toxicology Ctr., Michigan State University, EastLansing, MI.

#823 HISTONE H3.3 MODIFICATIONS DURINGREACTIVE OXYGEN SPECIES INDUCED DNADAMAGE. R. Xie, T. T. Monks and S. S. Lau.Pharmacology and Toxicolocy, University of Arizona,Tucson, AZ.

Program Description



TUES

DAY


POSTER SESSION: CARDIOVASCULAR DISEASE II

Chairperson(s): Paul Boor, University of Texas Medical Branch, Galveston,TX and Bernard Hennig, University of Kentucky, Lexington, KY.



#824 EVALUATION OF PLASMA VON WILLEBRANDFACTOR (VWF) AND VWF PROPEPTIDE INDRUG-INDUCED VASCULAR INJURY. D. Brott1,2,A. Katein1, K. Ershaw1, G. Evans3, H. Jones3, S.Gould3, G. Betton3, J. Valentin3, R. J. Richardson2 andC. Louden1,2. 1Global Safety Assessment, AstraZenecaPharmaceuticals, Wilmington, DE, 2ToxicologyProgram, Environmental Health Science Department,The University of Michigan, Ann Arbor, MI and3Global Safety Assessment, AstraZenecaPharmaceuticals, Alderley, United Kingdom.

#825 MORPHOLOGIC IMAGING OFEXTRACELLULAR MATRIX IN CHEMICAL-INDUCED DEVELOPMENTAL DISSECTINGAORTIC ANEURYSM USING MULTIPHOTONFLORESCENCE AND SECOND HARMONICGENERATION MICROSCOPY BIN GONG, JUSUN, GRACIE VARGAS, PAUL BOOR. B. gong1, J.Sun2, G. Vargas2 and P. boor1. 1pathology, UTMB atGalveston, Galveston, TX and 2biomedical engineeringcenter, UTMB at Galveston, Galveston, TX.

#826 EFFECTS OF GONADAL STEROIDS ONCALCIUM CURRENTS AND ACTIONPOTENTIALS IN GUINEA PIG CARDIACMUSCLES. S. Nagayama, K. Yunomae, S. Ichisaki, J.Matsuo, M. Haruyama, K. Fukuzaki, R. Nagata and G.Kito. Shin Nippon Biomedical Laboratories, Ltd(SNBL), Kagoshima, Japan.

#827 NUCLEOSIDE ANALOG REVERSETRANSCRIPTASE INHIBITOR (NRTI)-INDUCEDρρ– RAT CARDIAC MYOCYTES IN CELLCULTURE. A. Rolo, J. A. Bjork and K. B. Wallace.Biochemistry & Molecular Biology, University ofMinnesota Medical School, Duluth, MN.

#828 EPHENDRINE AND CAFFEINE CAUSESIGNIFICANT MORTALITY IN 14 WEEK OLDBUT NOT IN 7 WEEK OLD FISCHER RATS. P.Hanlon1, R. Howden2, J. Petranka1, S. Kleeberger2, J.Dunnick3, A. Nyska4 and E. Murphy1. 1Laboratory ofSignal Transduction, NIEHS, Research Triangle Park,NC, 2Laboratory of Respiratory Biology, NIEHS,Research Triangle Park, NC, 3Toxicology Branch,NIEHS, Research Triangle Park, NC, 4Laboratory ofEnvironmental Pathology, NIEHS, Research TrianglePark, NC and 5NIEHS, Research Triangle Park, NC.

#829 ACUTE HEMORRHAGIC MYOCARDIALNECROSIS AND SUDDEN DEATH OF RATSEXPOSED TO A COMBINATION OFEPHEDRINE AND CAFFEINE. A. Nyska1, E.Murphy2, J. F. Foley1, B. J. Collins4, J. Petranka2, R.Howden3, P. Hanlon2 and J. K. Dunnick4. 1Laboratoryof Experimental Pathology, NIEHS, Research TrianglePark, NC, 2Laboratory of Signal Transduction, NIEHS,Research Triangle Park, NC, 3Laboratory of RespiratoryBiology, NIEHS, Research Triangle Park, NC and4Environmental Toxicology Program, NIEHS, ResearchTriangle Park, NC.

#830 EFFECTS OF HYPOKALIEMIA ON THE QTINTERVAL IN DOGS. A. Yvon, J. Provost, Y.Rabemampianina and G. Hanton. Pfizer PGRD,Amboise, France. Sponsor: H. Sterz.

#831 DOES AUTONOMIC NERVOUS TONEDIRECTLY AFFECT THE QT INTERVAL? T.Harada, J. Abe, M. Shiotani, Y. Hamada and I. Horii.PGRD Nagoya Lab., Pfizer Inc., Taketoyo, Aichi, Japan.Sponsor: M. Kurata.

#832 SENSITIVITY OF CANINE AND RABBITCARDIAC REPOLARIZATION ASSAYS FORDETECTION OF POTENTIAL QT LIABILITY. J.Kramer. ChanTest, Inc., Cleveland, OH. Sponsor: T.Narahashi.

#833 ACCURATE EVALUATION OF QT INTERVAL INCONSCIOUS CYNOMOLGUS MONKEYS BYUSE OF TELEMETRY ECG. K. Kuwano, T.Jikuzono, S. Otsuka, M. Hijioka, T. Miyake, T. Uchino,M. Shoki, T. Koga, K. Fukuzaki, R. Nagata and G.Kito. Shin Nippon Biomedical Laboratories, Ltd.,(SNBL), Kagoshima, Japan.

#834 NEW SAFETY ASSESSMENT ON LEFTVENTRICULAR VOLUME AND ITS FUNCTIONIN MONKEYS USING THREE-DIMENSIONALECHOCARDIOGRAPHY. T. Yamada1, H. Tsusaki1,H. Yonamine1, A. Tamai1, M. Shimomoto2, G. Kito1

and R. Nagata1. 1Shin Nippon Biomedical Laboratories,Ltd.,, Kagoshima, Japan and 2Philips Medical Systems,Fukuoka, Japan.

#835 HERG LIABILITY: THINKING OUTSIDE THEBLOCK. B. Wible. ChanTest, Inc., Cleveland, OH.Sponsor: T. Narahashi.

#836 VARIABILITY IN THE MEASUREMENT OFHERG POTASSIUM CHANNEL INHIBITION:EFFECTS OF TEMPERATURE AND STIMULUSPATTERN. G. Kirsch. ChanTest, Inc., Cleveland, OH.Sponsor: T. Narahashi.

#837 VALIDATION OF QT EVALUATION INCONSCIOUS GUINEA PIGS WITH ATELEMETRY SYSTEM. M. Shiotani1, T. Harada1, J.Abe1, Y. Hamada1, K. Hashimoto2 and I. Horii1. 1PGRDNagoya Lab., Pfizer Inc., Taketoyo, Aichi, Japan and2Interdisciplinary Graduate School of Medicine andEngineering, University of Yamanashi, Nakakoma,Yamanashi, Japan. Sponsor: M. Kurata.

Program Description


TUESD

AY


#838 ASTEMIZOLE : SPECIES DIFFERENCES IN QTPROLONGATION AND ARRHYTHMOGENESIS.J. Le Bigot, P. Lainee, A. Betat, G. Froget, L. Camusand R. Forster. CIT, Evreux, France.

#839 VALIDATION OF THE ISOLATED RABBITHEART FOR CARDIOVASCULAR SAFETYASSESSMENT. E. Tanhehco, P. Senese and M.Gralinski. CorDynamics, Inc., Chicago, IL.

#840 NON-SURGICAL TELEMETRY TECHNIQUESFOR ELECTROCARDIOGRAM (ECG)DETERMINATION IN DOGS AND MONKEYSDURING TOXICOLOGY STUDIES. P. Shaver-Walker, M. Vezina, N. Leblond and C. Copeman. IPN,CTBR Bio-Research Inc., Senneville, QC, Canada.

#841 GENERATION OF BACKGROUNDELECTROCARDIOGRAM (ECG) TELEMETRYDATA IN DOGS USING A POSITIVE CONTROLSUBSTANCE (DL-SOTALOL) FOR QTPROLONGATION. M. Vezina, N. Leblond, K.Tenneson and C. Copeman. IPN, CTBR Bio-ResearchInc., Senneville, QC, Canada.

#842 THE ROLE OF CALPAIN-CALPASTATINSYSTEM IN 2-BUTOXYETHANOL-INDUCEDHEMOLYSIS. P. S. Palkar, V. S. Bhave, B. K. Philip,P. B. Limaye and H. M. Mehendale. Department ofToxicology, University of Louisiana at Monroe,Monroe, LA.

#843 ADHESION-MOLECULE CHANGES IN 2-BUTOXYETHANOL (BE) FISCHER F344 RATMODEL FOR THROMBOTIC SEQUELAE OFHEMOLYTIC ANEMIAS. T. L. Ortel2, A. Potti2, D.Lewis2, J. Wu2 and A. Nyska1. 1Laboratory ofExperimental Pathology, NIEHS, Research TrianglePark, NC and 2Division of Hematology, DukeUniversity Medical Center, Durham, NC.

#844 2-BUTOXYETHANOL FEMALE RAT MODEL OFHEMOLYSIS AND DISSEMINATEDTHROMBOSIS: X-RAY CHARACTERIZATIONOF OSTEONECROSIS AND GROWTH PLATESUPPRESSION. D. N. Lewis1, K. Johnson1, D.Malarkey1, S. Ward1, M. Streicker3, S. Shabat4, S.Peddada2, M. Nyska4 and A. Nyska1. 1Laboratory ofExperimental Pathology, NIEHS, Research TrianglePark, NC, 2Biostatistics Branch, NIEHS, ResearchTriangle Park, NC, 3Integrated Laboratory Systems(ILS), Research Triangle Park, NC and 4Department ofOrthopaedic Surgery, Sapir Medical Center, Kfar-Saba,44281, Israel.

#845 2, 3, 7, 8-TETRACHLORODIBENZO-P-DIOXINALTERS FETAL MURINE CARDIAC GROWTHAND GENE EXPRESSION, AND LEADS TOCARDIAC HYPERTROPHY AND ALTEREDCARDIAC FUNCTION AFTER BIRTH. E. A.Thackaberry, B. A. Nunez, I. D. Ivnitski-Steele and M.K. Walker. College of Pharmacy, U of New Mexico,Albuquerque, NM.

#846 SUB-CHRONIC, LOW LEVEL 2, 3, 7, 8-TETRACHLORODIBENZO-P-DIOXIN (TCDD)EXPOSURE INCREASES BLOOD PRESSURE INADULT MICE AS MEASURED BY TELEMETRY.P. G. Kopf, A. K. Lund and M. K. Walker. College ofPharmacy, University of New Mexico, Albuquerque,NM.


POSTER SESSION: PBPK MODELS

Chairperson(s): Jeffery Fisher, Univeristy of Georgia, Athens, GA and ElainaKenyon, U.S. EPA, Research Triangle Park, NC.



#847 A HARMONIZED PBPK MODEL FORTRICHLOROETHYLENE RISK ASSESSMENT. T.R. Covington1, H. J. Clewell1, J. W. Fisher2, D. A.Keys2, C. Hack3 and J. Q. Zhao3. 1ENVIRON HealthSciences Institute, Ruston, LA, 2University of Georgia,Athens, GA and 3Toxicology Excellence for RiskAssessment, Cincinnati, OH.

#848 PHYSIOLOGICAL MODELING OF THEDERMAL ABSORPTION OFOCTAMETHYLCYCLOTETRASILOXANE (D4)AND DECAMETHYLCYCLOPENTASILOXANE(D5). M. B. Reddy1, K. P. Plotzke2, J. R. Looney3, M. J.Utell3, M. L. Jovanovic2, J. M. McMahon2, D. A.McNett2 and M. E. Andersen4. 1Colorado StateUniversity, Fort Collins, CO, 2Dow CorningCorporation, Midland, MI, 3University of Rochester,Rochester, NY and 4CIIT, Research Triangle Park, NC.

#849 ALTERATION OF HEXACHLOROBENZENEDISPOSITION BY PCB126 COEXPOSURE ANDAPPLICATION OF PBPK MODELING IN AMEDIUM-TERM LIVER FOCI BIOASSAY. Y. LU,M. Lohitnavy, O. Lohitnavy, E. Perrigo and R. Yang.Environmental and Radiological Health Sciences,Colorado State University, Fort Collins, CO.

#850 PREDICTIVE PHYSIOLOGICALLY BASEDPHARMACOKINETIC (PBPK) MODELING OFPYRETHROID PESTICIDES. S. J. Godin1, R.Tornero-Velez2, E. J. Scollon3, M. F. Hughes3 and M. J.Devito3. 1Curriculum in Toxicology, University of NorthCarolina, Chapel Hill, NC, 2NERL, U.S. EPA, ORD,Research Triangle Park, NC and 3NHEERL, U.S. EPA,ORD, Research Triangle Park, NC.

#851 ROUTE-TO-ROUTE EXTRAPOLATION OFMETABOLIC INTERACTIONS IN MIXTURESOF ALKYLBENZENES USING A PBPK MODEL.R. Tardif, A. Nong and K. Krishnan. Occupational andEnvironmental Health, Universite de Montreal,Montreal, QC, Canada.

#852 A PBPK MODEL FOR A MIXTURE OF DIOXIN-LIKE CHEMICALS. M. Easterling1, N. J. Walker2, F.M. Parham2 and C. J. Portier2. 1Constella Group,Durham, NC and 2NIEHS, Durham, NC.

Program Description



TUES

DAY

#853 A HUMAN PBTK MODEL DESCRIBINGACETONE KINETICS IN BREATH AND BLOODAT DIFFERENT WORKLOADS. A. Mork and G.Johanson. Work Environment Toxicology, KarolinskaInstitute, Stockholm, Sweden.

#854 EVALUATION OF ORAL AND INTRAVENOUSROUTE PHARMACOKINETICS, PLASMAPROTEIN BINDING AND UTERINE TISSUEDOSE METRICS OF BISPHENOL A: APHYSIOLOGICALLY BASEDPHARMACOKINETIC APPROACH. J. G.Teeguarden1, J. M. Waechter3, H. J. Clewell2, T. R.Covington2 and H. A. Barton4. 1Biological Monitoringand Modeling, Pacific Northwest National Laboratory,Richland, WA, 2ENVIRON International, Ruston, LA,3The Dow Chemical Company, Midland, MI and4NHEERL, U.S. EPA, Research Triangle Park, NC.

#855 LACK OF BIOACCUMULATION WITHREPEATED, PERIODIC EXPOSURES OFCYCLIC SILOXANES. M. E. Andersen1, M. B.Reddy2 and K. P. Plotzke3. 1CIIT, Research TrianglePark, NC, 2Colorado State University, Fort Collins, COand 3Dow Corning Corporation, Midland, MI.

#856 IMPACT OF MODEL MISSPECIFICATION ON APHYSIOLOGICALLY-BASEDPHARMACOKINETIC MODEL FOR DMA. C. R.Eklund, M. V. Evans and E. M. Kenyon.ORD/NHEERL/ETD, U. S. EPA, Research TrianglePark, NC.

#857 HUMAN PBPK MODELING OF CLINICAL CASEREPORTS OF ETHYLENE GLYCOLOVERDOSING: INCORPORATION OFTHERAPEUTIC INTERVENTIONS. R. A. Corley1

and K. E. McMartin2. 1Battelle Northwest, Richland,WA and 2Louisiana State University Health SciencesCenter, Shreveport, LA.

#858 DEVELOPMENT OF A PHYSIOLOGICALLYBASED PHARMACOKINETIC (PBPK) MODELTO COMPARE DIFFERENCES IN DISPOSITIONOF TRICHLOROETHYLENE(TCE), ANDMETABOLITES IN ADULT VERSUS ELDERLYRATS. M. V. Evans1, R. Tornero-Velez2, M. J. DeVito2,M. Okino3, A. Geller2, J. Blancato2 and L. Birnbaum2.1U.S. EPA/NHEERL, Research Triangle Park, NC,2U.S. EPA/NERL, Research Triangle Park, NC and3U.S. EPA/NERL, LV, NV.

#859 A PBPK MODEL TO EVALUATE VARIABILITYIN RENAL CLEARANCE. R. S. DeWoskin1 and C.M. Thompson2. 1ORD/NCEA, U.S. EPA, ResearchTriangle Park, NC and 2Risk Policy Fellow / NCEA,AAAS, Washington, DC.

#860 DEVELOPMENT OF A PHYSIOLOGICALLYBASED PHARMACOKINETIC MODEL FORSCH-D IN THE RAT. G. Pastino1, C. Rosenfeld1,2, C.Cox1, I. Knemeyer1, K. Fellows1 and L. Sultatos2.1Schering Plough research Institute, Lafayette, NJ and2University of Medicine and Dentistry of New Jersey,Newark, NJ.

#861 PHYSIOLOGICALLY-BASEDPHARMACOKINETIC MODEL FOR ALL-TRANSRETINOIC ACID IN PREGNANT CD-1 MICE. J.L. Campbell1, D. Warren2, M. Smith1 and J. W. Fisher1.1Environmental Health Science, University of Georgia,Athens, GA and 2Program in Environmental Science,University of South Carolina-Beaufort, Beaufort, SC.

#862 PREDICTION OF DI-N-BUTYLPHTHALATE(DBP) LEVELS IN PREGNANT RATS USING APHYSIOLOGICALLY BASEDPHARMACOKINETIC (PBPK) MODEL. J. J.Kremer, R. A. Clewell and S. J. Borghoff. CIIT Centersfor Health Research, Research Triangle Park, NC.

#863 PULMONARY FUNCTION IN RATS DURINGPREGNANCY. T. Leavens, C. Parkinson, A. James, D.House and D. Dorman. CIIT Centers for HealthResearch, Research Triangle Park, NC.

#864 A PHYSIOLOGICALLY BASEDPHARMACOKINETIC (PBPK) MODEL FOR THEPESTICIDE MONOMETHYLARSONIC ACID(MMAV). E. M. Kenyon, M. F. Hughes, C. Eklund andM. V. Evans. U.S. EPA, Research Triangle Park, NC.

#865 DEVELOPMENT OF A HYBRID REACTIONNETWORK-PHYSIOLOGICALLY BASEDPHARMACOKINETIC MODEL OFBENZO(A)PYRENE AND ITS METABOLITES. K.F. Reardon1,2, K. H. Liao1,2 and R. S. Yang1.1Quantitative and Computational Toxicology Group,Center for Environmental Toxicology and Technology,Colorado State University, Fort Collins, CO and2Department of Chemical Engineering, Colorado StateUniversity, Fort Collins, CO.

#866 VALIDATION OF A HUMANPHYSIOLOGICALLY-BASEDPHARMACOKINETIC MODEL FOR VINYLACETATE AGAINST HUMAN NASALDOSIMETRY DATA. P. M. Hinderliter1, K. D.Thrall2, R. A. Corley2, L. J. Bloemen3 and B. S.Matthew1. 1Haskell Laboratory for Health andEnvironmental Sciences, Newark, DE, 2BiologicalSciences Division, Battelle Pacific NorthwestLaboratories, Richland, WA and 3Epidemiology, HealthServices, Dow Benelux NV, Terneuzen, Netherlands.

#867 DEVELOPMENT AND EVALUATION OF A PBPKMODEL FOR THE FATE OF 2-BUTOXYETHANOL IN HUMANS AFTERDERMAL AND INHALATION EXPOSURE. S.kezic, J. Kruse and I. Jakasa. Coronel Institute,Academic Medical Centre, Amsterdam, Netherlands.Sponsor: P. Boogaard.

#868 PHYSIOLOGICAL MODELING OF THETOXICOKINETICS OF METHYL TERT-BUTYLETHER (MTBE) AND ITS METABOLITE TERT-BUTANOL (TBA) IN HUMANS. K. Krishnan1,3, A.Nihlen2, L. Ernstgard3 and G. Johanson3. 1Universite deMontreal, Montreal, QC, Canada, 2Active BiotechResearch AB, Lund, Sweden and 3Work EnvironmentToxicology, Karolinska Institute, Stockholm, Sweden.

Program Description


TUESD

AY


#869 A HUMAN DIETARY IODIDE PBPK MODEL TOEVALUATE THE EFFECTS OF PERCHLORATEON THYROIDAL IODIDE CONTENT. J. W.Fisher1, J. L. Campbell1 and D. Guth2. 1EnvironmentalHealth Science, University of Georgia, Athens GA, GAand 2The Boeing Company, Seattle, WA.

#870 USE OF A PHYSIOLOGICALLY-BASEDPHARMACOKINETIC MODEL TO ESTIMATEABSORBED CARBARYL DOSE IN CHILDRENAFTER TURF APPLICATION. M. Okino1, F. W.Power1, J. B. Knaak4, R. Tornero-Velez2, C. Lunchick5,A. Lowit3, J. N. Blancato2 and C. C. Dary1.1NERL\EDRB, U.S. EPA, Las Vegas, NV, 2NERL, U.S.EPA, Research Triangle Park, NC, 3Office of PesticidePrograms, U.S. EPA, Washington, DC, 4Pharmacologyand Toxicology, SUNY, Buffalo, Buffalo, NY and5Bayer CropScience, Research Triangle Park, NC.

#871 ASSESSING THE RISKS ASSOCIATED WITHCHILDREN INGESTING LEAD IN SCHOOLDRINKING WATER: PBPK MODELING ANDRISK COMMUNICATION. M. K. Peterson, R. C.Pleus and S. M. Hays. Intertox, Inc., Seattle, WA.


POSTER SESSION: IMMUNOMODULATION

Chairperson(s): Deborah Keil, NIOSH, Morgantown, WV and GhulamAnsari, UTMB, Pathology, Galveston, TX.



#872 ENFUVIRTIDE DOES NOT IMPAIR HOSTRESISTANCE TO INFECTIONS IN RATS. T. D.Steele1, W. Geng1, F. Burleson2 and G. Burleson2.1Nonclinical Drug Safety, Hoffmann-LaRoche, Inc.,Nutley, NJ and 2Burleson Research Technologies,Raleigh, NC.

#873 EFFECTS OF METHYLPREDNISOLONE ONCELL PHENOTYPES IN A MURINE CANDIDAHOST DEFENSE MODEL. C. Maier, C. Genell, A.Hillegas and D. J. Herzyk. Safety Assessment,GlaxoSmithKline, King of Prussia, PA.

#874 AH RECEPTOR ACTIVATION ELEVATESINTERFERON GAMMA (IFNγγ) AND INDUCIBLENITRIC OXIDE SYNTHASE (INOS) LEVELS INTHE LUNGS OF MICE INFECTED WITHINFLUENZA A VIRUS. H. Neff-LaFord1 and B.Lawrence2. 1Pharmacology/Toxicology GraduateProgram, Washington State University, Pullman, WAand 2Pharmaceutical Sciences, Washington StateUniversity, Pullman, WA.

#875 INCREASED NUMBERS OF NEUTROPHILS INTCDD-TREATED MICE INFECTED WITHINFLUENZA A VIRUS ARE CAUSED BY AN AHRECEPTOR-MEDIATED MECHANISM THAT ISLIKELY SPECIFIC TO THE LUNG. S. Teske1, A. A.Bohn2 and B. Lawrence1,2. 1Pharmacology/ToxicologyGraduate Program, Washington State University,Pullman, WA and 2Department of Veterinary ClinicalSciences, Washington State University, Pullman, WA.

#876 ∆∆9-TETRAHYDROCANNABINOL ALTERS HOSTRESISTANCE TO INFLUENZA A/PR/8INFECTION IN C57BL/6 MICE. J. P. Buchweitz1,3,N. E. Kaminski1,3 and J. R. Harkema2. 1Pharmacologyand Toxicology, Michigan State University, EastLansing, MI, 2Pathobiology and DiagnosticInvestigation, Michigan State University, East Lansing,MI and 3Center for Integrative Toxicology, MichiganState University, East Lansing, MI.

#877 EXPOSURE TO THC, A MARIJUANACANNABINOID, INDUCES ALTERATIONS INTH1/TH2 CYTOKINE PROFILE RESULTING INSUPPRESSION OF IMMUNITY AND INCREASEDSUSCEPTIBILITY TO BREAST CANCER. R.McKallip1, P. S. Nagarkatti2 and M. Nagarkatti1.1Department Micro/Immunol, VCU/MCV, Richmond,VA and 2Pharmacology and Toxicology, VCU/MCV,Richmond, VA.

#878 IMMUNE FUNCTIONAL ANDHISTOPATHOLOGICAL ALTERATIONSFOLLOWING EXPOSURE IN FEMALE B6C3F1MICE TO THE WIDELY USED VEHICLEELMIRON® K. L. White Jr.1, A. Nyska2, R. D.Brown1, D. L. Musgrove1, T. L. Guo1 and D. R.Germolec2. 1Virginia Commonwealth University,Richmond, VA and 2NIEHS, Research Triangle Park,NC.

#879 INTERACTIONS OF MERCURY WITH LIVER-STAGE RESPONSES TO MALARIA INFECTION.J. F. Nyland1, A. Lima1, G. Mouton2, K. West3, F.Zavala1 and E. Silbergeld1. 1EHS & MMI, JohnsHopkins, Baltimore, MD, 2Grambling State, Grambling,LA and 3University Hosp of West Indies, Kingston,Jamaica.

#880 THE EFFECTS OF CIGARETTE SMOKEEXPOSURE AND PREGNANCY ON INNATE ANDADAPTIVE IMMUNE RESPONSES IN B6C3F1MICE. E. M. Vancza, S. P. Ng and J. T. Zelikoff. NewYork University School of Medicine, Tuxedo, NY.

#881 SMOKING DURING PREGNANCY REDUCESIMMUNE TUMOR SURVEILLANCEMECHANISMS IN THE OFFSPRING: ATOXICOLOGICAL MODEL. S. P. Ng1, A. E.Silverstone2, Z. Lai2 and J. T. Zelikoff1. 1Nelson Instituteof Environmental Medicine, New York UniversitySchool of Medicine, Tuxedo, NY and 2Department ofMicrobiology & Immunology, SUNY Upstate MedicalUniversity, Syracuse, NY.

Program Description



TUES

DAY

#882 GESTATIONAL EXPOSURE TO PFOSSUPPRESSES IMMUNOLOGICAL FUNCTION INF1 MICE. D. E. Keil1, T. Mehlman1, L. Butterworth1

and M. M. Peden-Adams2. 1Analytical Sciences Branch,NIOSH, Morgantown, WV and 2Department ofPediatrics, Medical University of South Carolina,Charleston, SC.

#883 CHANGES IN THE OVINE HYPOTHALAMIC-PITUITARY-ADRENAL AXIS DURINGPREGNANCY AND LACTATION FOLLOWINGCHALLENGE WITH ESCHERICHIA COLILIPOPOLYSACCHARIDE. L. C. Kabaroff1, N.Karrow1 and H. Boermans2. 1Animal and PoultryScience, University of Guelph, Guelph, ON, Canadaand 2Toxicology, University of Guelph, Guelph, ON,Canada.

#884 TETRACHLORODIBENZO-P-DIOXIN (TCDD)INHIBITS DIFFERENTIATION AND INCREASESAPOPTOTIC CELL DEATH OF PRECURSOR TCELLS IN THE FETAL MOUSE THYMUS. E.Besteman, K. Zimmerman, B. Smith and S. Holladay.Virginia Tech, Blacksburg, VA.

#885 POST-NATAL EXPOSURE OF THE RAT TOCYCLOSPORINE DOES NOT RESULT INPROLONGED IMPAIRMENT OF THE IMMUNESYSTEM. J. Descotes1, G. Ravel2, F. Horand2 and P.C. Barrow2. 1Poison Center, Lyon, France and 2MDSPharmacology Services, Saint Germain s/ L’Arbresle,France.

#886 EFFECT OF TRIBUTYLTIN CHLORIDE ONNATURAL IMMUNODEFENCES IN THE F1GENERATION IN MICE. Y. Sugita-Konishi1, K.Kimura2, K. Kobayashi1, M. Tsunoda3 and Y. Suzuki2.1Division of Microbiology, National Institute of HealthSciences, Tokyo, Japan, 2Department of VeterinarySciences, Azabu University, Sagamihara, Japan and3Department of Preventive Medicine and Public Health,Kitazato University, School of Medicine, Sagamihara,Japan.

#887 ALTERED SPLENOCYTE FUNCTIONS INFOURTEEN-MONTH OLD MICE PRENATALLYEXPOSED TO DIETHYLSTILBESTROL. R. M.Gogal1,2, J. Fenaux1, D. Lindsay1, C. Hardy1, D. Ward1,G. Saunders1 and S. Ahmed1. 1Biomedical Sciences andPathobiology, Va Tech, Blacksburg, VA and 2BiomecicalSciences, Via Virginia Colleg of Osteopathic medicine,Blacksburg, VA.

#888 T-CELL MEDIATED IMMUNITY IN ADULTSPRAGUE-DAWLEY RATS IMPLANTED WITHDEPLETED URANIUM. L. B. Healey1, J. M.Rutkiewicz1, S. R. Lohrke2, D. P. Arfsten2 and K. A.Grasman1. 1Wright State University, Dayton, OH and2Naval Health Research Center Environmental HealthEffects Laboratory, Wright-Patterson AFB, OH.

#889 IMMUNE FUNCTION IN ADULT RATSEXPOSED TO DBT IN DRINKING WATER. J.DeWitt1, C. Copeland2 and R. Luebke2. 1Curriculum inToxicology, UNC, Chapel Hill, NC and2NHEERL/ETD/ITB, U.S. EPA, Research TrianglePark, NC.

#890 IN VIVO AND IN VITRO IMMUNOSUPPRESSIVEEFFECTS OF 1, 2:5, 6-DIBENZANTHRACENE INFEMALE BALB/C MICE. C. Jin1, T. Jeon1, S. Lee1,S. Hyun1, D. Lee1, G. Kim1, I. Jun1, E. Lee1, H. Jeong2

and T. Jeong1. 1College of Pharmacy, YeungnamUniversity, Kyungsan, South Korea and 2College ofPharmacy, Chosun University, Gwangju, South Korea.

#891 EVALUATION OF THE IMMUNOMODULATORYEFFECTS OF DIBENZ(A, H)ANTHRACENE INADULT FEMALE B6C3F1MICE. D. M. Hernandez,W. Auttachoat, T. L. Guo and K. L. White Jr.. VirginiaCommonwealth University, Richmond, VA.

#892 CYTOCHROME P450 1B1 (CYP1B1) ISREQUIRED FOR 7, 12-DIMETHYLBENZ(A)-ANTHRACENE (DMBA) INDUCED SPLEENCELL IMMUNOTOXICITY IN C57BL/6N MICE.J. Gao, S. W. Burchiel, F. T. Lauer and S. Dunaway.College of Pharmacy Toxicology Program, TheUniversity of New Mexico, Albuquerque, NM.

#893 NONCOPLANAR PCB-INDUCEDIMMUNOTOXICITY IN A FISH MODEL IS NOTAHR-MEDIATED. J. T. Zelikoff and J. Duffy.Department of Environmental Medicine, New YorkUniversity School of Medicine, Tuxedo, NY.

#894 METALLOTHIONEIN INFLUENCES ONIMMUNE CAPACITY IN METAL-STRESSEDSYSTEMS. K. Zaffuto, D. Unfricht, E. Canpolat, G.Jin, N. Hadjout, X. Yin and M. A. Lynes. Molecular andCell Biology, University of Connecticut, Storrs, CT, CT.

#895 THE PARADOXICAL EFFECTS OF LEAD INIFNγγKNOCKOUT (KO) BALB/C MICE. D. Gao, J.Kasten-Jolly and D. A. Lawrence. Wadsworth Center,Albany, NY.

#896 ROLE OF COPPER CHELATION, ALTERATIONOF RED-OX BALANCE, AND STRESSMEDIATORS IN MODULATION OF CYTOKINERESPONSES BY SODIUMMETHYLDITHIOCARBAMATE. S. B. Pruett, C. L.Schwab, Q. Zheng and R. Fan. Cell. Biol. & Anatomy,LSU Health Sciences Center, Shreveport, LA.

#897 SODIUM METHYLDITHIOCARBAMATESUPPRESSES INNATE IMMUNITY: ROLE OFTLR SIGNALING AND CYTOKINEPRODUCTION. C. L. Schwab, Q. Zheng, R. Fan andS. B. Pruett. Cell. Biol. & Anatomy, LSU HealthSciences Center, Shreveport, LA.

#898 IDENTIFICATION OF BIOMARKERS FORDRUG-INDUCED STRESS: COMPARISON OFMOUSE AND RAT MODELS. P. Hebert1, S. B.Pruett1, J. M. LaPointe2 and T. T. Kawabata2. 1Cell.Biol. & Anatomy, LSU Health Sciences Center,Shreveport, LA and 2Safety Sciences, Pfizer, Inc.,Groton, CT.

#899 ROLE OF CORTICOSTERONE IN STRESS-MEDIATED SUPPRESSION OF TUMORRESISTANCE. J. Adams, S. B. Pruett and P. Hebert.Cell. Biol. & Anatomy, LSU Health Sciences Center,Shreveport, LA.

Program Description


TUESD

AY


#900 INVESTIGATION OF HABITUATION ORTOLERANCE IN THE STRESS RESPONSE ANDIMMUNOMODULATORY ACTIONS OFETHANOL. Q. Zheng, C. L. Schwab, R. Fan and S. B.Pruett. Cell. Biol. & Anatomy, LSU Health SciencesCenter, Shreveport, LA.

#901 ACUTE AND CHRONIC EFFECTS OF ETHANOLON MACROPHAGES. Q. Dai and S. B. Pruett. Cell.Biol. & Anatomy, LSU Health Sciences Center,Shreveport, LA.

#902 EVALUATION OF FLOW CTYOMETRICENDPOINTS FOR THE LYMPH NODEPROLIFERATION ASSAY (LNPA). J. L. Weaver andD. Broud. DAPR, U.S. FDA, Silver Spring, MD.

#903 ASSESSMENT OF EARLY IMMUNOLOGICALPARAMETERS IN THE POPLITEAL LYMPHNODE ASSAY TO DETECTIMMUNOMODULATING DRUGS. R. Pieters1, M.Aalbers1, R. Bleumink1, L. Boon2 and S. Nierkens1.1Immunotoxicology, Institute for Risk AssessmentSciences, Utrecht, Netherlands and 2Bioceros BV,Utrecht, Netherlands.

#904 INVESTIGATING THE MECHANISM OFNEVIRAPINE-INDUCED SKIN LESIONS IN THEFEMALE BROWN NORWAY RAT. M. Popovic, J.M. Shenton and J. P. Uetrecht. PharmaceuticalSciences, University of Toronto, Toronto, ON, Canada.

#905 ASSOCIATION OF ACETAMINOPHEN-INDUCEDHEPATOTOXICITY WITHIMMUNOSUPPRESSION. M. Masson1, R. Peterson2,M. L. Graf1, C. Chung1, D. Krull2, J. Sciarrotta2, C. W.Quall2, J. L. Ambroso2, R. Lightfoot2, M. Bourdi1 andL. R. Pohl1. 1Molecular and Cellular ToxicologySection, LMI, NHLBI, NIH, Bethesda, MD and 2SafetyAssessment, GlaxoSmithKline, Research Triangle Park,NC.

#906 ANTIBODIES AGAINST CYP2E1 AFTEREXPOSURE TO 1, 1, 1-TRIFLUOROETHANEAND 1, 1, 1, 2-TETRAFLUOROETHANE. S.Gunnare1, M. Vidali2, E. Albano2 and G. Johanson1.1Work Environment Toxicology, Karolinska Institutet,Stockholm, Sweden and 2Department of MedicalSciences, University of Piedmont, Novara, Italy.

#907 POTENTIAL AUTOIMMUNITY OFRECOMBINANT MOUSE IL-2 AS A CANCERTHERAPEUTIC AGENT IN TUMOR-BEARINGBALB/C MICE. H. Kim, Y. Cho, J. H. Eom, J. Gil, J.Lee and K. Park. Toxicology, National Institute forToxicological Research, Seoul, South Korea. Sponsor:Y. Heo.

#908 SILICA FAILS TO INDUCE FIBROSIS INSCAVENGER RECEPTOR DEFICIENT MICE. C.A. Beamer and A. Holian. Center for EnvironmentalHealth Sciences, University of Montana, Missoula, MT.

#909 COMPARISON OF CHLORDECONE ANDESTROGEN EFFECTS ON PHENOTYPICMARKERS ON IMMUNOCYTES. F. Wang1,2, S. M.Roberts1,3 and E. S. Sobel2. 1Depts of Pharmacologyand Therapeutics, University of Florida, Gainesville,FL, 2College of Medicine, University of Florida,Gainesville, FL and 3Physiological Sciences, Universityof Florida, Gainesville, FL.

#910 ADAPTATION OF THE SYSTEMIC LUPUSERYTHREMATOSUS PRONE (NZB X NZW)F1MOUSE STRAIN FOR AUTOIMMUNETOXICOLOGY EVALUATION. S. P. Keegan, K. L.Nadwodny, B. A. Speal, D. J. Herzyk and J. M. Soos.Safety Assessment, GlaxoSmithKline, King of Prussia,PA.

#911 ASBESTOS-INDUCED AUTOIMMUNITY INC57BL/6 MICE. J. C. Pfau, J. Sentissi, R. Thompsonand C. MacKenzie. Ctr for Environ HealthSciences/Biomed Pharmacology Sciences, University ofMontana, Missoula, MT.

#912 IMMUNOTOXICITY OF DICHLOROACETYLCHLORIDE AND DICHLOROACETICANHYDRIDE IN FEMALE MRL +/+ MICE. G.Ansari, P. Cai, M. F. Khan and B. S. Kaphalia.pathology, UTMB, Galveston, TX.

#913 IMMUNOTOXICITY OF OLEIC ACID ANILIDEAND ITS HYDROLYSIS PRODUCTS IN FEMALEMRL +/+ MICE. P. Cai, M. F. Khan, B. S. Kaphaliaand G. S. Ansari. Pathology, UTMB, Galveston, TX.


POSTER SESSION: RESPIRATORY TRACT II

Chairperson(s): Joel Pounds, Batelle NW, Richland, WA and MatthewCampen, Lovelace, Albuquerque, NM.



#914 A RESPIRATORY SAFETY PHARMACOLOGYASSESSMENT OF HYDROCODONEBITARTRATE AND NALTREXONEHYDROCHLORIDE. K. Hew1, S. Mason2 and H.Penton2. 1Safety Assessment, Purdue PharmacologyL.P., Ardsley, NY and 2Safety Pharmacology, CTBRBio-Research Inc., Senneville, NY.

#915 PARTICLE OVERLOAD IN RAT LUNGFOLLOWING INHALATION TO A POORLYSOLUBLE COMPOUND. S. Holt1, M. Pino1, N.Barlow1, E. Orton2 and T. M. Monticello1. 1Drug Safety& Evaluation, sanofi-aventis, Bridgewater, NJ and2GPD/Pharmaceutical Sciences, sanofi-aventis,Bridgewater, NJ.

Program Description



TUES

DAY

#916 ALTERED SUSCEPTIBILITY TO 1-NITRONAPHTHALENE OF RAT NASALMUCOSA AFTER CHRONIC OZONEEXPOSURE. M. G. Lee1, A. M. Wheelock2, M. V.Fanucchi1, A. R. Buckpitt2 and C. G. Plopper1.1VM:APC, UC Davis, Davis, CA and 2VM:MB, UCDavis, Davis, CA.

#917 QUANTITATION OF AIRWAY SPECIFIC GENEEXPRESSION OF ENDOTHELIN-1 AND IT’SRECEPTORS DURING NAPHTHALENE INJURYAND REPAIR IN THE ADULT MOUSE LUNG. G.L. Baker, K. L. Sutherland, C. D. Brown, C. G. Plopperand L. S. Van Winkle. VM: APC, UC Davis, Davis, CA.

#918 PROTEOMIC CHARACTERIZATION OFBRONCHOALVEOLAR LAVAGE FLUID (BALF),LUNG, AND SERUM IN A MOUSE EMPHYSEMAMODEL INDUCED BY ELASTASE. J. N. Adkins1,R. C. Barry1, M. E. Monroe1, R. D. Smith1, K. Lee2 andJ. G. Pounds1. 1Battelle, Pacific Northwest NationalLaboratory, Richland, WA and 2Battelle, ToxicologyNorthwest Division, Richland, WA.

#919 CHARACTERIZATION OF ELASTASE-INDUCEDEMPHYSEMA IN MOUSE LUNG PERHISTOPATHOLOGY, MORPHOMETRY, ANDBRONCHOALVEOLAR LAVAGE (BAL)MEASUREMENTS. K. M. Lee1, Q. Meng1, R. A.Renne1, K. M. Gideon1, S. J. Harbo1, J. T. Pierce1, L. A.Wisse1 and J. G. Pounds2. 1Battelle Toxicology NW,Richland, WA and 2Pacific Northwest NationalLaboratories, Richland, WA.

#920 THE USE OF LUNG MECHANICS FOR THEPHENOTYPING OF LUNG RESPONSES TOCIGARETTE SMOKE EXPOSURE IN MICE. M.G. Cosio2 and T. F. Schuessler1. 1SCIREQ Inc.,Montreal, QC, Canada and 2Meakins-Christie Labs,McGill University, Montreal, QC, Canada. Sponsor: N.Sponsor.

#921 EVALUATION OF RELATIVE CONTRIBUTIONSOF VAPOR PHASE AND PARTICULAR MATTERTO THE TOTAL CYTOTOXICITY OFCIGARETTE SMOKE. R. Meng, M. Clark, K.Hitchman and L. Wisse. Battelle, Richland, WA.Sponsor: K. lee.

#922 LUNG INFLAMMATION IN RATS AFTERACUTE EXPOSURE TO CIGARETTE SMOKE. P.Vanscheeuwijck1, E. Van Miert1 and B. Friedrichs2.1PHILIP MORRIS Research Laboratories bvba, Leuven,Belgium and 2PHILIP MORRIS Research LaboratoriesGmbH, Cologne, Germany. Sponsor: H. Haussmann.

#923 FOCAL PROLIFERATIVE LESIONS IN A/JMOUSE LUNG FOLLOWING 5-MONTHEXPOSURE TO CIGARETTE MAINSTREAMSMOKE. J. T. Hamm1, S. Yee1, N. Rajendran2, R. L.Morrissey3 and M. Misra1. 1Lorillard TobaccoCompany, Greensboro, NC, 2IIT Research Institute,Chicago, IL and 3PAI, Chicago, IL. Sponsor: C. Smith.

#924 INFLUENCE OF SUB-CHRONIC CIGARETTESMOKE EXPOSURE ON THE PROGRESSION OFMYOCARDIAL HYPERTROPHY INSPONTANEOUSLY HYPERTENSIVE RATS(SHR). K. von Holt1, K. Schlueter2, S. Ruf2, K.Meurrens3 and R. Schleef1. 1PHILIP MORRIS ResearchLaboratories GmbH, Cologne, Germany, 2Justus-Liebig-University, Giessen, Germany and 3PHILIP MORRISResearch Laboratories bvba, Leuven, Belgium. Sponsor:H. Haussmann.

#925 CIGARETTE SMOKE ENHANCES ENDOTOXIN-INDUCED PULMONARY INFLAMMATION. G.Kulkarni, P. Nadkarni, J. M. Cerreta and J. O. Cantor.Department of Pharmaceutical Sciences, Saint John’sUniversity, Jamaica, NY. Sponsor: L. Trombetta.

#926 TETRAHYDROCANNABINOL CAUSESPULMONARY CELL MITOCHONDRIAL INJURYIN VITRO AND IN VIVO. T. A. Sarafian1, N. Habib1,M. J. Oldham2, N. Seeram1, R. Lee1, D. P. Tashkin1 andM. D. Roth1. 1Medicine, UCLA, Los Angeles, CA and2Community and Environmental Medicine, UC Irvine,Irvine, CA.

#927 SPONTANEOUSLY HYPERTENSIVE RATS ARESUSCEPTIBLE TO AIRWAY DISEASE INDUCEDBY SULFUR DIOXIDE. M. C. Schladweiler1, A. D.Ledbetter1, D. L. Costa1, K. E. Pinkerton2, J. H.Richards1, P. Evansky1 and U. P. Kodavanti1.1NHEERL/ETD/PTB, U.S. EPA, Durham, NC and 2UCDavis, Davis, CA.

#928 HOST-DEPENDENT INCREASE IN LUNGEPITHELIAL MEMBRANE PERMEABILITYAFTER O3. E. McElvania TeKippe, K. G. Berman, J.W. Hollingsworth II, D. A. Schwartz and W. Foster.Pulmonary, Allergy, and Critical Care, Duke University,Durham, NC.

#929 EVALUATION OF THE SENSITIVITY TOINHALED OXIDANTS IN CSB MICE. I. M.Kooter1, P. H. Fokkens1, D. L. Leseman1, J. F. Boere1,M. E. Gerlofs-Nijland1, H. van Steeg2 and F. R.Cassee1. 1MGO, RIVM, Bilthoven, Netherlands and2TOX, RIVM, Bilthoven, Netherlands. Sponsor: H. vanLoveren.

#930 ZINC DEFICIENCY ENHANCES PRO-INFLAMMATORY RESPONSES AFTER OZONEEXPOSURE. I. Jaspers1,3, K. A. Bridge2, M. Doyle2,K. Sexton2, E. Ho4, M. Styblo3 and H. Jeffries2.1CEMALB, University of North Carolina, Chapel Hill,NC, 2ESE, University of North Carolina, Chapel Hill,NC, 3Pediatrics, University of North Carolina, ChapelHill, NC and 4Nutrition, Oregon State University,Corvallis, OR.

#931 MECHANISMS REGULATING ACTIVATION OFMACROPHAGES IN THE LUNG FOLLOWINGOZONE INHALATION. A. Conner1,3, J. D. Laskin2,3

and D. L. Laskin1,3. 1Pharmacology and Toxicology,Rutgers University, Piscataway, NJ, 2Environmental andOccupational Medicine, UMDNJ-Robert W JohnsonMed. Sch, Piscataway, NJ and 3Joint Graduate Programin Toxicology, Rutgers University, Piscataway, NJ.

Program Description


TUESD

AY


#932 3ββ-HYDROXY-5-OXO-5, 6-SECOCHOLESTAN-6-AL, A MAJOR OZONIZATION PRODUCT OFCHOLESTEROL, INDUCES APOPTOSIS INCARDIOMYOCYTES. M. Haque1, I. Sehgal1, S.Murthy2, J. Francis1 and R. Uppu3. 1LSU School ofVeterinary Medicine, Baton Rouge, LA, 2TulaneUniversity Health Sciences Center, New Orleans, LAand 3Southern University, Baton Rouge, LA.

#933 INCREASED SUSCEPTIBILITY OFHYPERTHYROID RATS TO OZONE: EARLYEVENTS AND MECHANISMS. L. Huffman1,2, C.Beighley3, D. Frazer1,2, W. McKinney1 and D. Porter1,2.1PPRB, NIOSH, Morgantown, WV, 2Physiology andPharmacology, West Virginia University, Morgantown,WV and 3Biostatistics, NIOSH, Morgantown, WV.

#934 INHIBITION OF TRANSFORMING GROWTHFACTOR BETA MNRA TRANSCRIPTION BYANTISENSE OLIGONUCLEOTIDES INAMIODARONE TREATED HAMSTERS. H.conway, U. doshi and J. M. cerreta. Department ofPharmaceutical Sciences, St. John’s University, Jamaica,NY.

#935 INVESTIGATION OF PREVENTION OFAMIODARONE- ANDDESETHYLAMIODARONE-INDUCEDTOXICITY IN HUMAN PERIPHERAL LUNGEPITHELIAL CELLS HPL1A. A. C. Nicolescu, J. F.Brien, W. J. Racz and T. E. Massey. Pharmacology &Toxicology, Queen’s University, Kingston, ON, Canada.

#936 GENE MICROARRAY ANALYSIS IN A RATMODEL OF SMOKE INHALATION-INDUCEDACUTE LUNG INJURY. S. S. Wong1, N. N. Sun1, C.D. Fastje1, R. Lantz2 and M. L. Witten1. 1Center forToxicology & Department of Pediatrics, The Universityof Arizona, Tucson, AZ and 2Center for Toxicology &Department of Cell Biology/Anatomy, The Universityof Arizona, Tucson, AZ.

#937 EXPRESSION AND CHARACTERIZATION OFTRPM8 RECEPTORS IN THE LUNGEPITHELIUM. A. S. Sabnis, M. E. Johansen, G. S.Yost and C. A. Reilly. Pharmacology & Toxicology,University of Utah, Salt Lake City, UT.

#938 AEROSOLIZED HYALURONAN MODIFIESENDOTOXIN-INDUCED LUNG INJURY IN ATIME-DEPENDENT MANNER. P. Nadkarni, G.Kulkarni and J. Cantor. Pharmacy and Allied HealthProfessions, St John’s University, New York. Sponsor:L. Trombetta.

#939 IMMUNE RESPONSE TO ZYMOSAN-INDUCEDPULMONARY INFLAMMATION IN RATS. S.Young, J. R. Roberts and J. M. Antonini. NIOSH,Morgantown, WV.

#940 HYDROGEN SULFIDE EXPOSURE CAUSESINTRACELLULAR ACIDIFICATION OF RATNASAL RESPIRATORY EPITHELIAL CELLS. E.S. Roberts, V. A. Wong, B. E. McManus and D. C.Dorman. CIIT Centers for Health Research, ResearchTriangle Park, NC.

#941 PERTURBATION OF COPPER HOMEOSTASISAND EXPRESSION OF COPPER-BINDINGPROTEINS IN CADMIUM-RESISTANT LUNGFIBROBLASTS. D. K. Chou1, Y. Zhao1, S. Gao1, L.Chen1, I. Chou2, P. Toselli1, P. Stone1 and W. Li1.1Biochemistry, Boston University School of Medicine,Boston, MA and 2Microbiology, Boston UniversitySchool of Medicine, Boston, MA.

#942 PHOTOCHEMICAL REACTIONS ENHANCEINFLAMMATORY RESPONSES IN HUMANLUNG CELLS. M. Doyle1, K. G. Sexton1, H. Jeffries1,K. Lichtveld1 and I. Jaspers2,1. 1ESE, UNC-CH, ChapelHill, NC and 2CEMALB, UNC-CH, Chapel Hill, NC.

#943 INHALATION EXPOSURE TO TERTIARY AMYLMETHYL ETHER (TAME) ALTERS THEACTIVITIES OF CYTOCHROME P450ISOZYMES IN HEPATIC AND RESPIRATORYTISSUES OF SPRAGUE DAWLEY RATS. J. L.Weissert and R. A. Schatz. Toxicology, NortheasternUniversity, Boston, MA.

#944 BIOPERSISTENCE OF ROCK WOOL (RW) INTHE RAT LUNG AFTER SHORT-TERMINHALATION VIA NOSE. Y. Kudo, Y. Sugiura, M.Tsunoda, T. Satoh and Y. Aizawa. Department ofPreventive Medicine and Public Health, KitasatoUniversity School of Medicine, Sagamihara, Japan.

#945 TWO-WEEK INHALATION STUDIES WITHDISK-SHAPED PARTICLES OF POTASSIUMTITANATE COMPOUNDS: TERRACESS PS ANDTERRACESS LS. S. Sakai1, K. Inada1, A. K. Tanaka1,D. P. Kelly3, G. Sykes3 and K. P. Lee4. 1OtsukaChemical Co. Ltd., Osaka, Japan, 2DuPont HaskellLaboratory, Newark, DE, 3Veterinary PathologyServices, West Grove, PA and 4Pathology Consulting,Newark, DE.

#946 CHRONIC LUNG TOXICITY IN RATS DUE TOEXPOSURE TO DIFFERENTCONCENTRATIONS OF THE MINERAL OIL. F.S. Abouzakhar1,2,3. 1Electrical Eng., Al-TahadiUniversity, Sirt, Libya, 2Forensic Med.& Toxicology, ElMinia University, El Minia, Egypt, 3Pharmacology &Therapeutics, Ain Shams University, Ain Shams, Egyptand 4Internal Medicine, Al-Tahady University, Sirt,Libya. Sponsor: F. Abouzakhar.

#947 SENSORY IRRITATION RESPONSE TO ATP, αα, ββ-METHYLENE-ATP AND ADENOSINEAEROSOLS. W. S. Wilkie and J. B. Morris.Toxicology Program, University of Connecticut, Storrs,CT.

Program Description



TUES

DAY


POSTER SESSION: REPRODUCTION AND DEVELOPMENT

Chairperson(s): Wendy Koch, Epona Associates LLC, Willington, CT and EveMylchreest, DuPont Haskell Laboratories, Newark, DE.



#948 EFFECTS OF GROUP HOUSING ONREPRODUCTIVE PARAMETERS IN THESEXUALLY MATURE CYNOMOLGUS MONKEY.G. Weinbauer1, M. Niehoff1, M. Bergmann2 and W.Mueller1. 1Covance Laboratories GmbH, 48163Muenster, Germany and 2Institute of VeterinaryAnatomy, University of Giessen, 35392 Giessen,Germany.

#949 28-DAY INHALATION ANDREPRODUCTIVE/DEVELOPMENTALSCREENING TOXICITY STUDIES OFTETRAMETHYLSILANE IN SPRAGUE-DAWLEYRATS. W. Siddiqui1, L. Meeker1, J. Tobin1, J.Crissman1, J. Knochel1, S. Crofoot1, G. Burin2 and K.Plotzke1. 1Health and Environmental Sciences, DowCorning Corporation, Midland, MI and 2ToxicologyDivision, Technology Sciences Group, Washington, DC.

#950 GLYCIDOXYPROPYLTRIMETHOXYSILANE(TMSPGE): ONE-GENERATIONREPRODUCTION STUDY IN THE RAT. W. H.Koch1 and H. Becker2. 1Epona Associates, LLC,Willington, CT and 2Toxicology/Safety Assessment 1,RCC Ltd., Fullinsdorf, Switzerland.

#951 DEVELOPMENTAL TOXICITY AND COMBINEDMALE AND FEMALE FERTILITY STUDIES INRATS EXPOSED TO 2, 3-DICHLORO-1, 3-BUTADIENE (DCBD) BY INHALATION. L. A.Malley, E. Mylchreest, A. O. O’Neill, T. A. Kegelman,G. P. Sykes and R. Valentine. DuPont HaskellLaboratory, Newark, DE.

#952 LACK OF FERTILITY OR ESTROUS CYCLEEFFECTS OF A FLUORINATED ORGANICETHOXYLATE SURFACTANT IN RATS. J. M.Lewis1, E. Mylchreest1, S. R. Frame1, R. C. Buck2 andJ. C. Stadler1. 1DuPont Haskell Laboratory, Newark,DE and 2DuPont, Wilmington, DE.

#953 DEVELOPMENTAL IMMUNOTOXICITY OFDEXAMETHASONE AND CYCLOSPORIN A. I. D.Waalkens-Berendsen, A. P. Wolterbeek, A. Dijkstra, F.C. Kuper, A. H. Penninks, M. Zijverden van, E. I. KleinKoerkamp, P. T. Berg van den and M. M. Tegelenbosch.Toxicology and Applied Pharmacology, TNO Nutritionand Food Research, Zeist, Netherlands. Sponsor: V.Feron.

#954 BEHAVIORAL ABNORMALITY ASSOCIATEDWITH ATTENTION DEFICIT HYPERACTIVEDISORDER IN RAT OFFSPRING PRENATALLYEXPOSED TO 5-BROMO-2’-DEOXYURIDINE. K.Orito1, M. Kuwagata2, T. Ogawa3, K. Muneoka3, M.Shirai1, F. Akahori1, K. Mishima4 and M. Fujiwara4.1Pharmacology, Azabu university School of VeterinaryMedicine, Sagamihara, Japan, 2Hatano ResearchInstitute, FDSC, Hadano, Japan, 3Anatomy I, ShowaUniversity School of Medicine, Tokyo, Japan and4Neuropharmacology, Faculty of PharmaceuticalSciences, Fukuoka University, Fukuoka, Japan.

#955 MATERNAL DETOXICATION VIA CYP1A1PREVENTS METABOLIC ACTIVATION ANDEMBRYO TOXICITY FOLLOWING ORALEXPOSURE TO BENZO(A)PYRENE. C. P. Curran1,M. L. Miller1, N. Dragin1, T. P. Dalton1, D. W. Nebert1

and S. Uno2. 1University of Cincinnati Medical Center,Cincinnati, OH and 2Nihon University School ofMedicine, Tokyo, Japan.

#956 MATURATION OF HEPATIC CYTOCHROMEP450 ISOZYMES IN DEVELOPING SPRAGUE-DAWLEY RATS. B. McPhail, S. Muralidhara, S.Anand and J. Bruckner. Pharmaceutical and BiomedicalSciences, University of Georgia, Athens, GA.

#957 RESISTANCE TO PCB INDUCTION OF P450 1A(CYP1A) ACTIVITY AND REACTIVE OXYGENSPECIES (ROS) PRODUCTION IN A POLLUTEDKILLIFISH (FUNDULUS HETEROCLITUS)POPULATIONS. X. Arzuaga1 and A. A. Elskus2.1Toxicology, University of Kentucky, Lexington, KYand 2Department of Biological Sciences, USGS, Orono,ME. Sponsor: B. Hennig.

#958 SUB-CHRONIC SODIUM ARSENATE EXPOSUREAFFECTS FERTILITY AND EARLYDEVELOPMENT IN HOMING PIGEONS: AMODEL FOR MIGRATORY BIRDS. J. Brasel1, A.C. Collier2 and C. A. Pritsos2,1. 1EnvironmentalSciences and Health Program, University of Nevada,Reno, NV and 2Nutrition, University of Nevada, Reno,NV.

#959 TRUE HERMAPHRODITISM IN A CD-1 MOUSE.A. Moran. Covance Laboratories Ltd., Harrogate,United Kingdom. Sponsor: D. Everett.

Program Description


TUESD

AY



POSTER SESSION: DEVELOPMENTAL NEUROTOXICITY I

Chairperson(s): Russell Carr, Mississippi State University, Mississippi State,MS and Bernie Jortner, Virginia Tech, Blacksburg, VA.



#960 CIGARETTE SMOKE INHALATION INJUVENILE RATS: A POTENTIAL ANIMALMODEL OF ADOLESCENT NICOTINEADDICTION. T. F. Murray1, J. M. Benson2, E. B.Barr2, J. McDonald2, M. D. Campen2, X. Yan1 and C. S.Hale1. 1Physiology and Pharmacology, University ofGeorgia, Athens, GA and 2Lovelace Biomedical andEnvironmental Institute, Albuquerque, NM.

#961 “SENSORIMOTOR PERFORMANCE DEFICITS,NEURONAL CELL LOSS, AND ELEVATEDGLIAL ACIDIC PROTEIN EXPRESSION INPURKINJE CELLS AND CA1 OF THEHIPPOCAMPUS IN ADULT OFFSPRINGFOLLOWING MATERNAL EXPOSURE TONICOTINE”. W. A. Khan, A. M. Dechkovskaia, A. A.Rahman, X. Guan and M. B. Abou-Donia.Pharmacology and Cancer Biology, Duke UniversityMedical Center, Durham, NC.

#962 “INCREASED EXPRESSION OF GLIALFIBRILLARY ACIDIC PROTEIN IN THE MOTORCORTEX AND HIPPOCAMPUS, ANDNEUROBEHAVIORAL DEFICITS IN THEOFFSPRING FOLLOWING GESTATIONALEXPOSURE TO IMIDACLOPRID”. A. A. Abdel-Rahman, A. M. Dechkovskaia, J. M. Sutton, T. Tu, W.A. Khan and M. B. Abou-Donia. Pharmacology andCancer Biology, Duke University Medical Center,Durham, NC.

#963 NONCHOLINESTERASE MECHANISM(S) OFCHLORPYRIFOS NEUROTOXICITYINDICATED BY GENE EXPRESSION PROFILESOF RAT BRAIN TISSUE. A. R. Stapleton1, N.DelRaso2 and V. Chan1. 1ManTech EnvironmentalTechnology, Inc., Wright-Patterson AFB, Dayton, OHand 2Applied Biotechnology Branch, HumanEffectiveness Directorate, Air Force ResearchLaboratory, Wright-Patterson AFB, Dayton, OH.Sponsor: J. Gearhart.

#964 OXIDATIVE MECHANISMS CONTRIBUTINGTO THE DEVELOPMENTAL NEUROTOXICITYOF NICOTINE AND CHLORPYRIFOS. D. Qiao, F.J. Seidler and T. A. Slotkin. Pharmacology & CancerBiology, Duke University Med. Ctr, Durham, NC.

#965 DEVELOPMENTAL CHLORPYRIFOSEXPOSURE TARGETS SEROTONIN FUNCTIONAND RELATED BEHAVIORS. J. E. Aldridge, E. D.Levin, F. J. Seidler and T. A. Slotkin. Pharmacol/CancerBiol, Duke U Med. Ctr, Durham, NC.

#966 YOUNG ANIMALS ARE DEFICIENT IN BOTHHEPATIC P450 AND CARBOXYLESTERASEDETOXIFICATION OF DELTAMETHRIN, APYRETHROID PESTICIDE. W. T. Haines1,2, R. S.Marshall2, D. L. Hunter2 and S. Padilla2. 1Curriculumin Toxicology, University of NC at Chapel Hill, ChapelHill, NC and 2Neurotoxicology Division, U.S. EPA,Research Triangle Park, NC.

#967 EFFECT OF ORGANOPHOSPHORUSINSECTICIDES AND THEIR METABOLITES ONDNA SYNTHESIS IN ASTROGLIAL CELLS. M.Guizzetti, S. Pathak, G. Giordano and L. G. Costa.EOHS, University of Washington, Seattle, WA.

#968 PON1 MODULATES OP TOXICITY DURINGDEVELOPMENT. C. Pettan-Brewer1, T. B. Cole1,2,3,J. Fisher3, B. Walter3, A. Forbes3, N. Yee1, L. G. Costa3

and C. E. Furlong1,2. 1Medical Genetics, University ofWashington, Seattle, WA, 2Genome Sciences,University of Washington, Seattle, WA and3Environmental and Occupational Health Sciences,University of Washington, Seattle, WA.

#969 REPEATED EARLY POSTNATAL EXPOSURE TOCHLORPYRIFOS AFFECTS WORKINGMEMORY PERFORMANCE IN THE 12-ARMRADIAL MAZE. F. O. Johnson, J. E. Chambers and R.L. Carr. Center For Environmental Health Sciences,College of Veterinary Medicine, Mississippi StateUniversity, Starkville, MS.

#970 DISRUPTION OF PERFORMANCE IN THE 12-ARM RADIAL MAZE IN RATS EXPOSED TOMETHYL PARATHION DURING THE EARLYPOSTNATAL PERIOD. R. L. Carr, J. E. Chambersand F. Johnson. Center for Environmental HealthSciences, College of Veterinary Medicine, MississippiState University, Mississippi State, MS.

#971 NGF GENE EXPRESSION AND PROTEINLEVELS IN THE JUVENILE HIPPOCAMPUSAFTER REPEATED EXPOSURE TOCHLORPYRIFOS AND METHYL PARATHION. A.M. Betancourt, S. C. Burgess and R. L. Carr. Center forEnvironmental Health Sciences, College of VeterinaryMedicine, Mississippi State University, MississippiState, MS.

#972 EFFECTS OF POSTNATAL TREATMENT WITHCHLORPYRIFOS AND METHYL PARATHIONON CHOLINERGIC PARAMETERS IN RATBRAIN REGIONS. S. Guo-Ross, J. A. Dobbs, M. B.Dail and J. E. Chambers. Center for EnvironmentalHealth Sciences, Mississippi State University,Mississippi State, MS.

#973 DEVELOPMENTAL PYRETHROID EXPOSUREALTERS DOPAMINERGIC NEUROCHEMISTRYRESULTING IN HYPERACTIVITY ANDENHANCED TOXICITY OF MPTP. J. R.Richardson, T. S. Guillot, M. Caudle, M. Z. Wang andG. W. Miller. Center for Neurodegenerative Disease andDepartment of Environmental and Occupational Health,Rollins School of Public Health, Emory University,Atlanta, GA.

Program Description



TUES

DAY

#974 NEONATAL EXPOSURE TO NICOTINEINDUCES INCREASED SUSCEPTIBILITY TOPARAOXON EXPOSURE AT ADULT AGE. E.Ankarberg, A. Fredriksson and P. Eriksson. Departmentof Environmental Toxicology, Uppsala University,Uppsala, Sweden.

#975 NEONATAL EXPOSURE TO A SINGLE LOWDOSE OF A TYPE I PYRETHROID(BIOALLETHRIN) AFFECTS SPONTANEOUSBEHAVIOR AND LEARNING IN ADULT MICEOF DIFFERENT STRAINS. C. Fischer, A.Fredriksson and P. Eriksson. Department ofEnvironmental Toxicology, Uppsala University,Uppsala, Sweden.

#976 STRUCTURAL IMPACT OF DIAZINON ANDMOLINATE ON NEURITE OUTGROWTH INN1E-115 CELLS. D. T. Edge1, R. D. Cannady2, J. S.Ross2, A. Umantsev2 and S. L. Chao2. 1Department ofChemistry, North Carolina State University, Raleigh,NC and 2Department of Natural Sciences, FayettevilleState University, Fayetteville, NC. Sponsor: J. Casida.

#977 NEUROPATHOLOGICAL FINDINGS INDEVELOPMENTAL NEUROTOXICITYTESTING: COMPARISON OF QUALITATIVEAND QUANTITATIVE EVALUATIONS. K.Raffaele1, W. Sette2, J. Doherty1, S. Makris1 and K.Crofton3. 1OPP, U.S. EPA, Washington, DC, 2OSA, U.S.EPA, Washington, DC and 3NHEERL, ORD, U.S. EPA,Research Triangle Park, NC.

#978 A SIMPLE METHOD TO ESTIMATE RAT PUPEXPOSURE IN DIETARY DEVELOPMENTALNEUROTOXICITY STUDIES. M. L. Weiner1, J. D.McCarty1, A. Chen1, M. Nemec2, G. Schaefer2 and J.Buelke-Sam3. 1Toxicology, FMC Corporation,Princeton, NJ, 2WIL Research Laboratories, Ashland,OH and 3Toxicology Services, Greenfield, IN.

#979 THALIDOMIDE-INDUCED OXIDATIVE STRESSIN RAT DORSAL ROOT GANGLIA (DRG) CELLCULTURES. R. Roman Gomez1, C. A. Flynn1, T. L.Builee1, P. A. Paximadis1, J. M. Hansen2, M. A.Philbert1 and C. Harris1. 1Environmental HealthSciences, University of Michigan, Ann Arbor, MI and2Biochemistry, Emory University, Atlanta, GA.

#980 EFFECTS OF DEVELOPMENTALHYPOTHYROIDISM INDUCED BY PTU ONBRAIN FUNCTION IN RATS. R. Tsuji, K.Kobayashi, T. Yoshioka, M. Sasaki, M. kushida, S.Yabushita, T. Mino and T. Seki. Sumitomo ChemicalCo., Ltd., Environmental Health Science Laboratory,Osaka, Japan. Sponsor: T. Yamada.

#981 EFFECT OF HYPOTHYROIDISM INDUCED BYPERINATAL EXPOSURE TO PTU ONCEREBELLAR GENE EXPRESSION. K. kobayashi,R. Tsuji, T. Yoshioka, M. Kushida, T. Mino and T. Seki.Sumitomo Chemical Co., Ltd.,, Osaka, Japan. Sponsor:T. Yamada.

#982 GABERGIC FUNCTION IS ALTEREDFOLLOWING DEVELOPMENTALHYPOTHYROIDISM: NEUROANATOMICALAND NEUROPHYSIOLOGICAL EVIDENCE. M.E. Gilbert1, L. Sui1,2, S. Thomas3, S. Smoller3, J.Schon3 and J. Goodman3. 1Neurotoxicology, U.S. EPA,Research Triangle Park, NC, 2NRC, Washington, DCand 3CNRRR, Helen Hayes Hosp, W Haverstraw, NY.

#983 VITAMIN E PROTECTS AGAINST THEBEHAVIORAL DEFICITS PRODUCED BYNEONATAL SODIUM VALPROATE EXPOSUREIN MICE. A. K. Halladay1,3, G. C. Wagner2,3, X.Ming3 and K. R. Reuhl1,3. 1Pharmacology &Toxicology, Rutgers University, Piscataway, NJ,2Psychology, Rutgers University, Piscataway, NJ and3Center for Childhood Neurotoxicology & ExposureAssessment, UMDNJ, New Brunswick, NJ.

#984 CAMPTOTHECIN-INDUCED APOPTOSIS INNEURAL STEM CELLS AND DIFFERENTIATEDCULTURES THROUGH TWO DIFFERENTMECHANISMS. J. Li, M. L. Spletter and J. A.Johnson. University of Wisconsin at Madison, Madison,WI.

#985 THE ROLE OF AMYLOID-ββ AND αα-SECRETASECLEAVED AMYLOID PRECURSOR PROTEINON NEUROGENESIS IN ADULT HUMANNEOCORTICAL SLICE CULTURES. J. Kim1, T. D.Stein2, N. J. Anders1 and J. A. Johnson1,2,3. 1School ofPharmacy, University of Wisconsin-Madison, Madison,WI, 2Neuroscience Training Program, University ofWisconsin-Madison, Madison, WI and 3WaismanCenter, University of Wisconsin-Madison, Madison, WI.

#986 BISPHENOL-A, AN ENVIRONMENTALCONTAMINANT THAT ACTS AS A THYROIDHORMONE RECEPTOR ANTAGONIST INVITRO, INCREASES SERUM THYROXINE ANDALTERS RC3/NEUROGRANIN EXPRESSION INTHE DEVELOPING RAT BRAIN. R. Bansal and C.Parris. Biology, University of Massachusetts, Amherst,MA. Sponsor: R. Zoeller.

#987 EXPOSURE OF RHESUS MONKEYS TOCOCAINE THROUGHOUT GESTATIONRESULTS IN DECREASED SENSITIVITY TOCOCAINE IN ADULTHOOD: EFFECTS OFCOCAINE ON TIMING BEHAVIOR. M. G.Paule1,3, M. P. GIllam1, S. A. Graham3 and J. J.Chelonis2,3,1. 1Division of Neurotoxicology, NationalCenter for Toxicological Research, Jefferson, AR,2Graduate School, University of Arkansas at LittleRock, Little Rock, AR and 3Pediatrics, ArkansasChildren’s Hosptal, Little Rock, AR.

#988 OBSERVATION OF CATECHOLAMINERGICNEURONS IN THE FETAL RAT BRAINEXPOSED TO THE GENOTOXIC COMPOUND,5-BROMO-2’-DEOXYURIDINE (BRDU). T.Ogawa1, M. Kuwagata1,2, K. T. Muneoka1 and S.Shioda1. 1Anatomy, Showa University School ofMedicine, Tokyo, Japan and 2Hatano Research Institute,Kanagawa, Japan.

#989 HETEROGENEOUS SENSITIVITY OF THEEMBRYONIC NERVOUS SYSTEM TO THEGENOTOXIC AGENT BRDU IN MICE. M.Kuwagata1,2, T. Ogawa2, K. T. Muneoka2, H. Ono1 andS. Shioda2. 1Toxicology, Hatano Research Institute,Food and Drug Safety Center, Kanagawa, Japan and2Anatomy, Showa University School of Mrdicine,Tokyo, Japan.


INFORMATIONAL SESSION: EXPRESSION PROFILING WITHBEADARRAYTM TECHNOLOGY: IDENTIFICATION OF GENESINDUCED BY LOW LEVEL OXIDATIVE STRESS — PRESENTED BYILLUMINA

We examined variability in bead-based oligonucleotide microarrays by evalua-tion of dispersion characteristics among hybridization and biological replicatesamples of lymphocyte RNA. Using a consecutive sampling and coincidencetest, we have identified genes whose expression was significantly altered by lowlevel exposure to oxidative stress.


INFORMATIONAL SESSION: TOXICITY TESTING: WHAT BONEMARROW CAN TELL US — PRESENTED BY STEMCELLTECHNOLOGIES, INC.

Over the past three decades, a spectrum of standardized assays has been devel-oped to characterize and measure bone marrow function and assess the multiplecell lineages it contains. In humans, bone marrow is one of the five major organsystems most sensitive to chronic low-dose chemical toxicants, making it animportant target to assess in toxicity screening. This session will illustrate therationale for targeting bone marrow for drug toxicity screening, assays that areemployed and importance of using primary human cells in functional cell-basedassays.

Tuesday Morning, March 811:00 AM to 12:00 NOONRoom 223

INFORMATIONAL SESSION: DESIGNING BETTER PRECLINICALSTUDIES USING GENE EXPRESSION ANALYSIS — PRESENTED BYGENE LOGIC

Understanding the expression pattern of a target protein in various tissues canhelp you plan your small molecule and biologics safety studies with more preci-sion by suggesting additional target tissues and potential areas for concern. Inthis presentation, you will hear case studies on how scientists can use GeneLogic’s web-based ASCENTA™ System to design better preclinical studies.

Tuesday Morning, March 811:00 AM to 12:00 NOONRoom 215

INFORMATIONAL SESSION: SEARCHING THE NTP DATABASES —PRESENTED BY NIEHS

The National Toxicology Program (NTP) conducts studies on potentially toxicagents to determine their impact on human health. Enhancing public access tothese data, this workshop provides information about what is available withinthe NTP databases, using real examples to demonstrate the search process.

Tuesday Afternoon

Tuesday Afternoon, March 812:00 NOON to 1:15 PMLa Louisiane Ballroom A

IN VITRO TOXICOLOGY LECTURE: USING IN VITROTOXICOLOGY TO PROTECT HUMAN HEALTH AND ADVANCEANIMAL WELFARE

Lecturer: William S. Stokes, DVM, NIEHS, Research Triangle Park, NC.

Sponsored by:The Colgate-Palmolive Company

This lecture will discuss the application of in vitro toxicology to regulatorysafety assessment and provide examples of how recently adopted in vitro testmethods have benefited animal welfare by refining and reducing animal usewhile providing for the protection of human heath. The process by which newtechnological methods evolve from development to regulatory acceptance willbe discussed, including the validation process necessary to determine theirusefulness and limitations for defined specific purpose. Dr. Stokes will alsodiscuss expected opportunities for an expanded role for in vitro toxicology in anintegrated approach to safety assessment.

Students register for this event on the Annual Meeting Registration form; a $5deposit per ticket is required and will be exchanged for the ticket at theluncheon. Seating is limited.

Program Description


TUESD

AY


Tuesday Afternoon, March 812:00 NOON to 1:00 PMLa Louisiane Ballroom B

SOT/EUROTOX DEBATE

Motion: Nanoparticles are a Major Threat to Human Health

Sponsored by:SOT (Society of Toxicology)EUROTOX (European Societies of Toxicology)

Debaters:

(Pro) SOT: Joseph V. Rodricks, Ph.D., DABT, The ENVIRONInstitute for Health Risk Sciences, Arlington, VA

(Con) EUROTOX: Anthony Seaton, Prof Emeritus, University of Aberdeen, Scotland.

Nanoparticles represent an explosively expanding technology for selective drugdelivery. The number of potential applications is limitless; However the highlypenetrant properties raises serious concern regarding wide-spread, uncontrolleddistribution and possible persistence of these particles within living systems.The discussants will produce strong and persuasive arguments both in supportand to refute adverse human health concerns of this rapidly emerging tech-nology.

Tuesday Afternoon, March 812:15 PM to 1:15 PMRoom 223

INFORMATIONAL SESSION: RAPID GENERATION OFPREDICTIVE TOXICOGENOMIC ANALYSIS — PRESENTED BYGENE LOGIC

Learn how to facilitate drug candidate selection by characterizing a compound'stoxicity profile using an easy, intuitive toxicogenomic-based software applica-tion. Several case studies will be discussed that demonstrate how these rapidlygenerated results can be combined with other data to help make better informcompound decisions.


INFORMATIONAL SESSION: LEVERAGING A MULTI-DIMENSIONAL CARDIOVASCULAR ASSESSMENT DURING LEADOPTIMIZATION — PRESENTED BY CORDYNAMICS

CorDynamics is a contract research organization focused on examining thecardiac effects of emerging drug candidates. Our models allow us to optimizethese lead candidates early in the drug development process. Focusing on thiscritical and dynamic phase improves the attrition rates of compounds selectedfor further testing, thereby reducing the overall costs and timelines associatedwith your projects.

Tuesday Afternoon, March 81:30 PM to 3:30 PMRoom RO2

FORUM ON GRANTSMANSHIP AND SOURCES FOR RESEARCHSUPPORT

Chairperson(s): Mitzi Nagarkatti, Virginia Commonwealth University,Richmond, VA and Rosita R. Proteau, Oregon State University, Corvallis, OR.

Sponsored by:Career Resource and Development Committee (formerly the PlacementCommittee)Education Committee

The Grantsmanship Forum will provide an overview of a variety of researchfunding sources and tips for successful applications for scientists at all stages oftheir research careers.

The first two talks will address NIH funding, including the reorganization of thereview process by the Center for Scientific Research (CSR), which reviews themajority of applications to NIH. For the toxicology community, this restruc-turing has meant the elimination of two of the study sections in which manytoxicology grant applications were reviewed. A third study section, used forneurotoxicology applications, was replaced. There has been confusion amongapplicants about the appropriate study section for their applications, as well asconcern about toxicology applications getting proper reviews. The first speakerwill provide a brief overview of the restructuring process, some resultsregarding toxicology applications from the first several review cycles, and somethoughts for applicants on how to work within the new system and hopefully bemore successful.

The second presentation will provide an overview of some of the specializedNIH grant mechanisms available to support research, training and career devel-opment. Included will be information on Career Development Awards (K seriesgrants), Fellowships (F series grants), Training (T series grants), and researchgrants designed for specialized goals (R series grants).

The EPA is another significant funding source for toxicologists. The thirdspeaker will discuss EPA’S extramural grants and fellowship program withparticular emphasis on Science to Achieve Results (STAR) Program. The EPAissues requests for applications in targeted areas that complement EPA’s intra-mural research programs. First, applications undergo a scientific review by anexternal peer panel, and then an internal programmatic review. These grants leadto interactions between extramural and intramural scientists. In addition, EPAsupports graduate students in environmental science and engineering throughthe STAR program.

Significant opportunities for research funding beyond NIH and EPA are alsoavailable. An experienced SOT investigator will provide perspectives on findingthese sources. Learn ways to identify these alternative funding sources and theirmissions. Each funding source has a set of goals that need careful considerationas you apply for dollars to support your research effort.

Time will be available for specific questions to these speakers.

1:30 PM Introduction, Mitzi Nagarkatti, VirginiaCommonwealth University, Richmond, VA.

1:35 PM Reorganization of NIH Study Sections, PatrickMastin, NIEHS, Research Triangle Park, NC.

2:10 PM Non-Conventional Sources of NIH Funding, CarolShreffler, NIEHS, Research Triangle Park, NC.

2:45 PM Funding from Environmental Protection Agency,Elaine Z. Francis, U.S. EPA, Washington, DC.

Program Description



TUES

DAY

Program Description


TUESD

AY


3:20 PM Funding Alternatives to NIH: Being Creative,Jean F. Regal, University of Minnesota MedicalSchool, Duluth, MN.


SYMPOSIUM SESSION: THE AHR IN CELL GROWTH AND DEATH

Chairperson(s): David Sherr, Boston University School of Public Health,Boston, MA and Prakash Nagarkatti, Virginia Commonwealth University,Richmond, VA.

Endorsed by:Immunotoxicology SS

Since its first description as a dioxin-binding protein in the 1980s, the arylhydrocarbon receptor (AhR) has been studied primarily for its control ofbiologic responses to environmental agonists. However, in the last few years ithas become apparent that the AhR, which clearly did not evolve to recognizeenvironmental pollutants, likely plays an important physiologic function.Indeed, the ability of the AhR to directly regulate important cellular genes andfactors such as Bax, the estrogen receptor, Rb, and NF-kB hints at a critical rolefor the AhR in cell growth and death. The presence of constitutively active AhRin cells that exhibit aberrant growth and apoptosis regulation, i.e. neoplasticcells, further supports this hypothesis. In this symposium we will present severalexamples of AhR-mediated control of cell growth and death and will begin todetail the molecular mechanisms through which this control is manifest. Insome studies presented herein, AhR function is revealed with exogenousagonists such as TCDD or PAH. In other cases, constitutive AhR function isdemonstrated by modulation of AhR expression and activity in the absence ofexogenous ligands. In all cases, the roles that the AhR may play in normalcellular physiology and the consequences of disrupting these functions withenvironmental agonists are discussed.

#990 1:30 THE AHR IN CELL GROWTH AND DEATH. D. H.Sherr1 and P. Nagarkatti2. 1Environmental Health,Boston University School of Public Health, Boston, MAand 2Department of Pharmacology and Toxicology,Virginia Commonwealth Unviersity, Richmond, VA.

#991 1:40 LIGATION OF AHR LEADS TO UP-REGULATION OF APOPTOTIC GENESTHROUGH DRE-DEPENDENT AND -INDEPENDENT PATHWAYS INVOLVING NF-KBAND CONSEQUENT INDUCTION OFAPOPTOSIS IN THYMOCYTES. P. S. Nagarkatti.Pharmacology and Toxicology, Medical College ofVirginia Campus, Virginia Commonwealth University,Richmond, VA.

#992 2:10 AHR CONTROL OF B LYMPHOCYTE DEATHAND GROWTH. S. H. David, H. Ryu, J. K. Emberley,L. L. Allan and J. J. Schlezinger. Environmental Health,Boston University School of Public Health, Boston,MA.

#993 2:40 REGULATION OF MAMMARY TUMORGROWTH THROUGH THE ARYLHYDROCARBON RECEPTOR. S. H. Safe.Veterinary Physiology, Texas A & M University,College Station, TX.

#994 3:10 CURRENT INSIGHTS INTO AHR-MEDIATEDLIVER CELL CYCLE CONTROL. C. J. Elferink.Pharmacology and Toxicology, University of TexasMedical Branch, Galveston, TX. Sponsor: D. Sherr.

#995 3:40 AHR CONTROL OF APOPTOSIS INDUCED BYAGENTS CAUSING LYSOSOMAL DAMAGE. J. J.Reiners. Institute of Environmental Health Sciences,Wayne State University, Detroit, MI. Sponsor: D.Sherr.


SYMPOSIUM SESSION: ORGANOPHOSPATES & CARBMATES:CHOLINERGIC VS. NONCHOLINERGIC MECHANISMS

Chairperson(s): Ramesh Gupta, Murray State University, Hopkinsville, KYand Carey N. Pope, Oklahoma State University, Stillwater, OK.

Endorsed by:Comparative and Veterinary SSNeurotoxicology SS*Risk Assessment SSStudent Advisory Committee

Organophosphates (OPs) and carbamates (CMs) are commonly used as pesti-cides in agriculture, industry, and around the home/garden. Some OPs have alsobeen used in chemical warfare and terrorism, while some CMs have been usedto treat diseases such as myasthenia gravis and dementia. Interestingly, the CMpyridostigmine is used prophylactically to protect soldiers from possible OPnerve agent exposure. Many compounds of both classes are extremely toxic andlack selectivity, thus their inadvertent/accidental use continues to pose a threatto human and animal health, aquatic systems and wildlife. While thesecompounds have a wide variety of toxic effects, neurotoxicity elicited by inhibi-tion of acetylcholinesterase (AChE) is generally of primary concern. In recentyears, a variety of novel mechanisms for OPs and CMs have been proposedwhich may modulate cholinergic neurotoxicity or lead to non-cholinergiceffects. Molecular studies of AChE and its interaction with inhibitors hasallowed a more thorough characterization of the structure, function, and regula-tion of this enzyme. In vitro studies indicate that NGF-differentiated SY5Y cellsmay distinguish between OPs that produce OPIDN and those that do not, andmay therefore be a suitable mechanistic model for exploring the effects ofdifferent classes of OPs. Evidence suggests that while cholinergic mechanismsplay a critical role in the initial stage of cholinergic toxicity, neuronaldamage/death may occur through non-cholinergic mechanisms including oxida-tive stress. The Food Quality Protection Act of 1996 requires EPA to considerthe cumulative risk to pesticides with a common mechanism of action. In thecase of OPs and CMs, this common mechanism is initiated by inhibition ofAChE (via phosphorylation or carbamylation, respectively). However,noncholinergic mechanisms are not currently considered in risk assessment.This symposium will review the latest developments in understanding of molec-ular mechanisms (cholinergic and non-cholinergic) for these toxicants, as wellas discuss current strategies of cumulative risk assessment for pesticides actingthrough a common mechanism.

#996 1:30 ORGANOPHOSPHATES & CARBAMATES:CHOLINERGIC & NONCHOLINERGICMECHANISMS. R. C. Gupta. Toxicology, MurrayState University, Hopkinsville, KY.

#997 1:40 CONTEMPORARY PROTEOMICS INACETYLCHOLINESTERASE AND RELATED αα,ββ HYDROLASE-FOLD PROTEINS AS TARGETSOF TOXICOLOGICAL MANIFESTATIONS ANDGENETIC DISORDERS. P. Taylor, Z. Radic, L.Jennings and S. Camp. Pharmacology, University ofCalifornia, San Diego, La Jolla, CA. Sponsor: R.Gupta.

Program Description



TUES

DAY

#998 2:10 ORGANOPHOSPHORUS AND CARBAMATECHOLINESTERASE INHIBITORS: USES ANDMISUSES OF A COMMON MECHANISM. C. N.Pope. Physiological Sciences, Oklahoma StateUniversity, Stillwater, OK.

#999 2:40 IN VITRO MODELS FOR TESTINGNEUROTOXICITY OF ORGANOPHOSPHORUSCOMPOUNDS AND PROTECTIVE EFFECTS OFOP HYDROLASE. E. Tiffany-Castiglioni. VeterinaryAnatomy and Public Health, Texas A&M University,College Station, TX.

#1000 3:10 OXIDATIVE STRESS INVOLVEMENT INNEUROTOXICITY OF ORGANOPHOSPHATESAND CARBAMATES. R. C. Gupta1, S. Milatovic2, T.J. Montine2, W. D. Dettbarn3 and D. Milatovic2.1Toxicology, Murray State University, Hopkinsville,KY, 2University of Washington, Seattle, WA and3Vanderbilt University, Nashville, TN.

#1001 3:40 EPA PERSPECTIVE: SCIENTIFICAPPROACHES FOR ASSESSING THECUMULATIVE RISK OFORGANOPHOSPHORUS AND N-METHYLCARBAMATE CHOLINESTERASE INHIBITINGPESTICIDES. A. Lowit. Office of Pesticide Programs,U.S. EPA, Washington, DC. Sponsor: R. Gupta.

Tuesday Afternoon, March 81:30 PM to 4:30 PMLa Louisiane Ballroom B

SYMPOSIUM SESSION: PROTEOMICS AND ANTIBODYMICROARRAYS: APPLICATIONS IN TOXICOLOGY

Chairperson(s): Richard Zangar, Pacific Northwest Laboratories, Richland,WA and Alex Merrick, National Institute for Envirornmental Health Sciences,Research Triangle Park, NC.

Endorsed by:Mechanisms SS*Molecular Biology SSStudent Advisory Committee

It is now possible to sequence a whole genome and predict the completeproteome of an organism. This information, when used in combination withsophisticated techniques for protein analysis such as tandem mass spectrometry(MS), allows for the rapid analysis of hundreds or thousands of proteins in asingle biological sample. These proteomic technologies offer the ability torapidly determine which of the identified proteins are altered in response totoxicity, xenobiotic exposure or various disease states. One specialized applica-tion of proteomics technology is the analysis of protein modifications. Sincemany of the toxic effects of xenobiotic exposure and oxidative stress are associ-ated with covalent protein modifications, this area of research is expected toresult in significant advances in our understanding of the molecular basis fortoxicity. Another rapidly developing technology is protein arrays, which can beused for broad comparisons of protein-protein interactions or quantitativeanalyses. In comparison to MS-based analyses, protein microarrays generallyhave greater throughput but are limited to a select group of proteins. Overall,these developing technologies are expected to provide a broader insight into themechanisms of toxicity and identify new markers of disease and toxicity.

#1002 1:30 PROTEOMICS AND ANTIBODYMICROARRAYS: APPLICATIONS INTOXICOLOGY. R. C. Zangar. Pacific NorthwestNational Laboratory, Richland, WA.

#1003 1:35 ANALYSIS OF MARKERS OF CANCER ANDXENOBIOTIC EXPOSURE USING ANTIBODYMICROARRAYS. R. C. Zangar1, S. M. Varnum1, D.S. Daly1, A. M. White1, C. Y. Covington2, S. Wiley1, B.D. Thrall1 and R. D. Stenner1. 1Pacific NorthwestNational Laboratory, Richland, WA and 2University ofCalifornia School of Nursing, Los Angeles, CA.

#1004 2:10 FINDING NEW SIGNAL TRANSDUCTIONPARADIGMS USING PROTEIN-DOMAINMICROARRAY. M. T. Bedford, A. Espejo and J.Daniel. MD Anderson Cancer Center, Bastrop, TX.Sponsor: R. Zanger.

#1005 2:45 PROTEOMIC ANALYSIS OF SERUM PROTEINSDURING ACUTE ACETAMINOPHEN TOXICITYIN RATS REVEALS ACUTE PHASE ANDANTIOXIDANT RESPONSE. B. A. Merrick1, K. B.Tomer1, M. E. Bruno1, J. H. Madenspacher1, B. A.Wetmore1, R. Pieper2, C. L. Gatlin2, M. M. Andrew2, A.J. Makusky2, M. Zhao2, J. Zhou2, J. Taylor2, S. Steiner2

and R. W. Tennant1. 1NCT, NIEHS, Research TrianglePark, NC and 2Proteomics, LSBC, Germantown, MD.

#1006 3:20 IDENTIFYING PROTEIN MODIFICATIONSRESULTING FROM OXIDATIVE STRESS USINGLC/ESI/MS. I. A. Blair, S. Lee and T. Oe.Pharmacology, University of Pennsylvania, Philadephia,PA. Sponsor: R. Zanger.

#1007 3:55 COMPARATIVE PROTEOMIC ANALYSIS OFCONTROL AND TUMOR-BEARING MOUSEPLASMA BY GEL-LC-MS/MS. S. R. Tannenbaum, V.B. Bhat, M. Choi and J. S. Wishnok. BiologicalEngineering Division, MIT, Cambridge, MA.

Program Description


TUESD

AY



SYMPOSIUM SESSION: UPDATE ON MECHANISMS FORENVIRONMENTAL TOBACCO SMOKE-INDUCED HEALTHEFFECTS

Chairperson(s): Chris A. Pritsos, University of Nevada, Reno, NV and KevinE. Pinkerton, University of California, Davis, Davis, CA.

Endorsed by:Occupational and Public Health SSRisk Assessment SS

Epidemiological evidence has demonstrated an association between exposure toenvironmental tobacco smoke (ETS) and disease. Diseases associated with ETSexposure include a variety of cancers, cardiovascular disease, COPD, asthmaand a number of perinatal manifestations, to name a few. While many of theseexposure/disease associations are strong, the mechanism(s) by which ETS expo-sure influences the etiology of these diseases remains unclear. There are a greatnumber of confounding factors which make ascribing any ETS-induced mecha-nism for disease difficult. Included amongst these factors is the immensecomplexity of the substituents which make up ETS. ETS is comprised of both avapor phase and particulate phase with over 4000 chemicals identified to date.One must not only consider the effect of individual compounds but must alsoconsider potential synergism between compounds. Another factor which needsto be considered is the fact that exposure to tobacco smoke compounds issubstantially less than for smokers, due to dilution of the smoke. Chemical reac-tivity or “aging” of the ETS components can also modify their chemical nature.Also, an individual’s susceptibility to the harmful effects of ETS exposure canbe greatly influenced by their genetic makeup. While quite complex, certainmechanistic themes are beginning to emerge as characteristic of ETS’s associa-tion with these diseases. The speakers will provide recent advances in ourunderstanding of the mechanisms by which ETS can influence the etiology ofthese diseases and provide a linkage between the epidemiological and biochem-ical/pathophysiological bases of disease. The symposium will have twopresentations each dealing with: ETS and cardiovascular disease, ETS andcancer and ETS and respiratory diseases.

#1008 1:30 UPDATE ON MECHANISMS FORENVIRONMENTAL TOBACCO SMOKE-INDUCED HEALTH EFFECTS. C. A. Pritsos1 andK. E. Pinkerton2. 1Nutrition, University of Nevada,Reno, NV and 2Center for Health and the Environment,University of California, Davis, CA.

#1009 1:35 IMPACT OF WORKPLACE ETS EXPOSURE ONRISK FACTORS FOR CORONARY HEARTDISEASE. C. A. Pritsos1, G. R. Cutter2, S. St. Jeor3, J.A. Ashley1, S. Perumean-Chaney2, S. Clodfelter1, J. E.Woodrow1, A. C. Collier1, L. D. Bowen1, N. J. Martin1

and K. L. Pritsos1. 1Nutrition, University of Nevada,Reno, NV, 2Biostatistics, University of Alabama,Birmingham, Birmingham, AL and 3Internal Medicine,University of Nevada, Reno, NV.

#1010 2:00 IMPACT OF PRENATAL CARDIOVASCULARDISEASE RISK FACTOR EXPOSURE ONMITOCHONDRIAL DAMAGE AND ADULTHEART DISEASE DEVELOPMENT. S. W.Ballinger1, Z. Yang1 and A. Penn2. 1Pathology,University Alabama at Birmingham, Birmingham, ALand 2Veterinary Medicine, Louisiana State University,Baton Rouge, LA.

#1011 2:30 IMMUNOLOGIC DETECTION OFCARCINOGEN-DNA AND PROTEIN ADDUCTS.R. M. Santella. Environmental Health Sciences,Columbia University, New York.

#1012 3:00 ETS IMPACT ON ALLERGIC AIRWAYSRESPONSES TO ANTIGEN. A. penn1, D. Paulsen2

and D. Horohov3. 1CBS, LSU Vet.Med., Baton Rouge,LA, 2PBS, LSU Vet.Med., Baton Rouge, LA and 3Vet.Sciences., University of KY, Lexington, KY.

#1013 3:30 GESTATIONAL STAGE-SPECIFIC ETS-INDUCED OXIDATIVE DNA DAMAGE. L. M.Anderson1, A. Maciag1, I. Espiritu2, A. Bialkowska1, K.Kasprzak1 and H. Witschi2. 1Lab. ComparativeCarcinogenesis, National Cancer Inst., Frederick, MDand 2Center for Health and the Environment, Universityof California, Davis, CA.

#1014 4:00 EFFECTS OF ENVIRONMENTAL TOBACCOSMOKE ON CYTOKINES ANDNEUROTROPHINS IN THE NEONATAL LUNG.K. E. Pinkerton, J. P. Joad and M. Yu. Center for Healthand the Environment, University of California, Davis,CA.



WORKSHOP SESSION: CURRENT AND FUTURE SCIENCE-BASEDAPPROACHES TO DRUG SAFETY EVALUATION: AN ASSESSMENTOF POTENTIAL CANCER RISK

Chairperson(s): Martha M. Moore, U.S. FDA, Jefferson, AR and DavidJacobson-Kram, U.S. FDA, Rockville, MD.

Endorsed by:Carcinogenesis SS*Regulatory and Safety Evaluation SSRisk Assessment SSStudent Advisory Committee

Currently the preclinical safety evaluation of pharmaceuticals for potentialcancer risk includes the application of genetic toxicology assays and the rodentcancer bioassay. While data from rodent carcinogenicity studies are generallyavailable prior to marketing approval, data from short-term studies is used toassess cancer risk during the drug development phases. Although this has gener-ally been a successful approach there is wide discussion as to the appropriaterole of the genetic toxicology assays and the possibility that other assays such asthe Syrian hamster embryo (SHE) test and the shorter term transgenic cancerbioassays (Trp53 and rasH2) might be useful. The emerging “omics” technolo-gies provide for possible new and improved approaches to understandingwhether new drugs might cause an increased cancer risk. In addition, bothpresent and future technologies have the potential to be applied within thecontext of the clinical trials. This session will provide a forum to discuss theseissues. The first speaker will provide an overview of the current approaches andissues relevant to preclinical drug safety assessment. Additional speakers willdiscuss the current thinking on the use of genetic toxicology assays, the SHEassay and the transgenic cancer bioassays. The last two speakers will considerboth the present and potential future applications of “omic” technologies andour ability to utilize individuals in clinical trials to provide a better assessmentof the potential human cancer risk from pharmaceutical drugs.

Program Description



TUES

DAY

#1025 1:30 CURRENT AND FUTURE SCIENCE-BASEDAPPROACHES TO DRUG SAFETYEVALUATION: AN ASSESSMENT OFPOTENTIAL CANCER RISK. M. Moore. DGRT,NCTR, Jefferson, AR.

#1026 1:35 OVERVIEW OF THE CANCER SAFETYASSESSMENT IN CDER/FDA. A. Jacobs. U.S. FDA,Rockville, MD.

#1027 2:10 THE ROLE OF GENETIC TOXICOLOGYASSAYS IN A WEIGHT-OF-WVIDENCE CANCERASSESSMENT FOR NEW PHARMACEUTICALS.D. Jacobson-Kram1. 1FDA, Rockville, MD and 2Officeof New Drugs, Center for Drug Evaluation andResearch, U.S. FDA, Rockville, MD.

#1028 2:45 TRANSGENIC CANCER BIOASSAYS: A USEFULADDITION TO CANCER SAFETY ASSESSMENTOF NEW PHARMACEUTICALS? R. D. Storer.Safety Assessment, Merck Research Laboratories, WestPoint, PA.

#1029 3:20 INTEGRATION OF OMIC DATA INTO CANCERRISK ASSESSMENT. Y. Dragan. Hepatic Toxicology,NCTR, Jefferson, AR.

#1030 3:55 CANCER BIOMARKERS: CAN THEIRAPPLICATION IN CLINICAL TRIALS IMPROVETHE SAFETY ASSESSMENT OF NEWPHARMACEUTICALS? R. J. Albertini. GeneticToxicology Lab., University of Vermont, Burlington,VT. Sponsor: M. Moore.


WORKSHOP SESSION: MOLECULAR PATHWAYS TO TOXICANT-INDUCED OSTEOPOROSIS

Chairperson(s): Maryka Bhattacharyya, Argonne National Laboratory,Argonne, IL and Edward Puzas, University of Rochester School of Medicine,Rochester, NY.

Endorsed by:Mechanisms SSMetals SS*Student Advisory CommitteeWomen in Toxicology SS

Osteoporosis is a disease characterized by low bone mass and structural deteri-oration of bone tissue, leading to bone fragility and an increased susceptibilityto fractures of the hip, spine, and wrist. This disease is responsible for more than1.5 million fractures annually; 44 million Americans have low bone mass suchthat they either have osteoporosis or are at significant risk of developing thedisease. Of the 10 million who actually have osteoporosis, 80 percent arewomen. Men suffer one-third of all hip fractures that occur, and approximatelyone-third of these men will not survive more than one year after the fracture.Our population is increasing in the fraction of elderly persons faster than at anyother time in human history. Understanding ways in which toxicants contributeto the development of osteoporosis is an important undertaking. In this work-shop, we will provide 1) basic information on pathways of bone formation andbone resorption and their role in the development of osteoporosis, 2) newinsights into how the important metals, lead and cadmium, affect bone cell path-ways and contribute to metabolic bone disease, 3) the role that alcoholconsumption may play in the development of osteoporosis, and 4) discussion byworkshop participants of the results presented with respect to their applicationand relevance to human health.

#1031 1:30 MOLECULAR PATHWAYS TO TOXICANT-INDUCED OSTEOPOROSIS. M. H. Bhattacharyya1,E. Puzas2, J. B. Lian3, D. J. Novack4 and M. J. Ronis5.1Biosciences Division, Argonne National Laboratory,Argonne, IL, 2University of Rochester School ofMedicine, Rochester, NY, 3University of MassachusettsMedical School, Worcester, MA, 4WashingtonUniversity School of Medicine, St. Louis, MO and5University of Arkansas Medical Sciences, Little Rock,AR.

#1032 1:35 MOLECULAR PATHWAYS REGULATINGOSTEOBLAST GROWTH ANDDIFFERENTIATION. J. B. Lian and G. S. Stein.Department of Cell Biology and Cancer Center,University of Massachusetts Medical School, Worcester,MA. Sponsor: M. Bhattacharyya.

#1033 2:05 MOLECULAR PATHWAYS REGULATINGOSTEOCLAST DIFFERENTIATION ANDFUNCTION. D. Novack. Medicine/Bone and Mineral,Washington University School of Medicine, St. Louis,MO. Sponsor: M. Bhattacharyya.

#1034 2:35 LEAD-INDUCED OSTEOPOROSIS. J. E. Puzas.Department of Orthopaedics, University of RochesterSchool of Medicine, Rochester, NY.

#1035 3:05 FROM ITAI-ITAI TO OSTEOCLASTS:PATHWAYS TO CADMIUM-INDUCED BONELOSS. M. H. Bhattacharyya, A. Regunathan and D. A.Glesne. Biosciences Division, Argonne NationalLaboratory, Argonne, IL.

Program Description


TUESD

AY


#1036 3:35 MECHANISMS OF ETHANOL-INDUCED BONELOSS DIFFER WITH PHYSIOLOGICAL STATE.M. J. Ronis1,2, T. Badger1,2, C. Lumpkin1, J. Aronson1,M. Hidestrand1, K. Shankar1 and R. Haley1,2.1University of Arkansas for Medical Sciences, LittleRock, AR and 2Arkansas Children’s Nutrition Center,Little Rock, AR.


PLATFORM SESSION: NANOPARTICLE TOXICITY

Chairperson(s): Anna Shvedova, NIOSH, Morgantown, WV and Lung ChiChen, NYU, Tuxedo, NY.

#1037 1:30 TOXICITIES OF NANOMATERIALS. C. Quan1, S.Wilson2 and L. Chen1. 1School of Medicine, NYU,Tuxedo, NY and 2New York University, New York.

#1038 1:50 EXPOSURE TO ULTRAFINE ELEMENTALCARBON PARTICLES (UCP) SIGNIFICANTLYINCREASE THROMBOGENESIS. V. M. Silva, N.Corson, A. Elder, R. Gelein and G. Oberdorster.Environmental Medicine, University of Rochester,Rochester, NY.

#1039 2:10 NANOPARTICLE DEPOSITION EFFICIENCY INHUMAN NASAL AIRWAY REPLICAS. B. A. Wong1,J. T. Kelly2, J. S. Kimbell1 and B. Asgharian1. 1CIITCHR, Research Triangle Park, NC and 2University ofCalifornia, Davis, CA.

#1040 2:30 ELECTRON MICROSCOPIC STUDY ON THETRANSLOCATION OF ULTRAFINE CARBONBLACK PARTICLES AT THE AIRWAY-CAPILLARY BARRIER IN LUNG. A. Shimada, N.Kawamura, T. Kaewamatawong, M. Okajima, M.Sawada and T. Morita. Veterinary Pathology, TottoriUniversity, Tottori-shi, Japan.

#1041 2:50 PULMONARY TOXICITY OF CARBONNANOTUBES. E. Kisin1, A. R. Murray3, V. Johnson2,O. Gorelik4,5, S. Arepalli4,5, V. Z. Gandelsman4,5, A. F.Hubbs1, R. R. Mercer1,3, P. Baron6, V. E. Kagan7, V.Castranova1,3,7 and A. A. Shvedova1,3. 1PPRB,HELD/NIOSH, Morgantown, WV, 2TMBB,HELD/NIOSH, Morgantown, WV, 3Physiology &Pharmacology, WVU, Morgantown, WV, 4LockheedMartin Corporation, Engineering Directorate, Material& Processes Branch, NASA-JSC, Houston, TX,5Nanotube Team, GBTech, Inc., NASA-JSC, Houston,TX, 6MRSA/DART, NIOSH, Cincinnati, OH and7University of Pittsburgh, Pittsburgh, PA.

#1042 3:10 RESPONSES OF LUNG PARENCHYMA TOCARBON NANOTUBES. R. R. Mercer1,2, J.Scabilloni1,2, K. Kisin1, O. Gorelik3,4, S. Arepalli3,4, A.R. Murray2, V. Castranova1,2 and A. A. Shvedova1,2.1HELD, NIOSH, Morgantown, WV, 2Physiology andPharmacology, West Virginia University, Morgantown,WV, 3Engineering Directorate, Materials and Processes,Lockheed Marting Corporation, Houston, TX and4Nanotube Team, GBTech, Inc. NASA-JSC, Houston,TX.

#1043 3:30 PULMONARY TOXICITY SCREENING STUDIESWITH NANO VS. FINE-SIZED QUARTZ ANDTIO2 PARTICLES IN RATS. D. B. Warheit1, K.Reed1, T. Webb1, C. Sayes2 and V. Colvin2. 1DuPontHaskell Laboratory, Newark, DE and 2Rice University,Houston, TX.

#1044 3:50 DEVELOPMENT OF ANIMAL MODELS OFINHALATION FEVER USING FINE ANDNANOPARTICLE ZINC OXIDE EXPOSURES. K.Reed, T. Webb and D. Warheit. DuPont HaskellLaboratory, Newark, DE.

#1045 4:10 PULMONARY EXPOSURE TO CARBONNANOTUBES INDUCES VASCULAR TOXICITY.Z. Li, R. Salmen, T. Huldermen, E. Kisin, A. Shvedova,M. I. Luster and P. P. Simeonova. HELD/TMBB,NIOSH, Morgantown, WV.


PLATFORM SESSION: LIVER

Chairperson(s): Jose Manautou, University of Connecticut, Storrs, CT andIvan Rusyn, University of North Carolina Chapel Hill, Chapel Hill, NC.

#1046 1:30 TOXICOGENETIC AND TOXICOGENOMICANALYSIS OF ALCOHOL-INDUCED LIVERINJURY. I. Rusyn1, M. Lee2, W. Tak1, J. Milton3, B.Bradford1, A. Maki1, M. Wheeler3, D. Threadgill4 and J.Marron2. 1Environmental Sciences and Engineering,UNC-CH, Chapel Hill, NC, 2Statistics and OperationsResearch, UNC-CH, Chapel Hill, NC, 3Nutrition, UNC-CH, Chapel Hill, NC and 4Genetics, UNC-CH, ChapelHill, NC.

#1047 1:50 EVIDENCE FOR OSTEOPONTIN INDUCTION INVIVO AND IN VITRO: A POSSIBLEMECHANISM FOR HIGHER NEUTROPHILTRANSMIGRATION AND HIGHER LIVERINJURY IN FEMALE ALCOHOLICS. A. Banerjee,U. M. Apte and S. K. Ramaiah. Pathobiology, TexasA&M University, College Station, TX.

#1048 2:10 ACETAMINOPHEN (APAP) USE INALCOHOLICS: HEPATIC FUNCTION DURINGAND FOLLOWING THERAPEUTIC DOSING. R.C. Dart1, J. L. Green1, E. K. Kuffner1, G. M. Bogdan1,P. Knox2 and E. Casper1. 1Denver Health/RockyMountain Poison & Drug Center, Denver, CO and2Recovery Centers of King County, Seattle, WA.

#1049 2:30 PHENOBARBITAL AND PHENYTOIN INDUCEDACETAMINOPHEN HEPATOTOXICITY DUE TODIRECT INHIBITION OF UGT1A6 AND UGT1A9.S. Kostrubsky1, S. C. Strom2, E. Urda1, S. Kulkarni1, J.F. Sinclair3,5 and A. Mutlib4. 1Safety Science, Pfizer,Ann Arbor, MI, 2Pathology, Pitsburgh Medical School,Pittsburgh, PA, 3Pharmcology/Toxicology, DartmouthMedical School, Hanover, NH, 4Pharmacokinetic,Dynamic and Metabolism, Pfizer, Ann Arbor, MI and5Veterans Administration Medical Center, White RiverJct, VT.

Program Description



TUES

DAY

#1050 2:50 GENDER DIFFERENCE OF ACETAMINOPHEN-INDUCED HEPATOTOXICITY IN MOUSE. G. Dai,N. Chou, L. He, M. Gyamfi, A. J. Mendy and Y. Y. Wan.Pharmacology, Toxicology and Therapeutics, Universityof Kansas Medical Center, Kansas City, KS.

#1051 3:10 ALTERED HEPATOBILIARY DISPOSITION OFACETAMINOPHEN GLUCURONIDE IN MRP3KNOCKOUT MICE AND THEIRSUSCEPTIBILITY TO HEPATOTOXICITY. J. E.Manautou1, R. de Waart2, N. Zelcer3, C. Kunne2, M.Goedken1, P. Borst3 and R. Oude Elferink2.1Department of Pharmaceutical Sciences, University ofConnecticut, Storrs, CT, 2Liver Center, AcademicMedical Center, Amsterdam, Netherlands and 3TheNetherlands Cancer Institute, Amsterdam, Netherlands.

#1052 3:30 RAPID ACTIVATION OF WNT/ββ-CATENINPATHWAY FOLLOWING ACETAMINOPHEN-INDUCED LIVER INJURY AND REGENRATION.U. M. Apte, A. Micsenyi and S. Monga. Department ofPathology, University of Pittsburgh School of Medicine,Pittsburgh, PA.

#1053 3:50 ROLE OF MITOCHONDRIAL BAXTRANSLOCATION IN ACETAMINOPHEN-INDUCED HEPATIC NECROSIS IN MICE. M.Bajt1, J. J. Lemasters2 and H. Jaeschke1. 1LiverResearch Institute, University of Arizona, Tucson, AZand 2Cell and Developmental Biology, University ofNorth Carolina at Chapel Hill, Chapel Hill, NC.

#1054 4:10 ACETAMINOPHEN-INDUCED UPREGULATIONOF PI-3K AND NF-κκB IN MOUSE LIVER:REGULATION BY TNFαα AND CAVEOLIN-1. C.Gardner1,3, H. Chiu1, J. D. Laskin2,3 and D. L. Laskin1,3.1Rutgers University, Piscataway, NJ, 2UMDNJ-RWJMed. School, Piscataway, NJ and 3EOHSI, Piscataway,NJ.

Tuesday Afternoon, March 81:30 PM to 4:30 PMExhibit Hall

POSTER SESSION: DEVELOPMENTAL NEUROTOXICITY II

Chairperson(s): Merle Paule, U.S. FDA, Jefferson, AR and John Barnett, WestVirginia University, Morgantown, WV.



#1055 EXPOSURE TO METHYLMERCURY ANDPCB153 DURING PREGNANCY ANDLACTATION. EFFECTS ON BRAIN ANDLYMPHOCYTE CHOLINERGIC MUSCARINICRECEPTORS IN RAT DAMS AND PUPS. T.Coccini1, A. F. Castoldi1, G. Randine1, P. Grandjean2

and L. Manzo1,3. 1Toxicology Division, MaugeriFoundation, Pavia, Italy, 2University of Odense,Odense, Denmark and 3University of Pavia, Pavia, Italy.

#1056 DEVELOPMENTAL NEUROPATHOLOGY OFMETHYL MERCURY CHLORIDE. D. M. deGroot1, B. Bisselink1, S. A. Hartgring1, L. van derHorst1, M. Pelgrim1, M. Waanders1, M. Kuijpers1, J.O’Callaghan2, W. Kaufmann3, J. Lammers1, B.Pakkenberg4, I. Waalkens1 and H. Gundersen5. 1TNONutrition and Food Research, Zeist, Netherlands,2NIOSH, Morgantown, VA, 3BASF, Ludwigshafen,Germany, 4Research Laboratory for Stereology andNeuroscience, Copenhagen, Denmark and 5Universityof Aarhus, Aarhus, Denmark. Sponsor: V. Feron.

#1057 PRENATAL EXPOSURE TO METHYLMERCURY OR METHYLAZOXY METHANOL:EFFECTS ON EARLY POSTNATAL MOTORACTIVITY. D. M. de Groot1, M. Kuijpers1, J.O’Callaghan2, M. van Dael1, H. Gundersen3, S.Hartgring1, L. van der Horst1, W. Kaufmann4, M. Otto1,B. Pakkenberg5, M. Pelgrim1, I. Waalkens1 and J.Lammers1. 1TNO Nutrition and Food Research, Zeist,Netherlands, 2NIOSH, Morgantown, VA, 3University ofAarhus, Aarhus, Denmark, 4BASF, Ludwigshafen,Germany and 5Research Laboratory for Stereology andNeuroscience, Copenhagen, Denmark. Sponsor: V.Feron.

#1058 METHYLMERCURY (MEHG) ELICITS ACUTEAND LONG-TERM EFFECTS ON NEWBORNRAT HIPPOCAMPAL NEUROGENESISTHROUGH CELL CYCLE MACHINERY. K.Burke1, Y. Cheng1, K. Reuhl2, A. Petrov1 and E.DiCicco-Bloom1. 1Neurosci & Cell Biol, Robert WoodJohnson Med. Sch, Piscataway, NJ and 2Pharmacol &Toxicology, Rutgers University, Piscataway, NJ.

#1059 MEHG DIFFERENTIALLY AFFECTS KINETICSOF SIPSCS OF RAT CEREBELLAR PURKINJEAND GRANULE CELLS. Y. Yuan and W. D. Atchison.Pharmacology/Toxicology, Michigan State University,East Lansing, MI.

#1060 GESTATIONAL LEAD EXPOSURE PRODUCESROD-MEDIATED ELECTRORETINOGRAPHIC(ERG) SUPERNORMALITY AND DECREASES INRETINAL DOPAMINE METABOLISM OF ADULTRATS. D. A. Fox1 and S. Kala2. 1University ofHouston, Houston, TX and 2Baylor College ofMedicine, Houston, TX.

#1061 GESTATIONAL LEAD EXPOSURE PRODUCES ASELECTIVE DECREASE IN MOUSE RETINALDOPAMINERGIC AMACRINE CELL DENSITYAND DISTRIBUTION. J. E. Johnson, A.Giddabasappa, Q. Chen and D. A. Fox. University ofHouston, Houston, TX.

#1062 DEVELOPMENTAL EXPOSURE TO LEADELEVATES APP AND AββLEVELS IN THE AGINGBRAIN BUT DOES NOT ALTER THEPROTEOLYTIC PROCESSING OF APP. M. Basha,M. Murali, W. Wei, H. K. Siddiqi and N. H. Zawia.Biomediacl and Pharmaceutical Sciences, University ofRhode Island, Kingston, RI.

Program Description


TUESD

AY


#1063 DEVELOPMENTAL EXPOSURE TO LEADMODULATES THE OCT-2 TRANSCRIPTIONFACTOR AND ITS TARGET GENES IN THE RATHIPPOCAMPUS. S. A. Bakheet and N. H. Zawia.Biomediacl and Pharmaceutical Sciences, University ofRhode Island, Kingston, RI.

#1064 MODULATION OF BRAIN CYTOKINE GENEEXPRESSION BY LEAD. J. Kasten-Jolly, N. Pabelloand D. A. Lawrence. Wadsworth Center, Albany, NY.

#1065 NMDAR SUBUNITS WERE AGGRESSIVELYREDUCED BY PB-EXPOSURE IN THE EARLYDEVELOPMENT OF RAT BRAIN. S. xu and B.Rajanna. Alcorn State University, Alcorn state, MS.

#1066 PRENATAL EXPOSURE TO INHALEDMANGANESE ALTERS DOPAMINERGICSUSCEPTIBILITY TO POSTNATALMETHAMPHETAMINE NEUROTOXICITY. A.rinderknecht1 and M. T. Kleinman2. 1EnvironmentalHealth Science and Policy, Univeristy of California,Irvine, Irvine, CA and 2Community and EnvironmentalMedicine, University of California, Irvine, Irvine, CA.

#1067 EFFECTS OF PRENATAL EXPOSURE OF MICETO CHROMIUM PICOLINATE, CHROMIUMCHLORIDE, OR PICOLINIC ACID. M. M. Bailey1,R. D. Hood2,1, J. F. Rasco1, J. G. Boohaker1, V. Stegall1,J. J. Jernigan3 and J. B. Vincent4. 1Department ofBiological Sciences, The University of Alabama,Tuscaloosa, AL, 2Ronald D. Hood & Associates,Toxicology Consultants, Tuscaloosa, AL, 3Departmentof Biology, Stillman College, Tuscaloosa, AL and4Department of Chemistry, The University of Alabama,Tuscaloosa, AL.

#1068 DEXAMETHASONE ALTERS NEURONALDEVELOPMENT: CELL ACQUISITION ANDDIFFERENTIATION IN PC12 CELLS. R. R.Jameson, F. J. Seidler and T. A. Slotkin.Pharmacol/Cancer Biol, Duke U Med. Ctr, Durham,NC.

#1069 PRENATAL OR NEONATAL GLUCOCORTICOIDTREATMENT, AT DOSES COMMENSURATEWITH PHARMACOTHERAPY IN PRETERMINFANTS, DISRUPTS BRAIN DEVELOPMENTAND EVOKES LASTING BEHAVIORALABNORMALITIES. M. L. Kreider, E. D. Levin, F. J.Seidler and T. A. Slotkin. Pharmacology & CancerBiology, Duke University Med. Ctr, Durham, NC.

#1070 PERSISTING BEHAVIORAL CONSEQUENCESOF PRENATAL DOMOIC ACID EXPOSURE INRATS. E. D. Levin1, K. Pizarro1, J. Harrison1, W. Pang1

and J. S. Ramsdell2. 1Department of Psychiatry andBehavioral Sciences, Duke University Med. Ctr,Durham, NC and 2Marine Biotoxins Program, NOAA-National Ocean Service, Charleston, SC.

#1071 PERINATAL PERCHLORATE EXPOSURE INTHE RAT: DOES THYROID STATUS AFFECTBRAIN MORPHOMETRY? S. Schettler1, M. R.Seeley1, T. A. Lewandowski2 and B. D. Beck1. 1GradientCorporation, Cambridge, MA and 2GradientCorporation, Seattle, WA.

#1072 BEHAVIORAL EFFECTS ASSOCIATED WITHCHRONIC DEVELOPMENTAL EXPOSURE TOKETAMINE OR REMACEMIDE IN RATS. L. K.Wright2,1, C. M. Fogle1, E. Pearson3, T. Hammond3 andM. G. Paule1,2. 1Division of Neurotoxicology, NCTR,Jefferson, AR, 2Department of Pharmacology andToxicology, University of Arkansas for MedicalSciences, Little Rock, AR and 3AstraZeneca SafetyAssessment, Leics, United Kingdom.

#1073 EXPOSURE TO KETAMINE DURINGNEONATAL LIFE INDUCES TRIGGEREDAPOPTOTIC NEURODEGENERATION ANDBEHAVIOURAL DEFICITS IN ADULTHOOD. F.Anders1, E. Ponten2, T. Gordh2 and P. Eriksson1.1Department of Environmental Toxicology, UppsalaUniversity, Uppsala, Sweden and 2Department ofAnaesthesiology, Uppsala University, Uppsala, Sweden.

#1074 DEVELOPMENTAL TOXICOLOGY IN THENEONATAL MOUSE: THE USE OF RANDOMLYSELECTED INDIVIDUALS AS STATISTICALUNIT COMPARED TO THE LITTER IN MICENEONATALLY EXPOSED TO PBDE 99. P.Eriksson1, D. von Rosen2, H. Viberg1 and A.Fredriksson1. 1Department of EnvironmentalToxicology, Uppsala University, Uppsala, Sweden and2Department of Biometry and Engineering, SwedishUniversity of Agricultural Sciences, Uppsala, Sweden.

#1075 POSTNATAL DEVELOPMENTALNEUROTOXICITY (DNT): EVALUATION OF P-MENTHANE 3, 8, DIOL BY DERMALADMINISTRATION IN NEONATAL RATS. J. F.Barnett1, D. B. Learn1, A. M. Hoberman1, U. Vedula2

and T. G. Osimitz3. 1Center for Photobiology, CharlesRiver Discovery and Development Services, ArgusDivision, Horsham, PA, 2S.C. Johnson & Sons, Inc.,Racine, WI and 3Science Strategies, LLC,Charlottesville, VA.

#1076 WATER DISINFECTANT BYPRODUCTS (DBP)AND ADVERSE PREGNANCY OUTCOMES(APO): CHLOROACETONITRILE (CAN)INDUCES GROWTH RESTRICTION ANDALTERS GENE EXPRESSION IN FETAL BRAIN.S. Jacob1, T. Wood2, H. Fouad1 and A. E. Ahmed1.1Pathology, University of TX Medical Brach,Galveston, TX and 2Molecular Genomics, University ofTX Medical Brach, Galveston, TX.

#1077 METHAMPHETAMINE-INITIATEDNEURODEVELOPMENTAL DEFICITS AREENHANCED IN COCKAYNE SYNDROME B (CSB)KNOCKOUT MICE. A. W. Wong1, W. Jeng1 and P. G.Wells1,2. 1Faculty of Pharmacy, University of Toronto,Toronto, ON, Canada and 2Department ofPharmacology, University of Toronto, Toronto, ON,Canada.

#1078 PERINATAL DIMETHYLTIN EXPOSUREALTERS SPATIAL LEARNING ABILITY INADULT RATS. K. D. Ehman1, K. L. McDaniel2, P. M.Phillips2 and V. C. Moser2. 1Curriculum in Toxicology,UNC, Chapel Hill, NC and 2NTD/NHEERL, U.S. EPA,Research Triangle Park, NC.

Program Description



TUES

DAY

#1079 PERTURBATION OF NEURAL CELL DAMAGERESPONSE SENSITIZES NRF2 KO MICE,INCREASING THE DURATION AND SEVERITYOF KAINATE-INDUCED SEIZURES. A. D. Kraft1,J. Lee2 and J. A. Johnson1,3,4. 1Pharmacy, University ofWisconsin, Madison, WI, 2Mass General Hospital,Boston, MA, 3Waisman Center, University ofWisconsin, Madison, WI and 4Toxicology, University ofWisconsin, Madison, WI.

#1080 EFFECTS OF PERINATAL EXPOSURE TO PCB153 ON THE TURNOVER OF BRAINNEUROTRANSMITTERS OF OFFSPRING RATS.T. Honma, M. Miyagawa, R. Wang, M. Suda and K.Kobayashi. Department of Research Planning, NationalInstitute of Industrial Health, Kawasaki, Japan. Sponsor:M. Chiba.

#1081 CHANGES IN GENE EXPRESSION PROFILE INTHE CEREBELLUM AND THE HIPPOCAMPUSFOLLOWING DEVELOPMENTAL EXPOSURETO A NEUROTOXICANT. P. R. Kodavanti, T. R.Ward and J. E. Royland. Neurotoxicology Division,U.S. EPA, Research Triangle Park, NC.

#1082 EFFECTS OF PCB 84 ATROPISOMERS ON [3H]PHORBOL ESTER BINDING IN RATCEREBELLAR GRANULE CELLS AND 45CA2+-UPTAKE IN RAT CEREBELLUM. H. Lehmler1, L.W. Robertson1, A. Garrison2 and P. S. Kodavanti3.1Occupational and Environmental Health, University ofIowa, Iowa City, IA, 2National Exposure ResearchLaboratory, Ecosystems Research Division, U.S. EPA,Athens, GA and 3Neurotoxicology Division, Cellularand Molecular Toxicology Branch, U.S. EPA, ResearchTriangle Park, NC.

#1083 PCBs REDUCE THE NUMBER OF DOPAMINENEURONS AND INDUCE NEURONAL CELLDEATH IN ORGANOTYPIC CO-CULTURES OFDEVELOPING RAT STRIATUM ANDSUBSTANTIA NIGRA. G. D. Lyng2, A. Snyder-Keller1,2 and R. F. Seegal1,2. 1NYS Department ofHealth, Wadsworth Center, Albany, NY and2Biomedical Sciences, School of Public Health,University at Albany, Albany, NY.

#1084 ALTERED COGNITIVE FUNCTION ANDDENDRITIC GROWTH IN WEANLING RATSEXPOSED DEVELOPMENTALLY TO AROCLOR1254. D. Yang and P. Lein. CROET, Oregon Health &Science University, Portland, OR.

#1085 DEVELOPMENTAL EXPOSURE TO PCBsCAUSES AUDITORY IMPAIRMENTS IN RATS. B.E. Powers1, J. J. Widholm2, D. M. Gooler1, R. E.Lasky3 and S. L. Schantz1. 1Neuroscience, University ofIllinois, Urbana, IL, 2Psychology, College ofCharleston, Charleston, SC and 3Health Science Center,University of Texas, Houston, TX.

#1086 PCB INDUCED HYPOTHYROXINEMIA ALTERSOLIGODENDROCYTE NUMBERS IN TWOWHITE MATTER TRACTS OF THEDEVELOPING RAT BRAIN. D. Sharlin, R. Bansaland R. Zoeller. Biology Department, University ofMassachusetts, Amherst, MA.

#1087 VITAMIN A HOMEOSTASIS IS DISRUPTED INOFFSPRING OF RAT DAMS EXPOSED TOPBDES DURING GESTATION AND LACTATION.R. Ellis-Hutchings, G. N. Cherr and C. L. Keen.Nutrition, University of California-Davis, Davis, CA.

#1088 TCDD MODULATES GENE EXPRESSIONASSOCIATED WITH CEREBELLAR GRANULENEURON MIGRATION ANDDIFFERENTIATION. M. Williamson and L.Opanashuk. Department Environmental Medicine,University of Rochester, Rochester, NY.

#1089 DEVELOPMENT OF A QUANTITATIVE ASSAYFOR DETERMINATION OF TCDD TOXICEQUIVALENTS IN F1 GENERATION CNSTISSUES. L. Brown1, E. Harris2, A. Smith3, J. Wu1, S.Johnson1 and D. B. Hood1. 1Department ofPharmacology & Center in Molecular and BehavioralNeuroscience, Meharry Medical College, Nashville, TN,2Department of Biology, Xavier University ofLouisianna, New Orleans, LA and 3Department ofBiology, Alabama A & M University, Huntsville, AL.


POSTER SESSION: NERVOUS SYSTEM: METHODS ANDFUNCTIONAL EFFECTS

Chairperson(s): David W. Herr, U.S. EPA, Research Triangle Park, NC andSyed F. Ali, NCTR FDA, Little Rock, AR.



#1090 THE RETURN OF THE “DARK” NEURON. AHISTOLOGICAL ARTIFACT COMPLICATINGNEUROTOXICOLOGIC INTERPRETATION. B. S.Jortner. Laboratory for Neurotoxicity Studies, VirginiaTech, Blacksburg, VA.

#1091 TEN-DAY EXPOSURE TO CARBONYL SULFIDEPRODUCE BRAINSTEM LESIONS ANDCHANGES IN BRAINSTEM AUDITORY EVOKEDRESPONSES IN FISCHER 344N RATS. D. W.Herr1, J. E. Graff1, P. B. Little2, V. C. Moser1, P. M.Phillips1, K. M. Crofton1, D. L. Morgan3 and R. C.Sills3. 1NTD, U.S. EPA, Research Triangle Park, NC,2PAI, Research Triangle Park, NC and 3NIEHS,Research Triangle Park, NC.

#1092 SELECTIVE NEURONAL DEGENERATION INTHE CENTRAL NERVOUS SYSTEM OF RATSEXPOSED TO 3, 3’-IMINODIPROPIONITRILE(IDPN), ALLYLNITRILE (AN), CIS-CROTONONITRILE (CIS-CN), TRANS-CROTONONITRILE (TRANS-CN) AND 2, 4-HEXADIENENITRILE (HDN). J. Llorens and P.Boadas-Vaello. D. Ciencies Fisiologiques II, Universitatde Barcelona, Hospitalet de Llobregat, Catalunya,Spain. Sponsor: K. Crofton.

Program Description


TUESD

AY


#1093 NORMAL VISUAL CONTRAST SENSITIVITY(VCS) AND COLOR VISION OF ADULTS ANDSCHOOL-AGE CHILDREN FOUR TO FIVEYEARS AFTER EXPOSURE TOPERCHLOROETHYLENE (PERC). K. A. Mazor1,R. L. Shultz2, M. Meldrum1, E. Lewis-Michl1, L.Gensburg1 and J. E. Storm1. 1Department of Health,New York State, Troy, NY and 2Cornea Consultants ofAlbany, Slingerlands, NY.

#1094 NEW ASSESSMENT OF NEUROBEHAVIORALCHANGES USING FUNCTIONALOBSERVATIONAL BATTERY (FOB) INMONKEYS. T. yoshikawa, Y. Deguchi, R. Anraku, K.Fukuzaki, G. Kito and R. Nagata. shin NipponBiomedical Laboratories, Ltd., (SNBL), Yoshida,Kagoshima, Japan.

#1095 NEUROBEHAVIORAL ASSESSMENT OF SIXNEUROTOXICANTS IN MALE SPRAGUE-DAWLEY RATS. K. Steinmetz, L. Rausch, A. Robb, G.Ganem, D. Lau, D. Middaugh and J. Mirsalis. SRI Int,Menlo Park, CA.

#1096 ASSESSMENT OF NEUROTOXICITY USINGZEBRAFISH AS A MODEL ORGANISM. N. Roy,C. Ton, Y. Lin and C. Parng. Phylonix Pharmaceuticals,Inc., Cambridge, MA. Sponsor: D. Monteith.

#1097 SENSITIVE DETECTION OF BEHAVIORALIMPAIRMENTS IN MODERATELY LESIONEDMPTP MICE BY AUTOMATED GAIT ANALYSIS.T. Guillot1, J. R. Richardson1,2 and G. W. Miller1,2.1Center for Neurodegenerative Disease, Atlanta, GA and22Environmental and Occupational Health, RollinsSchool of Public Health, Atlanta, GA.

#1098 ALTERATIONS OF GENE EXPRESSION INMICE INDUCED BY MPTP ADMINISTRATION:APPLICATION OF MICROARRAY ANALYSIS. Z.A. Xu1, D. R. Cawthon1, T. Han2, T. A. Patterson1, L.Shi2, H. Fang3, S. Ali1 and W. Slikker1.1Neurotoxicology, NCTR, Jefferson, AR, 2SystemToxicology, NCTR, Jefferson, AR and 3Division ofBioinformatics, Z-Tech Corporation, NCTR, Jefferson,AR.

#1099 MICROARRAY ANALYSIS DETECTED GENEEXPRESSION CHANGES IN PC12 CELLS AFTEREXPOSURE TO THE NEUROTOXIN MPP+ S. F.Ali1, Z. A. Xu1, T. Han2, T. A. Patterson1, L. Shi2, H.Fang3, D. R. Cawthon1 and W. Slikker1.1Neurotoxicology, NCTR, Jefferson, AR, 2SystemsToxicology, NCTR, Jefferson, AR and 3Division ofBioinformatics, Z-Tech Corporation, NCTR, Jefferson,AR.

#1100 COMPARISON OF MEMBRANE POTENTIAL-SENSITIVE FLUORESCENT DYES FORMEASUREMENT OF TOXIN-INDUCEDDEPOLARIZATION IN MURINE NEOCORTICALNEURONS: CHARACTERIZATION OFBREVETOXIN-AND KCL-INDUCEDDEPOLARIZATION. J. H. Peterson and T. F. Murray.Physiology and Pharmacology, University of Georgia,Athens, GA.

#1101 BREVENOL, A NATURAL BREVETOXINANTAGONIST: COMPETITIVE ANTAGONISTOR ALLOSTERIC MODULATOR? E. P. Gold1,2, H.Jacocks2, A. J. Bourdelais2 and D. G. Baden2,1.1Biological Sciences, UNCW, Wilmington, NC and2Center for Marine Science, UNCW, Wilmington, NC.

#1102 FEASIBILITY OF CONTINUOUSINTRACEREBRO-VENTRICULAR (ICV)INFUSION IN THE RAT FOR 28 DAYS. K.Tenneson and C. Copeman. Toxicology, CTBR,Senneville, QC, Canada. Sponsor: M. Vezina.

#1103 TEMPORAL ANALYSIS OF OPIATE-INDUCEDINTRATHECAL GRANULOMATUS MASSESPROGRESSION AND REGRESSION USING MRI.J. W. Allen1, K. Horais1, N. Tozier1, J. Corbeil2, R. F.Mattrey2 and T. L. Yaksh1. 1Anesthesiology, UniversityCA-San Diego, La Jolla, CA and 2Radiology, UniversityCA-San Diego, La Jolla, CA.

#1104 A COMPARATIVE EVALUATION OF ANIMALCHARACTERISTICS AND DEVELOPMENT OFCHOROIDAL NEOVASCULARIZATION (CNV)IN A LASER-INDUCED NON-HUMAN PRIMATEMODEL OF MACULAR DEGENERATION. M.Wills. Development and Discovery Services, CharlesRiver Laboratories, Sparks, NV.

#1105 ALZHEIMER’S DISEASE: THE CYNOMOLGUSMONKEY AS A MODEL IN TOXICOLOGICALRESEARCH? E. Buse, G. Habermann, S. Friderichs-Gromoll, J. Kaspareit and P. Nowak. CovanceLaboratories GmbH, 48163 Muenster, Germany.Sponsor: G. Weinbauer.

#1106 EXPERIMENTAL ALLERGICENCEPHALOMYELITIS (EAE) IN THE FEMALELEWIS RAT. S. Rowton and S. Grainger. CovanceLaboratories Ltd., Harrogate, United Kingdom.Sponsor: D. Everett.

#1107 ANALYSIS OF MYELIN LOSS USINGSCANNING ELECTRON MICROSCOPY (SEM)UNDER FULLY HYDRATED CONDITIONS:VALIDATION IN A MOUSE MODEL OFEXPERIMENTAL AUTOIMMUNEENCEPHALITIS. V. Behar3, E. Blaugrund3, A.Mayk3, E. Raymond3, N. Russek2, M. Horowitz2 and A.Nyska1. 1Laboratory of Experimental Pathology,NIEHS, Research Triangle Park, NC, 2QuantomiX,Ltd.,, Ness Ziona, Israel and 3Research & Development,Teva Pharmaceuticals Ltd.,, Sapir Industrial Zone,Israel.

Program Description



TUES

DAY


POSTER SESSION: FEMALE REPRODUCTIVE

Chairperson(s): Moussa Diawara, University of Southern Colorado, Pueblo,CO and Ulrike Luderer, University of California Irvine, Irvine, CA.



#1108 NEONATAL/PREPUBERTAL EXPOSURE TOBUTYL BENZYL PHTHALATE, BUT NOTBISPHENOL A, CAUSES SUBTLE ALTERATIONSTO THE RAT FEMALE REPRODUCTIVETRACT. C. A. Lamartiniere and E. Abdalla.Pharmacology and Toxicology, University Alabama atBirmingham, Birmingham, AL.

#1109 THE ARYL HYDROCARBON RECEPTOR (AHR)IS REQUIRED FOR NORMAL OVULATION INTHE MOUSE. D. Tomic, C. Greenfeld, J. K. Babusand J. A. Flaws. Epidemiology, University of MarylandSchool of Medicine, Baltimore, MD.

#1110 EFFECTS OF ESTROGEN RECEPTORMODULATORS ON UTERINE PATHOLOGY ANDGENE EXPRESSION. D. T. Gray1, J. A. Styles1, P.Greaves2 and I. N. White1. 1Cancer Studies andMolecular Medicine, MRC Molecular EndocrinologyGroup, Leicester, United Kingdom and 2MRCToxicology Unit, University of Leicester, Leicester,United Kingdom. Sponsor: A. Smith.

#1111 THE ARYL HYDROCARBON RECEPTOR (AHR)REDUCES EXPRESSION OF ENZYMES IN THEESTROGEN BIOSYNTHESIS PATHWAY. C. B.Mainor1, K. Barnett2, D. Tomic2 and J. Flaws2.1University of Maryland Baltimore County, Baltimore,MD and 2University of Maryland School of Medicine,Baltimore, MD.

#1112 THE ARYL HYDROCARBON RECEPTOR (AHR)REGULATES OVARIAN FOLLICLE GROWTHIN VITRO. K. Barnett, D. Tomic and J. Flaws.University of Maryland School of Medicine, Baltimore,MD.

#1113 ACTIVATION OF TH1 PRO-INFLAMMATORYCYTOKINE EXPRESSION BY ARYLHYDROCARBON RECEPTOR (AHR) LIGANDSIN HUMAN UTERINE ENDOMETRIAL CELLS.K. Shiverick1, T. Medrano1, N. Chegini2 and M. James3.1Department of Pharmacology & Therapeutics,University of Florida, Gainesville, FL, 2Department ofObstetrics & Gynecology, University of Florida,Gainesville, FL and 3Department of MedicinalChemistry, University of Florida, Gainesville, FL.

#1114 STIMULATORY AND INHIBITORY EFFECTS OFGENISTEIN ON UTERINE LEIOMYOMA CELLGROWTH IN VITRO IS DETERMINED BY DOSE.L. Castro, A. Moore, L. Yu, C. Bortner, M. Sifre, R.Newbold and D. Dixon. NIEHS, Research TrianglePark, NC.

#1115 SUPEROXIDE ANION, HYDROGEN PEROXIDE,AND HYDROXYL RADICALS IN CIGARETTESMOKE INHIBIT HAMSTER OOCYTECUMULUS COMPLEX PICKUP. C. Gieseke, R.Pederson and P. Talbot. Cell Biology and Neuroscience,University of California, Riverside, Riverside, CA.Sponsor: B. Krieger.

#1116 CHARACTERIZING THE OVOTOXICITY OFCYCLOPHOSPHAMIDE METABOLITES ONCULTURED MOUSE OVARIES IN VITRO. P. J.Devine. Institut Armand-Frappier, Institut national de larecherche scientifique, Pointe Claire, QC, Canada.

#1117 EFFECTS OF BUTHIONINE SULFOXIMINETREATMENT ON THE EXPRESSION OFGLUTAMATE CYSTEINE LIGASE SUBUNITS INTHE RAT OVARY. Y. D. Hoang1, A. P. Avakian2 andU. Luderer2,1,3. 1Community and EnvironmentalMedicine, University of California Irvine, Irvine, CA,2Medicine, University of California Irvine, Irvine, CAand 3Developmental and Cell Biology, University ofCalifornia Irvine, Irvine, CA.

#1118 CUMULATIVE EFFECTS OF THIRAM ANDAMITRAZ ON PREGNANCY MAINTENANCEAND DEVELOPMENT IN THE RAT. D. S. Best, M.G. Narotsky and R. L. Cooper. ReproductiveToxicology Division, U.S. EPA, ORD, NHEERL,Research Triangle Park, NC. Sponsor: T. Stoker.

#1119 DIBROMOACETIC ACID ATTENTUATES ADITHIOCARBAMATE-INDUCED SUPPRESSIONOF THE LH SURGE IN THE RAT. J. M. Goldman,A. S. Murr, A. R. Buckelew, W. McElroy and J. M.Ferrell. Endocrinol. Br., RTD, NHEERL, ORD, U.S.EPA, Res. Triangle Pk., NC. Sponsor: A. Cummings.

#1120 A SINGLE DOSE OF 8-METHOXYPSORALENREDUCES LUTEINIZING HORMONE LEVELSIN FEMALE RATS. M. M. Diawara1 and P. B.Hoyer2. 1Biology, Colorado State University-Pueblo,Pueblo, CO and 2Physiology, University of Arizona,Tucson, AZ.

#1121 EFFECTS OF FEED RESTRICTION ONFERTILITY AND EARLY EMBRYONICDEVELOPMENT IN FEMALE RATS. M. S.Gilman, T. L. Fleeman, R. E. Chapin, M. E. Hurtt andK. K. Terry. Pfizer Global Research & Development,Pfizer Inc., Groton, CT.

#1122 LATE GESTATIONAL ATRAZINE EXPOSUREALTERS MATERNAL NURSING BEHAVIOR INRATS. J. L. Rayner1 and S. E. Fenton2. 1DESE, UNC-Chapel Hill, Chapel Hill, NC and 2RTD, NHEERL,ORD, U.S. EPA, Research Triangle Park, NC.

#1123 PERIPHERAL BENZODIAZEPINE RECEPTORLIGAND PK11195 AFFECTS FEMALEFERTILITY AS DEMONSTRATED IN AN IN-VITRO MOUSE FOLLICLE BIOASSAY. E.Gobbers1, K. Van Wemmel1, J. Smitz2 and R.Cortvrindt1,2. 1EggCentris NV, Zellik, Belgium and2Follicle Biology Laboratory, Vrije Universiteit Brussel,Brussels, Belgium. Sponsor: R. De Coster.

Program Description


TUESD

AY



POSTER SESSION: METALS TOXICOLOGY

Chairperson(s): Elaine M. Faustman, Institute for Risk Analysis & RiskCommunication, Seattle, WA and Donald Sens, University of North Dakota,Grand Forks, ND.



#1124 THE CHEMICAL FORM OF ALUMINUMAFFECTS ITS PARACELLULAR FLUX ACROSSAND UPTAKE INTO CACO-2 CELLS. Y. Zhou1 andR. A. Yokel2,1. 1Graduate Center for Toxicology,University of Kentucky, Lexington, KY and 2College ofPharmacy, University of Kentucky, Lexington, KY.

#1125 ORAL ALUMINUM (AL) BIOAVAILABILITYFROM A FOOD CONTAINING AN AL FOODADDITIVE: RELEVANCE TO THE MAJORSOURCES OF AL EXPOSURE FOR HUMANS. R.A. Yokel1,2 and R. L. Florence1. 1College of Pharmacy,University of Kentucky Medical Center, Lexington, KYand 2Graduate Center for Toxicology, University ofKentucky Medical Center, Lexington, KY.

#1126 DOES ALUMINUM WELDING FUME CAUSECLINICALLY SIGNIFICANT PNEUMOCONIOSISAND LUNG CANCER?–AN ANALYSIS OFSPECIFIC CAUSATION. N. Zheng and B. Thomas.Risk Assessment and Management Group, Inc.,Houston, TX. Sponsor: A. Jabbour.

#1127 PHYSICAL AND CHEMICALCHARACTERIZATION OF BERYLLIUMPARTICLES FROM SEVERAL WORKPLACES INQUEBEC–PART A: DETERMINING METHODSFOR THE ANALYSIS OF LOW LEVELS OFBERYLLIUM. J. Zayed1, M. Rouleau1, C. Dion2, P.Plamondon3, G. Kennedy4 and G. L’Esperance3.1Environmental and occupational Health, University ofMontreal, Montreal, QC, Canada, 2Institut de rechercheRobert-Sauve en sante et en securite du travail,Montreal, QC, Canada, 3Centre for Characterization andMicroscopy of Materials, Polytechnique School,Montreal, QC, Canada and 4Physic Engineer,Polytechnique School, Montreal, QC, Canada.

#1128 PHYSICAL AND CHEMICALCHARACTERIZATION OF BERYLLIUMPARTICLES FROM SEVERAL WORKPLACES INQUEBEC, CANADA. PART B: TIME-OF-FLIGHTSECONDARY ION MASS SPECTROSCOPY. J.Zayed1, M. Rouleau1, C. Dion2, P. Plamondon3 and G.L’Esperance3. 1Environmental and occupational Health,University of Montreal, Montreal, QC, Canada, 2Institutde recherche Robert-Sauve en sante et en securite dutravail, Montreal, QC, Canada and 3Centre forCharacterization and Microscopy of Materials,Polytechnique School, Montreal, QC, Canada.

#1129 HUMAN SUSCEPTIBILITY GENE CONFERSBERYLLIUM HYPERSENSITIVITY ON FVB MICE.L. M. Tarantino1, C. Sorrentino1, Y. Zhu2, E. M. Rubin2,S. S. Tinkle3 and T. Gordon1. 1Department ofEnvironmental Medicine, NYU School of Medicine,Tuxedo, NY, 2Department of Genome Sciences,Lawrence Berkeley National Laboratory, Berkeley, CAand 3NIEHS, Research Triangle Park, NC.

#1130 THE ROLE OF HYPOXIA INDUCIBLE FACTOR1αα IN COBALT CHLORIDE INDUCED CELLDEATH IN MOUSE EMBRYONICFIBROBLASTS. A. Vengellur2,1 and J. LaPres1,3,4.1Biochemistry and Molecular Biology, Michigan StateUniversity, East Lansing, MI, 2Graduate Program inGenetics, Michigan State University, East Lansing, MI,3National Food Safety and Toxicology Center, MichiganState University, East Lansing, MI and 4Center forIntegrative Toxicology, Michigan State University, EastLansing, MI.

#1131 STUDIES OF MECHANISMS OF POTASSIUMDICHROMATE-INDUCED NEPHROTOXICITYIN ISOLATED RAT RENAL CORTICAL SLICES.J. chen and S. K. Chakrabarti. Department ofEnvironmental and Occupational Health, Faculty ofMedicine, Universite de Montreal, Montreal, QC,Canada.

#1132 PROTECTIVE EFFECT OF ALPHA-TOCOPHEROL ON RENAL INJURY CAUSED BYCHROMATE EXPOSURE. L. Arreola-Mendoza1, J.L. Reyes2, M. C. Namorado2, D. Martin2 and L. M. DelRazo1. 1Toxicology, Cinvesta-IPN, Mexico D.F, Mexicoand 2Physiol. Biophs.& Neurosci, Cinvesta-IPN,Mexico D.F, Mexico.

#1133 CHROMIUM(VI) ACTIVATES STAT3 INBRONCHIAL EPITHELIAL CELLS. K. A. O’Hara,R. J. Vaghjiani, L. R. Klei and A. Barchowsky.Environmental and Occupational Health, GraduateSchool of Public Health, University of Pittsburgh,Pittsburgh, PA.

#1134 CARCINOGENIC LEAD CHROMATE INDUCESDNA DOUBLE-STRAND BREAKS ANDACTIVATES ATM KINASE IN HUMAN LUNGCELLS. H. Xie1,2, S. S. Wise1,2, A. L. Holmes1,2 and J.P. Wise1,2. 1Wise Laboratory of Environmental andGenetic Toxicology, University of Southern Maine,Portland, ME and 2Maine Center for Toxicology andEnvironmental Health, University of Southern Maine,Portland, ME.

#1135 REPAIR OF CHROMATE-INDUCEDCHROMOSOME DAMAGE IS MEDIATED BYXRCC1. E. G. Duzevik1,2, S. S. Wise1,2, R. C.Munroe1,2 and J. P. Wise1,2. 1Maine Center forToxicology and Environmental Health, University ofSouthern Maine, Portland, ME and 2Wise Laboratory ofEnvironmental and Genetic Toxicology, University ofSouthern Maine, Portland, ME.

Program Description



TUES

DAY

#1136 IMPAIRMENT OF CHROMIUM-DNA ADDUCTFORMATION BY HYPOXIA. T. J. O’Brien1,2, H. G.Mandel1,2, K. D. Sugden4, A. Komarov3 and S. R.Patierno1,2. 1Pharmacology and Physiology, The GeorgeWashington University Med. Ctr., Washington, DC,2The GW Cancer Institute, The George WashingtonUniversity Med. Ctr., Washington, DC, 3Biochemistryand Molecular Biology, The George WashingtonUniversity Med. Ctr., Washington, DC and 4Chemistry,University of Montana, Missoula, MT.

#1137 ACUTE INHALATION TOXICITY OFTRIMETHYL GALLIUM IN RATS. G. R.Kiplinger1, G. P. Rosini2, S. V. Kala3, E. C. Bisinger,Jr.4 and J. L. Orr4. 1WIL Research Laboratories, Inc.,Ashland, OH, 2Akzo Nobel Polymer Chemicals LLC,Chicago, IL, 3Baylor School of Medicine, Houston, TXand 4Akzo Nobel Chemicals Inc., Chicago, IL.

#1138 OAT1 TRANSPORTS N-ACETYLCYSTEINE(NAC)-S CONJUGATES OF BOTHMETHYLMERCURY AND INORGANICMERCURY IN MDCK CELLS. S. Ahmad and R. K.Zalups. Basic Sciences, School of Medicine, MercerUniversity, Macon, GA.

#1139 MERCURIC CHLORIDE ALTERS BAX-BCL2RATIO IN LEYDIG CELLS TOWARDAPOPTOTIC PATHWAY. M. Mansour, J. Persaud, R.Ricks, K. Ali, H. El-kholy and A. Atkinson. College ofVeterinary Medicine, Nursing & Allied Health,Tuskegee University, Tuskegee, AL. Sponsor: R. Dalvi.

#1140 EFFECTS OF SUBCHRONIC EXPOSURE TOMERCURIC CHLORIDE ON RAT FERTILITYAND REPRODUCTIVE PERFORMANCE: ACROSSOVER MATING TRIAL STUDY. K. A. Ali,A. Atkinson, H. EL-Kholy, M. Mansour, C. Harris, D.Chaney and M. Campbell. College of VeterinaryMedicine, Nursing & Allied Health, TuskegeeUniversity, Tuskegee, AL. Sponsor: R. Dalvi.

#1141 MN INDUCED PULMONARY VEGF-EXPRESSION IN VIVO: A POTENTIALMECHANISM OF PULMONARY TOXICITY. K. K.Divine, M. M. Falgout, T. H. March and S. Bredow.Lovelace Respiratory Research Institute, Albuquerque,NM.

#1142 A POTENTIAL MECHANISM FOR PULMONARYMANGANESE-TOXICITY: MANGANESEINDUCES PULMONARY VEGF EXPRESSION INVITRO. S. Bredow, M. M. Falgout and K. K. Divine.Lovelace Respiratory Research Institute, Albuquerque,NM.

#1143 THE DISTURBANCE OF CELLULAR IRONREGULATION BY SOLUBLE NICKELEXPOSURE AND ITS POSSIBLE MECHANISMS.H. Chen, T. Davidson and M. Costa. EnvironmentalMedicine, New York University, Tuxedo, NY.

#1144 SOLUBLE NICKEL ALTERS IRONHOMEOSTASIS. T. L. Davidson1, H. Chen1, M. D.Garrick2, S. Singleton2 and M. Costa1. 1Department ofEnv. Med., New York University, Tuxedo, NY and2Department of Biochemistry, SUNY Buffalo, Buffalo,NY.

#1145 CHRONIC EXPOSURE TO LEAD IONS FROMLEAD CHROMATE INTERFERES WITHNORMAL MITOTIC PROGRESSION. A. L.Holmes1,2, S. J. Sandwick1,2, S. S. Wise1,2, N. Gordon3,2

and J. P. Wise1,2. 1Wise Laboratory of Environmentaland Genetic Toxicology, University of Southern Maine,Portland, ME, 2Maine Center for Toxicology andEnvironmental Health, University of Southern Maine,Portland, ME and 3Department of Chemistry, Universityof Southern Maine, Portland, ME.

#1146 MICRONUCLEUS FREQUENCY IN BLOODLYMPHOCYTES FROM CHILDRENENVIRONMENTALLY EXPOSED TO LEAD. M.Moreno1,2, F. Rios1, M. Sordo3, E. Vera2, L. C. Acosta-Saavedra2, M. E. Cebrian2, E. S. Calderon-Aranda2 andP. Ostrosky3. 1Facultad de Ciencias Quimico Biologicas,UAG, Chilpancingo, Gro., Mexico, 2Toxicologia,Cinvestav, Mexico, DF, Mexico and 3Instituto deInvestigaciones Biomedicas, UNAM, Mexico, DF,Mexico.

#1147 SPERM NUCLEUS UPTAKES LEAD FROMTESTIS AND EPIDIDYMIS, ALTERING SPERMCHROMATIN CONDENSATION. I. Hernandez-Ochoa1, M. Solis-Heredia1, V. Rosales-Garcia2 and B.Quintanilla-Vega1. 1Toxicology Section, CINVESTAV-IPN, Mexico City, D.F., Mexico and 2CentralLaboratory, CINVESTAV-IPN, Mexico City, D.F.,Mexico.

#1148 ASSOCIATIONS AMONG URIC ACID, LEADBIOMARKERS, RENAL FUNCTION ANDGENETIC POLYMORPHISMS IN KOREANLEAD WORKERS. V. M. Weaver1, B. S. Schwartz1,B. G. Jaar1, A. C. Todd2, K. Ahn3, K. T. Kelsey4, E. K.Silbergeld1, J. Wen1 and B. Lee3. 1Johns HopkinsUniversity BSPH, Baltimore, MD, 2Mount Sinai Schoolof Medicine, New York, 3SoonChunHyang University,Asan, South Korea and 4Harvard School of PublicHealth, Boston, MA.

#1149 PBPK MODELING OF THE EFFECT OFMICROGRAVITY ON THE RELEASE OF LEADFROM BONE INTO BLOOD. H. D. Garcia1 and S.Hays2. 1Life Sciences Systems and Services, WyleLaboratories, Houston, TX and 2Intertox, Lyons, CO.Sponsor: C. Lam.

#1150 PHARMACOKINETICS OF LEAD (PB) INSALIVA OF RATS FOLLOWING AN ACUTEORAL EXPOSURE. K. K. Weitz, D. A. Moore, R. A.Gies, H. Wu and C. Timchalk. Pacific NorthwestNational Laboratory, Richland, WA.

#1151 LEAD DISTRIBUTION FOLLOWINGRESPIRATORY EXPOSURE TO LEAD-CONTAINING MATERIALS IN SPRAGUE-DAWLEY RATS. G. M. Fent1, T. J. Evans1, D.Bannon2, M. Dunsmore1 and S. W. Casteel1. 1VeterinaryPathobiology, University of Missouri, Columbia, MOand 2US Army center for Health Promotion andPreventitive Medicine, Aberdeen Proving Ground, MD.

Program Description


TUESD

AY


#1152 ROLE OF PLASMA GLUTATHIONE IN HEPATICTOXICITY CAUSED BY VANADIUMCOMPOUNDS IN MICE. T. Hasegawa1, M. Satoh2

and Y. Seko1. 1Environmental Biochemistry, YamanashiInstitute of Environmental Sciences, Fujiyoshida,Yamanashi, Japan and 2Department of Hygienics, GifuPharmaceutical University, Gifu, Japan.

#1153 SPLEEN REPERCUSSIONS AFTER CHRONICINHALATION OF VANADIUM PENTOXIDE(V2O5) EVALUATED IN MICE. T. I. FORTOUL1, G.Pinon-Zarate1, A. Gonzalez-Villalva1, V. Rodriguez-Lara1, M. Rojas-Lemus1, P. Mussali-Galante1, M. Avila-Casado1, V. Delgado1, F. Pasos1, B. Chavez1 and M.AVILA-COSTA2. 1Biologia Celular Y Tisular, Facultadde Medicina, UNAM, Mexico, Mexico and2Neuromorfologia, Fes Iztacala, UNAM, Mexico,Mexico.

#1154 ROLE OF OXIDATIVE STRESS IN THEMODULATION OF AHR-REGULATED GENEEXPRESSION BY HEAVY METALS. R. H. Elbekaiand A. O. El-Kadi. University of Alberta, Edmonton,AB, Canada.

#1155 INTEGRATIVE ANALYSIS OF GENOME-WIDEGENE EXPRESSION AND PATHWAY MAPPINGIN MOUSE EMBRYONIC FIBROBLAST (MEF)EXPOSED TO CADMIUM, ARSENIC ANDMETHYLMERCURY: INDUCTION OFOXIDATIVE STRESS, DISRUPTION OFUBIQUITIN-PROTEASOME SYSTEM AND CELLCYCLE REGULATION. X. Yu, J. S. Sidhu, J. F.Robinson, S. Hong and E. M. Faustman. EnvironmentalHealth, IRARC, UW, Seattle, WA.

#1156 EFFECT OF COMBINED LEAD, CADMIUM ANDARSENIC EXPOSURE ON THE EXPRESSION OFCELLULAR PROTECTIVE FACTORS IN RATKIDNEYS AT LOEL DOSE LEVELS. G. Wang, X.Chen, M. M. Lipsky, M. H. Whittaker and B. A. Fowler.Toxicology Program, University of Maryland,Baltimore, MD.

#1157 COMPARISON OF METALS IN CYTOTOXICITY,FREE RADICAL GENERATION, AND HEATSHOCK PROTEIN EXPRESSION IN A HUMANBRONCHIAL EPITHELIAL CELL LINE, BEAS-2B. S. Han1,2 and V. Vallyathan1. 1Pathology andPhysiology Research Branch, National Institute forOccupational Safety and Health, Morgantown, WV and2Genetics and Developmental Biology, West VirginiaUniversity, Morgantown, WV.

#1158 METAL-INDUCED OXIDATION OFTHIOREDOXIN-1 AND THIOREDOXIN-2. J. M.Hansen and D. P. Jones. Medicine, Emory University,Atlanta, GA.

#1159 INDUCTION OF OXIDATIVE STRESS INRESPONSE TO INGESTION OF LEAD,CADMIUM AND ARSENIC MIXTURES. M. H.Whittaker, B. A. Fowler, G. Wang, C. Xue-Qing and M.Lipsky. Toxicology Program, The University ofMaryland, Baltimore, Baltimore, MD.

#1160 CHANGING METAL ACCUMULATION IN NEWORLEANS: DIFFERENCES BETWEEN SURVEYI (1992) AND SURVEY II (2000). H. W. Mielke1, E.Powell1, C. Gonzales1 and P. Mielke (Emeritus)2.1College of Pharmacy, Xavier University, New Orleans,LA and 2Statistics, Colorado State University, FortCollins, CO.


POSTER SESSION: GENE REGULATION: METALS

Chairperson(s): Jay Gandolfi, University of Arizona, Tucson, AZ.



#1161 TOXICOGENOMICAL STUDY ON HUMANBLADDER EPITHELIUM EXPOSED TOARSENIC. X. Zheng1, T. G. Bredfeldt1, G. S. Watts2

and A. Gandolfi1. 1Pharmacology/Toxicology, Collegeof Pharmacy, University of Arizona, Tucson, AZ and2Arizona Cancer Center, University of Arizona, Tucson,AZ.

#1162 DIFFERENTIAL EFFECTS OF CHRONIC LOWLEVEL ARSENIC EXPOSURES ONTRANSCRIPTION FACTOR BINDING INCARDIOVASCULAR TISSUES. L. R. Klei1,2, M. A.Ihnat3, N. V. Soucy2, A. A. Nemec1 and A.Barchowsky1,2. 1Environmental and OccupationalHealth, University of Pittsburgh Graduate School ofPublic Health, Pittsburgh, PA, 2Pharmacology andToxicology, Dartmouth Medical School, Hanover, NHand 3Cell Biology, University of Oklahoma HealthSciences Center, Oklahoma City, OK.

#1163 EUKARYOTIC TRANSLATION INITIATIONFACTOR 4E IS A CELLULAR TARGET FORARSENIC BUT NOT CHROMIUM TOXICITY. P.Joseph and S. Othumpangat. NIOSH, Morgantown,WV.

#1164 EFFECT OF ARSENITE ON PU.1, C/EBPS, ANDNFKB ACTIVATION IN U937 PROMONOCYTICLEUKEMIA CELLS. M. Yamamoto1, S. Hirano1, C.R. Jefcoate2 and F. Matsumura3. 1Environmental HealthSciences Division, National Institute for EnvironmentalStudies, Tsukuba, Ibaraki, Japan, 2Pharmacology,University of Wisconsin-Madison, Madison, WI and3Environmental Toxicology, University of California-Davis, Davis, CA.

#1165 IDENTIFICATION OF MOUSE SLC39A8 AS THETRANSPORTER RESPONSIBLE FORCADMIUM-INDUCED TOXICITY IN THETESTIS. L. He1, T. P. Dalton1, B. Wang1, M. L. Miller1,L. Jin1, K. F. Stringer2, X. Chang1, C. S. Baxter1 and D.W. Nebert1. 1Department of Environmental Health, andthe Center for Environmental Genetics (CEG),University of Cincinnati, Cincinnati, OH and2Department of Pathology, Cincinnati Children’sHospital Medical Center, Cincinnati, OH.

Program Description



TUES

DAY

#1166 ROLE OF EUKARYOTIC TRANSLATIONINITIATION FACTOR 4E (EIF4E) IN CADMIUM-INDUCED CYTOTOXICITY AND CELL DEATH.S. Othumpangat and P. Joseph. Toxicology andMolecular Biology Branch, NIOSH, Morgantown, WV.

#1167 MECHANISMS OF ARSENITE-STIMULATEDHEMEOXYGENASE-1 UPREGULATION INHUMAN KERATINOCYTES. K. L. Cooper and L. G.Hudson. College of Pharmacy, University of NM,Albuquerque, NM.

#1168 MERCURY, CADMIUM, ZINC, AND ARSENITEINHIBIT PAX3 DNA BINDING VIA THE PAIREDDOMAIN. F. A. Leal1, A. F. Machado2, M. D. Collins1

and J. M. Fukuto1. 1Molecular Toxicology IDP,University of California, Los Angeles, CA and2Department of Environmental and OccupationalHealth, California State University, Northridge, CA.Sponsor: O. Hankinson.

#1169 NFκκB MEDIATES ZINC-INDUCED COX-2EXPRESSION IN HUMAN BRONCHIALEPITHELIAL CELLS. W. wu1. 1Center forEnvironmental Medicine, University of North Carolina,Chapel Hill, NC and 2Human Studies Division, U.S.EPA, Research Triangle Park, NC. Sponsor: M.Madden.


POSTER SESSION: PHARMACEUTICALS-METHODS OFEVALUATION

Chairperson(s): Patrick Hayden, MatTek Corporation, Ashland, MA.



#1170 COMPARISON OF BCNU AND SARCNUTOXICITY IN LONG-TERM CULTURES OFPRECISION-CUT LUNG SLICES. C. A. Tyson, K.Amin, C. Ip and H. P. Behrsing. Toxicology Laboratory,SRI International, Menlo Park, CA.

#1171 A HIGH-THROUGHPUT IN VITRO MODEL OFHUMAN TRACHEAL/BRONCHIALEPITHELIUM (EPIAIRWAY) FOR PRECLINICALSAFETY AND EFFICACY TESTING OFPHARMACEUTICALS. P. J. Hayden, G. R. Jackson,J. Kubilus, J. E. Sheasgreen and M. Klausner. MatTekCorp., Ashland, MA.

#1172 VASCULAR PERMEABILITY IN THE RAT. S.Rowton and P. Robinson. Covance Laboratories Ltd.,Harrogate, United Kingdom. Sponsor: D. Everett.

#1173 REDUCED STRESS IN GROUP HOUSED NON-HUMAN PRIMATES. S. Grainger1, J. Hedley1 and M.Niehof2. 1Covance Laboratories Ltd., Harrogate, UnitedKingdom and 2Covance Laboratories GmbH, Munster,Germany. Sponsor: D. Everett.

#1174 PREDICTING ANTIEPILEPTIC DRUGTOXICITY USING HEPATIC PROTEINCOVALENT BINDING AND GENE EXPRESSIONPOTENTIAL. A. M. Leone1, L. M. Kao1, M.McMillian1, A. Y. Nie1, J. B. Parker1, M. F. Kelley1, M.D. Johnson1, E. Usuki2, A. Parkinson2 and P. Lord1.1Mechanistic Toxicology, Johnson & JohnsonPharmaceutical Research & Development, L.L.C.,Raritan, NJ and 2XenoTech LLC, Lenexa, KS.

#1175 IN VIVO AND IN VITRO NON-CLINICAL DRUGSAFETY ASSESSMENT: A KEY PARTNER FORANTICANCER DRUG DEVELOPMENT. N. Lhote1,Y. Sibiril3, D. Bazot1, A. Beamonte1, J. Delongeas1, D.Parent-Massin3 and N. Claude2. 1Servier Group, Gidy,France, 2Servier Group, Courbevoie, France and 3LTAEA3880, UBO Brest, France.

#1176 PHARMACOKINETICS AND ENHANCED ORALBIOAVAILABILITY OF NANOSTRUCTUREDDRUG CRYSTALS: COMPARISON OFPARTICLE ENGINEERING TECHNOLOGIESFOR DANAZOL, KETOCONAZOLE ANDNAPROXEN IN BEAGLE DOGS. G. G.Kupperblatt2, S. A. Saghir1, D. A. Markham1, T. L.Rogers2, C. J. Tucker3, J. E. Hitt2 and E. J. Elder2.1Toxicology & Environmental Research & Consulting,The Dow Chemical Company, Midland, MI,2Dowpharma, The Dow Chemical Company, Midland,MI and 3Corporate R&D, The Dow Chemical Company,Midland, MI.

#1177 REDUCTION AND REFINEMENT INRADIOLABELLED PRIMATE METABOLISMSTUDIES. J. Kelly, J. Hedley and R. Allen. CovanceLaboratories Ltd., Harrogate, United Kingdom.Sponsor: D. Everett.

#1178 ADJUVANT ARTHRITIS IN THE MALE LEWISRAT. S. Rowton and P. Robinson. CovanceLaboratories Ltd., Harrogate, United Kingdom.Sponsor: D. Everett.


POSTER SESSION: SAFETY EVALUATION-NONPHARMACEUTICAL

Chairperson(s): Eugenia Theophilus, R.J. Reynolds Tobacco Company,Winston Salem, NC.



#1179 EVALUATION OF GENOTOXICITY ANDSENSITIZATION POTENTIAL OF PEPTIDECOUPLING REAGENTS. D. A. Seid1, S. S. Kim2 andS. Kim1. 1Applied Biosystems, Foster City, CA and2University of California, Berkeley, CA.

#1180 COMPARISON OF PHOTOTOXICITY TESTINGMETHODS USED TO SCREEN LEADCOMPOUNDS L. LEE, G. STEVENS, AND B.JESSEN. PFIZER GLOBAL R&D. L. Lee. PfizerGlobal R&D, San Diego, CA. Sponsor: G. Stevens.

Program Description


TUESD

AY


#1181 SUBCHRONIC TOXICITY STUDY OFHEXACHLOROBENZENE (HCB) IN FEMALEHARLAN SPRAGUE-DAWLEY RATS. J. D.Johnson1, D. Vasconcelos1, M. Ryan1, A. Fuciarelli2, S.Graves1, M. Hejtmancik1, A. Braen3, M. Vallant4, H.Toyoshiba4, R. Chhabra4, N. Walker4 and M. Hooth4.1Health and Life Sciences, Battelle, Columbus, OH,2Colorado State University, Fort Collins, CO,3Hoffmann-La Roche, Nutley, NJ and 4NIEHS, NIH,Research Triangle Park, NC.

#1182 SUBCHRONIC TOXICITY OF ALPHA-METHYL-1, 3-BENZODIOXOLE-5-PROPIONALDEHYDEIN RATS. A. Lapczynski, D. Isola and A. Api. ResearchInstitute for Fragrance Material, Inc., Woodcliff Lake,NJ.

#1183 SUBCHRONIC TOXICITY OF ACETYLCEDRENE IN RATS. C. Letizia, D. A. Isola and A.Api. Research Institute for Fragrance Materials, Inc.,Woodcliff Lake, NJ.

#1184 CNS AND CARDIORESPIRATORY EFFECTS OFTWO NOVEL BISPYRIDINIUM OXIMES (ICD-39AND ICD-585). F. T. Chang, D. Spriggs and S. DeBus.Applied Pharmacology, USAMRICD, APG-EA, MD.Sponsor: A. Sciuto.

#1185 TOXICOLOGICAL EVALUATION OFCIGARETTES WITH TWO BANDEDCIGARETTE PAPER TECHNOLOGIES. E. H.Theophilus, D. R. Meckley, K. W. Shreve, P. H. Ayres,B. R. Bombick, M. F. Borgerding, C. D. Garner, D. H.Pence and J. E. Swauger. Research & Development, R.J. Reynolds Tobacco Company, Winston-Salem, NC.

#1186 TOXICOLOGICAL EVALUATION OF ACIGARETTE PAPER WITH REDUCEDIGNITION PROPENSITY: IN VITRO AND INVIVO TESTS. M. Misra1, R. D. Leverette1, J. T.Hamm1, M. B. Bennett1, J. D. Heck1, R. Morrissey2 andN. Rajendran3. 1Lorillard Tobacco Company,Greensboro, NC, 2PAI, Chicago, IL and 3IIT ResearchInstitute, Chicago, IL.

#1187 TOXICOLOGICAL EVALUATION OFDIAMMONIUM PHOSPHATE (DAP) AND UREAAS INGREDIENTS ADDED TO CIGARETTETOBACCO. M. S. Stavanja, P. H. Ayres, G. M. Curtin,B. R. Bombick, M. F. Borgerding, C. D. Garner, D. H.Pence and J. E. Swauger. R.J. Reynolds TobaccoCompany, Winston-Salem, NC.

#1188 IN VITRO TOXICITY EVALUATION OFTOOTHPASTES USING RECONSTRUCTEDHUMAN ORAL AND GINGIVAL MUCOSAMODELS. B. De Wever1, B. Vande Vannet2, P.Bottenberg2 and M. Cappadoro1. 1SkinEthicLaboratories, Nice, France and 2Free University ofBrussels, Brussels, Belgium.

#1189 IN VITRO SAFETY EVALUTION STUDIES OFLUTEIN AND ZEAXANTHIN. X. Chen1, B. A.Fowler2 and F. Khachik3. 1Program in Toxicology,Department of Epidemiology & Preventive Medicine,University of Maryland, Baltimore, Baltimore, MD,2Division of Toxicology, Agency for toxic Substancesand Disease Registry, Atlanta, GA and 3Chemistry andBiochemistry, University of Maryland, College Park,MD.

#1190 AEROSOL CHARACTERIZATION FORCONSUMER LAUNDRY ENZYME-CONTAININGSTAIN REMOVERS. F. Ayala-Fierro1, D. P. Davis1, J.Billman2, C. Jeng3, R. E. Rogers3 and A. Lefebvre3.1Clinical Studies and Toxicology, The Dial Corporation,Scottsdale, AZ, 2Research and Development, The DialCorporation, Scottsdale, AZ and 3Toxcon HSRC,Edmonton, AB, Canada.


POSTER SESSION: HYPERSENSITIVITY II

Chairperson(s): Frank Gerberick, Procter & Gamble, Miami ValleyLaboratories, Cincinnati, OH.



#1191 ENHANCING EFFECT OF CHLORINATEDORGANIC SOLVENTS ON INFLAMMATORYMEDIATOR PRODUCTION. M. Seo, M. Satoh andH. Nagase. DEPARTMENT OF HYGIENICS, GIFUPHARMACEUTICAL UNIVERSITY, GIFU, Japan.

#1192 RELATIONSHIP BETWEEN CD86/CD54EXPRESSION AND CELL VIABILITY IN INVITRO SKIN SENSITIZATION TEST OF WATER-SOLUBLE CHEMICALS USING THP-1 CELLS. T.Ashikaga1, H. Sakaguchi2, K. Yoneyama1, S. Sono1, M.Miyazawa2, Y. Yoshida2, Y. Ito2, H. Suzuki2, H. Itagaki1

and H. Toyoda1. 1Shiseido Co., Ltd.,, Kanagawa, Japanand 2Kao Corporation, Tochiga, Japan.

#1193 THE RELASHIONSHIP BETWEEN CD86/CD54EXPRESSION AND THP-1 CELL VIABILITY INAN IN VITRO SKIN SENSITIZATION TEST FORWATER-INSOLUBLE CHEMICALS. H.SAKAGUCHI1, T. ASHIKAGA2, M. MIYAZAWA1, Y.YOSHIDA1, Y. ITO1, K. YONEYAMA2, S. SONO2, H.ITAGAKI2, H. TOYODA2 and H. SUZUKI1. 1KaoCorporation, Tochigi, Japan and 2Shiseido Co., Ltd.,,Kanagawa, Japan.

#1194 PHENOTYPIC ALTERATIONS AND CYTOKINEPRODUCTION IN THP-1 CELLS IN RESPONSETO ALLERGENS. M. MIYAZAWA, Y. ITO, Y.YOSHIDA, H. SAKAGUCHI and H. SUZUKI. KaoCorporation, TOCHIGI, Japan. Sponsor: J. AVALOS.

#1195 EVALUATION OF CYTOKINES RELEASE FROMTHP-1 CELLS AS PREDICTIVE MARKERS OFCONTACT SENSITIZATION. R. Slim, R. Petty, M.S. LaGattuta and J. R. Piccotti. Worldwide SafetySciences, Pfizer Global Research & Development, AnnArbor, MI.

Program Description



TUES

DAY

#1196 USE OF HISTORICAL LOCAL LYMPH NODEDATA IN THE DEVELOPMENT OFALTERNATIVE TEST METHODS FOR SKINSENSITIZATION. C. Ryan1, P. Kern2, D. Basketter3,G. Patlewicz3, R. Dearman4, I. Kimber4 and F.Gerberick1. 1Procter & Gamble Company, Cincinnati,OH, 2Procter & Gamble Company, Brussels, Belgium,3SEAC, Unilever, Sharnbrook, United Kingdom and4Central Toxicology Laboratory, Syngenta,Macclesfield, United Kingdom.

#1197 DEVELOPMENT OF A PEPTIDE REACTIVITYMODEL FOR SCREENING THE SKINSENSITIZATION POTENTIAL OF CONTACTALLERGENS. J. D. Vassallo1, J. G. Chaney1, R. E.Bailey1, S. W. Morrall1, B. B. Price1, J. Lepoittevin2

and F. G. Gerberick1. 1Central Product Safety, Procter& Gamble, Cincinnati, OH and 2Laboratorie deDermatochimie, Universite Louis Pasteur, Strasburg,France.

#1198 IDENTIFICATION OF POTENTIAL MARKERSFOR THE PREDICTION OF SKINSENSITIZATION: REAL-TIME PCR ANALYSISOF ALLERGEN-TREATED DENDRITIC CELLS.L. Gildea1, C. A. Ryan1, B. C. Hulette1, L. Foertsch1, R.J. Dearman2, I. Kimber2 and F. Gerberick1. 1Procter &Gamble Company, Cincinnati, OH and 2SyngentaCentral Toxicology Laboratory, Macclesfield, UnitedKingdom.

#1199 EFFECTS OF LIPOPHILICITY AND VISCOSITYOF SOLVENTS ON DPM/LN BACKGROUNDLEVEL IN MURINE LOCAL LYMPH NODEASSAY (LLNA). W. Wang-Fan, L. G. Ullmann and G.Arcelin. Toxicology, RCC Ltd., Fuellinsdorf,Switzerland. Sponsor: K. Sachsse.

#1200 INFLUENCE OF AGEING ON LOCAL LYMPHNODE ASSAY RESPONSES TO HEXYLCINNAMIC ALDEHYDE. C. Betts, A. Banyard, L.Beresford, R. J. Dearman and I. Kimber. SyngentaCTL, Macclesfield, Cheshire, United Kingdom.

#1201 CORRELATION OF LLNA AND HUMAN SKINSENSITISATION THRESHOLDS. D. A. Basketter1,C. Clapp1, B. Safford1, D. Jefferies1, I. Kimber2, R.Dearman2, C. A. Ryan3 and F. Gerberick3. 1SEAC,Unilever, Sharnbrook, United Kingdom, 2SyngentaCTL, Macclesfield, United Kingdom and 3Procter &Gamble, Cincinnati, OH.

#1202 POTENCEY ESTIMATIONS FOR SEVERALFRAGRANCE MATERIALS IN THE LOCALLYMPH NODE ASSAY AND THEIRCORRELATION TO HUMAN STUDIES. J. Lalkoand A. Api. Research Institute for Fragrance Materials,Inc., Woodcliff Lake, NJ.

#1203 ASSESSMENT OF THE LOCAL LYMPH NODEASSAY USING A MODIFIED LOATSAUTOMATED MICRONUCLEUS ASSAYSYSTEM. J. Kerzee, Y. Xu and J. W. Parton.MicaGenix, Inc., Greenfield, IN.

#1204 CYTOKINE EXPRESSION PROFILES OF CD4AND CD8 CELLS FROM PEANUT ALLERGEN-PRIMED MICE. P. Wachholz, R. J. Dearman and I.Kimber. Immunology, Syngenta Central ToxicologyLaboratory, Macclesfield, United Kingdom.

#1205 ORAL AND SUBCUTANEOUS EXPOSURE TOPURIFIED PEANUT ALLERGENS AND PEANUTEXTRACT: THE FOOD MATRIX EFFECT. F. vanWijk1,2, R. Pieters1, S. Nierkens1, S. Koppelman2 andL. Knippels2. 1Immunotoxicology, IRAS, Utrecht,Netherlands and 2TNO, Zeist, Netherlands.

#1206 INFLUENCE OF BACTERIAL ENDOTOXIN ONIGE ANTIBODY RESPONSES PROVOKED INMICE BY PROTEIN ALLERGENS. R. J. Dearman1,D. Fox2, S. Attenborough2 and I. Kimber1. 1SyngentaCTL, Macclesfield, United Kingdom and 2SyngentaJealotts Hill, Bracknell, United Kingdom.

#1207 CYTOKINE FINGERPRINTING OF CHEMICALALLERGENS : COMPARISONS OF MESSAGEVERSUS PROTEIN. B. Flanagan1, C. J. Betts2, H. T.Caddick2, R. J. Dearman2 and I. Kimber2. 1LiverpoolUniversity, Liverpool, United Kingdom and 2SyngentaCTL, Macclesfield, United Kingdom.

#1208 IMPACT OF ROUTE AND INTENSITY OFEXPOSURE DURING SENSITIZATION IN BNRATS. J. H. Arts1, N. Bloksma2,3, A. H. Penninks1 andF. Kuper1. 1TAP, TNO Nutrition and Food Research,Zeist, Netherlands, 2Utrecht Institute for PharmaceuticalSciences, Utrecht, Netherlands and 3Faculty of Biology,Utrecht University, Utrecht, Netherlands. Sponsor: V.Feron.

#1209 TOPICAL EXPOSURE OF MICE TOPHTHALATE IS WITHOUT ADJUVANT EFFECT.D. Shaw, R. J. Dearman and I. Kimber. Syngenta CTL,Macclesfield, United Kingdom.

#1210 AUGMENTATION OF OVALBUMIN-INDUCEDIGE AND AIRWAY HYPERREACTIVITYRESPONSE BY PERFLUOROOCTANOIC ACID(PFOA). K. J. Fairley1, S. Kearns1, L. P. Myers1, R.Purdy2 and B. J. Meade1. 1Agriculture andImmunotoxicology Group, NIOSH, Morgantown, WVand 2Independent Toxiologist, River Falls, WI.

#1211 EVALUATION OF DERMAL SENSITIZATION TOWESTERN RED CEDAR EXTRACT ANDABIETIC ACID USING THE LOCAL LYMPHNODE ASSAY. R. A. Brundage, S. Azadi, B. J. Meade,P. D. Siegel and D. N. Weissman. HELD/ASB, NIOSH,Morgantown, WV.

#1212 INDUCTION OF CONTACT SENSITIZATION BYANNATTO EXTRACT BIXIN BUT NOT BYNORBIXIN IN FEMALE BALB/C MICE. W.Auttachoat1, D. R. Germolec2, K. L. White Jr1 and T. L.Guo1. 1Virginia Commonwealth University, Richmond,VA and 2NIEHS, Research Triangle Park, NC.

#1213 DIFFERENTIAL ALLERGIC ANDNEUROTROPHIN RESPONSES TO FUNGALCOMPONENT EXTRACTS IN MICE. M. Ward1, N.Haykal-Coates1, Y. Chung2, L. Copeland1 and M.Selgrade1. 1NHEERL, U.S. EPA, Research TrianglePark, NC and 2SPH, UNC, Chapel Hill, NC.

Program Description


TUESD

AY


#1214 EFFECTS OF DIESEL EXHAUST ONPULMONARY RESPONSES DURING ALLERGICSENSITIZATION TO AEROSOLIZEDOVALBUMIN IN BALB/C MICE. P. Singh1, M. J.Daniels1, D. L. Andrews1, E. H. Boykin1, T. Krantz1, W.P. Linak2 and I. Gilmour1. 1NHEERL, U.S. EPA,Research Triangle Park, NC and 2NRMRL, U.S. EPA,Research Triangle Park, NC.


POSTER SESSION: SIGNAL TRANSDUCTION I

Chairperson(s): Russell Thomas, CIIT, Research Triangle Park, NC.



#1215 GLABRIDIN INHIBITS INDUCIBLE NITRICOXIDE SYNTHASE EXPRESSION BYBLOCKING NUCLEAR FACTOR-κκBACTIVATION IN MURINE MACROPHAGES. J.Kang, Y. Yoon, I. Cho, M. Han, C. Lee, S. Park and H.Kim. Bioevaluation Center, Korea Research Institute ofBioscience and Biotechnology, Taejon, South Korea.

#1216 RHOA/ROCK SIGNALING NEGATIVELYREGULATES NUCLEAR FACTOR KAPPA B (NF-κκB) ACTIVATION VIA MODULATION OF IκκBααLEVELS IN KIDNEY EPITHELIAL CELLS. M. E.Ellis, W. W. Polk, J. V. Kushleika, P. L. Simmonds and J.S. Woods. Environmental Health, University ofWashington, Seattle, WA.

#1217 INDUCTION OF NUCLEAR FACTOR-KBACTIVATION THROUGH TAK1 AND NIK BYDIESEL EXHAUST PARTICLES IN L2 CELLLINES. J. Lee2, K. Lee2, Y. Lim1, H. Kim3 and H.Sohn4. 1Occ. & Env. Med., St. Mary’s Hospital, Seoul,South Korea, 2Pharmacology, The Catholic. Universityof Korea, Seoul, South Korea, 3Internal Med.,Youngdong Severance Hospital, Seoul, South Korea and4Preventive Med., Inje University, Busan, South Korea.Sponsor: I. Yu.

#1218 APPLICATION OF A HIGH-COVERAGE,FUNCTIONAL GENOMIC SCREEN TO DISSECTTHE NFκκB SIGNALING PATHWAY. T. A. Halsey, T.J. Page, L. Pluta and R. S. Thomas. CIIT Centers forHealth Research, Research Triangle Park, NC.

#1219 TRPV1 ANTAGONISTS INDUCETRANSLOCATION OF INTRACELLULARTRPV1 TO THE PLASMA MEMBRANEENHANCING VANILLOID-INDUCEDTOXICITIES. M. E. Johansen1, C. A. Reilly1, D. L.Lanza1, J. Lee2 and G. S. Yost1. 1Department ofPharmacology and Toxicology, University of Utah, SaltLake City, UT and 2College of Pharmacy, SeoulNational University, Shinlim-Dong, South Korea.

#1220 INDUCTION OF ORGANIC ANIONTRANSPORTING POLYPEPTIDE 2 EXPRESSIONBY CYCLIC AMP-DEPENDENT SIGNALINGPATHWAY IN MOUSE HEPA-1 CELLS. C. Chen, X.G. Cheng and C. D. Klaassen. University of KansasMedical Center, Kansas City, KS.

#1221 TOBACCO SMOKE-INDUCED EPITHELIALCELL PROLIFERATION AND SQUAMOUSMETAPLASIA IN THE LUNGS OF RATS: ROLEOF MAPK/AP-1 PATHWAY. C. Zhong, Y. Zhou andK. E. Pinkerton. CHE, University of California, Davis,CA.

#1222 MAPPING GENE EXPRESSION NETWORKS:USING WHOLE GENOME EXPRESSIONANALYSIS WITH RNAI TO DEFINE THE HEATSHOCK SIGNAL TRANSDUCTION CASCADE. T.Page, T. Halsey, L. Pluta and R. S. Thomas. CIIT,Research Triangle Park, NC.

#1223 IDENTIFICATION OF SIGNALING PATHWAYSACTIVATING REACTIVE GLIOSIS INMULTIPLE MODELS OF BRAIN INJURY: AGENOMIC, PROTEOMIC AND PROTEINPHOSPHORYLATION ANALYSIS. K. Sriram and J.P. O’Callaghan. Centers for Disease Control &Prevention (CDC)-NIOSH, Morgantown, WV.

#1224 CHANGES IN EXPRESSION OF TOTAL ANDPHOSPHORYLATED ERK1/2 IN TCDD-EXPOSED EMBRYONIC MOUSE PALATES. C. J.Wolf and B. Abbott. Reproductive Toxicology Division,U.S. EPA, ORD, NHEERL, Research Triangle Park,NC.

#1225 INTERACTIONS WITH THE TGF-ββ SIGNALINGPATHWAY: A KEY MECHANISM OFDEVELOPMENTAL TOXICITY? T. W. Thomas1,2

and C. A. Kimmel2. 1AAAS Risk Policy Fellow,Washington, DC and 2NCEA, U.S. EPA, Washington,DC.

#1226 DIABETES-INDUCED NEPHROPATHYASSOCIATES WITH AKT AND P38 KINASEACTIVATION. Y. Song, R. Wu, M. Barati, M. Raneand L. Cai. Medicine, University of Louisville,Louisville, KY.


POSTER SESSION: DISPOSITION/PHARMACOKINETICS

Chairperson(s): James Bruckner, University of Georgia, Athens, GA.



#1227 DISPOSITION OF TCDD IN A MOUSE MODELOF OBESITY AND TYPE II DIABETES. J. J.Diliberto, M. J. DeVito, D. G. Ross, V. M. Richardsonand L. S. Birnbaum. NHEERL, U.S. EPA, ResearchTriangle Park, NC.

Program Description



TUES

DAY

#1228 MATERNAL AND FETAL DISPOSITION OFGENISTEIN GLUCURONIDE AND SULFATECONJUGATES FOLLOWING 14-DAY IN UTEROEXPOSURE TO GENISTEIN. N. V. Soucy, H. D.Parkinson, M. A. Sochaski and S. J. Borghoff. CIITCenters for Health Research, Research Triangle Park,NC.

#1229 THE CANALICULAR TRANSPORTERMULTIDRUG RESISTANCE-ASSOCIATEDPROTEIN 2 FACILITATES BILIARYEXCRETION OF DIETHYLSTILBESTROL. M. Z.Dieter, T. L. Callaghan and C. D. Klaassen. Universityof Kansas Medical Center, Kansas City, KS.

#1230 DISPOSITION OF 2, 2′′, 4, 4′′, 5, 5′′-HEXABROMODIPHENYL ETHER IN F344 RATSAND B6C3F1 MICE. E. H. Lebetkin1, J. M.Sanders1,2, A. C. Creech1,3 and L. T. Burka1. 1LPC,NIEHS, Research Triangle Park, NC, 2Department ofToxicology, NCSU, Raleigh, NC and 3NCSU, Raleigh,NC.

#1231 METABOLISM AND TISSUE DOSIMETRY OFPENTAVALENT AND TRIVALENTMONOMETHYLATED ARSENIC AFTER ORALADMINISTRATION IN MICE. M. F. Hughes1, V.Devesa2, B. M. Adair1, M. Styblo2, E. M. Kenyon1 andD. J. Thomas1. 1ORD/NHEERL, U.S. EPA, ResearchTriangle Park, NC and 2CEMALB, University of NorthCarolina, Chapel Hill, NC.

#1232 PHARMACOKINETIC EVALUATION OFPERFLUOROOCTANOIC ACID IN THE MOUSE.C. Lau1, M. J. Strynar2, A. B. Lindstrom2, R. G.Hanson1, J. R. Thibodeaux1 and H. A. Barton3.1Reproductive Toxicology Division, NHEERL, ORD,U.S. EPA, Research Triangle Park, NC, 2HumanExposure and Atmospheric Sciences Division, NERL,ORD, U.S. EPA, Research Triangle Park, NC and3Experimental Toxicology Division, NHEERL, ORD,U.S. EPA, Research Triangle Park, NC.

#1233 INITIAL SKIN PENETRATION STUDY FORDETERMINING BIS-(2-CHLOROETHOXY)METHANE (CEM)TOXICOKINETICS AFTER A SINGLE DERMALAPPLICATION IN RODENTS. S. HONG1, J. D.Johnson1, S. W. Graves1, B. Burback1, J. Merrill1 andC. SMITH2. 1Battelle Memorial Institute, Columbus,OH and 2NIEHS, NIH, Research Triangle Park, NC.

#1234 RODENT PLASMA AND TISSUECONCENTRATION TIME COURSE DATA FORBIS (2-CHLOROETHOXY)METHANE: APRELIMINARY IV STUDY. J. W. Merrill1, J. D.Johnson1, S. Hong1, S. W. Graves1, B. Burback1 and C.Smith2. 1Battelle, Columbus, OH and 2NIEHS, NIH,Research Triangle Park, NC.

#1235 EFFECTS OF PARTICLE SIZE ON THESYSTEMIC BIOAVILABILITY IN RATSFOLLOWING INHALATION EXPOSURE. S. Hu1,B. Naumann2, M. Cwik1 and N. Rajendran1. 1IITResearch Institute, Chicago, IL and 2Merck & Co., Inc.,Whitehouse Station, NJ.

#1236 EVALUATION OF THE HALF-LIFE (T1/2) OFELIMINATION OF PERFLUOROOCTANOATE(PFOA) FROM HUMAN SERUM. D. Ehresman1, G.Olsen1, J. Burris1, J. Froehlich2, A. Seacat1 and J.Butenhoff1. 1Medical Department, 3M Company, St.Paul, MN and 2Pace Analytical, St. Paul, MN.

#1237 DISPOSITION OF [14C]DECAMETHYLCYCLOPENTASILOXANE([14C]D5) IN FISCHER 344 RATS FOLLOWINGSINGLE AND MULTIPLE INHALATIONEXPOSURE. J. M. Tobin, D. A. McNett, J. A. Durhamand K. P. Plotzke. Health and Environmental Sciences,Dow Corning Corporation, Auburn, MI.

#1238 TOXICOKINETICS OF 14C-RDX IN MINIATUREPIGS. G. Reddy1, M. A. Major1, M. A. Berge2 and S.Patzer2. 1Directorate Toxicology, U.S.Army Center forHealth Promotion and Preventive Medicine, AberdeenProving Ground, MD and 2Covance Laboratories Inc.,Madison, WI.

#1239 TOXICOKINETICS OFTETRABROMOBISPHENOL A IN HUMANSUBJECTS. W. Dekant, W. Voelkel and U. Schauer.Department of toxicology, University of Wuerzburg,Wuerzburg, Germany.

#1240 TISSUE DISTRIBUTION OF 14C-ACETAMINOPHEN IN THE MONKEY USINGQUANTITATIVE AUTORADIOLUMINOGRAPHYOR LIQUID SCINTILLATION COUNTING. O.Boutherin-Falson1, L. Faure1, A. Raynard1, M.Maynaud1 and J. Descotes2. 1MDS PharmacologyServices, St Germain s/ L’Arbresle, France and 2PoisonCenter, Lyon, France.

#1241 ETHYLENE GLYCOL UPTAKE INVOLUNTEERS EXPOSED BY INHALATION ANDBY THE DERMAL ROUTE. S. Upadhyay, J.Carstens, T. H. Faller, H. Greim, G. A. Csanady and J.G. Filser. Toxicology, GSF, Neuherberg, Germany.

#1242 STRATEGIES TO ASSESS SYSTEMICEXPOSURE OF TEST MATERIAL INSUBCHRONIC STUDIES. S. A. Saghir, A. L.Mendrala, M. J. Bartels, S. J. Day, S. C. Hansen, J. M.Sushynski and J. S. Bus. Toxicology & EnvironmentalResearch & Consulting, The Dow Chemical Company,Midland, MI.

#1243 THE EFFECT OF DOSE ON THE METABOLICPROFILE OF TRICHLOROETHYLENE. C. Hines2,S. Muralidhara2, C. A. White2 and J. V. Bruckner2.1University Of Georgia, Athens, GA, 2Pharmaceuticaland Biomedical Sciences, UGA, Athens, GA, 3UGA,Athens, GA and 4UGA, Athens, GA.

#1244 MATERNAL AND FETAL DISPOSITION OFLAMIVUDINE, ZIDOVUDINE, ANDLAMIVUDINE-ZIDOVUDINE IN THEPREGNANT RAT. S. Lewis1, Y. Alnouti2, M. Bartlett1

and C. White1. 1Pharmaceutical and BiomedicalSciences, University of Georgia, Athens, GA and2University of Kansas Medical Center, Kansas City, KS.Sponsor: J. Bruckner.

Program Description


TUESD

AY


#1245 TOXICOKINETICS OF DELTAMETHRIN INDIFFERENT VEHICLES IN RATS. H. J. Kim, K.Kim, S. Muralidhara and J. V. Bruckner. Pharmaceuticaland Biomedical Sciences, University of Georgia,Athens, GA.

#1246 PHARMACOKINETICS AND TOXICOKINETICSOF PHOSPHORODIAMIDATE MORPHOLINOOLIGOMERS AGAINST HEPATITIS C VIRUSAFTER SINGLE INTRAVENOUS INJECTION. A.Amantana, M. Cate, M. Reddy, D. Weller and P.Iversen. Toxicology, AVIBioPharma, Inc., Corvallis,OR.

#1247 TOXICOKINETIC STUDY FORDELTAMETHRIN AND ITS METABOLITE, 3-PHENOXYBENZOIC ACID, IN IMMATURE ANDADULT RATS. K. Kim, J. V. Bruckner and H. Kim.Pharmaceutical and Biomedical Sciences, University ofGeorgia, Athens, GA.

#1248 UPTAKE AND DISPOSITION OF INHALEDMETHANOL VAPORS IN HUMANS. L. Ernstgard1,G. Johanson1 and E. Shibata2. 1Institute ofEnvironmental Medicine, Karolinska Institutet,Stockholm, Sweden and 2Department of Health andPsycosocial Medicine, Aichi Medical University Schoolof Medicine, Nagakute-cho, Japan.

#1249 PERCUTANEOUS ABSORPTION OF WATERSOLUTION OF TRICHLOROETHYLENE INVOLUNTEERS DURING PRE-STEADY ANDSTEADY STATE. I. Jakasa1, J. Kruse2 and S. Kezic1.1Coronel Institute, Academic Medical Centre,Amsterdam, Netherlands and 2Kinetox, Vleuten,Netherlands. Sponsor: P. Boogaard.

#1250 INFLUENCE OF HEPATIC CLEARANCE ONTHE TOXICITY OF THE TYPE I PYRETHROIDSBIFENTHRIN AND PERMETHRIN. E. J. Scollon1,R. Tornero-Velez2, S. J. Godin3, M. F. Hughes1 and M. J.DeVito1. 1ORD/NHEERL, U.S. EPA, Research TrianglePark, NC, 2ORD/NERL, U.S. EPA, Research TrianglePark, NC and 3Curriculum in Toxicology, University ofNorth Carolina, Chapel Hill, NC.

#1251 METABOLISM OF DI(2-ETHYLHEXYL)PHTHALATE (DEHP) IN JUVENILE AND FETALMARMOSET AND RAT. Y. Kurata, F. Makinodan, N.Shimamura, M. Okada and M. Katoh. MitsubishiChemical Safety Institute Ltd.,, Ibaraki, Japan. Sponsor:M. Tsuchitani.

#1252 TRANSPLACENTAL TOXICOKINETICS OF 3’-AZIDO-3’-DEOXYTHYMIDINE (AZT) IN MICE.B. Collins2, S. Black1, P. Patel1, J. Demeter1, J. Blake1,S. Cooper1, R. Fernando1, M. Veselica1 and C. Garner1.1DMPK, RTI International, Research Triangle Park, NCand 2NIEHS, Research Triangle Park, NC.

#1253 DISPOSITION OF BDE 99 AND BDE 153 INFEMALE MICE. D. Bauer1, D. F. Staskal1, J. J.Dileberto2 and L. S. Birnbaum2. 1Curriculum inToxicology, University of North Carolina–Chapel Hill,Chapel Hill, NC and 2Experimental ToxicologyDivision, U.S. EPA, Research Triangle Park, NC.

#1254 DEVELOPMENT OF AN IN VITRO BLOOD-BRAIN BARRIER MODEL FOR BRAINDISPOSITION SCREENING OFPHARMACEUTICALS. G. Stolper, M. Klausner, J. E.Sheasgreen and P. J. Hayden. MatTek Corp., Ashland,MA.

#1255 PHARMACOKINETICS OF TAFA93, A NOVELPRO-DRUG OF THE MTOR INHIBITORRAPAMYCIN. D. G. Freitag, M. D. Abel, L. J.Aspeslet, P. R. Mayo, R. S. Barber, D. J. Trepanier, D.Ure, R. T. Foster and R. W. Yatscoff. Isotechnika,Edmonton, AB, Canada. Sponsor: J. Daniels.

#1256 RAT STRAIN DIFFERENCES IN ETHYLENEGLYCOL RENAL TOXICITY IS DRIVEN BY THERENAL CLEARANCE OF OXALIC ACID. W. M.Snellings1, M. Bartels2, R. Corley3, M. Dryzga2, D.Wilson2 and J. Domoradzki4. 1Global Environmental,Health & Safety, Dow Chemical, Danbury, CT,2Toxicology, Dow Chemical, Midland, MI, 3BattelleNorthwest, Richland, WA and 4Toxicology, DowCorning, Midland, MI.

#1257 DBDPO METABOLISM IN FISH ANDMAMMALS: CONTRIBUTION TO LOWERBROMINATED DIPHENYL ETHERS. M. Hardy.Albemarle Corporation, Baton Rouge, LA.

#1258 BIO-PHYSICO CHEMICAL DETERMINANTS OFTIME-TO-STEADY STATE FOR VOLATILEORGANIC COMPOUNDS (VOCS). D. A. Manca, G.Balagopal and P. Welsh. Standards DevelopmentBranch, Ontario Ministry of the Environment, Toronto,ON, Canada.


POSTER SESSION: GENETIC POLYMORPHISMS

Chairperson(s): Steven Myers, University of Louisville, Louisville, KY.



#1259 RELATIONSHIP BETWEEN CYP1A1 GENOTYPEAND BENZO(A)PYRENE (BP) HEMOGLOBIN(HB) ADDUCTS IN MATERNAL AND FETALBLOOD. T. Wright, C. Cunningham and S. R. Myers.Pharmacology and Toxicology, Center forEnvironmental and Occupational Health Sciences,University of Louisville, Louisville, KY.

#1260 ASSOCIATION BETWEEN GENETICPOLYMORPHISMS IN CYP1A1 AND CYP17,RACE, AND TAMOXIFEN SIDE EFFECTS INBREAST CANCER PATIENTS. M. M. Diawara1, J.B. Babus2, L. M. Lewis2 and J. A. Flaws2. 1Biology,Colorado State University-Pueblo, Pueblo, CO and2Epidemiology and Prev. Medicine, University ofMaryland School of Medicine, Baltimore, MD.

Program Description



TUES

DAY

#1261 STRUCTURAL HETEROGENEITY AT THE UDP-GLUCURONOSYLTRANSFERASE 1A LOCUS INA KOREAN POPULATION. S. Yea1,2, W. Kim2, S.Lee2, J. Sohn2, S. Oh2, Y. Park1 and J. Shin2.1Department of Biochemistry, Inje University, Pusan,Korea, South Korea and 2PharmacoGenomics ResearchCenter, Inje University, Pusan, South Korea. Sponsor:H. Kim.

#1262 ROLE OF ALCOHOL DEHYDROGENASEGENOTYPE IN PREDICTING DEVELOPMENTOF FETAL ALCOHOL SYNDROME (FAS). N. M.Spiegl1, J. L. Powell1, K. S. Squibb1, K. A. Strauss1, J.O’Kane2 and J. D. Cook2. 1Epidemiology andPreventive Medicine, University of Maryland School ofMedicine, Baltimore, MD and 2Medical and ResearchTechnology, University of Maryland School ofMedicine, Baltimore, MD.

#1263 CHARACTERIZATION OF THE VAL108METCOMT POLYMORPHISM. A. E. Doyle1, B. L.McAtee1, J. P. Bressler1,2, P. M. Silber3 and J. D.Yager1. 1Environmental Health Sciences, Johns HopkinsUniversity, Baltimore, MD, 2Kennedy-Krieger Institute,Baltimore, MD and 3In Vitro Technologies, Inc.,Baltimore, MD.

#1264 POLYMORPHISM IN N-ACETYLTRANSFERASE1 ALLELES NAT1*10 AND NAT1*14A INBENZIDINE-EXPOSED WORKERS IN THECHINESE DYESTUFF INDUSTRY: LACK OFASSOCIATION WITH CYTOLOGICALGRADING OF EXFOLIATED UROTHELIALCELLS. W. Guo1, G. Lin1, J. Chen2, K. Golka3 and J.Shen1. 1Institute of Plant Physiology and Ecology,Shanghai Institutes for Biological Sciences, ChineseAcademy of Sciences, Shanghai, China, 2MunicipalCenter for Disease Prevention and Control, Shanghai,China and 3Institute for Occupational Physiology at theUniversity of Dortmund, Dortmund, Germany.

#1265 INDIRECT EVIDENCE FOR EXTRAGENICAND/OR ENVIRONMENTAL INFLUENCE ONHUMAN NAT1 EXPRESSION: ANALYSIS OFPRIMARY HEPATOCYTES BY ALLELE-SPECIFIC QUANTITATIVE REAL-TIME RT-PCR. J. M. Walraven, D. F. Barker, M. A. Doll and D.W. Hein. Pharmacology & Toxicology, University ofLouisville, Louisville, KY.

#1266 FUNCTIONAL CHARACTERIZATION OFMOUSE N-ACETYLTRANSFERASES IN A NAT2KNOCKOUT MODEL. J. A. Loehle1, L. Wakefield2,H. Long2, M. A. Doll1, J. R. Neale1, E. Sim2 and D. W.Hein1. 1Pharmacology/Toxicology, University ofLouisville, Louisville, KY and 2Pharmacology,University of Oxford, Oxford, United Kingdom.

#1267 MECHANISTIC STUDY OF THE A411T (L137F)GENETIC POLYMORPHISM IN HUMAN N-ACETYLTRANSFERASE 2. Y. Zang, S. Zhao, J.States and D. W. Hein. Pharmacology & Toxicology,University of Louisville, Louisville, KY.

#1268 PARAOXONASE POLYMORPHISM LEU-MET55AND ITS RELATIONSHIP TO DIABETICCOMPLICATIONS IN PATIENTS WITH NON-INSULIN-DEPENDENT DIABETES MELLITUS.A. KARAKAYA. Toxicology, Ankara University,Ankara, Turkey. Sponsor: A. Ankara University.

#1269 GSTM1, GSTM3 AND SMOKING HABITS INBLADDER CANCER CASES FROM TWODIFFERENT INDUSTRIAL AREAS. K. Golka1, T.Schmidt1, T. Seidel2, H. Dietrich2, H. Roemer1,3, D.Loehlein3, T. Reckwitz4, J. Soekeland1,4, R. Thier1 andS. Selinski5. 1Institute for Occupational Physiology atthe University of Dortmund, Dortmund, Germany,2Department of Urology, Lutherstadt Wittenberg,Germany, 3Department of Surgery, Klinikum,Dortmund, Germany, 4Department of Urology,Klinikum, Dortmund, Germany and 5Department ofStatistics, University of Dortmund, Dortmund,Germany.

#1270 GST-T1, P53, AND CASPASE-8 POLYMORPHISMSAND COLON CANCER RISK. J. Goodman1,2 and C.C. Harris2. 1Gradient Corporation, Cambridge, MA and2Laboratory of Human Carcinogenesis, National CancerInstitute, Bethesda, MD.

#1271 THE GLUTAMATE CYSTEINE LIGASECATALYTIC SUBUNIT -129 C/T SINGLENUCLEOTIDE POLYMORPHISM ISASSOCIATED WITH THE LEVEL OF GAD65AUTOANTIBODIES IN TYPE 1 DIABETESPATIENTS WITH A DELAYED AGE-AT-ONSET. L.M. Bekris1, M. Janer2, T. J. Kavanagh1 and A.Lernmark3. 1Environmental and Occupational HealthSciences, University of Washington, Seattle, WA,2Institute for Systems Biology, Seattle, WA and3Medicine, University of Washington, Seattle, WA.

#1272 BIOLOGICAL CHARACTERIZATION OF THEMANGANESE SUPEROXIDE DISMUTASE(MNSOD) VAL-9ALA POLYMORPHISM. B. L.McAtee, A. E. Doyle and J. D. Yager. EnvironmentalHealth Sciences, Johns Hopkins Bloomberg School ofPublic Health, Baltimore, MD.

#1273 MOLECULAR ANALYSIS OFDIHYDROPYRIMIDINE DEHYDROGENASEAND THYMIDYLATE SYNTHASE GENEPOLYMORPHISMS IN A TURKISHPOPULATION. S. Suzen, N. Yuce, G. Guvenc and Y.Duydu. Toxicology, Ankara University, Ankara, Turkey.Sponsor: S. Suzen.

#1274 TWO POLYMORPHISMS IN THE DNA REPAIRGENE MGMT INCREASE HUMAN SENSITIVITYTO THE TOBACCO-SPECIFIC NITROSAMINENNK. C. E. Hill, A. A. Affatato, K. J. Wolfe, J. K.Wickliffe and S. Z. Abdel-Rahman. PMCH-Environmental Toxicology, University of Texas MedicalBranch, Galveston, TX.

#1275 ASSOCIATIONS BETWEEN MERCURY, BDNFPOLYMORPHISM, AND ATTENTIONALATTRIBUTES OF MOTOR FUNCTION. D.echeverria1,2, J. S. Woods1,2, N. J. Heyer1, F. M. Farin2,A. C. Bittner1, T. Li2 and C. Garabedian1. 1BattelleCPHRE, Seattle, WA and 2ENVH, U of Washington,Seattle, WA.

Program Description


TUESD

AY


#1276 IDENTIFICATION OF A NOVEL VARIANT OFTHE PREGNANE X RECEPTOR IN HEPATICADVERSE DRUG REACTION PATIENTS. J. D.Tugwood1, D. F. Carr2 and H. Pringle2. 1SafetyAssessment, AstraZeneca Pharmaceuticals,Macclesfield, United Kingdom and 2University ofLeicester, Leicester, United Kingdom. Sponsor: F.Pognan.


POSTER SESSION: BIOMONITORING

Chairperson(s): Steven Myers, University of Louisville, Louisville, KY andXiaofei Zhang, UC Riverside, Riverside, CA.



#1277 MEASURING CHOLINESTERASE ACTIVITY INHUMAN SALIVA. B. Claus Henn1,2,3, S. Padilla2 andS. McMaster3. 1ASPH Research Fellow, ResearchTriangle Park, NC, 2NTD, U.S. EPA, Research TrianglePark, NC and 3HSD, U.S. EPA, Research Triangle Park,NC.

#1278 A CONVERSION FACTOR BETWEEN TWOCHOLINESTERASE ASSAYS AND ITSAPPLICATION IN ESTABLISHING A NORMALRANGE FOR HUMAN RBC ACHE. D. E. Arrieta1,V. M. Nihart1, J. D. Henderson1, S. A. McCurdy2, L. J.Lefkowitz3 and B. W. Wilson1. 1EnvironmentalToxicology and Animal Science, University ofCalifornia, Davis, CA, 2Epidemiology and PreventiveMedicine, University of California, Davis, CA and 3USArmy Center for Health Promotion and PreventiveMedicine, Aberdeen Proving Ground, MD.

#1279 PESTICIDE EXPOSURE ASSESSMENT:CONCURRENT PASSIVE DOSIMETRY ANDBIOLOGICAL MONITORING OF TRICLOPYRAND 2, 4-D EXPOSURES OF A BACKPACKAPPLICATOR CREW. X. Zhang1,2, S. P. Acevedo1, Y.Chao1, T. M. Dinoff1, R. L. Williams1,2 and R. I.Krieger1,2. 1Personal Chemical Expsosure Program,Department of Entomology, University of California,Riverside, CA and 2Environmental Toxicology GraduateProgram, University of California, Riverside, CA.

#1280 ENVIRONMENTAL INDUCTION OF CYP1A-,CYP2M1- AND CYP2K1-LIKE PROTEINS INTROPICAL FISH SPECIES BY PRODUCEDFORMATION WATER ON THE NORTHWESTSHELF OF AUSTRALIA. S. Zhu1, S. CodiKing2 andM. L. Haasch1. 1Pharmacology, EnvironmentalToxicology Research Program, NCNPR, University ofMississippi, University, MS and 2Australian Institute ofMarine Science, Townsville, QLD, Australia.

#1281 ANALYSIS OF ENVIRONMENTALPOLLUTANTS IN BREAST MILK AND DNADAMAGE IN BREAST-MILK CELLS. K. F.Arcaro1,2, J. W. Staudenmayer3, A. P. DeCaprio3, J.Wang1 and M. T. Reece3. 1Environmental Sciences,Univeristy of Massachusetts, Amherst, MA, 2Veterinary& Animal Sciences, University of Massachusetts,Amherst, MA and 3University of Massachusetts,Amherst, MA.

#1282 AMBIENT AND BIOLOGICAL MONITORING OFEXPOSURE TO AROMATIC AMINES IN THERUBBER INDUSTRY. T. Weiss1,2, H. U. Kaefferlein2,T. Bruening2 and J. Angerer1. 1Institute of OccupationalMedicine, Friedrich-Alexander University, Erlangen,Germany and 2Institute of OccupationalMedicine–Center of Toxicology, Ruhr-University,Bochum, Germany.

#1283 SINGLE NUCLEOTIDE POLYMORPHISM ATEXON 4 IN THE MICROSOMAL EPOXIDEHYDROLASE GENE IS ASSOCIATED WITHINCREASED AFLATOXIN ALBUMIN ADDUCTSIN THE BLOOD OF HUMANS IN GHANA. B.Dash1, E. Afriyie-Gyawu1, H. J. Huebner1, J. Wang2, P.E. Jolly3 and T. D. Phillips1. 1Faculty of Toxicology,Texas A&M University, College Station, TX, 2TexasTech University, Lubbock, TX and 3University ofAlabama, Birmingham, AL.

#1284 CORRELATION OF MATERNAL HEMOGLOBIN(HB) 4-AMINOBIPHENYL ADDUCT LEVELSWITH RESPECT TO COTININE LEVELS ANDMATERNAL GENOTYPES. S. R. Myers, C.Cunningham and T. Wright. Pharmacology andToxicology, Center for Environmental and OccupationalHealth Sciences, University of Louisville, Louisville,KY.

#1285 CORRELATION OF MATERNAL AND FETALHEMOGLOBIN (HB) ADDUCTS IN SMOKERSWITH RESPECT TO GENOTYPE. C. Cunningham,T. Wright and S. R. Myers. Pharmacology andToxicology, Center for Environmental and OccupationalHealth Sciences, University of Louisville, Louisville,KY.

#1286 LEVELS OF POLYCYCLIC AROMATICHYDROCARBONS IN AMNIOTIC FLUIDSAMPLES FROM SMOKERS ANDNONSMOKERS. J. Weeks and S. R. Myers.Pharmacology and Toxicology, Center forEnvironmental and Occupational Health Sciences,University of Louisville, Louisville, KY.

#1287 INVESTIGATIONS OF VARIATION IN URINARYPROFILES BETWEEN SMOKERS AND NON-SMOKERS USING METABONOMIC (NMRSPECTROSCOPIC) URINALYSIS. M. Ogden. R&D,R. J. Reynolds, Winston-Salem, NC. Sponsor: D.Doolittle.

Program Description



TUES

DAY

#1288 RACE/ETHNICITY, INCOME ANDPERCHLOROETHYLENE (PERC) EXPOSURESAMONG ADULT AND CHILD RESIDENTS OFBUILDINGS WITH DRY CLEANERS. J. E. Storm1,M. J. McDermott1, K. M. Aldous1, B. C. Blount2, J.Serle3 and S. J. Shost1. 1Department of Health, NewYork State, Troy, NY, 2US Centers for Disease Controland Prevention, Atlanta, GA and 3Mt. Sinai School ofMedicine, New York.

#1289 HEALTH EVALUATION OF MARINE FISHESFROM JOHNSTON ATOLL NATIONALWILDLIFE REFUGE, A FORMER MILITARYINSTALLATION. D. M. Papoulias1, J. L. Zajicek1, M.L. Annis1, D. K. Nicks1, J. S. Candrl1, L. Woodward2

and D. E. Tillitt1. 1USGS, Columbia EnvironmentalResearch Center, Columbia, MO and 2USFWS,Honolulu, HI. Sponsor: C. Richter.

#1290 EXPOSURE ASSESSMENT IN CONTAMINATEDENVIRONMENTS. R. A. Lingenfelter1, L. Cizmas1,Z. Naufal1, C. Naspinski1, L. He1, G. Zhou1, T.McDonald1, G. Denoux1, R. Autenrieth1, A. Mekhtiev3,A. Islamzadeh2 and K. Donnelly1. 1Texas A&MUniversity, College Station, TX, 2Institute of Physiologyn.a. A.I.Karaev, Baku, Azerbaijan and 3Sumgayit CentreFor Environmental Rehabilitation, Sumgayit,Azerbaijan.

#1291 INTEGRATION OF BIOMONITORING DATAINTO THE RISK ASSESSMENT PROCESS. S. H.Robison1, L. Needham2, E. Faustman3, H. Zenick4 andL. Sheldon5. 1Procter & Gamble, Cincinnati, OH, 2CDC,Atlanta, GA, 3University of Washington, Seattle, WA,4NHEERL, U.S. EPA, Research Triangle Park, NC and5NERL, U.S. EPA, Research Triangle Park, NC.


POSTER SESSION: STATISTICAL AND BIOLOGICAL MODELS

Chairperson(s): Julia Kimbell, CIIT Centers for Health Research, ResearchTriangle Park, NC and Michael Zager, University of North Carolina, ResearchTriangle Park, NC.



#1292 A FLEXIBLE APPROACH FOR EVALUATINGFIXED RATIO MIXTURES OF FULL ANDPARTIAL AGONISTS FOR MIXTURES OF MANYCHEMICALS. C. Gennings1,2, H. Carter1,2, R. A.Carchman2, M. J. DeVito3, J. Simmons3 and K. M.Crofton3. 1Biostatistics, Virginia CommonwealthUniversity, Richmond, VA, 2Solveritas, LLC,Richmond, VA and 3NHEERL, ORD, U.S. EPA,Research Triangle Park, NC.

#1293 A BAYESIAN NETWORK MODEL TO PREDICTHAZARD POTENCY FOR SKIN SENSITISATION.D. Jefferies, L. J. Aspinall, R. J. Safford, C. J. Clapp, A.Madrigal, M. Chamberlain and D. A. Basketter. Safetyand Environmental Assurance Centre, Unilever,Bedford, United Kingdom.

#1294 TOXICITY-RELATED MOLECULARPARAMETERS CALCULATED FORALDEHYDES AND KETONES FOUND INDIESEL EXHAUST. P. Martin1, R. Garg2, M. C.Madden3 and C. J. Smith1. 1Lorillard Tobacco Co.,Greensboro, NC, 2Chemistry, Clarkson University,Potsdam, NY and 3U.S. EPA NHEERL, ResearchTriangle Park, NC.

#1295 THREE-DIMENSIONAL ANATOMICALRECONSTRUCTION OF THE UPPERRESPIRATORY TRACT OF B6C3F1 MICE. E. A.Gross1, D. R. Joyner1, A. M. Jarabek1,2 and J. S.Kimbell1. 1CIIT Centers for Health Research, ResearchTriangle Park, NC and 2National Center forEnvironmental Assessment, U.S. EPA, Washington, DC.

#1296 A PHARMACOKINETIC-PHARMACODYNAMICMODEL FOR GENE-REGULATED PROSTATEMAINTENANCE: COMPARING THE EFFECTSOF CASTRATION WITH ANTIANDROGENEXPOSURE IN THE RAT. M. G. Zager1,2, L. K.Potter1,2 and H. A. Barton2. 1Toxicology, University ofNorth Carolina, Research Triangle Park, NC and 2ORD,NHEERL, U.S. EPA, Research Triangle Park, NC.

#1297 PHYSIOLOGICALLY BASEDPHARMACOKINETIC/PHARMACODYNAMICMODELING FOR THE N-METHYLCARBAMATE PESTICIDE CARBARYL:INSIGHT INTO MECHANISM AND RISKASSESSMENT. J. Wang1, Y. Tan1, A. Tobia2, C.Lunchick2, M. Krolski2 and R. B. Conolly1. 1CIITCenters for Health Research, Research Triangle Park,NC and 2Bayer CropScience, Research Triangle Park,NC.

#1298 USE OF EXPOSURE RELATED DOSEESTIMATING MODEL (ERDEM) FORASSESSMENT OF AGGREGATE EXPOSURE OFINFANTS AND CHILDREN TO N-METHYLCARBAMATE INSECTICIDES. F. W. Power1, M.Okino1, J. B. Knaak4, R. Tornero-Velez2, A. Lowit3, J.N. Blancato2 and C. C. Dary1. 1NERL\EDRB, U.S.EPA, Las Vegas, NV, 2NERL, U.S. EPA, ResearchTriangle Park, NC, 3Office of Pesticide Programs, U.S.EPA, Washington, DC and 4Pharmacology andToxicology, SUNY, Buffalo, Buffalo, NY.

#1299 SPATIAL/TEMPORAL MODELING OFCYTOCHROME P450-MEDIATEDPHOSPHOROTHIONATE INSECTICIDEMETABOLISM IN THE RAT LIVER ACINUS. J. E.Chambers1, J. G. Baravik1, S. C. Burgess1, D. E.MaryBeth1, E. C. Meek1, S. F. Oppenheimer2 and E. B.Shows1. 1Center for Environmental Health Sciences,Mississippi State University, Mississippi State, MS and2Department of Mathematics and Statistics, MississippiState University, Mississippi State, MS.

#1300 BIOTRANS: A NEW TOOL FOR PREDICTINGTHE METABOLISM OF CHEMICAL MIXTURES.A. N. Mayeno, R. S. Yang and B. Reisfeld. Quantitativeand Computational Toxicology Group, Center forEnvironmental Toxicology and Technology, ColoradoState University, Fort Collins, CO.

Program Description


TUESD

AY


#1301 INTER-INDIVIDUAL VARIABILITY INBENZENE METABOLITES. S. Kim1, R. Vermeulen2,S. Waidyanatha1, Q. Lan2, M. T. Smith3, G. L. Li4, L.Zhang3, M. Shen2, S. Yin4, N. Rothman2 and S. M.Rappaport1. 1SPH, UNC, Chapel Hill, NC,2NCI/NIH/DHHS, Bethesda, MD, 3SPH, UC, Berkeley,CA and 4Chinese CDC, Beijing, China. Sponsor: I.Rusyn.

#1302 USING OBSERVED VARIABILITY AS ACRITERION FOR CELLULAR KINETICSMODELS AFTER FURAN EXPOSURE. M. V.Smith1, R. R. Maronpot2, T. L. Goldsworthy3, R. W.Morris4 and C. J. Portier5. 1Constella Health Sciences,Constella Group, Durham, NC, NC, 2ExperimentalPathology, NIEHS, Research Triangle Park, NC,3Integrated Laboratory Systems, Inc., Research TrianglePark, NC, 4Anesthesiology, Duke University MedicalCenter, Durhan, NC and 5Computational Biology andRisk Assessment, NIEHS, Research Triangle Park, NC.

#1303 QUANTITATIVE MODELS OF BYSTANDEREFFECTS FROM IONIZING RADIATION INNON-TARGETED CELLS. W. C. Griffith, E. Vigorenand E. Faustman. University of Washington, Seattle,WA.

#1304 A MECHANISTIC MODEL OF LIFETIMECANCER RISK FOR INHALATION EXPOSURESTO REACTIVE GASES. J. Kimbell1, D. L. Kalisak1,R. B. Conolly1, F. J. Miller1 and A. M. Jarabek1,2. 1CIITCenters for Health Research, Research Triangle Park,NC and 2National Center for EnvironmentalAssessment, U.S. EPA, Washington, DC.

#1305 PRELIMINARY DEVELOPMENT OF AMECHANISTIC THYROID HORMONE MODEL.E. A. Merrill1, J. M. Gearhart2, P. J. Robinson2, T. R.Sterner3 and D. R. Mattie4. 1Geo-Centers, Inc., Wright-Patterson AFB, OH, 2ManTech, Inc., Wright-PattersonAFB, OH, 3OpTech, Corp., Dayton, OH and4AFRL/HEPB, Wright-Patterson AFB, OH.

#1306 BIOLOGICALLY-BASED MODELING OF THESPONTANEOUS TRANSFORMATION OFHUMAN KEROTINOCYTES, RHEK-1. E. E.Perrigo, O. Lohitnavy, J. A. Campain, B. Reisfeld and R.Yang. Quantitative and Computational ToxicologyGroup, Center for Environmental Toxicology andTechnology, Department of Environmental andRadiological Health Sciences, Colorado StateUniversity, Fort Collins, CO.


POSTER SESSION: FOOD SAFETY AND NUTRITION TOXICOLOGY II

Chairperson(s): Christopher Chengelis, WIL Research, Ashland, OH andJohn Watkins, Indiana University School of Medicine, Bloomington, IN.



#1307 EVALUATION OF MOUSE MODELS FORASSESSING THE ALLERGENIC POTENTIAL OFPROTEINS. K. Thomas1, C. Herouet2, G. Bannon3, G.Ladics4, S. MacIntosh5, L. Privalle6 and M. Woolhiser7.1ILSI Health and Environmental Sciences Institute,Washington, DC, 2Bayer CropScience, SophiaAntipolis, France, 3Monsanto, St. Louis, MO, 4DuPontCompany, Newark, DE, 5Bayer BioScience, ResearchTriangle Park, NC, 6BASF, Research Triangle Park, NCand 7The Dow Chemical Company, Midland, MI.

#1308 VALIDATION OF FUMONISIN BIOMARKERS INF344 RATS. Q. Cai1,2, H. Guan1,2, L. Tang1,2, H.Luo1,2, M. Billam1,2, Z. Wang1,2, Y. Tang1,2 and J.Wang1,2. 1Environmental Toxicology, Texas TechUniversity, Lubbock, TX and 2The Institute ofEnvironmental and Human Health, Texas TechUniversity, Lubbock, TX.

#1309 SHORT-TERM SAFETY EVALUATION OFNOVASIL IN HUMANS. J. Wang1,2, T. Goldston3, H.Luo1,2, M. Billam1,2, Z. Wang1,2, H. Guan1,2, L. Tang1,2,E. Afriyie-Gyawu4, C. Lovett3, J. Griswold3, B. Brattin4,H. J. Huebner4 and T. D. Phillips4. 1EnvironmentalToxicology, Texas Tech University, Lubbock, TX, 2TheInstitute of Environmental and Human Health, TexasTech University, Lubbock, TX, 3Division of ClinicalResearch, TTUHSC, Lubbock, TX and 4College ofVeterinary Medicine, Texas A&M University, CollegeStation, TX.

#1310 COMPARISON OF FORMALIN FIXED ANDFROZEN TISSUES FOR SPHINGANINE ANDSPHINGOSINE DETERMINATION FOLLOWINGFUMONISIN B1 EXPOSURE IN SWINE. W. M.Haschek1, S. Hsiao1, M. E. Tumbleson2, G. Tyagi1 andP. D. Constable3. 1Veterinary Pathobiology, Universityof Illinois at Urbana-Champaign, Urbana, IL,2Agricultural and Biological Engineering, University ofIllinois at Urbana-Champaign, Urbana, IL and3Veterinary Clinical Medicine, University of Illinois atUrbana-Champaign, Urbana, IL.

#1311 INFLUENCE OF THE SOY ISOFLAVONESGENISTEIN AND DAIDZEIN ON THEEXPRESSION OF 17ββ-ESTRADIOL-METABOLIZING ENZYMES IN CULTUREDMCF-7 BUS127 CELLS. L. Lehmann, L. Jiang, E. W.Lerch and M. Metzler. Institute of Food Chemistry andToxicology, University of Karlsruhe, Karlsruhe,Germany.

#1312 MODIFIED METHOD FOR EXTRACTION ANDHPLC ANALYSIS OF SPHINGANINE ANDSPHINGOSINE FROM BODY FLUIDS, CELLSAND TISSUES. M. E. Tumbleson1, S. Hsiao2,3, G. L.Bargren3, P. D. Constable4 and W. M. Haschek2,3.1Agricultural and Biological Engineering, University ofIllinois at Urbana-Champaign, Urbana, IL, 2VeterinaryPathobiology, University of Illinois at Urbana-Champaign, Urbana, IL, 3Veterinary DiagnosticLaboratory, University of Illinois at Urbana-Champaign,Urbana, IL and 4Veterinary Clinical Medicine,University of Illinois at Urbana-Champaign, Urbana, IL.

#1313 EFFECT OF AFLATOXIN B1 ON DRY GRINDETHANOL PROCESS. G. S. Murthy1, D. E.Townsend1, G. L. Meerdink2, G. L. Bargren2, M. E.Tumbleson1,2 and V. Singh1. 1Agricultural andBiological Engineering, University of Illinois atUrbana-Champaign, Urbana, IL and 2VeterinaryDiagnostic Laboratory, University of Illinois at Urbana-Champaign, Urbana, IL. Sponsor: W. Haschek.

#1314 SERUM AND URINE SPHINGANINE AREUSEFUL BIOMARKERS OF FUMONISIN B1EXPOSURE IN SWINE DUE TO SLOWSYSTEMIC CLEARANCE. G. Tyagi1, S. Hsiao1, J.L. Marlatt2, M. E. Tumbleson3, P. D. Constable2, R. M.Eppley4 and W. M. Haschek1. 1Veterinary Pathobiology,University of Illinois at Urbana-Champaign, Urbana, IL,2Veterinary Clinical Medicine, University of Illinois atUrbana-Champaign, Urbana, IL, 3Agricultural andBiological Engineering, University of Illinois atUrbana-Champaign, Urbana, IL and 4CFSAN, U.S.FDA, Laurel, MD.

#1315 CLINOPATHOLOGY AND TISSUESPHINGOLIPID CLEARANCE AFTERFUMONISIN B1 EXPOSURE OF SWINE. J. L.Marlatt1, G. Tyagi2, S. Hsiao2, M. E. Tumbleson3, R. M.Eppley4, P. D. Constable1 and W. M. Haschek2.1Veterinary Clinical Medicine, University of Illinois atUrbana-Champaign, Urbana, IL, 2VeterinaryPathobiology, University of Illinois at Urbana-Champaign, Urbana, IL, 3Agricultural and BiologicalEngineering, University of Illinois at Urbana-Champaign, Urbana, IL and 4CFSAN, U.S. FDA,Laurel, MD.

#1316 SENSITIVE SCREENING BIOASSAY FORDEOXYNIVALENOL DETECTION IN FOODSAMPLES. C. A. Landgren and S. Hendrich. FoodScience and Human Nutrition, Iowa State University,Ames, IA.

#1317 INTEGRATION OF FDA DATABASES TODEVELOP METHODOLOGIES FORPREDICTIVE TOXICOLOGY. M. Cheeseman andM. Twaroski. CFSAN/OFAS, U.S. FDA, College Park,MD.

#1318 MATERNAL EXPOSURE TO GENISTEINDURING PREGNANCY SUPPRESSIVELYEFFECTS ON TUMOR INITIATION INDUCEDBY 7, 12-DIMETHYLBENZ[A]ANTHRACENE INSTEROIDOGENIC ORGANS OF F1 OFFSPRING.J. Watanabe, H. Okamoto, M. Satoh and H. Nagase.Department of Hygienics, Gifu PharmaceuticalUniversity, Gifu City, Gifu, Japan.

#1319 EFFECTS OF N-6 AND N-3 POLYUNSATURATEDFATTY ACIDS ON COLORECTALCARCINOGENESIS. G. Alink1, B. Ommen2 and Y.Dommels1,2. 1Wageningen University, Wageningen,Netherlands and 2TNO, Zeist, Netherlands. Sponsor: P.van Bladeren.



INFORMATIONAL SESSION: AN INTRODUCTION TOMICROARRAYS AND GENECHIP® TECHNOLOGY FORTOXICOGENOMICS — PRESENTED BY AFFYMETRIX

The Affymetrix GeneChip® System enables toxicologists to reliably generate,analyze, and manage large quantities of genetic information for acceleratedresearch and biomarker discovery. This course is an introduction to GeneChipmicroarray design, performance, and analysis for applications in toxicoge-nomics.


INFORMATIONAL SESSION: HEMOTOXICITY TESTING OFXENOBIOTICS AND NEW DRUGS FOR ALL STAGES OF THE DRUGDEVELOPMENT PIPELINE THE HALO PLATFORM - IN VITROHEMOTOXICITY TESTING FOR THE 21ST CENTURY —PRESENTED BY HEMOGENIX

HALO (Hemotoxicity Assays via Luminescence Output) is a multifunctionaland multiparameter testing platform that can detect and measure the effects ofvirtually any compound on up to 14 different proliferating cell populations from5 species simultaneously from the blood-forming system. The test system israpid, quantitative, highly sensitive and non-subjective with high-throughputcapability and is ideal for all phases of drug development, from screening tomonitoring the patient’s lympho-hematopoietic system during clinical trials.


SOT ANNUAL BUSINESS MEETING

Chairperson(s): Linda Birnbaum, SOT President

SOT Members Only.

Members are invited and encouraged to attend the SOT business meeting. If youhave long-range planning ideas that you would like added to the agenda, pleasesend them to Shawn Lamb at SOT Headquarters. The agenda includes a discus-sion of the Council 2005 Strategic Planning Session, financial summary, areview of the 2004–2005 activities, and plans for the future.

Program Description



TUES

DAY

Program Description


TUESD

AY



SUNSET SESSION: IN VITRO TOXICITY TESTING OF AIRPOLLUTANTS: PROS AND CONS

Chairperson(s): Ian Gilmour, U.S. EPA, Research Triangle Park, NC andJeanClare Seagrave, Lovelace Respiratory Research Institute, Albuquerque,NM.

Endorsed by:In Vitro SSInhalation SS*Risk Assessment SSStudent Advisory Committee

The increasing evidence for adverse health effects resulting from acute andchronic exposure to air pollution has driven efforts to identify which compo-nents cause these effects and by what mechanisms. This, in turn, has created aneed for rapid, cost-effective methods for in vitro screening and mechanisticstudies. The respiratory tract is the first target of aerosols, but in vitro studies ofthis system are complicated by species differences, varied regional anatomy andphysiology, as well as the fact that aerosols interact at the gas/air inter-phase ofthe lung surface. In addition to containing over forty different cell types thatmay respond quite differently to a given stimulus, host susceptibility factors thatmay be driven by genetics, and previous exposures may impact on observedeffects. The purpose of this session is to review issues regarding the selection ofmodels, exposure methods, doses, and endpoints and to determine how thesesystems may reflect inhalation exposures in the exposed population.

#1015 4:30 IN VITRO TOXICITY TESTING OF AIRPOLLUTANTS: PROS AND CONS. M. Gilmour1

and J. Seagrave2. 1NHEERL, U.S. EPA, ResearchTriangle Park, NC and 2LRRI, Albuquerque, NM.

#1016 4:35 CELL POPULATIONS WITHIN THERESPIRATORY TRACT. C. G. Plopper. Anatomy,Physiology and Cell Biology, Universtiy of California,Davis, CA.

#1017 4:45 SYSTEMS FOR EXPOSING LUNG CELLS TOAEROSOLS. J. Seagrave and J. D. McDonald.Lovelace Respiratory Research Institute, Albuquerque,NM.

#1018 5:00 ANALYTICAL TOOLS FOR ASSESSING AIRPOLLUTION TOXICITY USING DIFFERENT INVITRO CELL CULTURE MODELS. I. Jaspers.CEMALB, University of North Carolina, Chapel Hill,NC.

#1019 5:15 IN VITRO CORRELATION WITH IN VIVOEXPOSURES. R. Devlin and L. Dailey. U.S. EPA,Research Triangle Park, NC.


SUNSET SESSION: TOXICOLOGY INFORMATION AND DATAUPDATE

Chairperson(s): Philip Wexler, National Library of Medicine, Bethesda, MD.

Endorsed by:National Capital Area Chapter

As the Web and its online resources continue to expand and change rapidly,there is an increasing plethora of databases, documents, and other digital toolsavailable to the toxicology community. Toxicologists with even formidableresearch skills are often knowledgeable about only a small fraction of what isavailable, and they are often not kept apprised of the newest developments. Thissymposium highlights major Web-based resources from all sectors–government,academia, industry, non-profits–which can benefit toxicologists in their dailyresearch and other work. This program takes a look at a few of these resources.The National Library of Medicine’s Toxicology and Environmental HealthInformation Program is a major purveyor of toxicological information and datathrough its TOXNET system and other databases, geared to both the profes-sional and the public. The Center for Research on Environmental andOccupational Toxicology (CROET) focuses on health and safety in the work-force and supports a number of information activities, including its ToxicologyInformation Center. The National Institute of Environmental Health Sciences(NIEHS) and the National Toxicology Program offer a number of unique onlinedatabases and make available online numerous test reports and the Report onCarcinogens. EPA has recently unveiled its Distributed Structure SearchableToxicity (DSS-TOX) database, another powerful tool of potential interest.

#1020 4:30 TOXICOLOGY INFORMATION AND DATAUPDATE. P. Wexler. Toxicology and EnvironmentalHealth Information Program, National Library ofMedicine, Bethesda, MD.

#1021 4:32 THE NATIONAL LIBRARY OF MEDICINE’S(NLM) WORLD LIBRARY OF TOXICOLOGY,CHEMICAL SAFETY AND ENVIRONMENTALHEALTH. P. Wexler. Toxicology and EnvironmentalHealth Information Program, National Library ofMedicine, Bethesda, MD.

#1022 4:47 WEB-BASED RESOURCES SPONSORED BY THENATIONAL INSTITUTE OF ENVIRONMENTALHEALTH SCIENCES (NIEHS) AND THENATIONAL TOXICOLOGY PROGRAM (NTP). L.L. Wright. US Department of Health and HumanServices, National Institute of Environmental HealthSciences, Research Triangle Park, NC. Sponsor: P.Wexler.

#1023 5:02 THE CENTER FOR RESEARCH ONOCCUPATIONAL AND ENVIRONMENTALTOXICOLOGY (CROET). F. Berman. Oregon Healthand Science University, Portland, OR. Sponsor: P.Wexler.

#1024 5:22 DSSTOX STRUCTURE-SEARCHABLE PUBLICTOXICITY DATABASE NETWORK: CURRENTPROGRESS AND NEW INITIATIVES TOIMPROVE CHEMO-BIOINFORMATICSCAPABILITIES. A. M. Richard1 and B. A. Rogers1.1U.S. EPA, Research Triangle Park, NC and 2NCCUStudent COOP, U.S. EPA, Research Triangle Park, NC.Sponsor: L. King.


Program Description



WED

NES

DAY


REGIONAL CHAPTER CONTACTS FOR K–12 EDUCATIONMEETING

Chairperson(s): Marion Miller, University of California, Davis, Davis, CA.

Sponsored by:Education CommitteeEducation Subcommittee for K–12 Education

SOT Regional Chapter Contacts for K–12 Education and others interested inoutreach to schools and teachers are invited to attend an informal meeting todiscuss K–12 education activities at the regional level. Light refreshments willbe available.

Tuesday Evening

Tuesday Evening, March 86:00 PM to 7:30 PMSee Events Calendar on Pages 2–6 for Room Listings

SPECIALTY SECTION MEETINGS:BIOLOGICAL MODELING, CARCINOGENESIS, IN VITRO,INHALATION, METALS, NEUROTOXICOLOGY, REGULATORY ANDSAFETY EVALUATION

Tuesday Evening, March 86:00 PM to 11:00 PMSee Events Calendar on Pages 2–6 for Room Listings



Wednesday Morning

Wednesday Morning, March 98:30 AM to 9:30 AMRoom 215

INFORMATIONAL SESSION: DEFINING MOLECULARMECHANISMS OF TOXICITY USING AFFYMETRIX GENECHIP®ARRAYS — PRESENTED BY AFFYMETRIX

Though leaders in the use of Affymetrix microarray technologies will share thetechniques and strategies they have used successfully to apply GeneChip prod-ucts to their research.

Wednesday Morning, March 98:30 AM to 11:30 AMRoom RO4

SYMPOSIUM SESSION: BIOMARKERS OF OXIDATIVE STRESS:NEW PROSPECTS AND APPROACHES

Chairperson(s): Daniel C. Liebler, Vanderbilt University, Nashville, TN andMaria Kadiiska, National Institute of Environmental Health Sciences,Research Triangle Park, NC.

Endorsed by:Mechanisms SS*Risk Assessment SSStudent Advisory Committee

Oxidative stress plays a key role in the development of cardiovascular disease,neurodegenerative diseases, and cancer. Many toxic chemicals associated withincreased risk of these diseases also induce oxidative stress. Assessment ofoxidative stress in clinical studies has been hampered by a dearth of robust,sensitive, and well-validated biomarkers. This symposium will address newopportunities to develop oxidative stress biomarkers for application to humanclinical studies. Dr. Maria Kadiiska (NIEHS) will discuss the Biomarkers ofOxidative Stress Study (BOSS), which evaluated several different noninvasiveor minimally invasive chemical markers of carbon tetrachloride- or ozone-induced oxidative stress in rats. Dr. Stanley Hazen (Cleveland ClinicFoundation) will describe the development and validation of multiplexed LC-MS-MS assays for specific lipid and protein oxidation products in human serumand the application of these markers to assess oxidative stress endpoints as riskfactors for cardiovascular disease. Dr. Ian Blair (University of Pennsylvania)will present recent developments in the identification and LC-MS-MS-basedanalysis of products of oxidative DNA damage and DNA adducts derived fromelectrophilic lipid oxidation products. Dr. Lawrence Marnett (VanderbiltUniversity) will discuss recent findings that DNA adducts derived from elec-trophilic products of lipid oxidation undergo metabolism to a series of productsthat can be analyzed as potential urinary biomarkers of oxidative stress. Dr.Daniel Liebler (Vanderbilt University) will discuss the identification of albuminadducts formed by reactive products of lipid oxidation and the potential appli-cation of these adducts as serum biomarkers of oxidative stress in vivo.

#1320 8:30 BIOMARKERS OF OXIDATIVE STRESS: NEWPROSPECTS AND APPROACHES. D. C. Liebler.Department of Biochemistry, Vanderbilt UniversitySchool of Medicine, Nashville, TN.

#1321 8:35 PRODUCTS OF OXIDATION AS MEASURABLEINDICATORS OF OXIDATIVE STRESS:VALIDATION OF BIOMARKERS FROMRODENT CCL4 AND OZONE EXPOSURE. M.Kadiiska. Environmental Toxicology Program, NationalInstitute of Environmental Health Sciences, ResearchTriangle Park, NC. Sponsor: D. Liebler.

#1322 9:10 MOLECULAR MECHANISMS OF OXIDANTSTRESS IN AT-RISK SUBJECTS UNDERGOINGREVASCULARIZATION. S. Hazen. Department ofMolecular Medicine, Cleveland Clinic Foundation,Cleveland, OH. Sponsor: D. Liebler.

#1323 9:45 NOVEL BIOMARKERS OF OXIDATIVE STRESS-INDUCED DNA DAMAGE. I. Blair. Department ofPharmacology, University of Pennsylvania,Philadelphia, PA. Sponsor: D. Liebler.

#1324 10:20 URINARY DNA ADDUCTS AND THEIRMETABOLITES AS BIOMARKERS OFOXIDATIVE STRESS. L. Marnett. Department ofBiochemistry, Vanderbilt University School ofMedicine, Nashville, TN.

Program Description


WED

NESD

AY


#1325 10:55 PROTEIN ADDUCTS AS OXIDATIVE STRESSBIOMARKERS. D. C. Liebler. Department ofBiochemistry, Vanderbilt University School ofMedicine, Nashville, TN.


SYMPOSIUM SESSION: GENETIC SUSCEPTIBILITY AND METALTOXICITY

Chairperson(s): Ellen Silbergeld, Johns Hopkins, Baltimore, MD and BrianS. Schwartz, Johns Hopkins University School of Public Health, Baltimore,MD.

Endorsed by:Metals SS*Occupational and Public Health SSRisk Assessment SS

There are substantial individual differences in human susceptibilities to manytoxicants, including metals. Understanding these differences in susceptibility isfundamental to identifying factors important in assessing and managing healthrisks associated with metals such as lead, cadmium, mercury, and arsenic.Genetic factors may play a significant role in the variable human response tometal exposures. The goal of this symposium is to present and discuss informa-tion from both epidemiology and basic research that is relevant to refining ourknowledge of metal toxicity and the relationships between metal exposures andhuman diseases.

#1326 8:30 GENETIC BASIS FOR SUSCEPTIBILITY TOMETALS: METABOLISM AND MOLECULARTARGETS. E. K. Silbergeld. Environmental HealthSciences, Johns Hopkins University Bloomberg SchoolPublic Health, Baltimore, MD.

#1327 8:40 DO GENETIC POLYMORPHISMS MODIFY THEKINETICS OR TOXICITY OF LEAD? INSIGHTSFROM EPIDEMIOLOGY. B. S. Schwartz.Environmental Health Sciences, Johns HopkinsBloomberg School of Public Health, Baltimore, MD.

#1328 9:05 USE OF GENETICALLY ALTERED ANIMALS TODETERMINE THE ROLE OF CADMIUM INMETALLOTHIONEIN TOXICITY. C. D. Klaassen.Pharmacology, U Kansas Med. Ctr, Kansas City, KS.

#1329 9:30 ARSENIC METABOLISM: KNOCKOUT MICEAND POLYMORPHISM STUDIES. H. V. Aposhian,R. A. Zakharyan, U. K. Chowdhury, M. D. Avram, M.L. Wollenberg, A. Hernandez and M. M. Aposhian.Molecular and Cellular Biology, University of Arizona,Tucson, AZ.

#1330 9:55 MERCURY-INDUCED AUTOIMMUNITY INGENETICALLY SUSCEPTIBLE MICE. M.Monestier. Microbiology & Immunology, TempleUniversity School of Medicine, Philadelphia, PA.Sponsor: E. Silbergeld.

#1331 10:20 MOLECULAR MECHANISMS OF LEAD-INDUCED CARDIOVASCULAR DISEASES. E. K.Silbergeld. Environmental Health Sciences, JohnsHopkins University Bloomberg School Public Health,Baltimore, MD.


SYMPOSIUM SESSION: PESTICIDE NEUROTOXICITY IN ADULTS:INTEGRATING CONTRIBUTIONS FROM EPIDEMIOLOGY ANDTOXICOLOGY

Chairperson(s): William Boyes, U.S. EPA, Research Triangle Park, NC.

Endorsed by:Neurotoxicology SS*Occupational and Public Health SSRegulatory and Safety Evaluation SSRisk Assessment SSStudent Advisory Committee

Neurotoxicity of high-level pesticide exposure in adults is well-documented, butless is known about the consequences of chronic exposure to moderate doselevels. Results from human epidemiology studies and animal toxicology studiesare not always consistent. Recent human studies suggest that moderate pesticideexposure may be associated with increased risk of an array of neurologic symp-toms, particularly affective outcomes including depression and suicide.Laboratory animal studies do not address comparable outcomes, and typicallyhave not identified subtle neurological impairments that persist beyond theexposure period, despite higher dose levels than are typically experienced byhumans. Are these apparent species differences real? If so, are they related topharmacokinetic or pharmacodynamic factors? Alternatively, are differencesrelated to the types of outcomes assessed, duration of exposures, combinedexposures to multiple agents, or to other factors? Understanding and predictinghuman health risks from pesticide exposure requires complex integration of thediffering data provided by human and animal studies.

#1332 8:30 PESTICIDE NEUROTOXICITY AT THEINTERSECTION OF EPIDEMIOLOGY ANDTOXICOLOGY. W. K. Boyes1 and F. Kamel2. 1EPA,Research Triangle Park, NC and 2NIEHS, ResearchTriangle Park, NC.

#1333 8:40 NEUROTOXICITY OF CHRONIC PESTICIDEEXPOSURE IN LICENSED PESTICIDEAPPLICATORS IN THE AGRICULTURALHEALTH STUDY (AHS). F. Kamel1, L. S. Engel2, B.C. Gladen1, J. A. Hoppin1, M. R. Alavanja3 and D. P.Sandler1. 1NIEHS, NIH, DHHS, Research TrianglePark, NC, 2Memorial Sloan-Kettering Cancer Center,New York and 3NCI, NIH, DHHS, Rockville, MD.Sponsor: W. Boyes.

#1334 9:10 ORGANOPHOSPHATE EXPOSURE,DEPRESSION AND SUICIDE: MATCHINGEPIDEMIOLOGICAL DATA TO MODELS BASEDON ANIMAL STUDIES AND CASE SERIES. L.London1, A. Flisher2, V. Major3, H. Kromhout4 and D.Mergler5. 1School of Public Health and FamilyMedicine, University of Cape Town, Observatory, SouthAfrica, 2Department of Psychiatry and Mental Health,University of Cape Town, Observatory, South Africa,3Department of Health Sciences, Peninsula Technicon,Cape Town, South Africa, 4Institute for RiskAssessment Sciences, Utrecht University, Utrecht,Netherlands and 5CINBIOSE, University of Quebec aMontreal, Montreal, QC, Canada. Sponsor: W. Boyes.

#1335 9:40 ANIMAL MODELS OF CHRONIC PESTICIDETOXICITY. V. C. Moser, P. J. Bushnell, R. C.MacPhail, D. W. Herr, R. S. Marshall, D. L. Hunter andW. K. Boyes. NTD/NHEERL/ORD, U.S. EPA, ResearchTriangle Park, NC.

Program Description



WED

NES

DAY

#1336 10:10 DEVELOPMENT OF PHYSIOLOGICALLYBASED PHARMACOKINETIC ANDPHARMACODYNAMIC MODELS TODETERMINE DOSIMETRY, DYNAMICRESPONSE, AND TO ASSESS RISK FOLLOWINGEXPOSURE TO ORGANOPHOSPHORUSINSECTICIDES. C. Timchalk and T. S. Poet. PacificNorthwest National Laboratory, Richland, WA.

#1337 10:40 PESTICIDE NEUROTOXICITY IN ADULTS:IMPLICATIONS FOR PESTICIDE SAFETYTESTING AND PUBLIC HEALTH. W. K. Boyes.EPA, Research Triangle Park, NC.

Wednesday Morning, March 98:30 AM to 11:30 AMLa Louisiane Ballroom B

WORKSHOP SESSION: CURRENT REGULATORY AND SCIENTIFICVIEWS REGARDING CHEMICAL HAZARDS TO CHILDREN

Chairperson(s): Daland Juberg, Dow AgroSciences, LLC, Indianapolis, INand Dennis Paustenbach, ChemRisk, San Francisco, CA.

Endorsed by:Ethical Legal and Social Issues SSRegulatory and Safety Evaluation SSReproductive and Development SSRisk Assessment SS*

The evaluation of the health of children, specifically the estimated risk due toenvironmental chemical exposures, continues to receive increasing regulatoryattention. It has resulted in decision-making that has scientific, policy, andpublic health impacts. At the center of this discussion is whether children areuniquely susceptible and whether current regulatory approaches are protectiveof children. This workshop will discuss ongoing initiatives by the EPA and CDCaimed at characterizing children’s exposures and evaluating biomonitoring data.Other parameters that are influential in predicting susceptibility, namely, phar-macokinetics and pharmacodynamics, will also be addressed. The use ofuncertainty factors in setting environmental criteria and estimating safe doseswill be discussed and a case study from the VCCEP program will be presented.A view from the medical community, frequently the first responders to ques-tions and concerns over children’s health, will be offered. The scientificquestions about whether children are significantly more susceptible to toxicantsand the current regulatory response to this concern (e.g., FQPA, testing require-ments, basic research, cancer risk assessment guidelines) are the focus of thisworkshop. An anticipated outcome is the identification of those areas ofresearch that will give the toxicology community the opportunity to be a centralfigure in properly addressing this important public health question.

#1338 8:30 CURRENT REGULATORY AND SCIENTIFICVIEWS REGARDING CHEMICAL HAZARDS TOCHILDREN. D. R. Juberg1 and D. J. Paustenbach2.1Regulatory Laboratories, Dow AgroSciences,Indianapolis, IN and 2ChemRisk, San Francisco, CA.

#1339 8:40 OVERVIEW OF U.S. EPA RESEARCHACTIVITIES AIMED AT CHARACTERIZINGCHILDREN’S EXPOSURES. E. A. Cohen Hubal.U.S. EPA, Research Triangle Park, NC. Sponsor: D.Juberg.

#1340 9:00 USING CDC BIOMONITORING DATA FORASSESSING CHILDRENS’ EXPOSURES TOENVITONMENTAL CHEMICALS. L. L. Needham.NCEH, CDC, Atlanta, GA. Sponsor: P. Williams.

#1341 9:30 EVALUATION OF CHILDHOOD EXPOSURES TOINDUSTRIAL CHEMICALS THROUGH VCCEP.P. R. Williams. ChemRisk, Boulder, CO. Sponsor: D.Paustenbach.

#1342 10:00 EVALUATION AND PREDICTION OFDOSIMETRY IN CHILDREN: EMPIRICAL ANDMECHANISTIC APPROACHES. A. M. Jarabek.U.S. EPA Visiting Scientist, CIIT Centers for HealthResearch, Research Triangle Park, NC.

#1343 10:30 DIFFERENTIAL SENSITIVITY OF CHILDRENAND ADULTS TO CHEMICAL TOXICITY ANDTHE USE OF UNCERTAINTY FACTORS INREGULATING RISKS. G. Charnley3, M. L. Dourson1

and R. Scheuplein2. 1Toxicology Excellence for RiskAssessment (TERA), Cincinnati, OH, 2Keller andHeckman, Stafford, VA and 3HealthRisk Strategies,Washington.

#1344 11:00 AN EVALUATION OF ENVIRONMENTALHEALTH TRENDS AMONG CHILDREN BASEDON MEDICAL AND SCIENTIFIC EVIDENCE. D.A. Goldstein. A2NE, Monsanto Company, St. Louis,MO. Sponsor: P. Williams.


WORKSHOP SESSION: TOXICOLOGIC EVALUATION OF INHALEDVACCINES

Chairperson(s): Matthew Reed, Lovelace Respiratory Research Instisute,Albuquerque, NM and Robert House, Dynport Vaccine Company, Frederick,MD.

Endorsed by:Immunotoxicology SSInhalation SS*Regulatory and Safety Evaluation SS

Mucosal and systemic immunity stimulated by aerosolized vaccines have beenrecognized as effective pathways for preventative immunizations and therapiesfor pathogens and diseases ranging from flu (e.g., FluMist) to measles (WorldHealth Organization) to asthma. Likewise, in the face of an ever-present risk ofaerosol delivery of chemical and biological agents, inhaled vaccines make senseby stimulating immunity at the portal of pathogen/ chemical entry. However,several toxicological hurdles exist for those challenged with developing or regu-lating vaccines, especially those designed for administration to the respiratorytract. General toxicological assessment as are required for all vaccine subtypesare necessary as well as special considerations including safety pharmacology.Adjuvant type and possible transport to the brain via the olfactory pathway areof concern as well. This symposium will bring together experts in the field ofinhaled therapeutics and vaccine development, to give insight into the requiredand perceived toxicology of aerosolized vaccines.

#1345 8:30 TOXICOLOGIC EVALUATION OF INHALEDVACCINES. M. Reed. Toxicology, LovelaceRespiratory Research Institute, Albuquerque, NM.

#1346 8:45 AIRWAY DRUG DELIVERY OPTIONS FORINHALED BIOLOGICS AND VACCINES. C. Leach.Preclinical Development, Lovelace RespiratoryResearch Institute, Albuquerque, NM.

Program Description


WED

NESD

AY


#1347 9:10 IMMUNOGENICITY AND SAFETY TESTING OFVACCINES: A REGULATORY PERSPECTIVEON GENERAL REQUIREMENTS AND SPECIALISSUES OF THE RESPIRATORY TRACT. K. L.Hastings. Office of New Drugs, CDER, U.S. FDA,Rockville, MD.

#1348 9:35 UNIQUE ISSUES ASSOCIATED WITHTOXICOLOGY ASSESSMENT OF VACCINESFOR BIOWARFARE AGENTS. R. House. DynportVaccine Company, Frederick, MD.

#1349 10:00 WHO SPONSORED PRECLINICAL TOXICITYTESTS FOR INHALED MEASLES VACCINE. M.Papania. Centers for Disease Control and Prevention,Atlanta, GA. Sponsor: M. Reed.

#1350 10:25 NONCLINICAL SAFETY EVALUATION OF TLR4AGONISTS ADMINISTERED BY NASAL SPRAY.C. M. Lynch. Nonclinical Development, CorixaCorporation, Seattle, WA. Sponsor: M. Reed.


WORKSHOP SESSION: TOXICOLOGICAL RESEARCH ANDTESTING: BEST PRACTICES AND OPPORTUNITIES FORLABORATORY ANIMAL REFINEMENT, REDUCTION, ANDREPLACEMENT

Chairperson(s): Stephen Lasley, University of Illinois College of Medicine,Peoria, IL and William Stokes, National Institute of Environmental HealthSciences, Research Triangle Park, NC.

Endorsed by:Animals in Research*Risk Assessment SS

In the performance of toxicology studies, whether for purposes of product safetytesting or identifying mechanisms of toxicant action, it is becoming increasinglyimportant to adopt practices and approaches that refine, reduce, and replace thenumbers of laboratory animals utilized. Incorporation of best practices intostudies will help ensure that animals are used in the most humane and judiciousmanner consistent with successful attainment of the research or testing objec-tives. Adoption of these practices is of timely importance because of continuallyincreasing regulatory oversight of animal care and use, and thus considerationof these issues from different viewpoints is of broad interest to toxicologists.Best practices for regulatory testing involves careful consideration and appro-priate incorporation of in vitro methods, humane endpoints, and tiered testingstrategies (Stokes). Current best practices for housing and providing environ-mental enrichment for study animals should be consistently utilized, and factorsconsidered that might potentially influence study outcomes (Brown). GLPrequirements for pre-clinical safety studies are important factors to address, andoptimal animal welfare practices consistent with compliance must be ensured(McCormack). Application of toxicogenomics to pre-clinical safety studiesinvolving animals is an emerging concern, and potential opportunities for thesemethodologies to refine, reduce, and replace animal use are being developed(Schechtman). Finally, updating of European Union animal welfare lawscontinue to evolve, and their potential impact on harmonization of animal careprograms and toxicological research is a relevant concern to multinationalcompanies (Donovan).

#1351 8:30 TOXICOLOGICAL RESEARCH AND TESTING:BEST PRACTICES AND OPPORTUNITIES FORLABORATORY ANIMAL REFINEMENT,REDUCTION, AND REPLACEMENT. S. M. Lasley1

and W. S. Stokes2. 1Department of Pharmacology,University of Illinois College of Medicine, Peoria, ILand 2NICEATM, NIEHS/NIH/DHHS, ResearchTriangle Park, NC.

#1352 8:35 BEST PRACTICES FOR USING HUMANEENDPOINTS AND TIERED TESTINGSTRATEGIES TO REFINE, REDUCE, ANDREPLACE ANIMAL USE IN TOXICOLOGICALRESEARCH AND TESTING. W. S. Stokes.NICEATM, NIEHS/NIH/DHHS, Research TrianglePark, NC.

#1353 9:05 BEST PRACTICES FOR ENVIRONMENTALENRICHMENT AND HOUSING FORLABORATORY ANIMALS USED INTOXICOLOGICAL RESEARCH AND TESTING.M. J. Brown. Charles River Laboratories, East Thetford,VT. Sponsor: S. Lasley.

#1354 9:35 BALANCING ANIMAL WELFARE AND GLPCOMPLIANCE IN NONCLINICALLABORATORY SAFETY STUDIES. J. F.McCormack. Office of Regulatory Affairs, US Food andDrug Administration, Rockville, MD. Sponsor: W.stokes.

#1355 10:05 APPLICATION OF TOXICOGENOMICS TO PRE-CLINICAL SAFETY TESTING: VALIDATIONCONSIDERATIONS FOR POTENTIALLABORATORY ANIMAL REFINEMENT,REDUCTION, AND REPLACEMENT. L. M.Schechtman. FDA/NCTR, Rockville, MD.

#1356 10:35 REVISIONS TO EUROPEAN ANIMAL WELFARELEGISLATION: IMPACT ON ANIMAL CAREAND TOXICOLOGY STUDIES. J. C. Donovan.BioResources, Wyeth Research, Collegeville, PA.Sponsor: S. Lasley.


PLATFORM SESSION: AH RECEPTOR

Chairperson(s): Mark Hahn, Woods Hole Oceanographic Institute, WoodsHole, MA and Richard Pollenz, University of South Florida, Tampa, FL.

#1357 8:30 THE ROLE OF THE COOH-TERMINALTRANSACTIVATION DOMAIN OF THE MOUSEAH RECEPTOR IN LIGAND-DEPENDENT ANDINDEPENDENT DEGRADATION. R. S. Pollenz andJ. Popat. Biology, University of South Florida, Tampa,FL.

#1358 8:50 KINETIC STUDIES OF ARYL HYDROCARBONRECEPTOR ACTIVATION BY INDOLO[3, 2-B]CARBAZOLES, INDIGOS AND 2, 3, 7, 8-TETRACHLORODIBENZO-P-DIOXIN INHUMAN HEPG2 CELLS. A. Rannug1, S. Pettersson1,L. Poellinger2 and M. Backlund1,2. 1Institute ofEnvironmental Medicine, Karolinska Institutet,Stockholm, Sweden and 2Cell and Molecular Biology,Karolinska Institutet, Stockholm, Sweden.

Program Description



WED

NES

DAY

#1359 9:10 DRE BINDING IS NOT REQUIRED FORREPRESSION OF AHR SIGNALING BY AHRR. B.R. Evans1,2, L. L. Allan3,4, D. H. Sherr3 and M. E.Hahn1. 1Biology, Woods Hole OceanographicInstitution, Woods Hole, MA, 2Biology, BostonUniversity, Boston, MA, 3Environmental Health, BostonUniversity School of Public Health, Boston, MA and4Microbiology, Boston University School of Medicine,Boston, MA.

#1360 9:30 ERK KINASE ACTIVITY CONTRIBUTES TO AHRECEPTOR TARGETED PROTEINDEGRADATION AND TRANSCRIPTIONALPOTENTIAL. S. CHEN and R. H. Tukey. Laboratoryof Environmental Toxicology, Departments ofChemistry & Biochemistry and Pharmacology,University of California, San Diego, La Jolla, CA.

#1361 9:50 INVOLVEMENT OF KINASE SIGNALINGPATHWAYS IN AH-RECEPTOR MEDIATEDGENE EXPRESSION IN RAT LIVER CELLS. B. V.Madhukar1, G. Chen1, C. Sorrentino2 and M. S.Denison2. 1Pediatrics/Human Development, MichiganState University, East Lansing, MI and 2EnvironmentalToxicology, University of California at Davis, Davis,CA.

#1362 10:10 ACTIVATION OF THE ARYL HYDROCARBONRECEPTOR ALTERS IN VIVO HEPATOCYTEPROLIFERATION. K. A. Mitchell1, S. A. Hattenbach2

and C. J. Elferink1. 1Department of Pharmacology andToxicology, University of Texas Medical Branch,Galveston, TX and 2UTMB Summer UndergraduateResearch Program, University of Houston-Downtown,Houston, TX.

#1363 10:30 TEMPORAL AND DOSE-DEPENDENT HEPATICGENE EXPRESSION PATTERNS IN MICEPROVIDE NEW INSIGHTS INTO TCDD-MEDIATED HEPATOTOXICITY. D. R. Boverhof, L.D. Burgoon, C. Tashiro, B. Chittim, J. R. Harkema andT. R. Zacharewski. Biochemistry & Molecular Biology,National Food Safety & Toxicology Center, and Centerfor Integrative Toxicology, Michigan State University,East Lansing, MI.

#1364 10:50 EXPRESSION OF DOMINANT NEGATIVE N-CADHERIN RESULTS IN AHR-DEPENDENTGENE INDUCTION IN HEPA 1C1C7 WILD-TYPECELLS. L. M. Van Pay1 and B. Allen-Hoffmann1,2.1Molecular and Environmental Toxicology, Universityof Wisconsin, Madison, WI and 2Pathology andLaboratory Medicine, University of Wisconsin,Madison, WI.

#1365 11:10 ERαα IS A LIGAND-DEPENDENT MODULATOROF AHR TRANSCRIPTION: INTERPLAYBETWEEN THE TWO RECEPTOR SYSTEMS. J.Matthews, B. Whilen and J. Gustafsson. Department ofBiosciences, Karolinska Institute, Huddinge, Sweden.


PLATFORM SESSION: FEMALE AND MALE REPRODUCTIVESYSTEMS

Chairperson(s): Kimberly Miller, University of Maryland, Baltimore, MD andWendy Jefferson, NIEHS, Research Triangle Park, NC.

#1366 8:30 THERAPEUTIC CONCENTRATIONS OFHALOPERIDOL DO NOT DIRECTLY AFFECTOVARIAN FUNCTION AND OOCYTE QUALITYAS TESTED IN MOUSE OVARIAN FOLLICLECULTURE MODEL. R. Cortvrindt1,2, E. Gobbers1, V.Van Merris1 and J. Smitz1. 1EggCentris NV, Zellik,Belgium and 2Follicle Biology Laboratory, VrijeUniversiteit Brussel, Brussels, Belgium. Sponsor: G.Daston.

#1367 8:50 BCL-2 FAMILY MEMBERS PROTECT AGAINSTMETHOXYCHLOR-INDUCED TOXICITY OFMOUSE OVARIAN ANTRAL FOLLICLES INVITRO. K. P. Miller1, C. Greenfeld2 and J. A. Flaws1.1Program in Toxicology, University of Maryland-Schoolof Medicine, Baltimore, MD and 2Department ofPhysiology, University of Maryland-School ofMedicine, Baltimore, MD.

#1368 9:10 REVERSAL OF BENZO-A-PYRENE EFFECTSON OXYTOCIN-INDUCED CA2+

OSCILLATIONS IN HUMAN MYOMETRIALPHM1-41 CELLS. R. Barhoumi, I. Awooda, S. Safeand R. C. Burghardt. Faculty of Toxicology, TexasA&M University, College Station, TX.

#1369 9:30 EFFECTS OF ATRAZINE AND AN ATRAZINEMETABOLITE MIXTURE ON DIFFERENTIATEDMAMMARY EPITHELIAL CELL MILKPROTEIN PRODUCTION IN CULTURE. E. P.Hines, R. Barbee, M. Blanton, M. S. Pooler and S. E.Fenton. Reproductive Toxicology Division, U.S. EPA,ORD, NHEERL, Research Triangle Park, NC.

#1370 9:50 NEONATAL EXPOSURE TO THEPHYTOESTROGEN GENISTEIN ALTERSREPRODUCTION IN FEMALE CD-1 MICE. W.Jefferson1,2, E. Padilla-Bank1 and R. Newbold1.1Laboratory of Molecular Toxicology, NIEHS,NIH/DHHS, Research Triangle Park, NC and2Molecular and Environmental Toxicology Department,North Carolina State University, Raleigh, NC.

#1371 10:10 ESTROGEN-INDUCED PATTERN OF GENEEXPRESSION AT HIGH AND LOW DOSES INFETAL MALE RAT TESTIS. J. M. Naciff, K. M.Hess, J. E. Maritnez, G. J. Overmann, L. M. Foertsch,S. M. Torontali, G. J. Carr, J. P. Tiesman and G. P.Daston. Procter & Gamble Company, Cincinnati, OH.

#1372 10:30 LOW DOSE CELLULAR RESPONSES IN THEFETAL RAT TESTIS IN UTERO EXPOSED TO DI(N-BUTYL) PHTHALATE. E. Kleymenova, C.Swanson and K. W. Gaido. CIIT CHR, ResearchTriangle Park, NC.

Program Description


WED

NESD

AY


#1373 10:50 IDENTIFYING CANDIDATES FOR THE CDMGENE, WHICH CONFERS RESISTANCE TOCADMIUM-INDUCED TESTICULAR DAMAGEIN MICE. L. Martin1, H. Allayee2, D. Shih3, G. Lee1,D. Hovland4, R. Hess5, K. Carnes5, R. M. Cantor3,6, A.J. Lusis3 and M. Collins1. 1Molecular Toxicology,UCLA, LA, CA, 2Institute for Genetic Medicine, USC,LA, CA, 3Human Genetics, UCLA, LA, CA,4Toxicology, Amgen, Thousand Oaks, CA, 5VeterinaryBiosciences, University of Illinois, Urbana, IL and6Pediatrics, UCLA, LA, CA. Sponsor: O. Hankinson.

#1374 11:10 PERIPUBERTAL DEHP EXPOSURE INHIBITSANDROGEN-DEPENDENT DEVELOPMENT INSPRAGUE-DAWLEY RATS. N. Noriega, J. Furr, C.Lambright, V. S. Wilson and L. E. Gray. RTD, U.S. EPAORD NHEERL, Research Triangle Park, NC.


PLATFORM SESSION: TOXICOGENOMICS: ROLE INPREDICTIVE TOXICOLOGY AND CARCINOGENICITY

Chairperson(s): Alema Galijativic, Merck &Co., Inc., West Point, PA andSupratim Choudhary, U.S. FDA, College Park, MD.

#1375 8:30 GENE ONTOLOGY MAPPING OF EARLYTRANSCRIPTIONAL RESPONSES ASSOCIATEDWITH HEPATOCYTE PROLIFERATION IN THELIVER OF DIETHYLHEXYLPHTHALATE-EXPOSED MICE. R. Currie1, V. Bombail1, D. J.Moore1, F. Lim1, J. Oliver1, K. Chipman2, I. Kimber1,G. Orphanides1 and J. Moggs1. 1Syngenta CTL,Macclesfield, Cheshire, United Kingdom and2University of Birmingham, Birmingham, UnitedKingdom.

#1376 8:50 COMPARATIVE ANALYSIS OF GENENETWORKS AT MULTIPLE DOSES AND TIMEPOINTS IN LIVERS OF RATS EXPOSED TOACETAMINOPHEN. H. Sone1,2, H. Toyoshiba1,2, T.Yamanaka1, F. Parham1, R. Irwin1, G. Boorman1 and C.J. Portier1. 1ETP, NIEHS, Research Triangle Park, NCand 2Environmental Health Sciences Division, NIES,Tsukuba, Ibaraki, Japan.

#1377 9:10 A SIGNATURE GENE NETWORK APPROACHTO TOXICITY. S. Ekins1, C. Giroux2, Y. Nikolsky1,A. Bugrim1 and T. Nikoskaya1. 1GeneGo Inc., StJoseph, MI and 2Institute of Environmental HealthSciences, Wayne State University, Detroit, MI.

#1378 9:30 A GENETIC NETWORK APPROACH TOCOMPARATIVE TOXICOGENOMICS AND RISKASSESSMENT: THE OXIDATIVE STRESSRESPONSE. C. N. Giroux1, S. Ekins2, J. Fan1, I.Abdullah1, Y. Nikolsky2, A. Bugrim2 and T.Nikolskaya2. 1Institute of Environmental HealthSciences, Wayne State University, Detroit, MI and2GeneGo, Inc., St. Joseph, MI.

#1379 9:50 PREDICTION OF HEPATOCARCINOGENICITYOF CHEMICALS USING THE GENEEXPRESSION IN THE 28-DAY REPEAT-DOSETOXICITY STUDY. H. Matsumoto1, F. Saito1, Y.Yoshikuni1, Y. Sudo1, M. Otsuka1, H. Miyaura1, I.Fukuda5, K. Saito2, K. Sumida2, M. Sekijima3, K.Nakayama3 and T. Shirai4. 1Chemicals Evaluation andResearch Institute, Japan, Tokyo, Japan, 2SumitomoChemical Co., Ltd.,, Osaka, Japan, 3MitsubishiChemical Safety Institute Ltd.,, Ibaraki, Japan,4Graduate School of Medical Sciences, Nagoya CityUniversity, Nagoya, Japan and 5Mitsui KnowledgeIndustry Co., Ltd.,, Tokyo, Japan.

#1380 10:10 TOXICOGENOMICS FOCUSING ON THEHEMOPOIETIC STEM CELL TOXICOLOGY. Y.Hirabayashi1, B. Yoon1, K. Kitada2, T. Matsushita1,3, K.Kobayashi2, K. Igarashi1, Y. Kodama1, J. Kanno1 and T.Inoue4. 1Division of Cellular & Molecular Toxicology,National Institute of Health Sciences, Tokyo, Japan,2Kamakura Research Labs, Chugai Pharmaceutical, Co.,Ltd.,, Kamakura, Japan, 3Fuji Gotenba Research Labs,Chugai Pharmaceutical, Co., Ltd.,, Shizuoka, Japan and4Center for Biological Safety & Research, NationalInstitute of Health Sciences, Tokyo, Japan.

#1381 10:30 QC METRICS AND THRESHOLDS FORASSESSING THE OVERALL QUALITY OF AMICROARRAY STUDY. L. Shi1, W. Tong1, F.Goodsaid2, F. Frueh2, F. C. Fuscoe1 and D. A.Casciano3. 1Division of Systems Toxicology, NCTR,U.S. FDA, Jefferson, AR, 2Office of ClinicalPharmacology and Biopharmaceutics, CDER, U.S.FDA, Rockville, MD and 3Office of the Director,NCTR, U.S. FDA, Jefferson, AR.

#1382 10:50 PROTOCOLS FOR THE ASSURANCE OFMICROARRAY DATA QUALITY AND PROCESSCONTROL. L. D. Burgoon1,5,6, J. E. Eckel-Passow3,C. Gennings4, D. R. Boverhof2,5,6, J. W. Burt2,5,6, C. J.Fong2,5,6 and T. R. Zacharewski2,5,6. 1Pharmacology &Toxicology, Michigan State University, East Lansing,MI, 2Biochemistry & Molecular Biology, MichiganState University, East Lansing, MI, 3Health SciencesResearch, Mayo Clinic Cancer Center, Rochester, MN,4Biostatistics, Virginia Commonwealth University,Richmond, VA, 5National Food Safety and ToxicologyCenter, Michigan State University, East Lansing, MIand 6Center for Integrative Toxicology, Michigan StateUniversity, East Lansing, MI.

#1383 11:10 DBZACH: A COMPREHENSIVETOXICOGENOMIC INFORMATIONMANAGEMENT AND KNOWLEDGEDISCOVERY SYSTEM. R. Aiyar2,3,4, L. D.Burgoon1,3,4, P. C. Boutros2,3,4, E. Dere2,3,4, S.Doran2,3,4, S. S. Pai2,3,4, J. Vakharia2,3,4, R. Rotman2,3,4,A. Adams2,3,4, B. Lau2,3,4, R. Patel2,3,4 and T. R.Zacharewski2,3,4. 1Pharmacology & Toxicology,Michigan State University, East Lansing, MI,2Biochemistry & Molecular Biology, Michigan StateUniversity, East Lansing, MI, 3National Food Safety &Toxicology Center, Michigan State University, EastLansing, MI and 4Center for Integrative Toxicology,Michigan State University, East Lansing, MI.

Program Description



WED

NES

DAY

Wednesday Morning, March 99:30 AM to 12:30 PMExhibit Hall

POSTER SESSION: FOOD SAFETY AND NUTRITION TOXICOLOGY I

Chairperson(s): Debasis Bagchi, Interhealth Research Center, Benicia, CAand Kulbir Bakshi, National Research Council, Washington, DC.



#1384 LEVAMISOLE RESIDUES IN CHICKEN TISSUESAND EGGS. H. El-Kholy and B. W. Kemppainen.Anatomy, Physiology, Pharmacology, AuburnUniversity, Auburn, AL.

#1385 FUMONISIN B-GLUCOSE REACTIONPRODUCTS ARE LESS TOXIC WHEN FED TOSWINE. G. E. Fernandez1, G. D. Osweiler1, P. A.Murphy1, M. Yaeger1, G. Rottinghaus2, S. Hendrich1

and L. Buckley1. 1Toxicology, Iowa State University,Ames, IA and 2Veterinary Diagnostic Lab., Universityof Missouri, Columbia, MO.

#1386 THE NATIONAL RESIDUE PROGRAM AS AFOOD SAFETY TOOL. J. Vodela1, P. Zervos2, C.Deyrup3, R. Sutton4, M. O’Keefe5, D. Pagan-Rodriguez6 and H. Walker7. 1Residue Branch,USDA/FSIS, Washington, DC, 2Residue Branch,USDA, Washington, DC, 3Residue Branch, USDA,Washington, DC, 4Residue Branch, USDA, Washington,DC, 5Residue Branch, USDA, Washington, DC,6Residue Branch, USDA, Washington, DC and 7ResidueBranch, USDA, Washington, DC.

#1387 ASSESSMENT OF METALS CONCENTRATIONSIN SALMONBERRIES AND SOURDOCKCOLLECTED NEAR A MINING TRANSPORTROAD IN NORTHWEST ALASKA. M. Garry1,2, S.S. Shock2, L. J. Yost2, J. Kulas3 and W. J. Shields2. 1Uof Wash., Seattle, WA, 2Exponent, Bellevue, WA and3Teck Cominco, Anchorage, AK.

#1388 LACK OF EFFECTS OF BETA-CAROTENEDERIVED FROM BLAKESLEA TRISPORA, ANATURAL FOOD COLOR, IN A THIRTEEN-WEEK ORAL TOXICITY STUDY IN F344 RATS.K. Nabae1, T. Ichihara1,2, A. Hagiwara1, M. Kawabe1,M. Nishino3, T. Ogasawara3, Y. Sasaki3, M. Nakamura3

and T. Shirai2. 1Daiyu-Kai Institute of Medical Science,Inc., Ichinomiya, Japan, 2Department of ExperimentalPathology and Tumor Biology, Nagoya City UniversityGraduate School of Medical Sciences, Nagoya, Japanand 3San-Ei Gen F.F.I., Inc., Toyonaka, Japan.

#1389 DEPLETION OF T CELLS BY MONOCLONALANTIBODIES AGAINST MTHY-1.2 ANTIGENREDUCES FUMONISIN B1 TOXICITY IN MICE.N. Sharma, Q. He and R. P. Sharma. Physiology andPharmacology, university of Georgia, athens, GA.

#1390 SAFETY EVALUATION OF A NEW ANTI-STALING AMYLASE ENZYME FOR BAKERYAPPLICATIONS. Q. Q. Bui1, H. V. Thygesen2, L. S.Bollen3, Z. El-Salanti3 and C. N. Edwards3. 1GenencorInternational, Palo Alto, CA, 2Danisco A/S,Copenhagen, Denmark and 3Scantox A/S, LilleSkensved, Denmark.

#1391 TIME- AND DOSE-DEPENDENT CHANGES INSPHINGOID BASE 1 PHOSPHATES IN TISSUESFROM RATS FED DIETS CONTAININGFUMONISINS. R. T. Riley, J. L. Showker and K. A.Voss. Toxicology and Mycotoxin Research Unit, USDA-ARS, Athens, GA.

#1392 TOXICOLOGY STUDIES ON ALLANBLACKIASEED OIL. L. J. Lea and S. O’Hagan. Safety andEnvironmental Assurance Centre, Unilever, Bedford,United Kingdom. Sponsor: P. Hepburn.

#1393 SAFETY AND EFFICACY POTENTIAL OF ANOVEL ANTHOCYANIN-RICH MULTIPLEBERRY EXTRACT IN IN VIVO MODELS. M.Bagchi1, D. Bagchi1,2 and C. Sen3. 1InterHealthResearch Center, Benicia, CA, 2Creighton MedicalCenter, Omaha, NE and 3, Ohio State Medical Center,Columbus, OH.

#1394 A 90-DAY DIETARY TOXICITY STUDY OFHEATED DAG OIL AND HEATED TG OIL INRATS. C. P. Chengelis1, J. B. Kirkpatrick1, W. B.Lawrence1, O. Morita2, Y. Tamaki2 and H. Suzuki2.1WIL Research Laboratories, Inc., Ashland, OH and2Kao Corporation, Haga Tochigi, Japan.

#1395 ACCUMULATION OF SPHINGOID BASES ANDSPHINGOID BASE 1-PHOSPHATES: APOSSIBLE MECHANISM FOR FUSARIUMVERTICILLIOIDES CORN-SEEDLING DISEASE.L. D. Williams1,2, A. E. Glenn2, C. W. Bacon2, M. A.Smith1 and R. T. Riley2. 1Environmental HealthSciences, UGA, Athens, GA and 2TMRU, USDA,Athens, GA.

#1396 DEVELOPMENTAL TOXICITY OF DIETSCONTAINING FUMONISIN B1 TO LM/BC ANDCD1 MICE: A COMPARATIVE STUDY. K. A.Voss1, J. B. Gelineau-van Waes2, R. T. Riley1, T. D.Burns3 and C. W. Bacon1. 1Toxicology & MycotoxinResearch Unit, USDA-Agricultural Research Service,Athens, GA, 2Genetics, Cell Biology and Anatomy,University of Nebraska Medical Center, Omaha, NE and3Interdisciplinary Program in Toxicology, University ofGeorgia, Athens, GA.

#1397 A 90-DAY DIETARY STUDY ON CARRAGEENANWITH EMPHASIS ON THEGASTROINTESTINAL TRACT. D. C. Nuber1, M. L.Weiner1, W. Blakemore1, J. F. Harriman2 and S. M.Cohen3. 1Toxicology, FMC Corporation, Princeton, NJ,2Toxicology, WIL Research Laboratories, Ashland, OHand 3University of Nebraska Medical Center, Omaha,NE.

Program Description


WED

NESD

AY


#1398 TANNIC ACID IS A PROOXIDANT ANDINDUCES CYCLOOXYGENASE-2 IN HUMANCOLON CELLS. J. P. Gray1,2, V. Mishin1, D. E.Heck1,2 and J. D. Laskin2,3. 1Pharmacology andToxicology, Rutgers University, Piscataway, NJ, 2JointGraduate Program in Toxicology, Rutgers University,Piscataway, NJ and 3Environmental & OccupationalMedicine, UMDNJ–Robert Wood Johnson MedicalSchool, Piscataway, NJ.

#1399 GENOTOXICITY STUDIES ON DIETARYDIACYLGLYCEROL (DAG) OIL. T. Kasamatsu1, R.Ogura1, N. Ikeda1, O. Morita1, K. Saigo2, H. Watabe3,Y. Saito3 and H. Suzuki1. 1Safety and EnvironmentalResearch Section, Kao Corporation, Ichikai, Haga,TOCHIGI, Japan, 2Shin Nippon BiochemicalLaboratories, Ltd.,, Miyanoura, Yoshida,KAGOSHIMA, Japan and 3Mitsubishi Chemical SafetyInstitute, Ltd.,, Hasaki, Kashima, IBARAKI, Japan.Sponsor: C. Chengelis.

#1400 ISOTHERMAL MODELS FOR THEPREDICTION OF NUTRIENT INTERACTIONSWITH MYCOTOXIN SORBENTS. J. F. Taylor, E.Afriyie-Gyawu, H. J. Huebner and T. D. Phillips.Faculty of Toxicology, Texas A&M University, CollegeStation, TX.

#1401 EFFECTS OF A LOW-CARBOHYDRATE DIETON MARKERS OF OXIDATIVE STRESS INTISSUES FROM DIABETIC AND NON-DIABETICRATS. J. B. Watkins, Z. T. Kamuren, D. F. O’Neill andR. A. Sanders. Medical Sciences, Indiana UniversitySchool of Medicine, Bloomington, IN.

#1402 CHRONIC TOXICOLOGICAL EVALUATION OFNOVASIL CLAY IN THE DIET OF SPRAGUE-DAWLEY RATS. E. Afriyie-Gyawu1,2, J. Mackie3, B.Dash1,2, M. C. Wiles2, J. Taylor1,2, H. J. Huebner1,2, H.Guan4, T. Lili4, J. Wang4 and T. D. Phillips1,2. 1Facultyof Toxicology, Texas A&M University, College Station,TX, 2Veterinary Integrative Biosciences, Texas A&MUniversity, College Station, TX, 3VeterinaryPathobiology, Texas A&M University, College Station,TX and 4Texas Tech University, Lubbock, TX.

#1403 ACRYLAMIDE, HEAVY METAL COMBINATIONTOXICITY AND GLUTATHIONE DEPLETION. C.Siegers1, M. M. Schulze1 and J. B. Schulze2. 1Instituteof Experimental and Clinical Pharmacology andToxicology, Luebeck, Germany and 2Office of theDean, Medical Faculty, Frankfurt, Germany.

#1404 SAFETY ASSESSMENT OF LYSINE MAIZE. B.Hammond, T. Reynolds, J. Kronenberg and K. Glenn.Monsanto Company, St. Louis, MO.

#1405 EVALUATION OF THE SUBCHRONICTOXICITY OF 1507XNK603 TRANSGENICMAIZE. S. A. MacKenzie1, C. Pavely2, L. A. Malley1,N. E. Everds1, G. P. Sykes1, B. Delaney1 and I. Lamb2.1DuPont Haskell Laboratory for Health andEnvironmental Sciences, Newark, DE and 2Pioneer Hi-Bred International, Inc., Johnston, IL.

#1406 INDUCTION OF COLON TUMORS IN C57BL/6JMICE FED MEIQX, IQ OR PHIP FOLLOWED BYDEXTRAN SULFATE SODIUM TREATMENT. A.Nishikawa, T. Imazawa, Y. Kuroiwa, K. Kanki, Y. Ishii,Y. Kitamura, T. Umemura and M. Hirose. Pathology,National Institute of Health Sciences, Tokyo, Japan.Sponsor: M. Ema.

#1407 INHIBITION OF AFB1 ACTIVATION AND AFB1-DNA ADDUCT FORMATION BY DIETARYBUTYLATED HYDROXYTOLUENE INTURKEYS. J. A. Guarisco, J. O. Hall and R. A.Coulombe. Toxicology Graduate Program, Utah StateUniversity, Logan, UT.

#1408 SAFETY ASSESSMENT AND RISK/BENEFITANALYSIS OF THE USE OFAZODICARBONAMIDE IN BABY FOOD JARCLOSURE TECHNOLOGY: PUTTING TRACELEVELS OF SEMICARBAZIDE EXPOSUREINTO PERSPECTIVE. V. M. Lee-Brotherton, B. S.Lynch, K. Musa-Veloso, G. H. Goodfellow, E. Cheng, L.A. Haighton and E. R. Nestmann. CANTOX HealthScience Intl., Mississauga, ON, Canada.


POSTER SESSION: NATURAL PRODUCTS

Chairperson(s): Sidney Stohs, AdvoCare International LP, Carrollton, TX.



#1409 INHIBITORY EFFECTS OF PLATYCODONGRANDIFLORUM ON 4-(METHYLINITROSAMINO)-1-(3-PYRIDYL)-1-BUTANONE (NNK)-INDUCED LUNGTUMORIGENESIS IN A/J MICE. S. Roh4, D.Shin1,2, K. Lee1, Y. Chung3, C. Choi3, Y. Cho4 and H.Jeong1,2. 1Pharmacy, Chosun University, Kwangju,South Korea, 2Research Center for ProteineousMaterials, Chosun University, Kwangju, South Korea,3Division of Food Science, Chinju InternationalUniversity, Chinju, South Korea and 4Department ofR&D, Jangsaeng Doraji Co., Ltd.,, Chinju, South Korea.

#1410 FOUR WEEKS EXPOSURE TO A NOVELNUTRITIONAL MIXTURE CONTAINING ASERIES OF POLYPHENOLICPHYTOCHEMICALS ANTAGONIZESACETAMINOPHEN-INDUCEDHEPATOTOXICITY IN VIVO. S. Stohs1, A. Nagori2,A. Naqvi2, N. Shah2 and S. D. Ray2. 1Res & Dev,AdvoCare International, Carrollton, TX and 2Mol.Toxicology. Prog, Division of Pharmacology Scs., LongIsland University, Brooklyn, NY.

Program Description



WED

NES

DAY

#1411 IN VITRO EFFICACY OF PLANT-EXTRACTSUSED FOR ALTERNATIVE TREATMENT OFSNAKEBITES IN NIGERIA. I. U. Asuzu1, A.Harvey2 and H. M. Lantum3. 1Department of VeterinaryPhysiol. & Pharmacology, University of NigeriaNsukka, Enugu, Nigeria, 2Department of Physiol. &Pharmacology, University of Strathclyde, Glasgow,United Kingdom and 3African Society for ToxicologicalSciences (ASTS), Rochester, NY.

#1412 IMMUNOMODULATING AND ANTIOXIDANTEFFECTS OF MEXICAN STRAINS OFLENTINUS LEPIDEUS, GANODERMAAPPLANATUM AND ARMILLARIA TABESCENS.X. S. Ramirez-Garcia1, L. Garza-Ocanas1, F. Garza-Ocanas2, Y. Alcaraz-Contreras1 and M. Salinas-Carmona3. 1Farmacologia Y Toxicologia, Fac deMedicina, UANL, Monterrey, Neuvo Leon, Mexico,2Silvicultura, Fac de Ciencias Forestales, UANL,Monterrey, Nuevo Leon, Mexico and 3Inmunologia, Facde Medicina, UANL, Monterrey, Nuevo Leon, Mexico.

#1413 NUCLEAR TRANSLOCATION OF NF-KB/RELCOMPONENT BY PCSC22 ISOLATED FROMPORIA COCOS SCLEROTIUM. Y. J. Jeon.Pharmacology, Chosun University, Kwangju, SouthKorea. Sponsor: H. Kim.

#1414 SAFETY AND TOXICOLOGICAL EVALUATIONOF A NOVEL NIACIN-BOUND CHROMIUM. M.Shara1, T. Yasmin1, M. Bagchi2, A. Chatterjee1, H. G.Preuss3 and D. Bagchi2. 1Pharmacy Science, CreightonUniversity, Omaha, NE, 2Research Center, InterHealthUSA, Benicia, CA and 3Medical Center, GeorgetownUniversity, Washington, DC.

#1415 INHIBITORY EFFECTS OF KAHWEOL ANDCAFESTOL ON CARRAGEENAN-INDUCEDINFLAMMATION IN MOUSE AIR POUCHMODEL. H. Jeong1,2, J. Kim1,2 and K. Jung1,2.1Pharmacy, Chosun University, Kwangju, South Koreaand 2Research Center for Proteineous Materials, ChosunUniversity, Kwangju, South Korea.

#1416 UP-REGULATION OF CYCLOOXYGENASE-2EXPRESSION BY CHICKEN OVALBUMIN INMURINE MACROPHAGES. K. Jung1,2, J. Kim1,2

and H. Jeong1,2. 1Pharmacy, Chosun University,Kwangju, South Korea and 2Research Center forProteineous Materials, Chosun University, Kwangju,South Korea.

#1417 ANTIOXIDATIVE EFFECTS OF PAECILOMYCESTENUIPES ON CARBON TETRACHLORIDE-INDUCED HEPATOTOXICITY IN PRIMARYCULTURES OF ADULT RAT HEPATOCYTESAND IN VIVO. I. Jun1, S. Hyun1, J. Lee2, T. Jeon1, S.Lee1, C. Jin1, D. Lee1, G. Kim1 and T. Jeong1.1College of Pharmacy, Yeungnam University, Kyungsan,South Korea and 2College of Natural Resources,Yeungnam University, Kyungsan, South Korea.

#1418 NATURAL PRODUCTS DISCOVERY THROUGHDEVELOPMENT THE CHALLENGES AND THEOPPORTUNITIES. C. B. Spainhour and J. Fogleman.Calvert Laboratories, Olyphant, PA.

#1419 PRO-APOPTOTIC EFFECTS OF THE TROPICALGINGER COMPOUND, 1′′-ACETOXYCHAVICOLACETATE, ON HUMAN BREAST CANCERCELLS IN VITRO. H. E. Kleiner1,2 and C. T.Campbell1. 1Pharmacology, Louisiana State University-Health Sciences Center, Shreveport, LA and 2Feist-Weiller Cancer Center, Louisiana State University-Health Sciences Center, Shreveport, LA.

#1420 NOTOGINSENG ATTENUATES LPS-INDUCEDPRO-INFLAMMATORY MEDIATORS INANTIGEN PRESENTING CELLS. A. Rhule1, S.Navarro2, J. Smith1 and D. M. Shepherd1,2. 1Ctr forEnviron Health Sciences, University of Montana,Missoula, MT and 2Biomed Pharmacology Sciences,University of Montana, Missoula, MT.

#1421 EFFECTS OF MURINE CYP1A1 IN MOUSEHEPATOMA HEPA-1C1C7 CELLS BY CATECHINAND 3′′, 4′′, 3, 5, 7-O-METHYLATED CATECHIN.E. Han1,2, J. Kim1,2, H. Kim1,2, Y. Hwang1,2, T. Jeong3,E. Lee3 and H. Jeong1,2. 1Pharmacy, Chosun University,Kwangju, South Korea, 2Research Center forProteineous Materials, Chosun University, Kwangju,South Korea and 3Pharmacy, Yeungnam University,Kyungsan, South Korea.

#1422 SUPPRESSION OF MURINE CYP1A1 IN MOUSEHEPATOMA HEPA-1C1C7 CELLS BYFORMONONETIN. E. Hann1,2, J. Kim1,2 and H.Jeong1,2. 1Pharmacy, Chosun University, Kwangju,South Korea and 2Research Center for ProteineousMaterials, Chosun University, Kwangju, South Korea.

#1423 CAFFEIC ACID PHENETHYL ESTERSUPPRESSED IN B16F10 MELANOMA CELLMETASTASIS. D. Shin1,2 and H. Jeong1,2. 1Pharmacy,Chosun University, Kwangju, South Korea and2Research Center for Proteineous Materials, ChosunUniversity, Kwangju, South Korea.

#1424 SUPPRESSIVE EFFECT OF GAMMA-TOCOPHEROL ON PROSTATE CANCERDEVELOPMENT IN PB/SV40 T ANTIGENTRANSGENIC RATS. S. Sugiura1, S. Takahashi1, T.Murasaki1, M. M. Said1, S. Suzuki1, K. Abe2, M.Asamoto1 and T. Shirai1. 1Department of ExperimentalPathology and Tumor Biology, Nagoya City UniversityGraduate School of Medical Sciences, Nagoya, Japanand 2Eisai Co., Ltd., Tokyo, Japan.

#1425 SUBCHRONIC GAVAGE TOXICITY STUDY OFGINKGO BILOBA EXTRACT IN FISCHER 344RATS AND B6C3F1 MICE. L. M. Fomby1, M.Hejtmancik1, M. J. Ryan1, C. Colleton1, D. Orzech2 andP. Chan2. 1Battelle, Columbus, OH and 2NIEHS,Research Triangle Park, NC.

#1426 INHIBITORY EFFECT OF KAHWEOL ANDCAFESTOL ON TGF-BETA-INDUCED FIBROSISIN HEPATIC STELLATE CELLS. K. Jung1,2 and H.Jeong1,2. 1Pharmacy, Chosun University, Kwangju,South Korea and 2Research Center for ProteineousMaterials, Chosun University, Kwangju, South Korea.

Program Description


WED

NESD

AY


#1427 ANTI-ANGIOGENETIC EFFECTS OFCAFESTOL AND KAHWEOL ON HT-1080FIBROSARCOMA CELLS. Y. Chung3, D. Shin1,2, K.Oh1,2, E. Woo1,2, C. Choi3, D. Kim4 and H. Jeong1,2.1Pharmacy, Chosun University, Kwangju, South Korea,2Research Center for Proteineous Materials, ChosunUniversity, Kwangju, South Korea, 3Division of FoodScience, Chinju International University, Chinju, SouthKorea and 4Pathology, College of Oriental Medicine,Daejeon University, Daejeon, South Korea.

#1428 GREEN TEA INFUSION PREVENTS DUALPROMOTING EFFECTS OFPENTACHLOROPHENOL, ANENVIRONMENTAL POLLUTANT, ON HEPATO-AND CHOLANGIO-CARCINOGENESIS OFMICE INDUCED BY DIETHYLNITROSAMINE. T.Umemura1, R. Hasegawa2, K. Keita1, Y. Kitamura1, A.Nishikawa1 and M. Hirose1. 1Division of Pathology,National Institute of Health Sciences, Tokyo, Japan and2Division of Medical Safety Science, Natonal Instituteof Health Sciences, Tokyo, Japan.

#1429 TWO-GENERATION REPRODUCTION STUDYOF TEAVIGO™ (EPIGALLOCATECHINGALLATE) IN RATS. R. Isbrucker1, J. A. Edwards2,E. Wolz2 and E. Marsden3. 1Burdock Group,Washington, DC, 2DSM Nutritional Products Ltd.,,Kaiseraugst, Switzerland and 3MDS PharmacologyServices, L’Arbresle, France. Sponsor: J. Griffiths.

#1430 SUPPRESSION OF LIPOPOLYSACCHARIDE-ACTIVATED CYCLOOXYGENASE-2EXPRESSION BY BIOCHANIN A IN MURINEMACROPHAGE RAW 264.7 CELLS. J. Kim1,2, E.Han1,2 and H. Jeong1,2. 1Pharmacy, Chosun University,Kwangju, South Korea and 2Research Center forProteineous Materials, Chosun University, Kwangju,South Korea.

#1431 RUTAECARPINE IS AN AGONIST OF THE ARYLHYDROCARBON RECEPTOR. T. Jeong3, E. Han1,2,J. Kim1,2, H. Kim1,2, Y. Hwang1,2, E. Lee3 and H.Jeong1,2. 1Pharmacy, Chosun University, Kwangju,South Korea, 2Research Center for ProteineousMaterials, Chosun University, Kwangju, South Koreaand 3Pharmacy, Yeungnam University, Kyungsan, SouthKorea.

#1432 EXPRESSION PROFILING OF ESTROGENRESPONSIVE GENES FOR PHYTOESTROGENSBY DNA MICROARRAY ASSAY. D. Han1, R. Ise1, Y.Takahashi2, S. Terasaka1, A. Inoue1, M. Tanji1 and R.Kiyama1,3. 1Department R & D, InfoGenes Co., Ltd.,,Ibaraki, Japan, 2Industrial Research Institute of TottoriPrefecture, Tottori, Japan and 3National Institute ofAdvanced Industrial Science and Technology, Tsukuba,Japan. Sponsor: M. Denison.

#1433 MICROARRAY ANALYSIS OF T-2 TOXIN-INDUCED APOPTOTIC LESIONS OF THELIVER, PLACENTA AND FETAL LIVER INPREGNANT RATS. S. Sehata1, N. Kiyosawa1, F.Atsumi1, K. Ito1, T. Yamoto1, M. Teranishi1, K.Uetsuka2, H. Nakayama2 and K. Doi2. 1MedicinalSafety Research Laboratories, Sankyo Co., Ltd.,,Shizuoka, Japan and 2Department of VeterinaryPathology, Graduate School of Agricultural and LifeSciences, The University of Tokyo, Tokyo, Japan.

#1434 FUMONISIN B1 ACTIVATES SERINEPALMITOYLTRANSFERASE ANDSPHINGOSINE KINASE, ENZYMESIMPORTANT IN SPHINGOLIPID METABOLISM,IN MOUSE LIVER. H. Suzuki, Q. He and R. P.Sharma. The University of Georgia, Athens, GA.

#1435 IN VITRO STUDIES CONFIRM SYNERGISTICEFFECTS OF FUMONISIN B1 ANDOCHRATOXIN A IN VIVO. E. E. CREPPY1, P.Chiarappa2,1, I. Baudrimont1, P. Borracci2, S. Moukha3,1

and M. CARRATU2. 1Toxicology, University Bordeaux2, Bordeaux, France, 2Pharmacology and HumanPhysiology, Medical School, University of Bari, Bari,Italy and 3MycSA, INRA, Villenave d’Ornon, France.

#1436 CYTOKINE GENE EXPRESSION IN RATMICROGLIA EXPOSED TO THE MARINETOXIN DOMOIC ACID. A. M. Mayer, M. Guzman,R. Peksa, M. L. Hall and M. J. Fay. Pharmacology,Midwestern University, Downers Grove, IL. Sponsor:W. Prozialeck.

#1437 COMPARISON OF WEEKLY EXPOSURES TOANATOXIN-A AND NICOTINE ON THE MOTORACTIVITY OF RATS. K. A. Jarema, J. D. Farmer andR. C. MacPhail. NHEERL, U.S. EPA, ResearchTriangle Park, NC.

#1438 NICOTINE EFFECTS ON THE ACTIVITY OFMICE EXPOSED PRENATALLY TO THENICOTINIC AGONIST ANATOXIN-A. R. C.MacPhail, J. D. Farmer, K. A. Jarema and N. Chernoff.NHEERL, U.S. EPA, Research Triangle Park, NC.

#1439 HEAVY METAL EXPOSURE FROM HERBALSUPPLEMENTS IN NIGERIA. O. E. Orisakwe1, E.Obi1, D. N. Akunyili2, B. Ekpo3 and H. M. Lantum4.1Department of Pharmacology, College of HealthSciences, Nnamdi Azikiwe University, Nnewi, Nigeria,2National Agency for Food and Drug Administrationand Control (NAFDAC), Lagos, Nigeria, 3Departmentof Biochemistry, College of Medical Sciences, AbiaState University, Lagos, Nigeria and 4African Societyfor Toxicological Sciences (ASTS), Rochester, NY.

#1440 ADDITIVE EFFECTS OF FUMONISIN B1 ANDDEOXYNIVALENOL IN THE HUMANINTESTINAL CELL LINE, CACO2. E. E.CREPPY1, J. H. KOUADIO1,3, T. M. MOBIO1, I.BAUDRIMONT1, S. MOUKHA2 and S. D. DANO3.1Toxicology, University Bordeaux 2, Bordeaux, France,2MycSA, INRA, Villenave d’Ornon, France and3Faculty of Pharmacy, Toxicology, University ofAbidjan, Abidjan, Côte d’Ivoire, France.

Program Description



WED

NES

DAY


POSTER SESSION: RESPIRATORY TRACT III

Chairperson(s): Lee Kyeonghee, Batelle Toxicology NW, Richland, WA andJames Antonini, NIOSH, Morgantown, WV.



#1441 POLYNUCLEAR AROMATIC HYDROCARBONS(PAHS) FROM BUTADIENE SOOT ARECONCENTRATED WITHIN LIPID RESERVOIRSIN HUMAN RESPIRATORY EPITHELIALCELLS. G. Murphy, W. Henk, S. Barker and A. Penn.CBS, LSU School of Vet. Med., Baton Rouge, LA.

#1442 ACTIVATION OF INFLAMMATORYMEDIATORS AND POTENTIAL ROLE OF AIRPOLLUTION PARTICULATES AND AH-RECEPTOR LIGANDS IN FOAM CELLFORMATION. C. F. Vogel, E. M. Sciullo and F.Matsumura. ETOX, UC Davis, Davis, CA.

#1443 PULMONARY EXPOSURE TO RESIDUAL OILFLY ASH (ROFA) IMPAIRS SYSTEMICMICROVASCULAR ENDOTHELIUM-DEPENDENT DILATION. T. R. Nurkiewicz2, M. A.Boegehold2, D. W. Porter1,2, M. Barger1, A. F. Hubbs1,L. Millecchia1 and V. Castranova1,2. 1PPRB, NIOSH,Morgantown, WV and 2Physiology and Pharmacology,West Virginia University, Morgantown, WV.

#1444 DETECTION AND MOLECULAR ANALYSIS OFPARTICULATE AIR POLLUTION-INDUCEDCARDIOPULMONARY OXIDATIVE STRESSUSING A TRANSGENIC MOUSE MODEL ANDEMERGING TECHNOLOGIES. K. Dreher1, E.Roberts2, S. Malstrom3 and A. Malekafzali4. 1NHEERL,U.S. EPA, Research Triangle Park, NC, 2North CarolinaState University, Raleigh, NC, 3Xenogen Corp.,Alameda, CA and 4Arcturus Biosciences Inc., MountainView, CA.

#1445 CONCENTRATED AMBIENT AIR POLLUTIONCREATES OXIDATIVE STRESS IN CNSMICROGLIA. B. Veronesi1, O. Makwana2, M. Pooler2,J. Carter1, J. Royland1 and L. Chen3. 1NHEERL, U.S.EPA, Research Triangle Park, NC, 2ToxicologyProgram, NCSU, Raleigh, NC and 3Department ofEnvironmental Health, NYU, Tuxedo, NY.

#1446 EFFECTS OF PARTICULATE MATTER ON THEPULMONARY AND VASCULAR SYSTEM: TIMECOURSE IN SPONTANEOUSLY HYPERTENSIVERATS. M. E. Gerlofs-Nijland1, A. F. Boere1, D. C.Leseman1, J. A. Dormans1, T. Sandstrom2, R. O.Salonen3, L. Van Bree1 and F. R. Cassee1. 1Centre forEnvironmental Health Res., Lab. for Toxicol., Pathol. &Genetics or Environmental Assesment Agency, RIVM,Bilthoven, Netherlands, 2Respiratory Medicine andAllergy, University Hospital Umea, Umea, Sweden and3Department Environmental Health, National PublicHealth Institute, Kuopio, Finland.

#1447 ENDOTHELIAL INJURY IN PARTICULATEMATTER (PM)-INDUCED CARDIOVASCULARINJURY: KINETIC ANALYSIS OF GENEEXPRESSION PROFILES. S. S. Nadadur and D. L.Costa. Pulmonary Toxicology, U.S. EPA, ResearchTriangle Park, NC.

#1448 AIRBORNE PARTICULATE MATTERUPREGULATES INFLAMMATORY MARKERSIN THE MOUSE BRAIN: IMPLICATIONS FORNEURODEGENERATION. A. Campbell, A. Becaria,L. Mendez, S. C. Bondy, M. Oldham and M. Kleinman.Comm. & Env. Medicine, University of CA, Irvine,Irvine, CA.

#1449 SOLUBLE NICKEL ASSOCIATED WITHRESIDUAL OIL FLY ASH INCREASESSUSCEPTIBILITY TO PULMONARY INFECTIONIN RATS. J. R. Roberts1,2, S. Young1, J. M. Antonini1,2

and V. Castranova1,2. 1NIOSH, Morgantown, WV and2WVU, Morgantown, WV.

#1450 MEMBRANE PERMEABILITY AS ADETERMINANT OF ZN2+-INDUCEDSIGNALING IN HUMAN AIRWAY EPITHELIALCELLS. R. Silbajoris1, T. Tal2, D. Graff1, P. A.Bromberg3 and J. M. Samet1. 1Human Studies Division,NHEERL, U.S. EPA, Chapel Hill, NC, 2Curriculum ofToxicology, UNC-CH, Chapel Hill, NC and 3CEMALB,UNC-CH, Chapel Hill, NC. Sponsor: M. Madden.

#1451 ZINC CONTENT IN BALTIMORE PM2.5 SEASSAMPLES IS NOT SOLELY RESPONSIBLE FORCHEMOKINE OR CYTOKINE RESPONSE INA549 ATII CELLS OR RAW 264.7 MONOCYTES.R. J. Mitkus3,1, J. L. Powell1, J. Pancras2, J. M. Ondov2

and K. S. Squibb1. 1Epidemiology and PreventiveMedicine, University of Maryland, Baltimore, MD,2Chemistry and Biochemistry, University of Maryland,College Park, MD and 3Health Effects Division, Officeof Pesticides Prevention, U.S. EPA, Washington, DC.

#1452 EFFECT OF PULMONARY EPITHELIAL LININGFLUID ON OXIDATIVE STRESS AND DNADAMAGE: COMPARISON AMONG ULTRAFINEPARTICLES, FERROUS SULFATE AND DIESELPARTICLE EXTRACT. T. Cheng, Y. Cheng and Y.Lei. College of Public Health National TaiwanUniversity, Taipei, Taiwan. Sponsor: T. Ueng.

#1453 EFFECTS OF PM-ASSOCIATED METALS ONMACROPHAGE INOS AND ERK: A ROLE INALTERED IRON HOMEOSTASIS? C. Prophete1, P.Maciejczyk1, K. Salnikow2, T. Gould3, T. Larson3, P.Jaques4, J. Koenig3, C. Sioutas5, M. Lippmann1 and M.Cohen1. 1Environmental Medicine, New YorkUniversity School of Medicine, Tuxedo, NY, 2NCI,Bethesda, MD, 3University of Washington, Seattle, WA,4Clarkson University, Potsdam, NY and 5USC, LosAngeles, CA.

Program Description


WED

NESD

AY


#1454 MUTAGENICITY AND CYTOXICITY OFMANUAL METAL ARC STAINLESS STEELWELDING FUMES (MMA-SS) BY ITS PARTICLESIZE. I. Yu1,2, S. Maeng1, S. Kim1, J. Sung1,3, K.Chung2, S. Oh2, Y. Lee1 and K. Kim1. 1Center forOccupational Toxicology, Occupatinal Safety & HealthResearch Institute, KOSHA, Daejeon, South Korea,2College of Pharmacy, Sung Kyun Kwan University,Suwon, South Korea and 3College of VeterinaryMedicine, Seoul National University, Seoul, SouthKorea.

#1455 DNA DAMAGE IN ALVEOLAR EPITHELIALINDUCED BY INORGANIC AND ORGANICSOLUBLE FRACTIONS FROM MEXICO CITYURBAN AIRBORNE PARTICULATE. M. E.Gutierrez1,2, A. De Vizcaya-Ruiz1, M. Sordo3, P.Ostrosky3, D. A. Roubicek3,4 and M. E. Cebrian1.1Toxicology, CINVESTAV-IPN, Mexico City, Mexico,2Environmental Monitoring, CIIEMAD-IPN, MexicoCity, Mexico, 3IIB-UNAM, Mexico City, Mexico and4Mutagenesis and Cytotoxicity, CETESB, Sao Paulo,Brazil.

#1456 HEALTH EFFECTS OFENVIRONMENTALSHORT-TIME SULFUR DIOXIDE ( SO2 )EXPOSURE EMITTED FROM A VOLCANO INMIYAKEJIMA ISLAND, SOUTH OF TOKYO. H.Uno, H. Horiguchi and F. Kayama. Division ofEnvironmental Medicine, Center for CommunityMedicine, Jichi Medical School, Tochigi, Japan.Sponsor: T. Yoshida.

#1457 MEASUREMENT OF LUNG RESISTANCE ANDCOMPLIANCE FOR RESPIRATORY SAFETYPHARMACOLOGY STUDIES. S. Mason, K. Nortonand H. Penton. Safety Pharmacology, CTBR Bio-Research Inc., Senneville, QC, Canada. Sponsor: C.Banks.

#1458 RELATIVE ACCURACY OF BIDE AND GUYTONFORMULA FOR CALCULATING RESPIRATORYMINUTE VOLUME. K. Norton, S. Mason and A.Viau. Inhalation, CTBR Bio-Research Inc., Senneville,QC, Canada. Sponsor: C. Banks.

#1459 COUGHING MODEL BY INHALATION OFCITRIC ACID IN COMMON MARMOSET(CALLITHRIX JACCHUS). K. Wako, T. Kawasuso,H. Hiratsuka, M. Takechi and M. Tsuchitani. MitsubishiChemical Safety Institute Ltd.,, Kashima-gun, Ibaraki,Japan.

#1460 APPLICATION OF THE GUINEA PIG COUGHMODEL TO SCREEN FOR TUSSIGENIC ANDANTI-TUSSIVE PHARMACOLOGY. C. Banks, K.Norton and S. Groom. Toxicology, CTBR, Senneville,QC, Canada.

#1461 MULTIDRUG RESISTANCE RELATEDPROTEINS IN AIR-LIQUID INTERFACECULTURE OF HUMAN LUNG CELLS. H. Foth, A.W. Torky, A. Raemisch and E. Stehfest. EnvironmentalToxicology, University of Halle, Halle / Saale,Germany.

#1462 AN ASSESSMENT OF THE ESTROUS CYCLESOF SPRAGUE-DAWLEY RATS RESTRAINED INTUBES FOR NOSE-ONLY INHALATIONEXPOSURE. M. Stoute, K. Robinson, A. Viau, L.Pinsonneault, M. Adamo, L. Pouliot and C. Banks.Toxicology, CTBR, Senneville, QC, Canada.

#1463 IMPACT OF LOW FLOW OPERATION INTHREE NOSE-ONLY EXPOSURE SYSTEMS. O.R. Moss, A. R. James, C. U. Parkinson and B. A. Wong.Computational Biology, CIIT Centers for HealthResearch, Research Triangle Park, NC.

#1464 SUPPLEMENTAL DOSING IN PRECLINICALINHALATION STUDIES INCREASES SYSTEMICEXPOSURES. W. Lee1, F. Crofts2, A. Viau1, M. Pino2,C. Banks1, S. Holt2 and T. Monticello2. 1Inhalation,CTBR Bio-Research Inc., Senneville, QC, Canada and2Drug Safety Evaluation, Sanofi-Aventis, Bridgewater,NJ.

#1465 APPLICATION OF THE AERONEB®PROFESSIONAL NEBULISER TO INHALATIONDOSING SYSTEMS FOR DOGS AND PRIMATES.G. Ian, B. Canham, N. Shepherd and P. Newham.Covance Laboratories Ltd., Harrogate, United Kingdom.Sponsor: D. Everett.

#1466 PERFORMANCE OF FLOW-PAST ANDCONVENTIONAL NOSE-ONLY INHALATIONEXPOSURE SYSTEMS WITH POWDER ANDDROPLET AEROSOLS. I. Gilkison, B. Canham, N.Shepherd and P. Newham. Covance Laboratories Ltd.,Harrogate, United Kingdom. Sponsor: D. Everett.

#1467 ANALYSIS OF UNRESTRAINED WHOLE-BODYPLETHYSMOGRAPHY (WBP) DATA BY SIGNALPROCESSING AND MECHANISTIC MODELING.P. M. Schlosser1, M. Breen2, Z. Chen3, B. Ettinger4, A.M. Jarabek1,5, S. Nandi6, B. Tapia-Santos7, E.Tewksbury1, H. J. Trussell8, H. Wilson8 and B. A.Wong1. 1CIIT-CHR, Research Triangle Park, NC, 2CaseWestern Reserve U, Cleveland, OH, 3Florida State U,Tallahassee, FL, 4U of Georgia, Athens, GA, 5U.S. EPA,Washington, DC, 6U of Massachusetts, Amherst, MA,7Centro de Investigacion en Matematicas, Guanajuato,Mexico and 8North Carolina State U, Raleigh, NC.

#1468 DESIGN AND CHARACTERIZATION OF ANOVEL ROBOTIC WELDING FUMEINHALATION AND EXPOSURE SYSTEM FORLABORATORY ANIMALS. J. M. Antonini, A.Afshari, S. Stone, T. B. Chen, D. Schwegler-Berry, G.Fletcher, T. Goldsmith, K. Vandestouwe, W. McKinney,V. Castranova and D. Frazer. NIOSH, Morgantown,WV.

#1469 CONCENTRATION-DEPENDENCE OFSTABILITY OF AEROSOLS OF MONOMERICDIPHENYL-METHANE-4, 4-DIISOCYANATE(MDI). J. Pauluhn. Toxicology, Bayer HealthCare,Wuppertal, Germany.

Program Description



WED

NES

DAY

#1470 DEVELOPMENT OF A NOVEL TRIPLEMANIFOLD NOSE-ONLY RODENTINHALATION SYSTEM: ACUTE TOXICITY OFRICIN AEROSOLS IN BALB/C MICE. C. J. Roy1,N. Stahl2 and J. M. Hartings3. 1Center forAerobiological Sciences, USAMRIID, Fort Detrick,MD, 2Cambridge Systems, Chantilly, VA and 3GoldbeltRaven, Frederick, MD.

#1471 ESTABLISHMENT OF A BIOLOGICALBIOASSAY FOR DETECTION OF LUNGTOXICITY DUE TO FINE PARTICLES. M.Yokohira, K. Saoo, H. Takeuchi, Y. Matsuda, Y. Zengand K. Imaida. Pathology and Host-Defence, faculty ofmedicine, Kagawa university, Kita-gun, kagawa, Japan.Sponsor: T. Shirai.

#1472 GLASS BEAD INHALATION AND INDUCTIONOF SILICOSIS. L. Beyer and B. D. Beck. GradientCorp., Cambridge, MA.


POSTER SESSION: RISK ASSESSMENT FOR ACUTE INHALATIONEXPOSURES

Chairperson(s): Carol Wood, Oak Ridge National Laboratory, Oak Ridge, TNand George Alexeef, Cal/EPA, Oakland, CA.



#1473 DEVELOPMENT OF TOLUENE AEGLS USINGPBPK MODELING IN RATS AND HUMANS. J. E.Dennison1, C. M. Troxel2 and S. S. Talmage3. 1CETT,Colo State U, Ft. Collins, CO, 2CMTox, Inc., Lander,WY and 3ORNL, Oak Ridge, TN.

#1474 INTERIM ACUTE EXPOSURE GUIDELINELEVELS (AEGLS) FOR XYLENES. C. M. Troxel1,J. E. Dennison2 and R. Benson3. 1CMTox, Inc., Lander,WY, 2CETT, Colorado State University, Fort Collins,CO and 3U.S. EPA, Denver, CO.

#1475 A REVIEW OF THE BASIS FOR HYDROGENCHLORIDE OCCUPATIONAL EXPOSURELIMITS. A. Havics1 and M. P. DeLorme2. 1QEPI,Indianapolis, IN and 2DuPont Haskell Laboratory,Newark, DE.

#1476 DEVELOPMENT OF ACUTE EMERGENCYGUIDELINE LEVELS (AEGLS) USINGBENCHMARK DOSE (BMD) METHODOLOGYTO CALCULATE POTENTIALLY LETHALEXPOSURES. G. V. Alexeeff, W. Tong, R. Broadwinand A. G. Salmon. OEHHA, Cal/EPA, Oakland, CA.

#1477 USING ANIMAL LC50 DATA TO ESTIMATEACUTE EXPOSURE LETHALITY THRESHOLDSFOR WORKERS. A. J. Weinrich1, A. Maier2, A.Havics3, B. Gadagbui2 and M. Osier4. 1Education andInformation Division, US CDC-NIOSH, Cincinnati,OH, 2Toxicology Excellence for Risk Assessment,Cincinnati, OH, 3pH2 Environmental, Indianapolis, INand 4Syracuse Research Corporation, Syracuse, NY.

#1478 ACUTE EXPOSURE GUIDELINE LEVELS(AEGLS) FOR NITROGEN DIOXIDE ANDNITRIC OXIDE. C. S. Wood1 and L. D. Koller2. 1OakRidge National Laboratory, Oak Ridge, TN and 2LorenKoller & Associates LLC, Corvallis, OR.

#1479 ACUTE EXPOSURE GUIDELINE LEVELS(AEGLS) FOR NITRIC ACID. D. F. Glass1, C. S.Wood1 and L. D. Koller2. 1Oak Ridge NationalLaboratory, Oak Ridge, TN and 2Loren Koller &Associates LLC, Corvallis, OR.

#1480 INTERIM ACUTE EXPOSURE GUIDELINELEVELS (AEGLS) FOR AMMONIA. K. A.Davidson1, L. A. Gephart2 and S. D. Ripple3. 1OakRidge National Laboratory, Oak Ridge, TN,2ExxonMobil Chem. Europe, Machelen, Belgium and3Dow Chem. Co., Midland, MI.

#1481 EXTRAPOLATION OF LC50S TO SAFEEXPOSURE LEVELS–INSIGHTS FOREMERGENCY RESPONDERS. M. Fay1, B.Luukinen2 and J. Holler1. 1Toxicology, ATSDR/CDC,Atlanta, GA and 2Environmental Sciences andEngineering, University of North Carolina, Chapel Hill,NC. Sponsor: B. Fowler.

#1482 ACUTE EXPOSURE GUIDELINE LEVELS(AEGLS) FOR HYDROGEN SULFIDE. C. Bast1 andS. J. Barbee2. 1Oak Ridge National Laboratory, OakRidge, TN and 2Arch Chemicals, Inc., Norwalk, CT.

#1483 MINIMAL RISK LEVELS FOR HYDROGENSULFIDE–UPDATE. S. J. Chou1, M. Fay1, S. Keith1

and L. Ingerman2. 1Division of Toxicology, Agency forToxic Substances and Disease Registry, Atlanta, GA and2Syracuse Research Corporation, Syracuse, NY.Sponsor: B. Fowler.

#1484 ACUTE EXPOSURE GUIDELINE LEVELS(AEGLS) FOR HYDRAZINE (HZ),MONOMETHYLHYDRAZINE (MMH), ANDDIMETHYLHYDRAZINE (DMH). R. Young1 and R.Thomas2. 1ORNL, Oak Ridge, TN and 2INTERCET,Ltd.,, McLean, VA.

#1485 ACUTE EXPOSURE GUIDELINE LEVELS(AEGLS) FOR 1, 1, 1, 2-TETRAFLUOROETHANE.S. S. Talmage1, G. Rusch2 and H. T. Borges1. 1OakRidge National Laboratory, Oak Ridge, TN and2Honeywell, Morristown, NJ.

Program Description


WED

NESD

AY



POSTER SESSION: MODULATION OF CARCINOGENESIS

Chairperson(s): Howard P. Glauert, University of Kentucky, Lexington, KYand Coral Alfred Lamartiniere, University of Alabama at Birmingham,Birmingham, AL.



#1486 THE THERAPEUTIC EFFECTS OFLYOPHILIZED BLACK RASPBERRIES ONNMBA-INDUCED CARCINOGENESIS. R. M. Aziz,R. Nines and G. D. Stoner. Cancer Chemopreventionand Support, The Ohio State University, Columbus, OH.

#1487 EFFECTS OF DIETARY SELENIUM ON THEHEPATIC TUMOR PROMOTING ACTIVITIESOF PCBs. D. N. Stemm1, L. W. Robertson3, J. C.Tharappel2, B. T. Spear4, H. J. Lehmler3 and H. P.Glauert2. 1Graduate Center for Toxicology, Universityof Kentucky, Lexington, KY, 2Graduate Center forNutritional Sciences, University of Kentucky,Lexington, KY, 3School of Public Health, University ofIowa, Iowa and 4Department of Microbiology andImmunology, University of Kentucky, Lexington, KY.

#1488 EFFECTS OF SELECTED DIETARYANTIOXIDANT PHYTOCHEMICALS ON THEHEPATIC TUMOR PROMOTING ACTIVITY OFPCB-77. J. C. Tharappel1, D. N. Stemm2, R. P.Bunaciu1, L. W. Robertson3, H. J. Lehmler3, B. T.Spear4 and H. P. Glauert1. 1Graduate Center forNutritional Sciences, University of Kentucky,Lexington, KY, 2Graduate Center for Toxicology,University of Kentucky, Lexington, KY, 3School OfPublic Health, University of Iowa, Iowa and4Department of Microbiology and Immunology,University of Kentucky, Lexington, KY.

#1489 CHANGES IN DRUG METABOLISM AS APOTENTIAL MECHANISM FOR THESYNERGISTIC INDUCTION OF APOPTOSIS INMDA-MB-231 CELLS BY EGCG AND 4-OHTAMOXIFEN. E. C. Stuart, J. P. Wilson, B. J. Brayand R. J. Rosengren. Pharmacology & Toxicology,Univeristy of Otago, Dunedin, New Zealand.

#1490 PHYTOESTROGENS AND DIETARY FATTYACIDS INFLUENCE SPONTANEOUSMAMMARY TUMOR DEVELOPMENT IN INTG.NK (MMTV/C-NEU) MICE. M. Luijten1, A.Verhoef1, J. Dormans1, D. Beems1, H. Van Kranen2, N.Nagelkerke2, H. Adlercreutz2 and A. Piersma1.1National Institute for Public Health and theEnvironment, Bilthoven, Netherlands and 2FolkhalsanResearch Center, Helsinki, Finland. Sponsor: J. Vos.

#1491 INFLUENCE OF METHOXYCHLOR EXPOSUREON BREAST CANCER INCIDENCE IN FEMALESPRAGUE-DAWLEY RATS. S. M. Bandiera, J. K.Tai, E. G. Hrycay and T. K. Chang. Faculty ofPharmaceutical Sciences, University of BritishColumbia, Vancouver, BC, Canada.

#1492 BREAST CANCER CHEMOPREVENTION WITHTHE POLYPHENOL RESVERATROL. T. G.Whitsett and C. A. Lamartiniere. Toxicology, Universityof Alabama at Birmingham, Birmingham, AL.

#1493 RESVERATROL ACTION ON STERIOD ANDGROWTH FACTOR SIGNALING IN TRAMPMICE. C. E. Harper, B. B. Patel, J. Wang and C. A.Lamartiniere. Toxicology, University of Alabama atBirmingham, Birmingham, AL.

#1494 SUPRESSION OF MMP EXPRESSION ANDINVASION OF HUMAN CERVICAL CANCERCELL LINES HELA AND DOTC2 4510 BYNUTRIENTS. M. Roomi, V. Ivanov, A. Niedzwieckiand M. Rath. Cancer Division, Matthias Rath Research,Santa Clara, CA.

#1495 ALTERED TRANSCRIPTIONAL REGULATIONOF GENES INVOLVED IN AFLATOXINGENOTOXICITY BY SULFORAPHANE (SFN)AND DIINDOLYLMETHANE (DIM). K. Gross-Steinmeyer1, P. L. Stapelton1, F. Liu1, J. H. Tracy1, T. K.Bammler1, S. C. Strom2 and D. L. Eaton1. 1Env. Occup.Health Sciences., University Washington, Seattle, WAand 2Pathology, University Pittsburgh, Pittsburgh, PA.

#1496 MICROARRAY ANALYSIS OF LPS AND NAC-INDUCED GENE EXPRESSION ANDRESULTANT SYNERGISM, POTENTIATION,AND ANTAGONISM IN WEHI-231 BLYMPHOMA CELLS. K. R. Martin. NutritionalSciences, Penn State University, University Park, PA.

#1497 MODULATION OF ADULT RATBENZO(A)PYRENE (BAP) METABOLISM ANDDNA ADDUCT CONCENTRATIONS BYNEONATAL RESVERATROL (RVT) EXPOSURE.A. RAMESH. Pharmacology, Meharry Medical College,Nashville, TN.

#1498 EFFECT OF DIETARY FAT ONFLUORANTHENE (FLA) METABOLISM ANDDNA ADDUCT FORMATION IN F-344 RATS. S.WALKER, M. MATHIS, A. ADDAI and A. RAMESH.Pharmacology, Meharry Medical College, Nashville,TN.

#1499 TRANSPLACENTAL GENOTOXICITY OFDIBENZO[A, L]PYRENE (DBP) AND THEEFFECT OF INDOLE -3-CARBINOL (I3C) INTHE MATERNAL DIET. Z. YU1,2, B. Mahadevan1,L. K. Siddens1,2, D. J. Albershardt1, S. K. Krueger1,2,M. Louderback1, W. M. Baird1 and D. E. Williams1,2,3.1Environmental and Molecular Toxicity, Oregon stateuniversity, corvallis, OR, 2Linus Pauling Institute,Oregon State University, corvallis, OR and 3Marine andFreshwater Biomedical Sciences Center, Oregon StateUniversity, corvallis, OR.

#1500 STUDY OF THE INHIBITING EFFECT OFDIETARY HYDROQUINONE ONACETYLAMINO-FLUORENE INDUCTION OFINITIATION OF RAT LIVER CARCINOGENESIS.M. J. Iatropoulos, A. M. Jeffrey, J. Duan and G. M.Williams. New York Medical College, Valhalla, NY.

Program Description



WED

NES

DAY

#1501 ββ-SITOSTEROL IN PSYLLIUM SEED HUSKRESTORES GAP JUNCTIONNALINTERCELLULAR COMMUNICATION IN HA-RAS TRANSFECTED RAT LIVER EPITHELIALCELLS. Y. Nakamura1, I. Hiroki1, N. Yoshikawa1, K.Sato1, K. Ohtsuki1, C. Chang2, B. L. Upham2 and J. E.Trosko2. 1Food Science, Kyoto Pref. University, Kyoto,Japan and 2NFSTC, Michigan State University, Lansing,MI.

#1502 THE EFFECTS OF CO-ADMINISTRATION OFANTIOXIDANTS AND DIMETHYLARSINICACID (DMA) ON THE BLADDER EPITHELIUMOF FEMALE F344 RATS. S. M. Cohen1, L. L.Arnold1, M. Cano1 and M. Wei2. 1Path/Micro,University of Nebraska Medical Center, Omaha, NE and2Pathology, Osaka City University Medical School,Osaka, Japan.

#1503 RAPID INDUCTION OF COLORECTAL TUMORSIN RATS INITIATED WITH 1, 2-DIMETHYLHYDRAZINE FOLLOWED BYDEXTRAN SODIUM SULFATETREATMENT–POSSIBLE APPLICATION FOR ANEW MEDIUM-TERM RAT COLON BIOASSAY.T. Imai, J. Onose, M. Hasumura, Y. Cho and M. Hirose.Division of Pathology, National Institute of HealthSciences, Tokyo, Japan. Sponsor: M. Ema.


POSTER SESSION: CARCINOGENICITY BIOASSAYS

Chairperson(s): Marie Amoruso, ExxonMobil Biomedical Sciences Inc.,Annandale, NJ and James E. Swauger, RJR Tobacco Company, Winston Salem,NC.



#1504 LACK OF CARCINOGENIC EFFECTS IN F-344RATS FED BIS(2-ETHYLHEXYL)-1, 4-BENZENEDICARBOXYLATE (DEHT). L. E.Navarro1, K. M. Ruble1, J. A. Deyo1 and R. M. David2.1Eastman Chemical Company, Kingsport, TN and2Eastman Kodak Company, Rochester, NY.

#1505 DIMETHYLARSINIC ACID (DMA): RESULTSOF CHRONIC TOXICITY/ONCOGENICITYSTUDIES IN FISCHER F344 RATS AND B6C3F1MICE. M. Eldan1, L. L. Arnold2, M. van Gemert3 andS. M. Cohen2. 1Luxembourg Industries (Pamol) Ltd.,,Tel-Aviv, Israel, 2Path/Micro, University of NebraskaMedical Center, Omaha, NE and 3Exponent,Washington, DC.

#1506 GINGIVAL CARCINOGENICITY IN FEMALEHARLAN SPRAGUE-DAWLEY RATS AFTERORAL TREATMENT FOR TWO YEARS WITH 2,3, 7, 8-TETRACHLORODIBENZO-P-DIOXIN ANDDIOXIN-LIKE COMPOUNDS. K. Yoshizawa1, N. J.Walker2, M. P. Jokinen5, A. E. Brix6, D. M. Sells7, T.Marsh1, M. E. Wyde3, D. Orzech3, J. K. Haseman4 andA. Nyska1. 1Laboratory of Experimental Pathology,NIEHS, Research Triangle Park, NC, 2Laboratory ofComputational Biology and Risk Analysis, NIEHS,Research Triangle Park, NC, 3Toxicology OperationBranch, NIEHS, Research Triangle Park, NC,4Biostastistics Branch, NIEHS, Research Triangle Park,NC, 5Pathology Associates–A Charles River Company,Durham, NC, 6Experimental Pathology Laboratories,Research Triangle Park, NC and 7Battelle ColumbusLaboratories, Columbus, OH.

#1507 CHRONIC TOXICITY AND ONCOGENICITYSTUDY OFOCTAMETHYLCYCLOTETRASILOXANE (D4)IN FISCHER 344 RATS. K. P. Plotzke1, P. A. Jean1, J.W. Crissman1, K. M. Lee2 and R. G. Meeks1. 1DowCorning Corporation, Midland, MI and 2Battelle,Richland, WA.

#1508 CHRONIC TOXICITY AND ONCOGENICITYSTUDY OF HEXAMETHYLDISILOXANE(HMDS) IN FISCHER-344 RATS. M. L. Jovanovic1,S. D. Crofoot1, J. W. Crissman1, P. A. Smith2, K. P.Plotzke1 and R. G. Meeks1. 1Dow Corning Corporation,Midland, MI and 2RCC Ltd., Itingen, Switzerland.

#1509 CHRONIC TOXICITY AND ONCOGENICITYSTUDY OFDECAMETHYLCYCLOPENTASILOXANE (D5)IN FISCHER-344 RATS. S. D. Crofoot1, M. L.Jovanovic1, J. W. Crissman1, P. A. Smith2, K. P.Plotzke1 and R. G. Meeks1. 1Dow Corning Corporation,Midland, MI and 2RCC Ltd., Itingen, Switzerland.

#1510 CHRONIC TOXICITY AND ONCOGENICITYSTUDY OF POLYDIMETHYLSILOXANE (PDMS)10 CST FLUID IN FISCHER 344 RATS. R. G.Meeks1, P. A. Jean1, J. W. Mertens2, K. S. Regan3, J. W.Crissman1 and K. P. Plotzke1. 1Dow CorningCorporation, Midland, MI, 2WIL Research Laboratories,Ashland, OH and 3Regan Path/Toxicology Services,Ashland, OH.

#1511 HISTOGENESIS OF SPONTANEOUS LESIONS INTHE V-HA-RAS (TG.AC) MOUSE. A.HARGREAVES, M. Jacobsen, C. Sadler, S. Barrett andJ. Wright. CTL Pathology, Syngenta, Macclesfield,United Kingdom. Sponsor: I. Kimber.

#1512 A CARCINOGEN BIOASSAY FOR COMPLEXMIXTURES. K. LaDow1, D. Warshawsky1, R. Albert1,W. Xue1, S. Spalding1, G. P. Boivin2, D. Ginsburg1 andP. Succop1. 1Environmental Health, University ofCincinnati College of Medicine, Cincinnati, OH and2Pathology and Laboratory Medicine, University ofCincinnati College of Medicine, Cincinnati, OH.

Program Description


WED

NESD

AY


#1513 EVALUATION OF K6ODC TRANSGENIC MICEAS A DERMAL CARCINOGENICITY MODELFOR ONCOGENIC DNA. T. J. Miller1, P.Espandiari1, R. Honchel1, A. D. Knapton1, J. Zhang1, F.Sistare1, L. Sheng2, A. M. Lewis2, K. Peden2 and J. P.Hanig1. 1CDER, U.S. FDA, Silver Spring, MD and2CBER, U.S. FDA, Rockville, MD.

#1514 DETERMINATION OF THE SKIN CANCERPOTENTIAL OF PETROLEUM-DERIVEDMATERIALS USING K6/ODC MICE. M. A.Amoruso1, G. W. Trimmer1, R. C. Forgash1, S.Gilmour2 and J. J. Freeman1. 1Toxicology &Environmental Sciences, ExxonMobil BiomedicalSciences, Inc., Annandale, NJ and 2Lankenau Institutefor Medical Research, Wynnewood, PA.

#1515 COMPARATIVE 30-WEEK DERMAL TUMORPROMOTION STUDY USING SENCAR MICE:EVALUATION OF CIGARETTE SMOKECONDENSATE FROM A CONTROL CIGARETTEAND TEST CIGARETTES WITH TWO BANDEDCIGARETTE PAPER TECHNOLOGIES. D. R.Meckley1, D. H. Pence1, K. R. Van Kampen2, P. H.Ayres1 and J. E. Swauger1. 1R.J. Reynolds TobaccoCompany, Winston-Salem, NC and 2The Van KampenGroup, Hoover, AL.

#1516 COMPARATIVE 13-WEEK INHALATION STUDYOF MAINSTREAM CIGARETTE SMOKE FROMCIGARETTES CONTAINING CAST SHEETTOBACCO. R. Potts, D. R. Meckley, K. Shreve, P. H.Ayres, D. H. Pence, C. D. Garner, D. J. Doolittle and J.E. Swauger. Scientific & Regulatory Affairs, R. J.Reynolds Tobacco Company, Winston-Salem, NC.

#1517 DIFFERENTIATING INITIATING FROMPROMOTING EFFECTS OF CIGARETTEMAINSTREAM SMOKE IN THE PRODUCTIONOF LUNG TUMORS IN A MOUSE INHALATIONBIOASSAY. S. F. Yee, M. Misra, J. Hamm, R.Leverette, S. Vulimiri, D. Heck and N. Rajendran.Lorillard Tobacco Company, Greensboro, NC.

#1518 CIGARETTE MAINSTREAM SMOKE AND GASPHASE-DEPLETED PARTICULATE PHASEENHANCE LUNG TUMORIGENICITY IN A/JMOUSE. W. Stinn1, H. Haussmann1, A. Buettner1 andJ. H. Arts2. 1Philip Morris Research LaboratoriesGmbH, Cologne, Germany and 2TNO Nutrition andFood Research, Zeist, Netherlands.

#1519 INTERSPECIES SITE CONCORDANCE FORMAMMARY CARCINOGENESIS BYENVIRONMENTAL TOBACCO SMOKE. A. G.Salmon, M. D. Miller and M. A. Marty. OEHHA,California EPA, Oakland, CA.

#1520 DEVELOPMENT OF QUANTITATIVE QSARMODELS TO PREDICT CANCER POTENCY OFCHEMICALS. R. Venkatapathy1, C. Moudgal2 and R.Bruce2. 1ORISE/NCEA-U.S. EPA, Cincinnati, OH and2NCEA, U.S. EPA, Cincinnati, OH.

#1521 CANCER RISK ESTIMATION FOR EXPOSURETO NAPHTHALENE. S. Hoover, J. P. Brown, A. G.Salmon, M. S. Sandy, L. Zeise and M. A. Marty.OEHHA, California EPA, Oakland, CA.


POSTER SESSION: NERVOUS SYSTEM: MECHANISMS OFTOXICITY

Chairperson(s): Nasser H. Zawia, University of Rhode Island, Kingston, RI.



#1522 PROTECTIVE EFFECT OF NRF2 ON THEMUSCLE OF MICE WITH AMYOTROPHICLATERAL SCLEROSIS. J. C. Kern1,2, A. D. Kraft1,A. Vermeern1 and J. A. Johnson1,2. 1PharmaceuticalSciences, University of Wisconsin-Madison, Madison,WI and 2Molecular and Environmental ToxicologyCenter, University of Wisconsin-Madison, Madison, WI.

#1523 SENSITIVITY TO MITOCHONDRIAL COMPLEXII INHIBITORS, MALONATE AND 3-NITROPROPIONIC ACID IN NRF2 KNOCKOUTMICE. M. Calkins1,2, R. J. Jakel1,3,4 and J. A.Johnson1,2,5. 1School of Pharmacy, University ofWisconsin, Madison, WI, 2Molecular andEnvironmental Toxicology Center, University ofWisconsin, Madison, WI, 3Neuroscience TrainingProgram, University of Wisconsin, Madison, WI,4Medical Scientist Training Program, University ofWisconsin, Madison, WI and 5Waisman Center,University of Wisconsin, Madison, WI.

#1524 NEUROPROTECTIVE EFFECTS OFMETALLOTHIONEIN-III IN MUTANTEXPANDED POLYGLUTAMINE EXPRESSEDNEUROBLASTOMA CELLS. K. Lee1, Y. Hwang1,2,K. Jung1,2, D. Shin1,2, K. Oh1,2, J. Choi1,2 and H.Jeong1,2. 1Pharmacy, Chosun University, Kwangju,South Korea and 2Research Center for ProteineousMaterials, Chosun University, Kwangju, South Korea.

#1525 METALLOTHIONEIN III ATTENUATES 6-HYDROXYDOPAMINE-INDUCED APOPTOTICCELL DEATH IN SH-SY5Y CELLS. Y. Hwang1,2


#1526 MITOCHONDRIAL-DEPENDENT INITIATIONOF APOPTOSIS AND FEEDBACK REGULATIONBY PKCδδ IN PROTEOSOME INHIBITOR MG-132-INDUCED DOPAMINERGICDEGENERATION. F. Sun, A. Kanthasamy, Y. Yang, V.Anantharam and A. G. Kanthasamy. BiomedicalSciences, Iowa State University, Ames, IA.

#1527 PROTEOSOME INHIBITOR ACLARUBICININDUCES DOPAMINERGIC CELL DEATH ANDPARKINSON’S-LIKE SYMPTOMS IN MICE:IMPLICATIONS FOR UBIQUITIN-PROTEOSOME DYSFUNCTION INPARKINSON’S DISEASE. C. Latchoumycandane, A.Vellareddy, A. Kanthasamy and A. Kanthasamy.Department of Biomedical Sciences, Iowa StateUniversity, Ames, IA.

Program Description



WED

NES

DAY

#1528 THROMBIN PRECONDITIONING PREVENTSSTRIATAL ATROPHY AND DOPAMINERGICTERMINAL LOSS, BUT NOT DOPAMINEDEPLETION IN A 6−−HYDROXYDOPAMINEPARKINSON′′S DISEASE MODEL. J. R. Cannon1,2,Y. Hua1, G. Xi1 and R. F. Keep1,3. 1Department ofNeurosurgery, The University of Michigan, Ann Arbor,MI, 2Department of Envrionmental health Sciences, TheUniversity of Michigan, Ann Arbor, MI and3Department of Physiology, The University ofMichigan, Ann Arbor, MI.

#1529 ROLE FOR PROTEASE-ACTIVATEDRECEPTOR 1 (PAR1) IN MPTP-INDUCEDDOPAMINERGIC NEUROTOXICITY. C. Hamill1,M. Caudle2, J. R. Richardson2, G. W. Miller2 and S. F.Traynelis1. 1Department of Pharmacology, EmoryUniversity, Atlanta, GA and 2Center forNeurodegenerative Disease, Emory University, Atlanta,GA.

#1530 NICOTINE STIMULATION INDUCES THMESSENGER RNA EXPRESSION ANDTRANSCRIPTION RATE IN MN9D CELLS. P. M.Radcliffe1 and A. Tank2. 1Toxicology, University ofRochester, Rochester, NY and2Pharmacology/Physiology, Univer of Rochester,Rochester, NY.

#1531 NEUROPROTECTION AND NEURORESCUEAGAINST BETA-AMYLOID TOXICITY BYMETALLOTHIONEIN III. C. Choi3, Y. Hwang1,2, D.Oh1,2, D. Shin1,2, J. Choi1,2, D. Kim4 and H. Jeong1,2.1Pharmacy, Chosun University, Kwangju, South Korea,2Research Center for Proteineous Materials, ChosunUniversity, Kwangju, South Korea, 3Division of FoodScience, Chinju International University, Chinju, SouthKorea and 4Pathology, College of Oriental Medicine,Daejeon University, Daejeon, South Korea.

#1532 CHARACTERIZATION OF CEREBRAL SP1, AββAND APP IN RATS: ANIMMUNOHISTOCHEMICAL STUDY OF AGINGAND NEURODEGENERATION. B. Brock, K.DiPalma, M. Basha and N. H. Zawia. Biomediacl andPharmaceutical Sciences, University of Rhode Island,Kingston, RI.

#1533 THE CHOROID PLEXUS EXPRESSES THEENZYMES NECESSARY FOR BETA-AMYLOIDPRODUCTION. E. L. Smith, J. S. Crossgrove and W.Zheng. School of Health Sciences, Purdue University,West Lafayette, IN.

#1534 THE CHOROID PLEXUS ACCUMULATES BETA-AMYLOID FROM BRAIN CSF: IMPLICATIONSFOR ALZHEIMER’S DISEASE. J. S. Crossgrove, G.Li and W. Zheng. School of Health Sciences, PurdueUniversity, West Lafayette, IN.

#1535 DIFFERENTIAL EXPRESSION OF GRP78 ANDHSP70 IN PRIMARY BRAINSTEM ANDCORTICAL ASTROCYTES EXPOSED TO 1, 3-DINTROBENZENE. S. A. Runkle, S. R. Steiner andM. A. Philbert. Toxicology Program, University ofMichigan, Ann Arbor, MI.

#1536 MIXED INHIBITION OF THE PYRUVATEDEHYDROGENASE COMPLEX BY M-DINITROBENZENE. J. A. Miller and M. A. Philbert.Toxicology Program, University of Michigan, AnnArbor, MI.

#1537 NITRIC OXIDE MEDIATES MITOCHONDRIALDYSFUNCTION IN NEUROENDOCRINETOXICITY. D. E. Heck1,2, J. Gray1, D. Osbourn2 andP. J. Smith2. 1Rutgers University, Piscataway, NJ and2Marine Biological Laboratory, Woods Hole, MA.

#1538 NITRIC OXIDE ACTIVATES P53 AND INDUCESAPOPTOSIS IN NEURONAL PC12 CELLS. C.Brynczka1,2 and A. Merrick1. 1National Center ForToxicogenomics, NIEHS, Research Triangle Park, NCand 2Environmental and Molecular Toxicology, NCSU,Raleigh, NC.

#1539 EVALUATION OF THE INTERACTIONBETWEEN CAVEOLIN AND GLIALFIBRILLARY ACIDIC PROTEIN IN C6 GLIA. G.Velazquez1, E. E. Aquino1, N. Mayol2, H. Maldonado2

and W. I. Silva1. 1Physiology, UPR Medical SciencesCampus, San Juan, Puerto Rico and 2Pharmacology,Caribbean Central University, Bayamon, Puerto Rico.Sponsor: B. Jimenez Velez.

#1540 REACTIVE GLIOSIS IN NEUROTOXIC ANDMECHANICAL INJURY MODELS. C. L. Damiani,D. B. Miller and J. P. O’Callaghan. CDC-NIOSH,Morgantown, WV.

#1541 ERK1/2-RSK2 STIMULATION OF MEF2CTRANSCRIPTION PROMOTES CORTICALNEURON SURVIVAL. Y. Wang, L. Liu and Z. Xia.Environmental and Occupational Health Sciences,University of Washington, Seattle, WA.

#1542 DEVELOPMENTAL LEAD EXPOSURE AFFECTSTHE SURVIVAL OF GRANULE CELLS IN THERAT HIPPOCAMPUS. T. Verina, C. A. Rohde and T.R. Guilarte. Environmental Health Sciences, JohnsHopkins University, Baltimore, MD.

#1543 PPAR ALPHA ACTIVATION ENHANCESCYANIDE-INDUCED NEUROTOXICITY BY UP-REGULATION OF UCP-2. X. Zhang, L. Li, K.Prabhakaran, J. L. Borowitz and G. E. Isom. MedicinalChemistry and Molecular Pharmacology, PurdueUniversity, West Lafayette, IN.

#1544 NEUROPROTECTION AGAINSTMETHAMPHETAMINE (METH) AFFORDED BYPRETREATMENT WITH INCREASING DOSESOF THE DRUG IS DEPENDENT ON THEDOSING SCHEDULE OF METH USED DURINGTHE DRUG CHALLENGE. D. L. Graham1,2, P. H.Noailles1, B. Ladenheim1, T. H. Moran3 and J. L.Cadet1. 1Molecular Neuropsychiatry Branch,DHHS/NIH/NIDA/IRP, Baltimore, MD, 2Program inToxicology, University of Maryland School ofMedicine, Baltimore, MD and 3Department ofPsychiatry and Behavioral Sciences, The Johns HopkinsUniversity School of Medicine, Baltimore, MD.

Program Description


WED

NESD

AY


#1545 SUBCHRONIC EXPOSURE TO LOW LEVELS OFPOLYCHLORINATED BIPHENYLS REDUCESDOPAMINE TRANSPORTER AND VESICULARMONOAMINE TRANSPORTER 2 LEVELS. M.Caudle, J. R. Richardson and G. W. Miller. Center forNeurodegenerative Disease, Emory University, Atlanta,GA.

#1546 ACRYLAMIDE DISRUPTS UPTAKE OFDOPAMINE INTO RAT STRIATAL SYNAPTICVESICLES. R. M. LoPachin1 and D. S. Barber2.1Anesthesiology, Albert Einstein College of Medicine,Bronx, NY and 2Center for Environmental Health andToxicology, University of Florida, Gainesville, FL.

#1547 INHIBITION OF HUMAN αα7 NEURONALNICOTINIC ACETYLCHOLINE RECEPTORS BYTHE VOLATILE ORGANIC SOLVENTTRICHLOROETHYLENE. C. A. Meacham, A. S.Bale, P. J. Bushnell and T. J. Shafer. NeurotoxicologyDivision, NHEERL, ORD, U.S. EPA, Research TrianglePark, NC.

#1548 XYLENE BLOCKS VOLTAGE-GATED CALCIUMCURRENTS IN PHEOCHROMOCYTOMACELLS. T. J. Shafer. Neurotoxicology Division,NHEERL, ORD, U.S. EPA, Research Triangle Park,NC.

#1549 NEUROTOXIC (1, 2, 4-) AND NON-NEUROTOXIC(1, 3, 5-) TRIETHYLBENZENES. V. S. Palmer, D. D.Tshala-Katumbay, R. J. Kayton, P. S. Spencer and M. I.Sabri. Center for Research on Occupational andEnvironmental Toxicology, Oregon Health & ScienceUniversity, Portland, OR.

#1550 RAPID-ONSET GAMMA-DIKETONEAXONOPATHY IN HIPPOCAMPAL NEURONS INCULTURE. D. D. Tshala-Katumbay, B. Sampo, V. S.Palmer, G. A. Banker, M. I. Sabri and P. S. Spencer.Center for Research on Occupational andEnvironmental Toxicology, and Department ofNeurology, School of Medicine, Oregon Health &Science University, Portland, OR.

#1551 GAMMA-DIKETONE TOXICITY: A ROLE FORSTATHMIN IN NERVE AND TESTES DAMAGE?M. I. Sabri1, S. B. Hashemi1, S. Chohan1, S. Khalil1, A.B. Cranson1, D. D. Tshala-Katumbay1, V. S. Palmer1, J.G. Pounds2 and P. S. Spencer1. 1Center for Research onOccupational and Environmental Toxicology;Department of Neurology, School of Medicine, OregonHealth & Science University, Portland, OR and2Molecular Biosciences, Pacific Northwest NationalLaboratory, Richland, WA.

#1552 EFFECTS OF SUBACUTE AND CHRONICACRYLAMIDE DOSING ON FAST-TRANSPORTED PROTEINS INTO RATNEUROMUSCULAR JUNCTIONS. D. W. Sicklesand A. Testino. Cellular Biology and Anatomy, MedicalCollege of Georgia, Augusta, GA.

#1553 REDUCTIONS IN NEUROMUSCULARJUNCTION CHOLINESTERASE ACTIVITY BYSUBACUTE AND CHRONIC ACRYLAMIDEEXPOSURE. B. Newman, L. Oblak, D. Kumiski andD. Sickles. Cellular Biology and Anatomy, MedicalCollege of Georgia, Augusta, GA.


POSTER SESSION: BIOTRANSFORMATION/CYTOCHROME P450 II

Chairperson(s): Rao Uppu, Southern University and A&M College, BatonRouge, LA.



#1554 HUMAN FLAVIN-CONTAININGMONOOXYGENASE: QUANTIFICATION INHUMAN TISSUES. J. R. Cashman and J. Zhang.Human BioMolecular Research Institute, San Diego,CA. Sponsor: D. Schlenk.

#1555 OXIDATION OF SELENOMETHIONINE BYFLAVIN-CONTAINING MONOOXYGENASES(FMOS). D. Shi and D. Schlenk. Department ofEnvironmental Sciences, University of California,Riverside, CA.

#1556 COMPARISON OF MAJOR PHASE I AND PHASEII METABOLISM REACTIONS INCRYOPRESERVED CYNO MONKEY ANDHUMAN HEPATOCYTES. B. R. Snodgrass1, P. V.Gagne1, P. L. Picano1, K. J. Lohnes1, S. P. Cain2, G. G.Zhang1, C. J. Patten1 and C. L. Crespi1. 1Research &Development, BD Discovery Labware, Woburn, MAand 2Operations, BD Discovery Labware, Woburn, MA.

#1557 COMPARISON OF CELLULAR MODELS FORASSESSING LIVER TOXICITY. R. Maitra, K.Moore, S. Frank and A. Higgins. Icoria, Inc., ResearchTriangle Park, NC. Sponsor: J. Hamilton.

#1558 PANCREATIC AND HEPATIC ETHANOLTOXICITY IN HEPATIC ALCOHOLDEHYDROGENASE DEFICIENT DEER MICE:MORPHOLOGICAL AND BIOCHEMICALCHARACTERIZATION. K. Bhopale1, H. Wu1, P.Boor1, G. A. Ansari1 and B. S. Kaphalia1. 1Pathology,University of Texas Medical Branch, Galveston, TX,2Pathology, University of Texas Medical Branch,Galveston, TX, 3Pathology, University of Texas MedicalBranch, Galveston, TX, 4Pathology, University of TexasMedical Branch, Galveston, TX and 5Pathology,University of Texas Medical Branch, Galveston, TX.

#1559 VARIABILITY IN METABOLISM OF CHLORALHYDRATE IN HUMAN HEPATOCYTES. A.Bronley-DeLancey2, D. G. Hoel2 and D. C. McMillan1.1Department of Pharmacology, Medical University ofSouth Carolina, Charleston, SC and 2Department ofBiostatistics, Bioinformatics and Epidemiology, MedicalUniversity of South Carolina, Charleston, SC.

#1560 TOXICOKINETIC ASPECTS OF HEPATOTOXICINTERACTIONS BETWEEN BENZENE ANDTCE. A. Freidig1, H. Wortelboer1, W. Heijne1, R.Stierum1, M. Schut1, D. Jonker1, H. El-Masri2, D.Moffett2 and J. Groten1. 1TNO Voeding, Zeist,Netherlands and 2ATSDR, Atlanta, GA.

Program Description



WED

NES

DAY

#1561 IN VITRO AND IN VIVO KINETICS OFMIDAZOLAM IN COMMERCIALLY RAISEDGAMEBIRDS. K. Cortright and A. Craigmill.Environmental Toxicology, UC Davis, Davis, CA.

#1562 HEPATIC MICROSOMAL METABOLISN OFLITHOCHOLIC ACID. A. K. Deo and S. M.Bandiera. Faculty of Pharmaceutical Sciences,University of British Columbia, Vancouver, BC,Canada.

#1563 IN VITRO METABOLISM OF 4-VINYLPHENOLAND STYRENE IN MOUSE, RAT AND HUMANMICROSOMES. M. Bartels1, D. Rick1, F. Zhang1, E.Leibold2, H. Gelbke2 and G. Cruzan3. 1Toxicology,Dow Chemical, Midland, MI, 2BASF,Aktiengesellschaft, Ludwigshafen/Rhein, Germany and3ToxWorks, Bridgeton, NJ.

#1564 COVALENT MODIFICATION OF AMINO ACIDNUCLEOPHILES BY STYRENE OXIDE. W. Yuan,J. Chung and J. Zheng. Pharmaceutical Sciences,Northeastern University, Boston, MA.

#1565 NITROREDUCTION OF TATTOO PIGMENTYELLOW 74 BY XANTHINE OXIDASE:FORMATION OF A DNA ADDUCT ANDMUTAGENICITY OF THE NITROSOREDUCTION PRODUCT. P. C. Howard1, Y. Cui1, L.H. Couch1, M. I. Churchwell1, D. R. Doerge1, P. P. Fu1,J. Wang2, T. Chen2, N. Mei2 and M. M. Moore2.1Division Biochemical Toxicology, NCTR, U.S. FDA,Jefferson, AR and 2Division Genetic and ReproductiveToxicology, NCTR, U.S. FDA, Jefferson, AR.

#1566 REACTIONS OF NITRIC OXIDE-DERIVEDOXIDANTS WITH 4-ACETAMIDOPHENOL:FORMATION OF ELECTROPHILICINTERMEDIATES. R. M. Uppu1 and R. J. Martin2.1Environmental Toxicology, Southern University, BatonRouge, LA and 2School of Human Ecology, LouisianaState University, Baton Rouge, LA.

#1567 THE ROLES OF LIVER AND TARGET-TISSUEP450-MEDIATED DMBA METABOLISM INDMBA-INDUCED DNA ADDUCT FORMATIONIN THE MAMMARY GLAND. H. Cui, J. Gu, L.Zhang, Q. Zhang and X. Ding. Wadsworth Center,Albany, NY.

#1568 VINCLOZOLIN IN VITRO METABOLISM BYRAT LIVER MICROSOMES. A. Sierra-Santoyo1, R.Harrison2, B. Edwards2, H. A. Barton2 and M. F.Hughes2. 1Toxicology Section, CINVESTAV-IPN,Mexico City, D.F., Mexico and2NHEERL/ORD/ETD/PKB, U.S. EPA, ResearchTriangle Park, NC.

#1569 HYDROLYTIC METABOLISM OFPYRETHROIDS BY HUMANCARBOXYLESTERASES AND RODENT ANDHUMAN LIVER MICROSOMES. M. K. Ross1, P. M.Potter2 and A. Borazjani1. 1Center for EnvironmentalHealth Sciences, Mississippi State University,Mississippi State, MS and 2Mol. Pharmacology, St.Jude’s Children’s Research Hospital, Memphis, TN.

#1570 METABOLISM OF ARSENICALS MAYINFLUENCE THEIR PROLIFERATIVE EFFECTSON HUMAN CACO-2 CELLS. G. S. Bayse1, W. G.Kirlin2, A. M. Rollins-Hairston2 and K. Jackson1.1Chemistry, Spelman College, Atlanta, GA and2Pharmacology/Toxicology, Morehouse School ofMedicine, Atlanta, GA.

#1571 A NOVEL HALOENOL LACTONE DERIVATIVEPOTENTIATES CYTOTOXICITY INDUCED BYCISPLATIN RETARDING THE GLUTATHIONE-MEDIATED DETOXIFICATION OF CISPLATININ HUMAN RENAL TUMOR CELL LINES. J.Zheng and W. Wang. Pharmaceutical Sciences,Northeastern University, Boston, MA.

#1572 BIOACTIVATION OF 1-CHLORO-2-HYDROXY-3-BUTENE TO 1-CHLORO-3-BUTEN-2-ONE, ANOVEL CROSS-LINKING AGENT. A. A. Elfarra, R.J. Krause, X. Zhang and C. A. Klumb. Department ofComparative Biosciences, University of Wisconsin,Madison, WI.

#1573 4’-FLUORO SUBSTITUTION OFDESMETHYLATED ARZOXIFENE COULDDECREASE TOXICITY WHILE MAINTAININGANTIESTROGENIC ACTIVITY. H. liu, G. R.Thatcher and J. L. Bolton. Medicinal Chemsitry andPharmacognosy, University of Illinois at Chicago,Chicago, IL.

#1574 REDUCTION OF 1-FURAN-2-YL-3-PYRIDIN-2-YL-PROPENONE, AN ANTI-INFLAMMATORYAGENT, BY CARBONYL REDUCTASE IN RATLIVER MICROSOMES. S. Lee1, T. Jeon1, C. Jin1, S.Hyun1, G. Kim1, I. Jun1, D. Lee1, E. Lee1, Y. Jahng1, D.Kim2 and T. Jeong1. 1Yeungnam University, Kyungsan,South Korea and 2Bioanalysis and BiotransformationResearch Center, Seoul, South Korea.

#1575 PHASE 1 AND PHASE 2 METABOLISMS OFRUTAECARPINE IN MICE AND RATS. G. Kim, D.Lee, S. Lee, T. Jeon, S. Hyun, C. Jin, I. Jun, E. Lee, Y.Jahng and T. Jeong. College of Pharmacy, YeungnamUniversity, Kyungsan, Kyungbuk, South Korea.

#1576 METABOLIC SHIFT FOLLOWING MULTIPLEDOSES OF [14C]-1, 3-DINITROBENZENE TORATS. J. J. Tobias and T. Miller. Toxicology,University of Kentucky, Lexington, KY.

#1577 METABOLISM OF METHACRYLONITRILE TOCYANIDE: INHIBITION BY CAFFEINE ANDPOTENTIATION BY ALCOHOL. M. Y. Farooqui.Biology, University of Texas Pan American, Edinburg,TX.

#1578 METABOLISM OF GERANYL NITRILE ANDCITRONELLYL NITRILE BY PRIMARYHEPATOCYTES FROM MICE, RATS ANDHUMANS. R. A. Kemper1, D. L. Nabb1, S. A. Gannon1,T. A. Snow1 and A. Api2. 1DuPont Haskell Laboratory,Newark, DE and 2Research Institute for FragranceMaterials (RIFM), Woodcliff, NJ.

Program Description


WED

NESD

AY


#1579 KINETICS AND SCALING OF METABOLICBIOTRANSFORMATION IN FISH: ACOMPILATION OF RATE AND AFFINITYVALUES MEASURED UNDER PHYSIOLOGICALCONDITIONS. P. N. Fitzsimmons and J. W. Nichols.U.S. EPA/ORD/NHEERL/MED, Duluth, MN.

#1580 KINETICS AND SCALING OF METABOLICBIOTRANSFORMATION IN FISH: EFFECTS ONBIOACCUMULATION PREDICTED BYINCORPORATING IN VITRO DATA INTO TWOKINETIC MODELS. J. W. Nichols and P. N.Fitzsimmons. U.S. EPA/ORD/NHEERL/MED, Duluth,MN.

#1581 MECHANISMS OF INTERACTIVEDEVELOPMENTAL TOXICITY OFPOLYCYCLIC AROMATIC HYDROCARBONS INZEBRAFISH. S. Billiard, D. Wassenberg, E. Linneyand R. Di Giulio. Duke University, Durham, NC.


POSTER SESSION: ECOTOXICOLOGY

Chairperson(s): Richard Di Giulio, Duke University, Durham, NC and EvaOberdorster, Southern Methodist University, Dallas, TX.



#1582 ALTERED GENE EXPRESSION ANDDEVELOPMENT OF POTENTIAL BIOMARKERSIN MEDAKA (ORYZIAS LATIPES) BRAIN, LIVER,AND TESTIS FOLLOWING EXPOSURE TOFIBRATE PHARMACEUTICALS. D. C. Bencic1,2,D. C. Volz1, P. Chen1, A. D. Biales2, J. M. Lazorchak2,D. E. Hinton1 and S. W. Kullman1. 1IntegratedToxicology Program and Nicholas School of theEnvironment and Earth Sciences, Duke University,Durham, NC and 2Molecular Ecology Research Branch,EERD, NERL, ORD, U.S. EPA, Cincinnati, OH.

#1583 A CROSS-SPECIES APPROACH TO USINGGENOMICS TOOLS IN AQUATICTOXICOLOGY. A. Miracle1, I. Knoebl1, D. Bencic1,D. Lattier1, R. Wang1, D. Villeneuve2 and G. Ankley2.1EERD, U.S. EPA, Cincinnati, OH and 2MED, U.S.EPA, Duluth, MN. Sponsor: T. Reddy.

#1584 MICROARRAY ANALYSIS OF HEPATIC GENEEXPRESSION IN COHO SALMON(ONCORHYNCHUS KISUTCH). H. LaVire1, P.Stapleton1, R. Beyer1, N. Scholz2 and G. Evan1.1University of Washington, Seattle, WA and 2NOAA,Seattle, WA.

#1585 THE USE OF RNA MICROARRAYTECHNOLOGY AS A BIOMARKER FOREXPOSURE OF FATHEAD MINNOW(PIMEPHALES PROMELAS) TO 2, 4-DINITROTOLUENE. J. L. Yoo1, J. A. Steevens1, A.B. Gibson1, C. D. Vulpe2 and H. M. Wintz2.1Environmental Laboratory, USACE ERDC, Vicksburg,MS and 2Nutritional Sciences and Toxicology,University of California, Berkeley, CA.

#1586 GENE EXPRESSION PROFILING IN RAINBOWTROUT (ONORHYNCUS MYKISS), EXPOSEDTO A VARIETY OF MODEL TOXICANTS. I.Schultz, S. Hook and A. D. Skillman. Battelle PNNL,Sequim, WA.

#1587 NONYLPHENOL POLYETHOXYLATE INHIBITSTRANSPORT OF ESTROGENS INTO BILE INTHE CHANNEL CATFISH, ICTALARUSPUNCTATUS. G. C. Hummelke and K. M. Kleinow.Comparative Biomedical Sciences, Louisiana StateUniversity, Baton Rouge, LA. Sponsor: M. James.

#1588 ESTROGEN EQUIVALENTS ANDCORRESPONDING CHEMICAL ANALYSES OFMARINE WATER SAMPLES COLLECTEDALONG A CORAL REEF. A. M. Chaudhary1, L. R.Harrison2, S. I. Khan2, S. Singh3, A. Azua3, P.Gardinali3 and K. L. Willett1. 1Pharmacology andEnvironmental Toxicology Research Program, TheUniversity of Mississippi, University, MS, 2NationalCenter for Natural Product Research, The University ofMississippi, University, MS and 3Department ofChemistry, Florida International University, Miami, FL.

#1589 MERCURY DISTRIBUTION IN SEDIMENTS ANDUPTAKE BY PLANTS ALONG SNOW ANDCHOCCOLOCCO CREEKS IN NORTHEASTALABAMA. A. C. Nichols1, D. A. Steffy1 and S. Al-Hamdani2. 1Physical and Earth Sciences, JacksonvilleState University, Jacksonville, AL and 2Biology,Jacksonville State University, Jacksonville, AL.

#1590 IDENTIFICATION OF SELENOPROTEINS INSELENIUM-SENSITIVE TISSUES IN JAPANESEMEDAKA (ORYZIAS LATIPES) USINGTANDEMLY COUPLED HPLC-ICPMS. K. A.Thrippleton1, A. Mason3 and D. Schlenk2. 1Departmentof Environmental Toxicology, University of California,Riverside, Riverside, CA, 2Department ofEnvironmental Sciences, University of California,Riverside, Riverside, CA and 3Department of BiologicalSciences, California State University, Long Beach,Long Beach, CA.

#1591 ACUTE TOXICITY AND BIOACCUMULATIONOF TRIBUTYLTIN IN THE REEF BUILDINGCORAL SPECIES ACROPORA SP. (STAGHORNCORAL). J. Dwivedi2, K. Howell2, P. Nguyen3 and L.D. Trombetta1. 1Pharmaceutical Sciences, St. JohnsUniverstty, Jamaica, NY, 2Biological Sciences, St.John’s University, Jamaica, NY and 3BiologicalSciences, Borough of Manhattan Community College,CUNY, New York.

#1592 HYPERSENSITIVITY OF THEELASMOBRANCH UROLOPHUS JAMAICENSIS(YELLOW STINGRAY) TO TRIBUTYLTINEXPOSURE. J. Dwivedi2 and L. D. Trombetta1.1Pharmaceutical Sciences, St. Johns Universtty,Jamaica, NY and 2Biological Sciences, St. John’sUniversity, Jamaica, NY.

Program Description



WED

NES

DAY

#1593 IN SITU BIOMONITORING TO ASSESS THEGENOTOXICITY OF PAH-CONTAMINATEDSEDIMENTS TO JUVENILE COHO SALMON(ONCORHYNCHUS KISUTCH). G. C. Barbee1, J.Barich5, B. Duncan5, J. W. Bickham2, C. W. Matson2,C. J. Hintze3, R. L. Autenrieth4, G. Zhou6, T. J.McDonald6 and K. C. Donnelly6,1. 1VeterinaryIntegrative Biomedical Sciences, Texas A&MUniversity, College Station, TX, 2Wildlife and FisheriesSciences, Texas A&M University, College Station, TX,3Statistics, Texas A&M University, College Station, TX,4Civil Engineering, Texas A&M University, CollegeStation, TX, 5U.S. EPA, Seattle, WA and6Environmental and Occupational Health, Texas A&MUniversity System Health Science Center, CollegeStation, TX.

#1594 EXPOSURE OF FATHEAD MINNOW TOFULLERENE AND SINGLE-WALLED CARBONNANOTUBES. E. Oberdoerster2,1, A. Ortiz-Acevedo3,H. Xie3, P. Pantano3, R. H. Baughman3, I. H.Musselman3, R. K. Draper3 and G. R. Dieckmann3.1Biology, Southern Methodist University, Dallas, TX,2Duke University Marine Laboratory, Beaufort, NC and3Department of Chemistry and Nanotech Institute,University of Texas, Dallas, TX.

#1595 TEMPORAL PATTERNS OF MICROCYSTIN-LRCONTAMINATION IN LAKES OF WEST TEXAS.M. Billam1,2, Q. Cai1,2, L. Tang1,2, P. Wang1,2, S.Mukhi1,2, Z. Wang1,2, H. Luo1,2, H. Guan1,2 and J.Wang1,2. 1Environmental Toxicology, Texas TechUniversity, Lubbock, TX and 2The Institute ofEnvironmental and Human Health, Texas TechUniversity, Lubbock, TX.

#1596 GLUCURONIDATION OF DESMETHYL-METHOXYCHLOR IN THE CHANNEL CATFISHINTESTINE AND LIVER. L. D. Stuchal1, K. M.Kleinow2 and M. James1. 1University of Florida,Gainesville, FL and 2Louisiana State University, BatonRouge, LA.

#1597 DECABROMODIPHENYL OXIDE/ETHER (BDE-209): INVESTIGATION OF PHOTOLYTICDEGRADATION IN A CONSUMER PRODUCT. P.F. Ranken2, M. Hardy1 and S. D. Landry2. 1Health,Safety & Environment, Albemarle Corporation, BatonRouge, LA and 2Rearch & Development, AlbemarleCorporation, Baton Rouge, LA.

#1598 HIGH-THROUGHPUT CHEMICAL SCREENINGUSING PROTEIN PROFILING OF FISHPLASMA. R. T. Hudson, M. J. Hemmer, K. A. Salinas,S. S. Wilkinson, J. Watts, J. T. Winstead, P. S. Harris, A.Kirkpatrick and C. C. Walker. US-EPA, ORD,NHEERL, Gulf Breeze, FL. Sponsor: M. Barron.


POSTER SESSION: CADMIUM AND METALLOTHIONEIN

Chairperson(s): Lih-Nan Chou, Boston University School of Medicine,Boston, MA.



#1599 LOSS OF GLUTAMATE-CYSTEINE LIGASEMODIFIER SUBUNIT SENSITIZES CELLS TOCADMIUM TOXICITY. S. N. Schneider, H. Lei, Y.Chen, D. W. Nebert and T. P. Dalton. University ofCincinnati Medical Center, Cincinnati, OH.

#1600 CADMIUM AND TERT-BUTYLHYDROPEROXIDE-INDUCED DIFFERENTPATTERNS OF CHANGES IN ENERGY ANDREDOX STATES IN HEPG2 CELLS–THEIRCORRELATION WITH THE MODE OF CELLDEATH. L. C. Yu1, K. F. Tse1, S. W. Pat1, N. K. Mak1,R. C. Gupta2 and M. S. Yang1. 1Biology, Hong KongBaptist University, HOng Kong, China and 2Toxicology,Murray State University Breathitt Veterinary Center,Hopkinsville, KY.

#1601 IDENTIFICATION OF DOSE- AND TIME-DEPENDENT CHANGES IN CELLULARMETABOLIC EVENTS IN HEPG2 CELLS UPONEXPOSURE TO CADMIUM. M. S. Yang1, L. C. Yu1,S. W. Pat1, K. M. Li1, N. K. Mak1 and R. C. Gupta2.1Biology, Hong Kong Baptist University, Hong Kong,China and 2Toxicology, Murray State UniversityBreathitt Veterinary Center, Hopkinsville, KY.

#1602 CADMIUM DISRUPTS N-CADHERIN-DEPENDENT CELL-CELL JUNCTIONS ANDACTIVATES ββ-CATENIN MEDIATED NUCLEARSIGNALING IN ROS 17/2.8 CELLS. W. C.Prozialeck1, N. Chandar2, K. Kolman2, P. C. Lamar1

and M. J. Fay1. 1Pharmacology, Midwestern University,Downers Grove, IL and 2Biochemistry, MidwesternUniversity, Downers Grove, IL.

#1603 UPREGULATION OF γγ-GLUTAMYLCYSTEINESYNTHETASE EXPRESSION IN CADMIUM-TREATED RAT FETAL LUNG FIBROBLASTS. X.Luo1, D. Chou2,1, L. Chen2, Y. Zhao2, W. Li2 and I.Chou1. 1Microbiology, Boston University School ofMedicine, Boston, MA and 2Biochemistry, BostonUniversity School of Medicine, Boston, MA.

#1604 MECHANISMS OF CADMIUM TRANSPORT INMDCK CELLS. R. K. Zalups and S. Ahmad. BasicSciences, School of Medicine, Mercer University,Macon, GA.

#1605 CADMIUM NEPHROTOXICITY IS ASSOCIATEDWITH A LOSS OF N-CADHERIN MEDIATEDADHESION AND ALTERATIONS INEPITHELIAL POLARITY IN THE PROXIMALTUBULE. W. C. Prozialeck and P. C. Lamar.Pharmacology, Midwestern University, Downers Grove,IL.

Program Description


WED

NESD

AY


#1606 NECROSIS AND NOT APOPTOSIS IS THEPREDOMINANT MODE OF CELL DEATH INMORTAL HUMAN PROXIMAL TUBULE CELLSEXPOSED TO CADMIUM CHLORIDE. S. Somji1,S. H. Garrett1, M. Sens1 and D. A. Sens2. 1Pathology,University of North Dakota, Grand Forks, ND and2Surgery, University of North Dakota, Grand Forks,ND.

#1607 CADMIUM-INDUCED CELL CYCLE ARREST INRAT KIDNEY EPITHELIAL CELLS ISMEDIATED THROUGH P53 ACTIVATION. J. Xieand Z. A. Shaikh. Department of Biomedical andPharmaceutical Science, University of Rhode Island,Kingston, RI.

#1608 CADMIUM-INDUCED CARCINOGENICTRANSFORMATION OF HUMAN PANCREATICDUCTAL CELLS. W. Qu1, B. Diwan2, D. Broderick1,M. Tsao3 and M. Waalkes1. 1Laboratory of ComparativeCarcinogenesis, NCI at NIEHS, Research Triangle Park,NC, 2BRP, SAIC-Frederick, NCI at Frederick,Frederick, MD and 3Ontario Cancer Institute, Toronto,ON, Canada.

#1609 CADMIUM MAY AFFECT THE LIGANDINDUCED MIGRATORY ABILITY OFIMMORTALIZED EXTRAVILLOUSTROPHOBLAST CELLS. M. M. Alvarez and C.Chakraborty. Pathology, University of Western Ontario,London, ON, Canada. Sponsor: M. Cherian.

#1610 CHRONIC EXPOSURE TO CADMIUM INDUCESANEMIA WITH HIGH IRON STORAGETHROUGH DEFECTIVE IRON UTILIZATIONAND ENHANCED IRON ABSORPTION IN RATS.H. Horiguchi, E. Oguma, H. Uno and F. Kayama. JichiMedical School, Tochigi, Japan. Sponsor: T. Yoshida.

#1611 BEHAVIORAL ALTERATIONS OF C57BL ANDMETALLOTHIONEIN KNOCK-OUT MICEPERINATALLY EXPOSED TO LOW LEVEL OFCADMIUM. C. Watanabe1, A. Watanabe1, M. Satoh2,K. Yoshida3, K. Mori3, H. Ishitobi1 and A. Honda2.1Human Ecology, University of Tokyo, Tokyo, Japan,2Hygienics, Gifu Pharmaceutical University, Gifu, Japanand 3Endocrinology, Tohoku University School ofMedicine, Sendai, Japan.

#1612 MODULATION OF ACUTE HEPATOTOXICITYOF CADMIUM BY SIMULTANEOUSADMINISTRATION OF COBALT IN MICE. S.Himeno. Fac. of Pharmaceutical Sciences, TokushimaBunri University, Tokushima, Japan. Sponsor: M. Sato.

#1613 LIVER INJURY IN METALLOTHIONEIN-NULLMICE AFTER TREATMENT WITHTHIOACETAMIDE. S. Jiang and G. M. CHERIAN.Pathology, University.of Western Ont, London, ON,Canada.

#1614 THE NORMAL HUMAN PROSTATEEPITHELIAL CELL LINE, RWPE-1, AS AN INVITRO MODEL SYSTEM OFMETALLOTHIONEIN REGULATION IN THEPROSTATE. R. K. Singh1, S. Somji1, M. Sens1, D. A.Sens2 and S. H. Garrett1. 1Pathology, University ofNorth Dakota, Grand Forks, ND and 2Surgery,University of North Dakota, Grand Forks, ND.

#1615 METALLOTHIONEIN SUSTAINSMETALLOPROTEINASE2 GENE EXPRESSIONIN IMMORTALIZED FIBROBLAST CELLS. M.Takiguchi1,2, M. Higashimoto2, S. Suzuki2, S.Yoshihara1 and M. Sato2. 1Faculty of PharmaceuticalSciences, Hiroshima International University, Kure,Hiroshima, Japan and 2Faculty of PharmaceuticalSciences, Tokushima Bunri University, Tokushima,Japan.

#1616 POST-TRANSLATIONAL STABILIZATION OFMETALLOTHIONEIN ISOFORM 3 IN THENORMAL BLADDER CELL LINE, UROTSA. D. A.Sens1, S. Somji2, R. Singh2, M. Sens2 and S. H. Garrett2.1Surgery, University of North Dakota, Grand Forks, NDand 2Pathology, University of North Dakota, GrandForks, ND.

#1617 ACTIVITY OF METAL-RESPONSIVETRANSCRIPTION FACTOR 1 IS MODULATEDBY METALLOTHIONEIN. T. Kimura1, N. Itoh2, T.Sone1, M. Isobe1 and K. Tanaka2. 1Department ofToxicology, Faculty of Pharmaceutical Sciences,Setsunan University, Hirakata, Japan and 2Departmentof Toxicology, Graduate school of PharmaceuticalSciences, Osaka University, Suita, Japan.

#1618 THE EFFECT OF METALLOTHIONEINISOFORM-3 MUTANTS ON THEDIFFERENTIATION OF BREAST CANCER MCF-7 CELLS. M. Sens1, S. H. Garrett1, S. Somji1 and D. A.Sens2. 1Pathology, University of North Dakota, GrandForks, ND and 2Surgery, University of North Dakota,Grand Forks, ND.

#1619 PRODUCTION OF METALLOTHIONEINPOLYCLONAL ANTIBODIES USING CHICHENSAS MODEL. E. Brambila1, A. Ortiz/Bueno1, B. Leon-Chavez1, W. Achanzar2 and M. P. Waalkes2. 1ClinicalChemistry, Benemerita Universidad Autonoma dePuebla, Puebla, Mexico and 2NIH, Research TrianglePark, NC.


POSTER SESSION: IN VITRO

Chairperson(s): Mohamed Abou-Donia, Duke University, Durham, NC andBhupendra Kaphalia, University Of Texas, Galveston, TX.



#1620 INTERACTION OF PB AND DEET, ALONE ANDIN COMBINATION WITH P-GLYCOPROTEINEXPRESSED IN E. COLI LEAKY MUTANT. E. M.El-Masry and M. B. Abou-Donia. Pharmacology andCancer Biology, Duke University Medical Center,Durham, NC.

#1621 HORMESIS EFFECT OF TRACE METALS ONCULTURED NORMAL AND IMMORTAL HUMANMAMMARY CELLS. C. N. Cheng, A. Marino, C. M.Schmidt, R. Konsoula and F. A. Barile. PharmaceuticalSciences, St. John’s University College of Pharmacy,Jamaica, NY.

Program Description



WED

NES

DAY

#1622 INTERACTIVE TOXICITY OF MERCURY ANDPOLYCHLORINATED BIPHENYL IN THENEUROELECTROPHYSIOLOGY OF RATEMBRYO. G. Balagopal1 and H. Chan2. 1HumanToxicology Section–Standards Development Branch,Ontario Ministry of Environment, Toronto, ON, Canadaand 2Center for Indegenous People’s Nutrition andEnvironment, Macdonald Campus, McGill University,Montreal, QC, Canada.

#1623 COMPARATIVE EVALUATION OFSURFACTANTS ON IN VITRO RABBIT ANDHUMAN CORNEAS. H. F. Edelhauser1, B. Boykin1,G. Holley1 and M. E. Blazka2. 1Emory Eye Center,Emory University, Atlanta, GA and 2Colgate-PalmoliveCo., Piscataway, NJ.

#1624 ESTABLISHMENT OF AN IN VITRO BRAINBARRIER EPITHELIAL TRANSPORT SYSTEMFOR TOXICOLOGICAL STUDIES. L. Shi and W.Zheng. School of Health Sciences, Purdue University,West Lafayette, IN.

#1625 A GERM-LINE STEM CELL LINE AS A MODELFOR EVALUATING THE CYTOTOXICITY OFNANOPARTICLES IN VITRO. L. Braydich-Stolle1,S. Hussain2, J. Schlager3 and M. Hofmann1.1Department of Biology, University of Dayton, Dayton,OH, 2ManTech Environmental Technology, Inc.,Dayton, OH and 3Air Force Research Laboratory,Wright-Patterson AFB, Dayton, OH.

#1626 VALIDATION OF AN IN VITRO CELL LINE FORSCREENING MYELOTOXICITY. T. Huggett1, A.Saad2, T. Kelly1, F. Pognan3, M. Otieno1 and D. Brott1.1AstraZeneca Pharmaceuticals, Wilmington, DE,2AstraZeneca Pharmaceuticals, Sodertalje, Sweden and3AstraZeneca Pharmaceuticals, Alderly Park, UnitedKingdom.

#1627 CORRELATION OF IN VITRO CYTOTOXICITYWITH PARACELLULAR PERMEABILITY INCACO-2 CELLS. R. Konsoula and F. A. Barile.Pharmaceutical Sciences, St. John’s University Collegeof Pharmacy, Jamaica, NY.

#1628 PROTOCOL OPTIMIZATION FOR THEEVALUATION OF IN VITRO CYTOTOXICITYASSAYS FOR ESTIMATING RODENT ANDHUMAN ACUTE SYSTEMIC TOXICITY. M.Paris1,2, J. Strickland1,2, W. Stokes1, S. Casati3, R.Tice1,2, H. Raabe4, C. Cao5, R. Clothier6, J. Haseman7,P. Crockett8, M. Wenk9, M. Vallant7, G. Mun4, G.Moyer4, J. Madren-Whalley5, C. Krishna5, M. Owen6

and N. Bourne6. 1NICEATM, NIEHS, ResearchTriangle Park, NC, 2ILS, Inc., Research Triangle Park,NC, 3JRC, ECVAM, Ispra, Italy, 4IIVS, Gaithersburg,MD, 5ECBC, USArmy, Aberdeen Proving Ground, MD,6University of Nottingham, Nottingham, UnitedKingdom, 7NIEHS, Research Triangle Park, NC,8Constella Group, Research Triangle Park, NC and9BioReliance, Rockville, MD.

#1629 ETHANOL-INDUCED TOXICITY ANDAPOPTOSIS IN HEPG2 CELLS AND VA-13CELLS: ROLE OF FATTY ACID ETHYLESTERS. H. Wu1, K. Bhopale1, G. A. Ansari1 and B. S.Kaphalia1. 1Pathology, University of Texas MedicalBranch, Galveston, TX, 2Pathology, University of TexasMedical Branch, Galveston, TX, 3Pathology, Universityof Texas Medical Branch, Galveston, TX and4Pathology, University of Texas Medical Branch,Galveston, TX.

#1630 OPTIMIZATION OF AN IN VITRO LONG TERMCORNEAL CULTURE ASSAY. H. A. Raabe1, L.Bruner2, T. Snyder1, N. Wilt1 and J. W. Harbell1.1Institute for In Vitro Sciences, Gaithersburg, MD and2The Gillette Co., Boston, MA.

#1631 AN EXPANDED REFERENCE DATA-BASE OF INVITRO OCULAR IRRITATION SCORES FORMARKETED COSMETIC AND PERSONAL CAREPRODUCTS USING A TISSUE EQUIVALENTMODEL. R. R. Binetti, M. D. Hines, R. Hamid, S. D.Gettings and B. C. Jones. Avon Products Inc., Suffern,NY.

#1632 EFFECT OF THE PROTEASOME INHIBITORPS-341 ON NEURONAL CELLS IN VITRO. V.Csizmadia, A. Raczynski, J. Rottman, K. Ganley, P.Bouchard and V. Sasseville. Drug Safety andDisposition, Millennium Pharmaceuticals, Inc.,Cambridge, MA. Sponsor: A. Carl.

#1633 DEVELOPMENT OF IN VITROCARDIOTOXICITY ASSAY USING RATCARDIOMYOCYTES CULTURED ONCOLLAGEN GEL. T. Inoue, A. Shioda and K.Kobayashi. Pre-Clinical Research Department 2, ChugaiPharmaceutical Co., Ltd.,, Kamakura, Japan. Sponsor:R. Nagata.

#1634 EVALUATION OF CIGARETTE SMOKECYTOTOXICITY UNDER IN VITROCONDITIONS. H. E. Hartman, F. Sheabar, G.Holloway, J. Ye and S. Millett. Toxicology, AristaLaboratories, Inc., Richmond, VA.

#1635 IN VITRO MODEL FOR VASCULARDEVELOPMENT IN MOUSE EMBRYONIC STEMCELLS. G. RHEE1, G. Kim1, J. Seok1, S. Kim1, S.Kwack1, R. Lee1, S. Lee1, H. Chung2 and D. Cho1.1Department of Toxicology, National Institute ofToxicological Research, Seoul, South Korea and 2Celland Gene Therapy Research Institute, Pochon CHAUniversity, Seoul, South Korea.


POSTER SESSION: SAFETY EVALUATION-SPONTANEOUSDISEASE AND CONTROL PARAMETERS

Chairperson(s): Carol Auletta, Huntingdon Life Sciences, East Millstone, NJ.



#1636 HISTOPATHOLOGICAL BACKGROUNDFINDINGS IN THE COMMON MARMOSET(CALLITHRIX JACCHUS). S. Friderichs-Gromoll, J.Kaspareit and E. Buse. Covance Laboratories GmbH,48163 Muenster, Germany. Sponsor: G. Weinbauer.

#1637 HISTOPATHOLOGY DATABASE FORCARCINOGENICITY STUDIES WITH SPRAGUE-DAWLEY RATS. A. Babb, V. Price, M. Milligan, K.Davis, R. D. Jones and J. Seng. Toxicology, CharlesRiver Laboratories–DDS–Arkansas Division, Redfield,AR.

#1638 A COMPARISON OF PATHOLOGICAL CHANGEAND SURVIVAL IN DIFFERENT RODENTSTRAINS OVER A TWO-YEAR STUDYDURATION. J. Noakes, R. W. Lewis and J. A. Wright.Syngenta Central Toxicology Laboratory, Alderley Park,Macclesfield, United Kingdom. Sponsor: R. Dearman.

#1639 IN-LIFE PARAMETERS AND TUMOUR DATAFROM CHARLES RIVER CRL:CD-1 ® (ICR) BRMOUSE DIETARY AND ORAL GAVAGETUMORIGENICITY STUDIES TERMINATEDAFTER TWO YEARS. W. Hooks1, C. J. Groom1 andJ. K. Stewart2. 1Toxicology, Huntingdon Life Sciences,Huntingdon, Cambridgeshire, United Kingdom and2Pathology, Huntingdon Life Sciences, Huntingdon,Cambridgeshire, United Kingdom. Sponsor: C. Hardy.

#1640 SPONTANEOUS LESIONS IN CRJ:CD-1(ICR)-NU/NU MICE BY 106 WEEKS OF AGE DURINGTHE OBSERVATION PERIOD. T. Nakamura1, T.Shibanushi1, T. Satoshi1, K. Kuzutani1 and M.Takahashi2. 1Safety Research Department, KakenPharmaceutical Co., Ltd., Sizuoka, Japan and2Pathology Peer Review Center, Tokyo, Japan.

#1641 THROMBOCYTOPENIC PURPURA INGOTTINGEN MINIPIGS. C. Auletta, H. F. Bolte, S.J. Gosselin and C. Willard-Mack. Huntingdon LifeSciences, East Millstone, NJ.

#1642 CLINICAL PATHOLOGY DATABASE FOR NON-CLINICAL GLP STUDIES WITH LANDRACE -CROSS SWINE. T. Gartner, P. Powell, V. Price, J.Seng, R. D. Jones and K. Davis. Toxicology, CharlesRiver Laboratories–DDS–Arkansas Division, Redfield,AR.


Wednesday Morning, March 911:00 AM to 12:00 NOONRoom 215

INFORMATIONAL SESSION: BIOLUMINESCENT METHODS FORADME/TOX — PRESENTED BY PROMEGA CORP.

Bioluminescence offers significant advantages for configuring sensitive, simpleto perform, high through-put assays with ADME/Tox applications.Bioluminescent systems will be described that measure the cytotoxicity of testcompounds, their capacity to induce apoptosis, their impact on various CYP450activities and on the multi-drug transporter (MDR1/Pgp).

Wednesday Morning, March 911:00 AM to 12:00 NOONRoom 223

INFORMATIONAL SESSION: INTRODUCTION TO REAL-TIMEPCR — PRESENTED BY APPLIED BIOSYSTEMS

An introduction to the fundamentals of real-time PCR technology and applica-tions. This session will include; an overview of absolute and relativequantization methods, chemistry & instrument options, and assay designconsiderations.

Wednesday Afternoon

Wednesday Afternoon, March 912:00 NOON to 1:00 PMRoom RO1

SPECIAL WORKSHOPS: A CONVERSATION WITH THEDIRECTORS

The Meet the Directors session is a one-hour special session that will beformatted like a panel discussion with the leaders of several major federal agen-cies. The objective of this session is to provide meeting attendees a betterunderstanding of the toxicology research activities of the FDA, EPA, NIEHSand NTP. Emphasis will be on change of direction or new initiatives that mayimpact the practice of toxicology in the future. Speakers will also identifyopportunities for non-agency toxicologists to participate in the initiatives of theagency.

• New Direction for Intramural and Extramural Research, Dr. KenOlden, NIEHS.

• Changed Emphasis of NTP Based on the Recent Vision and Road Map,Dr. Chris Portier, NTP.

• Current and Future Impact on the FDA Regulatory Actions Based onNCTR Research, Dr. Dan Casciano, NCTR.

• Current and Future Impact of EPA Regulatory Actions Based on EPAResearch, Dr. Bill Farland, U.S. EPA.

Program Description


WED

NESD

AY


Program Description



WED

NES

DAY

Wednesday Afternoon, March 912:00 NOON to 1:00 PMRoom 208

ISSUES SESSION: REORGANIZATION OF THE NIH GRANTREVIEW PROCESS AND ITS POTENTIAL IMPACT ONTOXICOLOGY RESEARCH AND TRAINING

Chairperson(s): David Eaton, University of Washington, Seattle, WA.

Panelists: Anne Sassaman, Director of Extramural Programs, NIEHS;Richard Okita, Administrator, Pharmacological and Physiological SciencesBranch, NIGMS; Mary Vore, Chair, XNDA Study Section; Alvaro Puga,Member, XNDA Study Section (Former Chair of AL-TOX1); Elliot Postow,Center for Scientific Review; and Patricia Greenwel, Center for ScientificReview.

With the reorganization of the NIH Study Sections, significant changes haveoccurred in the way that toxicology-related grants are assigned to study sectionsand reviewed. This session will explore the advantages and disadvantages of thereorganization to our discipline, and the implications for toxicology researchand training of the next generation of environmental health scientists.

Wednesday Afternoon, March 912:00 NOON to 1:00 PMRoom RO8

ROUNDTABLE SESSION: CONDUCTING A COMPREHENSIVETOXICOLOGICAL AND SAFETY EVALUATION OFNANOMATERIALS: CURRENT CHALLENGES AND DATA NEEDS

Chairperson(s): William H. Farland, U.S. EPA, Washington, DC.

#1695 12:00 CONDUCTING A COMPREHENSIVETOXICOLOGICAL AND SAFETY EVALUATIONOF NANOMATERIALS: CURRENTCHALLENGES AND DATA NEEDS. M. P.Holsapple1 and W. H. Farland2. 1HESI, Washington,DC and 2U.S. EPA, Washington, DC.

#1696 12:05 INHALATION AS A CRITICAL EXPOSUREROUTE FOR EVALUATING NANOMATERIALS.T. D. Landry. Toxicology and Environmental Researchand Consulting, The Dow Chemical Company, Midland,MI.

#1697 12:10 DERMAL EXPOSURE ROUTE FOREVALUATING NANOMATERIALS. N. A. Monteiro-Riviere. Center for Chemical Toxicology Research andPharmacokinetics, North Carolina State University,Raleigh, NC.

#1698 12:15 THE VALUE OF EXISTING TESTINGSTRATEGIES FOR EVALUATINGNANOMATERIALS. J. M. Carter. Central ProductSafety, Procter & Gamble, Cincinnati, OH.

#1699 12:20 MODE OF ACTION CONSIDERATIONS IN THEEVALUATION OF SAFETY OF ENGINEEREDNANOSCALE MATERIALS. N. J. Walker. NIEHS,Research Triangle Park, NC.


Wednesday Afternoon, March 912:15 PM to 1:15 PMRoom 215

INFORMATIONAL SESSION: ADVANCES IN REAL-TIME PCR —PRESENTED BY APPLIED BIO SYSTEMS

An overview of recent advances including; Validated TaqMan® GeneExpression and SNP Assays for quantization and genotyping of theCytochromes P450 and other drug metabolizing enzymes, FAST thermal cyclingoptions, and TaqMan® Assays for microRNA quantization.

Wednesday Afternoon, March 91:30 PM to 4:30 PMRoom RO2

SYMPOSIUM SESSION: DEVELOPMENTAL TOXICOLOGY OF THELUNG

Chairperson(s): John M. Rogers, U.S. EPA, Research Triangle Park, NC andCharles G. Plopper, University of California, Davis, Davis, CA.

Endorsed by:Reproductive and Development SSStudent Advisory Committee

Respiratory problems account for a large proportion of hospital admissions topediatric wards, and the incidence of childhood asthma is increasing forunknown reasons. A number of toxicants have been demonstrated to adverselyaffect lung development in humans and/or laboratory animals. Lung develop-ment begins early in gestation and continues well after birth. The molecularcontrol of normal lung development has been intensely studied and is becomingwell elucidated, involving multiple complex signaling networks. In contrast,mechanisms of toxicity to the developing lung are poorly understood. Thissymposium will present an overview of normal lung development and examplesin humans and laboratory animal species of chemicals and conditions thatadversely affect lung development. Effects of tobacco smoke and constituentshave been well-studied and will be highlighted. Possible modes of action fordevelopmental toxicity to the lung will be presented and research needs will bediscussed.

#1643 1:30 DEVELOPMENTAL TOXICOLOGY OF THELUNG. J. M. Rogers. Developmental Biology Branch,U.S. EPA, Research Triangle Park, NC.

#1644 1:40 GENETIC PATHWAYS CONTROLLING LUNGMORPHOGENESIS. W. Cardoso. Pulmonary Biology,Cincinnati Children’s Hospital, Cincinnati, OH.Sponsor: J. Rogers.

#1645 2:10 EFFECTS OF ENVIRONMENTAL TOBACCOSMOKE (ETS) ON THE DEVELOPING LUNG. K.E. Pinkerton, J. L. Peake and J. P. Joad. Center forHealth and the Environment, University of California,Davis, CA.

#1646 2:40 EFFECT OF MATERNAL NICOTINE EXPOSUREDURING DIFFERENT PHASES OF LUNGDEVELOPMENT ON LUNG GROWTH IN THEOFFSPRING: PROTECTICE EFFECT OFCOPPER. G. S. Maritz. Medical Biosciences,University of the Western Cape, Bellville, WesternProvince, South Africa. Sponsor: J. Rogers.

#1647 3:10 PRENATAL PERFLUOROOCTANE SULFONATEEXPOSURE AFFECTS PERINATAL LUNGDEVELOPMENT AND CAUSES RESPIRATORYDISTRESS IN RATS. R. C. Grasty. Toxicology, UNCChapel Hill, Research Triangle Park, NC.

Program Description


WED

NESD

AY


#1648 3:40 EFFECTS OF ENVIRONMENTAL AIRPOLLUTANTS ON POSTNATAL LUNGDEVELOPMENT. M. Fanucchi. School of VeterinaryMedicine, University of California, Davis, CA.


SYMPOSIUM SESSION: ROLE OF CELL-CELL AND CELL-MATRIXINTERACTIONS IN REGULATION OF TOXICANT-MEDIATED CELLDEATH

Chairperson(s): Ronald Tjalkens, Colorado State University, Fort Collins,CO.

Endorsed by:Carcinogenesis SS*Mechanisms SSNeurotoxicology SS

Cell-cell interactions are key for the regulation of cell survival, cell death andcell proliferation. Thus, an understanding of the interdependency betweendifferent tissue cellular compartments is key to elucidating mechanisms of celldeath in response to toxicants. This symposium will provide a timely update onthe molecular mechanisms of cell death and its regulation, including the roleplayed by cell-cell and cell-matrix interactions. This will be illustrated by threeexamples of the role these pathways play in toxicant response in diverse tissues.The first speaker will consider how hepatic Kupffer cells are implicated innormal homeostasis and in hepatocarcinogenesis and can mediate both hepato-cyte survival or cell death, depending on the toxic insult. The second speakerwill address how gap junctional intercellular communication and cell adhesionare interrelated processes using the example of hexachlorobenzene whichinduces a down-regulation of connexins and E-cadherin in the liver of femalebut not male rats. The third speaker brings an external perspective and willdiscuss how the cell detects and signals damage leading to survival or cell death.The fourth speaker will address how neuronal trophic and communication func-tions are maintained by intricate coupling with associated astroglial cells withemphasis on neurotoxicants that selectively target astroglial cells, renderingneurons vulnerable to both physiologic and pathophysiologic stresses. The forthspeaker will also summarise the symposium by uncovering similarities andcommon themes in the role of the cellular environment in determining cell fateafter toxicant insult. This symposium will be of interest both to non-expertslooking to understand this field and those with a specific interest in cell biology,carcinogenesis, neurotoxicology, apoptosis or cell-cell communication.

#1649 1:30 ROLE OF CELL-CELL AND CELL-MATRIXINTERACTIONS IN REGULATION OFTOXICANT-MEDIATED CELL DEATH. R.Roberts1 and R. Tjalkens2. 1Safety Assessment,AstraZeneca, Alderley Park, United Kingdom and2Department of Environmental and Radiological HealthSciences, Colorado State University, Fort Collins, CO.

#1650 1:40 CELL-CELL INTERACTIONS AND THEIR ROLEIN TOXICANT-INDUCED HEPATIC CELLDEATH. R. Roberts. Safety Assessment, AstraZeneca,Alderley Park, United Kingdom.

#1651 2:20 MODULATION OF CELL-CELL INTERACTIONSBY EPIGENETIC HEPATOCARCINOGENS. M.Charbonneau, I. Plante, N. Raynal and D. G. Cyr.INRS-Institut Armand-Frappier, Universite du Quebec,Pointe-Claire, Montreal, QC, Canada.

#1652 3:00 THE REGULATION OF APOPTOSIS: SURVIVALSIGNALLING AND THE IMPORTANCE OFCELL TO CELL COMMUNICATION. C. Dive1,2, J.T. Erler1, I. J. Stratford2, D. A. Tennant1,3 and D. R.Tomlinson3. 1Cellular and Molecular PharmacologyGroup, Cancer Research UK Paterson Institute,Manchester, United Kingdom, 2School of Pharmacy andPharmaceutical sciences, University of Manchester,Manchester, United Kingdom and 3School of BiologicalSciences, University of Manchester, Manchester, UnitedKingdom. Sponsor: R. Roberts.

#1653 3:40 NEURO-GLIAL INTERACTIONS IN BASALGANGLIA DYSFUNCTION: INSIGHTS FROMMANGANESE NEUROTOXICITY. R. Tjalkens.Toxicology Section, Department of Environmental andRadiological Health Sciences, Colorado StateUniversity, Fort Collins, CO.


SYMPOSIUM SESSION: THE UBIQUITIN- PROTEASOME SYSTEMAS A BIOLOGICAL TARGET IN TOXIC RESPONSES AND DISEASE

Chairperson(s): Richard Pollenz, University of South Florida, Tampa, FL andElaine M. Faustman, Institute for Risk Analysis & Risk Communication,Seattle, WA.

Endorsed by:Mechanisms SSNeurotoxicology SS

The ubiquitin-proteasome system is an essential pathway involved in covalentlymodifying proteins to influence their function and turnover. The cascade is initi-ated by an activating enzyme (E1), that binds to the 76 amino acid ubiquitinprotein (UB). The E1 then transfers the UB to an E2 carrier protein. Followingthis transfer, a UB ligase enzyme (E3) covalently links the UB to a targetprotein. It is the E3, or E3/E2 complex that supplies the target specificity of theubiquitination event. Genome mining has identified 530 possible genesencoding E1, E2, E3, UB and deubiquitinating enzymes (DUB). Ubiquinatedsubstrates are usually recognized by the 20S or 26S proteasome complexes anddestroyed, although recent studies suggest that UB or UB-like modification doesnot always result in destruction. The proteasomes are huge multiproteincomplexes that can be found in both the cytoplasm and nucleus. Overall, theproteasome accounts for 1% of a cells protein. Due to the number of gene prod-ucts required for the ubiquitin-proteasome system, it is a prime target in varioushuman diseases states and cancer. Defects in the system have been implicated inneurodegenerative diseases such as Parkinsons and Alzheimers. In addition,studies continue to suggest that that the various enzymes of the pathway may betargets for toxicologically relevant compounds typified by arsenic, cadmium,TCDD and ethanol. In addition, the ubiquitin-proteasome system is implicatedin the ligand mediated degradation of important transcription factors such asp53, steroid hormone receptors and the aryl hydrocarbon receptor (AHR). Dueto these findings, the enzymes of the ubiquitin-proteasome pathway havebecome important targets in toxicology screens and in drug discovery para-digms.

#1654 1:30 THE UBIQUITIN- PROTEASOME SYSTEM AS ABIOLOGICAL TARGET IN TOXIC RESPONSESAND DISEASE. R. S. Pollenz. Biology, University ofSouth Florida, Tampa, FL.

Program Description



WED

NES

DAY

#1655 1:37 TOXICANT AFFECTS ON UBIQUITIN-PROTEOSOME SYSTEMS: LESSONS FROMCROSS-COMPOUND AND CROSS-SYSTEMASSESSMENTS. E. Faustman, X. Yu, J. Sidhu and J.Robinson. Department of Environmental andOccupational Health Sciences, University ofWashingotn, Seattle, WA.

#1656 2:17 ENVIRONMENTAL FACTORS, UBIQUITIN-PROTEOSOME DYSFUNCTION ANDPARKINSON’S DISEASE. A. G. Kanthasamy.Biomedical Sciences, Iowa State University, Ames, IA.

#1657 2:57 EFFECT OF ETHANOL ADMINISTRATION ONPROTEASOME ACTIVITY IN LIVER AND INCULTURED HEPATOMA CELLS. T. M. Donohue,N. A. Osna and D. L. Clemens. Research, VA MedicalCenter, Omaha, NE. Sponsor: R. Pollenz.

#1658 3:37 THE UBIQUITIN-PROTEASOME SYSTEM INREGULATION OF NUCLEAR TRANSCRIPTIONFACTORS AND SIGNAL TRANSDUCTIONPATHWAYS. R. S. Pollenz, J. Popat, M. de la Pena andJ. McQuown. Biology, University of South Florida,Tampa, FL.

Wednesday Afternoon, March 91:30 PM to 4:30 PMLa Louisiane Ballroom B

SYMPOSIUM SESSION: WHAT MAKES METALS NEUROTOXIC INNEURODEGENERATIVE DISORDERS?

Chairperson(s): Wei Zheng, Purdue University, West Lafayette, IN and RobertA. Yokel, University of Kentucky, Lexington, KY.

Endorsed by:Metals SS*Neurotoxicology SSRisk Assessment SS

Neurodegenerative diseases are characterized by progressive atrophy anddysfunction of anatomically or physiologically related neurologicalsystems.Cumulative evidence suggests a role of metals in the etiology ofnumerous such diseases.For example, excess manganese (Mn) and iron (Fe) inparticular brain regions have been associated with Parkinsonism; copper (Cu)and zinc (Zn) have been implicated in extracellular deposits of amyloid plaquesin Alzheimer’s brains; overload of aluminum (Al) in the brain has also beencontroversially related to Alzheimer’s disease.Moreover, exposure to organicmetals such as methylmercury (MeHg) has been linked to persistentpsychomotor disturbances. However, the imminent question remains as to whatfactors may render metals, either essential or xenobiotic, more prone to beingharmful in sporadic or hereditary neurodegenerative diseases. Understandably,interactions of these metals with genetic components, proteins, metal transportmachineries, and cellular redox mechanisms, may signify some of the keyfactors in metal-induced neurotoxicities. This symposium will address thecurrent understanding of biochemical characteristics of metals that are impli-cated in neurodegenerative disorders, including (1) metal-protein interactionsuch as Cu and Zn in beta-amyloid aggregation, (2) metal-metal interaction suchas Mn in alteration of brain Fe functions, (3) metal-subcellular structure inter-action such as MeHg and microtubules, (4) metal-transporter interaction such asAl speciation in brain Al metabolomics, and (5) metal-redox pathway interac-tion implicated in metal-induced oxidative stress. The symposium will be ofinterest to those who are engaged in metal toxicology, neuroscience, neurotoxi-cology, risk assessment, regulatory management, occupational health, andtoxicology education.

#1659 1:30 WHY METALS BECOME NEUROTOXIC. W.Zheng. School of Health Sciences, Purdue University,West Lafayette, IN.

#1660 1:50 SELECTIVE BLOOD-BRAIN BARRIERTRANSPORT OF ALUMINUM, MANGANESE,AND OTHER METALS IN METAL-INDUCEDNEURODEGENERATION. R. A. Yokel. College ofPharmacy, University of Kentucky Medical Center,Lexington, KY.

#1661 2:30 INTERACTION OF COPPER AND ZINC WITH ββ-AMYLOID IN PATHOGENESIS OFALZHEIMER’S DISEASE. A. I. Bush. Genetics andAging Research Unit, Harvard Medical School andMassachusetts General Hospital, Charlestown, MA.Sponsor: W. Zheng.

#1662 3:10 BINDING TO SUBCELLULAR STRUCTURES INMETHYLMERCURY-INDUCEDNEURODEGENERATIVE DAMAGE. K. R. Reuhl.Pharmacology & Toxicology, Rutgers University,Piscataway, NJ.

#1663 3:50 METAL-METAL INTERACTIONS INMANGANESE-INDUCED PARKINSONISM. W.Zheng. School of Health Sciences, Purdue University,West Lafayette, IN.


Program Description


WED

NESD

AY



WORKSHOP SESSION: CONFLICT OF INTEREST

Chairperson(s): Jacques Maurissen, The Dow Chemical Company, Midland,MI and Steven Gilbert, Institute of Neurotoxicology and NeurologicalDisorders, Seattle, WA.

Endorsed by:Board of Publications

Ethical Legal and Social Issues SS*Regulatory Affairs and Legislative Assistance CommitteeRegulatory and Safety Evaluation SS

The conflict of interest issue has recently been the subject of much attentionfrom the points of view of editorial policy and electoral policy to scientific advi-sory boards. The perception is that some scientists performing or evaluatingresearch may be tempted to overlook an adverse effect in a research project(hoping to please the sponsor and to secure future funding from the samesource); likewise, other scientists may be tempted to overemphasize the signifi-cance of a positive result in their research (to gain access to additional grantsupport from private or institutional foundations or to favor donations from thegeneral public). A number of scientific journals (including ToxicologicalSciences) have recently addressed or reviewed the issue of conflict of interest.Similarly, a number of institutions have also codified their policy to help in theselection of members for scientific advisory boards. A number of questions canbe asked around several themes: What is a financial conflict of interest? Whatabout grant renewal, university tenure? What is the importance of non-financialconflicts of interest in the decision process, e.g., number of publications,academic competition, public/professional visibility, satisfaction of accomplish-ment, loyalty? When does a conflict start and stop being a conflict, apparent orreal? Should a scientist with a real conflict of interest be prevented frompublishing an editorial or a review paper on the basis of a conflict of interest?What if the conflict is not real but perceived? Should a perceived conflict ofinterest be enough to disqualify an otherwise competent scientist from electionto a panel? What is the role of full disclosure in a successful conflict of interestpolicy? A group of five panelists (from diverse backgrounds) will present theirviews concerning the conflict of interest.

#1678 1:30 CONFLICT OF INTEREST. J. P. Maurissen2 and S.G. Gilbert1. 1INND, Seattle, WA and 2Neurotoxicology,Dow Chemical Company, Midland, MI.

#1679 1:45 WHAT IS A “CONFLICT OF INTEREST”? T. L.Beauchamp. Kennedy Institute of Ethics, GeorgetownUniversity, Washington, DC. Sponsor: S. Gilbert.

#1680 2:15 CONFLICT OF INTEREST IN THEPUBLICATION PROCESS. L. D. Lehman-McKeeman. Bristol Myers Squibb Co., Princeton, NJ.

#1681 2:45 ROLE OF GOVERNMENT OVERSIGHT. B. A.Schwetz. Office for Human Research Protections,Rockville, MD.

#1682 3:15 MANAGING CONFLICTS OF INTEREST: DOESDISCLOSURE GO FAR ENOUGH? M. Goozner.Cntr for Sciences. in the Public Intrst, Washington, DC.Sponsor: S. Gilbert.

#1683 3:45 CONFLICT OF INTEREST AND BIAS: AVIEWPOINT FROM INDUSTRY. C. Barrow. DowChemical Company, Washington, DC.


WORKSHOP SESSION: DOSIMETRY AND POTENTIAL IMPACTSON REPRODUCTIVE/DEVELOPMENTAL STUDY DESIGN ANDINTERPRETATION FOR RISK OR SAFETY ASSESSMENT

Chairperson(s): Hugh Barton, U.S. EPA, Research Triangle Park, NC and EdCarney, Dow Chemical Company, Midland, MI.

Endorsed by:Biological Modeling SSRegulatory and Safety Evaluation SSRisk Assessment SSStudent Advisory Committee

Reproductive and developmental toxicity studies in animals are utilized inassessing the potential adverse effects of chemicals and drugs in pregnantwomen, nursing infants, and children. The results of these studies are extrapo-lated to humans primarily based on the dose or the exposure in the mother dueto the complexity of describing the dose, pharmacokinetics, and tissuedosimetry of chemicals during pregnancy, lactation, and postweaning periods.Transporters are increasingly recognized as a key factor in dosimetry duringearly life along with development of metabolism and other clearance processes.For pharmaceuticals, measurement of maternal blood levels, and sometimesplacental and lactational transfer, are addressed for safety assessment. Classicaland physiologically-based pharmacokinetic analyses are increasingly beingapplied across these life stages of reproduction. Identification of the criticalwindow of sensitivity, and how this critical period and its associated pharmaco-kinetics correlates with humans, is a significant challenge. This workshop willpresent approaches to characterizing measures of internal dose in reproductiveand developmental toxicity studies, and how this impacts study designs andapplications for safety and risk assessment.

#1684 1:30 DOSIMETRY ANDREPRODUCTIVE/DEVELOPMENTAL STUDYDESIGN AND INTERPRETATION FOR RISK ORSAFETY ASSESSMENT. E. Carney2 and H. A.Barton1. 1U.S. EPA, Research Triangle Park, NC and2Toxicology & Environmental Research & Consulting,Dow Chemical Company, Midland, MI.

#1685 1:40 LIFE-STAGE DEPENDENT DOSIMETRY ANDPOTENTIAL IMPACTS ON RISK ASSESSMENT.H. A. Barton. U.S. EPA, Research Triangle Park, NC.

#1686 2:10 INCORPORATING DOSIMETRY INDEVELOPMENTAL TOXICITY ASSESSMENTS:STUDY DESIGN AND DATA INTERPRETATION.E. Mylchreest and S. A. Gannon. DuPont HaskellLaboratory, Newark, DE.

#1687 2:40 TRANSPORTERS DURING DEVELOPMENT. C.D. Klaassen. Pharmacology, U Kansas Med. Ctr,Kansas City, KS.

#1688 3:10 PHARMACEUTICAL PERSPECTIVE ONDOSIMETRY IN REPRODUCTIVE ANDDEVELOPMENTAL STUDIES AND THE IMPACTON DRUG DEVELOPMENT. G. Pastino. DrugMetabolism and Pharmacokinetics, Schering PloughResearch Institute, Lafayette, NJ.

#1689 3:40 PBPK MODELING OF EARLY LIFESTAGES ANDESTIMATION OF DOSIMETRY FOR RISKASSESSMENT. H. Clewell1 and R. Clewell2.1ENVIRON, Ruston, LA and 2CIIT Centers for HealthResearch, Research TrianglePark, NC.

Program Description



WED

NES

DAY


WORKSHOP SESSION: SKIN MODEL SELECTION FOR SAFETYASSESSMENT OF TOPICAL DRUG PRODUCTS: REGULATORYAND INDUSTRY PERSPECTIVES

Chairperson(s): Guilin Gary Qiao, U.S. FDA, Rockville, MD and AbbyJacobs, U.S. FDA, Rockville, MD.

Endorsed by:Regulatory and Safety Evaluation SSRisk Assessment SSStudent Advisory Committee

Improper skin model selection in drug R&D and regulatory approval mayunder- or over-estimate systemic toxicity risk of a topical drug, resulting insignificant resource and public health costs. Comparison and careful selectionof in vitro versus in vivo, animal versus human, healthy versus diseased skinmodels under various exposure conditions during topical drug development andapproval are critical. However, our knowledge base in chemical dermal absorp-tion is mainly built on the healthy skin absorption data. For this reason, theregulatory evaluation of drug safety profile has been largely based on healthyskin study data submitted by drug sponsors, especially in the animal drug sector.FDA, per its general guidelines, requires target animal safety profiles to betested in healthy subjects for veterinary drug products including topical drugs tobe applied to diseased skin. Human dermal drug safety testing employs a widerrange of animal models for various purposes. The question is weather thehealthy skin data can predict what happens in patients with compromised skinand weather our testing methods are reflecting the most recent progresses in thisfiled. Data have suggested diseased or damaged skin can compromise skinbarrier function, and thus enhance systemic as well as local toxicity risk. Thoseissues deserve closer research and regulatory attention. Through this workshop,impact of compromised skin barrier function by skin diseases or by other expo-sure variables on systemic versus local, short term versus long term risk areaddressed from academic research, industrial R&D, and regulatory approvalperspectives. Comparative skin histology, skin biology, skin barrier functionassessment, dermal absorption, cutaneous drug disposition, and governmentguidelines for safety testing of human and animal dermal drugs are to bediscussed with research data. Inputs from the scientific community on thoseissues are helpful for future government guideline revisions.

#1690 1:30 SKIN MODEL SELECTION FOR SAFETYASSESSMENT OF TOPICAL DRUG PRODUCTS:REGULATORY AND INDUSTRYPERSPECTIVES. G. G. Qiao. CVM and CDER, U.S.FDA, Rockville, MD.

#1691 1:40 COMPARATIVE MODEL SELECTIONBETWEEN SPECIES AND ABNORMAL SKIN:MORPHOLOGY, DERMAL DRUG DELIVERY,AND OVERALL BARRIER FUNCTION. N. A.Monteiro-Riviere. Center for Chemical ToxicologyResearch and Pharmacokinetics, North Carolina StateUniversity, Raleigh, NC.

#1692 2:20 SKIN MODEL SELECTION IN TOPICAL DRUGR&D AND REGULATORY APPROVAL:CHALLENGES AND SOLUTIONS IN DRUGSAFETY ASSESSMENT. G. G. Qiao1 and A. C.Jacobs2. 1CVM, U.S. FDA, Rockville, MD and 2CDER,U.S. FDA, Rockville, MD.

#1693 3:00 TEST METHODS AND MODELS USED IN THEDEVELOPMENT OF TOPICALLY-APPLIEDPRODUCTS. J. F. Nash. Central Product Safety,Procter & Gamble Company, Cincinnati, OH.

#1694 3:40 GUIDANCE AND ANIMAL MODEL SELECTIONFOR SAFETY ASSESSMENTS FOR DERMALDRUG PRODUCT DEVELOPMENT ANDAPPROVAL. A. Jacobs1 and G. Qiao2. 1CDER U.S.FDA, Rockville, MD and 2CVM U.S. FDA, Rockville,MD.

Abstracts 1695-1699 moved forward to follow 1642.


PLATFORM SESSION: BIOINFORMATICS: APPLICATIONS TOTOXICOLOGY

Chairperson(s): Kyle Kolaja, Iconix, Mountain View, CA and John Schlager,Wright Patterson, AFB, Wright-Patterson AFB, OH.

#1700 1:30 SUPPORT VECTOR MACHINE ALGORITHMFOR THE PREDICTION OF GENE FUNCTIONUSING A LARGE CHEMOGENOMICREFERENCE DATABASE. G. Natsoulis, M. Fielden,W. Hu, S. Dunlea, B. Eynon and K. Kolaja.Chemogenomics and Toxicology, IconixPharmaceuticals Inc., Mountain View, CA.

#1701 1:50 A MULTIVARIATE DATA ANALYSISTECHNIQUE FROM THE SYNTHESIS OF APRIORI KNOWLEDGE AND EMBEDDEDSTATISTICAL STRUCTURE. P. Wilson. Air ForceResearch Laboratory, Wright-Patterson AFB, OH.Sponsor: J. Schlager.

#1702 2:10 PROBING ALTERATIONS OF THEMITOCHONDRIAL MEMBRANE PROTEOME INA MURINE MODEL OF PARKINSON’S DISEASEUSING LIQUID CHROMATOGRAPHY-TANDEMMASS SPECTROMETRY. D. R. Cawthon1, J. A.Gantt2, M. B. Goshe2, Z. A. Xu1, W. Slikker1 and S. F.Ali1. 1Neurotoxicology, U.S. FDA/NCTR, Jefferson, ARand 2Molecular and Structural Biochemistry, NC StateUniversity, Raleigh, NC.

#1703 2:30 NOVEL NETWORK ANALYSIS FORTOXICOLOGY USING KEYMOLNET. H. Sato, M.Fukuda, M. Shigetaka, N. Iwasaki, Y. Inoue, Y.Kikushima, K. Nakanishi, M. Ogura, Y. Wakamatsu, H.Kuriki, Y. Mizoguchi, R. Taniguchi, T. Nanba, Y. Ozeki,A. Nogi and A. Itai. Bioinformatics, Institute ofMedicinal Molecular Design, Inc. (IMMD), Tokyo,Japan. Sponsor: Y. Aoki.

#1704 2:50 BIOINFORMATICS METHODS FOR LIVERCANCER ANALYSIS USING CROSS SPECIESMAPPING BASED ON RAT GENE EXPRESSIONPROFILING. W. Tong1, H. Fang2, R. Perkins2, L. Shi1,S. H. Yim3, J. M. Ward3 and Y. P. Dragan1. 1SystemsToxicology, National Center for ToxicolologicalResearch, Jefferson, AR, 2Division of Bioinformatics,Z-Tech, NCTR, Jefferson, AR and 3Center for CancerResearch, National Cancer Institiute, Bethesda, MD.

Program Description


WED

NESD

AY


#1705 3:10 ASSESSMENT OF SPECTRAL INTEGRATIONAND NORMALIZATION IN NMR-BASEDMETABONOMIC ANALYSES. B. Webb-Robertson1,D. F. Lowry1, K. H. Jarman1, S. J. Harbo2, Q. R.Meng2, J. G. Pounds1 and K. M. Lee2. 1PacificNorthwest National Laboratory, Richland, WA and2Toxicology Northwest, Battelle Memorial Institute,Richland, WA.

#1706 3:30 THE COMPARATIVE TOXICOGENOMICSDATABASE (CTD). C. Mattingly1, M. Rosenstein1, G.Colby1, J. N. Forrest2,1 and J. L. Boyer2,1. 1MDIBiological Laboratory, Salisbury Cove, ME and 2YaleUniversity School of Medicine, New Haven, CT.Sponsor: W. Toscano.

#1707 3:50 WITHIN- AND BETWEEN-ANIMAL VARIATION,AND REFERENCE RANGES OFHEMATOLOGICAL AND SERUMBIOCHEMICAL PARAMETERS INCYNOMOLGUS MONKEYS. T. Koga1,2, K.Kanefuji2 and R. Nagata3. 1SNBL, Kagoshima, Japan,2The Institute of Statistical Mathematics, Tokyo, Japanand 3SNBL, Tokyo, Japan.

#1708 4:10 THEORETICAL TARGET SEQUENCE FOR THEINTERACTION BETWEEN AFLATOXIN B1 ANDPROTEINS. J. Olivero-Verbel, I. Lans, I. Ospino, R.Vivas, E. Martínez and A. Padilla. Environmental andComputational Chemistry Group, University ofCartagena, Cartagena, Bolivar, Colombia.

#1709 4:30 A DATABASE FOR TRACKINGTOXICOGENOMIC SAMPLES ANDPROCEDURES WITH GENOMIC, PROTEOMICAND METABONOMIC COMPONENTS. W. Bao1,J. Fostel2, M. D. Waters2, B. Merrick2, D. Ekman1, M.Kostich1, J. Schmid1 and D. J. Dix1. 1Office ofResearch and Development, U.S. EPA, ResearchTriangle Park, NC and 2National Center forToxicogenomics, National Institute of EnvironmentalHealth Sciences, Research Triangle Park, NC.


PLATFORM SESSION: HYPERSENSITIVITY I

Chairperson(s): Jean Regal, University of Minnesota, Pharmacology, Duluth,MN and Marsha Ward, U.S. EPA, Environmental Toxicology, Research TrianglePark, NC.

#1710 1:30 INFLUENCE OF PROTEIN ALLERGENS ONDENDRITIC CELL ACTIVATION. S. M. George1,M. Cumberbatch2, C. Portsmouth2, A. Destrument2, R.J. Dearman2, D. Archer1, M. Alcocer1 and I. Kimber2.1School of Biological Sciences, Nottingham University,Nottingham, United Kingdom and 2Immunology,Syngenta CTL, Macclesfield, United Kingdom.

#1711 1:52 CUTANEOUS CYTOKINE SECRETIONPROFILES INDUCED IN MICE FOLLOWINGEXPOSURE TO IRRITANTS OR CHEMICALALLERGENS. M. Cumberbatch, R. J. Dearman and I.Kimber. Immunology, Syngenta CTL, Macclesfield,United Kingdom.

#1712 2:14 VALIDATION OF A MURINE MODEL OFCHEMICAL-INDUCED ASTHMA IN MICE,USING TRIMELLITIC ANHYDRIDE AND 1-CHLORO-2, 4-DINITROBENZENE. J. Vanoirbeek1,M. Tarkowski2, N. Ben1 and P. Hoet1. 1Lab. ofPneumology–Lungtoxicology, K.U.Leuven, Leuven,Belgium and 2Department of Immunotoxicology,Institute of Occupational Medicine, Lodz, Poland.

#1713 2:36 CCL2 KO MICE DEMONSTRATE ENHANCEDTH2 RESPONSES FOLLOWING DERMALSENSITIZATION. L. P. Myers1, P. Simeonova2 and B.J. Meade1. 1Agriculture and Immunotoxicology Group,NIOSH, Morgantown, WV and 2Health EffectsLaboratory Division, NIOSH, Morgantown, WV.

#1714 2:58 DOSE-DEPENDENT INCREASE IN THEPRODUCTION OF NERVE GROWTH FACTOR,NEUROTROPHIN-3, AND NEUROTROPHIN-4 INA PENICILLIUM CHRYSOGENUM-INDUCEDALLERGIC ASTHMA MODEL. Y. Chung1, A.Farraj2, N. H. Coates3, S. H. Gavett3 and M. D. Ward3.1Environmental Sciences and Engineering, UNC/U.S.EPA, Chapel Hill, NC, 2CVM, NCSU, Raleigh, NC and3ORD, NHEERL, U.S. EPA, Research Triangle Park,NC.

#1715 3:20 CYTOKINE, ANTIBODY AND PULMONARYRESPONSES IN BALB/C MICE FOLLOWINGDERMAL EXPOSURE TO SELECTEDDIISOCYANATES. E. H. Boykin1, N. H. Coates1, L.M. Plitnik2, D. L. Doerfler1, S. H. Gavett1 and M. K.Selgrade1. 1ETD, U.S. EPA, Research Triangle Park,NC and 2Merck and Co., Inc., West Point, PA.

#1716 3:42 IN UTERO EXPOSURE TO GENISTEIN (GEN) BYGAVAGE INCREASES IGE AND IGG1PRODUCTION BY ADULT B6C3F1 MICEFOLLOWING TREATMENT WITHRESPIRATORY ALLERGEN TRIMELLITICANHYDRIDE (TMA). T. L. Guo, R. P. Chi, W.Auttachoat, D. M. Hernandez and K. L. White, Jr..Virginia Commonwealth University, Richmond, VA.

#1717 4:04 DIFFERENTIAL EXPRESSION OF ARGINASE INOVALBUMIN (OA) AND TRIMELLITICANHYDRIDE (TMA) INDUCED ASTHMA. J. F.Regal1, A. L. Greene1, R. R. Regal2, M. Rutherford4, C.Giulivi3, G. Flickinger4, J. Hendrickson4 and M.Mohrman1. 1Biochemistry & Molecular Biology,University of Minnesota, Duluth, MN, 2Mathematics &Statistics, University of Minnesota, Duluth, MN,3Molecular Biosciences, University of California-Davis,Davis, CA and 4Veterinary & Biomedical Sciences,University of Minnesota, St. Paul, MN.

Program Description



WED

NES

DAY


PLATFORM SESSION: MOLECULAR MECHANISMS OFOXIDATIVE STRESS

Chairperson(s): Dennis Petersen, University of Colorado, Denver, CO andRamesh Gupta, Murray State University, Hopkinsville, KY.

#1718 1:30 4-HYDROXYNONENAL MODIFICATION OFMOLECULAR CHAPERONES IN A RAT MODELOF CHRONIC ALCOHOLIC LIVER INJURY. D.L. Carbone1, J. A. Doorn2, Z. Kiebler1 and D. R.Petersen1. 1University of Colorado Health SciencesCenter, Denver, CO and 2University of Iowa, Iowa City,IA.

#1719 1:50 TOXICITY ASSESSMENT OF SILVERNANOPARTICLES (AG 15, 100 NM) INALVEOLAR MACROPHAGES. S. Hussain1, K.Hess2, J. M. Gearhart1, K. T. Geiss3 and J. M.Schlager3. 1Mantech Environment Technology, Inc.,Wright-Patterson AFB, Dayton, OH, 2Geo-Centers, Inc.,Wright-Patterson AFB, Dayton, OH and 3HumanEffectiveness Directorate, Wright-Patterson AFB, OH.

#1720 2:10 LIPIDOMIC ANALYSIS OF THE EFFECT OFINHIBITION OF CA2+-INDEPENDENTPHOSPHOLIPASE A2 ON OXIDANT-INDUCEDNEURONAL CELL DEATH. B. Peterson, K. Guthrieand B. S. Cummings. Pharmacology and Biomed.Sciences., University of Georgia, Athens, GA.

#1721 2:30 IDENTIFICATION AND CHARACTERIZATIONOF SMALL MOLECULE ACTIVATORS OF THEANTIOXIDANT RESPONSE ELEMENT. J. T.Kern1, H. Luesch2, P. G. Schultz2,3 and J. A. Johnson1.1University of Wisconsin-Madison, Madison, WI, 2TheScripps Research Institute, La Jolla, CA and 3GenomicsInstitute of the Novartis Research Foundation, SanDiego, CA.

#1722 2:50 PI3 KINASE/AKT, A SURVIVAL PATHWAYAGAINST CYP2E1 DEPENDENT TOXICITY. A. A.Caro and A. I. Cederbaum. Pharmacology andBiological Chemistry, Mount Sinai School of Medicine,New York. Sponsor: D. Petersen.

#1723 3:10 INHIBITION OF HUMAN MITOCHONDRIALALDEHYDE DEHYDROGENASE BY 4-HYDROXYNON-2-ENAL AND 4-OXONON-2-ENAL. J. A. Doorn1, T. D. Hurley2 and D. R.Petersen3. 1Medicinal and Natural Products Chemistry,University of Iowa, Iowa City, IA, 2Biochemistry,Indiana University, Indianapolis, IN and3Pharmaceutical Sciences, University of Colorado,Denver, CO.

#1724 3:30 INDUCTION OF OXIDATIVE STRESS INHUMAN LUNG CELLS BY THE ESTROGENMETABOLITE, 4-METHOXYESTRADIOL. Y. J.Cheng1, P. Lin2 and L. W. Chang1. 1Division ofEnvironmental Health and Occupational Medicine,National Health Research Institutes, Kaoshiung, Taiwanand 2Institute of Toxicology, Chung Shan MedicalUniversity, Taichung, Taiwan.

#1725 3:50 PROTEOMIC IDENTIFICATION OFNONLETHAL OXIDATIVE INJURYBIOMARKERS. L. Xie and Q. M. Chen.Pharmacology, University of Arizona, Tucson, AZ.

#1726 4:10 GR-DEFICIENT MICE (GR1(A1NEU)) ARESUSCEPTIBLE TO DIQUAT-INDUCED HEPATICINJURY. L. K. Rogers, X. Meng, M. S. Augustine, S.E. Welty and C. V. Smith. Center for DevelopmentalPharmacology and Toxicology, Columbus Children’sResearch Institute, Columbus, OH.

Wednesday Afternoon, March 91:30 PM to 4:30 PMExhibit Hall

POSTER SESSION: ENDOCRINE DISRUPTORS

Chairperson(s): Stephen Safe, Texas A&M University, College Station, TXand Tammy Stoker, U.S. EPA, Research Triangle Park, NC.



#1727 CAN THE HERSHBERGER ASSAYSPECIFICALLY DETECT AN ANDROGENIC ORANTI-ANDROGENIC ACTIVITY OFCHEMICAL? -RELATIONSHIP BETWEEN INVITRO AND IN VIVO ASSAYS-. M. Nakai1, S.Noda1, M. Iida2, M. Takeyoshi1, Y. Minobe1, K.Yamasaki1, Y. Yakabe1 and M. Takahashi3. 1ChemicalsEvaluation and Research Institute, Kitakatsushika-gun,Japan, 2Otsuka Pharmceutical Co., Ltd.,, Tokushima,Japan and 3Pathology Peer Review Center, Tokyo,Japan.

#1728 ABILITY OF THE MALE RAT PUBERTAL ASSAYTO DETECT ENVIRONMENTAL CHEMICALSTHAT ALTER THYROID HORMONEHOMEOSTASIS. T. E. Stoker, S. C. Laws, J. M.Ferrell and R. L. Cooper. EB, RTD, NHEERL, ORD,U.S. EPA, Research Triangle Park, NC.

#1729 GENE EXPRESSION PROFILING REVEALSCOMMON TARGETS FOR VARIOUSANDROGEN RECEPTOR ANTAGONISTS INDEVELOPING FETAL RAT TESTIS. X. Mu, K. Liuand K. W. Gaido. CIIT Centers for Health Research,Research Triangle Park, NC.

#1730 APPLICATION OF GENE EXPRESSIONANALYSIS OF MANNOSE 6-PHOSPHATE/INSULIN-LIKE GROWTHFACTOR-II RECEPTOR (M6P/IGF2R) INVENTRAL PROSTATE FOR SCREENING OFCHEMICALS WITH ANDROGEN-MEDIATEDACTIVITIES IN THE RAT HERSHBERGERASSAY. T. Yamada, K. Bando, S. Kawamura, Y. Okunoand T. Seki. Environmental Health Science Laboratory,Sumitomo Chemical Company, Ltd.,, Osaka, Japan.

#1731 EFFECTS OF AN ANTIANDROGEN ONPROTEIN AND GENE PROFILES IN ADULT RATTESTES. C. Friry-Santini1,3, P. Kennel1, D. Rouquie1,M. Samson2, M. Benhamed3 and R. Bars1. 1ResearchCenter, Bayer CropScience, Sophia Antipolis, France,2Unit 638, INSERM, Nice, France and 3Unit 407,INSERM, Oullins, France. Sponsor: N. Carmichael.

Program Description


WED

NESD

AY


#1732 PROTEIN PROFILING OF ANTIANDROGENEFFECTS IN THE ADULT RAT VENTRALPROSTATE. C. Cayatte1,3, C. Pons1, J. Guigonis2, P.Kennel3, D. Rouquie3, R. Bars3, B. Rossi1 and M.Samson1. 1Unit 638, INSERM, Nice, France, 2IFR50Proteomic platform, INSERM, Nice, France and3Research Center, Bayer CropScience, Sophia-Antipolis, France. Sponsor: N. Carmichael.

#1733 THE ENDOCRINE PROFILE OF INTACTFEMALE RATS ON THE DAY OF PROESTRUSFOLLOWING EXPOSURE TO ATRAZINE. R. L.Cooper, A. Buckalew, S. C. Laws and T. E. Stoker.RTD, NHEERL, ORD, U.S. EPA, Research TrianglePark, NC.

#1734 ESTROGENICITY OF MIXTURES OFCHEMICALS ON UTERINE GROWTH OFPREPUBERAL RATS. J. V. Meeuwen1, A. Piersma2,M. van den Berg1 and J. Sanderson1. 1Biotoxicology,IRAS, Utrecht, Netherlands and 2RIVM, Bilthoven,Utrecht, Netherlands.

#1735 MOLECULAR CHARACTERIZATION OF THEUTEROTROPHIC ASSAY: TEMPORAL GENEEXPRESSION CHANGES IN THE UTERUSFOLLOWING ETHINYLESTRADIOL. H. J. Ahr,H. Ellinger-Ziegelbauer, A. Freyberger, E. Hartmann, A.Mahringer and F. Kroetlinger. Molecular and GeneticToxicology, Bayerhealthcare AG, Wuppertal, Germany.

#1736 COMPARATIVE GENE EXPRESSION ANALYSISOF THE MOLECULAR EFFECTS OFSYNTHETIC, PLANT-DERIVED ANDPHYSIOLOGICAL ESTROGENS IN THEIMMATURE RODENT UTERUS. J. G. Moggs, H.Tinwell, F. Lim, M. J. David, I. Kimber, J. Ashby andO. George. Syngenta CTL, Macclesfield, Cheshire,United Kingdom.

#1737 ESTRADIOL PROTECTS AGAINST ETHANOL-INDUCED BONE LOSS IN FEMALE RATS BYPREVENTING OSTEOCLAST ACTIVATION. R.Haley2, M. Hidestrand1,2, K. Shankar1,2, C. K.Lumpkin3, B. Yarberry2, T. M. Badger4,2 and M. J.Ronis1,2. 1Pharmacology & Toxicology, University ofArkansas for Medical Sciences, Little Rock, AR,2Arkansas Children’s Nutrition Center, Little Rock, AR,3Pediatrics, University of Arkansas for MedicalSciences, Little Rock, AR and 4Physiology &Biophysics, University of Arkansas for MedicalSciences, Little Rock, AR.

#1738 ONTOGENY OF P-GLYCOPROTEIN (PGP) INSELECTED TISSUES OF NEONATAL MALE ANDFEMALE CD-1 MICE. S. Yavanhxay1, M. Christian2,A. Hoberman2, J. C. Eldridge1 and J. T. Stevens1.1Physiology and Pharmacology, Wake Forest UniversitySchool of Medicine, Winston-Salem, NC and 2CharlesRivers Labs, Horsham, PA.

#1739 TRANSCRIPT PROFILING OF GENEEXPRESSION CHANGES ASSOCIATED WITHAN INCREASED INCIDENCE OF CANCERAFTER EXPOSURE OF NEONATAL MICE TOXENOESTROGENS. D. J. Moore, F. Lim, H. Tinwell,I. Kimber, J. Ashby, G. Orphanides and J. Moggs.Syngenta CTL, Macclesfield, Cheshire, UnitedKingdom.

#1740 THYROID HORMONE STATUS IN ADULTFEMALE RATS AFTER AN ORAL DOSE OFPERFLUOROOCTANESULFONATE (PFOS). J.Butenhoff1, M. Eastvold2, J. Bjork3, D. Ehresman1, R.Singh2, K. Wallace3 and S. Tanaka1. 13M Company, St.Paul, MN, 2Mayo Medical Laboratories, Rochester, MNand 3University of Minnesota, Duluth, MN.

#1741 THE EFFECTS OF POLYCHLORINATEDBIPHENYLS ON THYROID HORMONERECEPTOR MEDIATED ACTION IN VIVO ANDIN VITRO. K. J. Gauger, S. Giera and R. Zoeller.Biology Department, Program in Molecular andCellular Biology, University of Massachusetts, Amherst,MA.

#1742 COMPARISON OF INHIBITORY EFFECTS OFETHANOL AND METHYL T-BUTYL ETHER(MTBE) ON RAT LEYDIG CELLTESTOSTERONE PRODUCTION. R. Shuto, B. B.Goldberg and A. de Peyster. Graduate School of PublicHealth, San Diego State University, San Diego, CA.

#1743 CHANGES IN FETAL TESTIS GENEEXPRESSION AND STEROID HORMONESYNTHESIS INDUCED IN MALE OFFSPRINGAFTER MATERNAL TREATMENT WITH DEHP(DI-N-ETHYLHEXYL PHTHALATE). V. S. Wilson1,C. Lambright1, J. Furr1, K. Bobseine1, C. Wood1, K.Hosdeshell2 and L. E. Gray1. 1Reproductive ToxicologyDivision, U.S. EPA, ORD, NHEERL, Research TrianglePark, NC and 2NC State University, Raleigh, NC.

#1744 MECHANISM OF PHTHALATE-INDUCEDDEVELOPMENTAL REPRODUCTIVETOXICITY: INHIBITION OF TESTOSTERONEAND INSULIN-LIKE 3 HORMONEPRODUCTION BY FETAL LEYDIG CELLS. L. E.Gray, N. Noriega, C. Lambright, J. Furr and V. S.Wilson. ORD, NHEERL, RTD, EB, U.S. EPA, ResearchTriangle Park, NC.

#1745 REPRODUCTIVE SUCCESS AND AROMATASEACTIVITY IN THE FISH CUNNER(TAUTOGOLABRUS ADSPERSUS) EXPOSED TOATRAZINE OR OCTYLPHENOL IN THELABORATORY. L. J. Mills1, R. E. Gutjahr-Gobell1, S.C. Laws2, D. Borsay Horowitz1 and G. E. Zaroogian1.1U.S. EPA, NHEERL, Atlantic Ecology Division,Narragansett, RI and 2U.S. EPA, NHEERL,Reproductive Toxicology Division, Research TrianglePark, NC.

#1746 AROMATASE INHIBITION: LINKINGBIOCHEMICAL MECHANISM OF ACTION TOOUTCOME IN THE SHORT-TERM FATHEADMINNOW REPRODUCTION ASSAY. D. L.Villeneuve, K. M. Jensen, M. D. Kahl, E. J. Durhan, E.A. Makynen, A. L. Linnum, B. C. Butterworth and G. T.Ankley. Mid-Continent Ecology Division, U.S. EPA,Duluth, MN. Sponsor: J. Mata.

Program Description



WED

NES

DAY

#1747 EFFECTS OF VARIOUS LACTONE-DERIVATIVES ON AROMATASE (CYP19)ACTIVITY IN H295R HUMANADRENOCORTICAL CARCINOMA CELLS AND(ANTI)ANDROGENICITY IN TRANSFECTEDLNCAP HUMAN PROSTATE CANCER CELLS. T.Sanderson1, S. Nijmeijer1, D. Scholten1, M. van denBerg1, S. Cowell2, E. Guns2, C. Nelson2 and S.Ruchirawat3. 1Institute for Risk Assessment Sciences,Utrecht University, Utrecht, NL, Netherlands, 2TheProstate Centre, Vancouver General Hospital,Vancouver, BC, Canada and 3Laboratory of MedicinalChemistry, Chulabhorn Research Institute, Bangkok,Thailand.

#1748 IN VITRO EFFECTS OF BROMINATED FLAMERETARDANTS ON THE ADRENOCORTICALENZYME CYP17. A NOVEL ENDOCRINEMECHANISM OF ACTION? R. Fernandez Canton1,T. Sanderson1, S. Nijmeijer1, A. Bergman2 and M. vanden Berg1. 1Institute for Risk Assessment Sciences,IRAS, Utrecht, Netherlands and 2Department ofEnvironmental Chemistry and Analytical Chemistry.Stockholm University, Stockholm, Sweden.

#1749 ESTROGENIC ACTIVITY OF THEPOLYBROMINATED DIPHENYL ETHERSFLAME RETARDANTS. M. Mercado Feliciano1 andR. M. Bigsby2. 1Pharmacology and Toxicology, IndianaUniversity School of Medicine, Indianapolis, IN and2Obstetrics and Gynecology, Indiana University Schoolof Medicine, Indianapolis, IN. Sponsor: L. Kamendulis.

#1750 SCREENING ASSAYS FOR ANDROGENICACTIVITIES OF XENOBIOTICS. S. O. Mueller andS. Simon. Toxicology, Merck KGaA, Darmstadt,Germany.

#1751 EVALUATION OF POTENTIAL ESTROGENICAND ANDROGENIC ACTIVITY OFOCTAMETHYLCYCLOTETRASILOXANE (D4)AND DECAMETHYLCYCLOPENTASILOXANE(D5). A. L. Quinn, S. D. Crofoot, J. M. Tobin, J. M.Regan, J. M. McMahon and K. P. Plotzke. Dow CorningCorporation, Midland, MI.

#1752 ESTROGENIC ENDOCRINE DISRUPTORPOTENCY OF ORGANOCHLORINEPESTICIDES DETECTED USING THE LUMI-CELLTM ER BIOASSAY. J. D. Gordon1, A. C. Chu1,M. D. Chu2, M. S. Denison3 and G. C. Clark1.1Xenobiotic Detection Systems, Inc., Durham, NC,2Alta Analytical PerspectivesInc., Wilmington, NC and3Department of Environmental Toxicology, Universityof California, Davis, Davis, CA.

#1753 SENSITIVE METHOD FOR DETERMININGPESTICIDE ESTROGENIETY AT PICOMOLARLEVELS USING A SERUM-FREE BG-1 OVARIANCELL MODEL. P. Wong and F. Matsumura. Ctr forHealth and the Environment, UC Davis, Davis, CA.

#1754 GENE EXPRESSION PATTERNS OF THEAMPHIBIAN HPT-AXIS IN NORMALDEVELOPMENT AND AFTER EXPOSURE TOTHE MODULATORS METHIMAZOLE,PERCHLORATE AND PROPYLTHIOURACIL. J.J. Korte, H. M. Kerr, S. L. Batterman, G. W. Holcombe,P. A. Kosian, J. E. Tietge and S. J. Degitz. MED,NHEERL, ORD, U.S. EPA, Duluth, MN. Sponsor: J.Nichols.

#1755 PROTEIN PROFILING OF XENOPUS LAEVISBRAIN CELLS FOLLOWING EXPOSURE TO T4SYNTHESIS INHIBITORS: POTENTIALAPPLICATION TO THEASSESSMENT/DIAGNOSIS OF XENOBIOTICSTHAT PERTURB THE THYROID PATHWAY. J.Serrano1, B. Witthuhn2, L. Higgings2, J. Tietge1, J.Korte1, P. Kosian1, G. Holcombe1 and S. Degitz1.1ORD/NHEERL/MED, U.S. EPA, Duluth, MN and2Biochemistry and Molecular Biology, University ofMinnesota, St. Paul, MN. Sponsor: J. Nichols.

#1756 PHENOBARBITAL AFFECTS THYROIDHISTOLOGY AND LARVAL DEVELOPMENT INTHE AFRICAN CLAWED FROG, XENOPUSLAEVIS. M. J. Chowdhury, G. W. Holcombe, P. A.Kosian, J. E. Tietge and S. J. Degitz. Mid-ContinentEcology Division, U.S. EPA, Duluth, MN. Sponsor: J.Nichols.

#1757 SUBLETHAL EFFECTS OF CADMIUM ONDEVELOPMENT IN RANA PIPIENS ANDXENOPUS TROPICALIS. J. A. Gross1,2, T. Chen2 andW. H. Karasov2. 1Animal Sciences, University ofWisconsin–Madison, Madison, WI and 2WildlifeEcology, University of Wisconsin–Madison, Madison,WI.

#1758 MECHANISMS OF GERMINAL VESICLEBREAKDOWN (GVBD) INHIBITION BYPHENYL-SUBSTITUTED GLYCOL ETHERS INXENOPUS OOCYTES IN VITRO. D. J. Fort1, R. L.Rogers1, J. H. Thomas1, P. D. Guiney2 and J. A. Weeks2.1Fort Environmental Laboratories, Stillwater, OK and2Product Safety & Environmental Assessment, SCJohnson & Son, Racine, WI.

#1759 NON-ADDITIVE DOSE DEPENDENT GENEEXPRESSION PATTERNS EXHIBITED BY AMIXTURE OF 17-ALPHA ETHYNYLESTRADIOLAND GENISTEIN IN VIVO. R. Gupta2,3,4, L. D.Burgoon1,3,4, A. Harney2,3,4, D. R. Boverhof2,3,4, J.Kwekel2,3,4, C. Gennings5 and T. R. Zacharewki2,3,4.1Pharmacology & Toxicology, Michigan StateUniversity, East Lansing, MI, 2Biochemistry &Molecular Biology, Michigan State University, EastLansing, MI, 3Center for Integrative Toxicology,Michigan State University, East Lansing, MI, 4NationalFood Safety & Toxicology Center, Michigan StateUniversity, East Lansing, MI and 5Biostatistics, VirginiaCommonwealth University, Richmond, VA.

Program Description


WED

NESD

AY



POSTER SESSION: STEROID RECEPTORS

Chairperson(s): Timothy Zacharewski, Michigan State University, EastLansing, MI.



#1760 TEMPORAL GENE EXPRESSION ANALYSIS OFMOUSE HEPA-1C1C7 CELLS TREATED WITH17ββ-ESTRADIOL BY CDNA MICROARRAY. C. J.Fong, L. D. Burgoon, R. Gupta, D. G. Humes and T. R.Zacharewski. Biochemistry and Molecular Biology,Michigan State University, East Lansing, MI.

#1761 CONSTITUTIVE ANDROSTANE RECEPTOR(CAR)-DEPENDENT HEPATIC INDUCTION OFUDP-GLUCURONOSYLTRANSFERASES (UGTS)IN WISTAR-KYOTO RATS BY CYP2BINDUCERS. M. K. Shelby1, A. L. Slitt1, N. J.Cherrington2 and C. D. Klaassen1. 1University ofKansas Medical Center, Kansas City, KS and2University of Arizona, Tucson, AZ.

#1762 HEPATIC INDUCTION OF MOUSE UDP-GLUCURONOSYLTRANSFERASE (UGT) MNRAEXPRESSION BY PROTOTYPICALACTIVATORS OF VARIOUS TRANSCRIPTIONPATHWAYS. D. B. Buckley, J. S. Petrick and C. D.Klaassen. University of Kansas Medical Center, KansasCity, KS.

#1763 INDUCIBILITY OF MOUSE TRANSCRIPTIONFACTORS THAT REGULATE HEPATICMETABOLISM AND TRANSPORT. J. S. Petrick, D.B. Buckley and C. D. Klaassen. University of KansasMedical Center, Kansas City, KS.

#1764 VITAMIN D-INTERACTING PROTEIN 150(DRIP150) COACTIVATION OF ESTROGENRECEPTOR αα (ERαα) IN ZR-75 BREAST CANCERCELLS IS INDEPENDENT OF LXXLL MOTIFS. J.Lee1, K. Kim1 and S. Safe1,2. 1Veterinary Physiology &Pharmacology, Texas A&M University, College Station,TX and 2Institute of Biosciences & Technology, TexasA&M University System Health Science Center,Houston, TX.

#1765 GLUCOCORTICOID RECEPTOR AND STEROIDAND XENOBIOTIC RECEPTOR (SXR)REGULATION OF SXR PROMOTER ACTIVITY.L. M. Tompkins and A. D. Wallace. Environmental andMolecular Toxicology, North Carolina State University,Raleigh, NC.

#1766 HEPATOCYTE RXRALPHA REGULATES THEEXPRESSION OF THE GLUTATHIONE S-TRANSFERASE GENES AND MODULATESACETAMINOPHEN-GLUTATHIONECONJUGATION IN MOUSE LIVER. Y. Y. Wan, N.Chou, L. He, M. Gyamfi, A. J. Mendy and G. Dai.Pharmacology, Toxicology and Therapeutics, Universityof Kansas Medical Center, Kansas City, KS.

#1767 P38 MITOGEN-ACTIVATED PROTEIN KINASEIS INVOLVED IN CONSTITUTIVEANDROSTANE RECEPTOR SIGNALING TOREGULATE CYP2B INDUCTION BYXENOBIOTICS. F. Zhang, H. B. Hoffman and L. You.CIIT, Research Triangle Park, NC.

#1768 EVIDENCE FOR CAR-DEPENDENTHEPATOCELLULAR PROLIFERATION INTCPOBOP-TREATED CONSTITUTIVEANDROSTANE RECEPTOR KNOCKOUT (CAR-/-

) MICE. D. M. Nelson, V. Bhaskaran, B. Gemzik, B. D.Car and L. D. Lehman-McKeeman. DiscoveryToxicology, Bristol-Myers Squibb, Princeton, NJ.

#1769 EFFECTS OF 2, 2’, 4, 4, ‘-TETRABROMODIPHENYL ETHER ON CARAND PXR REGULATED GENE EXPRESSION INWEANLING FEMALE RATS. V. M. Richardson1, K.M. Crofton2,1 and M. J. DeVito1.1ORD/NHEERL/ETD/PKB, U.S. EPA, ResearchTriangle Park, NC and 2ORD/NHEERL/ETD/NTD,U.S. EPA, Research Triangle Park, NC.

#1770 TRANSCRIPTIONAL ACTIVATION OFCREATINE KINASE GENE EXPRESSION BYINSULIN-LIKE GROWTH FACTOR (IGF-I). F.Wang1 and S. Safe2. 1OB/GYN, The State University ofNew York, Buffalo, NY and 2Veterinary Physiology &Pharmacology, Texas A&M University, College Station,TX.

#1771 ANALYSIS OF GENE EXPRESSION DURINGUTERINE INDUCTION AND REGRESSION INIMMATURE, OVARIECTOMIZED RATSFOLLOWING TREATMENT WITH ETHYNYLESTRADIOL. J. C. Kwekel, H. A. Dalgleish, L. D.Burgoon, J. R. Harkema and T. R. Zacharewski.Department of Biochemistry and Molecular Biology,National Food Safety and Toxicology Center, Center forIntegrative Toxicology, Michigan State University, EastLansing, MI.

#1772 EFFECTS OF ESTROGEN ON IMMATURE,OVARIECTOMIZED MICE: A MULTI-APPROACH, TISSUE-BY-TISSUE COMPARISON.J. W. Burt1,2, L. D. Burgoon2, D. G. Humes1, J. C.Kwekel1,2, A. S. Harney1, J. R. Harkema3 and T. R.Zacharewski1,2. 1Biochemistry & Molecular Biology,Michigan State University, East Lansing, MI, 2Centerfor Integrative Toxicology, Michigan State University,East Lansing, MI and 3Pathobiology & DiagnosticInvestigation, Michigan State University, East Lansing,MI.

#1773 REGULATION OF TRANSCRIPTIONALACTIVATION OF LARGEMOUTH BASSESTROGEN RECEPTORS ALPHA, BETA 1 ANDBETA 2 BY ESTRADIOL AND THECONTAMINANTS NONYLPHENOL ANDMETHOXYCHLOR IN HEPG2 CELLS. N.Denslow1, J. Blum1 and T. Sabo-Attwood2. 1Universityof Florida, Gainesville, FL and 2University of Vermont,Burlington, VT.

Program Description



WED

NES

DAY

#1774 ESTROGEN INFLUENCES THE GROWTH OFCELLS THROUGH MODULATING THEINTRACELLULAR REDOX STATE. Q. Felty andD. Roy. Environmental & Occupational Health, FloridaInternational University, Miami, FL.

#1775 THE EFFECT OF POLYCHLORINATEDBIPHENYLS (PCBs) ON THYROID HORMONERECEPTOR (TR) AND CO-REGULATORINTERACTIONS ON DNA. S. You1, K. Gauger1 andR. Zoeller2,1. 1Molecular & Cellular Biology Program,University of Massachusetts, Amherst, MA and2Biology, University of Massachusetts, Amherst, MA.


POSTER SESSION: PHARMACEUTICALS-METABOLIC/CANCER

Chairperson(s): Thomas Mably, Bristol Meyers Squibb Co, Evansville, IN.



#1776 GENETIC TOXICOLOGY AND BONE MARROWCYTOTOXICITY STUDIES OF THECORTICOTROPIN-RELEASING HORMONE(CRH) RECEPTOR ANTAGONIST,ANTALARMIN. P. T. Curry1, M. Nagabhushan1, D. L.McCormick1, R. E. Parchment2, K. Calis3, P. W. Gold3,G. Cizza3, D. Charney3, E. R. Glaze4 and J. E.Tomaszewski4. 1IIT Research Institute, Chicago, IL,2SciTech Development LLC, Grosse Pointe, MI,3National Institute of Mental Health, Bethesda, MD and4National Cancer Institute, Bethesda, MD.

#1777 SUBCHRONIC ORAL TOXICITY OF THECORTICOTROPIN-RELEASING HORMONE(CRH) RECEPTOR ANTAGONIST,ANTALARMIN, IN DOGS. W. D. Johnson1, J.Harder1, D. L. McCormick1, R. L. Morrissey2, K.Calis3, P. W. Gold3, G. Cizza3, D. Charney3, E. R.Glaze4 and J. E. Tomaszewski4. 1IIT Research Institute,Chicago, IL, 2Pathology Associates, Chicago, IL,3National Institute of Mental Health, Bethesda, MD and4National Cancer Institute, Bethesda, MD.

#1778 SUBCHRONIC ORAL TOXICITY OF THECORTICOTROPIN-RELEASING HORMONE(CRH) RECEPTOR ANTAGONIST,ANTALARMIN, IN RATS. T. L. Horn1, W. D.Johnson1, D. L. McCormick1, R. L. Morrissey2, K.Calis3, P. W. Gold3, G. Cizza3, D. Charney3, E. R.Glaze4 and J. E. Tomaszewski4. 1IIT Research Institute,Chicago, IL, 2Pathology Associates, Chicago, IL,3National Institute of Mental Health, Bethesda, MD and4National Cancer Institute, Bethesda, MD.

#1779 CYPROHEPTADINE AND CYCLIZINE INHIBITINSULIN SECRETION IN RIN5F CELLS BYINHIBITING CALCIUM CHANNELS. M. Otieno1, N.Bavuso1, A. Katein1, T. Kelly1, J. Milano1 and F.Pognan2. 1Safety Assessment US, AstraZenecaPharmaceuticals, Wilmington, DE and 2SafetyAssessment UK, AstraZeneca Pharmaceuticals, AlderlyPark, United Kingdom.

#1780 REPEAT DOSE TOXICITY STUDIES IN RATSAND DOGS WITH TH0318, A DPP IV-RESISTANTANALOG OF NATURAL GLP-1. S. Fennell1, H.Loughrey1, M. Garino1, S. Abdullah1, M. Stilianesis2,K. Arjah2, B. Vu2 and E. Ferdinandi1.1Theratechnologies, Inc., Saint Laurent (Montreal), QC,Canada and 2CTBR Bio-Research Inc., Senneville, QC,Canada. Sponsor: C. Banks.

#1781 CARCINOGENICITY EVALUATION OFATAZANAVIR IN MICE. T. A. Mably1, T. P.Sanderson1, C. D. Houle2, B. E. Schilling1 and M. A.Dominick1. 1Drug Safety Evaluation, Bristol-MyersSquibb Co., Mt.Vernon, IN and 2ExperimentalPathology Laboratories, Inc., Research Triangle Park,NC.

#1782 MULTIPLE DOSE TOXICITY STUDY OFIMEXON IN FISCHER 344 RATS. Y. Chen1, E.Glaze2, J. Tomaszewski2, R. Morrissey3 and A.Lyubimov1. 1Toxicology Research Laboratory,University of Illinois at Chicago, Chicago, IL, 2Divisionof Cancer Treatment and Diagnosis, National CancerInstitute, Bethesda, MD and 3Pathology AssociatesDivision, Charles River Laboratories, Chicago, IL.

#1783 SEQUENCE DEPENDENT ANTAGONISMBETWEEN RALOXIFENE, 5-FLUOROURACILAND PEMETREXED. E. Fryar1, D. H. Jillian1, S. M.William2 and B. Donnell1. 1Pharmacology, HowardUniversity, Washington, DC and 2Biochemistry, HowardUniversity, Washington, DC.

#1784 UTILIZATION OF MULTIPLE ENDPOINTS TOINVESTIGATE DIFFERENTIAL TOXICITYPRODUCED BY TOPOISOMERASE IIINHIBITORS, DOXORUBICIN AND ETOPOSIDE.R. T. Dunn, E. S. Galambos, L. Healy, R. Morgan, J.Yamada, H. Hamadeh, A. Kwok, M. E. Cosenza and C.Afshari. Toxicology, Amgen Inc., Thousand Oaks, CA.

#1785 ORAL TOXICITY STUDY OF A RETINOIC ACIDANALOGUE, 9-CIS-UAB-30, IN RATS. R.Krishnaraj1, A. Lyubimov1, C. Detrisac2, I.Kapetanovic3, J. Crowell3, W. Brouillette4 and D.Muccio4. 1Pharmacology, University of Illinois atChicago, Chciago, IL, 2Pathology Associates, Chciago,IL, 3National Cancer Institute, Bethesda, MD and4Chemistry, University of Alabama at Birmingham,Birmingham, AL.

Program Description


WED

NESD

AY



POSTER SESSION: MECHANISMS OF CARCINOGENESIS

Chairperson(s): Michael A. Pereira, Ohio State University, Columbus, OHand Mark S. Miller, Wake Forest University School of Medicine, WinstonSalem, NC.



#1786 CHANGES IN THE METHYLATION STATUS OFGC-RICH REGIONS OF DNA DURING THEPROMOTION STAGE OF SKINTUMORIGENESIS. A. N. Carnell-Bachman1, G. M.Curtin2, D. J. Doolittle2 and J. I. Goodman1.1Pharmacology and Toxicology, Michigan StateUniversity, East Lansing, MI and 2Research andDevelopment, R. J. Reynolds Tobacco Company,Winston-Salem, NC.

#1787 DIETHANOLAMINE (DEA) ANDPHENOBARBITAL (PB) PRODUCE AN ALTEREDPATTERN OF METHYLATION IN GC-RICHREGIONS OF DNA IN B6C3F1 MOUSEHEPATOCYTES SIMILAR TO THAT RESULTINGFROM CHOLINE DEFICIENCY. J. I. Goodman1, L.M. Kamendulis2 and A. N. Carnell-Bachman1.1Pharmacology and Toxicology, Michigan StateUniversity, East Lansing, MI and 2Pharmacology andToxicology, Indiana University School of Medicine,Indianapolis, IN.

#1788 DNA HYPOMETHYLATION INDUCED BYDRINKING WATER DISINFECTION BY-PRODUCTS IN MOUSE AND RAT KIDNEY. L.Tao1, W. Wang1, P. M. Kramer2, L. Li2 and M. A.Pereira1,2. 1Internal Medicine, Ohio State University,Columbus, OH and 2Molecular Biology andBiochemistry, Medical College of Ohio, Toledo, OH.

#1789 LOSS OF HISTONE ACETYLATION BY NICKEL:AN EPIGENETIC MECHANISM OF NICKELCARCINOGENESIS. Q. ke, T. Kluz and M. Costa.Department of Environmental Health, New YorkUniversity School of Medicine, Nelson Institute,Tuxedo, NY.

#1790 SEXUAL DIMORPHISM IN DNA METHYLATIONIN THE LIVER OF HEXACHLOROBENZENE-TREATED RAT : A POSSIBLE MECHANISMFOR TUMOR PROMOTION. N. J. Raynal, M.Charbonneau, B. Alt, L. Lee and D. G. Cyr. INRS-Institut Armand-Frappier, Universite du Quebec, Pointe-Claire, QC, Canada.

#1791 LOSS OF BRG1 AND LUNG CANCERPATHOGENESIS. C. Bartlett1, G. Rosson2 and B.Weissman2,1. 1Curriculum in Toxicology, UNC-CH,Chapel Hill, NC and 2Pathology and LaboratoryMedicine, UNC-CH, Chapel Hill, NC. Sponsor: C.Harper.

#1792 SECONDARY GENETIC ALTERATIONS INLUNG TUMORS POSSESSING A PRIMARY KI-RAS MUTATION. H. S. Floyd1, J. Jennings-Gee1, N.D. Kock2 and M. S. Miller1. 1Cancer Biology, WakeForest University, Winston-Salem, NC and2Comparative Medicine, Wake Forest University,Winston-Salem, NC.

#1793 COMPARISON OF EXPRESSION PROFILES OFENU-INDUCED FORESTOMACH TUMORS ANDURETHANE-INDUCED LUNG TUMORS INRASH2 MICE. M. Okamura1, A. Unami2, Y. Oishi2, K.Sumida3, Y. Kashida1, N. Machida1 and K. Mitsumori1.1Tokyo university of agriculture and technology, Tokyo,Japan, 2Toxicology Research Laboratories, FujisawaPharmaceutical Co., Ltd.,, Osaka, Japan and3Environmental Health Science Laboratory, SumitomoChemical Co., Ltd.,, Osaka, Japan. Sponsor: M.Takahashi.

#1794 CYTOCHROME P4502E1 (CYP2E1) MEDIATEDMETABOLISM IS A PRE-REQUISITE FOR THEPATHOGENESIS OF URETHANE-INDUCEDGENOTOXICITY AND CARCINOGENICITY. U.Hoffler1,2, D. Dixon2, S. Peddada2 and B. I.Ghanayem2,1. 1Department of Pharmacology, MeharryMedical College, Nashville, TN and 2NIEHS/NIH,Research Triangle Park, NC.

#1795 EFFECTS OF AFB1 ON EXPRESSION OF P53AND MDM2 AND ON APOPTOSIS IN HUMANLUNG CELLS. T. L. Watterson1, T. R. Van Vleet2 andR. A. Coulombe1. 1Toxicology Graduate Program, UtahState University, Logan, UT and 2Drug SafetyEvaluation, Bristol-Myers Squibb Company, Mt.Vernon, IN.

#1796 NOVEL LAVENDAMYCINS AND AB RINGSYSTEM ANALOGUES: IN VITROCYTOTOXICITY, APOPTOSIS INDUCTION ANDMETABOLISM BY NAD(P)H:QUINONEOXIDOREDUCTASE 1 (NQO1). M. Hassani1, W.Cai2, K. C. Bray1, M. Behforouz2 and H. D. Beall1.1Center for Environmental Health Sciences, TheUniversity of Montana, Missoula, MT and 2Departmentof Chemistry, Ball State University, Muncie, IN.

#1797 HIGH PERFORMANCE LIQUIDCHROMATOGRAPHY ASSAY FOR N-GLUCURONIDATION 4-AMINOBIPHENYL INMICE LIVER MICROSOMES AND EXPRESSEDHUMAN SUPERSOMES. M. H. Al-Zoughool.Environmental Health, University of Cincinanti,Cincinnati, OH.

#1798 URINARY BLADDER ENDPOINTS IN WORKERSAND RATS EXPOSED TOPERFLUOROOCTANESULFONYL FLUORIDE(POSF) AND RELATED COMPOUNDS. G. Olsen1,B. Alexander2, S. Cohen3 and J. Butenhoff1. 13MCompany, St. Paul, MN, 2University of Minnesota,Minneapolis, MN and 3University of Nebraska Med.Ctr., Omaha, NE.

Program Description



WED

NES

DAY

#1799 DNA DAMAGE AND CYTOGENETIC EFFECTSOF OCHRATOXIN A IN RATS IN VIVO. A. Mally1,G. Pepe2, S. Ravoori3, M. Fiore2, R. C. Gupta3, P.Mosesso2 and W. Dekant1. 1Department of Toxicology,University of Wuerzburg, Wuerzburg, Germany,2Dipartimento die Agrobiologia e Agrochimica,Universita degli Studi della Tuscia, Viterbo, Italy and3Pharmacology&Toxicology, Brown Cancer Center,University of Louisville, Louisville, KY.

#1800 αα2U-GLOBULIN AND RENAL TUMORS INNATIONAL TOXICOLOGY PROGRAM (NTP)STUDIES. A. M. Doi, G. D. Hill, J. R. Hailey and J. R.Bucher. NTP, NIEHS, Research Triangle Park, NC.

#1801 THE TSC-2 TUMOR SUPPRESSOR GENEMODULATES MULTIPLE CELLPROLIFERATION PATHWAYS. M. T. Labenski1, X.Wei1, A. Hunt1, G. Tsaprailis1, M. S. Chacko2, M. D.Person2, J. Shen2, S. C. Hensley3, T. J. Monks1 and S. S.Lau1. 1Pharmacology and Toxicology, University ofArizona, Tucson, AZ, 2Pharmacology and Toxicology,University of Texas at Austin, Austin, TX and3UTMDACC, Science Park, Smithville, TX.

#1802 GLOBAL EXPRESSION PROFILING OF MALERAT KIDNEY: CO-ADMINISTRATION OF ASPECIFIC ESTROGEN RECEPTOR (ER)ANTAGONIST INHIBITS A DYNAMIC 17B-ESTRADIOL (E2) RESPONSE. P. H. Koza-Taylor1,G. D. Cappon4, J. D. Obourn3, J. C. Cook2 and M. P.Lawton1. 1MIT, Pfizer, Groton, CT, 2FD & LS, Pfizer,Groton, CT, 3ED, Pfizer, Groton, CT and 4ToxicologySciences, Pfizer, Groton, CT.

#1803 APOPTOSIS, SENESCENCE ANDCYTODIFFERENTIATION IN CARCINOGENICMODELING. N. H. Chiu4, G. Merlino2, K. H. Kim3,C. J. Kermp3 and J. Beaubier5. 1NCEADC, U.S. EPA,Washington, DC, 2Lab. Molecular Biology, NationalCancer Institute, Bethesda, MD, 3Division Human Biol,Public Health Sciences, Fred Hutchinson CancerResearch Center, Seattle, WA, 4Office ScienceTechnology Office of Water, U.S. EPA, Washington, DCand 5Office Pesticide Pollution Prevention Toxics, U.S.EPA, Washington, DC. Sponsor: D. Singh.

#1804 NUMBER OF CRITICAL CELL-CYCLE-EVENTSIN CANCER DEVELOPMENT OF P53-P27 KOMICE. N. Chiu3, K. H. Kim2, C. Kemp2 and J.Beaubier4. 1NCEADC, U.S. EPA, Washington DC, DC,2Division Human Biology Public Health Sciences, FredHutchindon Cancer Research Center, Seattle, WA,3Office Science & Technology, Office of Water, U.S.EPA, Washington, DC and 4Office Pollution Preventionand Toxics, U.S. EPA, Washington, DC. Sponsor: D.Singh.

#1805 ARNT, A PUTATIVE COACTIVATOR OF C-MYC/MAX SIGNALING PATHWAY, INTERACTSWITH C-MYC. R. wu, M. Hoagland and H. Swanson.University of Kentucky, Lexington, KY.

#1806 A POTENTIAL ROLE FOR C-MYB, BAX ANDTHE ARYL HYDROCARBON RECEPTOR INBENZENE-INITIATED TOXICITY. H. J. Badham1

and L. M. Winn1,2. 1Pharmacology and Toxicology,Queen’s University, Kingston, ON, Canada and 2Schoolof Environmental Studies, Queen’s University,Kingston, ON, Canada.

#1807 THE ESTROGENIC ACTIVITIES OF ARYLHYDROCARBON RECEPTOR AGONISTS AREDUE TO DIRECT ACTIVATION OF ESTROGENRECEPTOR αα M. Abdelrahim1, K. Kim2, S. Pearce3,E. Ariazi3, H. Liu3, V. Jordan3 and S. Safe1,2. 1Instituteof Biosciences & Technology, Texas A&M UniversitySystem Health Science Center, Houston, TX,2Veterinary Physiology & Pharmacology, Texas A&MUniversity, College Station, TX and 3Robert H. LurieComprehensive Cancer Center, NorthwesternUniversity, Chicago, IL.

#1808 INHIBITION OF ESTROGEN RECEPTOR-NEGATIVE BREAST CANCER CELL GROWTHBY ARYL HYDROCARBON RECEPTORAGONISTS. L. Kotha and S. Safe. VeterinaryPhysiology & Pharmacology, Texas A&M University,College Station, TX.

#1809 CONSEQUENCES OF INTERACTION OF THEEQUINE ESTROGEN METABOLITE, 4-HYDROXYEQUILENIN, WITH ESTROGENRECEPTOR αα M. Chang and J. L. Bolton. Universityof Illinois at Chicago, Chicago, IL.

#1810 G2/M BLOCK OF PRIMARY MAMMARYEPITHELIAL CELLS FROM PRE-MENOPAUSALWOMEN IN RESPONSE TO GENOTOXICCARCINOGEN EXPOSURE. J. Brooks1, J. Wang1,A. Humphrey1, J. Hearnes2, J. Pietenpol2, J. Price2 andS. E. Eltom1. 1Pharmacology, Meharry Medical College,Nashville, TN and 2Vanderbilt University, Nashville,TN.

#1811 CHANGES IN ESTROGEN METABOLISM INCATECHOL-O-METHYLTRANSFERASE (COMT)DEFICIENT MICE ARE ASSOCIATED WITHINCREASED DEVELOPMENT AND ALTEREDGENE EXPRESSION IN THE MOUSEMAMMARY GLAND. C. Borgeest1, C. A. Zahnow2,S. O. DaCosta1, B. L. McAtee1, J. A. Flaws3, J. K.Babus3, S. Biswal1 and J. D. Yager1. 1EnvironmentalHealth Science, Johns Hopkins University, Baltimore,MD, 2Cancer Biology, Johns Hopkins University,Baltimore, MD and 3Department of Epidemiology andPreventive Medicine, University of Maryland,Baltimore, MD.

#1812 INVESTIGATION OFOCTAMETHYLCYCLOTETRASILOXANE (D4)AND DECAMETHYLCYCLOPENTASILOXANE(D5) AS DOPAMINE D2-RECEPTOR AGONISTS.P. A. Jean, K. A. McCracken, J. A. Arthurton and K. P.Plotzke. Dow Corning Corporation, Midland, MI.

#1813 TRANSPLACENTAL AND POSTNATALEXPOSURE OF AIDS DRUGS ZIDOVUDINE(AZT) AND LAMIVUDINE (3TC) INC3B6F1TRP53(+/-) TRANSGENIC MICE. F. W. Lee,S. M. Lewis, C. Crawford, W. T. Allaben and J. E.Leakey. U.S. FDA, NCTR, Jefferson, AR.

Program Description


WED

NESD

AY


#1814 EFFECT OF A COMPLEX MIXTURE FROMCOAL TAR–SRM 1597 ON THE METABOLICACTIVATION OF CARCINOGENICPOLYCYCLIC AROMATIC HYDROCARBONS INCHINESE HAMSTER V79 CELLS. B. Mahadevan1,C. P. Marston1, W. Dashwood1, E. Brooks1, Y. Li2, C.Pereira2, J. Doehmer3 and W. M. Baird1. 1Environmentaland Molecular Toxicology, Oregon State University,Corvallis, OR, 2Department of Statistics, Oregon StateUniversity, Corvallis, OR and 3GenPharm ToxicologyBioTechAG, Martinsried, Germany.

#1815 COMPETING ROLES OF ALDO-KETOREDUCTASE 1A1 AND CYP1A1/CYP1B1 IN THEMETABOLIC ACTIVATION OF (+/-)-BENZO(A)PYRENE-7, 8-DIOL IN HUMANBRONCHOALVEOLAR CELLS: INFLUENCE OFCYP INDUCTION. H. Jiang, D. Vudathala, I. A. Blairand T. M. Penning. Department of Pharmacology,University of Pennsylvania School of Medicine,Philadelphia, PA. Sponsor: S. Burchiel.

#1816 COMPARISON OF GENE EXPRESSION INKIDNEY AND URINARY BLADDER FROM RATSTREATED WITH DIMETHYLARSINIC ACID. K.Bailey1, S. D. Hester1, A. Wang2, J. L. Robertson2, D.C. Wolf1 and B. Sen1. 1Environmental CarcinogenesisDivision, U.S. EPA, Research Triangle Park, NC and2Department of Biomed Sciences and Path, VA-MDRegional College of Vet. Med., Blacksburg, VA.

#1817 SPECIATION OF ARSENIC IN THE MATERNALAND FETAL MOUSE TISSUES FOLLOWINGGESTATIONAL EXPOSURE TO ARSENITE. V.Devesa1, B. Adair2, J. Liu3, M. Styblo1,4, M. P. Waalkes3

and D. J. Thomas2. 1CEMALB, University of NorthCarolina at Chapel Hill, Chapel Hill, NC, 2U.S. EPA,Research Triangle Park, NC, 3NCI at NIEHS, ResearchTriangle Park, NC and 4Pediatrics, UNC, Chapel Hill,NC.

#1818 UPTAKE OF INORGANIC AND ORGANICDERIVATIVES OF ARSENIC AND ASSOCIATIONWITH GENOTOXIC EFFECTS IN MAMMALIANCELLS IN VITRO. E. Dopp1, L. M. Hartmann2, A. M.Florea1, U. V. von Recklinghausen1, U. Rauen3, A. W.Rettenmeier1 and A. V. Hirner2. 1Institute of Hygieneand Occupational Medicine, University of Duisburg-Essen, Essen, NRW, Germany, 2Institute ofEnvironmental Chemistry, University of Duisburg-Essen, Essen, Germany and 3Institute of PhysiologicalChemistry, University of Duisburg-Essen, Essen,Germany. Sponsor: E. Nelson.

#1819 GENE EXPRESSION ANALYSIS TO IDENTIFYINTERSPECIES CONCORDANCE OF THEMECHANISMS OF ARSENIC-INDUCEDBLADDER CANCER. B. Sen1, R. Grindstaff1, Y.Turpaz2, J. Retief2 and D. C. Wolf1. 1EnvironmentalCarcinogenesis Division, U.S. EPA, Research TrianglePark, NC and 2Affymetrix, Santa Clara, CA.

#1820 PEROXISOME PROLIFERATOR-ACTIVATEDRECEPTOR ββ (PPARββ) SUPPRESSESANGIOGENESIS. A. D. Burdick1, A. N. Billin2, T. M.Willson2 and J. M. Peters1. 1Department of VeterinaryScience, Center for Molecular Toxicology andCarcinogenesis, The Pennsylvania State University,University Park, PA and 2Discovery Research,GlaxoSmithKline, Research Triangle Park, NC.

#1821 IMMUNOHISTOCHEMICAL ANALYSIS OFEXOCRINE PANCREATIC TOXICITY INDUCEDBY 2, 3, 7, 8-TETRACHLORODIBENZO-P-DIOXIN IN FEMALE HARLAN SPRAGUE-DAWLEY RATS. T. Marsh, J. F. Foley, A. Nyska, B.Cai, S. Peddada, N. J. Walker and K. Yoshizawa.NIEHS, Research Triangle Park, NC.

#1822 INCREASED MITOCHONDRIAL GLUTATHIONECONTENT ENHANCES APOPTOSIS IN NRK-52ECELLS INDUCED BY THE DNA ALKYLATINGAGENT CISPLATIN. L. H. Lash1, F. Xu1 and L. H.Matherly2,1. 1Pharmacology, Wayne State UniversitySch. Med., Detroit, MI and 2Karmanos Cancer Institute,Wayne State University Sch. Med., Detroit, MI.

#1823 CISPLATIN REDUCES VIABILITY, BUT NOTHEAT SHOCK PROTEIN LEVELS IN RATKIDNEY CELLS. J. A. Flaws1, J. K. Babus1, M.Lipsky2 and B. Fowler3. 1Department of Epidemiology,University of Maryland, Baltimore, MD, 2Departmentof Pathology, University of Maryland, Baltimore, MDand 3Division of Toxicology, ATSDR, Atlanta, GA.


POSTER SESSION: CARDIOVASCULAR DISEASE I–GENEEXPRESSION

Chairperson(s): Christopher States, University of Louisville, Louisville, KYand Ellen Silbergeld, Johns Hopkins, Baltimore, MD.



#1824 TCDD-INDUCED GENE EXPRESSION CHANGESIN DEVELOPING ZEBRAFISH HEARTS. S. A.Carney1, C. Burns2,3, R. E. Peterson1 and W.Heideman1. 1University of Wisconsin, Madison, WI,2Massachusetts General Hospital, Charlestown, MA and3Harvard Medical School, Boston, MA.

#1825 CHARACTERIZATION OF TCDDCARDIOTOXICITY IN EMBRYONICZEBRAFISH. D. S. Antkiewicz, R. E. Peterson and W.Heideman. University of Wisconsin, Madison, WI.

#1826 STUDIES TO IDENTIFY GENE CHANGES INTHE HEART DURING RECOVERY FROMHEART TOXICITY INDUCED BY BIS(2-CHLOROETHOXY)METHANE. J. Dunnick1, J.Parker2, P. Blackshear3 and A. Nyska1. 1Laboratory ofExperimental Pathology, NIEHS, Research TrianglePark, NC, 2Constella Group, Inc., Research TrianglePark, NC and 3Integrated Laboratory System, Inc.,Research Triangle Park, NC.

Program Description



WED

NES

DAY

#1827 INCREASED GENE EXPRESSION AND LEVELSOF ANTIOXIDANTS AND PHASE 2 ENZYMES INCARDIAC CELLS TREATED WITH 3H-1, 2-DITHIOLE-3-THIONE: PROTECTION AGAINSTOXIDANT AND ELECTROPHILE-INDUCEDCELL INJURY. Z. Cao1,2, H. Zhu1, D. Hardej1, L. D.Trombetta1 and Y. Li1. 1Pharmaceutical Sciences, St.John’s University, Jamaica, NY and 2Harvard MedicalSchool, Boston, MA.

#1828 DIFFERENTIAL GENE EXPRESSION INMICRODISSECTED MESENTERIC VASCULARELEMENTS OF RATS 1-HOUR FOLLOWINGFENOLDOPAM (SKF-82526) ADMINISTRATION.D. A. Dalmas1, M. S. Scicchitano1, Y. Chen2, H. Olsen2,L. A. Tierney1, P. K. Narayanan1, H. C. Thomas1, R. W.Boyce1, S. Clark2 and L. W. Schwartz1. 1SafetyAssessment, GlaxoSmithKline (GSK), King of Prussia,PA and 2Transcriptome Analysis, GSK, Collegeville,PA.

#1829 GENOMIC ANALYSIS OF THE MECHANISM OFCYCLOPHOSPHAMIDE-INDUCEDCARDIOTOXICITY IN RATS: COMPARISONWITH HUMAN CASES OF MYOCARDITIS. K. K.Daniels, M. S. Orr and W. B. Mattes. Toxicogenomics,Gene Logic Inc., Gaithersburg, MD.

#1830 A RAT HEART GENE-EXPRESSION SIGNATUREPREDICTIVE OF HERG POTASSIUM CHANNELBINDING. X. Xu, R. J. Brennan, G. Napolitano and K.Kolaja. Chemogenomics and Toxicology, IconixPharmaceuticals Inc., Mountain View, CA.

#1831 AHR AND ARNT SPECIFICALLY BINDPUTATIVE DIOXIN RESPONSE ELEMENTS(DRES) UPSTREAM OF BETA-ADRENERGICRECEPTOR GENES. J. M. Ciak and R. J. Sommer.Biology Department, Bates College, Lewiston, ME.

#1832 GLUTATHIONE-S-TRANSFERASE A4-4MODULATES INOS EXPRESSION THROUGHNF- κκB TRANSLOCATION. Y. Yang1, Y. Yang2, Y. C.Awasthi2 and P. J. Boor1. 1Pathology, UTMB,Galveston, TX and 2Human Biological Chemistry andGenetics, University of Texas Medical Branch,Galveston, TX.

#1833 CHEMICAL INDUCTION OF ANTIOXIDATIVEAND PHASE 2 DEFENSES INCARDIOVASCULAR TISSUES IN VIVO:INVOLVEMENT OF NRF2 SIGNALING ANDIMPLICATIONS FOR CARDIOVASCULARPROTECTION. Y. Li1, Z. Cao1, H. Zhu1, E. Hussey1,H. Scaramell1, K. Itoh2, M. Yamamoto2, J. M. Cerreta1

and L. D. Trombetta1. 1St. John’s University, Jamaica,NY and 2University of Tsukuba, Tsukuba, Japan.

#1834 UPREGULATION OF ENDOGENOUSANTIOXIDANTS AND PHASE 2 PROTEINS BYRESVERATROL IN CULTURED AORTICSMOOTH MUSCLE CELLS LEADS TOCYTOPROTECTION AGAINST OXIDATIVE ANDELECTROPHILIC STRESS. H. Zhu, Z. Cao and Y.Li. Pharmaceutical Sciences, St. John’s University,Jamaica, NY.

#1835 DEXRAZOXAN INHIBITS ALTERATIONS INGLYCOLYTIC AND OXIDATIVE CARDIACMETABOLISM INDUCED BY DOXORUBICIN. R.A. Carvalho1, R. B. Sousa1, C. M. Palmeira1 and K. B.Wallace2. 1Biochemistry, University of Coimbra,Coimbra, Portugal and 2Biochemistry & MolecularBiology, University of Minnesota School of Medicine,Duluth, MN.

#1836 METALLOTHIONEIN PROTECTION FROMPROTEIN NITRATION CAUSED BY LPS/TNF-ALPHA-DERIVED INTRACELLULARPEROXYNITRITE. J. Wang, Y. Kang and L. Cai.Medicine, University of Louisville, Louisville, KY.

#1837 THE ROLE OF ENDOTHELIN-1 AND REACTIVEOXYGEN SPECIES IN CARDIACHYPERTROPHY OBSERVED IN ARYLHYDROCARBON (AHR) NULL MICE. A. K. Lund1

and M. K. Walker1,2. 1College of Pharmacy, Universityof New Mexico, Albuquerque, NM and 2Department ofCell Biology and Physiology, University of NewMexico, Albuquerque, NM.

#1838 PCB-INDUCED INFLAMMATORY RESPONSE INCAVEOLIN-1 DEFICIENT MICE. Z. Majkova, E.Smart, A. Daugherty, M. Toborek and B. Hennig.University of Kentucky, Lexington, KY.

#1839 PREVENTION OF DIABETES-ENHANCED LPSCARDIOTOXICITY IN CARDIAC-SPECIFICMETALLOTHIONEIN-OVEREXPRESSINGTRANSGENIC MICE. L. Cai and Y. Kang. Medicine,Pharmacology and Toxicology, University of Louisville,Louisville, KY.

#1840 GENETIC BACKGROUND-DEPENDANTVARIATION IN EGFR-RELATED CARDIACDYSFUNCTION. D. J. Barrick1, M. La Merrill1, M.Rojas3, S. Smyth3 and D. W. Threadgill2,1. 1Curriculumin Toxicology, UNC-CH, Chapel Hill, NC, 2Genetics,UNC-CH, Chapel Hill, NC and 3CarolinaCardiovascular Biology Center, UNC-CH, Chapel Hill,NC.

#1841 EFFECTS OF ARSENIC ON ENDOTHELIALCELL ACTIVATION AND ACETYLATED-LDLUPTAKE BY MACROPHAGES. F. E. Pereira, M.Bunderson, J. C. Schneider, M. C. Schneider, D. D.Coffin and H. D. Beall. Center for EnvironmentalHealth Sciences, University of Montana, Missoula, MT.

#1842 EXAMINATION OF THE VASCULAR INJURY INSPRAGUE-DAWLEY (SD) RATS INDUCED BYTHE PHOSPHODIESTERASE (PDE) IVINHIBITOR SCH 534385: A COMPARISIONWITH SCH 351591. J. Zhang1, E. H. Herman1, A.Knapton1, T. J. Miller1, P. Espandiari1, R. Snyder2, J. P.Hanig1 and J. L. Weaver1. 1DAPR, U.S. FDA, SilverSpring, MD and 2Schering-Plough Research Institute,Lafayette, NJ.

Program Description


WED

NESD

AY


#1843 SMOOTH MUSCLE CELL MARKERS OFFENOLDOPAM INDUCED VASCULAR INJURY.D. Brott1,2, L. Foster-Brown1, E. Dubois1, H. Jones3, R.J. Richardson2 and C. Louden1,2. 1Global SafetyAssessment, AstraZeneca Pharmaceuticals, Wilmington,DE, 2Toxicology Program, EHS, The University ofMichigan, Ann Arbor, MI and 3Global SafetyAssessment, AstraZeneca Pharmaceuticals, Alderley,United Kingdom.

#1844 ACROLEIN-INDUCED DYSLIPIDEMIA IN MICE:A RISK FACTOR OF CARDIOVASCULARDISEASE. D. J. Conklin1, R. Prough2, D. Clark1, B.Hill1, S. Srivastava1, S. Liu1 and A. Bhatnagar1,2.1Cardiology, University of Louisville, Louisville, KYand 2Biochemistry and Molecular Biology, Universityof Louisville, Louisville, KY.


POSTER SESSION: OXIDATIVE STRESS II

Chairperson(s): Susan MacKenzie, DuPont Labs, Newark, DE and TimothyPhillips, University of Texas, College Station, TX.



#1845 ATTENUATION OF HYPEROXIA-INDUCEDRETINOPATHIES IN NEONATAL RATS BYRETINOIC ACID. X. I. Couroucli, L. Kong, Y. Wei,W. Jiang and B. Moorthy. Pediatrics, Baylor College ofMedicine, Houston, TX.

#1846 THE SUSCEPTIBILITY OF INBRED MOUSESTRAINS TO HYPEROXIA-INDUCED LUNGINJURY. G. S. Whitehead, K. G. Berman, L. H. Burch,W. Foster and D. A. Schwartz. Medicine, DukeUniversity, Durham, NC.

#1847 OXIDATION OF PURINE NUCLEOSIDES ANDNUCLEOTIDES WITH DIMETHYLDIOXIRANE:STRUCTURAL CHARACTERIZATION OFREACTION PRODUCTS. L. M. Ball, D. E. Degen,W. Ye, Y. Li, R. Sangaiah and A. Gold. EnvironmentalSciences and Engineering, University of North Carolinaat Chapel Hill, Chapel Hill, NC.

#1848 PI3-KINASE MEDIATED INDUCTION OF NRF-2PROTEIN BY OXIDANTS INCARDIOMYOCYTES. S. E. Purdom1 and Q. M.Chen2,1. 1Interdisciplinary Graduate Program inGenetics and Genomics, University of Arizona, Tucson,AZ and 2Department of Pharmacology, University ofArizona, Tucson, AZ.

#1849 HYPERGLYCEMIA-INDUCED OXIDATIVESTRESS ACTIVATES THE HEXOSAMINEPATHWAY AND INHIBITS MITOCHONDRIALBIOGENESIS. C. M. Palmeira1, J. Berthiaume2, J. A.Bjork2, A. P. Rolo1 and K. B. Wallace2. 1Department ofZoology, University of Coimbra, Center forNeurosciences and Cell Biology, Coimbra, Portugal and2Department of Biochemistry & Molecular Biology,University of Minnesota, Medical School, Duluth, MN.

#1850 HYDROQINONE, ρρ-BENZOQUINONE, BUT NOTBENZENE OR PHENOL CAUSE AN INCREASEIN REACTIVE OXYGEN SPECIES IN HD3CELLS. J. Wan1 and L. M. Winn1,2. 1Pharmacology andToxicology, Queen’s University, Kingston, ON, Canadaand 2School of Environmental Studies, Queen’sUniversity, Kingston, ON, Canada.

#1851 MEASUREMENT OF OXIDATIVE STRESSUSING KINETIC HIGH CONTENT CELL-BASEDASSAYS. V. Abraham and J. R. Haskins. Cellomics,Pittsburgh, PA. Sponsor: E. McGuire.

#1852 ANALYSIS OF THE ROLE OF THEANTIOXIDANT RESPONSE ELEMENT IN THEPROGRESSION OF AMYOTROPHIC LATERALSCLEROSIS. C. B. Rideaux, J. C. Kern, D. A. Johnsonand J. A. Johnson. Univeristy of Wisconsin-Madison,Madison, WI.

#1853 ORAL GLUTATHIONE RAPIDLY ELEVATESGLUTATHIONE LEVELS IN LUNG EPITHELIALLINING FLUID AND LAVAGED CELLS. C. T.kariya1, H. Leitner1, E. Min3 and B. J. Day3,1,2.1Molecular Toxicology and Environmental HealthSciences, UCHSC, Denver, CO, 2Medicine, UCHSC,Denver, CO and 3Medicine, National Jewish Medicaland Research Center, Denver, CO.

#1854 SELECTIVE ENHANCEMENT OF HYPEROXICLUNG INJURY BY AUROTHIOGLUCOSE INGLUTATHIONE-DEFICIENT MICE SUGGESTSCROSS-TALK BETWEEN THIOREDOXIN ANDGLUTATHIONE SYSTEMS. S. E. Welty, L. K.Rogers, T. E. Tipple, T. N. Hansen and C. V. Smith.Center for Developmental Pharmacolcogy andToxicology, Columbus Children’s Research Institute,Columbus, OH.

#1855 PHENOTYPIC ANCHORING OFACETAMINOPHEN-INDUCED OXIDATIVESTRESS AND GENE EXPRESSION PROFILES INRAT LIVER. C. L. Powell1,2, P. Ross2, A. Heinloth3,G. Boorman4, M. Cunningham4, R. Paules3 and I.Rusyn1,2. 1Curriculum in Toxicology, UNC, ChapelHill, NC, 2Department Envr Science & Engr, UNC,Chapel Hill, NC, 3NIEHS, National Center forToxicogenomics, Research Triangle Park, NC and4NIEHS, Envr Toxicology Program, Research TrianglePark, NC. Sponsor: I. Rusyn.

#1856 NEAR-INFRARED LIGHT TREATMENT IN ACELLULAR MODEL OF MITOCHONDRIALDYSFUNCTION. K. DeSmet1, M. M. Henry2, E.Buchmann3, M. Connelly3, H. T. Whelan3,1 and J. T.Eells1,3,2. 1Health Sciences, University of Wisconsin-Milwaukee, Milwaukee, WI, 2Ophthalmology, MedicalCollege of Wisconsin, Milwaukee, WI and 3Neurology,Medical College of Wisconsin, Milwaukee, WI.

#1857 TOLL-LIKE RECEPTOR 4 (TLR4)CONTRIBUTES TO OZONE-INDUCEDINCREASES IN COSTIMULATORY MOLECULE(CD86) EXPRESSION IN MICE. G. Backus1,2, A. K.Bauer2, H. Cho2 and S. R. Kleeberger2. 1Curriculum inToxicology, University of North Carolina, Chapel Hill,NC and 2NIH/NIEHS, Research Triangle Park, NC.



WED

NES

DAY

#1858 ARSENIC TRIOXIDE INDUCED OXIDATIVE STRESSIN SPRAGUE-DAWLEY RATS. A. K. patlolla and P. B.Tchounwou. Biology, Jackson State University, Jackson, MS.

#1859 EFFECT OF ACETAMINOPHEN ON CYTOSOLICAND MITOCHONDRIAL GLUTATHIONE IN THELIVERS OF WILD-TYPE, GCLM-HETEROZYGOUS,AND GCLM-NULL MICE. I. Mohar, L. A. McConnachie,C. Fernandez and T. J. Kavanagh. Department ofEnvironmental and Occupational Health Sciences, Universityof Washington, Seattle, WA.

#1860 ANTIOXIDANT GENE EXPRESSION LEVELS INBRAIN AREAS THAT ARE TARGETS OF 1, 3-DNBMEDIATED NEUROTOXICITY. T. R. Miller1 and P.Venkatakrishnan1. 1Graduate Center for Toxicology, Universityof Kentucky, Lexington, KY and 2Graduate Center forToxicology, University of Kentucky, Lexington, KY.

#1861 ENHANCED RENAL TOXICITY OF FERRICNITRILOTRIACETATE IN NRF2 DEFICIENT MICE.K. KANKI1, T. Umemura1, Y. Kitamura1, Y. Ishii1, Y.Kodama2, K. Itoh3, M. Yamamoto3, A. Nishikawa1 and M.Hirose1. 1Division of Pathology, National Institute of HealthSciences, Tokyo, Japan, 2Division of Toxicology, NationalInstitute of Health Sciences, Tokyo, Japan and 3Graduateschool of Comprehensive Human Sciences, TsukubaUniversity, Tsukuba, Japan.

#1862 THE BIO-NANO INTERFACE: EXAMINING THEINTERACTIONS BETWEEN WATER SOLUBLEFULLERENES AND BIOLOGICAL MEMBRANES. C.M. Sayes1, J. Mendez1, K. D. Ausman4, J. L. West2,4, J. H.Hafner3,4 and V. L. Colvin1,4. 1Chemistry, Rice University,Houston, TX, 2Bioengineering, Rice University, Houston, TX,3Physics and Astronomy, Rice University, Houston, TX and4Center for Biological and Environmental Nanotechnology,Rice University, Houston, TX.

#1863 INVOLVEMENT OF REACTIVE OXYGENFORMATION IN THE 3-HYDROXY-3-METHYLGLUTARYL-COA REDUCTASE INHIBITOR-INDUCED SKELETAL MUSCLE CELL DEATH. A.Wolf1, L. Ndountse-Tchapda1, U. Schramm1 and W. E.Trommer2. 1Biomarker Development, Novartis PharmacologyAG, Basel, Switzerland and 2Department of Chemistry,University of Kaiserslautern, Kaiserslautern, Germany.

#1864 SURFACE ACTIVITY OF ERIONITE SAMPLES FROMDIFFERENT LOCALITIES. M. Gulumian1,2, M. Semano1

and G. Hearne3. 1Toxicology, NIOH, Johannesburg, Gauteng,South Africa, 2Department of Haematology and MolecularMedicine, University of the Witwatersrand, Johannesburg,Gauteng, South Africa and 3Department of Physics,University of the Witwatersrand, Johannesburg, Gauteng,South Africa. Sponsor: M. Karol.


POSTER SESSION: IMMUNOTOXICOLOGY IN VITRO/MECHANISMS

Chairperson(s): Norbert Kaminski, Michigan State University, Pharmacology andToxicology, East Lansing, MI and Brian Freed, University of Colorado, ClinicalImmunology Laboratory, Denver, CO.



#1865 IDENTIFICATION OF NF-κκB MODIFICATIONSGENERATED BY CIGARETTE SMOKE ALDEHYDES.C. Lambert, J. Li, M. Portas, S. Lazis, M. Quintana, J.McCue and B. M. Freed. Allergy and Clinical Immunology,School of Medicine, University of Colorado Health SciencesCenter, Denver, CO.

#1866 2, 3, 7, 8-TETRACHLORODIBENZO-P-DIOXIN(TCDD) INDUCES THE EXPRESSION OF FAS ANDFAS LIGAND THROUGH DISTINCT PATHWAYSINVOLVING DRE AND NF-KAPPAB MOTIFS ON THEPROMOTERS. N. P. Singh1. 1Pharmacology & Toxicology,Virginia Commonwealth University, Richmond, VA and2Microbiology & Immunology, Medical College of VirginiaCampus, Virginia Commonwealth University, Richmond, VA.Sponsor: P. Nagarkatti.

#1867 2, 3, 7, 8-TETRACHLORODIBENZO-P-DIOXIN(TCDD) DISRUPTS THE NORMAL DAILY RHYTHMSOF HEMATOPOIETIC PRECURSORS. R. Garrett and T.A. Gasiewicz. Environmental Medicine, University ofRochester School of Medicine & Dentistry, Rochester, NY.

#1868 INTERFERON-GAMMA REVERSES TCDD-MEDIATED SUPPRESSION OF THE IGM ANTIBODYRESPONSE AND ATTENUATES CYP1A1 INDUCTION.N. Kaminski2,3, B. Kim1, R. Crawford2 and M. Holsapple2.1Biological Sciences and Immunomodulation ResearchCenter, University of Ulsan, Ulsan, South Korea,2Pharmacology and Toxicology, Michigan State University,East Lansing, MI and 3Center for Integrative Toxicology,Michigan State University, East Lansing, MI.

#1869 MAP KINASES, BUT NOT CALCIUM OR REACTIVEOXYGEN SPECIES, ARE INVOLVED IN PPARγγAGONIST-INDUCED PRO/PRE-B CELL APOPTOSIS.D. Liu, J. Emberley, D. Sherr and J. Schlezinger.Environmental Health, Boston University School of PublicHealth, Boston, MA.

#1870 CASPASE-8 IS NOT THE MOST PROXIMAL CASPASEINVOLVED IN DMBA-INDUCED BONE MARROW BCELL APOPTOSIS. D. H. Sherr, H. Ryu, J. K. Emberley, L.L. Allan and J. J. Schlezinger. Environmental Health, BostonUniversity, Boston, MA.

#1871 THE ROLE OF PAH METABOLISM IN AHR-DEPENDENT INHIBITION OF HUMAN B CELLPROLIFERATION. L. L. Allan1,2, J. J. Schlezinger2, M.Shansab2 and D. H. Sherr2. 1Microbiology, Boston UniversitySchool of Medicine, Boston, MA and 2Environmental Health,Boston University School of Medicine, Boston, MA.

#1872 DISTINCT EFFECTS OF TGF-B1 ON THE SURVIVALAND DIVISION OF CD4+ AND CD8+ T CELLS: AROLE FOR T CELL INTRINSIC SMAD3. S. C. McKarnsand R. H. Schwartz. Laboratory of Cellular and MolecularImmunology, National Institute of Allergy and InfectiousDiseases, NIH, Bethesda, MD.

Program Description


WED

NESD

AY


#1873 EXPOSURE TO TCDD AUGMENTS CD25EXPRESSION ON RECENTLY ACTIVATED TCELLS. C. J. Funatake, L. B. Steppan and N. I.Kerkvliet. Environmental and Molecular Toxicology,Oregon State University, Corvallis, OR.

#1874 ∆∆9-TETRAHYDROCANNABINOL (∆∆9-THC)ELICITS A CALCIUM ELEVATION IN T CELLSTHROUGH THE TRPC CHANNELS. G. Rao1,2 andN. E. Kaminski1,2. 1Pharmacology and Toxicology,Michigan State University, East Lansing, MI and2Center for Integrative Toxicology, Michigan StateUniversity, East Lansing, MI.

#1875 SODIUM ARSENITE DECREASESPROLIFERATION IN PHA-STIMULATEDLYMPHOCYTES, BY INHIBITINGINTERLEUKIN-2 EXPRESSION ANDSECRETION. P. C. Conde-Moo, L. C. Acosta-Saavedra, M. E. Cebrian and E. S. Calderon-Aranda.Toxicologia, Cinvestav, Mexico, DF, Mexico.

#1876 MECHANISMS OF 4-HYDROXYNONENAL-HNE(LIPID HYDROPEROXIDE) INDUCEDAPOPTOTIC DEATH IN CD4 T LYMPHOCYTES:RELEVANCE TO HIV AND HCVPATHOGENESIS. W. Chang1, R. Sahoo2, S.Srivastava2, C. J. McClain2,1, T. S. Chen1 and S. S.Barve2,1. 1Pharmacology & Toxicology, University ofLouisville, Louisville, KY and 2Medicine, University ofLouisville, Louisville, KY.

#1877 MECHANISMS OF LEAD-INDUCEDIMMUNOTOXICITY: THE ROLE OF IL-2 INALLO-ENHANCEMENT. S. M. Hueber, D. G. Farrerand M. J. McCabe. Environmental Medicine, School ofMedicine and Dentistry, University of Rochester,Rochester, NY.

#1878 ENFUVIRTIDE: IN VITRO STUDIES OFPUTATIVE IMMUNOTOXIC EFFECTSRELATED TO ACTIVATION OF N-FORMYLPEPTIDE RECEPTORS. F. Regenass1, M.Adibzadeh1, T. D. Steele2 and H. Kropshofer1.1Nonclinical Drug Safety, Hoffmann-LaRoche, Inc.,Basel, Switzerland and 2Nonclinical Drug Safety,Hoffmann-LaRoche, Inc., Nutley, NJ. Sponsor: A.Braen.

#1879 INFLAMMATORY RESPONSES IN MOUSERAW264.7 MACROPHAGES CAN BE ALTEREDBY INTERACTIONS BETWEEN INDOOR AIRMICROBES IN SIMULTANEOUS EXPOSURE. P.Penttinen1,2, K. Huttunen1, J. Pelkonen2,3 and M.Hirvonen1. 1Department of Environmental Health,National Public Health institute, Kuopio, Finland,2University of Kuopio, Kuopio, Finland and 3KuopioUniversity Hospital, Kuopio, Finland. Sponsor: M.Viluksela.

#1880 SIMULTANEOUS EXPOSURE TO MOLDYHOUSE MICROBES STREPTOMYCESCALIFORNICUS AND STACHYBOTRYSCHARTARUM CAUSE SYNERGISTICINFLAMMATORY RESPONSES IN HUMANWHOLE BLOOD CELL CULTURE. M. Roponen,K. Huttunen, M. Lappalainen and M. Hirvonen.Department of Environmental Health, National PublicHealth Institute, Kuopio, Finland. Sponsor: M.Viluksela.

#1881 THE BIOLOGICAL ACTIVITY OF GRAM-POSITIVE BACTERIA STREPTOMYCESCALIFORNICUS CANNOT BE COMPLETELYINHIBITED WITH LPS -INHIBITOR PMX. K.Huttunen, A. Halinen and M. Hirvonen. Department ofEnvironmental Health, National Public Health Institute,Kuopio, Finland. Sponsor: M. Viluksela.

#1882 IN VITRO AND IN VIVO IMMUNOLOGICRESPONSES BY POLYACRYLAMIDENANOPARTICLES TO MH-S CELLS AND RATS.R. J. Schneider1, R. Reddy2 and M. A. Philbert1.1Environmental Health Sciences, University ofMichigan, Ann Arbor, MI and 2Molecular Therapeutics,Inc., Ann Arbor, MI.

#1883 IMPACT OF EXPOSURE TO JET A JET FUEL ONCYTOKINE PRODUCTION IN RAT LUNGMACROPHAGES. D. L. Courson1, E. R. Wilfong1, J.R. Cunningham2, E. W. Johnson1 and S. Lohrke1.1Naval Health Research Center / Detachment EHELaboratory, Wright-Patterson AFB, Fairborn, OH and2Wright State University, Fairborn, OH.

#1884 MACROPHAGES ARE THE PROXIMALTARGET CELL IN LEAD-INDUCEDIMMUNOTOXICITY. D. G. Farrer and M. J.McCabe. Environmental Medicine, School of Medicineand Dentistry, University of Rochester, Rochester, NY.

#1885 WOOD DUST-INDUCED PULMONARYINFLAMMATION IN MICE. J. Maatta, M. Lehto, M.Leino, S. Tillander, H. Haataja, K. Savolainen and H.Alenius. Department of Industrial Hygiene andToxicology, Finnish Institute of Occupational Health,Helsinki, Finland.

#1886 ATRAZINE-INDUCED INHIBITION OF NK-CELLMEDIATED CYTOTOXICITY. A. M. Rowe1, K. M.Brundage1,2, R. Schafer2 and J. B. Barnett1,2.1Microbioloy, Immunology and Cell Biology, WestVirginia University, Morgantown, WV and 2Mary BabbRandolph Cancer Center, Morgantown, WV.

#1887 ALTERATIONS IN CYTOKINE PRODUCTION INTHE PRESENCE OF THE PESTICIDES,BENTAZON, ISOXAFLUTOLE AND TERBUFUS.K. M. Brundage1 and R. S. Ellis2. 1Microbiology,Immunology and Cell Biology, West VirginiaUniversity, Morgantown, WV and 2BlueField StateCollege, Bluefield, WV.

Program Description



WED

NES

DAY

#1888 THE FUNGICIDESETHYLENEBISDITHIOCARBAMATES INHIBITNF-KB ACTIVATION AND CYTOKINEPRODUCTION IN THE HUMANPROMYELOCYTIC CELL LINE THP-1. E.Corsini1, S. Birindelli2, M. Marinovich1, C. L. Galli1

and C. Colosio2. 1Pharmacological Sciences, Universityof Milan, Milan, Italy and 2ICPS, International Centrefor Pesticides and Health Risk Prevention, BustoGarolfo, Italy.

#1889 ANALYSIS OF THE PROTEOMIC CHANGESINDUCED BY PROPANIL ON A MACROPHAGECELL LINE. I. V. Ustyugova1, C. L. Walton1, K. M.Brundage1,2 and J. B. Barnett1,2. 1Proteomic CoreFacility, Department of Microbiology, Immunology andCell Biology, West Virginia University, Morgantown,WV and 2Mary Babb Randolph Cancer Center, WestVirginia University, Morgantown, WV.

#1890 ALTERED ACTIVATION OF T CELLS BYSILICA-EXPOSED ANTIGEN-PRESENTINGCELLS. C. T. Migliaccio and A. Holian. Ctr forEnviron Health Sciences/Biomed PharmacologySciences, University of Montana, Missoula, MT.

#1891 ROLE OF NEUTROPHILS IN 1-NITRONAPHTHALENE-INDUCEDPULMONARY INJURY AND REPAIR. L. Pantle, M.Fanucchi and C. Plopper. University of California,Davis, Davis, CA.

#1892 PARTICULATE MATTER-INDUCED AIRWAYINFLAMMATION CORRELATES WITHIMMUNE ADJUVANT POTENTIAL. C. de Haar, I.Hassing, R. Bleumink and R. Pieters. Institute for RiskAssessment Sciences, Utrecht, Netherlands.

#1893 IMMUNE RESPONSE OF HUMANLYMPHOBLASTOID AND BRONCHIALEPITHELIAL CELL LINES TO ORGANICCOMPOUNDS FROM FINE PARTICLES (PM2.5)IN PUERTO RICO. E. Fuentes-Mattei1,3, I.Rodriguez-Fernandez2,3, A. Gioda3, W. Delgado-Morales1 and B. D. Jimenez Velez1,3. 1Biochemistry,UPR Medical Sciences Campus, San Juan, Puerto Rico,2Biology, UPR Ponce Campus, Ponce, Puerto Rico and3Center of Environmental and Toxicological Research-UPR Medical Science Campus, San Juan, Puerto Rico.

#1894 MURINE PULMONARY MACROPHAGEEXPRESSION AND PRODUCTION OF TNFA ANDMIP-2 AFTER EXPOSURE TO DIESEL EXHAUSTPARTICLES (DEP) AND EXTRACTS. T. Stevens1,M. Daniels2 and I. Gilmour2. 1UNC, Chapel Hill, NCand 2EPA, Research Triangle Park, NC.

#1895 IN-VITRO INFLAMMATORY AND CYTOTOXICRESPONSES TO URBAN AIR FINE ANDULTRAFINE PARTICULATE SAMPLESCOLLECTED DURING CONTRASTINGPOLLUTION SITUATIONS IN SIX EUROPEANCITIES (PAMCHAR). P. Jalava1,2, R. O. Salonen1, A.I. Halinen1 and M. Hirvonen1. 1Department ofEnvironmental Health, National Public Health Institute(KTL), Kuopio, Finland and 2University of Kuopio,Kuopio, Finland. Sponsor: M. Viluksela.

#1896 EXPRESSION AND KINETICS OF TOLL-LIKERECEPTORS AND INFLAMMATORYCYTOKINE SECRETION IN MURINEALVEOLAR MACROPHAGES. K. M. Gowdy2,1, M.Daniels1, E. Boykin1 and M. Gilmour1. 1EnvironmentalToxicology Division, U.S. EPA, Research Triangle Park,NC and 2North Carolina State University, Raleigh, NC.


POSTER SESSION: LIVER II

Chairperson(s): Martin Ronis, University of Arkansas Medical Sciences,Little Rock, AR.



#1897 IMPROVED RAT MODELS FOR PREDICTIVETOXICOLOGY. S. Nye, N. Cozzi, J. Baye, A.Wittenburg, S. Korb, Y. Evrard, R. Roman and H.Jacob. Research & Development, PhysioGenix, Inc.,Wauwatosa, WI. Sponsor: Y. Dragan.

#1898 IN VIVO HEPATIC CELL PROLIFERATION ISAN EARLY, SENSITIVE MARKER OFHEPATOTOXICITY. S. Turner1, J. Gardner1, J.Stark1, D. Buffmum2 and M. Hellerstein3,2,1. 1Research,Kinemed Inc., Emeryville, CA, 2Medicine, UC SanFrancisco, San Francisco, CA and 3Nutritional Sciencesand Toxicology, UC Berkeley, Berkeley, CA. Sponsor:I. Heyman.

#1899 INVESTIGATIONS OF THE EFFECTS ONPROTEIN EXPRESSION INDUCED BYHEPATOTOXICANTS ON PRIMARY CULTUREDRAT HEPATOCYTES. T. Yamamoto, T. Fukushima,R. Kikkawa, H. Yamada and I. Horii. Worldwide SafetySciences, Pfizer Japan Inc., Taketoyo, Aichi, Japan.Sponsor: M. Kurata.

#1900 PROTEOMIC ANALYSIS OF LIVER AND SERUMFROM LIPOSACCHARIDE TREATED RATSDURING ACUTE INFLAMMATION. J. H.Madenspacher1, M. E. Bruno1, B. A. Wetmore1, R.Pieper2, C. L. Gatlin2, A. J. Makusky2, A. M. McGrath2,M. Zhao2, J. Zhou2, J. Taylor2, S. Steiner2, R. W.Tennant1, K. B. Tomer1 and B. A. Merrick1. 1NationalCenter for Toxicogenomics, NIEHS, Research TrianglePk, NC and 2Proteomics Division, Large Scale BiologyCorporation, Research Triangle Pk, NC.

#1901 EVALUATION OF THE BACKGROUND DATAOBTAINED IN THE TOXICOGENOMICSPROJECT IN JAPAN. H. Nitta, T. Miyazaki, H.Totsuka, T. Miyagishima, T. Urushidani and T. Nagao.Toxicogenomics Project, National Institute of HealthSciences, Tokyo, Japan. Sponsor: T. Inoue.

#1902 THIOACETAMIDE AND METHAPYRILENESHOWED A UNIQUE GENE EXPRESSIONPROFILE AMONG THE CHEMICALS IN THETOXICOGENOMICS PROJECT IN JAPAN. Y.Mizukawa, T. Miyagishima, T. Urushidani and T.Nagao. Toxicogenomics Project, National Institute ofHealth Sciences, Tokyo, Japan. Sponsor: T. Inoue.

Program Description


WED

NESD

AY


#1903 GENE EXPRESSION IN PORPHYRIA INDUCEDBY 2, 3, 7, 8-TETRACHLORO-DIBENZO-P-DIOXIN IN SUSCEPTIBLE MICE. A. G. Smith, B.Clothier and R. Davies. MRC Toxicology Unit,University of Leicester, Leicester, United Kingdom.

#1904 STRESS- AND INFLAMMATORY-RELATEDMNRA INDUCTION IN HEPATOCYTES ANDNON-PARENCHYMAL CELLS RESPONSE TOOXIDATIVE STIMULI. T. Yamamoto, H. Utsumi, N.Shimada and N. Tsutsui. Mitsubishi PharmacologyCorporation, Kisarazu, Chiba, Japan. Sponsor: J.Sugimoto.

#1905 DEVELOPMENT OF PROTEIN MICROARRAYTECHNOLOGY TO FACILITATEIDENTIFICATION OF PROTEINS ISOLATED BYGEL FILTRATION AND ION-EXCHANGECHROMATOGRAPHIES. H. Kim1,2, Y. Yuan1, D. J.Kaplan1, D. A. Putt1, Z. Li1 and K. Fleischmann1.1Detroit R&D, Inc., Detroit, MI and 2Institute ofEnvironmental Health Sciences, Wayne StateUniversity, Detroit, MI.

#1906 HEPATIC GENE EXPRESSION PROFILES OFRATS EXPOSED TOPERFLUOROOCTANESULFONATE (PFOS) INUTERO. J. A. Bjork1, J. M. Berthiaume1, C. Lau2, J. L.Butenhoff3 and K. B. Wallace1. 1Biochem. & Mol.Biology, Medical School, University of Minnesota,Duluth, MN, 2Reproductive Toxicology Division,NHEERL, U.S. EPA, Research Triangle Park, NC and33M Company, St. Paul, MN.

#1907 LIVER SLICE MODEL SYSTEM FOR BILIARYCELL EFFECTS: CHANGES IN CLINICALCHEMISTRY PARAMETERS. H. P. Behrsing, C. Ip,L. Jimenez and C. A. Tyson. Toxicology Laboratory, SRIInternational, Menlo Park, CA.

#1908 LIVER SLICE MODEL SYSTEM FOR BILIARYCELL EFFECTS: HISTOLOGICAL CHANGES. K.Amin, C. Ip, H. P. Behrsing and C. A. Tyson.Toxicology Laboratory, SRI International, Menlo Park,CA.

#1909 IMPAIRED G1 TO S-PHASE SIGNALINGEXPLAINS INHIBITED TISSUE REPAIR INTHIOACETAMIDE-TREATED TYPE 1 DIABETICRATS. S. S. Devi and H. M. Mehendale. Toxicology,The University of Louisiana at Monroe, Monroe, LA.

#1910 MOLECULAR MECHANISMS OF INHIBITEDCOMPENSATORY LIVER REPAIR UPONHEPATOTOXIC CHALLENGE IN TYPE 2DIABETIC RATS. S. P. Sawant1, A. V. Dnyanmote1, J.R. Latendresse2, A. Warbritton2 and H. M. Mehendale1.1The University of Louisiana at Monroe, Monroe, LAand 2NCTR, Jefferson, AR.

#1911 PPARββ-MEDIATED HEPATOTOXICITY IN ADIETARY MODEL OF NONALCOHOLICSTEATOHEPATITIS (NASH). M. A. Peraza, W.Shan, M. J. Kennett and J. M. Peters. VeterinarySciences, Center for Molecular Toxicology andCarcinogenesis, The Pennsylvania State University,University Park, PA.

#1912 INDUCTION OF CYTOTOXICITY IN PRIMARYRAT HEPATOCYTES AND HUMAN HEPG2CELLS BY SELECTED PPARγγ AGONISTS. L.Guo1, L. Muskhelishvili2, E. Blann1, S. Dial1, E.Hermann3 and Y. Dragan1. 1Systems Toxicology,National Center for Toxicolological Research, Jefferson,AR, 2Molecular Pathology Branch, Charles RiverLaboratories at NCTR, Jefferson, AR and 3Center forDrug Evaluation and Research, Jefferson, AR.

#1913 INDUCTION OF EARLY FIBROGENESIS INPRECISION-CUT HUMAN AND RAT LIVERSLICES AFTER CARBON TETRACHLORIDETOXICITY. M. van de Bovenkamp1, G. M.Groothuis1, A. L. Draaisma1, M. T. Merema1, D. K.Meijer1, S. L. Friedman2 and P. Olinga1.1Pharmacokinetics and Drug Delivery, University ofGroningen, Groningen, Netherlands and 2Division ofLiver Diseases, Mount Sinai School of Medicine, NewYork. Sponsor: A. Vickers.

#1914 HUMAN LIVER AND KIDNEY SLICE VIABILITYIS EXTENDED AND PATHWAYS OF FIBROSISARE CHARACTERIZED. A. E. Vickers1, R. L.Fisher2 and P. Olinga3. 1Safety Evaluation, Allergan,Inc., Irvine, CA, 2Vitron Inc., Tucson, AZ and3Department Pharmacokinetics & Drug Delivery,University Groningen, Groningen, Netherlands.

#1915 THE EFFECT OF THE PPARαα AGONIST WY-14,643 ON MITOCHONDRIAL MEMBRANEPOTENTIAL IN HUMAN AND RODENT LIVERCELL LINES. S. Barnes1, S. E. Boldt2, A. K.Hubbard1, J. Singh2 and D. E. Amacher2. 1Departmentof Pharmaceutical Sciences, University of Connecticut,Storrs, CT and 2Drug Safety Evaluation, Pfizer Inc.,Groton, CT.

#1916 IN SITU QUANTITATIVE EVALUATION OFPEROXISOMAL PROLIFERATION IN THE NON-HUMAN PRIMATE LIVER VIA LASERSCANNING CYTOMETRY (LSC). L. A. Obert1, V.Kostrubsky1, C. Okerberg1, J. Wijsman1, E. Urda1, J.Hanson1, K. Toy1, W. Collard1, W. Maier1, R. Bell1, L.Zwick2, S. Frantz2, R. Dunstan1 and R. Adler1.1WWSS, Pfizer Inc., Ann Arbor, MI and 2MPIResearch, Mattawan, MI.

#1917 COMPARISON OF ALDEHYDEDEHYDROGENASE (ALDH) ACTIVITY IN THELIVER AND LUNG. M. Yoon1,2, M. C. Madden2 andH. A. Barton2. 1NRC, The National Academies,Washington, DC and 2NHEERL, U.S. EPA, ResearchTriangle Park, NC.

#1918 ETHANOL HAS BIPHASIC EFFECTS ONEXPRESSION OF STEROL REGULATORYELEMENT BINDING PROTEIN-1 (SREBP-1) INRAT FGC-4 HEPATOMA CELLS WITHINHIBITION AT HIGH DOSES RESULTING ININDUCTION OF ADH CLASS I. L. He1,3, M. J.Ronis2,3, F. A. Simmen1,3 and T. M. Badger1,3.1Physiology & Biophysics, University of Arkansas forMedical Sciences, Little Rock, AR, 2Pharmacology &Toxicology, University of Arkansas for MedicalSciences, Little Rock, AR and 3Arkansas Children’sNutrition Center, Little Rock, AR.

Program Description



WED

NES

DAY

#1919 ETHANOL INDUCES RAT HEPATIC ALCOHOLDEHYDROGENASE (ADH) CLASS I BYINTERFERING WITH POST-TRANSLATIONALREGULATION OF STEROL REGULATORYELEMENT BINDING PROTEIN-1 (SREBP-1). T.M. Badger1,3, L. He1,3, F. A. Simmen1,3 and M. J.Ronis2,3. 1Physiology & Biophysics, University ofArkansas for Medical Sciences, Little Rock, AR,2Pharmacology & Toxicology, University of Arkansasfor Medical Sciences, Little Rock, AR and 3ArkansasChildren’s Nutrition Center, Little Rock, AR.

#1920 MICE WITH HEPATOCYTE-SPECIFIC RXRααDEFICIENCY HAVE ALTERED ALCOHOLMETABOLISM. M. G. Kocsis, A. J. Mendy, G. Daiand Y. Y. Wan. Pharmacology, Toxicology &Therapeutics, University of Kansas Medical Center,Kansas City, KS.

#1921 TEMPORAL AND ZONAL EXPRESSIONPATTERNS OF LIVER MRP4 AND NTCPFOLLOWING HEPATOTOXICANT EXPOSURE.L. Aleksunes1, G. Scheffer2 and J. Manautou1.1Pharmaceutical Sciences, University of Connecticut,Storrs, CT and 2Pathology, University Hospital FreeUniversity, Amsterdam, Netherlands.

#1922 METHYLENEDIANILINE INJURY TO LIVERSOF TR- [LIVER CANALICULAR MRP2TRANSPORTER-DEFICIENT] RATS IS NOTLINKED TO OXIDATIVE STRESS. M. F. Kanz, B.Ramasubramanian, Y. Chen, F. Nayeem and M. Treinen-Moslen. Pathology, University of Texas MedicalBranch, Galveston, TX.

#1923 PLASMA ESTERASE ACTIVITY PROTECTSAGAINST COCAINE HEPATOTOXICITY INFEMALE MICE. M. S. Abdel-Rahman1, R. M.Turkall1,2 and T. Visalli1. 1Pharmacology/Physiology,UMDNJ, Newark, NJ and 2Clinical LaboratorySciences, School of Health Related ProfessionsUMDNJ, Newark, NJ.

#1924 IDENTIFICATION OF NOVEL SUBSTRATESAND INHIBITORS OF SOLUBLE EPOXIDEHYDROLASE N-TERMINAL PHOSPHATASEACTIVITY BASED ON ITS SUBCELLULARLOCALIZATION. A. Enayetallah1, P. Srivastava1, M.Barber2, P. Mungalachetty1, B. Luo1 and D. Grant1.1Pharmaceutical sciences, University of Connecticut,Storrs, CT and 2Biotechnology/Bioservices Center,University of Connecticut, Storrs, CT.

#1925 EFFECTS OF BETAINE SUPPLEMENTATIONON HEPATIC METABOLISM OF SULFUR-CONTAINING AMINO ACIDS IN MICE. Y. C.Kim1 and S. K. Kim2. 1College of Pharmacy, SeoulNational University, Seoul, South Korea and 2Collegeof Pharmacy, Chungnam National University, Daijeon,South Korea. Sponsor: G. Carlson.

#1926 APPLICATION OF QSARS TO EVALUATEMOLECULAR MECHANISMS OFHALOBENZENE INDUCED CYTOTOXICITY INRAT HEPATOCYTES. K. Chan and P. J. O’Brien.Pharmaceutical Sciences, University of Toronto,Toronto, ON, Canada. Sponsor: G. Cherian.

#1927 ACTIVATION OF PROMUTAGENS WITHHUMAN LIVER S9 AND HUMANHEPATOCYTES USING CHINESE HAMSTEROVARY MICRONUCLEUS ASSAY. S. K. Roy1, A. P.Li2,3, B. Chris4, K. Paul1 and A. Thilagar1,2. 1SITEKResearch Laboratories, Rockville, MD, 2The ADMETGroup, LLC, Rockville, MD, 3In Vitro ADMETLaboratories, LLC, Rockville, MD and 4TissueTransformation Technologies Inc., Edison, NJ.

#1928 RUBRATOXIN B INDUCED TISSUE INHIBITOROF METALLOPROTEINASES (TIMP)-1SECRETION IN HEPG2 CELLS. H. Nagashima1, K.Maeda-Nakamura1, K. Iwashita1 and T. Goto2.1National Food Research Institute, Tsukuba, Ibaraki,Japan and 2Faculty of Agriculture, Shinshu University,Minamiminowa, Nagano, Japan. Sponsor: M.Fukayama.

#1929 FUMONISIN B1 AND TNFαα INDUCEDINCREASES IN SPHINGANINE ANDSPHINGOSINE IN HEPG2 HEPATOCYTES AREATTENUATED BY SP600125, A JNK INHIBITOR.S. Hsiao1, P. D. Constable2, M. E. Tumbleson3 and W.M. Haschek1. 1Veterinary Pathobiology, University ofIllinois at Urbana-Champaign, Urbana, IL, 2VeterinaryClinical Medicine, University of Illinois at Urbana-champaign, Urbana, IL and 3Agricultural and BiologicalEngineering, University of Illinois at Urbana-Champaign, Urbana, IL.

#1930 AUGMENTATION OF LIPOPOLYSACCHARIDE-INDUCED GENE EXPRESSION AND LIVERINJURY BY RANITIDINE BUT NOTFAMOTIDINE. J. P. Luyendyk1, L. D. Lehman-McKeeman2, D. M. Nelson2, V. Bhaskaran2, B. D. Car2,G. H. Cantor2, C. M. North1, S. W. Newport1, J. F.Maddox1, P. E. Ganey1 and R. A. Roth1. 1Department ofPharmacology and Toxicology, Michigan StateUniversity, East Lansing, MI and 2DiscoveryToxicology, Bristol-Myers Squibb, Princeton, NJ.

#1931 1H-NMR BASED METABONOMICS STUDY OFGALACTOSAMINE, METHYLENE DIANILINE,AND CLOFIBRATE IN RATS. N. Katsutani and T.Aoki. Eisai Co., Ltd.,, Drug Safety ResearchLaboratories, Hashima, Gifu-ken, Japan.

#1932 EVALUATION OF A NOVEL ANTI-TUMORDRUG USING IN VITRO TOXICITY SCREENINGIN RAT HEPATOMA (H4IIE) CELLS, NORMALRAT KIDNEY (NRK) CELLS, AND RATPRIMARY HEPATOCYTES. P. C. Wilga, J. M.McKim, Jr., J. F. Pregenzer and D. K. Petrella. CeeTox,Kalamazoo, MI.

#1933 UPREGULATION OF STEM CELL-DERIVEDTYROSINE KINASE (STK) EXPRESSION INLIVER MACROPHAGES AND ENDOTHELIALCELLS DURING ACUTE ENDOTOXEMIA ISINDEPENDENT OF TUMOR NECROSIS FACTORRECEPTOR-1. L. C. Chen, J. Laskin and D. Laskin.Joint Graduate Program in Toxicology, RutgersUniversity and UMDNJ-RWJMS, Piscataway, NJ.

Program Description


WED

NESD

AY


#1934 EVALUATION OF SYSTEMIC TOXICITY INMIXTURES OF TRICHLOROETHYLENE (TCE),HEPTACHLOR (HEPT), AND DI(2-ETHYLHEXYL)PHTHALATE (DEHP) ASSESSEDIN A 5X5X5 DESIGN. J. Simmons1, S. Yeatts2, J.Zhao2, C. Gennings2, A. McDonald1 and R. MacPhail1.1NHEERL/ORD, U.S. EPA, Resesarch Triangle Park,NC and 2Department Biostatistics, VCU, Richmond,VA.

#1935 FIRST-PASS EFFECTS ON THEBIOAVAILABILITY OF HISTAMINEDIHYDROCHLORIDE. A MULTIPLE-CANNULAE DOG MODEL FORINVESTIGATION OF HEPATIC ELIMINATION.B. M. Richard1, T. M. Tuell1, R. R. Lane1, J. M. Trang2,S. Authier3, C. A. Zerouala3, S. J. Watson3, L.Berryman3 and S. A. Tonetta1. 1Nonclinical, MaximPharmaceuticals, San Diego, CA, 2PK/PD, PK/PDInternational, Tucson, AZ and 3Toxicology, LAB Pre-Clinical Research International, Laval, QC, Canada.


POSTER SESSION: NEUROTOXICITY, PESTICIDES

Chairperson(s): Nikolay Filipov, Mississippi State University, MississippiState, MS and Timothy Shafer, U.S. EPA, Research Triangle Park, NC.



#1936 REACTIVITY AND MODELING STUDIESPREDICT THAT FLUORINATEDAMINOPHOSPHONATES (FAP) INHIBITCHOLINESTERASES (CHE) VIA P—C BONDCLEAVAGE. G. F. Makhaeva1, A. Y. Aksinenko1, V. B.Sokolov1, A. N. Razdolsky1, N. N. Strakhova1, V. V.Malygin1, J. W. Kampf2, F. A. Nasser3 and R. J.Richardson3. 1Institute of Physiologically ActiveCompounds RAS, Chernogolovka, Russian Federation,2Chemistry Department, University of Michigan, AnnArbor, MI and 3EHS Department, Toxicology Program,University of Michigan, Ann Arbor, MI.

#1937 X-RAY CRYSTAL STRUCTURES OFFLUORINATED AMINOPHOSPHONATE (FAP)COMPOUNDS SHOW AN ELONGATED P—CBOND AND DIMERIZATION. F. A. Nasser1, J. W.Kampf2, G. F. Makhaeva3, A. Y. Aksinenko3, V. B.Sokolov3, N. N. Strakhova3, V. V. Malygin3 and R. J.Richardson1. 1EHS Department, Toxicology Program,University of Michigan, Ann Arbor, MI, 2ChemistryDepartment, University of Michigan, Ann Arbor, MIand 3Institute of Physiologically Active CompoundsRAS, Chernogolovka, Russian Federation.

#1938 MASS SPECTOMETRY REVEALS THAT SERINEESTERASES ARE PHOSPHORYLATED ANDAGED BY FLUORINATEDAMINOPHOSPHONATE (FAP) COMPOUNDS. N.D. Miller1, J. S. Pierce1, P. Glynn2, R. M. Worden3, J.Sun3, G. F. Makhaeva4, A. Y. Aksinenko4, V. B.Sokolov4, V. V. Malygin4 and R. J. Richardson1.1University of Michigan, Ann Arbor, MI, 2University ofLeicester, Leicester, United Kingdom, 3Michigan StateUniversity, East Lansing, MI and 4Institute ofPhysiologically Active Compounds RAS,Chernogolovka, Russian Federation.

#1939 COMPARISON BETWEEN ELLMAN ANDRADIOMETRIC METHODS FOR ASSESSINGCHOLINESTERASE (CHE) INHIBITION IN RATSTREATED WITH N-METHYL CARBAMATEINSECTICIDES. D. L. Hunter1, D. Chen4, R. S.Marshall1, S. Padilla1, W. Setzer2, V. C. Moser1 and A.Lowit3. 1NTD, U.S. EPA, Research Triangle Park, NC,2ETD, U.S. EPA, Research Triangle Park, NC, 3OPP,U.S. EPA, Arlington, VA and 4Enloe High School,Raleigh, NC.

#1940 TIME COURSE AND DOSE RESPONSEASSESSMENT OF CHOLINESTERASE (CHE)INHIBITION IN ADULT RATS TREATEDACUTELY WITH CARBARYL, METHOMYL,METHIOCARB, OXAMYL OR PROPOXUR. S.Padilla1, R. S. Marshall1, D. L. Hunter1, P. Phillips1, K.McDaniel1, V. C. Moser1 and A. Lowit2. 1NTD, U.S.EPA, Research Triangle Park, NC and 2OPP, U.S. EPA,Arlington, VA.

#1941 COMPARISON OF ACUTE NEUROBEHAVIORALEFFECTS OF N-METHYL CARBAMATEINSECTICIDES. V. C. Moser1, P. M. Phillips1, K. L.McDaniel1, R. S. Marshall1, S. Padilla1 and A. Lowit2.1NTD/NHEERL, U.S. EPA, Research Triangle Park,NC and 2HED/OPP, U.S. EPA, Arlington, VA.

#1942 THE ORGANOPHOSPHOROUS INSECTICIDEFENTHION DOES NOT AFFECTPHAGOCYTOSIS OF ROD OUTER SEGMENTSBY RETINAL PIGMENT EPITHELIUM CELLSIN CULTURE. A. M. Geller and L. L. Degn.Neurotoxicology, U.S. EPA, Research Triangle Park,NC.

#1943 CONCURRENT EXPOSURE TO REPEATEDSTRESS AND CHLORPYRIFOS ALTERED NMDAAND TOTAL MUSCARINIC RECEPTORRESPONSES IN HIPPOCAMPUS, CEREBRALCORTEX AND HYPOTHALAMUS. T. Pung, K.Fuhrman, B. Klein, D. Blodgett, B. S. Jortner and M.Ehrich. Virginia Tech, Blacksburg, VA.

#1944 NEUROTROPHIN CONCENTRATION AFTER INVIVO EXPOSURE TO NEUROPATHIC AND NON-NEUROPATHIC ORGANOPHOSPHATES. M. J.Pomeroy-Black, M. F. Ehrich and B. S. Jortner.Laboratory for Neurotoxicity Studies, Department ofBiomedical Science and Pathobiology, Virginia-Maryland Regional College of Veterinary Medicine,Blacksburg, VA.

Program Description



WED

NES

DAY

#1945 CHLORPYRIFOS INDUCES APOPTOSIS INOLIGODENDROCYTE PROGENITOR (CG-4)CELLS. S. O. Heyliger1, M. D. Saulsbury1, D. J.Johnson1, D. P. Round1, J. K. Morse1 and S. Green2.1Pharmaceutical Sciences, Hampton University,Hampton, VA and 2Pharmacology, Howard UniversitySchool of Medicine, Washington, DC.

#1946 ROLE OF A-ESTERASES IN THE AGE-RELATEDDIFFERENCES IN ORGANOPHOSPHATEDETOXICATION. E. C. Meek1, H. Chambers2 and J.E. Chambers1. 1Center for Environmental HealthSciences, Mississippi State University, MississippiState, MS and 2Department of Entomology and PlantPathology, Mississippi State University, MississippiState, MS.

#1947 EFFECT OF ORGANOPHOSPHATEINSECTICIDE EXPOSURE ON DOPAMINEMETABOLISM IN STRIATAL SLICES. J. A.Whitehead1, E. C. Meek1, J. E. Chambers1, S. C.Sistrunk1, H. W. Chambers2 and N. M. Filipov1. 1Centerfor Environmental Health Sciences, Coll. Vet. Med.,Mississippi State University, Mississippi State, MS and2Entomology, Mississippi State University, MississippiState, MS.

#1948 THIOFLAVIN-T, AN ACETYLCHOLINESTERASEPERIPHERAL SITE LIGAND, DECREASESNG108-15 CELL PROLIFERATION. H. M.Campanha and E. J. Flynn. Pharmacology andPhysiology, UMD-New Jersey Medical School,Newark, NJ.

#1949 TOXICITY OF CHLORPYRIFOS ANDCHLORPYRIFOS OXON IN A TRANSGENICMOUSE MODEL OF THE HUMANPARAOXONASE (PON1) Q192RPOLYMORPHISM. T. B. Cole1,2,3, B. J. Walter1, D.M. Shih4, A. Tward4, A. J. Lusis4, L. G. Costa1 and C.E. Furlong2,3. 1Environmental and Occupational HealthSciences, University of Washington, Seattle, WA,2Medicine, Division of Medical Genetics, University ofWashington, Seattle, WA, 3Genome Sciences,University of Washington, Seattle, WA and4Microbiology and Molecular Genetics, UCLA, LosAngeles, CA.

#1950 EFFECTS OF DIAZINON AND CYPERMETHRINON DIFFERENTIATING NEURONAL ANDGLIAL CELL LINES. M. Sachana1, W. Harris3, J.Tack3, J. Flaskos2 and A. J. Hargreaves3. 1VeterinaryPathology, University of Liverpool, Neston, UnitedKingdom, 2Laboratory of Biochemistry and Toxicology,Faculty of Veterinary Medicine, Aristotelian University,Thessalonika, Greece and 3School of Science, Facultyof Science and Land Based Studies, Nottingham TrentUniversity, Nottingham, United Kingdom. Sponsor: R.Gupta.

#1951 GLUCOSE CONSUMPTION ENHANCESPARATHION TOXICITY: FUNCTIONAL ANDNEUROCHEMICAL CORRELATES. J. Liu, A.Abbey and S. Karanth. Physiological Sciences,Oklahoma State University, Stillwater, OK.

#1952 IMMEDIATE EARLY ALTERATION ANDDIFFERENTIAL PERSISTENCE OF PKA(PROTEIN KINASE A) / P-CREB(PHOSPHORYATED CREB) PATHWAY IN THECENTRAL NERVOUS SYSTEM OF HENSDEVELOPING DELAYED NEUROTOXICITY(OPDIN) BY A SINGLE DOSE OFDIISOPROPYLPHOSPHOROFLUORIDATE (DFP)TREATMENT. T. V. Damodaran, R. Gupta and M.Abou-Donia. Pharmacology/ Pediatrics, DukeUniversity Medical Center, Durham, NC.

#1953 ACTIONS OF PYRETHROID INSECTICIDES ONTHE SPONTANEOUS RELEASE OFGLUTAMATE FROM CULTUREDHIPPOCAMPAL NEURONS. D. A. Meyer2 and T. J.Shafer1. 1Neurotoxicology Division, NHEERL, ORD,U.S. EPA, Research Triangle Park, NC and 2Curriculumin Toxicology, University of North Carolina at ChapelHill, Chapel Hill, NC.

#1954 EFFECT OF PYRETHROIDS ON GLUTAMATERELEASE IN THE HIPPOCAMPUS OF FREELYMOVING RATS. H. Kobayashi1,3, M. M. Hossain1,3,T. Suzuki1,3, I. Sato1,3, T. Takewaki3 and K. Suzuki2.1Veterinary Medicine, Iwate University, Morioka, Iwate,Japan, 2Agro-bioscience, Iwate University, Morioka,Iwate, Japan and 3United Graduate School of VeterinarySciences, Gifu University, Gifu, Japan. Sponsor: G.Corcoran.

#1955 EFFECTS OF EXPOSURE TO THE PESTICIDEATRAZINE ON STRIATAL NEUROCHEMISTRYIN MALE C57BL/6 MICE ARE AGE-DEPENDENT. N. M. Filipov, A. Coban, S. C. Sistrunkand A. B. Norwood. Center for Environmental HealthSciences, Basic Sciences, Coll. Vet. Med., MississippiState University, Mississippi State, MS.

#1956 EFFECTS OF 14-DAY EXPOSURE TO THEHERBICIDE ATRAZINE ON DOPAMINENEURONS IN THE SUBSTANTIA NIGRA ANDVENTRAL TEGMENTAL AREA OF JUVENILEMALE C57BL/6 MICE. A. Coban, A. B. Norwoodand N. M. Filipov. Center for Environmental HealthSciences, Basic Sciences, Coll. Vet. Med., MississippiState University, Mississippi State, MS.

#1957 DECREASE OF THE STRIATAL DOPAMINERELEASE CAUSED BY ACUTE ATRAZINEEXPOSURE IS BLOCKED BY HALOPERIDOLADMINISTRATION. V. M. Rodriguez, M.Thiruchelvam and D. A. Cory-Slechta. Environmentaland Community Medicine, Environmental andOccupational Health Sciences Institute, The Universityof Medicine and Dentistry of New Jersey and Rutgers,Piscataway, NJ.

#1958 GENDER DIFFERENCES IN A PESTICIDEMODEL OF PARKINSON’S DISEASE. M.Thiruchelvam, H. Mehta, B. Winnik, B. Buckley, E. K.Richfield and D. A. Cory-Slechta. EOHSI,UMDNJ–Robert Wood Johnson Medical School,Piscataway, NJ.

Program Description


WED

NESD

AY


#1959 SIGNALING PATHWAYS OF PARAQUAT-INDUCED APOPTOSIS: A MODEL FORPARKINSON’S DISEASE. H. M. Klintworth1 and Z.Xia1,2. 1Env. & Occ. Health Sciences, University ofWashington, Seattle, WA and 2Phamacology, Universityof Washington, Seattle, WA.

#1960 THE ORGANOCHLORINE PESTICIDEMETHOXYCHLOR ALTERS BRAINMITOCHONDRIAL RESPIRATION, H2O2PRODUCTION AND CALCIUM/CAMPRESPONSE ELEMENT BINDING PROTEINLEVELS. R. A. Schuh3,1, T. Kristian1, J. Flaws3 and G.Fiskum1. 1Anesthesiology, University of MarylandBaltimore, Baltimore, MD, 2Anesthesiology, Universityof Maryland Baltimore, Baltimore, MD, 3Epidemiologyand Experimental Therapeutics, University of MarylandBaltimore, Baltimore, MD and 4Anesthesiology,University of Maryland Baltimore, Baltimore, MD.

#1961 DIELDRIN EXPOSURE CAUSES OXIDATIVEDAMAGE IN DOPAMINE NEURONS. J. M.Hatcher1, T. S. Guillot1, J. R. Richardson1,2 and G. W.Miller1,2. 1Center for Neurodegerative Disease, EmoryUniversity, Atlanta, GA and 2Environmental andOccupational Health, Rollins School of Public Health,Emory University, Atlanta, GA.

#1962 MECHANISM OF SELECTIVE TOXICITY OFIVERMECTIN IN INSECTS AND MAMMALS. T.Narahashi1, X. Zhao1, V. L. Salgado2 and J. Z. Yeh1.1Molecular Pharmacology and Biological Chemistry,Northwestern University Medical School, Chicago, ILand 2Bayer CropScience, Global Biology Insecticides,Monheim, Germany.

#1963 SULFONE METABOLITE OF FIPRONILBLOCKS GABA- AND GLUTAMATE-ACTIVATED CHLORIDE CHANNELS INMAMMALIAN AND INSECT NEURONS. X. Zhao1,J. Z. Yeh1, V. L. Salgado2 and T. Narahashi1.1Molecular Pharmacology and Biological Chemistry,Northwestern University Medical School, Chicago, ILand 2Bayer CropScience, Global Biology Insecticides,Monheim, Germany.

#1964 IMMORTALIZED MICROGLIAL CELLS AS AMODEL SYSTEM FOR OXIDATIVE STRESS:PESTICIDE-INDUCED GENOMIC CHANGES. J.E. Royland1, P. R. Kodavanti1, M. Pooler2, O.Makwana2 and B. Veronesi1. 1NeurotoxicologyDivision, U.S. EPA, Durham, NC and 2ToxicologyProgram, NC State University, Raleigh, NC.

#1965 NEUROTOXIC EFFECTS OF MANCOZEB ANDMANEB IN VIVO AND IN VITRO. L. M. Domico1,2, G. Zeevalk2, M. Thiruchelvam2 and K. R. Cooper1.1Joint Graduate Program in Toxicology, Rutgers, TheState University of New Jersey, Piscataway, NJ and2University of Medicine and Dentistry of New Jersey,Piscataway, NJ.

#1966 EFFECT OF PYRETHROIDS ON GABARELEASE IN THE HIPPOCAMPUS OF FREELYMOVING RATS. M. M. Hossain1,3, T. Suzuki1,3, I.Sato1,3, T. Takewaki3, K. Suzuki2 and H. Kobayashi1,3.1Veterinary Medicine, Iwate University, Morioka, Iwate,Japan, 2Agro-bioscience, Iwate University, Morioka,Iwate, Japan and 3United Graduate School of VeterinarySciences, Gifu University, Gifu, Japan. Sponsor: G.Corcoran.

#1967 EFFECTS OF PHENYL SALYGENINPHOSPHATE (PSP) AND PHENYLMETHANESULFONYL FLUORIDE (PMSF) ON RATDORSAL ROOT GANGLIA (DRG) CULTURES. E.Brigo1, A. Moretto1, P. Glynn2, D. E. Read2 and M.Lotti1. 1Medicina del Lavoro, Universita’ di Padova,Padova, Italy and 2Toxicology Unit, MRC, Leicester,United Kingdom.



SUNSET SESSION: ADVANCES IN MATERIAL SAFETY DATASHEET COMMUNICATION

Chairperson(s): Melissa McDiarmid, University of Maryland, Baltimore, MDand James Bus, Dow Chemical Company, Midland, MI.

Endorsed by:Occupational and Public Health SS*Regulatory and Safety Evaluation SSRisk Assessment SS

OSHA is currently reviewing its Material Safety Data Sheets (MSDS) require-ments, as is the American National Standards Institute (ANSI). Employers usinghazardous chemicals are required by OSHA’s Hazard Communications Standardto have MSDSs available to workers. Developing and providing effectivecommunication is a major challenge within the public health and occupationalhealth communities. Some MSDSs are difficult for workers to read; someMSDSs are outdated; and some MSDSs omit needed health information. On theother hand, some manufacturers produce what might be considered examples of“best practice” MSDS writing: excellent, readable, and timely information.Another source of information, the New Jersey Hazardous Substances FactSheets, covers only about 1, 600 workplace chemicals. However, the programreceives 80, 000 hits per month on its website for its fact sheets, which areconsidered by many environmental and labor advocates to be good sources ofessential health and safety information. The message that reproductive healthincludes both men and women, and that it can be affected by their workplaceexposures, needs to reach the workers and their employers through MSDScommunication. Paul and Kurtz surveyed Massachusetts MSDSs in 1994 forproducts containing two known reproductive toxicants, lead and glycol ethers,and found that over 60% did not mention possible reproductive health effects.They also found that where reproductive hazards were mentioned in MSDSs,they were 18 times more likely to address developmental effects than malereproductive risks. How can MSDS writing be improved to a best practice stan-dard while avoiding national or international standards conflicts? The NIOSHReproductive Health Research Team is interested in finding ways to improve thequality of MSDSs in general, and particularly the quality of reproductive healthinformation. Representatives from NIOSH, industry, academia, and the NewJersey Right to Know Program will present and discuss multiple facets of thisissue.

Program Description



WED

NES

DAY

#1664 4:30 ADVANCES IN MATERIAL SAFETY DATASHEET COMMUNICATION. M. McDiarmid1 and L.Frazier2. 1Occupational Health Project, University ofMaryland, Baltimore, MD and 2Department ofPreventive Medicine, University of Kansas School ofMedicine, Wichita, KS.

#1665 4:40 ISSUES WITH MSDS COMMUNICATION OFREPORDUCTIVE HAZARDS. L. Frazier1,2, M. J.Rall2 and D. B. Fromer1. 1Preventive Medicine andPublic Health, University of Kansas School ofMedicine-Wichita, Wichita, KS and 2Obstetrics andGynecology, University of Kansas School of Medicine-Wichita, Wichita, KS. Sponsor: M. McDiarmid.

#1666 5:00 DEVELOPING GOOD MSDSCOMMUNICATIONS IN INDUSTRY. J. S. Bus. TheDow Chemical Company, Midland, MI.

#1667 5:20 MSDSS IN CANADA AND THECOMMUNICATION OF REPRODUCTIVETOXICITY. P. Demers. School of Occ/Env Hygiene,University of British Columbia, Vancouver, BC,Canada. Sponsor: M. McDiarmid.

#1668 5:40 STRENGTHS OF THE NJ HAZARDOUSSUBSTANCE FACT SHEET PROGRAM: HOWTO WRITE A BETTER MSDS. R. Willinger, JDMPH and A. Sobieszczyk, MD PhD. Right to KnowProgram, New Jersey Department of Health and SeniorServices, Trenton, NJ. Sponsor: B. Grajewski.


SUNSET SESSION: THE SAFETY ASSESSMENT OFNUTRITIONALLY IMPROVED FOOD AND FEED CROPS

Chairperson(s): Bruce Hammond, Monsanto, St. Louis, MO and Philip M.Bolger, U.S. FDA, College Park, MD.

Endorsed by:Food Safety SS*Regulatory and Safety Evaluation SSStudent Advisory Committee

The first generation of food and feed crops developed through modern agricul-tural biotechnology were designed to improve agronomic characteristics such ascontrol of noxious weeds (herbicide tolerance) or protection against insect pests.The next generation of products under development include crops that haveimproved nutritional characteristics. Speakers for this workshop will discuss (1)various biotechnology approaches that are being used to improve nutritionalcharacteristics of feed/food crops, (2) a case study for the safety and nutritionalassessment of a nutritionally improved food/feed crop (3) recommendations ofthe EU ENTRANSFOOD working group on safety assessment of foods derivedfrom genetically modified crops (4) conclusions from a recent ILSI workshopentitled Nutritional and Safety Assessments of Foods and Feeds NutritionallyImproved through Biotechnology. At the end of the presentations, a paneldiscussion will compare and contrast recommendations from the SOT,ENTRANSFOOD and ILSI workgroups regarding the safety assessment ofnutritionally improved crops.

#1669 4:30 THE SAFETY ASSESSMENT OFNUTRITIONALLY IMPROVED FOOD AND FEEDCROPS. B. G. Hammond. Product Safety Center,Monsanto Company, St. Louis, MO.

#1670 4:32 IMPROVED NUTRITION THROUGH MODERNBIOTECHNOLOGY. M. Newell–McGloughlin.University of California Systemwide BiotechnologyResearch and Education Program, U.C. Davis, Davis,CA. Sponsor: B. Hammond.

#1671 4:47 CASE STUDY FOR THE SAFETY ASSESSMENTOF A NUTRITIONALLY IMPROVEDFEED/FOOD CROP. B. G. Hammond, T. Reynolds, G.Hartnell, E. Rice, R. McCoy and K. Glenn. ProductSafety Center, Monsanto Company, St. Louis, MO.

#1672 5:02 SAFETY ASSESSMENT OF NUTRITIONALLYIMPROVED CROPS THROUGH MODERNBIOTECHNOLOGY. H. A. Kuiper, G. A. Kleter andE. J. Kok. RIKILT, Institute of Food Safety,Wageningen University and Research Center,Wageningen, Netherlands. Sponsor: B. Hammond.

#1673 5:22 SAFETY AND NUTRITIONAL ASSESSMENT OFFOODS AND FEEDS NUTRITIONALLYIMPROVED THROUGH BIOTECHNOLOGY. I. C.Munro. CANTOX Health Sciences International,Mississauga, ON, Canada.


SUNSET SESSION: VINYL CHLORIDE: LEGACY AND LESSONSLEARNED

Chairperson(s): Roger O. McClellan, Toxicology and Human Health RiskAnalysis, Albuquerque, NM and Melvin Andersen, CIIT Centers for HealthResearch, Research Triangle Park, NC.

Endorsed by:Biological Modeling SSCarcinogenesis SSComparative and Veterinary SSRisk Assessment SS*

Vinyl chloride is a major commodity chemical that has been extensively studiedrelative to its toxicological and carcinogenic properties. Early researchconducted by producers and users of vinyl chloride focused on its toxicologicalproperties. The research results were used in a standard safety factor frameworkto derive threshold limit values for occupational exposure. Long-term rodentinhalation studies were initiated to investigate the potential for chronic toxicityand carcinogenicity. Almost concurrently, carcinogenic responses wereobserved in the rodent studies and case reports were published on a finding ofa rare cancer, hepatic angiosarcomas in workers exposed to high levels of vinylchloride. More stringent occupational exposure limits were instituted andfurther research on vinyl chloride initiated. This included epidemiologicalstudies of workers, animal carcinogenicity bioassays and mechanistic investiga-tions. The initial results, while confirming the carcinogenicity of vinyl chloridein humans and rodents, appeared to yield marked differences in carcinogenicpotency in humans and rodents. Further research on the metabolic kinetics andmolecular dosimetry of vinyl chloride and its metabolites provided a basis forreconciling the original apparent species differences in potency and provided amechanistic basis for the very specific carcinogenic response, hepatic angiosar-comas. The more stringent exposure standards have been effective in protectingworkers. In retrospect, the research conducted on vinyl chloride may be viewedas a success story for how mechanism-based findings can be used to establishappropriate health protective standards. Moreover, the research approach usedwith vinyl chloride has served as a template for evaluating the toxicity andcarcinogenicity of other chemicals.

Program Description


WED

NESD

AY


#1674 4:30 VINYL CHLORIDE: LEGACY AND LESSONSLEARNED. R. O. McClellan. Toxicology and HumanHealth Risk Analysis, Albuquerque, NM.

#1675 4:40 METABOLISM OF VINYL HALIDES ANDREACTIONS OF ELECTROPHILIC PRODUCTS.F. P. Guengerich. Biochemistry and Center in MolecularToxicology, Vanderbilt University, Nashville, TN.

#1676 5:00 VINYL CHLORIDE: ESTABLISHING THE ROLEOF DOSIMETRY IN RISK ASSESSMENT. M. E.Andersen. CIIT Centers for Health Research, ResearchTriangle Park, NC.

#1677 5:20 VINYL CHLORIDE: TOXICOLOGICAL ANDCARCINOGENIC RESPONSES IN HUMANS ANDLABORATORY ANIMALS. R. O. McClellan.Toxicology and Human Health Risk Analysis,Albuquerque, NM.

Abstract 1678 is located on page 178


SOT COUNCIL MEETING WITH STUDENTS/POST-DOCTORALFELLOWS

All students and post-doctoral fellows are encouraged to attend this meeting,which provides as a two-way dialog between SOT Council and students.

Wednesday Evening

Wednesday Evening, March 96:00 PM to 7:30 PMSee Events Calendar on Pages 2–6 for Room Listings

SPECIALTY SECTION MEETINGS:COMPARATIVE AND VETERINARY, DERMAL, DRUG DISCOVERY,FOOD SAFETY, MOLECULAR BIOLOGY, REPRODUCTIVE ANDDEVELOPMENTAL, WOMEN IN TOXICOLOGY.

Wednesday Evening, March 96:00 PM to 11:00 PMSee Events Calendar on Pages 2–6 for Room Listings



Thursday Morning

Thursday Morning, March 108:30 AM to 11:30 AMRoom RO4

SYMPOSIUM SESSION: CROSS-SPECIES TOXICOLOGY IN THEAGE OF GENOMICS

Chairperson(s): William B. Mattes, Gene Logic Inc., Gaithersburg, MD andTimothy P. Ryan, Eli Lilly and Company, Greenfield, IN.

Endorsed by:National Capital Area ChapterRisk Assessment SS

While animal models have been the cornerstone of experimental toxicology andsafety assessment for the last two centuries, the question often arises whetherthe results seen in one species are relevant to what may be expected in another,particularly when the extrapolation is being made to man. Genomic informationcould change this problem dramatically. At one level, comparisons of codingregions and upstream regulatory regions across genomes can provide clues as tosimilarities and differences between species vis-à-vis the molecular componentsof a cell and their regulation. One example where this approach has providedvaluable insights is the nuclear receptor gene family. These genomic compar-isons can also be used to inform the use of non-mammalian models of toxicitysuch as Caenorhabditis elegans. Complementary to such genomic comparisons,mRNA profiling with microarrays allows a global view of toxicant-inducedtranscriptome alterations in various cell types, tissues and species, and allows anexperimental view of similarities and differences in signaling and response path-ways. Thus transcriptome alterations can be compared in vivo between rat andcanine models, and in vitro between rat, canine, and human hepatocytes. Thepromise is that such tools will allow for any given toxic response a truly molec-ular assessment of the relevance of various animal models to one another and toman.

#1968 8:30 CROSS-SPECIES TOXICOLOGY IN THE AGEOF GENOMICS. W. B. Mattes1 and T. P. Ryan2.1Toxicogenomics, Gene Logic Inc., Gaithersburg, MDand 2Investigative Toxicology, Eli Lily and Company,Greenfield, IN.

#1969 8:40 INSIGHTS INTO EVOLUTION OF XENOBIOTICMETABOLISM IN MAMMALS FROMCOMPARATIVE GENOMICS OF THE NUCLEARRECEPTOR GENE FAMILY. D. A. Wheeler1,2, A. J.Cooney3 and Z. Zhang1. 1Human Genome SequencingCenter, Baylor College of Medicine, Houston, TX,2Molecular and Human Genetics, Baylor College ofMedicine, Houston, TX and 3Molecular and CellularBiology, Baylor College of Medicine, Houston, TX.Sponsor: W. Mattes.

#1970 9:05 COMPUTATIONAL AND EMPIRICALINVESTIGATION OF ESTROGEN AND DIOXINELICITED EFFECTS: A COMPARATIVEANALYSIS. T. Zacharewski. Biochemistry &Molecular Biology, Center for Integrative Toxicology,National Food Safety & Toxicology Center, MichiganState University, East Lansing, MI.

#1971 9:30 GENOMIC CHARACTERIZATION OF THEACUTE PHASE RESPONSE IN MICE, DOGS,AND RATS. T. P. Ryan. Investigative Toxicology, EliLily and Company, Greenfield, IN.

Program Description



THU

RSD

AY

#1972 9:55 CROSS-SPECIES COMPARISONS OFTRANSCRIPTIONAL RESPONSES IN PRIMARYHEPATOCYTES. W. B. Mattes, K. Daniels, D. L.Mendrick and M. S. Orr. Toxicogenomics, Gene LogicInc., Gaithersburg, MD.

#1973 10:20 TOXICO- AND PHARMACOGENETIC ANALYSISIN A NOVEL MODEL OF PARKINSON’SDISEASE: DOPAMINE NEURONDEGENERATION IN C. ELEGANS. R. Nass, C.Nichols, M. Fullard, M. Garrett and M. Marvanova.Anesthesiology and Pharmacology, and Center forMolecular Neuroscience, Vanderbilt University MedicalCenter, Nashville, TN. Sponsor: B. Mattes.

Thursday Morning, March 108:30 AM to 11:30 AMRoom 208

SYMPOSIUM SESSION: DEVELOPMENTAL EXPRESSION OFHUMAN PHASE I AND PHASE II TOXICANT METABOLIZINGENZYMES: IMPACT ON EARLY LIFE STAGE SUSCEPTIBILITY

Chairperson(s): Ronald Hines, Medical College of Wisconsin, Milwaukee, WIand Melissa A. Runge-Morris, Wayne State University, Detroit, MI.

Endorsed by:Mechanisms SSRisk Assessment SSStudent Advisory Committee

Over the past several years, there has been considerable interest in the dynamicchanges that occur in toxicokinetic factors during early life stages and how thesechanges may impact differential toxicant susceptibility. Advances in molecularand analytical techniques have allowed a better characterization of thesechanges, as well as some of the underlying control mechanisms. The objectivesof this symposium are to: 1) present examples of the information gained aboutmajor members of the oxidative Phase I enzymes and how this information hasled to the identification of common developmental themes; 2) present informa-tion on the developmental expression of two conjugative phase II enzymeclasses, N-acetyl transferases and sulfotransferases, and how, combined with theinformation regarding phase I enzymes, can inform regarding possible differen-tial susceptibility during ontogeny; and 3) demonstrate how such informationregarding developmental expression can be integrated into physiological-basedtoxicokinetic models for predicting temporal-specific changes in toxicant dispo-sition useful for early life stage risk assessment. These advances offer thepromise and challenge of predicting changing dose-response relationshipsduring early life and the possible prevention of developmental toxicity.

#1974 8:30 ONTOGENY OF HUMAN HEPATIC PHASE IAND PHASE II ENZYMES: IMPLICATIONS FORDIFFERENTIAL TOXICANT SUSCEPTIBILITY.R. N. Hines1 and M. A. Runge-Morris2. 1Pediatrics,Medical College of Wisconsin, Milwaukee, WI and2Inst. Env. Hlth. Sciences., Wayne State University,Detroit, MI.

#1975 8:35 HUMAN HEPATIC PHASE I ENZYMEDEVELOPMENTAL EXPRESSION. R. N. Hines.Pediatrics, Med. Col. Wisconsin, Milwaukee, WI.

#1976 9:15 SULFOTRANSFERASE EXPRESSION:IMPLICATIONS FOR PRENATAL TOXICITY. M.Runge-Morris. Inst. Envir. Health Sciences., WayneState University, Detroit, MI.

#1977 9:55 DEVELOPMENTAL EXPRESSION OF HUMANAND MURINE ARYLAMINE N-ACETYLTRANSFERASES(NAT):IMPLICATIONS FOR AROMATIC AMINEGENOTOXICITY. C. A. McQueen. University ofArizona, Tucson, AZ.

#1978 10:35 DEVELOPMENT OF PHYSIOLOGICALLY-BASED TOXICOKINETIC MODELS FOR EARLYLIFE STAGES: IMPLICATIONS FORDIFFERENTIAL TOXICANT SUSCEPTIBILITY.D. Hattis1, G. Ginsberg2, B. Sonawane3 and K. Walker4.1Clark University, Worcester, MA, 2CT Department ofPublic Health, Hartford, CT, 3U.S. EPA, Washington,DC and 4Clark University, Worcester, MA.

Thursday Morning, March 108:30 AM to 11:30 AMRoom 220

SYMPOSIUM SESSION: SYSTEMS BIOLOGY: APPROACHES ANDAPPLICATIONS TO TOXICOLOGY

Chairperson(s): William Slikker, Jr., National Center for ToxicologicalResearch, Jefferson, AR and Thomas Knudsen, University of Louisville, Schoolof Dentistry, Louisville, KY.

Endorsed by:Neurotoxicology SSReproductive and Development SSRisk Assessment SS*

Genomics and proteomics provide information on the cellular reaction to drugand chemical exposures but this is only part of what is needed to understandcomplex developing systems, where susceptibilities to exposure may advancethrough transitional states of varying susceptibilities. The NIH Director’s RoadMap has focused on the need to provide new tools to investigators, to speed theprocess of discovery, to encourage interdisciplinary research, and to promotetranslational research. Systems biology will contribute to this missive. Systemsbiology is the application of systems theory to solving biological problems andis a means to analyze complex behavior in a composite system that may bedecomposed into subsystems to facilitate understanding and modeling. In toxi-cology, it provides a means for identifying pathways that are critical to diseaseand to discovering on- and off- target effects of compounds. Devising computa-tional models and integrating these models with empirical data provideimportant insight into complex systems-level behaviors, ultimately striving todeliver the mechanism connecting small molecules (drug or chemical) with aclinical endpoint (phenotype or disease) with regards to metabolic and regula-tory networks. The integrative topic of systems biology and applicationexamples focused on several organ systems and stages of development willinterests toxicologists with backgrounds in mechanisms, reproduction, develop-ment, neuroscience, modeling, and safety and risk assessment.

#1979 8:30 SYSTEMS BIOLOGY: APPROACHES ANDAPPLICATIONS TO TOXICOLOGY. W. Slikker1

and T. B. Knudsen2. 1Division of Neurotoxicology,NCTR/FDA, Jefferson, AR and 2Department ofMolecular, Cellular and Craniofacial Biology BirthDefects Center, University of Lousiville, School ofDentistry, Louisville, KY.

#1980 9:00 EXTRACTING MEANING FROM EXPRESSIONDATA. J. Quackenbush. Institute for GenomicResearch, Rockville, MD. Sponsor: T. Knudsen.

Program Description


THU

RSDAY


#1981 9:30 MODELING GENE NETWORKS IN THENEURONAL ADAPTATION TO ALCOHOL. J. S.Schwaber. Department of Pathology, Anatomy and CellBiology, Thomas Jefferson University, Philadelphia, PA.Sponsor: W. Slikker.

#1982 10:00 SYSTEMS BIOLOGY AND DOSE RESPONSEASSESSMENT. M. Andersen. Division ofBiomathematics and Physical Sciences, CIIT, ResearchTriangle Park, NC.

#1983 10:30 AN ±±OMICS±± APPROACH TO ELUCIDATEMECHANIMS OF DISRUPTEDNEPHROGENESIS AND FUNCTIONALINTERACTIONS BETWEEN AHR ANDWILMS±±TUMOR SUPPRESSOR GENE. K. S.Ramos. Department of Biochemistry and MolecularBiology, University of Louisville, Louisville, KY.

#1984 11:00 COMPUTATIONAL SYSTEMS ANALYSIS OFDEVELOPMENTAL TOXICITY. T. B. Knudsen andA. V. Singh. Department of Molecular, Cellular andCraniofacial Biology, University of Louisville,Louisville, KY.


WORKSHOP SESSION: CELLULAR/MOLECULAR MECHANISMSINVOLVED IN ENVIRONMENTAL CHEMICALS- INDUCEDDOPAMINERGIC NEUROTOXICITY AND THE CONSEQUENCES ONNEURODEGENERATIVE DISEASES

Chairperson(s): Anumantha Kanthasamy, Iowa State University, Ames, IAand Syed F. Ali, NCTR FDA, Little Rock, AR.

Endorsed by:Neurotoxicology SS*Student Advisory Committee

Environmental neurotoxic chemical exposures are increasingly recognized asdominant risk factors in the etiology of many neurodegenerative disordersincluding Parkinson’s disease, Alzheimer’s disease Amyotrophic LateralSclerosis and Huntington’s disease. Exposure to environmental neurotoxicagents (metals, pesticides, PCBs and others) is often superimposed with thepathological hallmarks of neurodegenerative disorders. In recent years, celldeath mechanisms have been investigated extensively. Despite this growingamount of information regarding the cell death process, little effort has beenmade to integrate this body of knowledge with the area of neurotoxicology andestablish its relevance to neurodegenerative diseases. This workshop is designedto fill this gap by entertaining discussion of key cell death signaling moleculesand other cellular targets during neurotoxic chemical exposures that may impactthe disease process of neurodegenerative disorders. Specifically, novel findingsobtained from both in vitro and in vivo models of neurotoxicity using state-of-the-art approaches including toxicogenomics, transgenics, knock-outs, andRNA interference (RNAi) will be presented at this workshop. The workshoppresentations are expected to uncover unifying concepts and set the groundworkfor translation of key analogies between neurotoxicology research and neurode-generative disorders. Also, questions provided by the speakers will serve ascatalysts for discussion with the audience. Overall, this workshop is likely toaccelerate understanding of the role of environmental neurotoxic agents in theetiopathogenesis of neurodegenerative disorders as well as to foster the develop-ment of novel therapeutic strategies.

#1985 8:30 CELLULAR/MOLECULAR MECHANISMSINVOLVED IN ENVIRONMENTAL CHEMICALS-INDUCED DOPAMINERGIC NEUROTOXICITYAND THE CONSEQUENCES ONNEURODEGENERATIVE DISEASES. A. G.Kanthasamy. Iowa State University, Ames, IA.

#1986 8:35 OXIDATIVE STRESS-SENSITIVE KINASE INNEUROTOXINS-INDUCED SELECTIVEDOPAMINERGIC CELL DEATH: RELEVANCETO PARKINSON’S DISEASE. A. G. Kanthasamy.Biomedical Sciences, Iowa State University, Ames, IA.

#1987 9:15 ROLE OF PROINFLAMATORY CYTOKINES INCHEMICALLY-INDUCED DOPAMINERGICNEURODEGERATION. J. O’Callaghan.Neurotoxicology Laboratory, CDC/NIOSH,Morgantown, WV.

#1988 9:55 BIOLOGICAL BASES FOR PCB INDUCEDALTERATION IN DOPAMINE-MEDIATEDNEUROLOGICAL FUNCTION. R. F. Seegal2, K. L.Marek3, S. A. Factor4, R. J. McCaffrey5, R. F. Hasse5

and A. G. Kanthasamy1. 1Biomedical Sciences, IowaState University, Ames, IA, 2New York StateDepartment of Health, Wadsworth Center, Albany, NY,3Institute of Neurodegenerative Disorders, New Haven,CT, 4Albany Medical Center, Albany, NY and5University of Albany, Albany, NY.

#1989 10:35 ROLE OF NITRIC OXIDE INMETHAMPHETAMINE-INDUCEDDOPAMINERGIC NEUROTOXICITY IN MICE. S.F. Ali1 and Y. Itzhak2. 1Division of Neurotoxicology,NCTR/FDA, Jefferson, AR and 2Department ofPsychiatry and Behavioral Sciences, University ofMiami School of Medicine, Miami, FL.

Program Description



THU

RSD

AY


WORKSHOP SESSION: SAFETY ASSESSMENT OF BIOLOGICALTHERAPEUTIC PRODUCTS- DEFINING THE SCIENTIFIC ANDREGULATORY ISSUES

Chairperson(s): Andrea Weir, U.S. FDA, Rockville, MD and Barbara Mounho,Amgen, Inc., Thousand Oaks, CA.

Endorsed by:Immunotoxicology SSRegulatory and Safety Evaluation SS*Risk Assessment SSToxicologic and Exploratory Pathology SSWomen in Toxicology SS

Biological therapeutic products (BTPs) are proteins derived from living organ-isms or produced via biotechnology means that have provided the medicalcommunity with novel, highly targeted therapies for the diagnosis and treatmentdiseases in humans. An integral part of the safety evaluation of these products istoxicology studies. BTP—induced toxicities are typically limited to their phar-macological mechanism of action; therefore, toxicology studies need to beconducted in an animal model that expresses the receptor or epitope that is recog-nized by the product. Frequently, a non-human primate (NHP) is the relevantmodel. In recent years, the quality of NHPs and the availability of methods forassessing toxicity in these animals have increased. In spite of these advances,many challenges remain in the safety assessment of BTPs. For example, only avery limited toxicological assessment can be conducted if the only relevantmodel is a chimpanzee. In such cases, toxicologists use innovative approaches,including the development of surrogate molecules, to conduct toxicology studies.Therefore, identification of novel methods is an ongoing effort in the BTP arena.Regardless of the animal model used, the potential for animals to mount animmune response to BTPs (immunogenicity) exists. Because immunogenicitycan confound interpretation of toxicology studies, it is another challenge facingtoxicologists that can result in the need for innovative approaches to safetyassessment. Additionally, because immunogenicity can occur in humansreceiving BTPs, the development of animal models to predict this effect inhumans is an area of ongoing research. The need for innovative, flexibleapproaches when assessing the safety of BTPs is reflected in U.S. FDA and inter-national regulatory documents. The topics covered in this workshop will providetoxicologists with the most current information on the unique scientific proper-ties of BTPs and with state—of—the—art approaches to safety assessment ofBTPs.

#1990 8:30 SAFETY ASSESSMENT OF BIOLOGICALTHERAPEUTIC PRODUCTS — DEFINING THESCIENTIFIC AND REGULATORY ISSUES. A.Weir1 and B. J. Mounho2. 1FDA/CDER, Rockville, MDand 2Amgen Inc., Thousand Oaks, CA.

#1991 8:35 DIFFERENCES BETWEEN SMALLMOLECULES AND BIOLOGICALTHERAPEUTIC DRUG PRODUCTS. B. Mounho.Toxicology, Amgen, Inc., Thousand Oaks, CA.

#1992 9:05 IMMUNOGENICITY- IMPACT ONTOXICOLOGY STUDIES AND BEYOND. D.Wierda and H. Smith. Immunotoxicology, Eli LillyResearch Laboratories, Greenfield, IN.

#1993 9:35 THE NONHUMAN PRIMATE AS AN ANIMALMODEL FOR THE SAFETY EVALUATION OFBIOLOGICAL THERAPEUTIC PRODUCTS. J.Kapeghian. Discovery and Development Services,Charles River Laboratories, Sierra Division, Sparks,NV.

#1994 10:05 ALTERNATIVE METHODS FOR THE SAFETYEVALUATION OF BIOLOGICAL THERAPEUTICPRODUCTS — SURROGATE ANTIBODIES ANDBEYOND. J. Clarke. BiogenIdec, Cambridge, MA.

#1995 10:35 SAFETY ASSESSMENT OF BIOLOGICALPRODUCTS — A REGULATORY PERSPECTIVE.H. Ghantous. FDA/CDER/ODEVI/DTBIMP, Rockville,MD.

Thursday Morning, March 108:30 AM to 11:30 AMLa Louisiane Ballroom B

POSTER SESSION: ALTERNATIVES TO MAMMALIAN MODELS

Chairperson(s): Irvin Schultz, Battelle Pacific Northwest Laboratories,Sequim, WA and George DeGeorge, MB Research Laboratories, Spinnerstown,PA.

Displayed: 8:30 AM–11:30 AM


#1996 NOVEL REPORTER GENE ASSAY FORDEVELOPMENTAL TOXICITY TESTING. S.Schwengberg1, A. Ehlich1, H. Marquardt2, J. Hescheler3

and H. Bohlen1. 1Axiogenesis AG, Cologne, Germany,2Toxicology, University Hospital, Hamburg, Germanyand 3Neurophysiology, University Hospital, Cologne,Germany.

#1997 VALIDATION STATUS OF THE HENS EGGTEST-CHORIOALLANTOIC MEMBRANE (HET-CAM) TEST METHOD. N. Choksi1,2, D. Allen1,2, C.Inhof1,2, J. Truax1,2, R. Tice1,2 and W. Stokes1.1NICEATM, NIEHS, Research Triangle Park, NC and2ILS, Inc., Research Triangle Park, NC.

#1998 GENE EXPRESSION SIGNATURES FORCADMIUM, MERCURY, AND ACRYLAMIDEEXPOSURE IN CAENORHABDITIS ELEGANS. D.Jackson1, M. Szilagyi2, E. Gehman2 and E. Clegg1. 1USArmy Center for Environmental Health Research, FortDetrick, MD and 2Geo-Centers, Inc., Fort Detrick, MD.

#1999 CYTOKINE SECRETION PROFILES OF MOUSEDENDRITIC CELLS : IMPACT OF CELLTRAUMA. G. Beckwith1, C. J. Betts1, C. A. Ryan2, F.Gerberick2, R. J. Dearman1 and I. Kimber1. 1SyngentaCTL, Macclesfield, United Kingdom and 2Procter &Gamble, Cincinnati, OH.

#2000 MATRIX METALLOPROTEINASES ASBIOMARKERS FOR DIOXIN EXPOSURE INDEVELOPING JAPANESE MEDAKA (ORYZIASLATIPES). V. L. Prince, V. LaPrete, C. M. Villano andL. A. White. Biochemistry and Microbiology, RutgersUniversity, New Brunswick, NJ.

#2001 EPIOCULAR™ HUMAN CELL CONSTRUCT:TISSUE VIABILITY AND HISTOLOGICALCHANGES FOLLOWING EXPOSURE TOSURFACTANTS. M. E. Blazka1, M. Diaco2, J. W.Harbell2, H. Raabe2, A. Sizemore2, N. Wilt2 and D. M.Bagley1. 1Colgate-Palmolive Co., Piscataway, NJ and2Institute for In Vitro Sciences, Inc., Gaithersburg, MD.

Program Description


THU

RSDAY


#2002 LONG TERM REPRODUCIBILITY OFEPIOCULARTM, A THREE-DIMENSIONALTISSUE CULTURE MODEL OF THE HUMANCORNEAL EPITHELIUM. M. Klausner, J. E.Sheasgreen, J. Kubilus and P. J. Hayden. MatTekCorporation, Ashland, MA.

#2003 HIGH-THROUGHPUT IN VITRO MODELS OFHUMAN EPIDERMIS AND OCULAREPITHELIUM FOR PRECLINICAL SAFETY ANDEFFICACY TESTING OF CONSUMERPRODUCTS AND PHARMACEUTICALS. G. R.Jackson, J. Kubilus, M. Klausner, J. E. Sheasgreen andP. J. Hayden. MatTek Corp., Ashland, MA.

#2004 EVALUATION OF A TISSUE ENGINEEREDHUMAN SKIN EPIDERM 3-D CULTURE AS AMODEL TO STUDY IRRITATION AFTER JETFUEL EXPOSURE. A. Chatterjee, R. Babu and M.Singh. Florida A&M University, Tallahassee, FL.

#2005 VALIDATION STATUS OF THE BOVINECORNEAL OPACITY AND PERMEABILITY(BCOP) TEST METHOD. C. Inhof1,2, N. Choksi1,2, D.Allen1,2, J. Truax1,2, R. Tice1,2 and W. Stokes1.1NICEATM, NIEHS, Research Triangle Park, NC and2ILS, Inc., Research Triangle Park, NC.

#2006 ASSESSMENT OF THE SKINETHICRECONSTITUTED HUMAN EPIDERMALMODEL FOR THE PREDICTION OF THEDERMAL IRRITATION POTENTIAL OFPHARMACEUTICAL PROCESS MATERIALS. C.W. Seaman1, R. L. Guest2, A. Whittingham2, B. DeWever3, M. Cappadoro3, B. Bertino3 and E. Adriaens4.1GlaxoSmithKline, Ware, United Kingdom, 2SafePharmLaboratories, Derby, United Kingdom, 3SkinEthicLaboratories, Nice, France and 4University of Ghent,Ghent, Belgium.

#2007 VALIDATION STATUS OF THE ISOLATEDCHICKEN EYE (ICE) TEST METHOD. D. Allen1,2,N. Choksi1,2, C. Inhof1,2, J. Truax1,2, R. Tice1,2 and W.Stokes1. 1NICEATM, NIEHS, Research Triangle Park,NC and 2ILS, Inc., Research Triangle Park, NC.

#2008 VALIDATION STATUS OF THE ISOLATEDRABBIT EYE (IRE) TEST METHOD. J. Truax1,2, N.Choksi1,2, C. Inhof1,2, D. Allen1,2, R. Tice1,2 and W.Stokes1. 1NICEATM, NIEHS, Research Triangle Park,NC and 2ILS, Inc., Research Triangle Park, NC.

#2009 ASSESSMENT OF THE SKINETHICRECONSTITUTED HUMAN CORNEALEPITHELIUM MODEL FOR PREDICTION OFTHE OCULAR IRRITATION POTENTIAL OFPHARMACEUTICAL PROCESS CHEMICALS. R.L. GUEST1, C. SEAMAN2, B. DE WEVER3, M.CAPPADORO3, B. BERTINO3, A. WHITTINGHAM1,N. WARREN1 and E. ADRIAENS4. 1SafepharmLaboratories Ltd.,, Derby, United Kingdom,2GlaxoSmithKline, Ware, Hertfordshire, UnitedKingdom, 3Skinethic Laboratories, Nice, France and4Ghent University, Ghent, Belgium.

#2010 MELANOCYTE CONTAINING HUMANORGANOTYPIC EPIDERMIS AS A MODEL TOEVALUATE TOXICITY OF MELANIN BINDINGSUBSTANCES. F. Straube1, U. Junker2, S. Kretz1 andA. Wolf1. 1Biomarker Development, NovartisPharmacology, Basel, Switzerland and 2PreclinicalSafety, Novartis Pharmacology, Basel, Switzerland.

#2011 VALIDATION OF A FLOW CYTOMETRY-BASEDPHOTO-LOCAL LYMPH NODE ASSAY (PHOTO-LLNA) FOR THE IDENTIFICATION ANDCHARACTERIZATION OF PHOTO-ALLERGENS. M. K. Reeder, T. L. Ripper, D. R.Cerven and G. L. DeGeorge. MB ResearchLaboratories, Spinnerstown, PA.

#2012 COMPARISON OF ALTERNATIVE TOXICITYTEST METHODS FOR OCULAR IRRITATIONUSING THE AVIAN CHORIOALLANTOICMEMBRANE: HET-CAM VS. CAMVA. A. C.Gilotti, D. R. Cerven, S. Craig and G. L. DeGeorge. MBResearch Laboratories, Spinnerstown, PA.

#2013 EXPOSURE OF MUCOCILIARY HUMAN LUNGEPITHELIAL CULTURES TO WHOLECIGARETTE SMOKE. A. Richter, J. Phillips, N.Newland and E. D. Massey. R&D, British AmericanTobacco, Southampton, United Kingdom. Sponsor: J.Seagrave.

#2014 USE OF PLATEABLE CRYOPRESERVED RATHEPATOCYTES AS A MODEL TO ASSESSHEPATOTOXICITY AND DRUG-DRUGINTERACTIONS. T. A. Moeller, S. Lloyd, P. M.Silber and N. S. Jensen. In Vitro Technologies,Baltimore, MD.

#2015 THE SLUG MUCOSAL IRRITATION TEST: AUSEFUL TOOL FOR EVALUATING THE LOCALTOLERANCE OF PHARMACEUTICALFORMULATIONS. E. Adriaens, M. Dhondt and J.Remon. Lab. Pharmaceutical Technology, GhentUniversity, Gent, Belgium. Sponsor: C. Seaman.

#2016 ESTABLISHING THE TOXICOLOGY OFSELENIUM IN THE MODEL ORGANISM,CAENORHABDITIS ELEGANS. M. A. Nascarellaand S. M. Presley. Department of EnvironmentalToxicology, Texas Tech University, Lubbock, TX.

#2017 PROTEOMIC INDICATORS OF PESTICIDETOXICITY IN A CAENORHABDITIS ELEGANSMODEL. J. A. Lewis1, W. E. Dennis1, M. Szilagyi1 andD. A. Jackson2. 1Geo-Centers, Inc., Ft. Detrick, MD and2US Army Center for Environmental Health Research,Ft. Detrick, MD.

#2018 ZEBRAFISH: A GOOD MODEL FORDETECTING OTOTOXICITY. C. Ton and C. Parng.Phylonix Pharmaceuticals, Inc., Cambridge, MA.Sponsor: D. Monteith.

Program Description



THU

RSD

AY

#2019 THE ROLE OF RECOMBINANT ZEBRAFISHCYP1A IN THE METABOLIC ACTIVATION OFBENZO(A)PYRENE (BAP) AND IN THEGENERATION OF REACTIVE OXYGENSPECIES. W. Chung, C. L. Miranda, J. Wang, T.Musafia-Jaknic, W. M. Baird and D. R. Buhler.Environment & Molec. Toxicology, Oregon StateUniversity, Corvallis, OR.

#2020 DEVELOPMENT OF SPECIFIC ANTIPEPTIDEANTIBODIES AGAINST ZEBRAFISHXENOBIOTIC METABOLISING FORMS OFCYTOCHROME P450. J. Wang-Buhler1, W. Chung1,H. Tseng2, C. L. Miranda1, C. Hu2, T. Hseu3 and D. R.Buhler1. 1Environment & Molec. Toxicology, OregonState University, Corvallis, OR, 2Institute of MarineBiotechnology, National Taiwan Ocean University,Keelung, Taiwan and 3Department of Life Science,National Tsing-Hua University, Hsinchu, Taiwan.

#2021 ORAL ABSORPTION OF WATER SOLUBLE ANDLIPOPHILIC CONTAMINANTS IN THEJAPANESE MEDAKA. I. Schultz, E. Muirhead, S.Reed and A. Pratt. Battelle PND, Sequim, WA.

#2022 INTERACTION TRAPPING WITH A NON-TCDDBINDING ARYL HYDROCARBON RECEPTORFROM MYA ARENARIA. R. Butler and R. J. VanBeneden. University of Maine, Orono, ME.

#2023 GENOMICS RESPONSES ANDTOXICOLOGICAL ENDPOINTS AMONG FISHSPECIES EXPOSED TO ESTROGEN ANDPOTENTIAL EXTRAPOLATION OF FISHTOXICITY ASSAYS TO MAMMALIAN SPECIES.P. Cline1, N. Denslow2 and P. Larkin3. 1CH2M Hill,Gainesville, FL, 2University of Florida, Gainsville, FLand 3EcoArray, Inc., Alachua, FL.


POSTER SESSION: SAFETY EVALUATION-SAFETYPHARMACOLOGY

Chairperson(s): Catherine Kelly, Huntingdon Life Sciences, East Millston,NJ.



#2024 THE USE OF A ROTAROD IN CNS SAFETYPHARMACOLOGY STUDIES – A COMPARISONOF TRAINING AND TESTING METHODS. H.Penton and S. Mason. Safety Pharmacology, CTBRBioResearch Inc., Senneville, QC, Canada. Sponsor: C.Banks.

#2025 EVALUATION OF AN INTEGRATEDTELEMETRY SYSTEM (ITS) FORMEASUREMENT OF CARDIOVASCULAR ANDRESPIRATORY PARAMETERS INCYNOMOLGUS MONKEYS. M. Niehoff, P. Nowak,U. Zuehlke, W. Mueller, F. Vogel and G. Weinbauer.Covance Laboratories GmbH, 48163 Muenster,Germany.

#2026 VALIDATION OF SAFETY PHARMACOLOGYASSESSMENT OF CARDIOVASCULARFUNCTION IN CONSCIOUS DOGS WITH TWOPOSITIVE CONTROLS (SOTALOL ANDIBUTILIDE). Y. Chen, M. Lindeblad and A. Lyubimov.Toxicology Research Laboratory, University of Illinoisat Chicago, Chicago, IL.

#2027 INTEGRATED ASSESSMENT OF SMALLMOLECULE INTERACTION WITH THE HERGCHANNEL: WHAT DOES THE HERG BINDINGASSAY MISS? C. M. Doherty, V. Sasseville, P.Bouchard, C. L. Alden, P. F. Smith and V. J. Kadambi.Drug Safety and Disposition, MillenniumPharmaceuticals, Inc., Cambridge, MA.

#2028 MEASUREMENT OF CARDIOVASCULAREFFECTS OF PHARMACEUTICALS INMINIPIGS USING TELEMETRY. A. Makin, H.Saxtorph and R. J. Harling. Toxicology andPharmacology, Scantox A/S, Lille Skensved, Denmark.

#2029 VALIDATION OF A RADIOTELEMETRICSYSTEM FOR THE MEASUREMENT OFCARDIOVASCULAR PARAMETERS ANDTEMPERATURE IN THE CONSCIOUSCYNOMOLGUS MONKEY. J. L. Fogleman and C.B. Spainhour. Calvert Laboratories, Inc., Olyphant, PA.

#2030 A REVIEW OF THE RELATIONSHIP BETWEENHEART RATE AND QT INTERVAL IN THEBEAGLE DOG. J. Budnik1 and B. N. Olivier2.1Toxicology, CTBR, Senneville, QC, Canada and2Michigan State University, East Lansing, MI.

#2031 DEVELOPMENT OF THE METHODOLOGY FORRESPIRATORY RATE AND VOLUMEASSESSMENT USING LINEAR PNEUMATACHSAND BUXCO BIOSYSTEM XA SYSTEM IN THECONSCIOUS DOG AND CYNOMOLGUSMONKEY. C. M. Kelly, M. Miyamoto, S. Cracknelland S. J. Gosselin. Safety Assessment, Huntingdon LifeSciences, East Millstone, NJ.

#2032 USE OF GAMMA SCINTIGRAPHY FOR THESTUDY OF GASTRIC EMPTYING IN SAFETYPHARMACOLOGY. X. Manciaux1, S. Milano1, H.Barraud1, V. Roger1, S. Lerondel2, A. Lepape2 and J.Descotes3. 1MDS Pharmacology Services, SaintGermain s/L’Arbresle, France, 2Functional Imaging ofTransgenic Mice, CDTA-CNRS, Orleans, France and3Poison Center, Lyon, France.

Program Description


THU

RSDAY



POSTER SESSION: PERSISTENT ORGANIC POLLUTANTS

Chairperson(s): Jay Silkworth, General Electric Company, Schenectady, NY.



#2033 EFFECTS OF TCDD ON THE LEVELS OFBIOGENIC AMINES IN DIFFERENT BRAINREGIONS OF RATS AFTER SUBCHRONICEXPOSURE. K. Masters, J. Byers and E. A. Hassoun.Pharmacology, The University of Toledo, Toledo, OH.

#2034 IGF-1 MEDIATES THE EFFECTS OF TCDD ANDHXCDD ON BODY WEIGHT AND THEINHIBITION OF PEPCK. C. R. Croutch1, M.Lebofsky1, P. F. Terranova2 and K. K. Rozman1,3.1Pharmacology Toxicology and Ther, University of KSMed. Center, Kansas City, KS, 2Center for Reprod.Sciences. and Mol. and Integrative Phys., University ofKS Med. Center, Kansas City, KS and 3EnvironmentToxicology, GSF-Institut fur Toxikologie, Neuherberg,Germany.

#2035 COMPARATIVE 14-WEEK TOXICITY STUDIESOF 2, 3, 7, 8-TETRACHLORODIBENZO-P-DIOXIN (TCDD) IN FEMALE HARLANSPRAGUE-DAWLEY (HSD) AND FISCHER 344(F344) RATS. M. Hejtmancik1, L. Fomby1, D.Vasconcelos1, M. Ryan1, M. Vallant2, D. Orzech2, R.Chhabra2, A. Nyska2, H. Toyoshiba2, N. Walker2 and M.Hooth2. 1Battelle Columbus, Columbus, OH and 2ETP,NIEHS, Research Triangle Park, NC.

#2036 EFFECTS OF 2, 3, 7, 8-TETRACHLORODIBENZO-P-DIOXIN (TCDD)ON PROLACTIN (PRL) GENE EXPRESSION INVIVO AND IN VITRO. J. Cao and S. L. Petersen.Molecular and Cellular Biology Program, Amherst,MA.

#2037 INVOLVEMENT OF PROSTAGLANDINPATHWAY IN CIRCULATION FAILUREINDUCED BY 2, 3, 7, 8-TETRACHLORODIBENZO-P-DIOXIN INDEVELOPING ZEBRAFISH. H. Teraoka1, W.Dong1,2, A. Shindo1, Y. Harada3 and T. Hiraga1. 1Schoolof Veterinary Medicine, Rakuno Gakuen University,Ebetsu, Japan, 2College of Animal science andTechnology, Inner Mongolia University forNationalities, TongLiao, China and 3Graduate School ofMedical Science, Kitasato University, Sagamihara,Japan.

#2038 DOSE- AND TIME-DEPENDENT HEPATIC GENEEXPRESSION PROFILING IN FEMALE RATSEXPOSED TO PCB126. R. J. Foxenberg1, B. J.Ovando1, K. M. Kransler1, C. M. Vezina2 and J. R.Olson1. 1Pharmacology and Toxicology, SUNY atBuffalo, Buffalo, NY and 2Pharmacy, University ofWisconsin, Madison, WI.

#2039 EFFECTS OF AMMONIUM PERCHLORATE ONLIVER ENZYMES AND THE THYROID AXIS OFRATS PRETREATED WITH PCB126. E. D.McLanahan1, J. Campbell1, S. Muralidhara1, J. Hedge2,L. Narayanan3, J. Bruckner1, K. Crofton2, D. Mattie3,D. Keys1, M. Mumtaz4, D. Ferguson1 and J. Fisher1.1Interdisciplinary Toxicology Program, University ofGeorgia, Athens, GA, 2Neurotoxicology Division, U.S.EPA/ORD/NHEERL, Research Triangle Park, NC,3AFRL/HEPB, Wright-Patterson AFB, OH and4Division of Toxicology, ATSDR, Atlanta, GA.

#2040 2, 3, 7, 8-TETRACHLORODIBENZO-P-DIOXINMODULATES A TRANSLOCATION OF PKC-ββIIVIA RECEPTOR FOR ACTIVATED C KINASE(RACK-1) IN DEVELOPING NEURONAL CELLSIN CULTURE. J. Yang. Pharmacology/Toxicology,Catholic University of Daegu, Daegu, South Korea.Sponsor: P. Kodavanti.

#2041 TCDD ELICITS TYPICAL DEFENSIVE CELLSTRESS RESPONSES FROM MCF10A CELLS: ASTUDY ON THE MECHANISM OF ITS CELLRESCUING ACTION FROM UV-INDUCEDAPOPTOSIS. F. Matsumura and S. Park. Center forHealth and the Environment, University of California,Davis, Davis, CA.

#2042 SELECTIVE MODIFICATION OF BHLH/PASGENE EXPRESSION BY TCDD IN RATHYPOTHALAMUS. J. Linden1, M. Korkalainen2, J.Tuomisto2 and R. Pohjanvirta1,3,2. 1Department of Foodand Environmental Hygiene, University of Helsinki,Helsinki, Finland, 2Department of EnvironmentalHealth, National Public Health Institute, Kuopio,Finland and 3Kuopio Department, National Veterinaryand Food Research Institute, Kuopio, Finland.

#2043 COMPARISON OF THE TCDD-INDUCEDCYP1A1 GENE EXPRESSION PROFILE INLYMPHOCYTES FROM MICE, RATS ANDHUMANS. K. Nohara, Y. Miyamoto, K. Ao, T. Ito andC. Tohyama. National Institute for EnvironmentalStudies, Tsukuba, Japan.

#2044 ANALYSIS OF TEQ-EQUIVALENT AROCLORAND TCDD TREATED RATS REVEALSDIFFERENT GENE DOSE-RESPONSE PROFILESAMONG DIOXIN RESPONSIVE GENES. K.Illouz1, S. Goodwin3, A. Possolo1, S. B. Hamilton2, T.R. Sutter3 and J. B. Silkworth1. 1GE Global Research,Schenectady, NY, 2GE Corporate, Fairfield, CT and3Feinstone Center for Genomic Research, U Memphis,Memphis, TN.

#2045 DIOXIN-RESPONSIVE DOWN-REGULATION OFSERPINA7, CYP3A9/3A13, AND CES3 REQUIRESA FUNCTIONAL ARYL HYDROCARBONRECEPTOR. B. J. Ovando1, C. M. Vezina2 and J. R.Olson1. 1Pharmacology & Toxicology, University atBuffalo, Buffalo, NY and 2Pharmacy, Unviversity ofWisconsin, Madison, WI.

Program Description



THU

RSD

AY

#2046 COPLANAR POLYCHLORINATED BIPHENYLSACTIVATE ARYL HYDROCARBON RECEPTORIN DEVELOPING TISSUES OF TWO TCDD-RESPONSIVE LACZ MOUSE LINES. J. C. Bemis1,D. A. Nazarenko2 and T. A. Gasiewicz1. 1EnvironmentalMedicine, University of Rochester, Rochester, NY and2Toxicology and Applied Biology, Alkemes Inc.,Cambridge, MA.

#2047 CCN4 AND CCN5 ARE DOWN REGULATED INRESPONSE TO THE ADIPOGENICSTIMULATION WHILE 2, 3, 7,8–TETRACHLORODIBENZO-P-DIOXIN (TCDD)ELEVATES CCN5 MESSAGE IN C3H10T1/2MOUSE EMBRYO FIBROBLASTS. M. Cimafrancaand C. Jefcoate. Pharmacology, University ofWisconsin, Madison, WI.

#2048 DEVELOPMENT OF A NEW DIOXIN-ANALOGUE: 2, 3, 7, 8-TETRACHLOROPHENOTHIAZINE. K. W.Fried1,2, G. I. Georg3, P. F. Terranova4,5,6 and K. K.Rozman1,7. 1Pharmacology, Toxicology & Therapeutics,The University of Kansas Medical Center (KUMC),Kansas City, KS, 2Institute of Ecological Chemistry,GSF-National Research Center for Environment &Health, Neuherberg, Germany, 3Medicinal Chemistry,The University of Kansas, Lawrence, KS, 4Center forReproductive Sciences, KUMC, Kansas City, KS,5Molecular & Integrative Physiology, KUMC, KansasCity, KS, 6Obstetrics & Gynecology, KUMC, KansasCity, KS and 7Institute of Toxicology, GSF, Neuherberg,Germany.

#2049 COMPARISON OF GC/MS AND CALUX® BYXDS FOR DETECTION OF DIOXIN LIKECOMPOUNDS IN ENVIRONMENTAL SAMPLES.G. C. Clark1, A. C. Chu1, J. D. Gordon1, M. D. Chu2

and M. S. Denison3. 1Xenobiotic Detection Systems,Inc., Durham, NC, 2Alta Analytical Perspectives,Wilmington, NC and 3Department of EnvironmentalToxicology, University of California, Davis, Davis, CA.

#2050 INDUCTION OF EROD-ACTIVITY IN VITRO BY2, 3, 7, 8-TETRACHLOROPHENOTHIAZINE. K.W. Fried1,2, N. Chahbane2, C. Corsten2, K. Schramm2,A. Kettrup2 and K. K. Rozman3. 1Department ofPharmacology, Toxicology & Therapeutics, TheUniversity of Kansas Medical Center, Kansas City, KS,2Institute of Ecological Chemistry, GSF-NationalResearch Center for Environment & Health,Neuherberg, Germany and 3Institute of Toxicology,GSF, Neuherberg, Germany.

#2051 LYMPHOCYTES CHOLINERGIC MUSCARINICRECEPTORS: IN VIVO AND IN VITRO EFFECTSOF THE COMBINED EXPOSURE TOPOLYCHLORINATED BIPHENYLS ANDMETHYLMERCURY. L. Manzo1,2, A. F. Castoldi2, G.Randine2 and T. Coccini2. 1Toxicology Division,University of Pavia, Pavia, Italy and 2IRCCS MaugeriFoundation, Pavia, Italy.

#2052 THE ROLE OF SUPEROXIDE ANION IN 2, 2′′, 4,4′′-TETRACHLOROBIPHENYL-INDUCEDUPREGULATION OF COX-2 IN HL-60 CELLS. S.Bezdecny1,2,3, R. A. Roth1,2,3 and P. E. Ganey1,2,3.1Department of Pharmacology and Toxicology,Michigan State University, Lansing, MI, 2Center forIntegrative Toxicology, Michigan State University, EastLansing, MI and 3National Food safety and ToxicologyCenter, Michigan State University, East Lansing, MI.

#2053 RYR1 MALIGNANT HYPERTHERMIA POINTMUTATION R615C ENHANCESSUSCEPTIBILITY TO NON-COPLANAR 2, 2’, 3,5’-PENTACHLOROBIPHENYL (PCB 95). T. N. Ta1,B. R. Fruen2 and I. N. Pessah1. 1VM: MolecularBiosciences, UC Davis, Davis, CA and 2Department ofBiochemistry, Molecular Biology, and Biophysics,Minnesota.

#2054 ANALYSIS OF THE TUMOR PROMOTINGPOTENCY OF PCB 28 AND PCB 101 IN RATLIVER. S. Kunz1, H. Schmitz1, M. Schwarz2, B.Schilling3, O. Paepke3, H. Lehmler4, L. Robertson4 andD. Schrenk1. 1Food Chemistry and EnvironmentalToxicology, University of Kaiserslautern,Kaiserslautern, Germany, 2Department of Toxicology,University of Tuebingen, Tuebingen, Germany, 3ERGOResearch, Hamburg, Germany and 4Department ofOccupational and Environmental Health, University ofIowa, Iowa City, IA.

#2055 TRANSCRIPTIONAL PROFILING OF RATHEPATIC RESPONSES TO DIETARY EXPOSURETO AROCLOR 1254. T. M. Basford1,2 and J. C.Means1,2. 1Chemistry, Western Michigan University,Kalamazoo, MI and 2Great Lakes Environmental andMolecular Science Center, Kalamazoo, MI.

#2056 COMPARISON OF AROCLOR AND TCDDRESPONSIVE GENES BETWEEN IN VIVO ANDIN VITRO EXPOSURES USING DNAMICROARRAYS. M. Zhao1, S. Arunajadai2, K.Illouz1, A. Possolo1, A. Koganti3, S. B. Hamilton4, S.Goodwin5, T. R. Sutter5 and J. B. Silkworth1. 1GlobalResearch, GE, Schenectady, NY, 2U.C Berkeley,Berkeley, CA, 3In Vitro Technologies, Baltimore, MD,4GE Corporate, Fairfield, CT and 5U Memphis,Memphis, TN.

#2057 ACCUMULATION OF PBDE-47 IN PRIMARYCULTURES OF RAT NEOCORTICAL CELLS. W.Mundy1, T. M. Freudenrich1, K. M. Crofton1 and M. J.DeVito2. 1Neurotoxicolgy Division, U.S. EPA, ResearchTriangle Park, NC and 2Experimental ToxicologyDivision, U.S. EPA, Research Triangle Park, NC.

#2058 MIXTURE EFFECTS OF PCBs AND PBDESWITH OTHER CONTAMINANTS/DRUGS. H. L.Esch, L. W. Robertson and G. Ludewig. Department ofOccupational & Environmental Health, University ofIowa, Iowa City, IA.

Program Description


THU

RSDAY


#2059 EFFECT OF PBDES ON TCDD-INDUCEDCYP1A1 ACTIVITY (EROD) IN PRIMARYHEPATOCYTES OF CYNOMOLGUS MONKEYS.L. Peters1, A. Bergman2, J. T. Sanderson1 and M. vanden Berg1. 1Institute for Risk Assessment Sciences,University of Utrecht, Utrecht, Netherlands and2Department of Environmental Chemistry, University ofStockholm, Stockholm, Sweden.

#2060 2, 2’-DIBROMODIPHENYL ETHER BINDS ANDINDUCES CALCIUM RELEASE THROUGH THERYANODINE RECEPTOR IN AN FKBP12-DEPENDENT MANNER. J. Riehl and I. Pessah.School of Veterinary Medicine: Molecular Biosciences,University of California Davis, Davis, CA.

#2061 THE BROMINATED FLAME RETARDANTHBCDD INDUCES CYP2B AND CYP3A BUT NOTCYP1A IN RAT LIVER. S. Germer1, L. van der Ven2,A. H. Piersma2 and D. Schrenk1. 1Food Chemistry andEnvironmental Toxicology, University ofKaiserslautern, Kaiserslautern, Germany, 2Laboratoryfor Toxicology, Pathology and Genetics, NationalInstitute for Public Health and the Environment RIVM,Bilthoven, Netherlands and 3National Institute forPublic Health and the Environment RIVM, Bilthoven,Netherlands.

#2062 NEONATAL EXPOSURE TO POLYBROMINATEDDIPHENYL ETHERS, PBDE 183, PBDE 203, ANDPBDE 206, CAUSES NEUROTOXIC EFFECTS INADULT MICE. N. Johansson1, H. Viberg1, J.Eriksson2, A. Fredriksson1 and P. Eriksson1.1Department of Environmental Toxicology, UppsalaUniversity, Uppsala, Sweden and 2Department ofEnvironmental Chemistry, Stockholm University,Stockholm, Sweden.

#2063 EFFECT OF PERFLUOROOCTANE SULFONATE(PFOS) AND PERFLUOROOCTANOATE (PFOA)ON L-TYPE CALCIUM CURRENT IN GUINEAPIG VENTRICULAR MYOCYTES. K. Harada1, F.Xu2, K. Ono2, T. Iijima2 and A. Koizumi1. 1HealthEnvironmental Sciences, Kyoto University GraduateSchool of Medicine, Kyoto, Japan and 2Pharmacology,Akita University School of Medicine, Akita, Japan.

#2064 RENAL CLEARANCES OFPERFLUOROOCTANE SULFONATE ANDPERFLUOROOCTANOATE IN HUMANS, ANDSPECIES-SPECIFIC EXCRETION OF THESECHEMICALS. K. Harada1, K. Inoue1, A. Morikawa1,T. Yoshinaga1, N. Saito2, M. Kimura3, S. Shimbo4 andA. Koizumi1. 1Health Environmental Sciences, KyotoUniversity Graduate School of Medicine, Kyoto, Japan,2Research Institute for Environmental Sciences andPublic Health of Iwate Prefecture, Morioka, Japan,3Kyoto Prefectural University of Medicine, Kyoto,Japan and 4Kyoto Women’s University, Kyoto, Japan.

#2065 MAMMALIAN METABOLISM ANDDISTRIBUTION OF PERFLUOROOCTYLETHANOL AND ITS OXIDATIONMETABOLITES. W. M. Henderson1,2, E. J. Weber2, S.E. Duirk2 and M. Smith1. 1Interdisciplinary ToxicologyProgram, University of Georgia, Athens, GA and2NERL, U.S. EPA, Athens, GA.

#2066 MEASUREMENT OF THYROID HORMONES INRAT SERA CONTAININGPERFLUOROOCTANESULFONATE (PFOS). S.Tanaka1, J. Thibodeaux2, M. Eastvold3, J. Bjork4, D.Ehresman1, R. Singh3, K. Wallace4, C. Lau2 and J.Butenhoff1. 13M Company, St. Paul, MN, 2U.S. EPA,Research Triangle Park, NC, 3Mayo MedicalLaboratories, Rochester, MN and 4University ofMinnesota, Duluth, MN.

#2067 PROLONGATION OF K+-INDUCED BACKWARDSWIMMING OF PARAMECIUM CAUDATUM BYPFOS AND PFOA. Y. Yamazaki, K. Harada, A.Morikawa, T. Yoshinaga and A. Koizumi. HealthEnvironmental Sciences, Kyoto University GraduateSchool of Medicine, Kyoto, Japan.

#2068 A SIGNIFICANTLY LARGERBIOCONCENTRATION FACTOR OF PFOS THANTHAT OF PFOA IN WILD TURTLES: THE AIRIVER ECOLOGICAL STUDY IN JAPAN. A.Morikawa1, N. Kamei1, N. Saito2, K. Harada1, K.Inoue1, T. Yoshinaga1 and A. Koizumi1. 1KyotoUniversity Graduate School of Medicine, Kyoto, Japanand 2Research Institute for Environmental Sciences andPublic Health of Iwate Prefecture, Morioka, Japan.

#2069 ANALYTICAL METHOD VALIDATION FORQUANTITATION OF 1, 2, 3, 4, 6, 7HEXACHLORONAPHTHALENE FROM RATADIPOSE TISSUE. P. Schebler1, K. Brackman1, K.White1, D. Messer1, J. Algaier1, A. Clark1, R. Harris1,B. Jayaram2 and C. Smith2. 1Life Sciences Division,Midwest Research Institute, Kansas City, MO and2Environmental Toxicology Program, NIEHS, ResearchTriangle Park, NC.

#2070 14-WEEK COMPARATIVE STUDY OF 1, 2, 3, 4, 6,7-HEXACHLORONAPHTHALENE (PCN 66) AND1, 2, 3, 5, 6, 7-HEXACHLORONAPHTHALENE(PCN 67) IN FEMALE HARLAN SPRAGUE-DAWLEY (HSD) AND FISCHER 344 (F344) RATS.M. Hooth1, M. Vallant1, N. Walker1, A. Nyska1, H.Toyoshiba1, R. Chhabra1, M. Ryan2, D. Vasconcelos2,M. Hejtmancik2 and L. Fomby2. 1ETP, NIEHS, ResearchTriangle Park, NC and 2Battelle Columbus, Columbus,OH.

#2071 SOURCES AND DISTRIBUTION OFPOLYCYCLIC AROMATIC HYDROCARBONS INNEW ORLEANS AND DETROIT SOILS. G. Wang1,H. Mielke2, Q. Zhang1, P. Ma1, J. Rowden1 and C.Gonzales2. 1Chemistry, Xavier University of Louisiana,New Orleans, LA and 2College of Pharmacy, XavierUniversity of Louisiana, New Orleans, LA.

Program Description



THU

RSD

AY

#2072 DIOXINS AND DIOXIN LIKE COMPOUNDSFROM AGENT ORANGE AND OTHER SOURCESIN VIETNAM FROM THE 1970S TO THEPRESENT. A. J. Schecter1, H. T. Quynh2, O. Paepke3,J. D. Constable4, K. C. Tung1, R. Malisch5 and P.Fuerst6. 1Environmental Sciences, University of TexasSchool of Public Health, Dallas, TX, 2Center for CancerResearch, Hanoi, Viet Nam, 3ERGO ResearchLaboratory, Hamburg, Germany, 4Harvard MedicalSchool, Boston, MA, 5State Laboratory for Chemicaland Veterinary Analysis, Freiburg, Germany and6Chemical and Veterinary Control Laboratory,Muenster, Germany.


POSTER SESSION: RISK ASSESSMENT II

Chairperson(s): Mara Seeley, Gradient Corporation, Cambridge, MA andMichael Wade, Cal EPA, Sacramento, CA.



#2073 DEVELOPMENT OF FLORIDA-SPECIFIC RISK-BASED SOIL AND GROUNDWATER CLEANUPTARGETS FOR VOLATILIZATION OFCHEMICALS INTO INDOOR AIR. E. M.Tufariello1, C. M. Saranko1, R. Ettinger2, S. M. Roberts3

and J. K. Tolson1. 1GEOSYNTEC CONSULTANTS,Tampa, FL, 2GEOSYNTEC CONSULTANTS, SantaBarbara, CA and 3University of Florida, Gainesvile, FL.

#2074 A ROBUST ALGORITHM FOR CALCULATINGOPTIMAL 95 0/00 UPPER CONFIDENCE LIMITS(95 0/00 UCLS) ON THE MEAN FORENVIRONMENTAL DATASETS. J. K. Tolson1, C. J.Saranko1, S. M. Roberts2 and K. M. Portier2.1GEOSYNTEC CONSULTANTS, Tampa, FL and2University of Florida, Gainsville, FL.

#2075 THE EFFECT OF USING MULTIPLECONTAMINANT 95 0/00 UCLS ONCUMMULATIVE RISK ESTIMATES. C. J.Saranko, E. M. Tufariello and J. K. Tolson.GEOSYNTEC CONSULTANTS, Tampa, FL.

#2076 EVALUATION OF THE PREDICTIVITY OF AFISH UPTAKE MODEL FOR MERCURY USINGEMPERICAL DATA. R. P. Brellenthin1, J. K. Tolson1,K. Kessler2 and C. J. Saranko1. 1GeosyntecConsultants, Tampa, FL and 2Geosyntec Consultants,Atlanta, GA.

#2077 RETROSPECTIVE SCREENING-LEVEL HUMANHEALTH RISK ASSESSMENT FORRECREATIONAL EXPOSURE TOCONTAMINATED SEDIMENT. P. Welsh, M.Pagliarulo and D. A. Manca. Standards DevelopmentBranch, Ontario Ministry of the Environment, Toronto,ON, Canada.

#2078 PROVISIONAL REFERENCE DOSE FOR THEAROMATIC FRACTION OF JET FUEL:REASSESSMENT OF FRACTION RISK ANDIMPACT ON RISK BASED CLEANUP LEVELS. T.R. Sterner1, D. J. Vorhees2, D. R. Mattie3, D. A. Reed1

and W. H. Weisman4. 1OpTech Corp., Dayton, OH,2Menzie-Cura & Assoc., Inc., Winchester, MA,3AFRL/HEPB, Wright-Patterson AFB, OH and 4HQAF/SGOP, Bolling AFB, DC.

#2079 DESIGNATION OF NAPHTHALENE AS ACARCINOGEN: RISK ASSESSMENT FORINHALATION EXPOSURE PATHWAYS ATHAZARDOUS WASTE SITES. J. P. Christopher, J.M. Polisini, B. K. Davis and M. J. Wade. Department ofToxic Substances Control, California EnvironmentalProtection Agency, Sacramento, CA.

#2080 INORGANIC CHEMICALS IN GROUND WATERAND SOIL: BACKGROUND CONCENTRATIONSAT CALIFORNIA AIR FORCE BASES. P. M.Hunter1, B. K. Davis2 and F. Roach3. 1Center forEnvironmental Excellence, Air Force, San Antonio, TX,2Toxic Substances Control, Cal EPA, Sacramento, CAand 3Frontline Systems, Inc., San Antonio, TX.Sponsor: J. Christopher.

#2081 SCREENING FOR POTENTIAL HEALTH RISKSFOLLOWING ACUTE EXPOSURE TO HEAVYMETALS IN SOIL AT A FORMER MINING SITE.M. Pagliarulo and D. A. Manca. Standards DevelopmentBranch, Ontario Ministry of the Environment, Toronto,ON, Canada.

#2082 RISK ASSESSMENT FOR IRON: USING THEINSTITUTE OF MEDICINE’S TOLERABLEUPPER INTAKE LEVEL AS A SURROGATETOXICITY VALUE FOR IRON. M. L. Stifelman1, L.Ingerman2, W. C. Thayer2 and G. L. Diamond2. 1U.S.EPA, Seattle, WA and 2Syracuse Research Corporation,Syracuse, NY.

#2083 DETERMINING SOIL REMEDIAL ACTIONCRITERIA FOR ACUTE EFFECTS: THECHALLENGE OF COPPER. M. Seeley, C. S. Wells,S. Ren and B. D. Beck. Gradient Corporation,Cambridge, MA.

#2084 PERCUTANEOUS ABSORPTION OF ARSENICFROM ENVIRONMENTAL MEDIA. Y. Lowney1,M. V. Ruby1, R. C. Wester2, R. A. Schoof3, S. E. Holm4

and H. I. Maibach2. 1Exponent, Inc., Boulder, CO,2University of California, San Francisco, CA, 3IntegralConsulting, Inc., Mercer Island, WA and 4GeorgiaPacific Corporation, Atlanta, GA.

#2085 THE ROLE OF METHYLATED METABOLITESIN INORGANIC ARSENIC-INDUCED CANCER:A SYNTHESIS OF INFORMATION FROM INVITRO AND HUMAN BIOMONITORINGSTUDIES. A. Schoen and B. Beck. GradientCorporation, Cambridge, MA.

Program Description


THU

RSDAY


#2086 TOXICOLOGICAL EVALUATION OF 1, 1, 1-TRICHLOROETHANE AND RESULTINGMINIMAL RISK LEVELS. H. Abadin1, D. Moffett1,A. Dorsey1, C. Smith1 and D. Wohlers2. 1Agency forToxic Substances and Disease Registry, Atlanta, GA and2Environmental Science Center, Syracuse ResearchCorporation, Syracuse, NY. Sponsor: B. Fowler.

#2087 PEAK EXPOSURE AND KINETICS OF TOLUENEIN MAN INCLUDING PBTK MODELLINGEVALUATION. J. Bessems, A. Freidig, W. Meulingand J. Lammers. Food and Chemical Risk Analysis,TNO Chemistry, Zeist, Netherlands. Sponsor: V. Feron.

#2088 A META-ANALYSIS OF NEUROBEHAVIORALDEFICITS FROM LONG-TERM EXPOSURE TOSTYRENE. W. K. Boyes1, A. M. Geller1, P. J.Bushnell1, G. M. Woodall2 and V. A. Benignus1.1NHEERL, U.S. EPA, Research Triangle Park, NC and2NCEA, U.S. EPA, Research Triangle Park, NC.

#2089 ROUTE-DEPENDENT EFFECTS OF TOLUENEON SIGNAL DETECTION BEHAVIOR IN RATS.P. J. Bushnell1, T. E. Samsam1, W. M. Oshiro1, C. R.Eklund2 and M. V. Evans2. 1NHEERL /NTD, U.S. EPA,Research Triangle Park, NC and 2NHEERL/ETD, U.S.EPA, Research Triangle Park, NC.

#2090 WHY DO THE ACUTE BEHAVIORAL EFFECTSOF TOLUENE IN RATS DEPEND ON THEROUTE OF EXPOSURE? T. E. Samsam, W. M.Oshiro and P. J. Bushnell. NHEERL/NTD, U.S. EPA,Research Triangle Park, NC.

#2091 ASSESSING THE IMPORTANCE OF THEBEHAVIORAL EFFECT OF ACUTE EXPOSURETO TOLUENE IN HUMANS. V. A. Benignus1,2.1Human Studies Division, U.S. EPA, Research TrianglePark, NC and 2Neurotoxicology Division, U.S. EPA,Reasearch Triangle Park, NC. Sponsor: W. Boyes.

#2092 CARDIOVASCULAR ANDTHERMOREGULATORY RESPONSE TO ORALTOLUENE IN THE RAT. C. J. Gordon, W. M. Oshiro,T. E. Samsam, P. Becker and P. J. Bushnell.Neurotoxicology, U.S. EPA, Res. Tri. Park, NC.

#2093 BENCHMARK DOSE ANALYSIS BASED ONSTYRENE NEUROBEHAVIORAL META-DATA.G. M. Woodall1, W. K. Boyes2, A. M. Geller2, P. J.Bushnell2 and V. A. Benignus2. 1NCEA/ORD, U.S.EPA, Research Triangle Park, NC and 2NHEERL/ORD,U.S. EPA, Research Triangle Park, NC.

#2094 ACETYLCHOLINESTERASE AS THE CRITICALEFFECT WHEN ESTIMATING THE SAFE DOSEFOR CHLORPYRIFOS? Q. J. Zhao, B. Gadagbuiand M. Dourson. Toxicology Excellence for RiskAssessment (TERA), Cincinnati, OH.

#2095 CHARACTERIZATION OF DELTAMETHRIN(DLT) METABOLISM IN ADULT MALESPRAGUE-DAWLEY RATS. S. S. Anand1, W. T.Haines4,3, J. V. Bruckner1, J. W. Fisher2, S.Muralidhara1, D. L. Hunter3 and S. Padilla3.1Department.of Pharmaceutical and BiomedicalSciences, University of Georgia, Athens, GA,2Department of Environmental Health Sciences.,University of Georgia, Athens, GA, 3Neurotox.Division, U.S. EPA, Research Triangle Park, NC and4Curr. in Toxicology., UNC-CH, Chapel Hill, NC.

#2096 RISK OF TERATOGENICITY FROMTRICHLOROETHYLENE (TCE) ANDDICHLOROETHYLENE (DCE) IN DRINKINGWATER. B. J. Kelman1, B. D. Hardin2 and R. L.Brent3. 1GlobalTox, Redmond, WA, 2GlobalTox, HiltonHead Island, SC and 3Alfred I. DuPont Institute,Wilmington, DE.

#2097 DOES TRICHLOROETHYLENE CONTRIBUTETO CONGENITAL HEART DEFECTS? R. E.Watson1, W. Howard2 and J. M. DeSesso1. 1BiomedicalResearch Institute, Mitretek Systems, Falls Church, VAand 2AFIOH/RSRE, US Air Force, Brooks City-Base,TX.

#2098 HUMAN HEALTH RISK ASSESSMENT FOR 4-CHLORO-1, 2-BENZENEDIAMINE. V. Bhat, G.Ball, C. McLellan, C. Gillilland and J. Russell. NSFInternational, Ann Arbor, MI. Sponsor: M. Dourson.

#2099 ADVERSE EFFECTS OF CYANOBACTERIALPEPTIDES ON HUMAN HEALTH. S. Hoeger and D.Dietrich. Environmental Toxicology, University ofKonstanz, Konstanz, Germany.

#2100 EXAMINING POTENCY FOR DEVELOPMENTOF THE PRELIMINARY CONTAMINANTCANDIDATE LIST (PRE-CCL). J. Donhue1, S.Kueberuwa1, Y. Selby-Mohamadu2 and J. Shatkin3.1Health and Ecological Criteria Division, U.S. EPA,Washington, DC, 2Office of Ground Water and DrinkingWarer, U.S. EPA, Washington, DC and 3The CadmusGroup, Watertown, MA. Sponsor: E. Ohanian.

#2101 CLASS-BASED DRINKING WATER ACTIONLEVEL FOR ALKYL SUBSTITUTEDNAPHTHALENES. A. Gebhart1, M. H. Whittaker2, T.Clipson Miller2 and F. Hammer1. 1UnderwritersLaboratories Inc., Northbrook, IL and 2ToxServices,Washington, DC.

#2102 COMPARATIVE RISK ASSESSMENT OFMULTIMEDIA EXPOSURE TO PERCHLORATEAND OTHER AGENTS THAT INHIBIT IODIDEUPTAKE INTO THE THYROID GLAND. G. M.Bruce and R. C. Pleus. Intertox, Inc., Seattle, WA.

#2103 HUMAN HEALTH RISK ASSESSMENT FORTHIOCYANATE. J. Russell, C. McLellan, G. Ball andV. Bhat. NSF International, Ann Arbor, MI. Sponsor:M. Dourson.

#2104 DERIVATION OF A DRINKING WATER ACTIONLEVEL FOR TRIBUTYL PHOSPHATE. T. ClipsonMiller1, M. H. Whittaker1, A. Gebhart2 and F. Hammer2.1ToxServices, Washington., DC and 2UnderwritersLaboratories Inc., Northbrook, IL.

Program Description



THU

RSD

AY

#2105 CONSIDERATION OF SENSITIVEPOPULATIONS FOR RISK ASSESSMENT OFCHEMICALS IN DRINKING WATER. A. Fan, R. A.Howd and G. Alexeeff. OEHHA, Cal/EPA, Oakland,CA.

#2106 INHALATION EXPOSURE TO NONVOLATILECHEMICALS DURING SHOWERING D MMANGANARO M S HUTCHESON T ZEWDIE.MASSACHUSETTS DEPARTMENT OFENVIRONMENTAL PROTECTION, BOSTONMA, USA. T. Zewdie, D. M. Manganaro and M. S.Hutcheson. Office of Research and Standards,Massacusetts Department of Environmental Protection,Boston, MA.

#2107 MEASUREMENT OF AIR CONCENTRATION OFD CIS/TRANS ALLETHRIN GENERATED BY AMOSQUITO REPELLENT LAMP IN ANOUTDOOR ENVIRONMENT. S. Selim1 and J. J.Olson2. 1Golden Pacific Laboratory, Fresno, CA and2Product Toxicology, S. C. Johnson & Son Inc., Racine,WI.

#2108 MECHANOTRANSDUCTION IN PARTICLETOXICOLOGY. S. C. Brown1, M. Kamal2, N.Nasreen2, V. Antony2 and B. Moudgil1. 1ParticleEngineering Research Center and Department ofMaterials Science, University of Florida, Gainesville,FL and 2Division of Pulmonary and Critical CareMedicine, University of Florida, Gainesville, FL.Sponsor: S. Roberts.

#2109 A QUANTITATIVE CANCER RISK ASSESSMENTFOR AIRBORNE ASBESTOS GENERATED BYVEHICULAR TRAFFIC ON A ROAD PAVEDWITH ASBESTOS-CONTAINING SERPENTINEROCK. J. D. Budroe1, R. Fears2, F. Collier2, A.Salmon1 and M. A. Marty1. 1Office of EnvironmentalHealth Hazard Assessment (OEHHA), Oakland, CA and2Department of Toxic Substances Control, Sacramento,CA.

#2110 IMPROVED DOSIMETRIC ADJUSTMENTFACTORS FOR INTERSPECIESEXTRAPOLATION OF INHALED, POORLYSOLUBLE PARTICLES. B. Asgharian1, O. Price1, A.Jarabek2,1 and F. Miller1. 1Division of ComputationalBiology, CIIT Centers for Health Research, ResearchTriangle Park, NC and 2National Center forEnvironmental Assessment, U.S. EPA, Washington DC,DC.

#2111 DEVELOPMENT OF A CHRONIC INHALATIONREFERENCE EXPOSURE LEVEL FORRESPIRABLE CRYSTALLINE SILICA. J. F.Collins, A. G. Salmon, J. P. Brown, M. A. Marty and G.V. Alexeeff. OEHHA, California EPA, Oakland, CA.

#2112 EFFECT OF ARSENIC AND DIELDRIN ONFEMALE RATS: PRELIMINARY DOSE RANGESTUDIES. L. Ogden1, R. R. Dalvi1, M. Mansour1, T.Graham2, L. Billups2 and T. Datiri1. 1BiomedicalSciences, Tuskegee University, Tuskegee, AL and2Pathobiology, Tuskegee University, Tuskegee, AL.


POSTER SESSION: RENAL TOXICOLOGY

Chairperson(s): Lu Cai, University of Louisville, Louisville, KY and MonicaValentovic, Marshall University, Huntington, WV.



#2113 CHARACTERIZATION OF ISCHEMIA-REPERFUSION EFFECTS IN RENAL CELLS — ASCREENING APPROACH. A. Heussner, E. O’Brienand D. Dietrich. Environmental Toxicology, Universityof Konstanz, Konstanz, Germany.

#2114 OCHRATOXIN A- INDUCED GENEEXPRESSION DEREGULATIONS IN THEKIDNEY OF EKER RATS ANALYZED ONAFFYMETRIX CHIPS. K. Stemmer1, H. Ellinger2, T.Lampertsdoerfer1, M. Thiel2, H. Ahr2 and D. Dietrich1.1University of Konstanz, Konstanz, Germany and2Molecular and Genetic Toxicology, Bayer Health CareAG, Germany, Germany, Germany.

#2115 CHARACTERIZATION OF OCHRATOXIN A-TRANSPORTING ORGANIC ANIONTRANSPORTERS IN RENAL CELLS. M. Biester,E. O’Brien, A. Heussner and D. Dietrich.Environmental Toxicology, University of Konstanz,Konstanz, Germany.

#2116 CYTOTOXICITY OF THE NEPHROTOXINSARISTOLOCHIC ACID AND MAM-ACETATE ONHUMAN AND PORCINE KIDNEY CELL LINESAND PRIMARY KIDNEY CORTEX CELLS. S.Huljic1, E. Dorr2, B. Brune2 and D. Dietrich1.1University of Konstanz, Konstanz, Germany and2University of Kaiserslautern, Kaiserslautern, Germany.

#2117 EFFECT OF ETHYLENE GLYCOLMETABOLITES ON VARIOUS CYTOTOXICITYPARAMETERS IN HUMAN PROXIMAL TUBULECELLS. C. Guo, Y. Li, B. Crenshaw and K. McMartin.Pharmacology, LSU Health Sciences Center,Shreveport, LA.

#2118 PEROXIREDOXINS ARE MODIFIED BYQUINONE-GENERATED REACTIVE OXYGENSPECIES. J. Dong1,2, M. Person1, S. C. Hensley3, J.Shen3, S. S. Lau2 and T. J. Monks2. 1Division ofPharmacology and Toxicology, University of Texas atAustin, Austin, TX, 2Department of Pharmacology andToxicology, University of Arizona Health SciencesCenter, Tucson, AZ and 3Department of Carcinogenesis,University of Texas M. D. Anderson Cancer Center,Science Park-Research Division, Smithville, TX.

Program Description


THU

RSDAY


#2119 UP-REGULATION OF HEAT SHOCK PROTEIN27 AND RETINOL BINDING PROTEINCONTRIBUTES TO 11-DEOXY-16, 16-DIMETHYLPROSTAGLANDIN E2 MEDIATEDCYTOPROTECTION. J. L. Lord1, Z. Jia1, D. W.Cromey2, R. C. Lantz2, T. J. Monks1 and S. S. Lau1.1Department of Pharmacology& Toxicology, College ofPharmacy, University of Arizona, Tucson, AZ and 2CellBiol & Anat, College of Medicine, University ofArizona, Tucson, AZ.

#2120 ASSESSMENT OF IN VITRO TOXICITY OFSELECTED CHEMO-THERAPUETIC DRUGSUSING HUMAN PRIMARY RENAL CELLS. W. Li,M. Lam, A. Birkeland, L. Warfe, D. Choy, J. Post andM. Sullivan. Pharmacology, Berlex, Richmond, CA.

#2121 NEPHROTOXICITY OF N-(3, 5-DICHLOROPHENYL)-3-HYDROXYSUCCINAMIC ACID IN MALE ANDFEMALE FISCHER 344 RATS. G. O. Rankin, D. K.Anestis, K. R. Saunders and S. K. Hong. Pharmacology,Marshall University, Huntington, WV.

#2122 COMPARISON OF THE IN VITRONEPHROTOXIC POTENTIAL OF DICLOFENACAND ACETAMINOPHEN IN ISOLATED RENALPROXIMAL TUBULES FROM MALE FISCHER344 RATS. S. L. Miles, J. G. Ball and G. O. Rankin.Pharmacology, Marshall University, Huntington, WV.

#2123 IN VITRO GSH ADDUCT FORMATION:EVIDENCE FOR BIOACTIVATION OF THENEPHROTOXICANT N-(3, 5-DICHLOROPHENYL)SUCCINIMIDE THROUGHALCOHOL-O-GLUCURONIDATION ANDSULFATION. D. Cui1,2, G. O. Rankin3 and P. J.Harvison1. 1Department of Pharmaceutical Sciences,University of the Sciences in Philadelphia, Philadelphia,PA, 2Department of Pharmaceutical CandidatesOptimization, Bristol-Myers Squibb, Princeton, NJ and3Department of Pharmacology, Marshall UniversitySchool of Medicine, Huntington, WV.

#2124 EFFECT OF ENANTIOMER-BASED INHIBITORSOF CA2+-INDEPENDENT PHOSPHOLIPASE A2ON RENAL AND CANCER CELL DEATH. L.Zhang, W. Zhang and B. S. Cummings. Pharmaceuticaland Biomedical Sciences, University of Georgia,Athens, GA.

#2125 IDENTIFICATION AND CHARACTERIZATIONOF IPLA2γγ IN MITOCHONDRIA. G. R. Kinsey1, J.McHowat2 and R. G. Schnellmann1. 1PharmaceuticalSciences, Medical University of South Carolina,Charleston, SC and 2Pathology, St. Louis University, St.Louis, MO.

#2126 ISCHEMIA-INDUCED CLEAVAGE OFCADHERINS IN NRK CELLS: EVIDENCE FORA ROLE OF MT1-MMP. M. Pulido1, K. Bayless2, R.Burghardt3, G. Davis2 and A. Parrish1. 1Pharmacologyand Toxicology, Texas A&M University System HealthScience Center, College Station, TX, 2Pathology, TexasA&M University System Health Science Center,College Station, TX and 3Veterinary Anatomy, TexasA&M University, College Station, TX.

#2127 ROLE OF HEAT SHOCK PROTEINS ANDSIGNALING PATHWAYS IN DETERMININGRESPONSE OF HUMAN PROXIMAL TUBULARCELLS TO S-(1, 2-DICHLOROVINYL)-L-CYSTEINE (DCVC). D. A. Putt, L. H. Lash, S. E.Hueni and B. P. Horwitz. Pharmacology, Wayne StateUniversity Sch. Med., Detroit, MI.

#2128 IDENTIFICATION AND LOCALIZATION OFCALPAIN 10 TO MITOCHONDRIA. D. Arringtonand R. G. Schnellmann. Pharmaceutical Sciences,MUSC, Charleston, SC.

#2129 EPITHELIAL BARRIER CHARACTERISTICSAND EXPRESSION OF CELL ADHESIONMOLECULES IN PROXIMAL TUBULE-DERIVED CELL LINES COMMONLY USED FORIN VITRO NEPHROTOXICITY TESTING. W. C.Prozialeck, P. C. Lamar and C. S. Smith. Pharmacology,Midwestern University, Downers Grove, IL.

#2130 CYTOTOXICITY AND METABOLISM OF S-1, 2-DICHLOROVINYL-GLUTATHIONE (DCV-GSH)AND CHLORAL (CH) BY HUMAN PROXIMALTUBULE CELLS (HPTC) IN CULTURE. E. A. Lock,L. Tolliver-Ho and R. G. Schnellmann. PharmaceuticalSciences, Medical University of South Carolina,Charleston, SC.

#2131 PROTEOMIC CHARACTERIZATION OF THEEFFECTS OF A KINASE INHIBITOR ONPROTEIN EXPRESSION IN RAT KIDNEY. J.Leonard1, M. Courcol1, E. Boitier1, M. Duchesne2, F.Parker2, Z. Jayyosi3, R. A. Roberts1,4 and J. Gautier1.1Drug Safety Evaluation, Sanofi Aventis, Vitry-sur-Seine, France, 2Functional Genomics, Sanofi Aventis,Vitry-sur-Seine, France, 3Drug Safety Evaluation,Sanofi Aventis, Bridgewater, NJ and 4Safety Assessment(current address), Astra Zeneca, Alderley Park, UnitedKingdom.

#2132 REGULATION OF GRP78 IN THEGLOMERULAR MESANGIAL CELL STRESSRESPONSE. A. Nanez1,2, H. Falahatpisheh1,2, Y.Qian3, E. Tiffany-Castiglioni3 and K. S. Ramos1,2.1Biochemistry and Molecular Biology, University ofLouisville, Louisville, KY, 2Center for Genetics andMolecular Medicine, University of Louisville, Louiville,KY and 3Department of Veterinary Anatomy & PublicHealth, Texas A&M University, College Station, TX.

#2133 REDUCTION OF CYCLOSPORIN ANEPHROTOXICITY BY GADOLINIUMCHLORIDE. Z. Zhong and J. Sun. Cell andDevelopmental Biology, University of North Carolina,Chapel Hill, NC. Sponsor: J. Lemasters.

#2134 THE EFFECT OF S-ADENOSYL-L-METHIONINE(SAME) AND ASCORBIC ACID ON P-AMINOPHENOL TOXICITY IN RENAL SLICES.M. Valentovic, R. Harmon and D. Hoover.Pharmacology, Marshall University School of Medicine,Huntington, WV.

Program Description



THU

RSD

AY

#2135 HUMAN PRECISION-CUT KIDNEY-CORTEXSLICES AS A TOXICOLOGY MODEL FOREVALUATING THE HYPERAMMONEMICEFFECT OF VALPROATE: A CARBON 13 NMRSTUDY. G. Baverel, A. Vittorelli, C. Gauthier, C.Michoudet and G. Martin. Metabolic and RenalPathophysiology, INSERM U499, Lyon Cedex 08,France. Sponsor: J. Descotes.

#2136 UTILITY OF A SUBCLINICAL RENAL INJURYMODEL IN RATS FOR DETECTION OFINCREASED SENSITIVITY TO SITE-SPECIFICNEPHROTOXIC METALS. E. F. Madden, R. P.Brown and P. L. Goering. Center for Devices andRadiological Health, U.S. FDA, Silver Spring, MD.

#2137 PREPLACED RENAL CELL DIVISION IS THECRITICAL MECHANISM OF PROTECTION INMICE AGAINST S-1, 2-DICHLOROVINYL-L-CYSTEINE-INDUCED ACUTE RENAL FAILUREAND DEATH. M. C. Korrapati1, J. Chilakapati1, E. A.Lock2, J. Latendresse3, A. Warbritton3 and H. M.Mehendale1. 1ULM, Monroe, LA, 2MUSC, Charleston,SC and 3NCTR, Jefferson, AR.

#2138 INHIBITION OF TISSUE REPAIR LEADS TOPROGRESSION OF INJURY, ACUTE RENALFAILURE AND DEATH IN MICE. R. N. Reddy andH. M. Mehendale. Toxciology, University of LousianaMonroe, Monroe, LA.

#2139 ROLE OF LOWER PROGRESSION OF DCVC-INITIATED RENAL INJURY IN DIABETES-INDUCED PROTECTION FROMNEPHROTOXICITY. A. V. Dnyanmote1, H. M.Mehendale1, E. A. Lock2 and J. R. Latendresse3.1Toxicology, University of Louisiana at Monroe,Monroe, LA, 2Pharmaceutical Sciences, MUSC,Charleston, SC and 3Pathology Associates Intl., NCTR,Jefferson, AR.

#2140 TISSUE DISTRIBUTION AND RENALONTOGENY OF ORGANIC CATIONTRANSPORTERS IN MICE. Y. M. Alnouti, J. S.Petrick, T. R. Knight and C. D. Klaassen. University ofKansas Medical Center, Kansas City, KS.

#2141 DIETARY MODULATION OF THE RENALTOXICITY OF P-NONYLPHENOL (NP) INSPRAGUE-DAWLEY RATS. S. Cooper1, X. Fu1, J. R.Latendresse2 and K. B. Delclos1. 1NCTR, Jefferson, ARand 2Charles River Laboratories, Jefferson, AR.

#2142 ETIOLOGY OF HYDRONEPHROSIS WITHOUTOBSTRUCTION IN THE MOUSE KIDNEY BYLACTATIONAL EXPOSURE TO DIOXIN. N.Nishimura1, J. Yonemoto1, Y. Takeuchi1, C. Yokoi1, H.Nishimura3 and C. Tohyama2. 1Endocrine Disruptorsand Dioxin Project, National Institute for EnvironmentalStudiess and Dioxin Project, Tsukuba, Japan,2Environmental Health Sciences Division, NationalInstitute for Environmental Studies, Tsukuba, Japan and3Aichi Mizuho University, Toyota, Japan.


POSTER SESSION: PESTICIDES

Chairperson(s): Derek Gammon, CAL-EPA, Sacramento, CA and KevinCrofton, U.S. EPA, Research Triangle Park, NC.



#2143 EFFECTS OF CONAZOLE FUNGICIDES ONDEVELOPMENT AND PARTURITION IN THERAT. M. G. Narotsky1, J. C. Rockett1, C. R. Blystone2,A. K. Goetz2, H. Ren1, D. S. Best1, H. P. Nichols1, J. E.Schmid1 and D. J. Dix1. 1Reproductive ToxicologyDivision, U.S. EPA, ORD, NHEERL, Research TrianglePark, NC and 2Department of Environmental andMolecular Toxicology, North Carolina State University,Raleigh, NC.

#2144 TRIADIMEFON INDUCES RAT THYROIDTUMORS THROUGH A NON-TSH MEDIATEDMODE OF ACTION. D. C. Wolf1, J. Allen1, G. Sun1,J. R. Thibodeaux2, M. George1, S. D. Hester1, S. Thai1,D. Delker1, G. Nelson1, E. Winkfield1, B. Roop1, S.Leavitt1, W. Ward1 and S. C. Nesnow1. 1EnvironmentalCarcinogenesis Division, U.S. EPA, Research TrianglePark, NC and 2Reproductive Toxicology Division, U.S.EPA, Research Triangle Park, NC.

#2145 MYCLOBUTANIL AND TRIADIMEFONMETABOLISM BY RAT CYP ISOFORMS ANDLIVER MICROSOMES. J. Tang1, Y. Sey2, R.Murrel3, J. Rockett4, D. Dix4 and H. Barton2.1Curriculum in Toxicology, UNC-Chapel Hill, ChapelHill, NC, 2Experimental Toxicology Division, U.S. EPANHEERL, Research Triangle Park, NC, 3Department ofEnvironmental and Molecular Toxicology, NC StateUniversity, Raleigh, NC and 4Reproductive ToxicologyDivision, U.S. EPA NHEERL, Research Triangle Park,NC.

#2146 COMPARATIVE LIVER P450 ENZYMEACTIVITY AND HISTOPATHOLOGY IN MICETREATED WITH THE CONAZOLEFUNGICIDES: MYCLOBUTANIL,PROPICONAZOLE AND TRIADIMEFON. J. Allen,D. C. Wolf, M. George, S. D. Hester, G. Sun, S. Thai, D.Delker, G. Nelson, E. Winkfield, B. Roop, S. Leavitt,W. Ward and S. C. Nesnow. EnvironmentalCarcinogenesis Division, U.S. EPA, Research TrianglePark, NC.

#2147 COMPARISON OF HEPATIC GENEEXPRESSION PROFILES FROM MICEEXPOSED TO THREE TOXICOLOGICALLYDIFFERENT CONAZOLES. W. Ward, S. D. Hester,S. Thai, J. Allen, C. Jones, D. C. Wolf and S. Nesnow.Environmental Carcinogenesis Division, U.S. EPA,Research Triangle Park, NC.

Program Description


THU

RSDAY


#2148 REPRODUCTIVE EFFECTS OF EXPOSURE TOCONAZOLE FUNGICIDES IN THE MALE RAT.A. K. Goetz1, C. Blystone1, H. Ren2, J. E. Schmid2, H.P. Nichols2, W. Bao2, D. S. Best2, M. G. Narotsky2, D.C. Wolf2, J. C. Rockett2 and D. J. Dix2. 1Department ofEnvironmental and Molecular Toxicology, NorthCarolina State University, Raleigh, NC and 2NHEERL,Office of Research and Development, U.S. EPA,Research Triangle Park, NC.

#2149 COMPARISON OF GENE EXPRESSIONPROFILES FROM RATS FED THREETOXICOLOGICALLY DIFFERENTCONAZOLES. S. Hester, S. Thai, D. C. Wolf, W. Wardand S. C. Nesnow. Environmental CarcinogenesisDivision, U.S. EPA, Research Triangle Park, NC.

#2150 PROFILING GENE EXPRESSION IN HUMANH295R ADRENOCORTICAL CARCINOMACELLS AND RAT TESTES TO IDENTIFYPATHWAYS OF TOXICITY FOR CONAZOLEFUNGICIDES. H. Ren1, J. E. Schmid1, J. Retief2, Y.Turpaz2, X. Zhang3, P. D. Jones3, J. L. Newsted4, J. P.Giesy3, D. C. Wolf1, C. R. Wood1, W. Bao1 and D. J.Dix1. 1NHEERL/ORD, U.S. EPA, Research TrianglePark, NC, 2Affymetrix Inc., Santa Clara, CA,3Department of Zoology, Michigan State University,East Lansing, MI and 4ENTRIX Inc., East Lansing, MI.

#2151 REPRODUCTIVE TOXICITY OF EXPOSURE TOCONAZOLE FUNGICIDES IN THE FEMALERAT. J. C. Rockett1, M. G. Narotsky1, I.Thillainadarajah1, C. R. Blystone2,1, A. K. Goetz2,1, H.Ren1, D. S. Best1, R. N. Murrell2,1, H. P. Nichols1, J. E.Schmid1, K. E. Thompson3 and D. J. Dix1.1RTD/NHEERL/ORD, U.S. EPA, Research TrianglePark, NC, 2Department of Environmental and MolecularToxicology, North Carolina State University, Raleigh,NC and 3Reproductive Toxicology, PharmaceuticalResearch Institute, Bristol-Myers Squibb Company,New Brunswick, NJ.

#2152 A RISK ASSESSMENT OF THE TRIAZINEHERBICIDE ATRAZINE. D. W. Gammon, C. N.Aldous, W. C. Carr, J. R. Sanborn and K. F. Pfeifer.Department of Pesticide Regulation, California EPA,Sacramento, CA.

#2153 METHOXYCHLOR INHIBITS EXPRESSION OFANTIOXIDANT ENZYMES IN THE MOUSEOVARY. R. K. Gupta, K. P. Miller, D. Tomic and J. A.Flaws. Toxicology, University of Maryland atBaltimore, Baltimore, MD.

#2154 TRANSIENT ACTIVATION OFACETYLCHOLINESTERASE BY PARAOXON. C.A. Rosenfeld1 and L. G. Sultatos2. 1Drug Metabolismand Pharmacokinetics, Schering-Plough ResearchInstitute, Lafayette, NJ and 2Pharmacology &Physiology, UMD New Jersey Medical School, Newark,NJ.

#2155 EVALUATION FOR THE ADDITIVE TOXICINFLUENCE OF ORGANOPHOSPHORUSPESTICIDES. M. Tahara1,2, R. Kubota1, H.Nakazawa2, A. Hirose3, M. Ema3, H. Tokunaga1 and T.Nishimura1. 1Division of Environmental Chemistry,National Institute of Health Sciences, Tokyo, Japan,2Department of Analytical Chemistry, Hoshi University,Tokyo, Japan and 3Division of Risk Assessment,Biological, Safety Research Center, National Institute ofHealth Sciences, Tokyo, Japan.

#2156 BIOLOGICAL MONITORING OF EXPOSURE TOORGANOPHOSPHORUS INSECTICIDES INGREENHOUSE WORKERS. M. Bouchard1,3, G.Carrier1, R. C. Brunet2, N. Noisel1, G. Labarre1, P.Dumas3 and J. Weber3. 1Environmental andOccupational Health, University of Montreal, Montreal,QC, Canada, 2Mathematics and statistics, University ofMontreal, Montreal, QC, Canada and 3Risquesbiologiques, environnementaux et occupationnels,Institut national de sante publique du Quebec, Montreal,QC, Canada.

#2157 KINETIC DATA ON PESTICIDE METABOLISMIN HUMANS TO ALLOW PBPK/PD MODELSFOR PARATHION AND CHLORPYRIFOS TOPREDICT SUSCEPTIBILITY. J. R. Olson, J. B.Knaak, B. P. McGarrigle, K. M. Kransler, R. J.Foxenberg and P. J. Kostyniak. Pharmacology andToxicology, SUNY at Buffalo, Buffalo, NY.

#2158 ORGANOPHOSPHORUS PESTICIDES INHIBITPRENYLATED METHYLATED PROTEINMETHYL ESTERASE. N. S. Lamango. College ofPharmacy and Pharmaceutical Sciences, Florida A&MUniversity, Tallahassee, FL. Sponsor: A. Ndifor.

#2159 ASSESSING EXPOSURES TO FLEA CONTROLINSECTICIDES FROM THE FUR OF DOGSTREATED WITH FLEA COLLARS. K. Davis1, J.Chambers1, J. Moran1, N. Holifield1 and S. Boone2.1Basic Science, Mississippi State University,Mississippi State, MS and 2U.S. EPA, Stennis SpaceCenter, MS.

#2160 EFFECT OF PYRETHRINS ON CYTOCHROMEP450 FORMS IN CULTURED RAT AND HUMANHEPATOCYTES. B. G. Lake1, R. J. Price1, A. M.Giddings1, C. Meredith1 and T. G. Osimitz2. 1MolecularSciences, BIBRA International Ltd.,, Carshalton, Surrey,United Kingdom and 2Science Strategies LLC,Charlottesville, VA.

#2161 RELATIVE POTENCIES FOR ACUTE EFFECTSOF PYRETHROIDS ON MOTOR FUNCTION INRATS. M. J. Wolansky1, M. J. DeVito2, C. Gennings3,W. Carter3, R. A. Carchman3 and K. M. Crofton2.1National Research Council, Research Triangle Park,NC, 2NTD and ETD, U.S. EPA, Research Triangle Park,NC and 3Solveritas, LLC, Richmond, VA.

Program Description



THU

RSD

AY

#2162 USING ARRAY TECHNOLOGY TO IDENTIFYPOTENTIAL BIOMARKERS FOR PYRETHROIDINSECTICIDES. J. Harrill1, M. J. Wolansky2, S.Hester3, J. M. Hedge4 and K. M. Crofton4,1.1Curriculum in Toxicology, University of NorthCarolina, Chapel Hill, NC, 2National Research Council,Research Triangle Park, NC, 3ETD, NHEERL, ORD,U.S. EPA, Research Triangle Park, NC and 4NTD,NHEERL, ORD, U.S. EPA, Research Triangle Park,NC.

#2163 ACTIVATION OF MITOGEN-ACTIVATEDPROTEIN KINASE AND TRANSCRIPTIONALFACTORS PRECEDES CYCLOOXYGENASE-2GENE EXPRESSION IN MACROPHAGESEXPOSED TO THE O, P- DDT. J. Kim1,2, E. Han1,2


#2164 SUCCESSFUL ELIMINATION OF PARAQUAT BYHEMOPERFUSION USING PULSATILEEXTRACORPOREAL CIRCULATION. E. Hwang1,S. Lee2, J. Hwang2, J. Lee3, C. Lee4 and Y. Kim1.1Department of Thoracic and Cardiovascular Surgery,Konkuk University Chungju Hospital, Chungju, SouthKorea, 2Department of Thoracic and CardiovascularSurgery, Konkuk University Hospital, Seoul, SouthKorea, 3Department of Emergency Medicine, KonkukUniversity Chungju Hospital, Chungju, South Koreaand 4Department of Diagnostic and ExperimentalMedicine, Konkuk University Chungju Hospital,Chungju, South Korea.

#2165 DDT-INDUCED AROMATASE ANDCYCLOOXYGENASE-2 GENE EXPRESSION INTESTICULAR LEYDIG R2C CELLS. D. Oh1,2 andH. Jeong1,2. 1Pharmacy, Chosun University, Kwangju,South Korea and 2Research Center for ProteineousMaterials, Chosun University, Kwangju, South Korea.

#2166 INDUCTION OF CYP3A4 BY O, P’-DDT INHEPG2 CELLS. I. M. Medina and G. Elizondo-Azuela. Toxicology, CINVESTAV-IPN, Mexico City,D.F., Mexico. Sponsor: B. Quintanilla-Vega.

#2167 N-DEALKYLATION IS A KEY DETERMINANTIN THE HEPATOTOXICITY OFCHLOROACETANILIDE HERBICIDEALACHLOR. V. M. Kale and S. A. Meyer. Toxicology,University of Louisiana at Monroe, Monroe, LA.

#2168 TRIBUTYLTIN REGULATED STEROIDOGENICENZYME GENES EXPRESSION AND CHANGESSEXUAL HORMONE IN MOUSE TESTICULARLEYDIG CELLS. H. Kim1,2, K. Lee1, K. Jung1,2, D.Oh1,2, K. Oh1,2, J. Choi1,2 and H. Jeong1,2. 1Pharmacy,Chosun University, Kwangju, South Korea and2Research Center for Proteineous Materials, ChosunUniversity, Kwangju, South Korea.

#2169 TRIBUTYLTIN INDUCE CELL CYCLE ARRESTIN RAT TESTICULAR LEYDIG CELLS. D. Kim3,K. Lee1,2, D. Oh1,2, J. Kim1,2, H. Kim1,2, D. Shin1,2 andH. Jeong1,2. 1Pharmacy, Chosun University, Kwangju,South Korea, 2Research Center for ProteineousMaterials, Chosun University, Kwangju, South Koreaand 3Pathology, College of Oriental Medicine, DaejeonUniversity, Daejeon, South Korea.

#2170 THE BIPYRIDYL HERBICIDE PARAQUATCAUSES OXIDATIVE STRESS-MEDIATEDTOXICITY IN HUMAN NEUROBLASTOMA SH-SY5Y CELLS: RELEVANCE TO PARKINSON`SDISEASE. W. Yang and E. Tiffany-Castiglioni.Veterinary Integrative Biosciences, Texas A&MUniversity, College Station, TX.


POSTER SESSION: DERMAL TOXICOLOGY

Chairperson(s): James McDougal, Wright State University, Pharmacologyand Toxicology, Dayton, OH and Paul Howard, U.S. FDA, NCTR BiochemicalToxicology, Jefferson, AR.



#2171 DIFFERENTIAL INDUCTION OFCYCLOOXYGENASE-2 (COX-2) AND HEMEOXYGENASE-1 (HO-1) BY UVB LIGHT INGROWING AND CALCIUM-DIFFERENTIATEDPRIMARY CULTURES OF MOUSEKERATINOCYTES. A. T. Black1, M. P. Shakarjian2,D. R. Gerecke1,3, A. M. Vetrano3, D. E. Heck1,3 and J.D. Laskin1,4. 1Joint Graduate Program in Toxicology,Rutgers University, Piscataway, NJ, 2Department ofMedicine, UMDNJ-Robert W Johnson Med. Sch,Piscataway, NJ, 3Pharmacology and Toxicology,Rutgers University, Piscataway, NJ and 4Environmentaland Occupational Medicine, UMDNJ-Robert WJohnson Med. Sch, Piscataway, NJ.

#2172 DECREASING MALATHION APPLICATIONTIME FOR LICE TREATMENT REDUCESTRANSDERMAL ABSORPTION. R. Brand1,2, A.Charron1 and R. Brand1,2. 1Internal Medicine, EvanstonNorthwestern Healthcare, Evanston, IL and 2InternalMedicine, Feinberg School of Medicine at NorthwesternUniversity, Chicago, IL. Sponsor: P. Iversen.

#2173 DERMAL PENETRATION OF SODIUM LAURYLSULPHATE AND ITS EFFECT UPON THEABSORPTION OF OTHER CHEMICALS INVITRO. J. Wakefield1, D. Lockley2, R. Pendlington2

and F. Williams1. 1Environmental Medicine, Universityof Newcastle upon Tyne, Newcastle upon Tyne, UnitedKingdom and 2SEAC, Unilever Colworth, Sharnbrook,Bedfordshire, United Kingdom.

Program Description


THU

RSDAY


#2174 INVESTIGATION OF SKIN BARRIER CREAMSFOR LOWERING PENETRATION OF JP-8 JETFUEL THROUGH IN VITRO PIG SKIN. J. J.Schlager1, D. L. Pollard2, T. A. Minnick1, A. J. Guilfoil1

and S. C. Stevens1. 1HEPB, Applied BiotechnologyBranch, Air Force Research Laboratory, Dayton, OHand 2ManTech Environmental Technologies, Inc.,Dayton, OH.

#2175 EFFECT OF ACUTE AND CHRONIC EXPOSURETO THE CLEANSER, TRICHLOROETHYLENE,ON THE DERMAL ABSORPTION OF THEBIOCIDE TRIAZINE. J. L. Yeatts, R. E. Baynes, J. D.Brooks, B. M. Barlow and J. E. Riviere. Center forChemical Toxicology Research and Pharmacokinetics,North Carolina State University, Raleigh, NC.

#2176 EFFECT OF IN VIVO JET FUEL EXPOSURE ONSUBSEQUENT IN VITRO DERMALABSORPTION OF AROMATIC AND ALIPHATICHYDROCARBONS. F. Muhammad1, N. A. Monteiro-Riviere2, R. E. Baynes2 and J. E. Riviere2. 1Universityof Agriculture, Faisalabad, Pakistan and 2Center forChemical Toxicology Research and Pharmacokinetics,North Carolina State University, Raleigh, NC.

#2177 ABSORPTION OF LAWSONE THROUGHHUMAN SKIN. M. E. Kraeling1, C. T. Jung2 and R. L.Bronaugh1. 1Office of Cosmetics and Colors, U.S. FDA,Laurel, MD and 2Office of Pharmaceutical Science,U.S. FDA, Rockville, MD.

#2178 SKIN PENETRATION OF BREAK-FREE CLP INTHREE SPECIES; SPRAGUE DAWLEY RAT, CD-1 MOUSE, AND YORKSHIRE PIG. C. M. Garrettand J. N. McDougal. Pharmacology/Toxicology, WrightState University, Dayton, OH.

#2179 CHANGES IN GENE EXPRESSION IN RATEPIDERMIS AFTER JET FUEL (JP-8)EXPOSURE TO THE SKIN. C. M. Amato, C. M.Garrett and J. N. McDougal. Pharmacology/Toxicology,Wright State University, Dayton, OH.

#2180 PROTEOMIC ANALYSIS OF JP-8 JET FUELEXPOSURE IN HUMAN KERATINOCYTE CELLCULTURE. F. Witzmann1, N. Monteiro-Riviere2, A.Inman2, N. Pedrick1, H. Ringham1 and J. Riviere2.1Cellular & Integrative Physiology, Indiana UniversitySchool of Medicine, Indianapolis, IN and 2Center forChemical Toxicology Research & Pharmacokinetics,College of Veterinary Medicine, North Carolina StateUniversity, Raleigh, NC.

#2181 EXPRESSION PROFILING OF HUMANEPIDERMAL KERATINOCYTE RESPONSEFOLLOWING JP-8 EXPOSURE. C. Chou1, J. Yang2,N. A. Monteiro-Riviere3 and J. J. Chen4. 1Department ofVeterinary Medicine, National Chung-Hsing University,Taichung, Taiwan, 2Department of Dermatology,Chung-Shan Medical University Hospital, Taichung,Taiwan, 3Center for Cutaneous Toxicology andResearch Pharmacokinetics, North Carolina StateUniversity, Raleigh, NC and 4Institute of MolecularBiology, National Chung-Hsing University, Taichung,Taiwan.

#2182 JP-8 JET FUEL EXPOSURE INDUCESINFLAMMATORY CYTOKINES IN RAT SKIN. R.Gallucci1, S. K. O’Dell1, D. Faulkner1 and L. D.Fechter2. 1Pharmaceutical Sciences, OU HealthSciences Center, Oklahoma City, OK and 2Jerry PettisMemorial Veterans Medical Center, Loma Linds, CA.

#2183 PROTEOMIC ANALYSIS OF NANOPARTICLEEXPOSURE IN HUMAN KERATINOCYTE CELLCULTURE. N. A. Monteiro-Riviere1, Y. Y. Wang2, S.M. Hong3, A. O. Inman1, R. J. Nemanich2, J. Tan3, F. A.Witzmann3 and J. E. Riviere1. 1Center for ChemicalToxicology Research and Pharmacokinetics, NorthCarolina State University, Raleigh, NC, 2Department ofPhysics, North Carolina State University, Raleigh, NCand 3Department of Cellular & Integrative Physiology,Indiana University School of Medicine, Indianapolis,IN.

#2184 NANTOTUBE DISPERSAL IN HUMANKERATINOCYTE CELL CULTURE USINGSURFACTANTS. A. O. Inman1, Y. Y. Wang2, R. J.Nemanich2, J. E. Riviere1 and N. A. Monteiro-Riviere1.1Center for Chemical Toxicology Research andPharmacokinetics, North Carolina State University,Raleigh, NC and 2Department of Physics, NorthCarolina State University, Raleigh, NC.

#2185 LOCALIZATION OF INTRADERMALLYINJECTED QUANTUM DOT NANOPARTICLESIN REGIONAL LYMPH NODES. D. W. Roberts1, N.V. Gopee1, B. J. Miller1, D. Norton2, A. R. Warbritton2,J. R. Bucher3, W. W. Yu4, C. M. Sayes4, V. L. Colvin4

and P. C. Howard1. 1Biochemical Toxicology, NCTR,Jefferson, AR, 2Pathology, Charles River Co., Jefferson,AR, 3National Toxicology Program, NIEHS, ResearchTriangle Park, NC and 4Center for Biological andEnvironmental Nanotechnology, Rice University,Houston, TX.

#2186 IMAGING THE PENETRATION OF RUBPY-DOPED SILICA NANOPARTICLES INTOHUMAN AND MOUSE SKIN WITHFLUORESCENT MICROSCOPY. S. C. Wasdo, S. M.Roberts, S. Santra, J. Munson and Y. Song. Universityof Florida, Gainesville, FL.

#2187 MODULATORY EFFECTS OF SUBCHRONICEXPOSURE TO SIMULATED SOLAR LIGHT ONTATTOOED SKIN IN SKH-1 MICE. N. V. Gopee1,2,Y. Cui1,2, G. R. Olson3, A. R. Warbritton3, B. J.Miller1,2, L. H. Couch1,2, W. G. Wamer4 and P. C.Howard1,2. 1NCTR, U.S. FDA, Jefferson, AR, 2NTPCenter for Phototoxicology, NCTR, U.S. FDA,Jefferson, AR, 3Charles River Co., Jefferson, AR and4CFSAN, U.S. FDA, College Park, MD.

#2188 ROLE OF VITAMIN E IN THE ANTIOXIDANTDEFENSE SYSTEM OF SKIN IN YOUNG ANDOLD MICE EXPOSED TO CUMENEHYDROPEROXIDE. A. R. Murray1, E. Kisin2, K.Kawai3, V. E. Kagan3, C. Kommineni2, V. Castranova1,2

and A. A. Shvedova1,2. 1Physiology and Pharmacology,WVU, Morgantown, WV, 2PPRB, NIOSH,Morgantown, WV and 3University of Pittsburgh,Pittsburgh, PA.

Program Description



THU

RSD

AY

#2189 DETECTION OF BENZO(A)PYRENE-INDUCEDDNA DAMAGE IN THE SKIN OF CD-1 MICEUSING THE COMET ASSAY. J. W. Parton, Y. Xu andJ. K. Kerzee. MicaGenix, Inc., Greenfield, IN.

#2190 EFFECT OF METHYL SUBSTITUTION OFBENZENE ON THE PERCUTANEOUSABSORPTION AND SKIN IRRITATIONHAIRLESS RATS. J. Ramapuram1, E. AHAGHOTU1

and M. SINGH1. 1Florida A&M University, Tallahassee,FL and 2SOT, E\TEST, AL.

#2191 LONG TERM REPRODUCIBILITY OFEPIDERMTM, AN EPIDERMAL MODEL FORDERMAL TESTING AND RESEARCH. M.Klausner, J. Kubilus, J. E. Sheasgreen and P. J. Hayden.MatTek Corporation, Ashland, MA.

#2192 DETERMINING SKIN IRRITATION POTENTIALOF INDUSTRIAL FLUIDS IN HUMANS USINGTRANS-EPIDERMAL WATER LOSS (TEWL). M.Wragg1 and S. Signs2. 1Lubrizol Limited, Derby, UnitedKingdom and 2The Lubrizol Corporation, Wickliffe,OH.

#2193 EVALUATION OF HISTORICAL POSITIVECONTROL DATA FOR RESPONSECONSISTENCY AND REDUCTION IN ANIMALUSE IN PHOTOTOXICITY ANDPHOTOALLERGY ASSESSMENTS. D. B. Learn, C.P. Sambuco, M. Arocena, M. L. Davis, T. S. Coston, P.D. Forbes and A. M. Hoberman. Center forPhotobiology, Charles River Discovery andDevelopment Services, Argus Division, Horsham, PA.

#2194 QUANTIFICATION OF MIXTUREINTERACTIONS ON DERMALPERMEABILITY–A SOLVATOCHROMATICAPPROACH. R. E. Baynes, B. M. Barlow, X. R. Xia,J. L. Yeatts, J. D. Brooks and J. E. Riviere. Center forChemical Toxicology Research and Pharmacokinetics,North Carolina State University, Raleigh, NC.

#2195 PREDICTING HUMAN SKIN ABSORPTION OFCHEMICALS: DEVELOPMENT OF A NOVELQUANTITATIVE STRUCTURE ACTIVITYRELATIONSHIP. W. Luo1, S. Medrek2, H. Nguyen1

and W. Fung1. 1Toxicology, L’Oreal USA, Clark, NJand 2Department of Chemical Engineering, PrincetonUniversity, Princeton, NJ.

#2196 A NOVEL SYSTEM COEFFICIENT APPROACHFOR QUANTITATIVE ASSESSMENT OFDERMAL ABSORPTION FROM CHEMICALMIXTURES BY USING THE MEMBRANE-COATED FIBER TECHNIQUE. X. R. Xia, R. E.Baynes, N. A. Monteiro-Riviere and J. E. Riviere. Centerfor Chemical Toxicology Research andPharmacokinetics, North Carolina State University,Raleigh, NC.

#2197 PREDICTION OF DERMAL ABSORPTION OFCHEMICAL MIXTURES USING BOTHPENETRANT AND MIXTURE COMPONENTPROPERTIES IN A HYBRID QUANTITATIVESTRUCTURE PERMEABILITY RELATIONSHIP(QSPR). J. E. Riviere and J. D. Brooks. Center forChemical Toxicology Research and Pharmacokinetics,North Carolina State University, Raleigh, NC.

#2198 COMPUTER-CONTROLLED SYSTEM FORGENERATION OF CHEMICAL VAPORS IN INVITRO DERMAL UPTAKE STUDIES. M. Raumaand G. Johanson. Work Environment Toxicology,Karolinska Institutet, Stockholm, Sweden.

#2199 CAN CHRONIC SKIN IRRITATION BEPREDICTED BY AN ACUTE TEST? C. M. deJongh, J. J. Jacobs, S. Kezic and M. M. Verberk.Coronel Institute for Occupational and EnvironmentalHealth, AMC, University of Amsterdam, Amsterdam,Netherlands. Sponsor: P. Boogaard.

#2200 ANTI-PSORIASIS MODEL IN THE MOUSE. S.Rowton and P. Long. Covance Laboratories Ltd.,Harrogate, United Kingdom. Sponsor: D. Everett.

#2201 EVALUATION OF THE TOXICITY OF MEDICALCOUNTERMEASURES FOR SULFUR MUSTARD.D. M. Moore1, R. C. Kiser1, N. A. Niemuth1, B. M.Biddle1, M. C. Babin1, I. Koplovitz2 and W. J. Smith2.1Battelle Memorial Institute, Columbus, OH and 2USArmy Medical Reasearch Institute of ChemicalDefense, Aberdeen, MD.

#2202 MOUSE EAR VESICANT MODEL (MEVM)EVALUATION OF TREATMENTCOMBINATIONS AGAINST TOPICAL SULFURMUSTARD CHALLENGE. R. C. Kiser1, D. M.Moore1, N. A. Niemuth1, B. M. Biddle1, M. C. Babin1,R. P. Casillas1, I. Koplovitz2 and W. J. Smith2. 1BattelleMemorial Institute, Columbus, OH and 2US ArmyMedical Research Institute of Chemical Defense,Aberdeen, MD.

#2203 90-DAY SUBCHRONIC DERMAL TOXICITY OFINSECT REPELLENT SS-220I IN RATS. J. T.Houpt and G. J. Leach. US Army Center for HealthPromotion and Preventive Medicine, Aberdeen ProvingGround, MD.


POSTER SESSION: GENOTOXICITY

Chairperson(s): Martha M. Moore, U.S. FDA, Jefferson, AR.



#2204 DATABASE CONSOLIDATION BASED ONTOXML OF GENETIC TOXICITY DATASUBMITTED TO CFSAN/OFAS AND CDER. J.Mayer1, M. Cheeseman1, C. Nelson1, R. Benz2, E.Matthews2, N. Kruhlak2, J. Contrera2, M. Twaroski1, K.Arvidson1 and C. Yang3. 1CFSAN/OFAS, U.S. FDA,College Park, MD, 2CDER/OPS/ICSAS, U.S. FDA,Rockville, MD and 3Leadscope, Inc., Columbus, OH.

Program Description


THU

RSDAY


#2205 INTER-LABORATORY EVALUATION OFBIOLUMINESCENT SALMONELLA REVERSEMUTATION ASSAY USING TEN (10) MODELCHEMICALS. J. I. Ackerman1, T. Hayashi2, J.Hitchcock3, L. Li4, S. Lu4, Y. Nagai2, F. Spence3 and J.Aubrecht1. 1Safety Sciences, Pfizer Inc., Groton, CT,2Safety Sciences, Pfizer Inc., Nagoya, Japan, 3SafetySciences, Pfizer Inc., Sandwich, United Kingdom,4Safety Sciences, Pfizer Inc., La Jolla, CA, 5SafetySciences, Pfizer Inc., La Jolla, CA, 6Safety Sciences,Pfizer Inc., Nagoya, Japan, 7Safety Sciences, Pfizer Inc.,Sandwich, United Kingdom and 8Safety Sciences,Pfizer Inc., Groton, CT.

#2206 MEASUREMENT OF MUTANT FREQUENCY INT-CELL RECEPTOR GENE BY FLOWCYTOMETRY ON EL-4 MOUSE LYMPHOMACELLS. N. Kunugita1, N. Mei2,3, T. Goncharova2 andT. Norimura2. 1School of Health Sciences, University ofOccupational and Environmental Health, Kitakyushu,Japan, 2Department of Radiation Biology & Health,University of Occupational and Environmental Health,Kitakyushu and 3NCTR, Jefferson, AR.

#2207 A HIGH-THROUGHPUT UNSCHEDULED DNASYNTHESIS (UDS) ASSAY USING FLOWCYTOMETRY. C. A. Kirk, D. R. Cerven and G. L.DeGeorge. MB Research Laboratories, Spinnerstown,PA.

#2208 MODIFIED BACTERIAL MUTATION TESTPROCEDURES FOR EVALUATION OFPEPTIDES AND AMINO ACID-CONTAININGMATERIAL. C. Thompson. Toxicology, CTBR,Senneville, QC, Canada. Sponsor: C. Banks.

#2209 DEVELOPMENT OF A NOVEL MICRONUCLEUSASSAY USING THE HUMAN 3-D SKIN MODEL,EPIDERM™ R. D. Curren1, G. Mun1, D. P. Gibson2

and M. J. Aardema2. 1Institute for In Vitro Sciences,Inc., Gaithersburg, MD and 2Procter & Gamble Co.,Cincinnati, OH.

#2210 INCREASED MICRONUCLEI FOLLOWINGOXYMORPHONE ADMINISTRATION ARESECONDARY TO INCREASED BODYTEMPERATURE. D. Shuey1, R. Gudi2, L.Krsmanovic2 and R. Gerson1. 1Endo PharmaceuticalsInc., Chadds Ford, PA and 2BioReliance, Rockville,MD.

#2211 THE CONTRIBUTION OF NON-CHEMICALLYINDUCED HYPOTHERMIA IN THEFORMATION OF MICRONUCLEI (MN) IN THEMOUSE BONE MARROW MICRONUCLEUSTEST (MNT). P. J. Spencer, J. G. Grundy, J. M.Waechter and B. Gollapudi. Toxicology &Environmental Research and Consulting, The DowChemical Company, Midland, MI.

#2212 IN VITRO MICRONUCLEUS SCORING BYFLOW CYTOMETRY: DIFFERENTIALSTAINING OF MICRONUCLEI AND APOPTOTICCHROMATIN ENHANCES ASSAY RELIABILITY.S. D. Dertinger, S. Avlasevich, S. Cairns and D. K.Torous. Litron Laboratories, Rochester, NY.

#2213 ESTABLISHMENT OF HUMANIZED IN VITROGENOTOXICITY TEST SYSTEM. M. Honma1, A.Hakura2, H. Oka3, W. Takasaki4, Y. F. Sasaki5, S.Suzuki6 and T. Sato6. 1National Institute of HealthSciences, Tokyo, Japan, 2Eisai Co.Ltd.,, Gifu, Japan,3Taiho Pharmacology Co.Ltd.,, Tokushima, Japan,4Sankyo Co.Ltd.,, Shizuoka, Japan, 5Hachinohe NCT,Aomori, Japan and 6HAB Bio Res Inst, Chiba, Japan.

#2214 DIFFERENTIAL S-9 ACTIVATION OFHYDROCODONE BITARTRATE ANDNALTREXONE HYDROCHLORIDE WITHHUMAN LIVER S-9 AND RAT LIVER S-9 IN THEMOUSE LYMPHOMA FORWARD MUTATIONASSAY. K. W. Hew1, M. A. Cifone2 and T. Lawal2.1Purdue Pharmacology L.P., Ardsley, NY and 2CovanceLaboratories Inc., Vienna, VA.

#2215 APPLICATION OF HUMAN EXOGENOUSMETABOLIC SYSTEM IN GENOTOXICITYEVALUATION. A. P. LI2,1,3, S. K. Roy3, C. Bode4, P.Kirby2,3 and A. Thilagar2,3. 1Advanced PharmaceuticalSciences, Columbia, MD, 2The ADMET Group LLC,Rockville, MD, 3Sitek Laboratories Inc., Rockville, MDand 4Tissue Transformation Technologies, Inc., Edison,NJ.

#2216 MOLECULAR ANALYSIS OF SPONTANEOUSAND 3’-AZIDO-3’-DEOXYTHYMIDINE-INDUCED L5178Y TK-/- MOUSE LYMPHOMACELL MUTANTS. J. Wang1,2, L. Chen1,3, T. Chen1

and M. M. Moore1,2. 1DGRT, NCTR, Jefferson, AR,2Department of Pharmacology and Toxicology,University of Arkansas for Medical Sciences, LittleRock, AR and 3College of Life Science and Technology,Shanghai Jiao Tong University, Shanghai, China.

#2217 GENOTOXIC EFFECTS OF 4-HYDROXYNONENAL TRIACETATE, ACHEMICALLY PROTECTED FORM OF THELIPID PEROXIDATION PRODUCT 4-HYDROXYNONENAL, AS ASSAYED IN L5178YMOUSE LYMPHOMA CELLS. S. P. Singh1, L.Chen3, N. Mei2, T. Chen2, E. McLain1, V. Samokyszyn1,M. Moore2 and P. Zimniak1. 1Toxicology, UAMS, LittleRock, AR, 2Genetic and Reproductive Toxicology,NCTR, Jefferson, AR and 3College of Life Sciences,Shanghai Jiao Tong University, Shanghai, China.

#2218 PHOTOMUTAGENICITY OF RETINYLPALMITATE AND ANHYDRORETINOL INMOUSE LYMPHOMA CELLS. N. Mei1, Q. Xia2, L.Chen1, P. P. Fu2, M. M. Moore1 and T. Chen1. 1Divisionof Genetic and Reproductive Toxicology, NCTR/FDA,Jefferson, AR and 2Division of Biochemical Toxicology,NCTR/FDA, Jefferson, AR.

#2219 GENETIC TOXICOLOGICAL STUDIES FORLUPINUS TERMIS ALCOHOLIC EXTRACT. M.R. Santiago1, Z. Ramos2, I. Oquendo2, M. Antoun2 andD. Herreno-Saenz1. 1Pharmacology and Toxicology,School of Medicine, University of Puerto Rico, SanJuan, Puerto Rico and 2School of Pharmacy, Universityof Puerto Rico, San Juan, Puerto Rico.

Program Description



THU

RSD

AY

#2220 TAXOL INDUCES MUTATIONS IN THE TKGENE OF L5178Y/TK+/- MOUSE LYMPHOMACELLS THROUGH A MITOTIC NON-DISJUNCTION MECHANISM. M. M. Moore, N.Mei, L. Chen and T. Chen. Division of Genetic andReproductive Toxicology, NCTR/FDA, Jefferson, AR.

#2221 INCREASED GERMLINE MUTATIONFREQUENCIES INDUCED BY ETHYLENEDICHLORIDE IN MALE MICE. H. J. Daigle and V.L. Wilson. Biological Science, Louisiana StateUniversity, Baton Rouge, LA.

#2222 MICROARRAY GENE EXPRESSION ANALYSISREVEALS DIFFERENCES BETWEEN LARGEAND SMALL COLONY THYMIDINE KINASEMUTANTS OF L5178Y MOUSE LYMPHOMACELLS. T. Han1,2, J. Wang3, T. Chen3, J. C. Fuscoe1,2

and M. M. Martha3. 1Center for Functional Genomics,NCTR/U.S. FDA, Jefferson, AR, 2Division of SystemsToxicology, NCTR/U.S. FDA, Jefferson, AR and3Division of Genetic and Reproductive Toxicology,NCTR/U.S. FDA, Jefferson, AR.

#2223 MICRONUCLEUS INDUCTION AND DNADAMAGE IN V 79 CELLS IN VITRO BY DUSTSFROM HARD METAL SINTERING ANDDETONATION COATING PROCESSES. M. J.Keane and W. E. Wallace. Health Eff. Lab. Division,NIOSH, Morgantown, WV.

#2224 TRICHLROETHYLENE (TCE) INHALATIONDID NOT INDUCE CYTOGENETIC DAMAGE INTHE RAT BONE MARROW MICRONUCLEUSTEST (MNT). J. W. Wilmer, P. J. Spencer, J. G.Grundy, V. A. Linscombe, S. M. Krieger and B.Gollapudi. Toxicology & Environmental Research andConsulting, The Dow Chemical Company, Midland, MI.

#2225 ABILITY OF ALKYLTIN COMPOUNDS TOPENETRATE CELL MEMBRANES AND ITSRELATION TO INDUCTION OF GENOTOXICEFFECTS IN CHINESE HAMSTER OVARY(CHO) CELLS. E. Dopp1, A. M. Florea1, L. M.Hartmann2, B. Shokouhi1, U. von Recklinghausen1, A.V. Hirner2 and A. W. Rettenmeier1. 1Institute ofHygiene and Occupational Medicine, University ofDuisburg-Essen, Essen, NRW, Germany and 2Instituteof Environmental Chemistry, University of Duisburg-Essen, Essen, Germany. Sponsor: E. Nelson.

#2226 RAT ERYTHROCYTE MICRONUCLEUS TEST:ROLE OF ERYTHROPOIESIS AND EFFECT OFCIGARETTE MAINSTREAM SMOKE. E. VanMiert and P. Vanscheeuwijck. PHILIP MORRISResearch Laboratories bvba, Leuven, Belgium. Sponsor:H. Haussmann.

#2227 THE EFFECT OF BREVENAL ON DNA DAMAGEIN HUMAN LYMPHOCYTES INDUCED BYBREVETOXINS 2 AND 3 (PBTX-2 OR 3). J. E.Gibson1,4, A. N. Sayer4,1, A. J. Bourdelais2 and D. G.Baden2,3. 1Pharmacology and Toxicology, The BrodySchool of Medicine at East Carolina University,Greenville, NC, 2Center for Marine Science, Universityof North Carolina at Wilmington, Wilmington, NC,3Chemistry, University of North Carolina atWilmington, Wilmington, NC and 4Biology, EastCarolina University, Greenville, OR.

#2228 BISPHENOL A-INDUCED DNA DAMAGE INC57BL/6N MICE: PRACTICAL IN VIVOAPPLICATIONS OF THE COMET ASSAY. Y. Xu, J.W. Parton and J. K. Kerzee. MicaGenix, Inc.,Greenfield, IN.

#2229 THE EFFECT OF PUFF VOLUME ON THESPECIFIC ACTIVITY OF CIGARETTE SMOKECONDENSATE AS MEASURED IN THE AMESASSAY. R. Leverette, M. B. Bennett, J. T. Hamm, M.Misra, S. V. Vulimiri and S. F. Yee. Lorillard,Greensboro, NC.

#2230 GENOTOXICITY PROFILES OF COMMONALKYL HALIDES AND ALKYL ESTERS. J. J.Osowski1, M. E. Masucci1, Z. Kirpnick2, E. E.Rubitski1, J. K. Cheung1, J. I. Ackerman1, W. W. Ku1, R.H. Schiestl2 and J. Aubrecht1. 1Safety Sciences, Pfizer,Inc., Groton, CT and 2Departments of Pathology,Environmental Health and Radiation Oncology, GeffenSchool of Medicine and School of Public Health,UCLA, Los Angeles, CA.

#2231 DETECTING ANTHRACYCLINE-INDUCEDINTRACHROMOSOMAL RECOMINBINATIONIN SACCHAROMYCES CEREVISIAE USING ADEL ASSAY. J. Armagost and W. J. Mackay. Biology,Edinboro University, Edinboro, PA.

#2232 CARCINOGENIC CR(VI) AND THENUTRITIONAL SUPPLEMENT CR(III) INDUCEDNA DELETIONS IN YEAST AND MICE. Z.Kirpnick, R. Reliene, N. Carls and R. H. Schiestl.Pathology, David Geffen School of Medicine at UCLA,Los Angeles, CA.

#2233 YEAST DEL ASSAY DETECTS CLASTOGENS. E.E. Rubitski1, Z. Kirpnick2, M. Homiski1, M.Repnevskaya2, N. Howlett3, R. H. Schiestl2 and J.Aubrecht1. 1Safety Sciences, Pfizer, Inc., Groton, CT,2Departments of Pathology, Environmental Health andRadiation Oncology, Geffen School of Medicine andSchool of Public Health, UCLA, Los Angeles, CA and3Department of Pediatric Oncology, Dana-FarberCancer Institute, Boston, MA.

#2234 NUCLEAR LOCALISATION AND DNA REPAIRCAPACITY OF HOGG1 VARIANTSPOLYMORPHIC AT RESIDUE 326 FOLLOWINGTRANSFECTION OF OGG1-/- NULL MOUSEFIBROBLASTS. D. Smart, N. Hodges and K.Chipman. School of Biosciences, The University ofBirmingham, Birmingham, United Kingdom. Sponsor:T. Hammond.

#2235 A COMPARATIVE STUDY OF UVB AND UVCMUTAGENESIS IN DNA REPAIR PROFICIENTAND MISMATCH REPAIR DEFICIENT (PMS2)MOUSE CELLS. A. Skinner2,1, C. Shin-Darlak1,2 andM. Turker1,2. 1Center for Research on Occupational andEnvironmental Toxicology, Oregon Health and SciencesUniversity, Portland, OR and 2Environmental andMolecular Toxicology, Oregon State University,Corvallis, OR.

Program Description


THU

RSDAY


#2236 MODULATION OF NNK-INDUCED GENETICDAMAGE BY POLYMORPHISM IN THE BASEEXCISION REPAIR GENE APE1 IN SMOKERS. K.Wolfe, A. A. Affatato, C. E. Hill, J. K. Wickliffe and S.Z. Abdel-Rahman. University of Texas Medical Branch,Galveston, TX.


POSTER SESSION: DEVELOPMENTAL TOXICOLOGYMECHANISMS

Chairperson(s): Asok Dasmahapatra, University of Mississippi, University,MS and Mary Haasch, University of Mississippi, University, MS.


Attended: 8:30 AM-10:00 AM

#2237 THE MECHANISMS OF DITHIOCARBAMATEDEVELOPMENTAL TOXICITY. F. Tilton1,2,3 and R.L. Tanguay1,2,3. 1Environmental and MolecularToxicology, Oregon State University, Corvallis, OR,2Marine & Freshwater Biomedical Sciences Center,Oregon State University, Corvallis, OR and3Environmental Health Sciences Center, Oregon StateUniversity, Corvallis, OR.

#2238 TCDD ALTERS GENE EXPRESSION INZEBRAFISH OVARY: INSIGHT INTO THEMECHANISMS BY WHICH TCDD IMPACTSREPRODUCTION IN FISH. T. King Heiden1,2, M.Rise1, M. Hessner3, R. Hutz1,2 and M. J. Carvan1. 1UW-Milwaukee Great Lakes WATER Inst, Milwaukee, WI,2Biological Sciences, UW-Milwaukee, Milwaukee, WIand 3Pediatrics, Medical College of Wisconsin,Milwaukee, WI.

#2239 MATRIX METALLOPROTEINASE INHIBITIONDURING ZEBRAFISH EMBRYOGENESISFOLLOWING EXPOSURE TOHYDROCORTISONE AND DEXAMETHASONE. J.M. Hillegass, C. M. Villano, L. A. White and K. R.Cooper. Biochemistry & Microbiology, Rutgers, TheState University of New Jersey, New Brunswick, NJ.

#2240 EARLY EMBRYONIC RESPONSES OFZEBRAFISH TO DIESEL PARTICULATEMATTER. M. D. Smith, S. J. D’Surney, V. Tillis, E.Johnson and E. Eiland. Biology, University ofMississippi, University, MS.

#2241 ARYL HYDROCARBON RECEPTOR (AHR)ACTIVATION INHIBITS ZEBRAFISH EARLYLIFE STAGE CAUDAL FIN REGENERATION. L.K. Mathew, E. A. Andreasen and R. L. Tanguay.Environmental and Molecular Toxicology, TheEnvironmental Health Sciences Center, and The Marineand Freshwater Biomedical Sciences Center, OregonState University, Corvallis, OR.

#2242 TCDD IMPAIRS EXTRACELLULAR MATRIXREMODELING IN THE REGENERATINGZEBRAFISH CAUDAL FIN. E. A. Andreasen, J. M.Zodrow, L. K. Mathew, R. Hasson and R. L. Tanguay.Environmental and Molecular Toxicology TheEnvironmental Health Sciences Center, and The MarineFreshwater Biomedical Sciences Center, Oregon StateUniversity, Corvallis, OR.

#2243 ETHANOL- AND ACETALDEHYDE-MEDIATEDDEVELOPMENTAL TOXICITY IN ZEBRAFISH.M. Reimers, J. La Du, A. Flockton and R. Tanguay.Department of Environmental and MolecularToxicology, The Environmental Health Sciences Center,and The Marine/Freshwater Biomedical Sciences Center,Oregon State University, Corvallis, OR.

#2244 EFFECTS OF ETOPOSIDE ON HUMAN FETALHEMATOPOIETIC STEM CELLS. C. G.Moneypenny, P. L. Stapleton and E. P. Gallagher.Environmental and Occupational Health Sciences,University of Washington, Seattle, WA.

#2245 DOSE-DEPENDENT SURVIVAL DIFFERENCESIN CHICKENS DEVELOPMENTALLY CO-EXPOSED TO NEAR-INFRARED LIGHTTHERAPY AND DIOXIN. R. L. Yeager1, J. A.Franzosa1, D. S. Millsap1, J. T. Eells2, H. T. Whelan3

and D. S. Henshel1. 1School of Public andEnvironmental Affairs, Indiana University,Bloomington, IN, 2Department of Health Science,University of Wisconsin-Milwaukee, Milwaukee, WIand 3Department of Neurology, Medical College ofWisconsin, Milwaukee, WI.

#2246 ALTERATION OF NORMAL CARDIACDEVELOPMENT BY TRICHLOROETHYLENEAND ITS METABOLITE TRICHLOROACETICACID. V. J. Drake1, S. L. Koprowski2, J. W. Lough2 andS. M. Smith1. 1Nutritional Sciences, University ofWisconsin-Madison, Madison, WI and 2Cell Biology,Anatomy and Neurobiology, Medical College ofWisconsin, Milwaukee, WI. Sponsor: R. Hines.

#2247 TOXICOGENOMICS IN MALFORMATIONSINDUCED BY FUNGICIDE FLUCONAZOLE. C. L.Galli1, E. Menegola2, E. Giavini2, E. Corsini1 and M.Marinovich1. 1Department.Pharmacological Sciences,University of Milan, Milan, Italy and 2Department ofBiology, University of Milan, Milan, Italy.

#2248 RELATIVE POTENCIES OF SELECTEDDIHALOACETIC ACIDS AND THEIR MAJORMETABOLITES IN MOUSE WHOLE EMBRYOCULTURE. S. Hunter, M. Blanton and E. Rogers. RTD,NHEERL, ORD, U.S. EPA, Research Triangle Park,NC. Sponsor: J. Rogers.

#2249 EVALUATION OF GLYCOLIC ACID IN RABBITWHOLE EMBRYO CULTURE. E. W. Carney, B.Tornesi and N. Moore. Toxicology & EnvironmentalResearch and Consulting, The Dow Chemical Company,Midland, MI.

Program Description



THU

RSD

AY

#2250 ENDOGENOUS EMBRYONIC CATALASEACTIVITY DURING ORGANOGENESIS INEMBRYO CULTURE, IN VIVO AND AFTEREXPOSURE TO PHENYTOIN-ENHANCEDOXIDATIVE STRESS. J. Perstin1 and P. G. Wells1,2.1Faculty of Pharmacy, University of Toronto, Toronto,ON, Canada and 2Department of Pharmacology,University of Toronto, Toronto, ON, Canada.

#2251 IN VITRO STUDY ON THE EMBRYOTOXICPOTENTIAL OF N-METHYL-PYRROLIDONE(NMP) AND ITS METABOLITES. B. Flick1, R.Jaeckh2 and S. Klug1. 1Institute of ClinicalPharmacology and Toxicology, Berlin, Germany and2BASF AG, Ludwigshafen, Germany. Sponsor: J.Sherman.

#2252 IN VITRO STUDY ON THE EMBRYOTOXICPOTENTIAL OF BRANCHED-CHAINCARBOXYLIC ACIDS. B. Flick1, R. Jaeckh2 and S.Klug1. 1Institute of Clinical Pharmacolgoy andToxicology, Berlin, Germany and 2BASF AG,Ludwigshafen, Germany. Sponsor: J. Sherman.

#2253 CHARACTERIZATION OF ALCOHOLMETABOLIZING ENZYMES IN JAPANESEMEDAKA. X. Wang2,1, E. S. Williams2,1, M. L.Haasch1,2 and A. K. Dasmahapatra1,2. 1EnvironmentalToxicology Research Program, NCNPR, RIPS,University of Mississippi, University, MS and2Department of Pharmacology, University ofMississippi, University, MS.

#2254 VISUALIZATION OF TISSUE DISTRIBUTIONAND METABOLISM OF BENZO(A)PYRENE INEMBRYONIC MEDAKA (ORYZIAS LATIPES). M.W. Hornung, R. D. Johnson, P. M. Cook and J. W.Nichols. NHEERL, MED, U.S. EPA, Duluth, MN.

#2255 PFOA INDUCES DYSMORPHOGENESIS INMOUSE WHOLE EMBRYO CULTURE. M. R.Blanton1, J. M. Padowski2, S. S. Hunter1, J. M. Rogers1

and C. Lau1. 1RTD, NHEERL, ORD, U.S. EPA,Research Triangle Park, NC and 2Curriculum inToxicology, UNC, Chapel Hill, NC.

#2256 THALIDOMIDE DEPLETES GLUTATHIONEAND INITIATES OXIDATIVE STRESS IN RATNEURAL CREST CELLS. C. Harris and P. A.Paximadis. Environmental Health Sciences, Universityof Michigan, Ann Arbor, MI.

#2257 EXAMINATION OF METAL-INDUCED CELLCYCLE ALTERATIONS AND APOPTOSIS INC57BL/6 AND SWV MOUSE EMBRYONICFIBROBLASTS. J. F. Robinson, X. Yu, J. S. Sidhu, S.Hong, E. Kim and E. M. Faustman. Environmental andOccupational Health Sciences, University ofWashington, Seattle, WA.

#2258 IDENTIFICATION OF GENE CLUSTERS ANDSIGNALLING PATHWAYS AFFECTED BYDIBUTYL PHTHALATE–NUCLEAR RECEPTORINTERACTIONS IN FOETAL RAT TESTES. S.Plummer1, N. Hallmark2, R. Sharpe2 and C. Elcombe1.1CXR Biosciences Ltd., Dundee, United Kingdom and2MRC Human Reproductive Sciences Unit, Edinburgh,United Kingdom.

#2259 VALPROIC ACID INCREASES CONSERVATIVEHOMOLOGOUS RECOMBINATIONFREQUENCY: IMPLICATIONS FOR AMECHANISM OF VALPROIC ACID-INDUCEDNEURAL TUBE DEFECTS. E. Defoort1, P. M. Kim1

and L. M. Winn1,2. 1Pharmacology and Toxicology,Queen’s University, Kingston, ON, Canada and 2Schoolof Environmental Studies, Queen’s University, Kingston,ON, Canada.

#2260 TERATOGENIC EFFECTS OF FORSKOLIN,CYCLOPAMINE AND ETHANOL ON EARLYBRAIN AND EYE DEVELOPMENT. E. Loucks andS. Ahlgren. Childrens Memorial Research Center,Chicago, IL.

#2261 PROTECTION AGAINST MNU-INDUCED FETALMALFORMATIONS AND PLACENTALMALDEVELOPMENT WITH DIETARYBUTYLATED HYDROXYTOLUENESUPPLEMENTATION. M. R. Prater1,2, L. Pinn2, J.Keay2 and S. D. Holladay2. 1Biomedical Sciences,Edward Via Virginia College of Osteopathic Medicine,Blacksburg, VA and 2Biomedical Sciences andPathobiology, Virginia-Maryland Regional College ofVeterinary Medicine, Virginia Tech, Blacksburg, VA.


POSTER SESSION: DNA AND PROTEIN ADDUCTS

Chairperson(s): Scott W. Burchiel, University of New Mexico, Albuquerque,NM and Judy L. Bolton, University of Illinois, Chicago, IL.



#2262 N1- AND N7-DEOXYGUANOSINE ADDUCTS OFDIEPOXYBUTANE EXHIBIT DIFFERENTSTABILITIES AND DECOMPOSITIONPATTERNS UNDER PHYSIOLOGICALCONDITIONS. X. Zhang and A. A. Elfarra.Department of Comparative Biosciences, University ofWisconsin-Madison, Madison, WI.

#2263 DEPURINATION OF NUCLEOSIDES INDUCEDBY HALOGENATED ALKANES IN THEPHYSIOLOGICAL CONDITION. J. Kim, J.Sherchan, B. Arjun, B. Choi, E. Kim, Y. Jahng, T. Jeongand E. Lee. College of Pharmacy, Yeungnam University,Kyongsan, Kyongbuk, South Korea.

#2264 EXPOSURE-BASED SAFETY ASSESSMENT OFTHE NATURALLY OCCURRING FLAVOURINGMETHYL EUGENOL. J. Ellis1, P. L. Carmichael2,1

and N. J. Gooderham1. 1Biological Chemistry, ImperialCollege London, London, United Kingdom and2SEAC–Safety and Environmental Assurance, Unilever,Sharnbrook, United Kingdom.

Program Description


THU

RSDAY


#2265 DETECTION OF ELEVATED 8-HYDROXYDEOXYGUANOSINE IN FRESHLYISOLATED MOUSE LUNG CELLS FOLLOWINGIN VIVO TREATMENT WITH AFLATOXIN B1 K.A. Guindon, S. L. Graham, L. L. Bedard and T. E.Massey. Pharmacology and Toxicology, Queen,Kingston, ON, Canada.

#2266 LIPID HYDROPEROXIDE-DERIVED DNAADDUCTS GENERATED THROUGH REDOXCYCLING OF BENZO(A)PYRENE QUINONE. J.Xu, S. Lee and I. A. Blair. Department of Pharmacology,University of Pennsylvania, Philadelphia, PA. Sponsor:S. Burchiel.

#2267 METABOLISM OF 7H-DIBENZO[C,G]CARBAZOLE (DBC) OR BENZO[A]PYRENE(BAP) IN CYP1A2 OR AHR GENE KNOCKOUTS:IMPLICATIONS FOR CARCINOGENICITY. D.Ginsburg, G. Talaska, K. LaDow, B. Schumann, A. Pugaand D. Warshawsky. Environmental Health, Universityof Cincinnati College of Medicine, Cincinnati, OH.

#2268 CHARACTERIZATION OF STABLEBENZO[A]PYRENE-7, 8-QUINONE-DNAADDUCTS IN CALF THYMUS DNA. J. A. Ross, G.Nelson, W. T. Padgett, N. Balu, G. R. Lambert and S.Nesnow. Environmental Carcinogenesis Division, U.S.EPA, Research Triangle Park, NC. Sponsor: D. Wolf.

#2269 INDUCTION AND PERSISTENCE OFBENZO(A)PYRENE- AND DIBENZO[A,L]PYRENE-DNA ADDUCTS IN DNA REPAIR-PROFICIENT AND DEFICENT CELLS. W. A.Spencer and D. K. Orren. Toxicology, University ofKentucky, Lexington, KY. Sponsor: M. Vore.

#2270 COMPARISON OF DNA ADDUCT FORMATIONBETWEEN TISSUES FROM MICE TREATEDWITH COMPLEX PAH MIXTURES. T. D. Phillips,A. M. Gillespie, L. Cizmas, G. Zhou, T. J. McDonald, Y.Qian and K. C. Donnelly. Texas A&M University,College Station, TX.

#2271 METABOLIC ACTIVATION AND PAH-DNAADDUCT FORMATION FROM URBAN DUSTPARTICULATE MATTER (SRM 1649A) INHUMAN MAMMARY EPITHELIAL CELLS INCULTURE. L. A. Courter and W. M. Baird.Environmental and Molecular Toxicology, Oregon StateUniversity, Corvallis, OR.

#2272 DIESEL EXHAUST PARTICLES CAUSEINCREASED LEVELS OF DNA DELETIONS ANDDNA ADDUCT FORMATION AFTERTRANSPLACENTAL EXPOSURE IN MICE. R.Reliene1, A. Hlavacova1, B. Mahadevan2, W. M. Baird2

and R. H. Schiestl1. 1Pathology, Environmental Healthand Radiation Oncology, UCLA, Los Angeles, CA and2Environmental Molecular Toxicology, Oregon StateUniversity, Corvallis, OR.

#2273 MLH1-DEFICIENT MICE AREHYPERSENSITIVE TO PHIP-INDUCEDMUTATION AND ABERRANT CRYPT FOCI:EVIDENCE FOR DIFFERENTIAL PROCESSINGOF PHIP ADDUCT MISPAIRS BY THEMISMATCH REPAIR PATHWAY. S. Smith-Roe, S.S. Crain and A. B. Buermeyer. Environmental andMolecular Toxicology, Oregon State University,Corvallis, OR. Sponsor: L. Curtis.

#2274 OXIDATIVE METABOLISM OF THE SERM,RALOXIFENE LEADS TO PROTEIN COVALENTMODIFICATION. J. Liu, Q. Li, C. Luckie, X. Yang,M. Chang, R. B. van Breemen, G. R. Thatcher and J. L.Bolton. Medicinal Chemistry and Pharmacognosy,College of Pharmacy, University of Illinois at Chicago,Chicago, IL.

#2275 IDENTIFICATION OF ELECTROPHILEBINDING MOTIFS ON QUINONE-THIOETHERADDUCTED RENAL PROTEINS. M. E. Bowen1, M.T. Labenski1, C. Kernag1, G. Tsaprailis1, M. A. Ali2, E.A. Mash2, T. J. Monks1 and S. S. Lau1. 1Pharmacologyand Toxicology, University of Arizona, Tucson, AZ and2Chemistry, University of Arizona, Tucson, AZ.


POSTER SESSION: APOPTOSIS

Chairperson(s): Jessica Berthiaume, University of Minnesota, Duluth, MN.



#2276 MOLECULAR MECHANISMS OFHYDROQUINONE INDUCED APOPTOSIS. S. H.inayat-hussain1,2, V. Gogvadze3, S. Orrenius3 and D.Ross1. 1Pharmacology Sciences, University of Colorado,denver, CO, 2Biomedical Sciences, Faculty of AlliedHealth Sciences, Universiti Kebangsaan Malaysia,Kuala Lumpur, wp, Malaysia and 3Toxicology Division,Karolinska Institutet, Stockholm, Sweden.

#2277 BIOCHEMICAL AND MICROARRAY ANALYSESOF BUPIVACAINE-INDUCED APOPTOSIS. A.Unami1,3, Y. Shinohara2, K. Omura1, M. Matsumoto1, Y.Oishi1 and Y. Baba3. 1Toxicology ResearchLaboratories, Fujisawa Pharmaceutical Co., Ltd.,,Osaka, Japan, 2Institute for Genome Research, TheUniversity of Tokushima, Tokushima, Japan and3Faculty of Pharmaceutical Sciences, The University ofTokushima, Tokushima, Japan. Sponsor: M. Takahashi.

#2278 1, 1-DICHLOROETHYLENE-INDUCEDMITOCHONDRIAL DAMAGE PRECEDESAPOPTOTIC CELL DEATH OF BRONCHIOLAREPITHELIAL CELLS IN MURINE LUNG. E. J.Martin and P. Forkert. Department of Anatomy and CellBiology, Queen’s University, Kingston, ON, Canada.

Program Description



THU

RSD

AY

#2279 TMT TOXICITY IN HIPPOCAMPAL CELLS ISASSOCIATED WITH INDUCTION OF BAX ANDINOS EXPRESSION. L. zhang, L. li, K. Prabhakaran,J. L. Borowitz and G. E. Isom. Medicinal Chemistry andMolecular Pharmacology, Purdue University, WestLafayette, IN.

#2280 GENDER -SPECIFIC DIFFERENCES INAPOPTOTIC INDICES IN RAT LIVER AFTERCHRONIC ETHANOL CONSUMPTION. T. V.Curry-McCoy2, R. L. White1, S. L. Todero1 and T. M.Donohue1. 1Research, VA Medical Center, Omaha, NEand 2Pathology/Microbiology, University of NebraskaMedical Center, Omaha, NE. Sponsor: R. Pollenz.

#2281 CALYCULIN A, A PP1/PP2A INHIBITOR, DELAYSAPOPTOTIC SIGNALING IN TGHQ-TREATEDHL-60 CELLS. M. Yang, S. S. Lau and T. J. Monks.Pharmacology and Toxicology, University of Arizona,Tucson, AZ.

#2282 SINGLE-WALLED CARBON NANOTUBESACTIVATE RAW 264.7 MACROPHAGES: ROLEIN OXIDATIVE STRESS AND INFLAMMATORYRESPONSE. A. I. Potapovich1, A. N. Osipov1, E. R.Kisin2, D. Schwegler-Berry2, A. A. Shvedova2 and V. E.Kagan1. 1Department of EOH, Center for Free Radical& Antioxidant Health, University of Pittsburgh,Pittsburgh, PA and 2Pathology & Physiology ResearchBranch, NIOSH, Morgantown, WV.

#2283 PHYSICAL AND CHEMICAL INTERACTIONBETWEEN CARDIOLIPIN AND CYTOCHROMEC. N. A. Belikova1,2, A. N. Osipov1,2, A. A. Kapralov1,2,M. V. Potapovich1,2 and V. E. Kagan1,2. 1Center for FreeRadical and Antioxidant Health, University ofPittsburgh, Pittsburgh, PA and 2Department ofEnvironmental and Occupational Health, University ofPittsburgh, Pittsburgh, PA.

#2284 CARDIOLIPIN DESTABILIZES CYTOCHROMEC IN MITOCHONDRIA AND MAKES ITSCATALYTIC SITE ACCESSIBLE TO SMALLLIGANDS: ROLE IN APOPTOSIS. A. N. Osipov1,2,I. V. Kurnikov2, Y. A. Vladimirov2, N. A. Belikova1,2, D.A. Stoyanovsky3, M. V. Potapovich1,2, G. G.Borisenko2, A. A. Kapralov1,2, Y. Y. Tyurina1,2, V. A.Tyurin1,2, J. Jiang1,2, V. Kini1,2, A. Lysytsya2, V. B.Ritov1, A. M. Choi3, S. W. Ryter3 and V. E. Kagan1,2.1Center for Free Radical & Antioxidant Health,University of Pittsburgh, Pittsburgh, PA, 2Department ofEnvironmental and Occupational Health, University ofPittsburgh, Pittsburgh, PA and 3Department ofPulmonary Medicine and Surgery, University ofPittsburgh, Pittsburgh, PA.

#2285 BLOCKADE OF N-METHYL-D-ASPARTATERECEPTORS BY KETAMINE PRODUCES LOSSOF MONKEY FRONTAL CORTICAL NEURONSIN CULTURE. C. Wang1, N. Sadovova3, X. Fu2, A.Scallet1, L. Schmued1, J. Hanig4 and W. Slikker1.1Division of Neurotoxicology, NCTR/FDA, Jefferson,AR, 2Charles River Laboratories, Jefferson, AR,3Division of Biochemical Toxicology, NCTR/FDA,Jefferson, AR and 4CDER/FDA, Rockville, MD.

#2286 ACTIVATION OF PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTORALPHA ENHANCES HEPATOCYTE APOPTOSIS.S. Xiao1, S. P. Anderson2, C. Swanson1, R. Bahnemann3,K. A. Voss4, A. J. Stauber1 and J. C. Corton5,1. 1CIIT,Research Triangle Park, NC, 2GSK, Research TrianglePark, NC, 3BASF, Ludwigshafen, Germany, 4USDA,Athens, GA and 5ToxicoGenomics, Chapel Hill, NC.

#2287 METABOLISM OF NITRO-PAHS ELICITSAPOPTOTIC AND NECROTIC RESPONSES INHEPA 1C1C7 CELLS. N. Asare1, K. Ask2, N.Landvik1 and J. A. Holme1. 1National Public HealthInstitute, Oslo, Norway and 2Macmaster University,Hamilton, ON, Canada. Sponsor: E. Dybing.

#2288 THE ROLES OF MITOCHONDRIA ANDCASPASE-6 IN 7-12-DIMETHYL-BENZ[αα]ANTHRACENCE-INDUCED BONEMARROW B CELL APOPTOSIS. J. K. Emberley1, J.J. Schlezinger2, H. Ryu2 and D. H. Sherr2.1Microbiology, Boston University School of Medicine,Boston, MA and 2Environmental Health, BostonUniversity School of Public Health, Boston, MA.

#2289 AMELIORATION OF PARAQUAT ANDCADMIUM CHLORIDE INDUCED APOPTOSISBY κκ-CARRAGEENAN IN RAT PLEURALMESOTHELIAL CELL CULTURES. P. Kanade andJ. M. Cerreta. Department of Pharmaceutical Sciences,Saint John’s University, Jamaica, NY. Sponsor: L.Trombetta.

#2290 STUDY ON THE TOXICITY OF CADMIUM ANDTHE PROTECTIVE EFFECT OF FOODCOMPONENTS IN CELLS WITH HORMONERECEPTORS. T. Kim, T. Kang, H. Moon, I. Kang, Y.Lee and S. Han. Endocrine Toxicology Division,National Institute of Toxicological Research, Seoul,South Korea.

#2291 DIFFERENTIATION OF CISPLATIN-INDUCEDDNA DAMAGE AND APOPTOSIS BYPHOSPHORYLATION OF HISTONE H2A.X. X.Feng1, A. Modi2, K. Stams3 and P. Lord1. 1Johnson &Johnson PRD, Raritan, NJ, 2Columbia University, NewYork City, NY and 3AstraZeneca Pharmaceuticals LP,Waltham, MA. Sponsor: C. Wang.

#2292 CISPLATIN-INDUCED APOPTOSIS OF GC1TESTICULAR GERM CELLS MAY OCCUR BYAN AUTOCRINE MECHANISM INVOLVINGFASL/FAS- OR TRAIL/DR5-MEIDATEDSIGNALING. Y. Ye and J. H. Richburg. College ofPharmacy, The University of Texas at Austin, Austin,TX.

#2293 A DECREASE IN AKT LEVELS CORRELATESWITH SENSITIVITY TO ARSENIC-INDUCEDGROWTH INHIBITION. M. Colombo, W. H. Millerand K. K. Mann. Lady Davis Institute for MedicalResearch, McGill University, Montreal, QC, Canada.

#2294 CARDIOLIPIN IS A PREFERRED SUBSTRATEFOR CYTOCHROME C INDUCED OXIDATIONDURING INTRINSIC APOTOSIS. V. A. Tyurin1, Y.Y. Tyurina1, A. Lysytsya1, A. A. Amoscato2, J. Jiang1,Q. Zhao1, M. Zou1, V. B. Ritov3 and V. E. Kagan1.1Department of Environmental and OccupationalHealth, Center for Free Radical and Antioxidant HealthUniversity of Pittsburgh, Pittsburgh, PA, 2MassSpectrometry Facility, University of Pittsburgh,Pittsburgh, PA and 3Department of Medicine, Universityof Pittsburgh, Pittsburgh, PA.

#2295 CYTOCHROME C CATALYZED CARDIOLIPINOXIDATION IS ESSENTIAL FOR THE RELEASEOF PROAPOPTOTIC FACTORS FROMMITOCHONDRIA. J. Jiang1, V. A. Tyurin1, Y. Y.Tyurina1, V. Kini1, P. Cai1, V. B. Ritov2 and V. E.Kagan1. 1Center for Free Radical and AntioxidantHealth, Department of Environmental and OccupationalHealth, University of Pittsburgh, Pittsburgh, PA and2Department of Medicine, University of Pittsburgh,Pittsburgh, PA.

#2296 TWO FACETS OF ETOPOSIDE:PRO-APOPTOTIC AGENT AND ANTIOXIDANT. V. A.Kini1, Y. Y. Tyurina1, V. A. Tyurin1, A. Lysytsya1, J.Yalowich2,1 and V. E. Kagan1,2. 1Department of EOH,Center for Free Radical and Antioxidant Health,University of Pittsburgh, Pittsburgh, PA and2Department of Pharmacology, University of Pittsburgh,Pittsburgh, PA.

#2297 HL-60 CELLS WITH METABOLICALLYBIOENGINEERED POLYUNSATURATEDCARDIOLIPIN MOLECULAR SPECIES EXERTINCREASED SENSITIVITY TO APOPTOSIS. Y. Y.Tyurina, V. A. Tyurin, Y. Fujii and V. E. Kagan.Department of Environmental and Occupational Health,Center for Free Radical and Antioxidant Health,University of Pittsburgh, Pittsburgh, PA.

#2298 IDENTIFICATION OF NUR77 AGONISTS THATINDUCE APOPTOSIS AND INHIBIT CANCERCELL SURVIVAL THROUGH NUCLEARPATHWAYS. S. Chintharlapalli1, S. Papineni1, R.Burghardt2 and S. Safe1,3,4. 1Biochemistry &Biophysics, Texas A&M University, College Station,TX, 2Veterinary Anatomy & Public Health, Texas A&MUniversity, College Station, TX, 3Veterinary Physiology& Pharmacology, Texas A&M University, CollegeStation, TX and 4Institute of Biosciences & Technology,Texas A&M University Health Science Center, Houston,TX.

#2299 THE IBM OF SMAC IS DISPENSABLE FORAPOPTOTIC FUNCTION. S. P. Burke and J. B.Smith. Pharmacology and Toxicology, University ofAlabama Birmingham, Birmingham, AL. Sponsor: C.Lamartiniere.

#2300 INVOLVEMENT OF THE AP-1 COMPLEX INTHE NEUROPROTECTIVE EFFECT OF PACAPAGAINST CERAMIDE-INDUCED TOXICITY. N.Aubert1,2, A. Falluel-Morel2, C. Fisch1, D. Vaudry2, S.de Jouffrey1, A. Fournier3, R. Forster1, H. Vaudry2 andB. Gonzalez2. 1CIT, Evreux, France, 2INSERM-IFRMP23, Rouen, France and 3INRS-Institut Armand Frappier,Quebec, Canada.

#2301 ACTIVATION OF ENDONUCLEASE, ORCASPASE-ACTIVATED DNASE (CAD), AS AMARKER OF APOPTOSIS RATHER THANNECROSIS IN DRUG- OR CHEMICAL-INDUCEDONCOSIS IN VIVO. S. D. Ray1, S. Stohs2 and G. B.Corcoran3. 1Mol. Toxicology. Prog./Pharmacology Scs.,AMS College of Pharmacology/LIU, Brooklyn, NY,2AdvoCare International, Carrollton, TX and3Pharmaceutical Sciences, Wayne State University,Detroit, MI.

#2302 APOPTOSE TRIGGERED MICRONUCLEI: THEROLE OF APOPTOSIS ON THE OUTCOME OFMICRONUCLEUS ASSAY. M. Kabiri. Sanofi-Aventis, Hattersheim, Germany. Sponsor: M. Bonnefoi.

#2303 ISOLATION OF THE APOPTOSIS INDUCINGCONSTITUENTS OF GUAIACUM SANCTUM L.AND GUAIACUM OFFICINALE L.(ZYGOPHYLLACCEAE) ON HUMAN BREASTCELLS IN VITRO. K. J. Chavez1, S. Schwaiger2, K.Renner3, J. A. Flanders4, H. Stuppner2 and E.Rodriguez5. 1Department of ComparativeEnvironmental Toxicology, Cornell University, Ithaca,NY, 2Institute fur Pharmazie, Abt Pharmakognosie,Universitae Innsbruck, Innsbruck, Austria, 3Biozentrum,Division Molekulare Pathophysiologie, MedizinischeUniversitae Innsbruck, Innsbruck, Austria, 4Departmentof Clinical Sciences and Molecular Medicine, CornellUniversity, Ithaca, NY and 5Department of PlantBiology, Cornell University, Ithaca, NY.

Program Description


THU

RSDAY


AU

TH

OR

IND

EX



Author IndexA

Aalbers, M ............................................... 903Aardema, M J ........................................ 2209Aase, A ..................................................... 450Abadin, H .............................................2086*Abbey, A ................................................. 1951Abbott, B ................................................ 1224Abbott, B D .............................................680*Abbott, L C ...................................... 618, 619Abdalla, E ...............................................1108Abdel-Rahman, A A ..............................962*Abdel-Rahman, M S ............................1923*Abdel-Rahman, S Z .................... 1274, 2236Abdelrahim, M ....................................1807*Abdullah, I ............................................ 1378Abdullah, S ............................................ 1780Abe, J ................................................ 831, 837Abe, K .................................................... 1424Abel, M D .............................................. 1255Abel, S J .................................................... 647Abel, S ..................................................... 113*Abou-Donia, M ..................................... 1952Abou-Donia, M B ................. 961, 962, 1620Abou-Hadeed, A H .................................. 79Abouzakhar, F S ....................................946*Abraham, V ..........................................1851*Abraham, W ............................................ 474Abromovitz, M W .................................. 372Acevedo, S ............................................... 414Acevedo, S P ......................................... 1279Achanzar, W .......................................... 1619Ackerman, J I .............................2205*, 2230Acosta-Saavedra, L C ..........627, 1146, 1875Adair, B .................................................. 1817Adair, B M ....................................692*, 1231Adami, H ................................................. 295Adamo, M ............................. 262, 558, 1462Adams, A ............................................... 1383Adams, D F ............................................536*Adams, J .................................................899*Adams, R J ............................................... 678Addai, A ................................................. 1498Adibzadeh, M ....................................... 1878Adkins, J N .............................................918*Adler, R .................................................. 1916Adlercreutz, H ...................................... 1490Adriaens, E ..................................... 481, 482, .............................................2006, 2009, 2015*Afan, R ..................................................... 473Affatato, A A ................................ 1274, 2236Afriyie-Gyawu, E ...................... 1283, 1309, .......................................................1400, 1402*Afshari, A ............................................... 1468Afshari, C .............................................. 1784Afshari, C A ............................................. 121Agca, Y ..................................................... 546Ahaghatu, E .......................................... 2190Ahlgren, S .............................................. 2260Ahmad, S .................................... 1138*, 1604Ahmed, A E ..................................214*, 1076Ahmed, R ................................................ 154Ahmed, S ................................................. 887Ahn, K .....................................................1148Ahn, M ..................................................... 552Ahr, H .....................................................2114Ahr, H J .................................................1735*Aiyar, R .................................................1383*Aizawa, Y ................................ 459, 607, 944Akahori, F ................................................ 954Aksinenko, A Y ................. 1936, 1937, 1938Akunyili, D N ....................................... 1439Al-Hamdani, S ...................................... 1589Al-Zoughool, M H ..............................1797*Alatorre Rico, J ........................................ 252Alavanja, M R ....................................... 1333Albano, E ................................................. 906Albershardt, D J .................................... 1499Alberston, T E ........................................... 46Albert, R ................................................. 1512Albertini, R J .........................................1030*Albores, A ................................................ 567Alcaraz-Contreras, Y ............................ 1412Alcocer, M .............................................. 1710Alden, C L ............................................. 2027Aldous, C N .......................................... 2152Aldous, K M .......................................... 1288Aldridge, J E ...........................................965*

Aleksunes, L .........................................1921*Aleksunes, L M ................................. 67, 815Aleman, F ................................................ 684Alenius, H ............................................. 1885Aleo, M D ................................................ 520Alepee, N ................................................. 481Alex, L ...................................................... 466Alexander, B .......................................... 1798Alexander, M .......................................... 678Alexeeff, G ............................................. 2105Alexeeff, G V .............................. 1476*, 2111Alexiadis, V ............................................. 109Aley, P ...................................................... 608Algaier, J ................................................ 2069Ali, K .......................................................1139Ali, K A ................................................. 1140*Ali, M A .................................................. 2275Ali, M Y ...................................................516*Ali, S ....................................................... 1098Ali, S F ............................. 1099*, 1702, 1989*Alink, G ................................................1319*Allaben, W T ......................................... 1813Allan, L L ..................992, 1359, 1870, 1871*Allayee, H .............................................. 1373Allen, B ...................................................398*Allen, D ...................1997, 2005, 2007*, 2008Allen, D A ................................................ 663Allen, J ..............................2144, 2146*, 2147Allen, J W ............................................. 1103*Allen, R ...................................................1177Allen-Hoffmann, B ....................... 105, 1364Allgood, J C ............................................. 735Allison, H M ............................................ 159Alnafisi, A ................................................ 503Alnouti, Y .............................................. 1244Alnouti, Y M .........................................2140*Alt, B ...................................................... 1790Alvarez, M M .......................................1609*Alvey, J D ................................................. 180Amacher, D ............................................. 490Amacher, D E ........................ 533, 716, 1915Amantana, A ........................................1246*Amaratunga, D ....................................... 755Amato, C A .............................................. 344Amato, C M ..........................................2179*Amberg, A ............................ 114, 510*, 1038Ambroso, J L ........................................... 905Ambrosone, C ........................................298*Amin, K ...................................... 1170, 1908*Ammenheuser, M ................................. 1042Amoruso, M A .....................................1514*Amoscato, A A ...................................... 2294An, J Y ...................................................... 720Anahara, R .............................................556*Anand, S .................................................. 956Anand, S S ......................................73, 2095*Anantharam, V ............................. 633, 1526And, N ..................................................... 578Anders, F ..............................................1073*Anders, N J .............................................. 985Andersen, M ........................................1982*Andersen, M E ........... 276, 848, 855*, 1676*Anderson, D ............................................ 437Anderson, G R .......................................713*Anderson, K E ......................................... 727Anderson, L M .....................................1013*Anderson, S A ......................................... 465Anderson, S P ....................57, 58*, 59, 2286Andreas, C ............................................1038*Andreasen, E A ..........................2241, 2242*Andrew, A S ............................................ 154Andrew, M M ........................................ 1005Andrews, D L ........................................ 1214Andrews, L .............................................. 805Andrus, A K ............................................ 269Anestis, D K .......................................... 2121Angerer, J ............................................... 1282Ankarberg, E ..........................................974*Ankley, G ............................................... 1583Ankley, G T ........................................... 1746Annaert, P ................................................ 268Annalora, A ............................................. 715Annalora, A J ..........................................724*Annis, M L ............................................. 1289Anraku, R .............................................. 1094Ansari, G ...........................................82, 912*Ansari, G A .................................. 1558, 1629Ansari, G S .............................................. 913

Ansari, R .................................................. 706Anthony, J ........................................ 776, 787Anthony, J S ............................................773*Antkiewicz, D S ...................................1825*Antonini, J M .....................939, 1449, 1468*Antony, V ............................................... 2108Antoun, M ............................................. 2219Antrobus, K ............................................. 124Ao, K ...................................................... 2043Aoki, T ................................................... 1931Aoki, Y ............................................. 393, 816Aouabdi, S ..............................................580*Api, A ........................1182, 1183, 1202, 1578Aposhian, H V .............................153, 1329*Aposhian, M M ..................................... 1329Apte, U ....................................................... 59Apte, U M ...................................1047, 1052*Aquino, E E ........................................... 1539Arakawa, S .............................................. 708Aravantinou, M .....................................609*Arcaro, K F ...........................................1281*Arcelin, G ...............................................1199Archer, D ............................................... 1710Arepalli, S ........................................ 701, 702Arfsten, D P ....................545*, 783, 792, 888Argonza, D .............................................. 473Ariazi, E ................................................. 1807Arimoto, R ............................................... 199Arjah, K .................................................. 1780Arjun, B .................................................. 2263Armagost, J ...........................................2231*Armour, C ................................................ 287Arnold, L L .................................. 1502, 1505Arocena, M ............................................ 2193Aronson, J .............................................. 1036Aronson, J F ..................................... 469, 498Arreola-Mendoza, L ............................ 1132*Arrieta, D E ..........................................1278*Arrington, D .........................................2128*Arthurton, J A ....................................... 1812Arts, J H ......................................1208*, 1518Arunajadai, S ........................................ 2056Arvidson, K ........................................... 2204Arzuaga, X ..............................................957*Asamoto, M ................................... 765, 1424Asare, N ................................................2287*Aschner, J ................................................. 620Aschner, M .....................486, 595, 599, 620*Asgharian, B ................................. 699, 2110*Ashby, J ................................ 124, 1736, 1739Ashikaga, T ................................ 1192*, 1193Ashley, J A ............................................. 1009Ask, K ..................................................... 2287Aspeslet, L J ........................................... 1255Aspinall, L J ........................................... 1293Asuzu, I U ............................................ 1411*Atchison, D K .........................................623*Atchison, W D ............... 623, 624, 625, 1059Atkins, J ................................................... 767Atkinson, A ..................................1139, 1140Atsumi, F ............................................... 1433Attenborough, S ................................... 1206Attia, M .................................................... 470Au, C .......................................................486*Aubert, N ..............................................2300*Aubrecht, J .............................333, 334*, 335, .............................................. 2205, 2230, 2233Auerbach, S ............................................. 290Augustine, M S ..................................... 1726Auletta, C .............................................1641*Auman, J T .............................................757*Ausman, K D ........................................ 1862Aust, A E .................................................638*Autenrieth, R ........................................ 1290Autenrieth, R L ..................................... 1593Authier, S ............................................... 1935Auttachoat, W ....................891, 1212*, 1716Avadhani, N G ........................................ 205Avakian, A P ...........................................1117Avila-Casado, M ....................................1153Avila-Costa, M ............................. 608*, 1153Avlasevich, S ......................................... 2212Avram, M D ................................... 153, 1329Awasthi, Y C ......................................... 1832Awooda, I .............................................. 1368Ayala-Fierro, F ..................................... 1190*Ayres, P H .................1185, 1187, 1515, 1516Azadi, S ...................................................1211

Aziz, R M ..............................................1486*Azua, A .................................................. 1588

BB’Hymer, C .....................................190*, 191Baba, Y ................................................... 2277Babb, A ..................................................1637*Babin, M C ................................... 2201, 2202Babu, R ................................................... 2004Babus, J .................................................... 422Babus, J B ............................................... 1260Babus, J K ............................1109, 1811, 1823Backes, W L ..................................... 725, 740Backlund, M .......................................... 1358Backstrom, M .......................................... 679Backus, G ..............................................1857*Bacon, C W .................................. 1395, 1396Badeaux, J V .............................................. 74Baden, D .................................................474*Baden, D G ...........................527, 1101, 2227Badger, T ................................................ 1036Badger, T M ........74, 274, 1737, 1918, 1919*Badham, H J .........................................1806*Bae, O ......................................................150*Bagchi, D ............................. 809, 1393, 1414Bagchi, M ............................809, 1393*, 1414Bagi, C ...................................................... 540Bagley, D M ........................................... 2001Bahnemann, R ................................. 58, 2286Bai, Y ........................................................ 817Bailey, A ................................................... 715Bailey, G P ................................................ 268Bailey, G S ................................................ 758Bailey, K ................................................1816*Bailey, M M ..........................................1067*Bailey, R E ...............................................1197Bailey, W J .................................................. 56Bain, L ...................................................... 576Baird, W M ................................. 1499, 1814, .............................................. 2019, 2271, 2272Bajt, M ...................................................1053*Baker, D .................................................... 530Baker, G .................................................... 210Baker, G L ...............................................917*Baker, S ............................................362, 625*Baker, V ............................................ 560, 577Bakheet, S A ..........................................1063*Balagopal, G .......................................... 1258Balagopal, g ..........................................1622*Balduchelly, Y ......................................... 219Bale, A S ..........................................49*, 1547Ball, G ........................................... 2098, 2103Ball, J G .................................................. 2122Ball, L M ........................................500, 1847*Balletta, L D ............................................... 60Ballinger, S W .......................................1010*Balu, N ................................................... 2268Bammler, T .............................................. 579Bammler, T K ........................................ 1495Bandiera, S M .............................1491*, 1562Bando, K ................................................ 1730Banerjee, A ............................................1047*Banker, G A ............................................ 1550Banks, C ............................1460*, 1462, 1464Bannon, D ...............................................1151Bannon, G .............................................. 1307Bansal, R .......................................986*, 1086Banyard, A ............................................. 1200Bao, A ......................................................... 47Bao, W ...............................1709*, 2148, 2150Barati, M ................................................ 1226Baravik, J G ........................................... 1299Barbee, G C ...........................................1593*Barbee, R ................................................ 1369Barbee, S J .............................................. 1482Barber, D .................................131, 161, 600*Barber, D S ............................................. 1546Barber, M ............................................... 1924Barber, R S ............................................. 1255Barchowsky, A .............................1133, 1162Barger, M ....................................... 360, 1443Barger, M W ............................................ 212Bargren, G L ................................ 1312, 1313Barhoumi, R .........................................1368*Barich, J .................................................. 1593Baril, M .................................................... 244

The numerals following the author’s names refer to the abstract numbers. The asterisk after the abstract number indicates the author is the first presenter.

226

AU

TH

OR

IND

EX

SOT's 44th Annual Meeting


Author Index (Continued)

Barile, F A .................................... 1621, 1627Barker, A M .............................................. 626Barker, D F ............................................. 1265Barker, S ................................................. 1441Barlow, B M ................................. 2175, 2194Barlow, N ................................................. 915Barnes, S ...............................................1915*Barnett, J B ................................... 1886, 1889Barnett, J F ............................................1075*Barnett, K .....................................1111, 1112*Baron, P .................................................... 701Barone, S .........................................378*, 512Barr, E ....................................................... 444Barr, E B ........................................... 162, 960Barraud, H ............................................. 2032Barrett, J C ............................................. 1044Barrett, S .................................................1511Barrick, D J ...........................................1840*Barrow, C ..............................................1683*Barrow, P C .............................................. 885Barry, R C ................................................. 918Bars, R .......................................... 1731, 1732Bartels, M ....................................1256, 1563*Bartels, M J .................................. 1041, 1242Bartlett, C ..............................................1791*Bartlett, M ...................................... 416, 1244Bartock, J .................................................. 508Barton, H ............................................... 2145Barton, H A ..................... 9, 854, 1232, 1296, ...................................1568, 1684, 1685*, 1917Barton, S ................................................... 277Barve, S S ............................................... 1876Basford, T M .........................................2055*Basha, M .....................................1062*, 1532Basketter, D ............................................1196Basketter, D A .............................1201*, 1293Baskin, S I ........................................ 795, 796Bast, C ...................................................1482*Baston, D ................................................. 353Batki, C ..................................................... 133Batotsyrenov, B V ................................... 468Battelli, L .................................................. 360Batterman, S L ....................................... 1754Baudrimont, I .............................. 1435, 1440Bauer, A K .............................................. 1857Bauer, D ................................................1253*Bauer, L .................................................... 684Baughman, R H .................................... 1594Baumel, I .................................................. 768Baumel, I P .............................................. 328Baumgardner, J N ....................................74*Baumgartner, R ....................................... 240Baverel, G .............................................2135*Bavuso, N .............................................. 1779Baxter, C S ...............................................1165Baye, J ..................................................... 1897Bayless, K .............................................. 2126Baynes, R E .............2175, 2176, 2194*, 2196Bayse, G S .............................................1570*Bazot, D ..................................................1175Beall, H D ............................ 686, 1796, 1841Beamer, C A ............................................908*Beamonte, A ...........................................1175Beaubier, J .................................... 1803, 1804Beauchamp, T L ...................................1679*Becaria, A ............................................... 1448Beck, B .................................................... 2085Beck, B D .................... 384, 1071, 1472, 2083Beck, G R ................................................. 186Beck-Speier, I ........................................... 204Becker, E .................................................. 373Becker, H .................................................. 950Becker, P ................................................. 2092Becker, S ................................................... 457Beckwith, G ..........................................1999*Bedard, L L ............................................ 2265Bedford, M T ........................................1004*Beems, D ................................................ 1490Beger, R D ....................................... 509, 511*Begin, D ................................................... 244Behar, V ................................................. 1107*Behforouz, M ........................................ 1796Behrsing, H P ................... 1170, 1907*, 1908Beighley, C ............................................... 933Beischlag, T ..............................................90*Bejjani, B .................................................. 715Bekris, L M ...........................................1271*Belikova, N A .............................2283*, 2284

Bell, D A ....................................................115Bell, D R ..................................................681*Bell, M ...................................................... 428Bell, R ..................................................... 1916Bellum, S .........................................618, 619*Belski, T ........................................... 776, 787Bemis, J C ................................84, 555, 2046*Ben, N .................................................... 1712Benbrahim-Tallaa, L ..............136, 138, 141*Bench, G ................................................... 162Bencherif, M ............................................ 471Bencic, D ................................................ 1583Bencic, D C ...........................................1582*Benhamed, M ........................................ 1731Benignus, V A ..................2088, 2091*, 2093Benkovic, S A ...........................................48*Bennett, M B .................................1186, 2229Benson, J .................................................. 527Benson, J M ............................................. 960Benson, R ............................................... 1474Bently, M .................................................. 686Benton, B .................................................. 793Benton, B J ............................................... 788Benz, R ................................................... 2204Beresford, L ........................................... 1200Berg van den, P T ................................... 953Berge, M A ............................................. 1238Berger, A .................................................. 537Bergman, A .................................. 1748, 2059Bergmann, M .......................................... 948Berman, F .............................................1023*Berman, K G .................................. 928, 1846Bermudez, E ...........................................517*Bermudez de Leon, M ........................... 567Berryman, L ........................................... 1935Berthiaume, J ......................................... 1849Berthiaume, J M ...........................206*, 1906Bertino, B ..................................... 2006, 2009Bessems, J .............................................2087*Bessems, J G ................................................ 9Best, D S .................. 1118*, 2143, 2148, 2151Besteman, E ............................................884*Betancourt, A M .....................................971*Betat, A ..................................................... 838Bettencourt, B .......................................... 462Betton, G .................................................. 824Betts, C J ....................................... 1207, 1999Betts, c ...................................................1200*Betz, L ......................................................539*Betz, L J .................................................... 518Beushausen, S ..........................................28*Beyer, J C .................................................. 804Beyer, L .................................................1472*Beyer, L A ................................................. 384Beyer, R .................................................. 1584Beyer, R P ................................................. 579Bezdecny, S ...........................................2052*Bhaskaran, V ............................... 1768, 1930Bhat, V .........................................2098*, 2103Bhat, V B ................................................ 1007Bhatnagar, A .......................................... 1844Bhatt, P ..................................................... 780Bhattacharyya, M H ................ 1031*, 1035*Bhave, V S .......................................... 77, 842Bhopale, K ..................................1558*, 1629Biagini, R E .............................................772*Biales, A D ............................................. 1582Bialkowska, A ....................................... 1013Bichet, N .......................................... 560, 577Bickham, J W ......................................... 1593Biddle, B M .................................. 2201, 2202Bieber, M .................................................. 801Biester, M .............................................. 2115*Bigsby, R M ............................................ 1749Bility, M T ...............................................588*Billam, M ..........................1308, 1309, 1595*Billiard, S ......................................687, 1581*Billin, A N ................ 55, 586, 587, 588, 1820Billings, K E ....................................146*, 147Billinton, N ............................................ 1037Billman, J ................................................1190Bills, P ....................................................... 413Billups, L .................................................2112Binder, E .................................................. 600Binetti, R R ............................................1631*Bion, A ...................................................... 446Birindelli, S ............................................ 1888Birkeland, A .......................................... 2120

Birnbaum, L ......................32, 309*, 310, 858Birnbaum, L S ..............311, 395, 1227, 1253Bisinger, Jr., E C .....................................1137Bisselink, B ............................................ 1056Bisson, J L ............................................... 611*Biswal, S ..................................................1811Bittner, A .......................................... 569, 755Bittner, A C ............................................ 1275Bjork, J .......................................... 1740, 2066Bjork, J A .............................827, 1849, 1906*Black, A T ......................................217, 2171*Black, S ................................................... 1252Blackshear, P ......................................... 1826Blackwell, D ............................................ 540Blair, I ....................................................1323*Blair, I A ..................1006*, 1043, 1815, 2266Blair, L ...................................................... 455Blake, J ................................................... 1252Blakemore, W ........................................ 1397Blancato, J ................................................ 858Blancato, J N .................................. 870, 1298Blann, E .................................................. 1912Blanton, C ................................................ 425Blanton, M ................................... 1369, 2248Blanton, M R ................................683, 2255*Blaugrund, E ..........................................1107Blazka, M E ................................1623, 2001*Bleumink, R ................................... 903, 1892Blodgett, D ............................................ 1943Bloemen, L J ............................................ 866Bloksma, N ............................................ 1208Blomme, E ......................................121, 557*Blomme, E A ............................................ 647Blonder, J M ............................................766*Blount, B C ............................................ 1288Blum, J .................................................... 1773Blystone, C ............................................ 2148Blystone, C R ............................... 2143, 2151Boadas-Vaello, P ................................... 1092Bobb, A J .......................................... 783, 792Bobseine, K ............................................ 1743Bobst, S M ...............................................376*Bode, C ........................................... 485, 2215Bodian, D ................................................... 61Boegehold, M A .................................... 1443Boekelheide, K ............................................ 8Boere, A F ............................................... 1446Boere, J F .................................................. 929Boermans, H ........................................... 883Bogdan, G M ......................................... 1048Bogue, M A ................................................ 60Bohlen, H ............................................... 1996Bohn, A A ................................................. 875Bohonowych, J ........................................ 353Bohonowych, J E .............................95*, 106Boitier, E ..........................................118, 2131Boivin, G P ............................................. 1512Bolanos, B ................................................ 445Boldt, S E ....................................... 716, 1915Bolger, P M .............................................292*Bollen, L S .............................................. 1390Bolte, H F ............................................... 1641Bolton, J L .......................... 1573, 1809, 2274Bombail, V ............................................. 1375Bombick, B R ................................1185, 1187Bondy, G .................................................. 128Bondy, S C ............................................. 1448Bonventre, J V ......................................... 197Boobis, A R .............................................669*Boohaker, J G ......................................... 1067Boon, L ..................................................... 903Boon, N A ................................................ 437Boone, S ................................................. 2159Boor, P .................................................... 1558Boor, P J .................................................. 1832Boor, p ...................................................... 825Boorman, G ................................. 1376, 1855Boorman, G A ......................................... 127Borazjani, A ........................................... 1569Bordelon, N R ........................................584*Boren, M .................................................. 540Borgeest, C ........................................... 1811*Borgerding, M F ...........................1185, 1187Borgert, C ................................................370*Borgert, C J ...............................................31*Borges, H T ............................................ 1485Borghi, L .................................................. 242Borghoff, S J ................................... 862, 1228

Borisenko, G G ...................................... 2284Born, J ......................................................... 89Borne, N ................................................... 484Borowitz, J L ................................ 1543, 2279Borracci, P .............................................. 1435Borsay Horowitz, D ............................. 1745Borst, P ................................................... 1051Bortner, C ................................................1114Botta, D .................................................... 579Bottenberg, P ..........................................1188Bouchard, M .................................432, 2156*Bouchard, P ......................... 464, 1632, 2027Bouldin, A ................................................ 326Bounous, D I ..............................................11Bourdelais, A J .....................474, 1101, 2227Bourdelais, A J .......................................527*Bourdi, M ................................................. 905Bourne, N .............................................. 1628Boutherin-Falson, O ............................1240*Boutros, P C ........................................... 1383Boverhof, D R ...........101, 1363*, 1382, 1759Bowen, L D ............................................ 1009Bowen, M E ..........................................2275*Bowen, N ......................................... 560, 577Bowlus, C L ............................................637*Bowman, B .............................................. 356Bowman, Z .............................................207*Boyce, R W ............................................ 1828Boyd, H .................................................... 680Boyer, J L ........................................ 465, 1706Boyes, W K ....................................49, 1332*, ................................. 1335, 1337*, 2088*, 2093Boykin, B ............................................... 1623Boykin, E ............................................... 1896Boykin, E H ................................1214, 1715*Boysen, G ................................. 193, 523, 525Brackman, K .......................................... 2069Bradford, B ............................................ 1046Bradford, B U .................................... 60, 759Bradlee, C A ............................................ 284Brady-Roberts, E .................................... 768Braen, A ..................................................1181Brambila, E ...........................................1619*Bramble, L A ............................................ 449Brand, R .................................... 2172*, 2172*Brasel, J ...................................................958*Braselton, E W ........................................ 534Brasic, J R ................................................. 678Brattin, B ................................................ 1309Braun, K ................................................. 1038Bray, B J .................................................. 1489Bray, C .......................................................83*Bray, K C ................................................ 1796Braydich-Stolle, L ................................1625*Bredfeldt, T G ....................... 146, 147*, 1161Bredow, S .................................... 1141, 1142*Breen, M ................................................. 1467Brees, D .................................................... 490Brellenthin, R P ....................................2076*Brennan, R ..............................126, 338*, 522Brennan, R J ........................................... 1830Brent, R L ............................................... 2096Bressler, J P ............................................ 1263Breysse, P ................................................. 428Bricarello, A ............................................. 804Bridge, K A .............................................. 930Brien, J F ................................................... 935Brignoli, S R ............................................ 806Brigo, E .................................................1967*Brimfield, A A ........................................781*Brix, A E ................................................. 1506Broadwin, R .......................................... 1476Brock, B .................................................1532*Broderick, D .......................................... 1608Brodsky, B ........................................ 779, 784Brody, A R ................................................ 635Bromberg, P A ....................................... 1450Bronaugh, R L ....................................... 2177Bronley-DeLancey, A ..........................1559*Bronstein, R ............................................. 412Brooks, A .................................................645*Brooks, D ................................................. 686Brooks, E ................................................ 1814Brooks, J ................................................1810*Brooks, J D ......................... 2175, 2194, 2197Brorby, G .................................................. 409Brott, D .............................. 824*, 1626, 1843*Broud, D .................................................. 902

AU

TH

OR

IND

EX




Broughton, D S ......................................272*Brouillette, W ........................................ 1785Brown, A P ..............................................529*Brown, C .......................................... 210, 425Brown, C D .............................................. 917Brown, J P .....................................1521, 2111Brown, K G .............................................388*Brown, L ...............................................1089*Brown, M J ............................................1353*Brown, P J ...............................................737*Brown, P W ............................................. 532Brown, R .......................................... 378, 584Brown, R D .............................................. 878Brown, R P ............................................. 2136Brown, S C ............................................2108*Brown-Borg, H ........................................ 582Brownawell, A ........................................ 374Brubaker, G ............................................. 696Bruce, G M ............................................2102*Bruce, R .................................................. 1520Bruce, R M ..............................................383*Bruckner, J ..................................... 956, 2039Bruckner, J V ................................ 402, 1243, .............................................. 1245, 1247, 2095Bruckner*, J V ......................................... 729Bruening, T ............................................ 1282Brundage, K M ................1886, 1887*, 1889Brundage, R A ...................................... 1211*Brune, B ..................................................2116Bruner, L ................................................ 1630Brunet, R C ............................................ 2156Bruno, M E ...........................64*, 1005, 1900Bruschi, S ................................................. 813Bryant, S ........................................... 569, 755Brynczka, C ..........................................1538*Bucher, J ................................................... 793Bucher, J R ............................. 33, 1800, 2185Buchmann, E ......................................... 1856Buchweitz, J P ........................................876*Buck, R C ................................................. 952Buckalew, A ........................................... 1733Buckelew, A R ........................................1119Buckley, B .............................................. 1958Buckley, D B ...............................1762*, 1763Buckley, L .............................................. 1385Buckpitt, A ............................................... 210Buckpitt, A R ........................................... 916Budnik, J ...............................................2030*Budroe, J D ...........................................2109*Buelke-Sam, J .......................................... 978Buermeyer, A B ..................................... 2273Buettner, A ............................................. 1518Buffington, C ........................................... 355Buffmum, D .......................................... 1898Bugrim, A .................................... 1377, 1378Buhler, D R .......................... 738, 2019, 2020Bui, Q Q ................................................1390*Builee, T L ................................................ 979Bullard, B ................................................. 537Bulliet, R ...........................................201, 711Bunaciu, R P .......................................... 1488Bunderson, M ....................................... 1841Bunn, W B ................................................ 400Burback, B ................................... 1233, 1234Burback, B L ...........................................194*Burch, L H ............................................. 1846Burchiel, S W ..................................302*, 892Burdick, A D .................................302, 1820*Burgess, J ................................................. 732Burgess, M F .............................................17*Burgess, S C ................................... 971, 1299Burghardt, R ................................ 2126, 2298Burghardt, R C ...................................... 1368Burgin, D E .............................................395*Burgoon, L D .....................101, 1363, 1382*, .......................... 1383, 1759, 1760, 1771, 1772Burin, G .................................................... 949Burka, L .................................................... 732Burka, L T .......................................116, 1230Burke, K ................................................1058*Burke, S P .............................................2299*Burleson, F ............................................... 872Burleson, G .............................................. 872Burnett, D ................................................ 793Burnett, D C ............................ 775, 788, 794Burnett, J .................................................246*Burnett, V L ............................................108*Burns, A M ............................................... 759

Burns, C ................................................. 1824Burns, F J ............................................... 1045Burns, K A ................................................53*Burns, L M ............................................... 268Burns, T D ............................................. 1396Burns-Naas, L ......................................... 314Burris, J .................................................. 1236Burt, J W .....................................1382, 1772*Bus, J S .........................................1242, 1666*Buse, E ................................. 168, 1105*, 1636Bush, A I ................................................1661*Bushel, P R ................................................119Bushman, W .............................................110Bushman, W A ........................................ 550Bushnell, P J ............... 49, 1335, 1547, 2088, ...................................2089*, 2090, 2092, 2093Bussiere, J L ............................................. 499Butala, J H ................................................ 264Butenhoff, J .............1236, 1740*, 1798, 2066Butenhoff, J L ........................................ 1906Butler, R ................................................2022*Butterworth, B C ................................... 1746Butterworth, L ......................................... 882Byers, J ................................................... 2033Byrd, D M ...............................................374*

CCabonce, M ............................................. 532Caddick, H T ......................................... 1207Cadena, L ................................................. 597Cadet, J L ............................................... 1544Caguyong, M J ........................................ 589Cahill, P ................................................. 1037Cai, B ...................................................... 1821Cai, L .................................1226, 1836, 1839*Cai, P .....................................912, 913*, 2295Cai, Q ..........................................1308*, 1595Cai, W ..................................................... 1796Cai, Z ........................................................ 537Cain, S P ................................................. 1556Cairns, S ................................................. 2212Calderon, R L .......................................... 692Calderon-Aranda, E ............................... 253Calderon-Aranda, E S ....... 627*, 1146, 1875Calderwood, D J ..................................... 462Caldwell, J C ........................................... 401Caldwell, R .............................................169*Cali, J ............................................. 201*, 711*Calimlin, M ............................................. 473Calis, K ............................... 1776, 1777, 1778Calkins, M ............................................1523*Calkins, M J ............................................. 814Callaghan, T L ....................................... 1229Camacho, I .............................................. 365Camacho, S .............................................. 254Camp, S .................................................... 997Campain, J A ......................................... 1306Campanha, H M ..................................1948*Campbell, A ..........................................1448*Campbell, C T ....................................... 1419Campbell, J .................................... 416, 2039Campbell, J L ..................................861*, 869Campbell, M ..........................................1140Campbell, M R .........................................115Campen, M D .......................................... 960Campen, M J ..........................................455*Camus, L .................................................. 838Candelas, R ............................................. 253Candrl, J S .............................................. 1289Canerdy, T ............................................... 809Canham, B ................................... 1465, 1466Cannady, R D .......................................... 976Cannon, J R ..........................................1528*Cano, M ................................................. 1502Canpolat, E .............................................. 894Cantor, G H ........................................... 1930Cantor, J ................................................... 938Cantor, J O ............................................... 925Cantor, R M ........................................... 1373Cao, C ............................................. 484, 1628Cao, J .....................................................2036*Cao, Y ......................................................... 89Cao, Z ................................1827*, 1833, 1834Capen, C .................................................. 671Cappadoro, M ....................1188, 2006, 2009Cappon, G D ................................. 273, 1802

Car, B D ........................................ 1768, 1930Carbone, D L ................................209, 1718*Carchman, R ............................................ 408Carchman, R A ............................ 1292, 2161Carlisle, J C .............................................. 254Carlock, L L ............................................. 499Carls, N .................................................. 2232Carlson, T ................................................ 529Carmichael, P L ..................................... 2264Carnell-Bachman, A N ..............1786*, 1787Carnes, K ............................................... 1373Carney, E ...............................................1684*Carney, E W ..................................282, 2249*Carney, S A ...........................................1824*Caro, A A ..............................................1722*Carpenter, S .................................. 802*, 803*Carr, D F ................................................ 1276Carr, G J ................................................. 1371Carr, R L ..................................969, 970*, 971Carr, W C ............................................... 2152Carratu, M ............................................. 1435Carrier, G ....................................... 432, 2156Carruthers, C M .....................................551*Carstens, J .............................................. 1241Carte, B K ................................................... 94Carter, H ................................................ 1292Carter, J .......................................... 204, 1445Carter, J M ............................................1698*Carter, W ................................................ 2161Carter, Jr., W ............................................ 408Carvalho, R A .......................................1835*Carvan, M J ........................................... 2238Casati, S ......................................... 484, 1628Casavant, R H ......................................... 783Casbohm, S L .......................................... 780Casciano, D A ........................................ 1381Casella, G ................................................. 370Cashman, J .............................................. 109Cashman, J R ........................................1554*Casillas, R P ................................... 780, 2202Casper, E ................................................ 1048Cassee, F .........................................307*, 437Cassee, F R ..................................... 929, 1446Castaigne, J .............................. 170, 544, 807Casteel, S W ............................................1151Castellino, S ............................................. 491Castle, J .................................................... 287Castoldi, A F ................................ 1055, 2051Castorena-Torres, F ...............................567*Castranova, V ...................... 701, 702, 1443, .............................................. 1449, 1468, 2188Castro, L ................................................ 1114*Cate, M ................................................... 1246Catlin, M .................................................. 431Catranova, V ........................................... 212Cattley, R C .............................................. 581Caudle, M ...........................973, 1529, 1545*Cawley, T J ............................................... 282Cawthon, D R ..................1098, 1099, 1702*Cayatte, C .............................................1732*Cebrian, M ............................................... 427Cebrian, M E ..............252, 1146, 1455, 1875Cederbaum, A I ..................................... 1722Cerbon, M ................................................ 139Cerreta, J M ......................... 925, 1833, 2289Cerreta, J M ............................................. 934Cerven, D R ........................2011, 2012, 2207Chacko, M S .......................................... 1801Chahbane, N ......................................... 2050Chakrabarti, S K ....................................1131Chakraborty, C ...................................... 1609Chamberlain, M .................................... 1293Chambers, H ......................................... 1946Chambers, H W .................................... 1947Chambers, J ........................................... 2159Chambers, J E ......................... 969, 970, 972, .............................................1299*, 1946, 1947Chan, D W ............................................... 254Chan, H .................................................. 1622Chan, J Y .......................................... 815, 821Chan, K .................................................1926*Chan, P ................................................... 1425Chan, V ...........................................571*, 963Chan, W K ................................................. 98Chandar, N ............................................ 1602Chandler, C M ......................................... 719Chandraratna, R ....................................... 57Chandraratna, R A ................................... 59

Chaney, D ...............................................1140Chaney, J G .............................................1197Chang, C ........................................ 710, 1501Chang, F T ............................................ 1184*Chang, L W ........................................... 1724Chang, M ....................................1809*, 2274Chang, S ..................................................186*Chang, T K ............................................ 1491Chang, W .................................... 454*, 1876*Chang, X ................................. 92*, 104, 1165Chang, Y .................................................. 780Chao, S L .................................................. 976Chao, Y ................................................... 1279Chapin, R E ........................................8, 1121Chappell, L L ..........................................155*Charbonneau, M ................764, 1651*, 1790Charles, G D ...........................................585*Charney, D ......................... 1776, 1777, 1778Charnley, G ...........................................1343*Charron, A ............................................. 2172Chatterjee, A ...............................1414, 2004*Chaudhary, A M ..................................1588*Chavez, B ........................................608, 1153Chavez, K J ...........................................2303*Cheeseman, M ...........................1317*, 2204Cheever, K L ...................................190, 191*Chegini, N ..............................................1113Chelonis, J J ............................................. 987Chen, A .................................................... 978Chen, C .................................................1220*Chen, D .................................................. 1939Chen, G .........................................187*, 1361Chen, H ....................................... 1143*, 1144Chen, J ............................................ 241, 1264Chen, J J ................................................. 2181Chen, L ...........................305*, 440, 574, 697, ..................................... 941, 1445, 1603, 2216, .............................................. 2217, 2218, 2220Chen, L C ..............................................1933*Chen, M ..................................................631*Chen, M K ............................................... 678Chen, P ................................................... 1582Chen, Q .................................................. 1061Chen, Q M ............................112, 1725, 1848Chen, S ..................................................1360*Chen, T ...............................747*, 1565, 1757, .......................... 2216, 2217, 2218, 2220, 2222Chen, T B ............................................... 1468Chen, T S ................................................ 1876Chen, X ....................................... 1156, 1189*Chen, Y .................................227*, 466, 1599, ................................. 1782*, 1828, 1922, 2026*Chen, Z .................................................. 1467Chen, J ................................................... 1131*Cheng, C N ...........................................1621*Cheng, D .................................................725*Cheng, E ................................................ 1408Cheng, H ...................................................42*Cheng, J ...................................................... 42Cheng, T .......................434, 435, 454, 1452*Cheng, X .................................................564*Cheng, X G ............................................ 1220Cheng, Y ...................................... 1058, 1452Cheng, Y J .............................................1724*Chengelis, C P ......................................1394*Cherian, G ................................................. 78Cherian, G M ......................................... 1613Chernoff, N ........................................... 1438Cherr, G N ............................................. 1087Cherrington, N J ........................... 815, 1761Chetty, C S ..............................................613*Cheung, J K ........................................... 2230Cheung, P ................................................ 348Chhabra, R ..........................1181, 2035, 2070Chi, R P .................................................. 1716Chiarappa, P ......................................... 1435Chiaro, C .................................................. 715Chiaro, C R ...............................................89*Chibout, S .................................................. 61Chico-Galdez, V ................................... 1039Chigurupati, M ..............................590*, 591Chilakapati, J ................................731*, 2137Chintharlapalli, S ................................2298*Chipman, K ................................. 1375, 2234Chittim, B .............................................. 1363Chiu, H .................................................. 1054Chiu, N .................................................1804*Chiu, N H .............................................1803*

228

AU

TH

OR

IND

EX




Cho, D ............................................ 186, 1635Cho, H .................................................... 1857Cho, I ...................................................... 1215Cho, J .........................................................111Cho, M ............................................... 41, 186Cho, T M .................................................358*Cho, Y ................................... 907, 1409, 1503Chohan, S .............................................. 1551Choi, A M .............................................. 2284Choi, B ...................................590, 591*, 2263Choi, C ..............................1409, 1427, 1531*Choi, C J ..................................................633*Choi, J ................................. 1524, 1531, 2168Choi, M .......................................... 156, 1007Choi, Y W ...............................770, 771*, 774Choich, J ................................................... 768Choksi, N ................1997*, 2005, 2007, 2008Choksi, N Y ....................................662, 663*Chou, C .................................................2181*Chou, D .................................................. 1603Chou, D K .......................................574, 941*Chou, I ................................... 574, 941, 1603Chou, J W .................................................119Chou, N ....................................... 1050, 1766Chou, S J ...............................................1483*Chou, Y .................................................... 414Choudhury, E .......................................... 483Choudhury, H ................................285*, 383Chouinard, L ........................................... 173Chow, J C ................................................. 304Chowdhury, M J ..................................1756*Chowdhury, U K .........................153*, 1329Choy, D .................................................. 2120Chris, B .................................................. 1927Christian, B J ........................................... 804Christian, M .......................................... 1738Christiani, D C ........................................ 441Christopher, J P ....................................2079*Chu, A C ...................................... 1752, 2049Chu, M D ..................................... 1752, 2049Chung, C .................................................. 905Chung, H ............................................... 1635Chung, J ......................................... 150, 1564Chung, K ....................................... 717, 1454Chung, W ...........................738, 2019*, 2020Chung, Y ............... 1213, 1409, 1427*, 1714*Chung, Y H .............................................. 202Churchwell, M I ............ 293, 361, 502, 1565Ciaccio, P ........................................173, 508*Ciak, J M ...............................................1831*Ciencewicki, J M ....................................447*Cifone, M A ........................................... 2214Cimafranca, M .....................................2047*Cisneros, B ............................................... 567Ciurlionis, R ............................ 121, 557, 647Cizmas, L ..................................... 1290, 2270Cizza, G ............................. 1776, 1777, 1778Clapp, C ................................................. 1201Clapp, C J ............................................... 1293Clark, A .................................................. 2069Clark, A J .................................................. 269Clark, C ............................................ 776, 787Clark, D .................................................. 1844Clark, G C ...................................1752, 2049*Clark, K .................................................... 410Clark, M ................................................... 921Clark, O E ...............................................782*Clark, S ................................................... 1828Clarke, J ................................................1994*Claude, J .................................................. 470Claude, N ...............................................1175Claus, R .................................................... 486Claus Henn, B ......................................1277*Clegg, E .................................................. 1998Clemens, D L ......................................... 1657Clewell, H .....................................261, 1689*Clewell, H J ............................. 350, 847, 854Clewell, R .............................................. 1689Clewell, R A ....................................276*, 862Cline, P ..................................................2023*Clipson Miller, T ........................2101, 2104*Cloak, C ..................................................677*Clode, S .................................................... 681Clodfelter, S ........................................... 1009Clothier, B .............................................. 1903Clothier, R ...................................... 484, 1628Coates, N H ................................. 1714, 1715Coatney, R ..............................................341*

Coban, A .....................................1955, 1956*Coccini, T ....................................1055*, 2051CodiKing, S ........................................... 1280Coeshott, C .............................................. 766Coffey, E M .............................................. 121Coffey, T ..................................................389*Coffin, D D ............................................ 1841Coffin, J ...................................................686*Cohen, B .................................................. 171Cohen, J ...................................................431*Cohen, M ......................................636*, 1453Cohen, S ......................................... 672, 1798Cohen, S M ............. 668*, 1397, 1502*, 1505Cohen Hubal, E A ................................1339*Cohen-Hubal, E ...................................... 378Colangelo, J L .................................. 520, 532Colatsky, T ............................................... 537Colby, G ................................................. 1706Cole, T B ........................................968, 1949*Coleman, M ............................................768*Colet, J M ................................................. 519Colin-Barenque, L .................................. 608Collard, W ............................................. 1916Colleton, C ............................................. 1425Collette, W W .......................................... 515Collier, A C .................................... 958, 1009Collier, F ................................................. 2109Collins, B ...............................................1252*Collins, B J ............................................... 829Collins, J ................................................... 121Collins, J F ............................................ 2111*Collins, M .............................................. 1373Collins, M D ...........................................1168Colman, J ................................................. 155Colombo, M .........................................2293*Colosio, C .............................................. 1888Colvin, V .................................................. 703Colvin, V L .............................1*, 1862, 2185Commissaris, R ......................................602*Compton, D ............................................. 798Conde-Moo, P C ..................................1875*Congdon, W ............................................ 492Conklin, D J ..........................................1844*Conlon, D ................................................ 462Connelly, M ........................................... 1856Conner, A ................................................931*Conner, M W ..............................................8*Connolly, T ...............................................114Conolly, R ......................................... 30*, 34*Conolly, R B ......... 344, 403, 404, 1297, 1304Constable, J D ....................................... 2072Constable, P D ........................... 1310, 1312, .............................................. 1314, 1315, 1929Contrera, J .............................................. 2204Conway, h ...............................................934*Coogan, T P ............................................. 268Cook, J C ................................................ 1802Cook, J D ................................................ 1262Cook, P M .............................................. 2254Cooke, G .................................................. 568Cooke, P S ................................................ 554Cooney, A J ............................................ 1969Cooper, K L .......................................... 1167*Cooper, K R ................................. 1965, 2239Cooper, R L ....................... 1118, 1728, 1733*Cooper, S .....................................1252, 2141*Copeland, C ............................................ 889Copeland, L ........................................... 1213Copeman, C ..........................476, 477*, 479, ...................................................840, 841, 1102Corbeil, J .................................................1103Corbett, A H ...........................................656*Corcoran, G B ........................................ 2301Corley, R ................................................ 1256Corley, R A ..............................347, 857*, 866Cornwell, P D ...................................56*, 589Corsini, E ....................................1888*, 2247Corson, N ........................................ 443, 698Corsten, C .............................................. 2050Corthals, S M ..................................751*, 752Corton, J C ..........57, 58, 59*, 581, 582, 2286Cortright, K ..........................................1561*Cortvrindt, R .............................. 1123, 1366*Cory-Slechta, D ....................................... 645Cory-Slechta, D A ............... 217, 1957, 1958Coryell, V H ...........................................158*Cosenza, M .............................................. 467Cosenza, M E ........................................ 1784

Cosio, M G ..............................................920*Costa, D L ...................... 433, 441, 927, 1447Costa, L G .............................. 967, 968, 1949Costa, M ..............................1143, 1144, 1789Coston, T S ............................................ 2193Couch, L H .........................502*, 1565, 2187Coudouel, H ............................................ 487Coulombe, R A ............................ 1407, 1795Courcol, M ............................................. 2131Couroucli, X I .......................................1845*Courson, D L ........................................1883*Courter, L A ..........................................2271*Courtney, C ............................................. 529Coussement, W ....................................... 268Cover, C ....................................................63*Covington, C Y ..................................... 1003Covington, T R .......................350, 847*, 854Cowan, G S .............................................. 355Cowell, S ................................................ 1747Cowlen, M S ...........................................465*Cox, C ....................................................... 860Cozzi, N ................................................. 1897Cracknell, S ........................................... 2031Craig, S ................................................... 2012Craigmill, A ........................................... 1561Crain, S S ............................................... 2273Cranson, A B ......................................... 1551Craven, V ................................................. 409Crawford, C .......................................... 1813Crawford, R ........................................... 1868Crean, C S ................................................ 465Creasy, D ...................................................... 8Creech, A C ............................................ 1230Creim, J A ................................................ 238Crenshaw, B ...........................................2117Creppy, E E ............................... 1435*, 1440*Crespi, C L ............................................. 1556Crincoli, C M ......................................70*, 81Crissman, J .............................................. 949Crissman, J W ......... 1507, 1508, 1509, 1510Critser, J K ............................................... 546Crittenden, P L .......................................617*Crockett, P ............................................. 1628Crockett, P W ............................................ 33Crofoot, S ................................................. 949Crofoot, S D ......................1508, 1509*, 1751Crofton, K ...................................... 977, 2039Crofton, K M .............................. 1091, 1292, .................................... 1769, 2057, 2161, 2162Crofts, F ................................................. 1464Cromey, D W ..........................................2119Crooks, D R ............................................629*Crosier, R B .............................................. 788Crossgrove, J S ...................591, 1533, 1534*Crouch, E ................................................394*Crouse, C ......................................... 776, 787Crouse, C L .............................................. 773Croutch, C R .........................................2034*Crowell, J ............................................... 1785Cruzan, G .............................................. 1563Csanady, G A ......................................... 1241Csizmadia, V ................................464, 1632*Cui, D ....................................................2123*Cui, H ............................................723, 1567*Cui, Y ............................................ 1565, 2187Culwell, J ................................................. 473Cumberbatch, M ........................ 1710, 1711*Cummings, B S ........................... 1720, 2124Cunningham, C ...............1259, 1284, 1285*Cunningham, J R .................................. 1883Cunningham, M ....................45*, 671, 1855Cunningham, M L ...........................116, 759Cunningham-Hill, M ............................. 472Curran, C P .............................................955*Curran, I .........................................128*, 568Curren, R D ..........................................2209*Currie, R ...............................................1375*Curry, P T ..............................................1776*Curry-McCoy, T V ...............................2280*Curtin, G M ..................................1187, 1786Cushing, C ............................................... 258Cutter, G R ............................................. 1009Cwik, M ................................................. 1235Cyr, D G ............................... 764, 1651, 1790

DD’ Angelo, D ........................................... 733D’Ambrozio, A ................................ 776, 787D’Souza, S E ............................................ 691D’Surney, S J .......................................... 2240Dabisch, P A ...................................788, 794*DaCosta, S O ..........................................1811Dai, G ................................1050*, 1766, 1920Dai, Q ............................................901*, 1043Dai, X ........................................................ 589Daigle, H J ............................................2221*Dail, M B .................................................. 972Dailey, L ................................................. 1019Dalgleish, H A ....................................... 1771Dalmas, D A .........................................1828*Dalmasso, E ............................................. 532Dalton, T P ....................227, 955, 1165, 1599Dalvi, R R ...............................................2112Daly, D S ................................................ 1003Damiani, C L ........................................1540*Damodaran, T V ..................................1952*Daniel, J .................................................. 1004Daniels, K .............................................. 1972Daniels, K K .................................753, 1829*Daniels, M ................................... 1894, 1896Daniels, M J ........................................... 1214Danilenko, D M ...................................... 806Dankovic, D A ........................................387*Dano, S D ............................................... 1440Danoff, E .................................................. 325Dargent, F ................................................ 470Dart, R C ...............................................1048*Dary, C C ....................................... 870, 1298Dash, B ........................................1283*, 1402Dashwood, W ....................................... 1814Dasmahapatra, A K .............................. 2253Daston, G P ........................................... 1371Datiri, T ...................................................2112Daugherty, A ......................................... 1838Davey, J C ...............................................133*David, M J ............................................. 1736David, R ................................................... 264David, R M ............................................ 1504David, S H ..............................................992*Davidson, K A ......................................1480*Davidson, T ............................................1143Davidson, T L ....................................... 1144*Davies, R ................................................ 1903Davis, A .................................................... 602Davis, B K .................................... 2079, 2080Davis, D P ...............................................1190Davis, G ................................................. 2126Davis, J ..................................................... 732Davis, J W ................................................ 302Davis, K ............425, 493, 1637, 1642, 2159*Davis, M L ............................................. 2193Davis, R .................................................... 528Day, B J ................................................... 1853Day, K C ..................................................359*Day, S J ................................................... 1242De Abrew, K N .......................................105*de Groot, D M .......................... 1056*, 1057*de Haar, C .............................................1892*de Jongh, C M ......................................2199*de Jouffrey, S ................................. 470, 2300de la Pena, M ......................................... 1658de Peyster, A .................................. 515, 1742De Rosa, C T ............................................ 390De Schaepdrijver, L M ..........................268*De Souza, A T ...................................56, 589*de Villa, F P ............................................270*De Vizcaya-Ruiz, A .............................. 1455de Waart, R ............................................ 1051De Wever, B ................................. 481*, 482*, ............................................. 1188*, 2006, 2009de Wolff, F A .................................... 606, 634Dean, J .......................................................24*Dearman, R ..................................1196, 1201Dearman, R J ....................... 37*, 1198, 1200, ..................................1204, 1206*, 1207, 1209, ...............................................1710, 1711, 1999DeBus, S ..................................................1184DeCaprio, A P ....................................... 1281Dechkovskaia, A M ........................ 961, 962DeCristofaro, M F ....................................61*DeCuir-Charbonnet, C .......................... 356Defoort, E .............................................2259*

AU

TH

OR

IND

EX




Degen, D E ............................................ 1847DeGeorge, G L ...................2011, 2012, 2207Degitz, S ................................................. 1755Degitz, S J .................................... 1754, 1756Degn, L L ............................................... 1942DeGroot, D .......................................94*, 353Deguchi, Y ............................................. 1094Dekant, W ...................................1239*, 1799Del Razo, L M ................................603, 1132Delaney, B .............................................. 1405DelCarpini, J ............................................ 805Delclos, K B ........................................... 2141Delgado, V ......................................608, 1153Delgado-Morales, W ............................ 1893Delker, D ...................................... 2144, 2146Dellarco, V L ...........................................672*Delnomdedieu, M .................................. 540Delongeas, J ............................................1175DeLorme, M ...........................................235*Delorme, M P ........................ 231, 234, 1475DelRaso, N ...................................... 571, 963DelRaso, N J ............................................ 526Demers, P .............................................1667*Demeter, J .............................................. 1252Deng, X ...................................................... 69Denison, M .............................................. 353Denison, M S .............................94, 95, 106*, .............................................. 1361, 1752, 2049Dennis, A O ............................................. 613Dennis, W E ........................................... 2017Dennison, J E ......................377, 1473*, 1474Denoux, G ............................................. 1290Denslow, N .........................575, 1773*, 2023Deo, A K ................................................1562*DeParle, L ................................................ 809Dere, E ...........................................101*, 1383Derk, R C ................................................. 549Dertinger, S D ......................................2212*Descotes, J ...........................885*, 1240, 2032Desdouets, C ............................................118DeSesso, J M .......................................... 2097Desilets, G ............................................... 174DeSmet, K .............................................1856*Destrument, A ....................................... 1710Detrisac, C ............................................. 1785Dettbarn, W D ....................................... 1000Dettmer, K ............................................... 106Devesa, V ............................148, 1231, 1817*Devi, S S ................................................1909*Devine, P J ............................................ 1116*DeVito, M .................................................. 32DeVito, M J ....................311, 850, 858, 1227, .......................... 1250, 1292, 1769, 2057, 2161Devlin, M K ............................................587*Devlin, R ..................................... 303*, 1019*Dewe, W .................................................. 519DeWitt, J ..................................................889*DeWoskin, R S ............................. 294*, 859*Deyo, J A ................................................ 1504Deyrup, C .............................................. 1386Dhondt, M ............................................. 2015Di Giulio, R ..................................687*, 1581Diaco, M ................................................ 2001Dial, S ............................................. 762, 1912Diamond, G L ....................................... 2082Diawara, M M .......................... 1120*, 1260*Diaz-Sanchez, D ..................................... 458DiCicco-Bloom, E ................................. 1058Dickinson, T ............................................ 362Dieckmann, G R ................................... 1594Dieter, M Z ...................564, 815, 821, 1229*Dietrich, D ...... 2099, 2113, 2114, 2115, 2116Dietrich, H ............................................. 1269Dietzel, K ................................................416*Dijkstra, A ................................................ 953Dileberto, J J .......................................... 1253Diliberto, J J .......................... 311, 395, 1227*Dillman, J F ............................125, 182, 774*Ding, X ........................................... 723, 1567Dinoff, T ................................................... 414Dinoff, T M ............................................ 1279Dion, C ..........................................1127, 1128Dionnet, F ................................................ 446DiPalma, K ............................................ 1532Dive, C ..................................................1652*Divine, K K ................................. 1141*, 1142Diwan, B ........................ 138, 144, 694, 1608Dix, D ..................................................... 2145

Dix, D J .......................188, 644*, 1709, 2143, .............................................. 2148, 2150, 2151Dixit, R .............................................7A*, 7B*Dixit, R M .................................................... 9Dixon, D ........................................1114, 1794Dnyanmote, A V ..................62, 1910, 2139*Dobbs, J A ................................................ 972Dobson, A ................................................ 486Dodge, D .................................................248*Doehmer, J ............................................. 1814Doerfler, D L .......................................... 1715Doerge, D R ..................293*, 361, 502, 1565Doerr, C L ................................................ 152Doherty, C M ........................................2027*Doherty, J ................................................. 977Doi, A M ................................................1800*Doi, K ..................................................... 1433Doi, Y .......................................................746*Dolinoy, D C ...........................................572*Doll, M A ..................................... 1265, 1266Domann, F E ........................................... 147Domico, L M ........................................1965*Dominick, M A ...................................... 1781Dommels, Y ........................................... 1319Domoradzki, J ....................................... 1256Domotor, S ..............................................332*Donahower, B ..........................................68*Donaldson, K .......................................... 437Dong, J .................................................. 2118*Dong, W ................................................. 2037Donhue, J ..............................................2100*Donnell, B .............................................. 1783Donnelly, K .................................... 524, 1290Donnelly, K C .............................. 1593, 2270Donohue, T M ............................1657*, 2280Donovan, J C ........................................1356*Doolittle, D J ................................ 1516, 1786Doorn, J A ...................185, 209, 1718, 1723*Dopp, E ..................................... 1818*, 2225*Doran, S ................................................. 1383Dorman, D ............................................... 863Dorman, D C ..................................675*, 940Dormans, J ............................................. 1490Dormans, J A ......................................... 1446Dorr, E .....................................................2116Dorsch, L M ............................................. 774Dorsey, A ................................................ 2086Doshi, M .................................................. 715Doshi, U ................................................... 934Dougherty, E ............................................. 86Dourson, M ........................................... 2094Dourson, M L ........................................ 1343Downend, A B ......................................... 534Doyle, A E ...................................1263*, 1272Doyle, E ................................................... 733Doyle, M .........................................930, 942*Draaisma, A L ....................................... 1913Dragan, Y ............563, 671, 762, 1029*, 1912Dragan, Y P ............................511, 666, 1704Dragin, N ................................................. 955Drake, V J .............................................2246*Draper, R K ............................................ 1594Dreher, K ...............................................1444*Dreiem, A ................................................621*Drobna, Z ................................................148*Drolet, D .................................................. 244Drupa, C .................................................532*Dryzga, M .............................................. 1256Duan, J ........................................... 741, 1500Dubois, E ............................................... 1843Duchesne, M ......................................... 2131Duchesneau, M ....................................... 174Duffy, C .................................................... 754Duffy, J ..................................................... 893Dugan, C M ............................................... 69Duirk, S E .............................................. 2065Dumas, P ............................................... 2156Dumont, J .............................................1039*Dunaway, S ............................................. 892Duncan, B .............................................. 1593Dunlea, S ............................................... 1700Dunn, C .............................................. 57, 581Dunn, R T .............................................1784*Dunnick, J .....................................828, 1826*Dunnick, J K ............................................ 829Dunsmore, M .........................................1151Dunstan, R ............................................. 1916Dupin-Roger, I ........................................ 470

Durham, J A ........................................... 1237Durhan, E J ............................................ 1746Duydu, Y ............................................... 1273Duzevik, E G ........................................ 1135*Dwivedi, J ................................. 1591*, 1592*Dybing, E ......................................... 307, 385

EEarl, L ....................................................... 528Earl, L K ..................................................249*Easter, M D .............................................418*Easterling, M ..........................................852*Eastvold, M ................................. 1740, 2066Eaton, D L .............................................. 1495Echeverria, D .......................................1275*Eckel-Passow, J E .................................. 1382Edelhauser, H F ...................................1623*Edge, D T ................................................976*Edmond, C .............................................. 540Edward, D ............................................... 715Edwards, B ............................................ 1568Edwards, C N ....................................... 1390Edwards, J A .......................................... 1429Edwards, P A ..........................................288*Edwards, T R ........................................... 473Eells, J T ....................................... 1856, 2245Egan, B ..................................................... 109Ehlich, A ................................................. 1996Ehman, K D ..........................................1078*Ehresman, D .....................1236*, 1740, 2066Ehrich, M ......................161, 316*, 600, 1943Ehrich, M F .................................... 626, 1944Eiland, E ................................................. 2240Ekins, S ........................................1377*, 1378Eklund, C ................................................. 864Eklund, C R ..................................856*, 2089Ekman, D ............................................... 1709Ekpo, B ................................................... 1439El-Kadi, A O ...........................................1154El-kholy, H ........................ 1139, 1140, 1384*El-Masri, H ............................................ 1560El-Masri, H A .......................................... 390El-Masry, E M ......................................1620*El-Salanti, Z ........................................... 1390El-Tawil, O S .............................................79*Elbekai, R H ......................................... 1154*Elcombe, B ............................................... 277Elcombe, C ...................277*, 733, 761, 2258Eldan, M ...............................................1505*Elder, A ............................................443*, 698Elder, A P ................................................. 449Elder, E J .................................................1176Eldridge, J C .......................................... 1738Elfarra, A A .................................1572*, 2262Elferink, C J ..................................994*, 1362Elizondo-Azuela, G .............................. 2166Ellinger, H ..............................................2114Ellinger-Ziegelbauer, H ....................... 1735Ellis, J .....................................................2264*Ellis, M E .......................................184, 1216*Ellis, R s .................................................. 1887Ellis-Hutchings, R ...............................1087*Elnabawi, A M ........................................ 632Elsayed, N ..............................................767*Elskus, A A .............................................. 957Eltom, S E .............................................. 1810Ema, M ..........................................281*, 2155Emberley, J ..................................... 367, 1869Emberley, J K ......................992, 1870, 2288*Emeigh Hart, S ................................ 173, 508Emeigh Hart, S G ..................................... 11*Emeny, R T .............................................189*Enayetallah, A ......................................1924*End, P ......................................................... 61Engel, L S ............................................... 1333Engelhardt, S ........................................... 165Ennulat, D ....................................... 173, 536Eom, J H ................................................... 907Eppley, R M ................................. 1314, 1315Eremenko, A V ........................................ 192Erickson, J E ............................................ 462Erikson, K M ........................................... 599Eriksson, J .............................................. 2062Eriksson, P ...................... 312, 405, 974, 975, .............................................1073, 1074*, 2062Erler, J T ................................................. 1652

Ernstgard, L ..................................868, 1248*Ershaw, K ................................................. 824Esch, H L ...............................................2058*Eskes, C ...........................................664*, 665Espandiari, P ......................263*, 1513, 1842Espejo, A ................................................ 1004Espiritu, I ............................................... 1013Ettinger, B .............................................. 1467Ettinger, R .............................................. 2073Euling, S ................................................... 378Euling, S Y ..............................................255*Evan, G .................................................. 1584Evans, B R .............................................1359*Evans, G ................................................... 824Evans, M G .............................................. 530Evans, M V ...................856, 858*, 864, 2089Evans, R ........................................... 776, 787Evans, R A ....................................... 773, 775Evans, R M ........................................ 65, 137Evans, T J ...................................... 546*, 1151Evansky, P ............................................... 927Evansky, P A ............................................ 448Everds, N E ........................................... 1405Everett, D ................................................247*Everitt, J ..................................................... 59Evrard, Y ................................................ 1897Eynon, B ................................................. 1700

FFactor, S A .............................................. 1988Fahl, W ..................................................... 817Fail, P A .................................................... 547Fairchild, D .............................................. 801Fairley, K J ............................................1210*Falahatpisheh, H .................................. 2132Falduto, M T .............................................. 45Falgout, M M ...............................1141, 1142Falk, M ..................................................... 374Falk Filipsson, A ..................................... 405Faller, T H .............................................. 1241Falluel-Morel, A .................................... 2300Fan, A ....................................................2105*Fan, J ....................................................... 1378Fan, R ....................................... 896, 897, 900Fang, H .............................. 1098, 1099, 1704Fangman, T J ........................................... 546Fanucchi, M ................................1648*, 1891Fanucchi, M V ................................. 359, 916Farah, V ..................................................791*Fare, T L ................................................... 121Farin, F M .............................................. 1275Fariss, M W ............................................. 206Farland, W H .................................32*, 1695Farmer, J D ................................... 1437, 1438Farooqui, M Y ......................................1577*Farraj, A ................................................. 1714Farraj, A K ...............................................448*Farrar, D ................................................... 277Farrer, D G ..................................1877, 1884*Fastje, C D ............................................... 936Faulconer, L ............................................365*Faulkner, D ............................................ 2182Faure, L .................................................. 1240Faustman, E ......................1291, 1303, 1655*Faustman, E M .....................346, 1155, 2257Fausto, N ................................................. 813Fay, M ..........................................1481*, 1483Fay, M J ........................................ 1436, 1602Fears, R .................................................. 2109Fechter, L D ........................................... 2182Fechter, L D ..............................................50*Fedor, M ................................................... 537Fedoruk, M J ..........................................412*Fehling, K ................................................ 410Feldman, R .............................................. 374Feldman, R A .......................................... 576Felice, J A ................................................. 473Fellows, K ................................................ 860Felty, Q ..................................................1774*Fenaux, J .................................................. 887Feng, X ..................................................2291*Fennell, S ..............................................1780*Fennell, T ................................................505*Fennell, T R ............................................. 361Fent, G M .............................................. 1151*Fenton, S ....................................... 297*, 299*

230

AU

TH

OR

IND

EX




Fenton, S E ....................................1122, 1369Ferdinandi, E ......................................... 1780Ferguson, D ........................................... 2039Ferguson, J ................................................. 10Fernandes, A ........................................... 681Fernandez, C ......................... 225, 813, 1859Fernandez, G E ....................................1385*Fernandez, S ............................................ 196Fernandez Canton, R ..........................1748*Fernando, R ........................................... 1252Ferrell, J M ....................................1119, 1728Fetter, B .................................................... 272Feuers, R J ................................................ 355Feuston, M ..........................................7A, 7BFickert, P .................................................... 63Fielden, M .....................126, 521*, 522, 1700Fielden, M R ............................................ 353Fields, C J ................................................284*Filipov, N M .............617, 1947, 1955*, 1956Filser, J G ................................................ 1241Finco-Kent, D .......................................... 171Finke, K L ................................................ 782Finkelstein, J ............................................ 443Finkelstein, J N ......................................306*Finley, B ..........................................392, 409*Fiore, M .................................................. 1799Firat, H ....................................................... 61Fisch, C .........................................470*, 2300Fischer, C ................................................975*Fishel, J ..................................................... 169Fisher, J ................................... 416, 968, 2039Fisher, J W .............402, 847, 861, 869*, 2095Fisher, M .................................................363*Fisher, R L .............................................. 1914Fiskum, G .............................................. 1960Fitsanakis, V A .......................................599*Fitzgerald, S D ........................................ 534Fitzsimmons, P N ......................1579*, 1580Flagler, N ................................................. 779Flaherty, J M ............................................ 230Flanagan, B ...........................................1207*Flanders, J A .......................................... 2303Flaskos, J ................................................ 1950Flaws, J ................................ 1111, 1112, 1960Flaws, J A ...................422, 1109, 1260, 1367, ............................................. 1811, 1823*, 2153Fleeman, T L ...................................273, 1121Fleener, S .................................................. 272Fleischmann, K ..................................... 1905Fletcher, G .............................................. 1468Flick, B ....................................... 2251*, 2252*Flickinger, G .......................................... 1717Flisher, A ................................................ 1334Flockton, A ............................................ 2243Florea, A M .................................. 1818, 2225Florence, R L ...........................................1125Floyd, H S .............................................1792*Flynn, C A ................................................ 979Flynn, E J ............................................... 1948Foertsch, L ..............................................1198Foertsch, L M ........................................ 1371Fogle, C M ............................................. 1072Fogleman, J ............................................ 1418Fogleman, J L .......................................2029*Fokkens, P H ........................................... 929Foley, J ...................................................... 757Foley, J F ................................. 784, 829, 1821Follansbee, M H ...................................... 399Fomby, L ...................................... 2035, 2070Fomby, L M ..........................................1425*Fong, C J .....................................1382, 1760*Forbes, A .................................................. 968Forbes, P D ...................................... 10, 2193Ford, S M ................................................324*Foreman, B D .........................................213*Forgash, R C .......................................... 1514Forkert, P ....................................... 730, 2278Foroozesh, M .......................................... 356Forrest, J N ............................................ 1706Forster, J ................................................... 793Forster, J S ................................................ 788Forster, R ................................ 265, 838, 2300Fort, D J .................................................1758*Fortoul, T I .................................... 608, 1153*Fostel, J ................................................... 1709Fostel, J M .................................................. 64Foster, N ................................................... 493Foster, P .................................................... 551

Foster, P M ............................................... 681Foster, R T .............................................. 1255Foster, W ........................................ 928, 1846Foster-Brown, L .................................... 1843Foth, H ..................................................1461*Fouad, H ................................................ 1076Foulon, O ................................................265*Foureman, G L ........................................ 388Fournier, A ............................................. 2300Fowler, B ................................................ 1823Fowler, B A ................. 390, 1156, 1159, 1189Fox, D ............................................. 500, 1206Fox, D A ..............................429, 1060*, 1061Fox, S ........................................................ 528Foxenberg, R J ............................2038*, 2157Frame, S R ............................................... 952Frampton, N ............................................ 272Francis, J .................................................. 932Frank, S .................................................. 1557Franklin, P ............................................... 492Franks, S .................................................345*Frantz, S ................................................. 1916Frantz, S W .............................................. 808Franzosa, J A ......................................... 2245Frazer, D ........................................ 933, 1468Frazier, L .....................................1664, 1665*Fredriksson, A ........................ 312, 405, 974, ................................................ 975, 1074, 2062Freed, B M ............................................. 1865Freed, W J ................................................ 629Freeman, J J ........................................... 1514Freeman, M ............................................. 817Freeman, R .............................................. 428Freidig, A ....................................1560*, 2087Freitag, D G ..........................................1255*French, J E .....................................500, 1044*Freney, E .................................................. 437Freudenrich, T M .................................. 2057Freyberger, A ......................................... 1735Friderichs-Gromoll, S ....... 168, 1105, 1636*Frieauff, W ............................................... 336Fried, K W ................................ 2048*, 2050*Friedman, M .................................. 398, 1039Friedman, M A ........................................ 505Friedman, S L ........................................ 1913Friedrichs, B ............................................ 922Frings, W ................................................167*Friry-Santini, C ....................................1731*Fritz, L K .................................................. 238Fritz, W A ...............................................550*Froehlich, J ............................................. 1236Froget, G .................................................. 838Fromer, D B ........................................... 1665Frueh, F ...........................................29*, 1381Fruen, B R .............................................. 2053Fryar, E ..................................................1783*Fu, P P .......................................... 1565, 2218Fu, X ............................................. 2141, 2285Fuchsbichler, A ......................................... 63Fuciarelli, A ............................................1181Fuciarelli, A F .......................................... 506Fuentes-Mattei, E ........................445, 1893*Fuerst, P ................................................. 2072Fuhrman, K ........................................... 1943Fujii, Y .................................................... 2297Fujimoto, S .............................................. 121Fujiwara, M ............................................. 954Fukuda, I ............................................... 1379Fukuda, M ............................................. 1703Fukushima, S .......................... 742, 746, 750Fukushima, T ...............129*, 531, 543, 1899Fukushima, Y .......................................... 544Fukuto, J M .............................................1168Fukuzaki, K ................... 496, 826, 833, 1094Fullard, M .............................................. 1973Funatake, C J ........................................1873*Fung, W ................................................. 2195Furlong, C E .................................. 968, 1949Furnes, B .................................................. 739Furr, J .................................. 1374, 1743, 1744Furuhama, K ................................... 267, 812Furuhashi, K ..........................................278*Furukawa, E .................................... 175, 631Furukawa, T ............................................ 708Fuscoe, F C ............................................ 1381Fuscoe, J C ............................121, 563*, 2222

GGadagbui, B ................................. 1477, 2094Gagne, P V ............................................. 1556Gagnon, N ............................................... 244Gaido, K W .......................... 276, 1372, 1729Galambos, E S ....................................... 1784Galbert, L ............................................... 1042Gales, T L ................................................. 536Galinsky, R .............................................. 325Gallagher, E P ........................................ 2244Galli, C L .....................................1888, 2247*Galliard, N ....................................... 203, 480Gallicchio, L ............................................ 422Gallo, M A ............................................... 721Galloway, S .........................................7A, 7BGallucci, R ............................................2182*Gammon, D W .............................283, 2152*Gandelsman, V Z ................................... 701Gandolfi, A .............................................1161Gandolfi, A J .................................... 146, 147Gandy, J ...........................................424*, 706Ganem, G ............................................... 1095Ganey, P E .............................. 69, 1930, 2052Ganley, K ............................................... 1632Gannon, S ...............................................236*Gannon, S A ................................ 1578, 1686Ganter, B .........................................126, 514*Gantt, J A ............................................... 1702Gao, D .....................................................895*Gao, J .......................................................892*Gao, S ..............................................574*, 941Gao, X ....................................................... 542Gaoua, W ................................................. 265Garabedian, C ....................................... 1275Garcia, H D ........................................... 1149*Garcia, R .................................................. 427Garcia, S J ........................................595*, 599Garcia-Arenas, G .................................... 253Garcia-Chavez, E ...................................603*Garcia-Vargas, G ..................................... 253Garcia-Vargas, G G ................................252*Gardinali, P ........................................... 1588Gardner, C ............................................1054*Gardner, J ....................................... 246, 1898Garg, R ................................................... 1294Gargas, M ........................................ 233, 240Gargas, M L .................... 231, 232, 234, 235, ............................................ 236, 237, 238, 347Garino, M .............................................. 1780Garner, C .......................................732*, 1252Garner, C D ........................1185, 1187, 1516Garrett, C M .......................344, 2178*, 2179Garrett, M .............................................. 1973Garrett, R ..............................................1867*Garrett, S H .................................616*, 1606, .............................................. 1614, 1616, 1618Garrett-Engele, P .................................... 287Garrick, M D ..........................................1144Garrison, A ............................................ 1082Garry, M ................................................1387*Gartner, T ..............................................1642*Garza-Ocanas, F ................................... 1412Garza-Ocanas, L ................................... 1412Gasiewicz, T A ........ 84, 97, 555, 1867, 2046Gatlin, C L ............................. 64, 1005, 1900Gatto, G J ................................................. 471Gauger, K ............................................... 1775Gauger, K J ...........................................1741*Gauthier, C ............................................ 2135Gautier, J .........................................114, 2131Gavett, S H .......................... 448, 1714, 1715Gaviola, B ................................................ 793Gaviola, B P ..................................... 775, 788Gearhart, C A ............................................ 50Gearhart, J ..............................................785*Gearhart, J M ....................... 786, 1305, 1719Gebhart, A ..................................2101*, 2104Gehman, E ............................................. 1998Geiss, K T ............................................... 1719Gelbke, H ............................................... 1563Gelein, R .......................................... 443, 698Gelein, R M .............................................. 223Gelinas, C ................................................ 195Gelineau-van Waes, J B ...............684*, 1396Gellein, K ................................................. 595Geller, A ................................................... 858Geller, A M .......................1942*, 2088, 2093

Gelzleichter, T R ....................................806*Gemzik, B .............................................. 1768Genell, C .................................................. 873Genell, C A .............................................. 179Geng, W ................................................... 872Gennings, C .................................... 389, 408, .........................1292*, 1382, 1759, 1934, 2161Gensburg, L ........................................... 1093Genter, M ................................................. 103Gentry, P .................................................. 350Gentry, R .................................................. 261Geoly, F .................................................... 540Georg, G I .............................................. 2048George, M .................................... 2144, 2146George, O ............................................... 1736George, S M ..........................................1710*Georgieva, N I ........................................523*Gephart, L A .......................................... 1480Gerberick, F ..............1196, 1198, 1201, 1999Gerberick, F G ........................................1197Gerecke, D R ................................780*, 2171Gerin, M ................................................... 244Gerl, M ..................................................... 510Gerlofs-Nijland, M E ...................929, 1446*Germer, S ..............................................2061*Germolec, D R ................... 5, 362, 878, 1212Gerson, R ............................................... 2210Gettings, S D ......................................... 1631Ghanayem, B ........................................... 732Ghanayem, B I .....................361*, 728, 1794Ghanem, M M ........................................360*Ghantous, H .........................................1995*Ghio, A J ..................................................640*Ghosh, D .................................................. 622Giavini, E ............................................... 2247Gibbons, D R ........................................... 357Gibbs, A C ...............................................538*Gibson, A B ............................................ 1585Gibson, D P ........................................... 2209Gibson, G ................................................. 580Gibson, J E ............................................2227*Giddabasappa, A .................................. 1061Giddings, A M ...................................... 2160Gideon, K M ............................................ 919Giera, S ................................................... 1741Gies, R A .................................................1150Gieseke, C ............................................. 1115*Giesy, J P ................................................ 2150Gigliotti, A ............................................... 455Gil, J .......................................................... 907Gilbert, K ................................................. 172Gilbert, M E ............................................982*Gilbert, S G ............................................ 1678Gildea, L ............................................... 1198*Gilkison, I .............................................1466*Gill, S S ....................................................... 59GIllam, M P ............................................. 987Gillardeaux, O ................................ 560, 577Gillespie, A .............................................524*Gillespie, A M ....................................... 2270Gillies, P ....................................................40*Gillilland, C ........................................... 2098Gilman, M S ................................. 273, 1121*Gilmour, I .................................... 1214, 1894Gilmour, M ..............308*, 639*, 1015*, 1896Gilmour, P S ............................................ 441Gilmour, S .............................................. 1514Gilotti, A C ............................................2012*Ginsberg, G ........................................... 1978Ginsburg, D ................................1512, 2267*Gioda, A ........................................445*, 1893Giordano, G ............................................. 967Giroux, C ............................................... 1377Giroux, C N ..........................................1378*Giulivi, C ............................................... 1717Gladen, B C ........................................... 1333Glass, D F ..............................................1479*Glauert, H P ................................ 1487, 1488Glaze, E .........................................466*, 1782Glaze, E R .......................... 1776, 1777, 1778Glenn, A E .............................................. 1395Glenn, K ....................................... 1404, 1671Glesne, D A ............................................ 1035Glynn, P ....................................... 1938, 1967Go, Y ......................................................... 820Goad, J ..................................................... 809Gobbers, E .................................. 1123*, 1366Godard, C ................................................ 487

AU

TH

OR

IND

EX




Godin, S J ......................................850*, 1250Godwin, D ............................................... 325Goedken, M ........................................... 1051Goering, P L .......................................... 2136Goetz, A K ........................2143, 2148*, 2151Gogal, R M .............................................887*Gogvadze, V .......................................... 2276Gohlke, J M .............................................346*Goins, S .................................................... 103Gold, A ........................................... 500, 1847Gold, E P ............................................... 1101*Gold, P W .......................... 1776, 1777, 1778Goldberg, B B ........................................ 1742Goldman, J M ............................... 547, 1119*Goldsmith, T ......................................... 1468Goldstein, D A .....................................1344*Goldstein, R A ......................................... 532Goldston, T ............................................ 1309Goldsworthy, T L .................................. 1302Golka, K ......................................1264, 1269*Gollapudi, B .................................2211, 2224Gollapudi, B B ............................... 585, 1041Goncharova, T ...................................... 2206Gong, B ...................................................825*Gonsebatt, M E ....................................... 139Gonzales, C ..................................1160, 2071Gonzalez, B ........................................... 2300Gonzalez, I ............................................... 576Gonzalez-Villalva, A .....................608, 1153Gooderham, N J .................................... 2264Goodfellow, G H ................................... 1408Goodin, M G ........................................... 707Goodman, J ..................................982, 1270*Goodman, J I ......................669, 1786, 1787*Goodsaid, F ........................................... 1381Goodwin, S ............................ 93, 2044, 2056Goodyear, A W ....................................... 504Gooler, D M ........................................... 1085Goozner, M ...........................................1682*Gopee, N V .........................502, 2185, 2187*Gopinathan, L ..........................................54*Gorbunov, N ........................................... 767Gordh, T ................................................. 1073Gordon, C J ...........................................2092*Gordon, J D ................................1752*, 2049Gordon, M K ........................................... 780Gordon, N ..............................................1145Gordon, T ...............................303, 305, 1129Gore, E R .................................................166*Gore, L ...................................................... 173Gorelik, O ........................................ 701, 702Gorman, N ............................................... 218Goshe, M B ............................................ 1702Gosselin, S J ................................. 1641, 2031Goto, K ....................................................267*Goto, T ................................................... 1928Gould, S ................................................... 824Gould, T ................................................. 1453Gowdy, K M .........................................1896*Gower, J K ............................................... 166Goytia-Acevedo, R ................................253*Graf, M L ................................................. 905Graff, D .................................................. 1450Graff, J E ................................................ 1091Graham, B ................................................ 508Graham, D L .........................................1544*Graham, J ................................................. 210Graham, S A ............................................ 987Graham, S L ........................................... 2265Graham, T ...............................................2112Grainger, S .........................463*, 1106, 1173*Gralinski, M ............................................ 839Grandjean, P .......................................... 1055Grant, D ................................................. 1924Grasman, K A .......................................... 888Grasty, R C ............................................1647*Graves, S ....................................... 391*, 1181Graves, S W ......................... 194, 1233, 1234Gray, C A .................................................... 44Gray, D T ............................................... 1110*Gray, J ..................................................... 1537Gray, J P ..................................54, 217, 1398*Gray, L E ...........................1374, 1743, 1744*Graziano, M ............................................ 529Greaves, P ...............................................1110Green, J L ............................................... 1048Green, S .................................................. 1945Green, T ................................... 743, 744, 745

Greene, A L ............................................ 1717Greenfeld, C .................................1109, 1367Greenlee, A R .........................................682*Greenwell, R J ......................................... 686Gregory, G S ............................................ 797Gregus, Z ........................................140, 149*Greim, H ................................................ 1241Griffin, D .................................................. 493Griffith, W C ................................346, 1303*Grindstaff, R .......................................... 1819Griswold, J ............................................. 1309Grivas, P C ................................................. 72Groom, C J ............................................. 1639Groom, S ...............................181*, 479, 1460Groothuis, G M ..................................... 1913Gross, C L ...............................................777*Gross, E A .............................................1295*Gross, J A ..............................................1757*Gross-Steinmeyer, K ...........................1495*Groten, J ................................................. 1560Grubbs, R D ............................................789*Grundy, J G ...................................2211, 2224Grzemski, F ............................................530*Gu, J ...............................................723*, 1567Gu, X .......................................................721*Guadarrama, J C ..................................... 603Guallar, E ................................................. 430Guan, H ................... 1308, 1309, 1402, 1595Guan, X .................................................... 961Guarisco, J A .........................................1407*Gucer, P .................................................... 165Gudi, R ................................................... 2210Guengerich, F P ...................................1675*Guerriero, F J ..................................372*, 472Guest, R L ...................................2006, 2009*Guidotti, T L ............................................ 381Guigonis, J ............................................. 1732Guilarte, T R ...........52, 631, 673, 678*, 1542Guilfoil, A J ............................................ 2174Guillot, T ...............................................1097*Guillot, T S ..................................... 973, 1961Guindon, K A .......................................2265*Guiney, P .................................................. 370Guiney, P D ........................................... 1758Guizzetti, M ...........................................967*Gulumian, M ........................................1864*Gunasekar, P G ....................................... 622Gundersen, H .............................. 1056, 1057Gunnare, S ..............................................906*Guns, E ................................................... 1747Guo, C ................................................... 2117*Guo, L ....................................................1912*Guo, T L ......................878, 891, 1212, 1716*Guo, W ..................................................1264*Guo, Y .....................................................348*Guo, X .....................................................171*Guo-Ross, S ............................................972*Gupta, R ............................1759*, 1760, 1952Gupta, R C ........................... 215, 809*, 996*, ...................................1000*, 1600, 1601, 1799Gupta, R K ............................................2153*Gustaffson, J .............................................. 57Gustafson, S C ......................................... 526Gustafsson, J ................................... 59, 1365Guth, D .................................................... 869Guthrie, K .............................................. 1720Gutierrez, M E .....................................1455*Gutierrez-Valdez, A ................................ 608Gutjahr-Gobell, R E .............................. 1745Gutting, B W ..........................................769*Guvenc, G .............................................. 1273Guzman, M ........................................... 1436Gwiazda, R .............................597, 598*, 630Gyamfi, M ................................... 1050, 1766

HHa, P ......................................................... 480Haasch, M L .......................735*, 1280, 2253Haataja, H .............................................. 1885Haber, L T .......................................373*, 379Habermann, G ............................. 168*, 1105Habib, N .................................................. 926Hack, C .................................................... 847Hadjout, N ....................................... 507, 894Hafner, J H ............................................. 1862Hageman, G ............................................ 426

Hagiwara, A .........................742*, 746, 1388Hahn, F F ........................................162*, 164Hahn, M E ....................................... 94, 1359Haighton, L A ........................................ 1408Hailey, J R .............................................. 1800Haines, W T ..................................966*, 2095Hakkinen, P J .......................................... 379Hakulinen, P ........................................... 749Hakura, A .............................................. 2213Hale, C S .................................................. 960Haley, J D ................................................. 338Haley, P J .................................................173*Haley, R .......................................1036, 1737*Halinen, A .............................................. 1881Halinen, A I ................................... 436, 1895Hall, A H .................................................. 487Hall, J O ................................................. 1407Hall, K W ..................................................72*Hall, M L ................................................ 1436Halladay, A K .........................................983*Hallberg, C .............................................. 727Halleema, F ............................................. 247Hallmark, N .......................................... 2258Halpen, A M ............................................ 178Halsey, T ................................................ 1222Halsey, T A ...........................................1218*Halstead, B .............................................. 519Halvey, P J ..............................................820*Hamada, Y ..............129, 531, 543*, 831, 837Hamade, a k ...........................................442*Hamadeh, H .......................................... 1784Hamadeh, H K ........................................ 121Hamid, R ............................................... 1631Hamill, C ..............................................1529*Hamilton, B F .......................................... 491Hamilton, J W ................................. 133, 154Hamilton, S B .............................. 2044, 2056Hamlin, R ...............................................340*Hamm, J ................................................. 1517Hamm, J T .......................... 923*, 1186, 2229Hammer, F ................................... 2101, 2104Hammock, B D ....................................... 106Hammond, B ........................................1404*Hammond, B G ........................ 1669*, 1671*Hammond, J A ........................................ 269Hammond, T ......................................... 1072Han, D ...................................................1432*Han, E .....................1421*, 1430, 1431, 2163Han, M ................................................... 1215Han, S .................................. 256, 1157*, 2290Han, T .......................563, 1098, 1099, 2222*Hancock, S ............................................... 161Hancock,, S .............................................. 600Hanig, J .......................................... 263, 2285Hanig, J P ..................................... 1513, 1842Hanley, T R .............................................. 585Hanlon, P ........................................828*, 829Hann, E .................................................1422*Hansen, D ................................................ 509Hansen, J M .......................... 820, 979, 1158*Hansen, S C ........................................... 1242Hansen, T N .......................................... 1854Hanson, J ............................................... 1916hanson, N ................................................ 540Hanson, R G .................................. 280, 1232Hanton, G ................................................ 830Happo, M S ............................................436*Haque, M ................................................932*Hara, H .................................................... 281Harada, K .................................. 175*, 2063*, .............................................2064*, 2067, 2068Harada, T ........................................831*, 837Harada, Y ............................................... 2037Harbell, J ...........................................10*, 484Harbell, J W ................................. 1630, 2001Harbison, R D ........................... 72, 419, 420Harbo, S J ............................... 506, 919, 1705Hardej, D ....................................... 609, 1827Harder, J ................................................. 1777Hardin, B D ........................................... 2096Hardy, C ................................................... 887Hardy, M .....................................1257*, 1597Hargreaves, A ...................................... 1511*Hargreaves, A J ..................................... 1950Harkema, J R .......................... 347, 438, 439, .............................449*, 876, 1363, 1771, 1772Harleman, J ............................................... 61Harling, R J ............................................ 2028

Harmon, A W .................................. 135, 148Harmon, R ............................................. 2134Harney, A ............................................... 1759Harney, A S ............................................ 1772Harper, C E ...........................................1493*Harpur, E ............................................11, 669Harreman, M T ....................................... 656Harrill, J ................................................2162*Harriman, J F ........................................ 1397Harris, A J ................................................ 424Harris, C ............................. 979, 1140, 2256*Harris, C C ............................................ 1270Harris, D T ................................................20*Harris, E ................................................. 1089Harris, P S .............................................. 1598Harris, R ................................................ 2069Harris, W ............................................... 1950Harris, M A .............................................392*Harrison, J ............................................. 1070Harrison, L R ......................................... 1588Harrison, R ............................................ 1568Harrison, S ............................................... 362Harrod, K S ............................................. 460Hartgring, S ........................................... 1057Hartgring, S A ....................................... 1056Hartings, J M ......................................... 1470Hartman, H E .......................................1634*Hartmann, A ..........................................336*Hartmann, E .......................................... 1735Hartmann, L M ........................... 1818, 2225Hartnell, G ............................................. 1671Hartung, T ............................ 660*, 664, 665*Haruyama, M .......................................... 826Harvey, A ................................................1411Harvey, E ........................................518*, 539Harvey, R G ........................................... 1043Harvison, P J ............................. 70, 81, 2123Hasan, A .................................................. 713Haschek, W M ..........................1310*, 1312, .............................................. 1314, 1315, 1929Hasegawa, R ......................................... 1428Hasegawa, T ......................................... 1152*Haselden, J N .......................................... 491Haseman, J ............................................ 1628Haseman, J H .........................................662*Haseman, J K ........................................ 1506Hashemi, S B ......................................... 1551Hashim, G ............................................... 622Hashimoto, K .......................................... 837Haskins, J R ........................................... 1851Hassani, M ............................................1796*Hasse, R F .............................................. 1988Hassing, I ............................................... 1892Hassler, C ................................................342*Hasson, R ............................................... 2242Hassoun, E A ......................................... 2033Hastings, K L ........................................1347*Hasumura, M ........................................ 1503Hatcher, J M .........................................1961*Hattan, D G ..............................................39*Hattenbach, S A .................................... 1362Hattis, D ................................................1978*Hauschild, V ..........................................329*Haussmann, H ...................................... 1518Havel, P ................................................... 210Havics, A .....................................1475*, 1477Hawkridge, F M ..................................... 796Hawks, R ................................................808*Hayakawa, T ........................................... 151Hayashi, S ................................................ 175Hayashi, T ..................................... 270, 2205Hayden, P J ...................... 1171*, 1254, 2002, ........................................................ 2003, 2191Haykal-Coates, N ......................... 448, 1213Hays, A ....................................................154*Hays, A M ........................................ 143, 157Hays, S ............................................258, 1149Hays, S M .......................................351*, 871Hazen, S ................................................1322*He, B ......................................................... 499He, J .......................................................... 709He, L ................................... 524, 1050, 1165*, ...................................1290, 1766, 1918*, 1919He, Q .....................................76*, 1389, 1434He, W ....................................................... 686He, Y ......................................................... 121Healey, L B ..............................................888*Healy, L .................................................. 1784

232

AU

TH

OR

IND

EX




Hearne, G .............................................. 1864Hearnes, J .............................................. 1810Hebert, P .........................................898*, 899Heck, D .................................................. 1517Heck, D E ..................217, 1398, 1537*, 2171Heck, J D .................................................1186Hedge, J ................................................. 2039Hedge, J M ............................................. 2162Hedley, J ........................................1173, 1177Heffernan, J K ........................................800*Heflich, R H ............................................ 747Hege, A .....................................................60*Hege, A I .................................................. 774Heideman, W .................. 88, 91, 1824, 1825Heijne, W ............................................... 1560Hein, D W .......................... 1265, 1266, 1267Heinloth, A ............................................ 1855Heinloth, A N .........................................127*Heinz, J .................................................... 613Hejtmancik, M ....... 1181, 1425, 2035*, 2070Held, G ..................................................... 680Hellerstein, M ....................................... 1898Hemmer, M J ......................................... 1598Henderson, A .......................................... 356Henderson, I ............................................811Henderson, J D ..................................... 1278Henderson, R ............................................ 21Henderson, W M .................................2065*Hendrich, S .................................. 1316, 1385Hendricks, J D ......................................... 758Hendrickson, J ...................................... 1717Hendry, L B ........................................... 1040Henk, W ................................................. 1441Hennes, E C ............................................. 271Hennig, B ............................................... 1838Henry, E C ................................................84*Henry, M M ........................................... 1856Henry, S H ..............................................296*Henry, S P .................................................16*Henshel, D S .......................................... 2245Hensley, S C .................................1801, 2118Herbert, K ................................................ 540Herlich, J .......................................... 569, 755Herman, E H ......................................... 1842Hermann, E ........................................... 1912Hernandez, A ................................ 153, 1329Hernandez, D M ..........................891*, 1716Hernandez, L G .....................................730*Hernandez, M ......................................... 427Hernandez-Ochoa, I ............................ 1147*Herouet, C ............................................. 1307Herr, D W ...................................1091*, 1335Herreno-Saenz, D ................................. 2219Herring, S .............................................. 1042Herzyk, D J ...................... 166, 179, 873, 910Hescheler, J ............................................ 1996Hess, K ................................................... 1719Hess, K M .............................................. 1371Hess, R ................................................... 1373Hess, R A ................................................. 546Hessner, M ............................................. 2238Hester, S ......................................2149*, 2162Hester, S D ............... 1816, 2144, 2146, 2147Hesterberg, T .......................................... 418Hesterberg, T W ....................................400*Heussner, A ................................ 2113*, 2115Hew, K ....................................................914*Hew, K W .............................................2214*Heyer, N J .............................................. 1275Heyliger, S O ........................................1945*Hicks, S M ..............................................554*Hidestrand, M ............... 74, 274, 1036, 1737Hierlihy, A ......................................128, 568*Higa, T ....................................................... 94Higashimoto, M .................................... 1615Higgings, L ............................................ 1755Higgins, A .............................. 527, 537, 1557Hijioka, M ................................................ 833Hilakivi-Clarke, L A ..............................300*Hill, A J ......................................................91*Hill, B ..................................................... 1844Hill, C E ......................................1274*, 2236Hill, G D ................................................. 1800Hillegas, A ............................................... 873Hillegas, A E ...........................................179*Hillegass, J M .......................................2239*Himeno, S .............................................1612*

Himmelstein, M W ........................ 230, 231, ...................................................234*, 235, 236Hinckley, J ....................................... 161, 600Hinderliter, P M .....................................866*Hines, C ................................................1243*Hines, E P .............................................1369*Hines, M D ............................................ 1631Hines, R ................................................... 259Hines, R N ................................ 1974*, 1975*Hinson, J A .............................................. 224Hinton, D E ........................................... 1582Hintze, C J ............................................. 1593Hirabayashi, Y .....................................1380*Hiraga, T ................................................ 2037Hirano, S .........................................151, 1164Hirao, J ....................................................708*Hiratsuka, H ......................................... 1459Hirner, A V .................................. 1818, 2225Hiroki, I .................................................. 1501Hirose, A ........................................ 281, 2155Hirose, M ................. 1406, 1428, 1503, 1861Hirst, G C ................................................. 462Hirvonen, M ................................. 436, 1879, .............................................. 1880, 1881, 1895Hitchcock, J ........................................... 2205Hitchman, K ............................................ 921Hite, P ...................................................... 413Hitt, J E ....................................................1176Hlavacova, A ......................................... 2272Ho, E ......................................................... 930Ho, H .......................................................813*Hoadley, K ..............................................123*Hoagland, M ......................................... 1805Hoang, Y D ........................................... 1117*Hoberman, A ......................................... 1738Hoberman, A M .................. 804, 1075, 2193Hochberg, K ............................................ 695Hodel, A E ............................................... 656Hodge-Bell, K C .....................................506*Hodges, N ............................................. 2234Hodgson, E .............................. 358, 726, 781Hodson, P ................................................ 687Hoeger, S ...............................................2099*Hoel, D G ............................................... 1559Hoet, P ................................................... 1712Hoffler, U ..............................................1794*Hoffman, H B ........................................ 1767Hofmann, M .......................................... 1625Holcombe, G ......................................... 1755Holcombe, G W .......................... 1754, 1756Holian, A ........................................ 908, 1890Holifield, N ........................................... 2159Holladay, S .............................................. 884Holladay, S D ...............................685*, 2261Holler, J .................................................. 1481Holley, G ................................................ 1623Hollingshead, B D .................................. 657Hollingsworth II, J W ............................ 928Holloway, G .......................................... 1634Holm, S E ............................................... 2084Holman, T ................................................ 630Holme, J A ............................................. 2287Holmes, A L ........................ 160, 1134, 1145*Holsapple, M ........................................ 1868Holsapple, M P .......................... 666*, 1695*Holson, J F ............................ 3*, 3*, 239, 240Holt, S ...........................................915*, 1464Homiski, M ........................................... 2233Honchel, R ............................................. 1513Honda, A ................................................1611Hong, S ..................................194, 382, 1155, .............................................1233*, 1234, 2257Hong, S K .............................................. 2121Hong, S M .............................................. 2183Honma, M ............................................2213*Honma, T ......................................542, 1080*Hood, D B .............................................. 1089Hood, R D .......................................... 3, 1067Hook, S .................................................. 1586Hooks, W ..............................................1639*Hooser, S B .............................................. 501Hooson, J ................................................. 480Hooth, M .......................... 1181, 2035, 2070*Hoover, D .............................................. 2134Hoover, S ..............................................1521*Hope, B ...................................................330*Hopke, P .................................................. 443Hopkins, N E .........................................356*

Hoppin, J A ............................................ 1333Horai, H ................................................... 496Horai, N ..................................................496*Horais, K .................................................1103Horand, F ................................................ 885Horie, K ................................................... 605Horiguchi, H ......................423, 1456, 1610*Horii, I ............ 129, 531, 543, 831, 837, 1899Horn, T L ..............................................1778*Horner, M ...............................................499*Hornung, M W ....................................2254*Horohov, D ............................................ 1012Horowitz, M ...........................................1107Horsmon, M ............................................ 793Horwitz, B P .......................................... 2127Hosdeshell, K ........................................ 1743Hossain, M M .............................1954, 1966*Houle, C D ............................................. 1781Houpt, J T .............................................2203*House, D .................................................. 863House, R .......................................467, 1348*House, R V ..................................... 810*, 811Hovland, D ............................................ 1373Howard, P C ..................................502, 652*, .............................................1565*, 2185, 2187Howard, W ............................................ 2097Howd, R A ............................................. 2105Howden, R ...................................... 828, 829Howell, K ............................................... 1591Hower, M ..................................................114Howlett, N ............................................. 2233Howroyd, P ......................................58, 581*Hoyer, P B ...............................................1120Hrubec, T C ............................................. 685Hrycay, E G ........................................... 1491Hseu, T ................................................... 2020Hsiao, S .........1310, 1312, 1314, 1315, 1929*Hu, C ...................................................... 2020Hu, C X .................................................... 536Hu, J J ......................................................301*Hu, S ......................................................1235*Hu, W ....................................126, 353*, 1700Hua, Y .................................................... 1528Huang, C ................................................. 305Huang, Y .................................................... 93Hubbard, A K ........................................ 1915Hubbard, J ............................................... 172Hubbs, A F ............................. 360, 701, 1443Hudgens, E E .......................................... 692Hudson, L G ...........................................1167Hudson, R T .........................................1598*Hueber, S M ..........................................1877*Huebner, H J ........... 1283, 1309, 1400, 1402Hueni, S E .............................................. 2127Huffman, L .............................................933*Huggett, T ............................................1626*Hughes, A ................................................ 732Hughes, B ...............................................413*Hughes, J ................................................. 503Hughes, M F ................................... 850, 864, .............................................1231*, 1250, 1568Huldermen, T ......................................... 705Hulet, S W ......................................775, 788*Hulette, B C ............................................1198Huljic, S ................................................. 2116*Humes, D G ................................ 1760, 1772Hummelke, G C ...................................1587*Humphrey, A ......................................... 1810Hung, C ................................................... 566Hunt, A .................................................. 1801Hunter, D L ................................... 966, 1335, .............................................1939*, 1940, 2095Hunter, P M ..........................................2080*Hunter, S ...............................................2248*Hunter, S S ............................................. 2255Hunter III, E S ......................................... 683Hurban, P .........................................119, 537Hurley, T D ............................................ 1723Hurst, H E ............................................... 516Hurtt, M E ......................................273, 1121Husain, K ................................................222*Hussain, S ...................................1625, 1719*Hussey, E ............................................... 1833Hutcheson, M S .................................... 2106Huttunen, K .....................1879, 1880, 1881*Hutz, R ................................................... 2238Hwang, E ..............................................2164*Hwang, J ........................................ 305, 2164

Hwang, Y ......1421, 1431, 1524, 1525*, 1531Hyun, S .............. 717, 890, 1417, 1574, 1575

IIan, G .....................................................1465*Iatropoulos, M J ...........................741, 1500*Ichihara, G ............................................... 278Ichihara, T .............................................. 1388Ichimura, T .............................................. 197Ichisaki, S ................................................. 826Igarashi, K ............................................. 1380Ihnat, M A ...............................................1162Iida, M .................................................... 1727Iijima, T .................................................. 2063Ikeda, N ................................................. 1399Ikeda, T .................................................... 176Ikeda, Y .................................................... 423Illouz, K ................................93, 2044*, 2056Imai, N ..................................................... 746Imai, T ...................................................1503*Imaida, K ............................................... 1471Imaoka, M ..............................................812*Imazawa, T ............................................ 1406Inada, K ................................................... 945Inayat-Hussain, S H ................................47*Inayat-hussain, s h ..............................2276*Ingerman, L ................................. 1483, 2082Ingram, L ................................................. 133Inhof, C ................................. 662, 663, 1997, .............................................2005*, 2007, 2008Inman, A ................................................ 2180Inman, A O .................................2183, 2184*Inoue, A .................................................. 1432Inoue, K ....................................... 2064, 2068Inoue, T .......................................1380, 1633*Inoue, Y .......................................... 459, 1703Ionescu, M ..............................................174*Iordanova, V ..................................170, 807*Ip, C .....................................1170, 1907, 1908Ireson, R ................................................... 418Ironside, J ................................................. 464Irwin, R .................................................. 1376Isaacs, K R ................................................118Isbrucker, R ..........................................1429*Ise, R ....................................................... 1432Ishii, Y .......................................... 1406, 1861Ishino, F ................................................... 556Ishitobi, H ...............................................1611Islamzadeh, A ....................................... 1290Isobe, M ................................................. 1617Isola, D ....................................................1182Isola, D A ................................................1183Isom, G E ..................................... 1543, 2279Itagaki, H ......................................1192, 1193Itai, A ...................................................... 1703Ito, K ............................................... 708, 1433Ito, T ..............................................130*, 2043Ito, Y .................................... 1192, 1193, 1194Itoh, K .......................... 459, 816, 1833, 1861Itoh, N .................................................... 1617Itoh, T ......................................................604*Itzhak, Y ................................................. 1989Ivanov, V ................................................ 1494Iversen, P ............................................... 1246Ivnitski-Steele, I D .................................. 845Iwasaki, N ............................................. 1703Iwashita, K ............................................ 1928Iyer, P R ...................................................283*

JJaar, B G ..................................................1148Jabbour, J .................................................. 492Jackson, D .............................................1998*Jackson, D A .......................................... 2017Jackson, E R ............................................533*Jackson, G R ............................... 1171, 2003*Jackson, K .............................................. 1570Jacob, H .................................................. 1897Jacob, S ..........................................214, 1076*Jacobs, A .................................... 1026*, 1694*Jacobs, A C ....................................... 10, 1692Jacobs, J J ................................................ 2199Jacobs, J M ............................................... 137Jacobsen, M ............................................1511Jacobson-Kram, D ......... 7A, 7B, 672, 1027*

AU

TH

OR

IND

EX




Jacocks, H ...............................................1101Jaeckh, R ...................................... 2251, 2252Jaeschke, H ...................................... 63, 1053Jahng, Y .............................. 1574, 1575, 2263Jahun, J ....................................................475*Jain, A K ..................................................819*Jaiswal, A K ..................................... 818, 819Jakasa, I .........................................867, 1249*Jakel, R J ........................................220*, 1523Jakubowski, E ................................. 776, 785Jakubowski, E M ..........................773, 775*, .................................................... 786, 787, 794Jalava, P ........................................436, 1895*James, A ................................................... 863James, A R .............................................. 1463James, J T ................................................650*James, L P .................................................. 68James, M .......................................1113, 1596Jameson, R R ........................................1068*Janer, M .................................................. 1271Jang, G ...................................................... 467Januszkiewicz, A .................................... 767Jaques, P ................................................. 1453Jarabek, A ...............................................2110Jarabek, A M ...........1295, 1304, 1342*, 1467Jarema, K A .................................1437*, 1438Jarman, K H .......................................... 1705Jarnagin, K ............................................... 121Jarvis, J ............................................. 776, 787Jarvis, J R ................................................. 788Jaskot, R H ............................................... 441Jaspers, I ...................... 447, 930*, 942, 1018*Jasti, S L .................................................... 284Jayara, K .................................................. 500Jayaram, B ............................................. 2069Jayyosi, Z ........................................114, 2131Jean, P A ............................1507, 1510, 1812*Jefcoate, C .............................................. 2047Jefcoate, C R ...........................................1164Jeffcoat, A ................................................. 732Jefferies, D ..................................1201, 1293*Jefferson, W ..................................260, 1370*Jeffery, E H ................................................. 65Jeffrey, A M ...................................741*, 1500Jeffries, H ......................................... 930, 942Jeng, C .....................................................1190Jeng, W ................................................... 1077Jenkins, C M ............................................ 696Jenkins, S ................................................. 512Jennings, L ............................................... 997Jennings-Gee, J ...................................... 1792Jensen, K M ........................................... 1746Jensen, N S ............................................. 2014Jeon, T ...............717*, 890, 1417, 1574, 1575Jeon, Y J .................................................1413*Jeong, H ...................890, 1409, 1415*, 1416, ......................... 1421, 1422, 1423, 1426, 1427, ......................... 1430, 1431, 1524, 1525, 1531, .................................... 2163, 2165, 2168, 2169Jeong, T ................................. 717, 890, 1417, .........................1421, 1431*, 1574, 1575, 2263Jeong, S ................................................... 111*Jerat, S ...................................................... 480Jernigan, J J ............................................ 1067Jia, L .......................................................... 466JIA, N ....................................................... 542Jia, Z ........................................................2119Jiang, H .................................................1815*Jiang, J ...............................2284, 2294, 2295*Jiang, L ....................................................1311Jiang, S ..........................................748, 1613*Jiang, W ................................. 714, 756, 1845Jikuzono, T .............................................. 833Jillian, D H ............................................. 1783Jimenez, I ................................................. 603Jimenez, L .............................................. 1907Jimenez Velez, B D ............................... 1893Jimenez-Velez, B D ................................. 445Jin, C ..................717, 890*, 1417, 1574, 1575Jin, G ................................................. 196, 894Jin, L ........................................................1165Jin, X ......................................................... 305Jindo, T ..................................................... 267Jirtle, R L .................................................. 572Joad, J P ........................................ 1014, 1645Johansen, M E ..............................937, 1219*Johanson, G ...........................352*, 853, 868, ................................................ 906, 1248, 2198

Johansson, N ........................................2062*Johnson, D A ......................... 220, 814, 1852Johnson, D J ........................................... 1945Johnson, E .............................................. 2240Johnson, E W ................545, 783, 792*, 1883Johnson, F ................................................ 970Johnson, F O ...........................................969*Johnson, J ................................................719*Johnson, J A ...................220, 814*, 984, 985, .......................... 1079, 1522, 1523, 1721, 1852Johnson, J D .............. 194, 1181*, 1233, 1234Johnson, J E ..........................................1061*Johnson, J M ...........................................287*Johnson, K ............................................... 844Johnson, M D .........................569, 755, 1174Johnson, R ............................................... 408Johnson, R D ......................................... 2254Johnson, S .............................................. 1089Johnson, V ............................................... 701Johnson, W D .............................1777*, 1778Johnson, W H .......................................... 159Jokinen, M P .......................................... 1506Jollow, D J ................................................ 207Jolly, P E ................................................. 1283Jones, A .................................................... 345Jones, A D .................................................. 89Jones, B C ............................................... 1631Jones, C .................................................. 2147Jones, D P ........................................820, 1158Jones, H .......................................... 824, 1843Jones, L ..................................................... 540Jones, P D ............................................... 2150Jones, R ...........................................247, 493*Jones, R D .................................... 1637, 1642Jones, T ..................................................... 784Jonker, D ................................................ 1560Jordan, H L .............................................. 491Jordan, V ................................................ 1807Jortner, B .................................................. 600Jortner, B S ................161, 1090*, 1943, 1944Jose, J .......................................................... 44Joseph, P ..................................... 1163*, 1166Joung, K E ........................................ 202, 720Jovanovic, M L ...................848, 1508*, 1509Joyner, D R ............................................ 1295Juberg, D R ...........................................1338*Jun, I ..................717, 890, 1417*, 1574, 1575Jung, C T ................................................ 2177Jung, K ........ 1415, 1416*, 1426*, 1524, 2168Junker, U ................................................ 2010Juretschke, H ....................................114, 510

KKabaroff, L C ..........................................883*Kabiri, M ...............................................2302*Kabirov, K ...............................................489*Kadambi, V J ......................................... 2027Kadiiska, M ..................................759, 1321*Kadry, A M .............................................242*Kaefferlein, H U .................................... 1282Kaetzel, R S .............................................. 693Kaewamatawong, T ............................... 700Kagan, V E ................ 701, 2188, 2282, 2283, .......................... 2284, 2294, 2295, 2296, 2297Kahl, M D .............................................. 1746Kai, M ....................................................... 556Kaiser, E ..................................................230*Kaiser, S J ................................................. 682Kala, S .................................................... 1060Kala, S V .................................................1137Kale, V M ..............................................2167*Kalisak, D L ........................................... 1304Kalra, R ...................................................... 21Kamal, M ............................................... 2108KAMATA, E ............................................ 281Kamboj, S ................................................. 332Kamei, N ................................................ 2068Kamel, F ......................................1332, 1333*Kamendulis, L M .........751, 752*, 760, 1787Kamenosono, T ....................................... 806Kamikawa, Y ........................................... 709Kaminski, N .........................................1868*Kaminski, N E ....................... 369, 876, 1874Kampf, J W .................................. 1936, 1937Kamuren, Z T ........................................ 1401Kan, L ....................................................... 585

Kan, Z ....................................................... 287Kanade, P ..............................................2289*Kanefuji, K ............................................. 1707Kang, H .....................................................111Kang, I .................................................... 2290Kang, J ...................................................1215*Kang, T ................................................... 2290Kang, Y ......................................... 1836, 1839Kang, Y J ............................................... 6*, 6*Kanhai, H ................................................ 606Kanki, K ......................................1406, 1861*Kannan, S ................................................818*Kannan, S - .............................................221*Kanno, J ................................................. 1380Kanthasamy, A ............................... 633, 633, .............................................. 1526, 1527, 1527Kanthasamy, A G ......................1526, 1656*, ........................................... 1985*, 1986*, 1988Kanz, M F .....................................498, 1922*Kao, L M .................................................1174Kapeghian, J .........................................1993*Kapetanovic, I ....................................... 1785Kaphalia, B S ......... 82, 912, 913, 1558, 1629Kaphalia, L .....................................469*, 498Kaplan, B L .............................................369*Kaplan, D J ............................................ 1905Kapralov, A A .............................. 2283, 2284Karakaya, A ..........................................1268*Karanth, S ........................................ 51, 1951Karasov, W H ........................................ 1757Kardas, M .................................................. 67Kari, F W ................................................ 1044Kariya, c t ..............................................1853*Karlsson, J ................................................ 162Karoly, E D .............................................683*Karrow, N ................................................ 883Kasahara, T ...............................................117Kasamatsu, T ........................................1399*Kashida, Y ......................................211, 1793Kaspareit, J ...........................168, 1105, 1636Kasprzak, K ................................... 694, 1013Kasten-Jolly, J ...............................895, 1064*Katein, A ........................................ 824, 1779Katoh, M ................................................ 1251Katsutani, N .........................................1931*Kaufmann, W .............................. 1056, 1057Kaufmann, W K .......................................119Kavanagh, T .................................... 225, 813Kavanagh, T J ...................... 579, 1271, 1859Kawabata, T ............................................ 171Kawabata, T T ......................................... 898Kawabe, M ............................................ 1388Kawahara, J ............................................. 175Kawai, K ................................................ 2188Kawamura, N ......................................... 700Kawamura, S ......................................... 1730Kawano, Y ..............................................763*Kawasuso, T .......................................... 1459Kayama, F ...........................423*, 1456, 1610Kaysser-Kranich, T ................................. 121Kayton, R J ............................................. 1549Kazim, S ................................................... 222Ke, S .................................................. 107, 721Ke, q ......................................................1789*Keane, M J ............................................2223*Kearns, S ................................................ 1210Keay, J ..................................................... 2261Keebaugh, M ........................................... 795Keegan, S P .............................................910*Keeler, G J ........................................ 438, 439Keen, C L ............................................... 1087Keenan, J J ..............................................415*Keep, R F ............................................... 1528Kegelman, T A ........................................ 951Keil, D E ..................................................882*Keita, K .................................................. 1428Keith, S ................................................... 1483Keller, L H ................................................ 275Kelley, M F ..............................................1174Kelley, R W ...................................... 725, 740Kelly, C M .............................................2031*Kelly, D P ................................................. 945Kelly, J ................................................... 1177*Kelly, J B ..................................................796*Kelly, J T ................................................... 699Kelly, T ......................................... 1626, 1779Kelman, B J ...........................................2096*Kelman, D R ...........................................555*

Kelsey, K T ..............................................1148Kemmerer, M .................................. 569, 755Kemp, C ................................................. 1804Kemper, R A .........................231, 234, 1578*Kemppainen, B W ................................ 1384Kende, A S ................................................. 84Kenne, K .................................................. 508Kennedy, G .............................................1127Kennel, P ...................................... 1731, 1732Kennett, M J ...........................................1911Kensler, T ................................................... 93Kensler, T W ........................................ 58, 59Kenyon, E M ........................856, 864*, 1231Keravec, V ............................................... 446Kerfoot, E J .............................................. 284Kerger, B D .....................................257*, 412Kerkvliet, N I ........................................ 1873Kermp, C J ............................................. 1803Kern, C ............................................597*, 598Kern, J C ......................................1522*, 1852Kern, J T ........................................220, 1721*Kern, P ....................................................1196Kernag, C ............................................... 2275Kerr, H M ............................................... 1754Kerzee, J ................................................1203*Kerzee, J K ................................... 2189, 2228Keshava, N .............................................401*Kessler, K ............................................... 2076Kester, J E ................................................350*Kettrup, A .............................................. 2050Keys, D ................................................... 2039Keys, D A ........................................402*, 847Kezic, S ......................................... 1249, 2199kezic, s .....................................................867*Khachik, F ...............................................1189Khalil, S .................................................. 1551Khan, M ................................................... 221Khan, M F ........................................ 912, 913Khan, S H ..................................................82*Khan, S I ................................................ 1588Khan, W A ......................................961*, 962Khan-Malek, R ................................ 560, 577Kiebler, Z ....................................... 209, 1718Kikkawa, R ...........................129, 531*, 1899Kikuchi, Y ................................................ 175Kikushima, Y ......................................... 1703Kim, B .............................................. 41, 1868Kim, D ..................................720, 728*, 1427, .............................................1531, 1574, 2169*Kim, D J ..................................586*, 587, 588Kim, E .......................................... 2257, 2263Kim, G .....717, 890, 1417, 1574, 1575*, 1635Kim, H .................................552*, 552*, 907*, ................................... 1043, 1215, 1217, 1247, ....................... 1421, 1431, 1905*, 2168*, 2169Kim, H J ................................................1245*Kim, J ............................41, 985*, 1415, 1416, ..................................1421, 1422, 1430*, 1431, ........................................... 2163*, 2169, 2263*Kim, J S .................................................... 202Kim, K ................................ 46*, 1245, 1247*, .............................................. 1454, 1764, 1807Kim, K H ...................................... 1803, 1804Kim, P M ................................................ 2259Kim, S ........................... 156, 188*, 379*, 428, ........................... 719, 1179, 1301*, 1454, 1635Kim, S K ................................................. 1925Kim, S S ...................................................1179Kim, T ...................................................2290*Kim, W ................................................... 1261Kim, Y ............................................ 256, 2164Kim, Y C ................................................1925*Kim, Y W ................................................. 720Kimbell, J ..............................................1304*Kimbell, J S ............................ 347, 699, 1295Kimber, I .................. 5*, 37, 124, 1196, 1198, ......................... 1200, 1201, 1204, 1206, 1207, .......1209, 1375, 1710, 1711, 1736, 1739, 1999Kimbrough, C ........................................... 59Kimmel, C A .................................. 378, 1225Kimura, K ................................................ 886Kimura, M ............................................. 2064Kimura, T .............................................1617*Kind, C ..................................................... 508King Heiden, T ....................................2238*Kini, V .......................................... 2284, 2295Kini, V A ...............................................2296*Kiningham, K ............................................ 66

234

AU

TH

OR

IND

EX




Kinsey, G R ...........................................2125*Kinter, L B .......................................339*, 343Kinzell, J ................................... 233, 239, 240Kinzell, J H ............................. 230, 231, 232, ............................ 234, 235, 236, 237, 238, 347Kiplinger, G R ...................................... 1137*Kirby, P ................................................... 2215Kirk, C A ...............................................2207*Kirkpatrick, A ....................................... 1598Kirkpatrick, J B ..................................... 1394Kirlin, W G ............................................ 1570Kirpnick, Z .......................2230, 2232*, 2233Kirsch, G .................................................836*Kirschten, N P ......................................... 795Kiser, G L ................................................. 121Kiser, R C ....................774, 780, 2201, 2202*Kishnani, N ............................................. 798Kisin, E ..................................701*, 705, 2188Kisin, E R ............................................... 2282Kisin, K .................................................... 702Kitada, K ................................................ 1380Kitamura, Y ....................... 1406, 1428, 1861Kitchin, K T ............................................142*Kito, G ............................ 826, 833, 834, 1094Kitoh, J ..................................................... 278Kittelson, D ............................................. 443Kiyama, R .............................................. 1432Kiyosawa, N .................................. 708, 1433Klaassen, C D ................... 67, 564, 570, 815, ....................................821, 1220, 1229, 1328*, .........................1687*, 1761, 1762, 1763, 2140Klapper, D G ........................................... 500Klaunig, J E .....................670*, 751, 752, 760Klausner, M .................................1171, 1254, ........................................... 2002*, 2003, 2191*Kleeberger, S ........................................... 828Kleeberger, S R ...................................... 1857Klei, L R ...................................... 1133, 1162*Klein, B ................................................... 1943Klein Koerkamp, E ................................. 177Klein Koerkamp, E I .............................. 953Kleiner, H E ..........................................1419*Kleinman, M ......................................... 1448Kleinman, M T .............................. 442, 1066Kleinow, K M .............................. 1587, 1596Kleter, G A ............................................. 1672Kleymenova, E .....................................1372*Kligerman, A D ......................................152*Kline, T M ................................................ 656Klinefelter, G R ....................................... 547Klintworth, H M ..................................1959*Klug, S .......................................... 2251, 2252Klumb, C A ............................................ 1572Kluz, T .................................................... 1789Knaak, J B ............................ 870, 1298, 2157Knadle, S .................................................254*Knall, C .................................................... 456Knapton, A .................................... 263, 1842Knapton, A D ........................................ 1513Knecht, D ................................................. 507Knemeyer, I ............................................. 860Knight, A ................................................ 1037Knight, T .................................................... 63Knight, T R ............................................ 2140Knippels, L ............................................ 1205Knochel, J ................................................. 949Knoebl, I ................................................ 1583Knox, P ................................................... 1048Knudsen, T B ..............................1979, 1984*Kobayashi, H .............................1954*, 1966Kobayashi, K .........................459*, 886, 980, .............................................. 1080, 1380, 1633Kobayashi, T ..........................130, 451*, 452Kobayashi, Y ..........................................151*kobayashi, k ...........................................981*Kocbach, A ..............................................417*Kocerha, J ................................................575*Koch, W H ..............................................950*Kock, N D .............................................. 1792Kocsis, M G ..........................................1920*Kodama, Y ................................... 1380, 1861Kodavanti, P R ...........................1081*, 1964Kodavanti, P S ...................................... 1082Kodavanti, U P ..............433, 441*, 504, 927Koenig, J ................................................ 1453Koga, T ..........................................833, 1707*Koganti, A .............................................. 2056Koike, E ...........................................451, 452*

Koizumi, A .............. 2063, 2064, 2067, 2068Kok, E J .................................................. 1672Kolaja, K ...... 126, 353, 521, 522, 1700, 1830Kolaja, K L ............................ 514, 642*, 646*Koller, L D ................................... 1478, 1479Kolman, K ............................................. 1602Komarov, A .............................................1136Komiskey, H ...........................................596*Komiyama, M ......................................... 543Kommineni, C ....................................... 2188Komulainen, H ....................................... 749Kondraganti, S ...............................714, 756*Kong, L ................................................... 1845Konno, N ................................................. 607Konsoula, R ................................1621, 1627*Kooter, I M ..............................................929*Kopchick, J J ............................................ 582Kopf, P G ................................................846*Koplovitz, I .................................. 2201, 2202Koppelman, S ........................................ 1205Kopplin, M .............................................. 153Kopplin, M J ............................................ 146Koprowski, S L ..................................... 2246Korb, S .................................................... 1897Kordaz, K ................................................. 252Korkalainen, M ..................................... 2042Kornman, K ..............................................38*Korrapati, M C .......................75, 731, 2137*Korte, J ................................................... 1755Korte, J J ................................................1754*Korte, S ..................................................... 478Kosian, P ................................................ 1755Kosian, P A .................................. 1754, 1756Kostich, M ............................................. 1709Kostrubsky, S .......................................1049*Kostrubsky, V ...............................490*, 1916Kostyniak, P J ........................................ 2157Kotha, L ................................................1808*Kouadio, J H .......................................... 1440Kovalenko, A L ....................................... 468Kovelesky, R ............................................ 461Koza-Taylor, P H .................................1802*Kracko, D ................................................199*Kraeling, M E .......................................2177*Kraft, A D ....................................1079*, 1522Kramer, J .........................................790, 832*Kramer, K ................................................ 519Kramer, P M .......................................... 1788Kransler, K M .............................. 2038, 2157Krantz, Q T ................................................ 49Krantz, T ................................................ 1214Krause, R J ............................................. 1572Krauthauser, C ................................ 776, 787Krauthauser, C L ..................................... 788Kreider, M L .........................................1069*Kremer, J J ...............................................862*Kretz, S ................................................... 2010Kreyling, W ............................................. 204Krieger, R ................................................. 415Krieger, R I ...................................414*, 1279Krieger, S M ........................................... 2224Kris-Etherton, P ........................................ 40Krishna, C ...................................... 484, 1628Krishnamoorthy, R ................................. 465Krishnan, K ....................259, 349, 851, 868*Krishnaraj, R ........................................1785*Kristian, T .............................................. 1960Kroetlinger, F ........................................ 1735Krolski, M .............................................. 1297Kromhout, H ......................................... 1334Kronenberg, J ........................................ 1404Kronenwetter-Koepel, T A .................... 682Kropshofer, H ....................................... 1878Krsmanovic, L ....................................... 2210Krueger, S K .......................................... 1499Kruhlak, N ............................................. 2204Krull, D .................................................... 905Kruse, J ........................................... 867, 1249Ku, W W ................................................ 2230Kubaszky, R E ........................................203*Kubilus, J ..................1171, 2002, 2003, 2191Kubota, K ................................................. 709Kubota, R ............................................... 2155Kudo, Y ...................................459, 607, 944*Kueberuwa, S ........................................ 2100Kuffner, E K ........................................... 1048Kuijpers, M .................................. 1056, 1057Kuiper, H A ..........................................1672*

Kulas, J ................................................... 1387Kulkarni, G .....................................925*, 938Kulkarni, S ..................................... 490, 1049Kullman, S W ........................................ 1582Kumagai, Y .............................................. 183Kumiski, D ............................................ 1553Kunne, C ................................................ 1051Kunugita, N .........................................2206*Kunz, S ..................................................2054*Kuper, F ................................................. 1208Kuper, F C ................................................ 953Kupperblatt, G G ................................. 1176*Kurail, E ................................................... 166Kurata, Y ...............................................1251*Kurian, B .................................................. 214Kuriki, H ................................................ 1703Kurnikov, I V ......................................... 2284Kurochkin, I N ........................................ 192Kuroiwa, Y ............................................ 1406Kurosky, A ............................................... 214Kurz, M .............................................114, 510Kushida, M .............................. 750, 980, 981Kushleika, J V ............................... 184, 1216Kuwabara, H ........................................... 678Kuwagata, M ..........................954, 988, 989*Kuwano, K .............................................833*Kuzutani, K ................................... 799, 1640Kwack, S ................................................ 1635Kwak, M .............................................. 58, 59Kwekel, J ................................................ 1759Kwekel, J C .................................1771*, 1772Kwok, A ................................................. 1784

LL’Esperance, G .............................1127, 1128La Du, J .................................................. 2243La Merrill, M ................................712*, 1840Labarre, G .............................................. 2156Labenski, M T ............................1801*, 2275Labhart, P ................................................ 109LaCasse, E R ...........................................805*Ladenheim, B ........................................ 1544Ladics, G ................................................ 1307Ladics, G S ..............................................314*LaDow, K ............................103, 1512*, 2267LaGattuta, M S .......................................1195Lai, K P ....................................................553*Lai, Z ........................................................ 881Lainee, P .................................................. 838Lake, B G ......................................669, 2160*Lakin, M ................................................... 418Laliberte, J ....................................... 203, 480Lalko, J ..................................................1202*Lalla, J ...................................................... 222Lallli, J ...................................................... 486Lam, C ...................................................... 650Lam, M ................................................... 2120Lam, T ...................................................... 442Lamango, N S ......................................2158*Lamar, P C ......................... 1602, 1605, 2129Lamartiniere, C A ............ 1108*, 1492, 1493Lamb, I ................................................... 1405Lamb, J C ................................................319*Lambert, C ............................................1865*Lambert, G R ......................................... 2268Lambright, C ..................... 1374, 1743, 1744Lammers, J ........................ 1056, 1057, 2087Lampertsdoerfer, T ................................2114Lan, L ......................................................... 65Lan, Q ..................................................... 1301Landauer, M R .......................................790*Landgren, C A ......................................1316*Landry, M ................................................ 480Landry, S D ............................................ 1597Landry, T D ..........................................1696*Landvik, N ............................................ 2287Lane, R R ............................................... 1935Langley, R .................................................. 21Lans, I ..................................................... 1708Lantum, H M .......................475, 1411, 1439Lantz, C ...................................143*, 154, 157Lantz, R .................................................... 936Lantz, R C .......................................159, 2119Lanza, D L ............................................. 1219Lapczynski, A ...................................... 1182*Lapin, C ................................................... 418

Lapin, C A ................................................ 400Lapointe, G .............................................. 244Lapointe, J ............................................... 173LaPointe, J M ........................................... 898Lappalainen, M ..................................... 1880LaPres, J ..................................................1130LaPrete, V .............................................. 2000Lariviere, J ............................................... 133Larkin, P ................................................ 2023Larsen, R D .............................................710*Larson, T ................................................ 1453Larsson, S ................................................ 679Lash, L H ....................................1822*, 2127Laskin, D ................................................ 1933Laskin, D L .................................... 931, 1054Laskin, J ................................................. 1933Laskin, J D ......... 217, 931, 1054, 1398, 2171Lasky, R E .............................................. 1085Lasley, S M .................................. 628*, 1351*Latchoumycandane, C ........................1527*Latendresse, J .................................. 59, 2137Latendresse, J R ........................... 62, 73, 77, .............................................. 1910, 2139, 2141Lattier, D ................................................ 1583Lau, B ..................................................... 1383Lau, C ..............280, 1232*, 1906, 2066, 2255Lau, D ..................................................... 1095Lau, S S ........................147, 823, 1801, 2118, ...............................................2119, 2275, 2281Lauer, F T ......................................... 302, 892Laughter, A ...............................................57*Lavin, A .................................................11, 28Lavin, A L .................................................. 24LaVire, H ..............................................1584*Lawal, T ................................................. 2214Lawrence, B ....................544*, 807, 874, 875Lawrence, D ............................................ 196Lawrence, D A ...................... 189, 895, 1064Lawrence, T N .......................................273*Lawrence, W B ...................................... 1394Laws, S C ........................... 1728, 1733, 1745Lawton, M ............................... 535, 540, 559Lawton, M P .................................643*, 1802Lazis, S ................................................... 1865Lazorchak, J M ...................................... 1582Le Bigot, J ...............................................838*Lea, L J ...................................................1392*Leach, C ................................................1346*Leach, G J ............................................... 2203Leakeas, C L ............................................ 526Leakey, J ................................................... 706Leakey, J E ..................................... 355, 1813Leakey, T I ............................................... 355Leal, F A ................................................ 1168*Learn, D B ...................................1075, 2193*Leatherberry, G ....................................... 169Leavens, T ..............................................863*Leavitt, S ...................................... 2144, 2146Lebetkin, E H .......................................1230*Leblond, N ...................................... 840, 841Lebofsky, M ........................................... 2034Ledbetter, A D ................. 433, 441, 448, 927Lee, B .......................................................1148Lee, C ........................................... 1215, 2164Lee, D ........... 60, 717, 890, 1417, 1574, 1575Lee, D W .................................................223*Lee, E ........................... 552, 890, 1421, 1431, .............................................. 1574, 1575, 2263Lee, F W ................................................1813*Lee, F Y .................................................... 288Lee, G ..................................................... 1373Lee, J .............................41, 907, 1079, 1217*, ...................................1219, 1417, 1764*, 2164Lee, K ...................................... 108, 122, 186, .................918, 1217, 1409, 1524*, 2168, 2169Lee, K M ......................506, 919*, 1507, 1705Lee, K P .................................................... 945Lee, L ........................................... 1180*, 1790Lee, M .................................................... 1046Lee, M G .................................................916*Lee, P C ...................................................266*Lee, R .............................. 743, 744, 926, 1635Lee, R B .................................................... 164Lee, R V .................................................... 428Lee, S ............................717, 729*, 890, 1006, ..................................1261, 1417, 1574*, 1575, .............................................. 1635, 2164, 2266Lee, T ........................................................ 410

AU

TH

OR

IND

EX




Lee, W ...........................................156, 1464*Lee, Y ............................................ 1454, 2290Lee-Brotherton, V M ...........................1408*Lefebvre, A .............................................1190Lefkowitz, L J ........................................ 1278Lehman-McKeeman, L D ..................1680*, ........................................................ 1768, 1930Lehmann, L .......................................... 1311*Lehmler, H ..................................1082*, 2054Lehmler, H J ................................ 1487, 1488Lehto, M ................................................. 1885Lei, H ...................................................... 1599Lei, Y ........................... 434*, 435*, 454, 1452Leibold, E ............................................... 1563Leimgruber, R M .................................... 532Lein, P .................................................... 1084Leino, M ................................................. 1885Leiter, K W ............................................... 782Leitner, H ............................................... 1853Lemasters, J J ......................................... 1053Lemay, F ................................................... 244Leon-Chavez, B ..................................... 1619Leonard, J ..................................... 114, 2131*Leone, A M ........................... 569, 755, 1174*Lepape, A ............................................... 2032LePoire, D ................................................ 332Lepoittevin, J ..........................................1197Lerch, E W ..............................................1311Lernmark, A .......................................... 1271Lerondel, S ............................................ 2032LeSauteur, L .................................... 174, 195Lesch, C A ................................................ 530Leseman, D C ........................................ 1446Leseman, D L .......................................... 929Letizia, C ............................................... 1183*Leung, H W ............................................. 257Leverette, R ................................1517, 2229*Leverette, R D ........................................1186Levin, A A .................................................. 16Levin, E D ...........................965, 1069, 1070*Lewandowski, T A ....................... 284, 1071Lewandowski, T A ................................384*Lewis, A M ............................................ 1513Lewis, D ................................................... 843Lewis, D N ..............................................844*Lewis, E M ............................................... 544Lewis, J ..................................................... 162Lewis, J A ..............................................2017*Lewis, J M ...............................................952*Lewis, K ................................................... 374Lewis, L .................................................... 422Lewis, L M ............................................. 1260Lewis, M W ............................................. 601Lewis, R W ............................................ 1638Lewis, S .................................................1244*Lewis, S M ............................................. 1813Lewis-Michl, E ...................................... 1093Lhote, N ................................................ 1175*LI, A P ................................ 485*, 1927, 2215*Li, G .......................................590, 593*, 1534Li, G L ..................................................... 1301Li, J .........................................814, 984*, 1865Li, J G ........................................................ 594Li, K M ................................................... 1601Li, L ..................................... 1543, 1788, 2205LI, Q ...............................................440*, 2274Li, T ........................................................ 1275Li, W ............................574, 941, 1603, 2120*Li, Y ..............................98*, 523, 1814, 1827, ................................... 1833*, 1834, 1847, 2117Li, Z ...............................................705*, 1905Li, L ......................................................... 2279Lian, J B .......................................1031, 1032*Liao, G ...................................................... 348Liao, K H ........................................403*, 865Liao, S ....................................................... 193Lichtveld, K ............................................. 942Liebler, D C .............................. 1320*, 1325*Lieckfield, R ............................................ 419Lightfoot, R ............................................. 905Lili, T ...................................................... 1402Lim, F ........................124*, 1375, 1736, 1739Lim, K ...................................................... 150Lim, L ....................................................... 287Lim, Y ..................................................... 1217Lima, A ..................................................... 879Limaye, P ................................................... 59Limaye, P B ......................................77*, 842

Lin, G ...................................................... 1264Lin, P ...................................................... 1724Lin, T ...............................130, 548*, 554, 555Lin, Y ...................................................... 1096Linak, W P ............................................. 1214Lind, M P ................................................679*Lindeblad, M ......................................... 2026Linden, J ................................................2042*Lindsay, D ................................................ 887Lindstrom, A B ...................................... 1232Lingenfelter, R A ..................................1290*Linney, E ................................................ 1581Linnum, A L .......................................... 1746Linscombe, V A ..................................... 2224Lipinski, R J ............................................ 110*Lippmann, M ........................................ 1453Lipscomb, J C .....................................9*, 377Lipsky, M ......................................1159, 1823Lipsky, M M ...........................................1156Little, P B ............................................... 1091Liu, D .................................... 711, 817, 1869*Liu, F ...................................................... 1495Liu, H ..................................................... 1807Liu, J .........................58, 136*, 138, 144, 582, ........................... 593, 694, 1817, 1951*, 2274*Liu, K .............................................. 682, 1729Liu, L ...................................................... 1541Liu, S ...................................................... 1844Liu, X ............................................... 115*, 569Liu, H ....................................................1573*Llorens, J ...............................................1092*Lloyd, R S .............................................. 1042Lloyd, S .................................743*, 745, 2014Lobenhofer, E K .......................................119Lock, E A ...........................2130*, 2137, 2139Lockley, D .............................................. 2173Lodestro, C ................................................ 60Loehle, J A ............................................1266*Loehlein, D ............................................ 1269Logue, B A ..............................................795*Lohitnavy, M ........................................... 849Lohitnavy, O .................................. 849, 1306Lohnes, K J ............................................ 1556Lohrke, S ................................................ 1883Lohrke, S L .............................................. 783Lohrke, S R .............................................. 888Loizou, G ................................................. 681Lombard, C A .........................................368*London, L .............................................1334*Long, H .................................................. 1266Long, P ................................................... 2200Looney, J R ............................................... 848LoPachin, R M .....................................1546*Lopez, P ................................................... 252Lopez-Carrillo, L .................................... 427Lord, J L ................................................ 2119*Lord, P ...........................................1174, 2291Lord, P G .......................................... 569, 755Lorenzana, R M ...................................... 155Lotti, M .................................................. 1967Loucks, E ..............................................2260*Louden, C ...................................... 824, 1843Louden, C S ................................................. 6Louderback, M ...................................... 1499Lough, J W ............................................. 2246Loughrey, H .......................................... 1780Lovett, C ................................................ 1309Lovik, M .......................................... 450, 453Lowit, A .............................870, 1001*, 1298, .............................................. 1939, 1940, 1941Lowndes, H E ......................................... 610Lowney, Y .............................................2084*Lowry, D F ............................................. 1705Lu, B ................................................. 535, 559Lu, H .......................................................570*Lu, S ........................................................ 2205Lu, Y ........................................................849*Lucas, S .................................................... 455Lucchini, R .............................................. 597Luckie, C ................................................ 2274Lucot, J B .................................................. 789Luderer, U ..............................................1117Ludewig, G ............................................ 2058Luebke, R ......................................... 512, 889Luesch, H ............................................... 1721Luijten, M .............................................1490*Luke, A M ...............................................193*Lumley, L ................................................. 785

Lumley, L A ....................................776*, 787Lumpkin, C ........................................... 1036Lumpkin, C K ....................................... 1737Lumpkin, M H ...............................402, 419*Lunchick, C ................................... 870, 1297Lund, A K .....................................846, 1837*Luo, B ..................................................... 1924Luo, H ................................ 1308, 1309, 1595Luo, W ..................................................2195*Luo, X ....................................560, 577, 1603*Lusis, A J ...................................... 1373, 1949Luster, M I ............................................... 705Luu, T C ..................................................... 98Luukinen, B ........................................... 1481Luyendyk, J P .......................................1930*Lynch, B S .............................................. 1408Lynch, C M ...........................................1350*Lynch, J P ................................................145*Lynch, K M .............................................. 536Lynch, M .................................................. 461Lynes, M A ............................... 196, 507, 894Lyng, G D .............................................1083*Lyons, R M ...............................................14*Lyons-Darden, T ....................................512*Lysytsya, A ........................ 2284, 2294, 2296Lyubimov, A .............. 489, 1782, 1785, 2026

MMa, D .................................................201, 711Ma, J K ..................................................... 212Ma, J Y .....................................................212*Ma, P ...................................................... 2071Maatta, J ................................................1885*Mably, T A ............................................1781*MacGregor, J T ................................... 11, 25*Machado, A F .........................................1168Machida, N .....................................211, 1793Maciag, A ............................................... 1013Maciejczyk, P ........................................ 1453MacIntosh, S .......................................... 1307Mackay, W J ........................................... 2231MacKenzie, B A ....................................... 772MacKenzie, C ...........................................911MacKenzie, S A ....................................1405*Mackie, J ................................................ 1402Mackie, R S .............................................. 769MacNee, W .............................................. 437MacNicoll, A ........................................... 681MacPhail, R ........................................... 1934MacPhail, R C ..................1335, 1437, 1438*Maczka, C ................................................ 242Maddaloni, M A ....................................327*Madden, E F .........................................2136*Madden, M .............................................. 447Madden, M C .....................457*, 1294, 1917Maddox, J ................................................ 684Maddox, J F ..................................... 69, 1930Madenspacher, J H ..............64, 1005, 1900*Madhukar, B V .............................187, 1361*Madl, A ........................................... 410, 411*Madren-Whalley, J ........................ 484, 1628Madrigal, A ........................................... 1293Maeda, K ................................................. 278Maeda-Nakamura, K ........................... 1928Maekawa, A ............................................ 763Maekawa, M ........................................... 556Maeng, S ................................................ 1454Magnuson, S R .......................................... 45Mahadevan, B ..................1499, 1814*, 2272Maher, J M ..............................564, 815, 821*Mahle, D .................................................526*Mahringer, A ......................................... 1735Maibach, H .............................................. 482Maibach, H I .......................................... 2084Maier, A .................373, 375*, 379, 381, 1477Maier, C ...................................................873*Maier, C C ................................................ 179Maier, W ................................................ 1916Mainor, C B .......................................... 1111*Maitra, R ...............................................1557*Majkova, Z ...........................................1838*Major, M A ............................................. 1238Major, V ................................................. 1334Mak, N K ..................................... 1600, 1601Makhaeva, G F .........192, 1936*, 1937, 1938Maki, A ............................................. 60, 1046

Maki-Paakkanen, J ................................. 749Makin, A ...............................................2028*Makinodan, F ........................................ 1251Makris, S .......................................... 378, 977Makris, S L ..........................................3, 380*Makusky, A J ......................... 64, 1005, 1900Makwana, O ........................ 204, 1445, 1964Makynen, E A ........................................ 1746Malard, J M ............................................. 122Malarkey, D ............................................. 844Maldonado, H ....................................... 1539Maleeff, B E ............................................. 536Malekafzali, A ....................................... 1444Malinczak, C Y ........................................ 180Malisch, R .............................................. 2072Malley, L A ....................................951*, 1405Mally, A .................................................1799*Malmfors, T ............................................251*Malstrom, S ........................................... 1444Malygin, V V ............192*, 1936, 1937, 1938Manautou, J ........................................... 1921Manautou, J E ........................67, 815, 1051*Manca, D A .......................1258*, 2077, 2081Manciaux, X .........................................2032*Mandel, H G ..........................................1136Mandsager, J ........................................... 492Manetz, S ..........................................810, 811Manganaro, D M .................................. 2106Mann, K K ....................................688*, 2293Mansour, M ...................... 1139*, 1140, 2112Manthei, J ................................................ 793Manthei, J H ............................................ 788Manzo, L .....................................1055, 2051*March, T H .............................................1141Marcus, C .................................89, 325*, 715Marcus, C B ............................................. 724Marek, K L ............................................. 1988Marin, H E ................................................55*Marino, A ............................................... 1621Marinovich, M ............................ 1888, 2247Maritnez, J E .......................................... 1371Maritz, G S ............................................1646*Markham, D A .......................................1176Marlatt, J L ..................................1314, 1315*Marlowe, J L ...........................................104*Marnett, L .............................................1324*Maronpot, R ............................................ 672Maronpot, R R ...................................... 1302Marquardt, H ........................................ 1996Marr, R ..................................................... 199Marron, J ................................................ 1046Marroquin, L D ......................................488*Marsden, E ............................................ 1429Marsh, T ......................................1506, 1821*Marshall, P .............................................. 169Marshall, R S ................................ 966, 1335, .............................................. 1939, 1940, 1941Marston, C P ......................................... 1814Martha, M M ......................................... 2222Martin, D ................................................1132Martin, E J .............................................2278*Martin, G ............................................... 2135Martin, K R .................................1044, 1496*Martin, L ...............................................1373*Martin, M ................................................. 300Martin, N J ............................................. 1009Martin, P ...............................................1294*Martin, R J ............................................. 1566Marty, M A ................1519, 1521, 2109, 2111Marty, M S ..............................................269*Martínez, E ............................................ 1708Marusanov, V E ...................................... 468Maruyama, W ........................................393*Marvanova, M ...................................... 1973MaryBeth, D E ...................................... 1299Mash, E A ............................... 146, 147, 2275Masjedizadeh, M .................................... 348Mason, A ................................................ 1590Mason, A M ............................................. 403Mason, E .......................................... 776, 787Mason, R P .............................................. 759Mason, S ...................914, 1457*, 1458, 2024Massart, C .............................................. 1039Massey, E D ........................................... 2013Massey, T E ............................ 737, 935, 2265Masson, M ..............................................905*Master, Z R .............................................354*Masters, K .............................................2033*

236

AU

TH

OR

IND

EX




Masters, O ............................................. 1042Masucci, M E ......................................... 2230Matherly, L H ........................................ 1822Mathew, L K ...............................2241*, 2242Mathews, J ............................................... 732Mathieu, L ..............................................487*Mathis, M .............................................. 1498Matis, S .................................................... 508Matson, C W ......................................... 1593Matson, K L ............................................. 773Matsuda, Y ............................................ 1471Matsumoto, H ......................................1379*Matsumoto, M .....................281, 816*, 2277Matsumura, F ......... 1164, 1442, 1753, 2041*Matsuo, J .................................................. 826Matsushita, T ...............................562*, 1380Mattes, W B ............ 753, 1829, 1968*, 1972*Matthew, B S ........................................... 866Matthews, E .......................................... 2204Matthews, J ...........................................1365*Mattie, D ................................................ 2039Mattie, D R .................................. 1305, 2078Mattingly, C ..........................................1706*Mattrey, R F ............................................1103Matunis, M J ...........................................658*Mauderly, J L ........................................... 444Maurissen, J P ..............................269, 1678*Mayeno, A N ........................................1300*Mayer, A M ...........................................1436*Mayer, J .................................................2204*Mayk, A ...................................................1107Maynard, A D ........................................649*Maynaud, M .......................................... 1240Mayo, P R .............................................. 1255Mayol, N ................................................ 1539Mays, D .................................................... 408Mazor, K A ............................................1093*McAtee, B L ...................... 1263, 1272*, 1811McAvoy, S ........................................ 776, 787McCabe, M J ........ 134, 689, 690, 1877, 1884McCaffrey, R J ....................................... 1988McCarty, J D ............................................ 978McCarver, D G ........................................ 259McClain, C J .......................................... 1876McClellan, R O ......................... 1674*, 1677*McClure, P ............................... 406, 407, 768McClure, P R ........................................... 399McCollum Lehmann, G ........................134*McConnachie, L .....................................225*McConnachie, L A ................................ 1859McCormack, J F ...................................1354*McCormick, D L ............... 1776, 1777, 1778McCoy, R ............................................... 1671McCracken, K A .................................... 1812McCue, J ................................................ 1865McCullough, S S ....................................... 68McCurdy, S A ........................................ 1278McDaniel, K .......................................... 1940McDaniel, K L ............................. 1078, 1941McDaniel, L ..................................... 293, 361McDermott, M J .................................... 1288McDiarmid, M .............................165, 1664*McDiarmid, M A ...................................163*McDonald, A ......................................... 1934McDonald, J ...................199, 444*, 455, 960McDonald, J D ...................................... 1017McDonald, T ......................................... 1290McDonald, T A ...............................313*, 396McDonald, T J ..................... 524, 1593, 2270McDonough, J ................................. 776, 785McDonough, J H ..................................... 787McDougal, J N ...................344*, 2178, 2179McElroy, W .............................................1119McElvania TeKippe, E ..........................928*McGarrigle, B P .................................... 2157McGee, J ................................................... 441McGinnis, P ..................... 155, 406, 407, 768McGinnis, P M ........................................ 399McGlothan, J L .................................. 52, 678McGrath, A M ................................. 64, 1900McGraw, J E ............................................. 734McGuire, J ........................................ 776, 787McGuire, J M ................................... 773, 775McHowat, J ........................................... 2125McIntyre, B .............................................798*McKallip, R ............................................877*McKarns, S C .......................................1872*McKee, R .................................................264*

McKee, R H ............................................275*McKelvey, K .............................................. 71McKim, Jr., J M ................................ 80, 1932McKinney, W ................................. 933, 1468McKinney, W J ...............................506, 635*McLain, E ............................................... 2217McLanahan, E D ..................................2039*McLellan, C ................................. 2098, 2103McMahon, J M .............................. 848, 1751McMahon, T ...........................................241*McManus, B E ......................................... 940McMartin, K ...........................................2117McMartin, K E ........................................ 857McMaster, S ........................................... 1277McMillan, D C .............................. 207, 1559McMillan, J M ..........................................71*McMillian, M .........................................1174McMillian, M K .............................569*, 755McNally, A ......................................131*, 600McNeely, S C ..................................689*, 690McNett, D A .................................. 848, 1237McPhail, B ..............................................956*McQueen, C A ......................................1977*McQuown, J ...................................86*, 1658Meacham, C A ......................................1547*Meade, B J ...........................1210, 1211, 1713Means, J C ...................................... 565, 2055Meckley, D R .................... 1185, 1515*, 1516Medeiros, M .............................................119Medina, I M ..........................................2166*Medrano, T .............................................1113Medrek, S ............................................... 2195Medvedovic, M ....................................... 103Meek, E C .........................1299, 1946*, 1947Meeker, L ................................................. 949Meeks, R G .............1507, 1508, 1509, 1510*Meerdink, G L ....................................... 1313Meeuwen, J V .......................................1734*Mehendale, H M .............59, 62, 73, 75*, 77, ....................................... 731, 842, 1909, 1910, .............................................. 2137, 2138, 2139Mehlman, T ............................................. 882Mehta, H ................................................ 1958Mei, H ...................................................... 527Mei, N ................................. 747, 1565, 2206, .............................................2217, 2218*, 2220Meier, H L ...............................................778*Meijer, D K ............................................. 1913Meissner, A .............................................. 519Meistrich, M L ......................................... 541Mekhtiev, A ........................................... 1290Meldrum, M .......................................... 1093Melendez, K F ......................................... 302Mendez, E ................................................ 380Mendez, J ............................................... 1862Mendez, L .............................................. 1448Mendrala, A L ....................................... 1242Mendrick, D L ....................................... 1972Mendy, A J ......................... 1050, 1766, 1920Menegola, E ........................................... 2247Meng, Q ..........................................122*, 919Meng, Q R ............................................. 1705Meng, R ...................................................921*Meng, X .................................................. 1726Mercado Feliciano, M .........................1749*Mercer, P .................................................. 443Mercer, R R .....................................701, 702*Meredith, C ........................................... 2160Merema, M T ......................................... 1913Mergler, D .............................................. 1334Merlino, G ............................................. 1803Merrick, A .............................................. 1538Merrick, B .............................................. 1709Merrick, B A .........................64, 1005*, 1900Merrill, E A ...........................................1305*Merrill, J ......................................... 194, 1233Merrill, J W ...........................................1234*Mertens, J W .......................................... 1510Messer, D ............................................... 2069Metzler, M ..............................................1311Meuling, W ............................................ 2087Meurrens, K ............................................ 924Meyer, D A ............................................1953*Meyer, J .................................................... 687Meyer, K E ............................................... 808Meyer, S ................................................... 492Meyer, S A ...................................... 736, 2167Meza-Velazquez, M ................................ 253

Michaux, A .............................................. 174Michel, C ................................................. 118*Michoudet, C ........................................ 2135Micsenyi, A ............................................ 1052Middaugh, D ......................................... 1095Mielke, H ............................................... 2071Mielke, H W ......................................... 1160*Mielke (Emeritus), P .............................1160Miettinen, H M ....................................... 679Migliaccio, C T .....................................1890*Mikami, N ............................................... 750Milano, J ........................................573*, 1779Milano, S ................................................ 2032Milatovic, D ..................................215*, 1000Milatovic, S ............................................ 1000Miles, S L ..............................................2122*Milicic, I ................................................... 557Millecchia, L .......................................... 1443Miller, A L ................................................ 782Miller, B G ................................................ 681Miller, B J ..................................... 2185, 2187Miller, C A ..............................................503*Miller, D ................................... 776, 787, 793Miller, D B ............... 48, 775, 788, 794, 1540Miller, F ...................................................2110Miller, F J ............................................... 1304Miller, G W ...... 973, 1097, 1529, 1545, 1961Miller, H L ....................................... 690, 691Miller, J A ..............................................1536*Miller, K P ...................................1367*, 2153Miller, M D ............................................ 1519Miller, M L ..............................227, 955, 1165Miller, M S ............................................. 1792Miller, N D ............................................1938*Miller, R T ................................................ 584Miller, S .................................................... 422Miller, T .......................................... 263, 1576Miller, T J ....................................1513*, 1842Miller, T R .....................................229, 1860*Miller, W H .................................... 688, 2293Millett, S ................................................. 1634Milligan, M ............................................ 1637Mills, J B ................................................... 357Mills, L J ................................................1745*Mills, N L ................................................437*Millsap, D S ........................................... 2245Milton, J ................................................. 1046Min, E ..................................................... 1853Min, K N .......................................... 202, 720Min, W ..................................................... 467Minakawa, A ........................................... 176Minard, K R ............................................. 347Ming, X .................................................... 983Minnick, T A .......................................... 2174Mino, T ............................................. 980, 981Minobe, Y .............................................. 1727Minsavage, G D .....................................182*Mioduszewski, R .................... 776, 785, 793Mioduszewski, R J ........................ 773, 775, ............................................ 786, 787, 788, 794Miracle, A .............................................1583*Mirajkar, N ................................................ 51Miranda, C L ......................738*, 2019, 2020Miranda, S R ..........................................736*Mirsalis, J ....................................... 801, 1095Mirsky, M L ............................................. 532Mishima, K .............................................. 954Mishin, V ............................................... 1398Mishin, V M ............................................ 217Mishra, N ........................................... 21, 189Misra, M ................... 923, 1186*, 1517, 2229Mitchell, K A ........................................1362*Mitkus, R J .........................315*, 318*, 1451*Mitra, M S .................................................62*Mitsumori, K ..................................211, 1793Miyagawa, M ........................................ 1080Miyagishima, T ....117, 561, 562, 1901, 1902Miyajima-Tabata, A ...............................709*Miyake, T ................................................. 833Miyamaoto, K ......................................... 423Miyamoto, M ........................................ 2031Miyamoto, Y .......................................... 2043Miyata, E .................................................. 742Miyaura, H ............................................ 1379Miyazaki, T ........................................... 1901Miyazawa, M ................... 1192, 1193, 1194*Mizoguchi, Y ......................................... 1703Mizukawa, Y ........................................1902*

Mobio, T M ............................................ 1440Modi, A .................................................. 2291Moeller, T A ..........................................2014*Moffett, D ............................ 390, 1560, 2086Moffit, J S ..................................................67*Moggs, J ............................... 124, 1375, 1739Moggs, J G ............................................1736*Mohamadin, A M ..................................... 79Mohan, S .................................................606*Mohar, I .........................................225, 1859*Mohrman, M ......................................... 1717Moilanen, L H ........................................407*Moldovan, H M ...................................... 203Monbaliu, J .............................................. 268Mondal, M ............................................... 515Monestier, M ........................................1330*Moneypenny, C G ...............................2244*Monforte, J ............................................... 754Monga, S ................................................ 1052Monica, Y ................................................159*Monks, T J .......1801, 2118, 2119, 2275, 2281Monks, T T .............................................. 823Monroe, M E ........................................... 918Monroe, P J .............................................. 108Monteiro-Riviere, N ............................. 2180Monteiro-Riviere, N A ........... 1691*, 1697*, .........................2176, 2181, 2183*, 2184, 2196Monteith, D ......................................13*, 519Monticello, T ......................................... 1464Monticello, T M .................................4*, 915Montine, T J ................................... 215, 1000Moon, C ................................................... 717Moon, H ................................................. 2290Moore, A .................................................1114Moore, D A .............................................1150Moore, D J ..........................124, 1375, 1739*Moore, D M ................................2201*, 2202Moore, K .......................................492*, 1557Moore, M ....................................1025*, 2217Moore, M M ...........1565, 2216, 2218, 2220*Moore, N ................................................ 2249Moorthy, B ............................714*, 756, 1845Moraga, A .................................................. 43Moran, A .................................................959*Moran, J ................................................. 2159Moran, T H ............................................ 1544Moreland, J A .......................................... 160Moreno, M ............................................ 1146*Moretto, A .............................................. 1967Moretz, R A ............................................. 788Morgan, D L .......................................... 1091Morgan, E T ............................................. 722Morgan, K .................................................114Morgan, R ...................................... 519, 1784Mori, C ..................................... 129, 543, 556Mori, K ....................................................1611Mori, S ...................................................... 742Morikawa, A ....................2064, 2067, 2068*Morimura, K ................................... 746, 750Morin, D R ............................................... 359Morin, J ...................................................446*Morishita, M .................................... 438, 439Morita, O ..................................... 1394, 1399Morita, T .................................................. 700Mork, A ...................................................853*Morrall, S W ...........................................1197Morris, J B ..................................... 2*, 2*, 947Morris, J E ...............................................238*Morris, M ......................................... 789, 791Morris, R W ........................................... 1302Morris, S .................................................. 810Morrissey, R .................466, 798, 1186, 1782Morrissey, R L ..................... 923, 1777, 1778Morrow, J D ............................................. 207Morse, J K .............................................. 1945Morseth, S ........................................ 544, 807Morsman, J ...................................... 560, 577Mosadeghi, S ..........................................739*Mosby, A .................................................320*Mosby, A C .............................................. 318Moser, V C ...............389, 1078, 1091, 1335*, .............................................1939, 1940, 1941*Mosesso, P ............................................. 1799Moss, J R .................................................... 52Moss, O R .....................................517, 1463*Moto, M .................................................. 211*Moudgal, C ........................... 285, 383, 1520Moudgil, B ....................................... 43, 2108

AU

TH

OR

IND

EX




Moukha, S ................................... 1435, 1440Mould, A .................................................. 467Mounho, B ............................................1991*Mounho, B J ........................................... 1990Mouton, G ............................................... 879Mowat, F .................................................. 409Moya, J ..................................................... 378Moyer, G ........................................ 484, 1628Mu, X .....................................................1729*Mucci, L ..................................................295*Muccio, D .............................................. 1785Muehlbauer, P A ....................................337*Mueller, S O ..........................................1750*Mueller, W ............................. 478, 948, 2025Muhammad, F .....................................2176*Muirhead, E .......................................... 2021Mukai, M ................................................. 554Mukhi, S .......................................494*, 1595Mukhopadhyay, R .................................217*Mullen, T E ...............................................119Mumtaz, M ............................................ 2039Mumtaz, M M ..................................73, 390*Mun, G ................................. 484, 1628, 2209Mundandhara, S ..................................... 457Mundy, W .............................................2057*Munehito, M ........................................... 423Muneoka, K ............................................. 954Muneoka, K T ................................. 988, 989Mungalachetty, P .................................. 1924Mungapen, L ........................................... 265Munro, I C ............................................1673*Munroe, R C ...........................................1135Munson, J .............................................. 2186Murai, T ................................................... 742Murali, B .................................................... 75Murali, M ............................................... 1062Muralidhara, S ..................... 729, 956, 1243, .............................................. 1245, 2039, 2095Muramatsu, K ......................................... 708Murasaki, T ........................................... 1424Muro-Cacho, C ......................................... 72Murono, E P ...........................................549*Murphy, D J ............................................. 339Murphy, E ........................................ 828, 829Murphy, G ............................................1441*Murphy, K A ...........................................102*Murphy, P A .......................................... 1385Murphy, V A .............................................. 10Murr, A S .................................................1119Murray, A R ..........................701, 702, 2188*Murray, T F ................................... 960*, 1100Murrel, R ............................................... 2145Murrell, R N .................................. 188, 2151Murthy, G S ..........................................1313*Murthy, S ................................................. 932Mus, M ....................................................476*Musa-Veloso, K ..................................... 1408Musafia-Jaknic, T .................................. 2019Muse, W ................................................... 793Muse, W T ....................................... 775, 788Musgrove, D ........................................... 362Musgrove, D L ........................................ 878Muskhelishvili, L .................................. 1912Mussali-Galante, P ........................608, 1153Musselman, I H .................................... 1594Muthiah, K .............................................. 756Mutkus, L ................................................ 486Mutlib, A ................................................ 1049Muto, N ................................................... 270Myers, L P ...................................1210, 1713*Myers, S R .......516, 1259, 1284*, 1285, 1286Mylchreest, E .......................951, 952, 1686*

NN, A U .....................................................565*Nabae, K ...............................................1388*Nabb, D L .............................231*, 234, 1578Naciff, J M .............................................1371*Nadadur, S S ........................................1447*Nadkarni, P ....................................925, 938*Nadwodny, K L ...................................... 910Nagabhushan, M .................................. 1776Nagai, H .................................................. 130Nagai, Y ................................................. 2205Nagao, T ...............117, 561, 562, 1901, 1902Nagarkatti, M .................. 363, 365, 368, 877

Nagarkatti, P ................................... 365, 990Nagarkatti, P S ...............363, 368, 877, 991*Nagase, H .....................................1191, 1318Nagashima, H ......................................1928*Nagata, R ........................ 492, 496, 826, 833, ................................................ 834, 1094, 1707Nagayama, S ..........................................826*Nagelkerke, N ....................................... 1490Nagori, A ............................................... 1410Naito, A ...........................................563, 762*Najarian, T ............................................... 170Nakae, D .................................................. 763Nakagawa, H .......................................... 270Nakagi, Y ................................................. 604Nakai, K ........................................... 604, 709Nakai, M ...............................................1727*Nakamura, J ............................................ 525Nakamura, M ........................................ 1388Nakamura, T ................................799, 1640*Nakamura, Y ........................................1501*Nakanishi, K ......................................... 1703Nakano, K ................................................ 607Nakayama, H ........................................ 1433Nakayama, K ................................ 763, 1379Nakazawa, H ........................................ 2155Nallapaneni, A .........................................51*Namorado, M C .....................................1132Namork, E ............................................... 417Nanba, T ................................................ 1703Nandi, S ................................................. 1467Nanez, A ...............................................2132*Napolitano, G ....................................... 1830Naqvi, A ................................................. 1410Narahashi, T ...............................1962*, 1963Narayanan, L ........................................ 2039Narayanan, P K .................................... 1828Narotsky, M G ........ 1118, 2143*, 2148, 2151Nascarella, M A ...................................2016*Nash, J F ..........................................10, 1693*Naspinski, C .......................................... 1290Nasreen, N ............................................ 2108Nass, R ..................................................1973*Nasser, F A ..................................1936, 1937*Nath, J ...................................................... 360Natsoulis, G ..................................521, 1700*Nau, M ..................................................... 793Naufal, Z ................................................ 1290Naumann, B .......................................... 1235Navarro, L ............................................... 264Navarro, L E .........................................1504*Navarro, S .....................................364*, 1420Navas-Acien, A ....................................... 430Navetta, K A ...........................................520*Nayeem, F ............................................. 1922Nazarenko, D A .................................... 2046Ndountse-Tchapda, L .......................... 1863Nduaka, C I ............................................540*Neale, J R ............................................... 1266Nealley, E W .................................... 777, 782Nebert, D W .................227, 955, 1165, 1599Needham, L ........................................... 1291Needham, L L ......................................1340*Neff-LaFord, H ......................................874*Nelms, L ..........................................535*, 540Nelson, C ..................................... 1747, 2204Nelson, D M ...............................1768*, 1930Nelson, G ........................... 2144, 2146, 2268Nelson, J ................................................... 798Nelson, S .................................................. 813Nemanich, R J ............................. 2183, 2184Nemec, A A .............................................1162Nemec, M ................................................ 978Nemec, M D ...................................239*, 240Nemeti, B ........................................140*, 149Nesnow, S .................................... 2147, 2268Nesnow, S C ...................... 2144, 2146, 2149Nestmann, E R ...................................... 1408Nethery, K A ............................................ 469Neuforth, A E .......................................... 526Newbold, R ..........................260, 1114, 1370Newby, D E ............................................. 437Newell - McGloughlin, M ..................1670*Newham, P .................................. 1465, 1466Newland, N ........................................... 2013Newman, B ...........................................1553*Newport, S W ................................69*, 1930Newsted, J L .......................................... 2150Ng, S P .......................................22, 880, 881*

Nguyen, H ............................................. 2195Nguyen, P .............................................. 1591Nguyen, T ................................................ 803Nicholls, A W .......................................... 491Nicholls, I M .............................................. 61Nichols, A C .........................................1589*Nichols, C .............................................. 1973Nichols, H P ...................... 2143, 2148, 2151Nichols, J W ......................1579, 1580*, 2254Nichols, R C ............................................ 137Nicks, D K ............................................. 1289Nicolescu, A C ........................................935*Nie, A Y ................................. 569, 755*, 1174Niedzwiecki, A ..................................... 1494Niehof, M ...............................................1173Niehoff, M ....................................948, 2025*Niemuth, N A ............................. 2201, 2202Nierkens, S .................................... 903, 1205Nihart, V M ........................................... 1278Nihlen, A .................................................. 868Niino, N ................................................... 708Nijmeijer, S .................................. 1747, 1748Nikolskaya, T ........................................ 1378Nikolsky, Y .................................. 1377, 1378Nikoskaya, T ......................................... 1377Nines, R ................................................. 1486Nipwoda, M T ........................................ 777Nishikawa, A ....................1406*, 1428, 1861Nishikibe, M ............................................ 176Nishimura, H ........................................ 2142Nishimura, M .......................................... 708Nishimura, N .......................................2142*Nishimura, T ......................................... 2155Nishino, M ............................................. 1388Nitta, H .................................................1901*Nixon, P ................................................... 374Noailles, P H ......................................... 1544Noakes, J ...............................743, 744, 1638*Noda, S .................................................. 1727Nodikum-Moffor, F ................................ 718Nogi, A ................................................... 1703Nohara, K .....................................130, 2043*Noisel, N .......................................432*, 2156Noker, P ................................................... 466Nolan, J P ................................................. 433Nomura, M .............................................. 270Nong, A ...........................................259*, 851Nord, P ..................................................... 352Nordone, A J .............................................44*Noreault, T L ..........................................137*Noriega, N ..................................1374*, 1744Norimura, T .......................................... 2206North, C M ............................................ 1930Norton, D ............................................... 2185Norton, K ..........................1457, 1458*, 1460Norwood, A B ............................. 1955, 1956Novack, D .............................................1033*Novack, D J ........................................... 1031Nowak, P ............................ 478*, 1105, 2025Nowakowski, M ..................................... 540Nozaki, K ................................................. 812Nuber, D C ...........................................1397*Nunez, B A .............................................. 845Nurkiewicz, T R ..................................1443*Nye, S ....................................................1897*Nygaard, U C .................................450*, 453Nyland, J F .............................................879*Nylander-French, L A ...........................500*Nyska, A ................... 33, 441, 670, 779, 784, ..................................828, 829*, 843, 844, 878, .................1107, 1506, 1821, 1826, 2035, 2070Nyska, M ................................................. 844

OO’Brien, E .....................................2113, 2115O’Brien, P J ............................................ 1926O’Brien, T J ........................................... 1136*O’Callaghan, J ..................1056, 1057, 1987*O’Callaghan, J P .................... 48, 1223, 1540O’Connor, E ............................................. 462O’Connor, J C .......................................... 234O’Dell, S K ............................................. 2182O’Hagan, S ............................................ 1392O’Hara, K A .......................................... 1133*O’Kane, J ................................................ 1262O’Keefe, M ............................................ 1386

O’Keefe, R ................................................ 695O’Malley, B W ........................................291*O’Malley, M ..................................... 776, 787O’Neill, A O ............................................. 951O’Neill, D F ........................................... 1401Oberdoerster, E ....................................1594*Oberdorster, G ........................ 443, 449, 698Obert, L A .............................................1916*Obi, E ...................................................... 1439Oblak, L ................................................. 1553Obourn, J D ........................................... 1802Odin, M ...........................................399, 406*Oe, T ....................................................... 1006Oeda, K .................................................... 750Ogasawara, T ........................................ 1388Ogata, H ................................................... 709Ogawa, K ................................................. 765Ogawa, T ................................954, 988*, 989Ogden, L ............................................... 2112*Ogden, M ..............................................1287*Oguma, E ....................................... 423, 1610Ogunmosin, O ........................................ 622Ogura, M ............................................... 1703Ogura, R ................................................ 1399Oh, D .......................1531, 2165*, 2168, 2169Oh, K .................................. 1427, 1524, 2168Oh, S ............................................. 1261, 1454Ohno, Y .................................................... 709Ohta, E ..................................................... 176Ohtake, N ................................................ 175Ohtani, K ................................................. 542Ohtsuki, K ............................................. 1501Oishi, Y ........................................ 1793, 2277Oka, H .................................................... 2213Okada, M ............................................... 1251Okajima, M .............................................. 700Okamoto, H ........................................... 1318Okamoto, K ............................................515*Okamura, M ................................. 211, 1793*Okerberg, C ........................................... 1916Okino, M ...............................858, 870*, 1298Okuno, Y ................................................ 1730Oldham, M ............................................ 1448Oldham, M J ............................................ 926Olin, S ......................................245, 261*, 386Olinga, P ...................................... 1913, 1914Oliveira, P ................................................ 206Oliver, J .................................................. 1375Oliver, J R ..................................................78*Oliver, M .................................................. 165Olivero-Verbel, J ..................................1708*Olivier, B N ............................................ 2030Olsen, G ......................................1236, 1798*Olsen, H ................................................. 1828Olsen, L .................................................... 413Olson, G R ............................................. 2187Olson, J J ................................................ 2107Olson, J R ..........................2038, 2045, 2157*Olson, M J .......................................372, 472*Omdahl, J ................................................. 715Omdahl, J L ............................................. 724Omiecinski, C ............................... 286*, 290*Ommen, B .............................................. 1319Omura, K ............................................... 2277Ondov, J M ............................................ 1451Ono, H ...................................................... 989Ono, K .................................................... 2063Onose, J .................................................. 1503Opanashuk, L ........................................ 1088Opanashuk, L A ...................................... 223Oppenheimer, S F ................................. 1299Oquendo, I ............................................ 2219Oravitz, M S ............................................ 778Orberg, J ................................................... 679Ordonez-Librado, J ................................ 608Ordonio, R ............................................... 473Oreffo, V .................................................. 508Orehek, M ................................................ 793Orisakwe, O E ......................................1439*Orito, K ...................................................954*Orozco, J .................................................157*Orphanides, G .................... 124, 1375, 1739Orr, J L .....................................................1137Orr, M S ...............................753*, 1829, 1972Orren, D K ............................................. 2269Orrenius, S ............................................. 2276Ortel, T L .................................................843*Ortiz-Acevedo, A .................................. 1594

238

AU

TH

OR

IND

EX




Ortiz/Bueno, A ..................................... 1619Orton, E .................................................... 915Orzech, D ........................... 1425, 1506, 2035Osborne, T ............................................... 540Osbourn, D ............................................ 1537Oshiro, W M ...................... 2089, 2090, 2092Osier, M .................................................. 1477Osimitz, T G ................................ 1075, 2160Osipov, A N ......................2282, 2283, 2284*Osna, N A .............................................. 1657Osorio, E .................................................. 427Osowski, J J ..........................................2230*Ospino, I ................................................ 1708Ostrosky, P ....................................1146, 1455Osweiler, G D ........................................ 1385Othumpangat, S ........................ 1163, 1166*Otieno, M ....................................1626, 1779*Otstot, J .................................................... 136Otsuka, M .............................................. 1379Otsuka, S .................................................. 833Otto, C M ................................................. 534Otto, M ................................................... 1057Oude Elferink, R ................................... 1051Ouyang, Y ................................................ 369Ovando, B J ................................2038, 2045*Overmann, G J ...................................... 1371Owen, M ........................................ 484, 1628Owens, S T ............................................... 504Ozaki, K ................................................... 750Ozawa, S .................................................. 709Ozeki, Y .................................................. 1703

PPabello, N .............................................. 1064Pabst Marra, T ........................................ 467Padgett, W T ......................................... 2268Padilla, A ............................................... 1708Padilla, S ............................. 966, 1277, 1939, .............................................1940*, 1941, 2095Padilla-Bank, E ..................................... 1370Padilla-Banks, E .....................................260*Padovani, A M ........................................ 688Padowski, J M ....................................... 2255Paepke, O ............................ 310, 2054, 2072Pagan, I ...................................................371*Pagan-Rodriguez, D ............................. 1386Page, J G ................................................... 797Page, T ..................................................1222*Page, T J ................................................. 1218Pagliarulo, M .............................2077, 2081*Pai, S S .................................................... 1383Paigen, K .................................................... 60Pakkenberg, B ............................. 1056, 1057Palazuelos, M ...........................................43*Palermo, C M ...........................................97*Palkar, P S ...................................73, 77, 842*Palmeira, C M ............................1835, 1849*Palmer, V S .......................1549*, 1550, 1551Pancras, J ............................................... 1451Pandey, R ................................................. 154Pang, W .................................................. 1070Pantano, P .............................................. 1594Pantle, L ................................................1891*Papagiannis, C N ............................ 170, 807Papania, M ...........................................1349*Papineni, S ............................................. 2298Papoulias, D M ....................................1289*Parchment, R E ..................................... 1776Parent, R .................................................. 635Parent-Massin, D ...................................1175Parham, A ................................................ 732Parham, F .............................................. 1376Parham, F M ............................................ 852Parikh, S ................................................... 710Paris, B L .................................................. 718Paris, M .........................................484, 1628*Park, E ...................................................... 156Park, J ......................................................156*Park, K ............................................. 156, 907Park, S ...................................111, 1215, 2041Park, Y .................................................... 1261Parker, A .................................................. 375Parker, F ................................................. 2131Parker, J .................................................. 1826Parker, J B ...............................569, 755, 1174Parkinson, A ...........................................1174

Parkinson, C ............................................ 863Parkinson, C U ...................................... 1463Parkinson, H D ..................................... 1228Parng, C ....................................... 1096, 2018Parod, R ................................................... 264Parod, R J ................................................. 284Parran, D K .............................................626*Parris, C ................................................... 986Parrish, A ............................................... 2126Parton, J W .......................1203, 2189*, 2228Pasos, F ...........................................608, 1153Passaint, L ...............................................592*Pastino, G ................................... 860*, 1688*Pastoor, T ................................................671*Pastoor, T P .............................743, 744, 745*Pastusyzn, A ............................................ 724Pat, S W ........................................ 1600, 1601Patel, B B ................................................ 1493Patel, N N ...........................................70, 81*Patel, P ................................................... 1252Patel, R ................................................... 1383Pathak, S .................................................. 967Patierno, S R ...........................................1136Patino, R .................................................. 494Patlewicz, G ...........................................1196Patlolla, A K .........................................1858*Paton, S J .................................................. 791Patten, C .................................................. 710Patten, C J .............................................. 1556Patterson, R M .......................................362*Patterson, T A .............................. 1098, 1099Patton, D .................................................245*Patzer, S ................................................. 1238Paul, D S .................................................135*Paul, K .................................................... 1927Paul, S D .................................................. 419Paule, M G ....................................987*, 1072Paules, R ................................................ 1855Paules, R S ........................119, 121, 127, 757Paulsen, D ............................................. 1012Pauluhn, J .............................................1469*Paustenbach, D ........................................411Paustenbach, D J ..................257, 410*, 1338Pavco, P A .................................................15*Pavely, C ................................................ 1405Pavkov, K L ............................................. 275Pawliuk, R ............................................... 805Paximadis, P A .............................. 979, 2256Peachee, V L .....................................23, 178*Peake, J L ............................................... 1645Pearce, S ................................................. 1807Pearson, C .......................................126*, 522Pearson, E .............................................. 1072Peddada, S ................... 779, 844, 1794, 1821Peden, K ................................................. 1513Peden-Adams, M M ............................... 882Pedersen, T .............................................. 106Pederson, R ............................................1115Pedrick, N .............................................. 2180Peffer, R ............................................ 744, 745Peksa, R .................................................. 1436Pelgrim, M ................................... 1056, 1057Pelkonen, J ............................................. 1879Pelletier, D ..............................................559*Peltz, G ..................................................... 348Pence, D H ................1185, 1187, 1515, 1516Pendlington, R ...................................... 2173Penn, A ......................................... 1010, 1441penn, a ...................................................1012*Penning, T M ............................... 1043, 1815Penninks, A ............................................. 177Penninks, A H ............................... 953, 1208Penton, H ............................914, 1457, 2024*Penttinen, P ..........................................1879*Pepe, G ................................................... 1799Peraza, M A .......................................... 1911*Perdew, G .......................................657*, 715Perdew, G H ................................ 89, 90, 654Pereira, C ............................................... 1814Pereira, F E ...........................................1841*Pereira, M A .......................................... 1788Perentes, E ................................................. 61Perez, R M ............................................... 270Perez-Polo, J R ........................................ 214Perkins, R ............................................... 1704Perou, C M .............................................. 123Perrigo, E ................................................. 849Perrigo, E E ...........................................1306*

Persaud, J ................................................1139Person, M ................................................2118Person, M D ........................................... 1801Perstin, J ................................................2250*Perumean-Chaney, S ............................ 1009Pescovitz, O H ........................................ 255Pessah, I ................................................. 2060Pessah, I N ....................................... 46, 2053Peters, J M ......................... 55, 583, 586, 587, .........................................588, 759, 1820, 1911Peters, L ................................................2059*Petersen, D D .........................................250*Petersen, D R ..............185, 209*, 1718, 1723Petersen, S L .......................................... 2036Peterson, B ............................................1720*Peterson, J H ......................................... 1100*Peterson, M K ................................248, 871*Peterson, R .............................................. 905Peterson, R E ................ 87, 88, 91, 130, 548, ................................ 550, 554, 555, 1824, 1825Peterson, W M ........................................ 465Petranka, J ....................................... 828, 829Petrella, D K .................................... 80, 1932Petrick, J S .................143, 1762, 1763*, 2140Petrov, A ................................................. 1058Petsikas, D ............................................... 737Pettan-Brewer, C ....................................968*Pettersson, I ............................................. 679Pettersson, S .......................................... 1358Petty, R ....................................................1195Pezzoli, P ................................................. 754Pfau, J C .......................................... 686, 911*Pfeifer, K F ............................................. 2152Pham, C ................................................... 790Phelps, R L ................................................... 6Philbert, M A ............. 979, 1535, 1536, 1882Philip, B K .........................................73*, 842Phillips, C S ....................................125*, 774Phillips, J ................................................ 2013Phillips, P ............................................... 1940Phillips, P M ...................... 1078, 1091, 1941Phillips, T D ....................... 524, 1283, 1309, .............................................1400, 1402, 2270*Pi, J ...........................................................817*Picano, P L ............................................. 1556Piccotti, J R ................................... 180*, 1195Piechta, L ................................................. 755Pieper, R ................................. 64, 1005, 1900Pierce, J S ............................................... 1938Pierce, J T ................................................. 919Pierce, R ................................................... 225Piersma, A ................................... 1490, 1734Piersma, A H ......................................... 2061Pietenpol, J ............................................ 1810Pieters, R .............................903*, 1205, 1892Pine, P S ..................................................121*Pinkerton, K E ...................... 504, 927, 1008, ........................................... 1014*, 1221, 1645*Pinn, L .................................................... 2261Pino, M ....................................114, 915, 1464Pinon-Zarate, G .............................608, 1153Pinsonneault, L ....................262, 558*, 1462Pitot, H C ................................................667*Pitot, III, H ............................................... 671Pittinger, C ............................................... 375Pittman, G S .............................................115Pitts, D K .........................................601*, 602Pizarro, K ............................................... 1070Plamondon, P ...............................1127, 1128Plant, N .................................................... 580Plante, I .........................................764*, 1651Platoff, G E ...................................... 795, 796Pleus, R C .............................. 248, 871, 2102Plewa, M .................................................. 408Plitnik, L M ............................................ 1715Plopper, C .............................................. 1891Plopper, C G .................359, 916, 917, 1016*Plotzke, K ................................................ 949Plotzke, K P .......................... 848, 855, 1237, ...............1507*, 1508, 1509, 1510, 1751, 1812Plummer, S ................................. 761*, 2258*Pluta, L ......................................... 1218, 1222Poellinger, L .......................................... 1358Poet, T .....................................................233*Poet, T S ................................................. 1336Pognan, F ............................. 508, 1626, 1779Pohjanvirta, R ....................................... 2042Pohl, H ..................................................... 390

Pohl, L R .................................................. 905Polisini, J M ........................................... 2079Polk, W W .....................................184*, 1216Pollard, D L ........................................... 2174Pollenz, R S ......86, 100, 1357*, 1654*, 1658*Pomeroy-Black, M .................................. 315Pomeroy-Black, M J ............................1944*Pomper, M G ..........................................676*Ponce, R ................................................... 800Pons, C ................................................... 1732Ponten, E ................................................ 1073Poole, C A ................................................ 254Poole, T J .................................................. 686Pooler, M .............................204*, 1445, 1964Pooler, M S ............................................ 1369Popat, J ......................................... 1357, 1658Pope, C ....................................................... 51Pope, C N ...............................................998*Popovic, M .............................................904*Popp, J ...................................................... 670Portas, M ................................................ 1865Porter, D ................................................... 933Porter, D W ............................................ 1443Porter, K ..................................................541*Portier, C J ..................... 33, 852, 1302, 1376Portier, K M ........................................... 2074Portsmouth, C ....................................... 1710Possolo, A .............................. 93, 2044, 2056Post, J ...................................................... 2120Postlethwait, E ............................................ 2Potapovich, A I ....................................2282*Potapovich, M V ......................... 2283, 2284Potnis, P A ..............................................381*Pottenger, L H ......................................1041*Potter, L K .............................................. 1296Potter, P M ............................................. 1569Potti, A ..................................................... 843Potts, R ..................................................1516*Pouliot, L ..............................262*, 558, 1462Pounds, J G ............................. 108, 122, 918, ................................................ 919, 1551, 1705Pouyatos, B ................................................ 50Powell, C L ...........................................1855*Powell, E .................................................1160Powell, J L .................................... 1262, 1451Powell, K ................................................. 527Powell, P ................................................ 1642Power, F W ...................................870, 1298*Powers, B E ..........................................1085*Powers, K .................................................. 43Powley, M W ..................................198*, 525Powrie, R ......................................... 277, 733Prabhakaran, K ........................... 1543, 2279Prabu, S K ................................................ 205Prasch, A L ..........................................88*, 91Prater, M R ............................................2261*Prater, R ................................................... 685Pratt, A ................................................... 2021Pregenzer, J F .................................80*, 1932Presley, S M ........................................... 2016Preuss, H G ........................................... 1414Price, B B .................................................1197Price, J .................................................... 1810Price, K ....................................................349*Price, O ....................................................2110Price, R J ................................................. 2160Price, V ......................................... 1637, 1642Price, W A ................................................ 789Prince, V L ............................................2000*Pringle, H .............................................. 1276Pritsos, C A ....................... 958, 1008*, 1009*Pritsos, K L ............................................ 1009Privalle, L ............................................... 1307Proctor, D ...................................... 382*, 421*Prohaska, J R ........................................... 279Prophete, C ...........................................1453*Proscura, E .............................................. 784Prough, R ............................................... 1844Provost, J .................................................. 830Prozialeck, W C ............1602*, 1605*, 2129*Prucha, M ................................................ 575Pruett, S B .......896*, 897, 898, 899, 900, 901Pruimboom-Brees, I ............................... 490Pu, X ......................................................... 760Puga, A ............... 92, 99, 103, 104, 132, 2267Pulido, M ..............................................2126*Pung, T ..................................................1943*Puppala, D ................................................85*

AU

TH

OR

IND

EX




Purdom, S E .........................................1848*Purdy, R ................................................. 1210Putt, D A .....................................1905, 2127*Puzas, E .................................................. 1031Puzas, J E .................................... 695*, 1034*Pyatskowit, J ..........................................279*Pyatt, D ........................................... 258*, 411Pyo, M ...................................................... 256

QQadri, I ..................................................... 713Qian, X ............................................... 58, 136Qian, Y ................................614*, 2132, 2270Qiao, D ....................................................964*Qiao, G ................................................... 1694Qiao, G G .................................. 1690*, 1692*Qu, W ....................................136, 748, 1608*Quackenbush, J ....................................1980*Quall, C W ............................................... 905Quan, C ...................................................697*Quattrochi, L C ....................................... 713Quinn, A L ............................................1751*Quinn, C P ............................................... 772Quintana, M .......................................... 1865Quintanilla-Vega, B ...............................1147Quintas, P E ............................................. 520Quynh, H T ........................................... 2072

RRaabe, H .............................. 484, 1628, 2001Raabe, H A ............................................1630*Rabemampianina, Y ............................... 830Rachman, N J .......................................... 653Racz, W J .................................................. 935Raczynski, A .................................. 464, 1632Radcliffe, P M .......................................1530*Radic, Z .................................................... 997Raemisch, A ........................................... 1461Raffaele, K ..............................................977*Raffaele, K C ........................................... 380Raghavan, N ........................................... 755Rahman, A A ........................................... 961Rajanna, B .............................................. 1065Rajendran, N ..............923, 1186, 1235, 1517Rall, M J ................................................. 1665Ralston, R ................................................ 798Ramadoss, P ............................................ 657Ramaiah, S K ......................................... 1047Ramapuram, J ......................................2190*Ramasubramanian, B ........................... 1922Ramesh, A ...................................1497*, 1498Ramirez, P ..............................................139*Ramirez-Alcantara, V ...........................498*Ramirez-Garcia, X S ............................1412*Ramos, K S .........................614, 1983*, 2132Ramos, Z ................................................ 2219Rampersand, C R ................................... 473Ramsdell, J S ......................................... 1070Randine, G ................................... 1055, 2051Rane, M .................................................. 1226Ranken, P F ..........................................1597*Rankin, G O ......................2121*, 2122, 2123Rannug, A .............................................1358*Rao, G ....................................................1874*Rao, G K ................................................... 369Rao, P S ................................................... 114*Rappaport, S M ..................................... 1301Rasco, J F ................................................ 1067Rath, M .................................................. 1494Rauen, U ................................................ 1818Rauma, M .............................................2198*Rausch, L ............................................... 1095Ravel, G ................................................... 885Ravoori, S .............................................. 1799Ray, R ....................................................... 724Ray, S D .......................................1410, 2301*Raymond, C ............................................ 287Raymond, E ............................................1107Raynal, N ............................................... 1651Raynal, N J ...........................................1790*Raynard, A ............................................. 1240Rayner, J L .................................... 299, 1122*Raza, H ....................................................205*Razani-Boroujerdi, S ................................ 21Razdolsky, A N ..................................... 1936

Read, D E ............................................... 1967Reams, R .................................................. 615Reaney, S .................................................. 630Reardon, K F ..........................................865*Rebelatto, M ............................................ 170Reckwitz, T ............................................ 1269Reddy, G ...............................................1238*Reddy, J K .................................................. 77Reddy, M ............................................... 1246Reddy, M B .....................................848*, 855Reddy, R ................................................. 1882Reddy, R N ...........................................2138*Reddy, V .................................................... 13Reece, J ..................................................... 817Reece, M T ............................................. 1281Reed, D A ............................................... 2078Reed, J R ..........................................725, 740*Reed, K ............................................703, 704*Reed, M ............................... 455, 460*, 1345*Reed, S ................................................... 2021Reeder, M K .......................................... 2011*Regal, J F ...............................................1717*Regal, R R .............................................. 1717Regan, J M ............................................. 1751Regan, K S ............................................. 1510Regenass, F ...........................................1878*Regnier, F E ............................................. 501Regunathan, A ...................................... 1035Reichard, J F ...........................................132*Reid, A B .................................................224*Reid, K R .................................................. 737Reilly, C A ...................................... 937, 1219Reily, M D .........................................511, 530Reimers, M ...........................................2243*Reiners, J J ...............................................995*Reisfeld, B .................................... 1300, 1306Reliene, R ............................208, 2232, 2272*Remon, J ................................................. 2015Ren, H .....................2143, 2148, 2150*, 2151Ren, S ............................................. 806, 2083Renne, R A ....................................... 506, 919Renner, J ........................................... 776, 787Renner, K ............................................... 2303Rentz, S S ................................................. 797Reo, N V ................................................... 526Repnevskaya, M ................................... 2233Resau, R ..................................................317*Retief, J ......................................... 1819, 2150Retief, J D ................................................. 121Rettenmeier, A W ........................ 1818, 2225Reuhl, K ................................................. 1058Reuhl, K R .................... 610, 611, 983, 1662*Reutter, S A .............................................. 794Reyes, J L ................................................1132Reyes-Olivera, A ..................................... 608Reynolds, J D .......................................... 359Reynolds, T ................................. 1404, 1671Rhee, G ..................................................1635*Rhomberg, L ...........................................386*Rhomberg, L R ........................................ 384Rhule, A ................................................1420*Rice, E ..................................................... 1671Rice, J M ................................................... 669Richard, A M ........................................1024*Richard, B M ................................718, 1935*Richards, J H ................................... 441, 927Richardson, J R ...........................973*, 1097, .............................................. 1529, 1545, 1961Richardson, R J .............................. 192, 824, .................................... 1843, 1936, 1937, 1938Richardson, T .........................................722*Richardson, V M ........................1227, 1769*Richburg, J H ......................................... 2292Richfeild, E .............................................. 645Richfield, E K ........................................ 1958Richter, A ..............................................2013*Richter, R ................................................. 409Richter, R O ............................................. 412Richter, W R ...................................770*, 771Rick, D ............................................ 269, 1563Ricks, R ...................................................1139Rideaux, C B .........................................1852*Riehl, J ...................................................2060*Riffle, J ...................................................... 486Riley, D J .................................................. 780Riley, R T ...........................1391*, 1395, 1396Rinderknecht, A ...................................1066*Ringeissen, S A ........................................ 491

Ringham, H ........................................... 2180Rintala, E ................................................749*Riordan, W .............................................. 464Rios, F ......................................................1146Rioux, K ................................................... 181Ripp, S L .................................................357*Ripper, T L ..............................................2011Ripple, S D ............................................. 1480Rise, M ................................................... 2238Ritov, V B ........................... 2284, 2294, 2295Ritz, S A .................................................... 458Riviere, J ................................................. 2180Riviere, J E .................................. 2175, 2176, .........................2183, 2184, 2194, 2196, 2197*Roach, F ................................................. 2080Robb, A .................................................. 1095Robert, D .................................................. 437Roberts, A E .................................. 560*, 577*Roberts, D W ........................................2185*Roberts, E .............................................. 1444Roberts, E S ............................................940*Roberts, J R ...................................939, 1449*Roberts, R ................................. 1649*, 1650*Roberts, R A ....................................118, 2131Roberts, S M ......................... 696, 909, 2073, ........................................................ 2074, 2186Robertson, D G ................................511, 530Robertson, J L ........................................ 1816Robertson, L .......................................... 2054Robertson, L W ....... 1082, 1487, 1488, 2058Robertson, S A ......................................... 772Robinson, J ............................................ 1655Robinson, J F .............................. 1155, 2257*Robinson, K ....................262, 411, 558, 1462Robinson, M ............................................ 744Robinson, P ..........................785, 1172, 1178Robinson, P J ................................786*, 1305Robinson, S D .......................................... 437Robison, C ....................................... 776, 787Robison, S H .........................................1291*Robosky, L C ........................................... 530Rockett, J ................................................ 2145Rockett, J C ...............188, 2143, 2148, 2151*Rockwell, C E .......................................... 369Rockwood, G A ............................... 795, 796Rodgers, P ............................................... 768Rodriguez, C ........................................... 461Rodriguez, E ......................................... 2303Rodriguez, G ........................................... 253Rodriguez, V M ...................................1957*Rodriguez-Fernandez, I ...................... 1893Rodriguez-Lara, V .........................608, 1153Roemer, H .............................................. 1269Roesch, S .................................................. 492Roger, V ................................................. 2032Rogers, B A ............................................ 1024Rogers, C ................................................. 805Rogers, E ................................................ 2248Rogers, J M .....................3, 280, 1643*, 2255Rogers, J V ....................................... 770, 771Rogers, L K .................................1726*, 1854Rogers, R E .............................................1190Rogers, R L ............................................ 1758Rogers, T L .............................................1176Rogers, W J .............................................. 106Rogge, M ................................................. 800Roh, S ....................................................1409*Rohde, C A ............................................ 1542Rohr, A C ........................................438, 439*Rojas, M ................................................. 1840Rojas-Lemus, M .............................608, 1153Rolfe, M ................................................... 464Rollins-Hairston, A M .......................... 1570Rolo, A .....................................................827*Rolo, A P ................................................ 1849Romach, B H ........................................... 584Roman, R ............................................... 1897Roman Gomez, R ..................................979*Ronis, M J ............................... 74, 274, 1031, ...................................1036*, 1737, 1918, 1919Ronquillo, D ............................................ 252Roomi, M ..............................................1494*Roop, B ......................................... 2144, 2146Roponen, M ..........................................1880*Rosado, J L ............................................... 252Rosales, G ................................................ 253Rosales-Garcia, V ..................................1147Rosdy, M .................................................. 482

Rose, M .................................................... 681Rose, P ...................................................... 745Rose, R L .......................................... 358, 726Rosenfeld, C ............................................ 860Rosenfeld, C A .....................................2154*Rosengren, R J ............................... 707, 1489Rosenstein, M ........................................ 1706Rosenthal, A F ......................................... 629Rosenthal, G ............................................ 766Rosenzweig, B A ..................................... 121Rosier, R ................................................... 695Rosini, G P ..............................................1137Ross, D ............................................. 47, 2276Ross, D G ............................................... 1227Ross, J A ................................................2268*Ross, J S .................................................... 976Ross, M K ..............................................1569*Ross, P .................................................... 1855Ross, S M ................................................. 276Rossi, B ................................................... 1732Rossman, T G .......................................1045*Rosson, G ............................................... 1791Roszell, L E .............................................164*Roth, M D ................................................ 926Roth, R A ................................ 69, 1930, 2052Rothenberg, J C ....................................... 429Rothenberg, S J ......................................429*Rothman, N ........................................... 1301Rotman, R .............................................. 1383Rottinghaus, G ...................................... 1385Rottman, J .............................................. 1632Roubicek, D A ....................................... 1455Rouleau, M ...................................1127, 1128Rouleau, N .....................................174, 195*Round, D P ............................................ 1945Rouquie, D .................................. 1731, 1732Rowan, W H ............................................ 433Rowden, J .............................................. 2071Rowe, A M ............................................1886*Rowland, T ...................................... 776, 787Rowton, S ...........1106*, 1172*, 1178*, 2200*Roy, C J ..................................................1470*Roy, D ..................................................... 1774Roy, N ....................................................1096*Roy, S K .......................................1927*, 2215Royland, J .............................................. 1445Royland, J E ................................1081, 1964*Royster, S ................................................. 795Rozman, K K ..................... 2034, 2048, 2050Ruan, Q .................................................1043*Rubin, E M .............................................1129Rubio-Andrade, M ......................... 252, 253Rubitski, E E ...............................2230, 2233*Ruble, K M ............................................ 1504Ruby, M V .............................................. 2084Ruchirawat, S ........................................ 1747Rudge Jr., T L .......................................... 780Ruf, S ........................................................ 924Rumbeiha, W K .....................................534*Runge-Morris, M .................................1976*Runge-Morris, M A .............................. 1974Runkle, S A ...........................................1535*Runnion, V .............................................. 419Rusch, G ................................................. 1485Russek, N ................................................1107Russel, L T ..............................................632*Russell, J .....................................2098, 2103*Russo, M .................................................. 497Rusyn, I .........................60, 759, 1046*, 1855Rutherford, M ....................................... 1717Rutkiewicz, J M ...................................... 888Ryan, C .................................................. 1196*Ryan, C A ............................1198, 1201, 1999Ryan, J ...................................................... 310Ryan, M ...............................1181, 2035, 2070Ryan, M J ............................................... 1425Ryan, T P .....................................1968, 1971*Ryter, S W .............................................. 2284Ryu, H .................................. 992, 1870, 2288

SSaad, A ................................................... 1626Sabnis, A S ..............................................937*Sabo-Attwood, T .................................. 1773Sabourin, C L .................. 770, 771, 774, 780Sabri, M I ..........................1549, 1550, 1551*

240

AU

TH

OR

IND

EX




Sachana, M ...........................................1950*Sadler, C ..................................................1511Sadovova, N .......................................... 2285Safe, S .......................................... 1368, 1764, .................................... 1770, 1807, 1808, 2298Safe, S H ..................................................993*Safford, B ............................................... 1201Safford, R J ............................................. 1293Sagelsdorff, P .........................................219*Saghir, S A ................................... 1176, 1242*Sahoo, R ................................................. 1876Said, M M .............................................. 1424Saigo, K .................................................. 1399Saito, F .................................................... 1379Saito, K ........................................... 750, 1379Saito, N ........................................ 2064, 2068Saito, Y ................................................... 1399Sakaguchi, H .................... 1192, 1193*, 1194Sakai, S ....................................................945*Sakai, Y .................................................... 485Salgado, V L ................................ 1962, 1963Salinas, K A ........................................... 1598Salinas-Carmona, M ............................ 1412Salinas-Moreno, J E ................................ 567Salmen, R ................................................. 705Salmon, A .............................................. 2109Salmon, A G ........... 1476, 1519*, 1521, 2111Salnikow, K ..................................641*, 1453Salonen, R O ........................ 436, 1446, 1895Samaniego, A .......................................... 766Sambuco, C P ........................................ 2193Samet, J .................................................... 428Samet, J M .............................................. 1450Sammons, D L ......................................... 772Samokyszyn, V ..................................... 2217Sampey, B P ............................................185*Sampo, B ................................................ 1550Samsam, T E .....................2089, 2090*, 2092Samson, M ................................... 1731, 1732Samuelsen, M .................................450, 453*Samura, K ................................................ 176Sanborn, J R ........................................... 2152Sanchez, J ................................................. 629Sanchez-Pena, L C .................................. 603Sand, S .....................................................405*Sanders, J M ................................. 116*, 1230Sanders, R A .......................................... 1401Sanderson, J ........................................... 1734Sanderson, J T ....................................... 2059Sanderson, T ......................513, 1747*, 1748Sanderson, T P ...................................... 1781Sandler, D P ........................................... 1333Sandstrom, T ................................. 307, 1446Sandwick, S J ..........................................1145Sandy, M S ....................................396*, 1521Sangaiah, R ............................................ 1847Sanner, T .................................................385*Sano, M .................................................... 742Santamaria, A B .....................................653*Santella, R M ........................................ 1011*Santhanam, P .......................................... 449Santiago, M R .......................................2219*Santiago, P ............................................... 242Santory, J .................................................. 373Santostefano, M J ...................................491*Santra, S ................................................. 2186Saoo, K ................................................... 1471Sarafian, T A ...........................................926*Saranko, C J ......................2074, 2075*, 2076Saranko, C M ........................................ 2073Sarisky, J ................................................... 425Sartor, M .................................................. 103Sasaki, M .......................................... 176, 980Sasaki, S ................................................... 423Sasaki, Y ................................................. 1388Sasaki, Y F .............................................. 2213Sasser, L B ................................................ 238Sasseville, V ................................. 1632, 2027Sasseville, V G .......................................464*Sato, H ...................................604, 816, 1703*Sato, I ............................................ 1954, 1966Sato, K .................................................... 1501Sato, M ..........................................226*, 1615Sato, T .................................................... 2213Satoh, H ................................................... 812Satoh, M ............ 605, 1152, 1191, 1318, 1611Satoh, T ............................................ 459, 944Satoshi, T ............................................... 1640

Saulsbury, M D ..................................... 1945Saunders, G ............................................. 887Saunders, K R ....................................... 2121Saunders, M D .......................................528*Savateeva, T N ........................................ 468Savolainen, K ........................................ 1885Sawada, M ....................................... 605, 700Sawant, S P .....................................62, 1910*Saxtorph, H ........................................... 2028Sayer, A N .............................................. 2227Sayes, C .................................................... 703Sayes, C M ..................................1862*, 2185Scabilloni, J .............................................. 702Scallet, A ................................................ 2285Scandlyn, M J .........................................707*Scaramell, H .......................................... 1833Scaramella, P ............................................411Schadt, E .................................................. 287Schaefer, G ............................................... 978Schaefer, G J ............................................ 473Schaeffer, D J ........................................... 545Schafer, R ............................................... 1886Schantz, S L ........................................... 1085Schatz, R A ............................................... 943Schauer, U .............................................. 1239Schebler, P ............................................2069*Schechtman, L M .................................1355*Schecter, A J ........................ 309, 310*, 2072*Scheffer, G .............................................. 1921Schehl, T L ............................................... 491Schettler, S ............................................1071*Scheuplein, R ........................................ 1343Schiestl, R ...............................................335*Schiestl, R H ...................... 208*, 333*, 2230, .............................................. 2232, 2233, 2272Schilling, B ............................................. 2054Schilling, B E ......................................... 1781Schilling, C .............................................422*Schisler, M R .......................................... 1041Schladweiler, M C .........................441, 927*Schladweiler, M J .................................... 433Schlager, J .............................................. 1625Schlager, J J ...........................................2174*Schlager, J M .......................................... 1719Schleef, R ................................................. 924Schlenk, D ............................ 739, 1555, 1590Schlesinger, R B .......................................... 2Schlezinger, J ................................367*, 1869Schlezinger, J J ........... 992, 1870, 1871, 2288Schlosser, P M ......................................1467*Schlueter, K ............................................. 924Schmid, J ................................................ 1709Schmid, J E ........................... 188, 683, 2143, .............................................. 2148, 2150, 2151Schmidt, C M ........................................ 1621Schmidt, T ............................................. 1269Schmitz, H ............................................. 2054Schmued, L ............................................ 2285Schnaas, L ................................................ 427Schnackenberg, L K ....................... 509*, 511Schneider, J C ........................................ 1841Schneider, M C ...................................... 1841Schneider, R J .......................................1882*Schneider, S N ..............................227, 1599*Schnellmann, R G ............. 2125, 2128, 2130Schoen, A ..............................................2085*Scholten, D ............................................ 1747Scholz, N ................................................ 1584Schomaker, S ........................................... 490Schomaker, S J ........................................716*Schon, J .................................................... 982Schoof, R A ............................................ 2084Schramm, K ........................................... 2050Schramm, U ........................................... 1863Schrenk, D ................................... 2054, 2061Schuessler, T F ......................................... 920Schuetz, E G .....................................65, 289*Schuh, R A ............................................1960*Schuler, M J ............................................. 337Schultz, I ................................... 1586*, 2021*Schultz, P G ........................................... 1721Schulze, J B .................................... 397, 1403Schulze, M M ........................................ 1403Schumann, B ......................................... 2267Schut, M ................................................. 1560Schwab, C L ............................896, 897*, 900Schwaber, J S ........................................1981*Schwaiger, S .......................................... 2303

Schwartz, A J ........................................... 462Schwartz, B S ...................... 430, 1148, 1327*Schwartz, D A ............................... 928, 1846Schwartz, L W ............................... 536, 1828Schwartz, R H ....................................... 1872Schwarz, E ............................................... 695Schwarz, M ............................................ 2054Schwarze, P E .......................................... 417Schwegler-Berry, D ..................... 1468, 2282Schweikart, K .......................................... 801Schwengberg, S ....................................1996*Schwetz, B A .........................................1681*Sciarrotta, J .............................................. 905Scicchitano, M S .................................... 1828Sciullo, E M ........................................... 1442Scollon, E J ....................................850, 1250*Scott, P ..............................................257, 411Scotto, J .................................... 776, 787, 793Scotto, J A ......................................... 775, 788Scrafford, C G ......................................... 693Seacat, A ................................................. 1236Seagrave, J ........ 2, 2, 455, 456*, 1015, 1017*Seaman, C .............................................. 2009Seaman, C W ................................372, 2006*Secrest, J T ............................................... 808Seegal, R F ..........................621, 1083, 1988*Seeley, M ...............................................2083*Seeley, M R ............................................ 1071Seeram, N ................................................ 926Segarra, A ...............................................624*Segura, B .................................................. 603Sehata, S ................................................1433*Sehgal, I ................................................... 932Seid, D A ....................................... 379, 1179*Seidel, T ................................................. 1269Seidler, F J .................... 964, 965, 1068, 1069Seki, T ..................................... 980, 981, 1730Sekijima, M .................................... 763, 1379Seko, Y .....................................................1152Sekowski, J W ........................................793*Selby-Mohamadu, Y ............................ 2100Selevan, S G ..................................... 255, 378Selgrade, M ............................ 18*, 19*, 1213Selgrade, M K ....................................... 1715Selim, S ..................................................2107*Selinski, S ............................................... 1269Sellers, T S ............................................... 536Sells, D M ............................................... 1506Semano, M ............................................. 1864Sen, B ...................................371, 1816, 1819*Sen, C ..................................................... 1393Sen, U ....................................................... 691Senese, P .................................................. 839Seng, J ........................................... 1637, 1642Seng, J E ..................................................706*Sens, D A ............................... 146, 147, 1606, .............................................1614, 1616*, 1618Sens, M ....................1606, 1614, 1616, 1618*Sentissi, J ...................................................911Seo, M .................................................... 1191*Seo, M J .................................................... 202Seok, J ..................................................... 1635Serle, J .................................................... 1288Serrano, J ..............................................1755*Sette, W .................................................... 977Setzer, W ................................................ 1939Sexton, K .................................................. 930Sexton, K G .............................................. 942Sey, Y ...................................................... 2145Shabat, S .................................................. 844Shafer, T J ....................49, 1547, 1548*, 1953Shah, I .....................................................537*Shah, N .................................................. 1410Shaikh, Z A ............................................ 1607Shakarjian, M P ............................. 780, 2171Shan, W ......................................... 583*, 1911Shankar, K ....................74, 274*, 1036, 1737Shanker, G ............................................... 620Shansab, M ............................................ 1871Shara, M ................................................1414*Sharlin, D ..............................................1086*Sharma, N .............................................1389*Sharma, R P ........................... 76, 1389, 1434Sharpe, R ................................................ 2258Sharrett, E ................................................ 430Sharrett, R ................................................ 430Shatkin, J ................................................ 2100Shaver-Walker, P ...................................840*

Shaw, D .................................................1209*Sheabar, F .............................................. 1634Shearer, J ......................................... 810, 811*Sheasgreen, J E ............................1171, 1254, .............................................. 2002, 2003, 2191Shedlofsky, S I ........................................727*Sheehan, P ............................................... 409Sheen, Y Y ..................................... 202*, 720*Shelby, M K ..........................................1761*Sheldon, L .............................................. 1291Shelley, J T ............................................... 159Shen, A ..................................................... 490Shen, D ..................................................... 227Shen, J ....................... 144*, 1264, 1801, 2118Shen, M .................................................. 1301Sheng, L ................................................. 1513Sheng, T ................................................... 721Shenton, J M ............................................ 904Shepherd, D M .............................. 364, 1420Shepherd, N ................................ 1465, 1466Sherchan, J ............................................. 2263Sherr, D .......................................... 367, 1869Sherr, D H ....................................990*, 1359, .............................................1870*, 1871, 2288Shertzer, H G ........................................... 227Sheth, C M ............................................... 178Sheu, T ..................................................... 695Shi, D .....................................................1555*Shi, L ............ 1098, 1099, 1381*, 1624*, 1704Shi, S ........................................................579*Shibanushi, T ........................................ 1640Shibata, E ............................................... 1248Shields, W J ........................................... 1387Shigetaka, M ......................................... 1703Shih, D ................................................... 1373Shih, D M ............................................... 1949Shih, T .............................................. 776, 785Shih, T M ................................................. 787Shima, H .................................................. 451Shimada, A .....................................605, 700*Shimada, N ............................................ 1904Shimamura, N ....................................... 1251Shimbo, S ............................................... 2064Shimizu, J ................................................ 210Shimomoto, M ........................................ 834Shin, C ...................................................... 256Shin, D .............................1409, 1423*, 1427, .............................................. 1524, 1531, 2169Shin, J ..................................................... 1261Shin-Darlak, C ...................................... 2235Shindo, A ............................................... 2037Shinohara, Y .......................................... 2277Shioda, A ................................................ 1633Shioda, S .......................................... 988, 989Shiotani, M .....................................831, 837*Shipp, A ................................................... 398Shirai, M .................................................. 954Shirai, T ...................... 765, 1379, 1388, 1424Shiverick, K .................................. 370, 1113*Shock, S S ............................................... 1387Shoki, M ................................................... 833Shokouhi, B ........................................... 2225Short, B G ..............................................6, 12*Shost, S J ................................................ 1288Showker, J L .......................................... 1391Shows, E B ............................................. 1299Shreve, K ................................................ 1516Shreve, K W ............................................1185Shuey, D ................................................2210*Shugar, D ................................................. 817Shultz, R L ............................................. 1093Shultz, V .......................................... 560, 577Shum, M .................................................. 412Shuto, R .................................................1742*Shvedova, A ............................................ 705Shvedova, A A ............. 701, 702, 2188, 2282Siacotos, T J ............................................. 473Sibanushi, T ............................................. 799Sibiril, Y ..................................................1175Sickles, D ............................................... 1553Sickles, D W .........................................1552*Siddens, L K .......................................... 1499Siddiqi, H K ........................................... 1062Siddiqui, W ............................................949*Sidhu, J ................................................... 1655Sidhu, J S .......................................1155, 2257Siegel, D M .............................................. 254Siegel, P D ...............................................1211

AU

TH

OR

IND

EX




Siegers, C .................................... 397*, 1403*Sierra-Santoyo, A .................................1568*Sifre, M ....................................................1114Signs, S ................................................... 2192Sigolaeva, L V ......................................... 192Silbajoris, R ...........................................1450*Silber, P M .................................... 1263, 2014Silbergeld, E ............................................ 879Silbergeld, E K ..............................430*, 627, ........................................... 1148, 1326*, 1331*Silkworth, J ................................................ 93Silkworth, J B .............................. 2044, 2056Sills, R C ................................................. 1091Silva, V M ...............................................698*Silva, W I ............................................... 1539Silver, D ...................................................420*Silverstone, A E ....................................... 881Sim, E ..................................................... 1266Simeonova, P ........................................ 1713Simeonova, P P ....................................... 705Simmen, F A ........................ 274, 1918, 1919Simmonds, P L .............................. 184, 1216Simmons, J ..........................408, 1292, 1934*Simmons, T W .............................. 321*, 322*Simon, S ................................................. 1750Simon, S L ...............................................331*Simpson, D A ...........................................119Sina, J ........................................................ 121Sinclair, J F ....................... 65, 137, 218, 1049Sinclair, P R ...............................65, 137, 218*Singh, A V .............................................. 1984Singh, J ................................................... 1915Singh, M ....................................... 2004, 2190Singh, N P .............................................1866*Singh, P .................................................1214*Singh, R .............................. 1616, 1740, 2066Singh, R K .............................................1614*Singh, S .................................................. 1588Singh, S P ..............................................2217*Singh, V ................................................. 1313Singleton, S .............................................1144Sinz, M ..................................................... 719Sioutas, C ............................................... 1453Sistare, F ................................................. 1513Sistare, F D .............................................. 121Sistrunk, S C ................................ 1947, 1955Sivils, J .....................................................576*Sizemore, A ................................... 484, 2001Skakkebaek, N E ..................................... 255Skare, J ..................................................... 733Skillman, A D ........................................ 1586Skinner, A .............................................2235*Slikker, W .......................... 673*, 674*, 1098, ...................................1099, 1702, 1979*, 2285Slim, R ................................................... 1195*Slim, R M ................................................. 180Slitt, A L ................................815*, 821, 1761Slitt, A M .................................................... 67Sloan, C .................................................... 732Sloan, C S ................................................547*Sloter, E .................................................... 231Sloter, E D .......................................239, 240*Slotkin, T A .................. 964, 965, 1068, 1069Smalstig, T ............................................... 412Smart, D ................................................2234*Smart, E .................................................. 1838Smith, A ......................................... 670, 1089Smith, A G ............................................1903*Smith, B .................................................... 884Smith, C ... 194, 391, 1233, 1234, 2069, 2086Smith, C J ............................................... 1294Smith, C S .............................................. 2129Smith, C V ................................... 1726, 1854Smith, D ................................................... 598Smith, D J ................................................760*Smith, D R ..............................597, 629, 630*Smith, E L .............................................1533*Smith, H ................................................. 1992Smith, J ................................................... 1420Smith, J B ............................................... 2299Smith, J P ................................................. 772Smith, K R ..............................................504*Smith, M ........................................ 861, 2065Smith, M A ............................................. 1395Smith, M D ...........................................2240*Smith, M T ............................................. 1301Smith, M V ...........................................1302*Smith, P A .................................... 1508, 1509

Smith, P F ............................................... 2027Smith, P J ............................................... 1537Smith, R D ............................................... 918Smith, R G ............................................... 635Smith, S M ............................................. 2246Smith, T .................................................... 356Smith, W J .................... 777, 782, 2201, 2202Smith-Roe, S .........................................2273*Smithson, S .............................................. 766Smitz, J ..........................................1123, 1366Smoller, S ................................................. 982Smyth, S ................................................. 1840Snawder, J E ............................................ 772Snellings, W M .....................................1256*Snodgrass, B R .....................................1556*Snow, T A ............................................... 1578Snyder, R ................................ 260, 361, 1842Snyder, R D ..........................................1040*Snyder, R W ............................................. 505Snyder, T ................................................ 1630Snyder-Keller, A .................................... 1083Sobel, E S ................................................. 909Sobieszczyk, MD PhD, A ..................... 1668Sochaski, M A ....................................... 1228Soderstrom, C ......................................... 171Soekeland, J ........................................... 1269Soelberg, J ................................................ 233Soelberg, J J .............................................. 232Sohn, H .................................................. 1217Sohn, J .................................................... 1261Sokolov, V B ...................... 1936, 1937, 1938Sokolovskaya, L G .................................. 192Solis-Heredia, M ....................................1147Soloviev, M .............................................473*Somji, S ...................1606*, 1614, 1616, 1618Sommer, R J ........................................... 1831Sommerville, D R ................................... 788Sonawane, B .................................. 378, 1978Sone, H ..................................................1376*Sone, T .................................................... 1617Song, A ..................................................... 806Song, Y ................................353, 1226*, 2186Soni, M G ..................................................35*Sonich-Mullin, C .................................... 328Sonnewald, U .......................................... 620Sono, S ...........................................1192, 1193Soos, J M .................................................. 910Sopori, M ..................................................21*Sordo, M .......................................1146, 1455Sorrentino, C ........................353, 1129, 1361Soshilov, A ............................................... 353Soucy, N V .................................. 1162, 1228*Sousa, R B .............................................. 1835South, N ................................................... 391Spainhour, C B ...........................1418*, 2029Spalding, S ............................................. 1512Speal, B A ................................................. 910Spear, B T ..................................... 1487, 1488Spence, F ................................................ 2205Spencer, P J ................................. 2211*, 2224Spencer, P S ..............578*, 1549, 1550, 1551Spencer, W A ........................................2269*Spiegl, N M ..........................................1262*Spirkl, H ................................................. 1038Spletter, M L ............................................ 984Sprague, G L ............................................ 372Spriggs, D ...............................................1184Springer, D .............................................355*Sprugel, K ................................................ 461Squibb, K ................................................. 163Squibb, K S .................165*, 632, 1262, 1451Srinivasan, V ........................................... 790Sriram, K ...............................................1223*Srivastava, P .......................................... 1924Srivastava, S ........................ 691, 1844, 1876St-Pierre, A ............................................... 558St. Jeor, S ................................................ 1009Stachlewitz, R F .....................................462*Stadler, J C ............................................... 952Staedtler, F ................................................. 61Stahl, N .................................................. 1470Stammberger, I .............................. 510, 1038Stams, K ................................................. 2291Stamyr, K ................................................. 352Stanley, L .................................................733*Stapelton, P L ........................................ 1495Stapleton, A R ................................571, 963*Stapleton, B ............................................715*

Stapleton, P ........................................... 1584Stapleton, P L ........................................ 2244Stark, J .................................................... 1898Starmer, R ................................................ 768Staskal, D ........................................ 310, 311*Staskal, D F ............................................ 1253States, J ..........................689, 690, 691*, 1267Stauber, A J ...................................582*, 2286Staudenmayer, J W ............................... 1281Stavanja, M S ........................................ 1187*Stearns, D M ............................ 157, 158, 159Steele, T D .....................................872*, 1878Steevens, J A .......................................... 1585Steever, K ................................................. 540Steffensen, K R .................................... 57, 59Steffy, D A .............................................. 1589Stegall, V ................................................ 1067Stehfest, E .............................................. 1461Steigerwalt, R .......................................... 461Stein, G S ................................................ 1032Stein, T D ................................................. 985Steiner, S ................................ 64, 1005, 1900Steiner, S R ............................................. 1535Steinmetz, K ............................... 801*, 1095*Stelck, R ................................................... 210Stemm, D N ................................1487*, 1488Stemmer, K ........................................... 2114*Stenner, R D ........................................... 1003Stephenson, A P .....................................615*Steppan, L B .......................................... 1873Sterling, S ................................................328*Sterner, T R .................................1305, 2078*Stevens, G J ...................................... 488, 515Stevens, J T ............................................ 1738Stevens, S C ........................................... 2174Stevens, T ..............................................1894*Stewart, C ................................................ 802Stewart, J ...........................................27*, 375Stewart, J K ............................................ 1639Stewart, K E ............................................. 254Stickney, J A ............................................399*Stierum, R .............................................. 1560Stifelman, M L ......................................2082*Stilianesis, M ................................479*, 1780Still, K R ................................................... 545Stineman, C ............................................. 428Stinn, W ................................................1518*Stock, A L ................................................425*Stohs, S ........................................1410*, 2301Stoker, T E ...................................1728*, 1733Stokes, W ............................ 484, 1628, 1997, .............................................. 2005, 2007, 2008Stokes, W S ....................................660, 661*, .......................................662, 663, 1351, 1352*Stolper, G ..............................................1254*Stoltzfus, R J ............................................ 252Stone, P ............................................ 574, 941Stone, S ................................................... 1468Stoner, G D ............................................ 1486Stoner, M .................................................. 290Storer, R D ............................................1028*Stork, L G ................................................408*Storm, J E ....................................1093, 1288*Stott, W .................................................... 670Stout, M D ..............................................525*Stoute, M ..............................................1462*Stoyanovsky, D A ................................. 2284Strakhova, M ........................................... 557Strakhova, N N ................... 192, 1936, 1937Stratford, I J ........................................... 1652Straube, F ......................................481, 2010*Strauss, K A ........................................... 1262Streicker, M .............................................. 844Stresser, D M ........................................... 719Strickland, J ..................................484*, 1628Striley, C A ............................................... 772Stringer, K F ...........................................1165Strom, S C .................................... 1049, 1495Strynar, M J ............................................ 1232Stuart, E C .............................................1489*Stuchal, L D ..........................................1596*Stulnig, T M ......................................... 57, 59Stump, D G .................................. 3, 239, 275Stuppner, H ........................................... 2303Styblo, M .............. 135, 148, 930, 1231, 1817Styles, J A ................................................1110Su, T .......................................................... 723Suarez, J C ............................................... 497

Succop, P ................................................ 1512Suda, M .......................................... 542, 1080Sudo, Y ................................................... 1379Sugawara, T ............................................ 812Sugden, K D ...........................................1136Sugita-Konishi, Y ............................ 459, 607Sugita-Konishi, y ...................................886*Sugiura, S ..............................................1424*Sugiura, Y ................................................ 944Sui, L ......................................................... 982Sukata, T .................................................750*Sulentic, C E ...........................................366*Sullivan, M ............................................ 2120Sultatos, L ................................................ 860Sultatos, L G .......................................... 2154Sumida, K ............................ 750, 1379, 1793Sun, F ....................................................1526*Sun, G ........................................... 2144, 2146Sun, H ..................................................... 112*Sun, J .................................... 825, 1938, 2133Sun, N N .................................................. 936Sun, Y ......................................................183*Sung, J .................................................... 1454Sunouchi, M ............................................ 709Suresh, C .................................................. 613Sushynski, J M ...................................... 1242Sutherland, K .......................................... 210Sutherland, K L ....................................... 917Sutter, C ....................................................93*Sutter, T ...................................................... 93Sutter, T R ............................ 354, 2044, 2056Sutton, J M ............................................... 962Sutton, R ................................................ 1386Suzen, S .................................................1273*Suzuki, H ........................... 1192, 1193, 1194, .............................................1394, 1399, 1434*Suzuki, K ..................................... 1954, 1966Suzuki, S .................... 765, 1424, 1615, 2213Suzuki, T .............................. 812, 1954, 1966Suzuki, Y .................................................. 886Swanson, C .............. 57, 58, 581, 1372, 2286Swanson, H ..................................... 85, 1805Swauger, J E .............1185, 1187, 1515, 1516Sweatman, B C ........................................ 491Sweatt, A .................................................. 196Sweeney, L M .................................236, 237*Swenberg, J A .................. 193, 198, 523, 525Swiatek, P J .............................................. 723Syed, J ...................................................... 462Sykes, G ................................................... 945Sykes, G P ...................................... 951, 1405Sylvester, A J ............................................ 774Symons, M J ............................................ 428Syversen, T ...................................... 595, 620Syversen, T L ........................................... 599Szabo, N J ...............................................696*Szilagyi, M ................................... 1998, 2017

TTa, T N ...................................................2053*Tack, J ..................................................... 1950Tahara, M ..............................................2155*Tai, J K .................................................... 1491Tak, W .................................................... 1046Takada, S .................................................. 267Takahashi, M ....................... 799, 1640, 1727Takahashi, S ........................................... 1424Takahashi, Y .......................................... 1432Takasaki, W ........................................... 2213Takechi, M ............................................. 1459Takeuchi, H ........................................... 1471Takeuchi, Y .................................... 278, 2142Takewaki, T ................................. 1954, 1966Takeyoshi, M ......................................... 1727Takiguchi, M ........................................1615*Tal, T ....................................................... 1450Talaska, G .............................................. 2267Talbot, P ..................................................1115Talmage, S S ...............................1473, 1485*Tamai, A ................................................... 834Tamaki, Y ............................................... 1394Tamano, S ................................................ 746Tamura, K ...............................................561*Tan, J ....................................................... 2183Tan, M ...................................................... 710Tan, Y ...............................34, 403, 404*, 1297

242

AU

TH

OR

IND

EX




Tan, Z ........................................................99*Tanaka, A K ............................................. 945Tanaka, H ................................................. 709Tanaka, K ............................................... 1617Tanaka, S .....................................1740, 2066*Tang, J ....................................................2145*Tang, L ................................ 1308, 1309, 1595Tang, Y ................................................... 1308Tanguay, R ............................................. 2243Tanguay, R L ................ 88, 2237, 2241, 2242Tanhehco, E ............................................839*Taniguchi, R .......................................... 1703Tanji, M .................................................. 1432Tank, A ................................................... 1530Tannenbaum, S R .................................1007*Tao, L .....................................................1788*Tapia-Santos, B ..................................... 1467Tapscott, N .............................................. 472Tarabelsi, L .............................................. 719Tarantino, L M ..................................... 1129*Tardif, R ..........................................244, 851*Tarkowski, M ........................................ 1712Tarloff, J B ...............................213, 321, 323*Tashiro, C ............................................... 1363Tashkin, D P ............................................ 926Taylor, B ..........................................689, 690*Taylor, J ........................ 64, 1005, 1402, 1900Taylor, J F ..............................................1400*Taylor, M J ............................................... 473Taylor, M L ...................................... 770, 771Taylor, P ..................................................997*Tchao, R ........................................ 70, 81, 216Tchounwou, P B .................................... 1858Teeguarden, J .......................................... 671Teeguarden, J G .....................................854*Tegelenbosch, M M ................................ 953Teng, N ..................................................... 801Tennant, A H ........................................... 152Tennant, D A ......................................... 1652Tennant, R .................................................. 60Tennant, R W ......................... 64, 1005, 1900Tenneson, K .................................. 841, 1102*Teranishi, M .......................................... 1433Teraoka, H ............................................2037*Terasaka, S ............................................. 1432Terneus, M ................................................66*Terranova, P F ............................. 2034, 2048Terry, K K ................................................1121Teske, S ....................................................875*Testino, A ............................................... 1552Tewksbury, E ......................................... 1467Thackaberry, E A ...................................845*Thai, S ...................... 2144, 2146, 2147, 2149Tharappel, J C ............................1487, 1488*Thatcher, G R .............................. 1573, 2274Thayer, W C .......................................... 2082Theobald, H M .......................................... 87Theophilus, E H ................................... 1185*Thibault, S ............................................... 798Thibodeaux, J ...............................280*, 2066Thibodeaux, J R .......................... 1232, 2144Thiel, M ...................................................2114Thier, R ................................................... 1269Thilagar, A ................................... 1927, 2215Thillainadarajah, I ................................ 2151Thiruchelvam, M ........................... 217, 645, .............................................1957, 1958*, 1965Thomas, B ...............................................1126Thomas, C E ...........................................519*Thomas, D J ................. 148, 692, 1231, 1817Thomas, F ................................................ 376Thomas, H C ......................................... 1828Thomas, J H ........................................... 1758Thomas, K ............................................1307*Thomas, P E ............................................. 721Thomas, R .............................................. 1484Thomas, R S ................................. 1218, 1222Thomas, S ................................................ 982Thomas, T ................................................ 378Thomas, T W ........................................1225*Thomford, P J .......................................... 804Thompson, C ................................181, 2208*Thompson, C M .............................. 378, 859Thompson, K .......................................... 121Thompson, K E ............................. 188, 2151Thompson, R ............................................911Thompson, S ........................................... 785Thomson, S .............................. 776, 793, 794

Thomson, S A .......... 773, 775, 786, 787, 788Thorpe, P E ...................................... 802, 803Thrall, B D ............................................. 1003Thrall, K D ..............................232*, 238, 866Thran, B ................................................... 329Threadgill, D ......................................... 1046Threadgill, D W ...................... 60, 712, 1840Thrippleton, K A ..................................1590*Thuett, K A .....................................618*, 619Thurmond, T S .......................................... 39Thygesen, H V ...................................... 1390Tian, B .....................................................797*Tian, Y .............................................. 107, 721Tibbetts, B ................................................ 527Tice, R .................................. 484, 1628, 1997, .............................................. 2005, 2007, 2008Tice, R R ........................................... 662, 663Tierney, L A ............................................ 1828Tiesman, J P ........................................... 1371Tietge, J .................................................. 1755Tietge, J E ..................................... 1754, 1756Tiffany-Castiglioni, E ............................ 614, ...............................................999*, 2132, 2170Tigner, J C .................................................. 10Tillander, S ............................................. 1885Tiller, M .................................................... 606Tillis, V ................................................... 2240Tillitt, D E .............................................. 1289Tilton, F .................................................2237*Tilton, S C ...............................................758*Timchalk, C ................................ 1150, 1336*Tina, R ...................................................... 797Tinkle, S S ...............................................1129Tinwell, H ............................ 124, 1736, 1739Tipple, T E ............................................. 1854Tirmenstein, M A .................................... 536Tjalkens, R ..................................1649, 1653*Tobia, A .................................................. 1297Tobias, J J ..............................................1576*Tobias, L ..................................................161*Tobin, J ..................................................... 949Tobin, J M ...................................1237*, 1751Toborek, M ............................................ 1838Tocker, J .................................................... 499Toda, Y ..................................................... 742Todd, A C ................................................1148Todero, S L ............................................. 2280Toghill, A ......................................... 743, 744Tohyama, C ......................... 130, 2043, 2142Tokado, H ................................................ 496Tokunaga, H .......................................... 2155Tolliver-Ho, L ........................................ 2130Tolson, J K ...............2073, 2074*, 2075, 2076Tomaszewski, J ..................... 466, 801, 1782Tomaszewski, J E .............. 1776, 1777, 1778Tomer, K B ............................. 64, 1005, 1900Tomic, D ................... 1109*, 1111, 1112, 2153Tomlinson, D R ..................................... 1652Tompkins, L M .....................................1765*Ton, C ..........................................1096, 2018*Tonetta, S A ...................................718*, 1935Tong, W .............................1381, 1476, 1704*Toops, K ................................................... 685Torky, A W ............................................. 1461Tornero-Velez, R ............................ 850, 858, ................................................ 870, 1250, 1298Tornesi, B ............................................... 2249Tornier, C ................................................. 482Torontali, S M ........................................ 1371Torous, D K ........................................... 2212Torres-Sanchez, L ..................................427*Toscano, C D ............................................52*Toselli, P ........................................... 574, 941Tosheva, R T ............................................ 727Toshimori, K ............................................ 556Totsuka, H ......................................117, 1901Totura, A .................................................. 787Townsend, D E ...................................... 1313Toy, K ...................................................... 1916Toyama, Y ................................................ 556Toyoda, H .....................................1192, 1193Toyoshiba, H ............1181, 1376, 2035, 2070Tozier, N ..................................................1103Tracy, J H ................................................ 1495Traina, V M .............................................471*Tran, D ..................................................... 573Tran, J ....................................................... 412Tran, L ...................................................... 681

Trang, J M .............................................. 1935Trask, H W ....................................... 137, 218Trauner, M ................................................. 63Travlos, G ........................................ 518, 539Traynelis, S F ......................................... 1529Trease, H E ..............................................347*Trease, L L ................................................ 347Treinen Moslen, M ................................. 469Treinen-Moslen, M ....................... 498, 1922Tremblay, C ............................................. 558Trepanier, D J ........................................ 1255Trevena, K A ............................................ 357Trimmer, G W ............................... 275, 1514Tripp, L ..................................................... 273Trivedi, S .................................................779*Troast, R ................................................... 155Troester, M A ........................................... 123Trombetta, L D ............................... 592, 612, .................................... 1591, 1592, 1827, 1833Trommer, W E ....................................... 1863Trosko, J E ...................................... 822, 1501Troxel, C M .................................1473, 1474*Truax, J .................................. 662, 663, 1997, .............................................2005, 2007, 2008*Truchon, G ............................................... 244Trussell, H J ........................................... 1467Tsang, M .................................................216*Tsang, M M .............................................612*Tsao, M ................................................... 1608Tsaprailis, G ................................ 1801, 2275Tse, K F ................................................... 1600Tseng, H ................................................. 2020Tshala-Katumbay, D D ....1549, 1550*, 1551Tsivinsky, A D ........................................468*Tsuchitani, M ................................ 763, 1459Tsuchiya, T .............................................176*Tsuji, J S ......................................... 648*, 693*Tsuji, R .............................................980*, 981Tsujimura, K ...........................................765*Tsukamura, H ......................................... 278Tsunoda, M .....................459, 607*, 886, 944Tsunoda, S ..............................................799*Tsusaki, H ........................................ 496, 834Tsutsui, N .............................................. 1904Tu, T .......................................................... 962Tucker, C J .......................................121, 1176Tuell, T M ............................................... 1935Tufariello, E M ...........................2073*, 2075Tugendreich, S ...............................126, 495*Tugwood, J D .......................................1276*Tukey, R H ............................................. 1360Tumbleson, M E ........................1310, 1312*, .................................... 1313, 1314, 1315, 1929Tung, K ..................................................... 310Tung, K C ............................................... 2072Tuomisto, J ............................................. 2042Turkall, R M .......................................... 1923Turker, M ............................................... 2235Turner, J N ............................................... 189Turner, S ................................................1898*Turpaz, Y ............................. 121, 1819, 2150Twaddle, N C .................................. 293, 361Tward, A ................................................ 1949Twaroski, M ................................. 1317, 2204Twerdok, L ...............................................23*Tyagi, G .............................1310, 1314*, 1315Tyl, R W ................................................... 547Tyson, C A ........................ 1170*, 1907, 1908Tyurin, V A ......................2284, 2294*, 2295, ........................................................ 2296, 2297Tyurina, Y Y ................................ 2284, 2294, .............................................2295, 2296, 2297*

UUchino, T ................................................. 833Uddin, A N ............................................ 1045Ueda, H ................................................... 117*Ueng, T ...................................................566*Uetrecht, J P ............................................. 904Uetsuka, K ............................................. 1433Ullmann, L G ..........................................1199Ulrich, R G ......................................... 56, 589Umantsev, A ............................................ 976Umemura, T ............. 211, 1406, 1428*, 1861Unami, A .....................................1793, 2277*Unfricht, D .....................................196*, 894

Unice, K ....................................................411Uno, H .........................................1456*, 1610Uno, S ....................................................... 955Upadhyay, S .........................................1241*Upham, B ................................................822*Upham, B L ........................................... 1501Uppu, R ................................................... 932Uppu, R M .................................. 200*, 1566*Upton, P B ............................................... 523Urda, E ......................................... 1049, 1916Ure, D ..................................................... 1255Urushidani, T .......117, 561, 562, 1901, 1902Usmani, K A ...........................................726*Ustyugova, I V .....................................1889*Usuka, J .................................................... 348Usuki, E ..................................................1174Utell, M J .................................................. 848Utrecht, J .................................................. 375Utsumi, H .............................................. 1904Uwagawa, S ............................................ 750

VVachon, S ................................................. 480Vaghjiani, R J ..........................................1133Vahey, M .................................................. 793Vahidnia, A .............................................634*Vaidya, V S .............................................197*Vakharia, J ............................................. 1383Valdes, J J ................................................. 793Valencia, F ............................................... 614Valentin, J ................................................ 824Valentine, R ............................................. 951Valentovic, M .................................66, 2134*Valerio, M .................................................114Vallant, M .........484, 1181, 1628, 2035, 2070Vallyathan, V ..........................................1157Van Beneden, R J .................................. 2022Van Bree, L ............................................. 1446van Breemen, R B ................................. 2274van Dael, M ........................................... 1057van de Bovenkamp, M .......................1913*van den Berg, M .......................... 513, 1734, .............................................. 1747, 1748, 2059van den Berg, P ....................................... 177van der Hoek, J ....................................... 426van der Horst, L .......................... 1056, 1057van der Laan, G ...................................... 426van der Ven, L ....................................... 2061van Duursen, M .....................................513*Van Fleet, J ............................................... 269van Gemert, M ...................................... 1505Van Goethem, F ...................................... 481van Hout, M ............................................ 426Van Kampen, K R ................................. 1515Van Kerkhove, M D ............................... 693Van Kranen, H ...................................... 1490Van Merris, V ........................................ 1366Van Miert, E .................................922, 2226*van Ommen, B .........................................36*Van Pay, L M ........................................1364*Van Sande, J ........................................... 1039van Steeg, H ............................................ 929Van Vleet, T R ....................................... 1795Van Wemmel, K .....................................1123van Wijk, F ............................................1205*Van Winkle, L S ..............................210*, 917van Zijverden, M ...................................177*Vancza, E M ............................................880*Vande Vannet, B ....................................1188Vanden Heuvel, J ...................................... 40Vanden Heuvel, J P ............................ 53, 54Vandervoet, G B .............................. 606, 634Vandestouwe, K .................................... 1468Vanoirbeek, J ........................................1712*Vansant, G ..............................................754*Vanscheeuwijck, P .......................922*, 2226Vargas, G ................................................. 825Varnum, S M ......................................... 1003Vasconcelos, D ...................1181, 2035, 2070Vassallo, J D .......................................... 1197*Vassieva, O .............................................. 761Vaudry, D ............................................... 2300Vaudry, H .............................................. 2300Vaughn, C ................................................ 254Vedula, U ............................................... 1075Velazquez, G ........................................1539*

AU

TH

OR

IND

EX




Vellareddy, A ......................................... 1527Vemuri, M C ............................................ 613Veneziale, R ............................................. 798Vengellur, A .......................................... 1130*Venkatakrishnan, P .....................229*, 1860Venkatapathy, R ...................285, 383, 1520*Vera, E .....................................................1146Veranth, J M ...........................................304*Verberk, M ..............................................426*Verberk, M M ........................................ 2199Verderber, E ............................................. 766Verhoef, A .............................................. 1490Verina, T ................................................1542*Vermeern, A ........................................... 1522Vermeulen, R ......................................... 1301Veronesi, B ..........................204, 1445*, 1964Veselica, M ............................................. 1252Vetrano, A M ......................................... 2171Vezina, C ...................................................87*Vezina, C M ................................. 2038, 2045Vezina, M ................................477, 840, 841*Viau, A ................................ 1458, 1462, 1464Viau, C ..................................................... 244Viberg, H ....................312*, 405, 1074, 2062Vick, K D .................................................. 547Vickers, A E ..........................................1914*Victorin, K ............................................... 405Vidali, M .................................................. 906Vietti, K R ................................................ 628Vigoren, E .............................................. 1303Villano, C M ................ 102, 120, 2000, 2239Villeneuve, D ........................................ 1583Villeneuve, D L ....................................1746*Viluksela, M ............................................ 679Vincent, J B ............................................ 1067Visalli, T ................................................. 1923Visich, J .................................................... 800Vittorelli, A ............................................ 2135Vivas, R .................................................. 1708Vladimirov, Y A .................................... 2284Vladimirova, A ..............................126, 522*Vodela, J ................................................1386*Voelkel, W ............................................. 1239Vogel, C F ..............................................1442*Vogel, F .......................................... 478, 2025Volz, D C ................................................ 1582von Holt, K .............................................924*von Recklinghausen, U ....................... 2225von Recklinghausen, U V .................... 1818von Rosen, D ................................. 405, 1074Vorhees, D J ........................................... 2078Voss, K A .............59, 582, 1391, 1396*, 2286Vu, B ....................................................... 1780Vudathala, D ......................................... 1815Vugmeyster, Y ......................................... 806Vulimiri, S .............................................. 1517Vulimiri, S V .......................................... 2229Vulpe, C D ............................................. 1585Vyskocil, A ..............................................244*

WWaalkens, I .................................. 1056, 1057Waalkens-Berendsen, I D .....................953*Waalkes, M ............136, 138, 141, 144, 694*, .......................................................... 817, 1608Waalkes, M P ............... 582, 593, 1619, 1817Waanders, M ......................................... 1056Wachholz, P ..........................................1204*Wachter, E ................................................ 493Wade, M J .............................................. 2079Waechter, F ...................................... 743, 744Waechter, J M .................................854, 2211Wagner, G C ............................................ 983Wagner, J G .............................438*, 439, 449Waidyanatha, S ..................................... 1301Wakamatsu, Y ....................................... 1703Wakefield, J ..........................................2173*Wakefield, L .......................................... 1266Wako, K .................................................1459*Walker, C C ............................................ 1598Walker, D B .............................................. 497Walker, H ............................................... 1386Walker, J C ..............................................497*Walker, K ............................................... 1978Walker, M K ........................... 845, 846, 1837Walker, N ....................362, 1181, 2035, 2070

Walker, N J ...............................33*, 497, 852, .............................................1506, 1699*, 1821Walker, S ...............................................1498*Walker, V ................................................. 523Walker, V E .............................................. 198Wallace, A D .......................................... 1765Wallace, K .................................... 1740, 2066Wallace, K A ............................................ 142Wallace, K B ...... 206, 827, 1835, 1849, 1906Wallace, W E ......................................... 2223Waller, D P ..............................................734*Wallo, A .................................................... 332Walmsley, R M .....................................1037*Walraven, J M .......................................1265*Walter, B ................................................... 968Walter, B J .............................................. 1949Walter, G ...................................................... 4Walters, E M ............................................ 546Walton, C L ............................................ 1889Walton-Strong, B W ................................. 65Wamer, W G .................................. 502, 2187Wan, J ....................................569, 755, 1850*Wan, Y Y ...........................1050, 1766*, 1920Wang, A .................................................. 1816Wang, B ...................................................1165Wang, C ................................................2285*Wang, F ....................................... 909*, 1770*Wang, G ...................503, 1156*, 1159, 2071*Wang, H ........................................... 171, 278Wang, J .................. 34, 348, 738, 1281, 1283, ...................... 1297*, 1308, 1309*, 1402, 1493, ..................................1565, 1595, 1810, 1836*, .............................................2019, 2216*, 2222Wang, J - ................................................... 221Wang, K ................................................... 527Wang, M Z ............................................... 973Wang, P .................................................. 1595Wang, R ...............................542*, 1080, 1583Wang, S X ................................................. 590Wang, T ...................................................461*Wang, W .............................228*, 1571, 1788Wang, X ....................................... 594*, 2253*Wang, Y .................................560, 577, 1541*Wang, Y Y .................................... 2183, 2184Wang, Z .............................. 1308, 1309, 1595Wang-Buhler, J .....................................2020*Wang-Fan, W ....................................... 1199*Wanibuchi, H .......................................... 746Warbritton, A ........................ 62, 1910, 2137Warbritton, A R ........................... 2185, 2187Ward, D .................................................... 887Ward, J .................................................... 1042Ward, J M ............................................... 1704Ward, M ................................................1213*Ward, M D ............................................. 1714Ward, S ..................................................... 844Ward, T R ............................................... 1081Ward, W ..................2144, 2146, 2147*, 2149Warfe, L .................................................. 2120Warheit, D ................................................ 704Warheit, D B ............................. 1, 651*, 703*Waring, J ...........................................113, 557Waring, J F ....................................... 121, 647Warner, B ................................................. 103Warren, D ................................................ 861Warren, M E ...........................................109*Warren, N .............................................. 2009Warshawsky, D ..................103*, 1512, 2267Wasdo, S C ....................................696, 2186*Washer, G ........................................203, 480*Wassenberg, D .............................. 687, 1581Watabe, H .............................................. 1399Watanabe, A ...........................................1611Watanabe, C ......................... 604, 605, 1611*Watanabe, H ............................................ 176Watanabe, J ...........................................1318*Waterfield, C ..........................................744*Waterland, R A ........................................ 572Waters, K M ............................................. 122Waters, M D .................................... 64, 1709Waters, S B ............................................... 148Watkins, J B ..........................................1401*Watkinson, W P .............................. 433, 441Watson, J G .............................................. 304Watson, P S .............................................. 465Watson, R E ..........................................2097*Watson, S J ............................................. 1935Watson, T M ............................................ 806

Watson, W H ...............654*, 655*, 659*, 820Watterson, T L ......................................1795*Watts, G S .......................................146, 1161Watts, J ................................................... 1598Watts, W ................................................... 443Way, R ...................................................... 793Way, R A ................................................... 775Weaver, J L ....................................902*, 1842Weaver, V M ......................................... 1148*Webb, T ............................................ 703, 704Webb-Robertson, B ..............................1705*Webber, M ................................................ 141Weber, E J ............................................... 2065Weber, J .................................................. 2156Weeks, J .................................................1286*Weeks, J A .............................................. 1758Wei, M .................................................... 1502Wei, W .................................................... 1062Wei, X ..................................................... 1801Wei, Y ..................................................... 1845Weig, B C ................................................610*Weinbauer, G ........................167, 948*, 2025Weiner, M L ..................................978*, 1397Weinrich, A J .........................................1477*Weir, A ...................................................1990*Weisman, W H ...................................... 2078Weiss, T .................................................1282*Weissert, J L ............................................943*Weissman, B .......................................... 1791Weissman, D N ......................................1211Weitz, K K ............................................. 1150*Wekking, E .............................................. 426Welch, N .................................................. 629Weller, D ................................................ 1246Weller, P ................................................... 348Wells, C S ............................................... 2083Wells, D F ................................................. 530Wells, P G ..................................... 1077, 2250Welsch, F .................................................271*Welsh, P ......................................1258, 2077*Welty, S E ....................................1726, 1854*Wen, J ......................................................1148Wen, S ......................................170*, 544, 807Weng, C C ................................................ 541Wenk, M ......................................... 484, 1628Wentworth, J ....................................86, 100*West, J L ................................................. 1862West, K ..................................................... 879Wester, R C ............................................ 2084Westerink, M ........................................... 766Westrick, M P .......................................... 526Wetmore, B A ........................ 64, 1005, 1900Wexler, P ................................... 1020*, 1021*Whalley, C ............................... 776, 785, 793Whalley, C E ...........................................787*Wheeler, D A ........................................1969*Wheeler, M ............................................ 1046Wheeler, M T ........................................... 387Wheelock, A M ....................................... 916Whelan, H T ................................ 1856, 2245Whilen, B ............................................... 1365White, A M ............................................ 1003White, C ......................................... 813, 1244White, C A ..................................... 729, 1243White, I .................................................... 671White, I N ...............................................1110White, K ......................................... 362, 2069White, K L .......................................... 23, 178White, L A ...................102, 120*, 2000, 2239White, R ................................................... 428White, R L .............................................. 2280White, S .................................................... 681White Jr, K L .......................................... 1212White Jr., K L ..................................878*, 891White, Jr., K L ........................................ 1716Whitehead, G S ....................................1846*Whitehead, J A .....................................1947*Whitekus, M J ........................................458*Whitman, S .............................................. 630Whitney, K ............................................... 557Whitsett, J A .........................................1644*Whitsett, T G ........................................1492*Whitt, R .................................................... 497Whittaker, M H ...... 1156, 1159*, 2101, 2104Whittingham, A .......................... 2006, 2009Wible, B ...................................................835*Wichers, L B ....................................433*, 438Wickliffe, J ............................................1042*

Wickliffe, J K ............................... 1274, 2236Widholm, J J .......................................... 1085Wier, P J ........................................................ 8Wierda, D ..............................................1992*Wijsman, J .............................................. 1916Wilberding, J ........................................... 684Wild, S L ..................................................467*Wiles, M C ............................................. 1402Wiley, S ................................................... 1003Wilfong, E ...............................................783*Wilfong, E R .......................... 545, 792, 1883Wilga, P C .......................................80, 1932*Wilkie, W S .............................................947*Wilkins, S ................................................. 172Wilkinson, S S ....................................... 1598Will, M ..................................................... 510Will, Y ....................................................... 488Willard-Mack, C ................................... 1641Willett, K L ............................326*, 354, 1588William, J ................................................. 817William, S M .......................................... 1783Williams, C .............................................. 428Williams, D E ................................ 758, 1499Williams, E S ......................................... 2253Williams, F ............................................. 2173Williams, G .............................................. 670Williams, G M ............................... 741, 1500Williams, H I ..........................................428*Williams, L D .......................................1395*Williams, P R ........................................1341*Williams, R L ......................................... 1279Williams III, F .......................................... 546Williamson, M ......................................1088*Willinger, JD MPH, R ..........................1668*Willis, L .................................................... 802Wills, M ................................................. 1104*Willson, T M ............ 55, 586, 587, 588, 1820Wilmer, J W ..........................................2224*Wilson, B W ........................................... 1278Wilson, C R .............................................501*Wilson, D ............................................... 1256Wilson, D M ...........................................282*Wilson, H ............................................... 1467Wilson, J P .............................................. 1489Wilson, P ...............................................1701*Wilson, S .................................................. 697Wilson, V L ............................................ 2221Wilson, V S .......................1374, 1743*, 1744Wilt, N .......................................... 1630, 2001Wiman, A ................................................. 428Wing, M ..................................................172*Winkfield, E ................................. 2144, 2146Winn, L M .......................... 1806, 1850, 2259Winnik, B ............................................... 1958Winship, K W .......................................... 497Winstead, J T ......................................... 1598Wintz, H M ............................................ 1585Wise, J P .............. 145, 160, 1134, 1135, 1145Wise, S S ............ 145, 160*, 1134, 1135, 1145Wishnok, J S .......................................... 1007Wisse, L .................................................... 921Wisse, L A ................................................ 919Witschi, H .............................................. 1013Witten, M ........................................... 20, 416Witten, M L .............................................. 936Wittenburg, A ........................................ 1897Witthuhn, B ........................................... 1755Witzmann, F .........................................2180*Witzmann, F A ...................................... 2183Wohlers, D ............................................. 2086Wohlers, D W .......................................... 399Wojke, M ...................................................114Wolansky, M J ............................2161*, 2162Wolf, A ........................................1863*, 2010Wolf, C J ................................................1224*Wolf, D ..................................................... 672Wolf, D C .........................1816, 1819, 2144*, .......................... 2146, 2147, 2148, 2149, 2150Wolf, K K ..................................................65*Wolfe, K ................................................2236*Wolfe, K J ............................................... 1274Wollenberg, M ........................................ 153Wollenberg, M L ................................... 1329Wolterbeek, A P ...................................... 953Wolz, E ................................................... 1429Wong, A W ...........................................1077*Wong, B A ...........................699*, 1463, 1467Wong, C ................................................... 739

244

AU

TH

OR

IND

EX




Wong, C K ......................................... 96, 553Wong, D ................................................... 407Wong, D F ................................................ 678Wong, J S .................................................... 59Wong, M H ........................................ 96, 553Wong, P .................................................1753*Wong, S S ................................................936*Wong, V A ............................................... 940Woo, E .................................................... 1427Wood, B .................................................... 187Wood, C ......................................... 680, 1743Wood, C R .............................................. 2150Wood, C S ...................................1478*, 1479Wood, S G .................................................. 65Wood, T .................................................. 1076Woodall, G M .............................2088, 2093*Woodrow, J E ......................................... 1009Woods, C G ............................................759*Woods, J S ............................ 184, 1216, 1275Woodstock, A D ...................................... 232Woodward, L ........................................ 1289Woolhiser, M ......................................... 1307Worden, R M ......................................... 1938Working Group, I ........................... 261, 386Wormser, U .....................................779, 784*Wortelboer, H ........................................ 1560Wragg, M ..............................................2192*Wright, J ..................................................1511Wright, J A ............................................. 1638Wright, L K ...........................................1072*Wright, L L ............................................1022*Wright, T ...........................1259*, 1284, 1285Wrighton, S A .................................... 65, 137Wu, F .......................................................243*Wu, H ........................ 233, 1150, 1558, 1629*Wu, J ............................................... 843, 1089Wu, R ...................................................... 1226Wu, R .....................................................1805*Wu, W ................................................... 1169*Wullenweber, A ...................................... 379Wyde, M E ....................................... 33, 1506

XXi, G ........................................................ 1528Xia, Q ...................................................... 2218Xia, X R .......................................2194, 2196*Xia, Y .......................................................... 99Xia, Z ............................................ 1541, 1959Xiao, R ...................................................... 274Xiao, S ...................................................2286*Xie, H .......................................... 1134*, 1594Xie, J ............................................1042, 1607*Xie, L .....................................................1725*Xie, R .......................................................823*Xie, W ....................................................... 721Xie, Y .......................................136, 138*, 144Xu, F ............................................. 1822, 2063Xu, J .......................................................2266*Xu, X ..............................................689, 1830*Xu, Y ..................................1203, 2189, 2228*Xu, Z A ..............................1098*, 1099, 1702Xu, S ......................................................1065*Xue, W .................................................... 1512Xue-Qing, C ...........................................1159

YYabe, K ..................................................... 267Yabushita, S ............................................. 980Yaeger, M ............................................... 1385Yager, J D ............................1263, 1272, 1811Yakabe, Y ............................................... 1727Yaksh, T L ...............................................1103Yalowich, J ............................................. 2296Yamada, H ..................................... 531, 1899Yamada, J ............................................... 1784Yamada, T ................................... 834*, 1730*Yamamoto, M ........... 816, 1164*, 1833, 1861Yamamoto, T ............ 129, 531, 1899*, 1904*Yamamoto, Y ........................................... 267Yamanaka, T .......................................... 1376Yamasaki, K ........................................... 1727Yamauchi, H ............................................ 604Yamazaki, Y ..........................................2067*Yamoto, T ............................................... 1433Yan, S .......................................................483*

Yan, X ....................................................... 960Yang, C ................................................... 2204Yang, D ..................................................1084*Yang, J .........................................2040*, 2181Yang, M ....................................... 256*, 2281*Yang, M S ....................................1600, 1601*Yang, R ........................................... 849, 1306Yang, R S ...............................377*, 865, 1300Yang, S Y .................................................. 202Yang, W .........................................723, 2170*Yang, X ............................................119, 2274Yang, Y ...........113, 647*, 1526, 1832*, 1832*Yang, Z ................................................... 1010Yano, B L .................................................. 282Yarberry, B ..................................... 274, 1737Yarberry, B N ............................................. 74Yashiro, C ................................................ 459Yasmeen, R .............................................622*Yasmin, T ............................................... 1414Yasuda, K ................................................... 65Yatscoff, R W ......................................... 1255Yavanhxay, S ........................................1738*Yazzie, M ................................................. 157Ye, J ......................................................... 1634Ye, W ...................................................... 1847Ye, Y .......................................................2292*Yea, S .....................................................1261*Yeager, R L ............................................2245*Yeatts, J L ....................................2175*, 2194Yeatts, S .................................................. 1934Yee, N ....................................................... 968Yee, S ........................................................ 923Yee, S F ........................................1517*, 2229Yeh, J Z ......................................... 1962, 1963Yeow, A .................................................... 155Yeung, H Y .............................................. 553Yieh, L .............................................. 569, 755Yim, S H ................................................. 1704Yin, S ...................................................... 1301Yin, X ...............................................507*, 894Yin, X J ...................................................... 212Yokel, R A ........................1124, 1125*, 1660*Yokohira, M ..........................................1471*Yokoi, C .................................................. 2142Yokota, H ................................................. 267Yonamine, H ........................................... 834Yonemoto, J ........................................... 2142Yoneyama, K ................................1192, 1193Yoo, J L ..................................................1585*Yoon, B ................................................... 1380Yoon, L ................................................. 57, 59Yoon, M .................................................1917*Yoon, T ....................................................... 41Yoon, Y ................................................... 1215York, M J ...............................................6, 26*Yoshida, K ..............................................1611Yoshida, M ..............................................605*Yoshida, T ................................................ 604Yoshida, Y ........................... 1192, 1193, 1194Yoshihara, S ........................................... 1615Yoshikawa, N ........................................ 1501Yoshikawa, T ........................................1094*Yoshikuni, Y .......................................... 1379Yoshinaga, T ...................... 2064, 2067, 2068Yoshino, H ............................................... 746Yoshioka, T ...................................... 980, 981Yoshizawa, K ..............................1506*, 1821Yost, G S ................................. 304, 937, 1219Yost, L J .................................................. 1387You, L ..................................................... 1767You, S .....................................................1775*Young, J F ................................................ 293Young, R ...............................................1484*Young, S ........................................939*, 1449Yttri, K E .................................................. 417Yu, B ......................................................... 300Yu, C ......................................................... 332Yu, C K ......................................................96*Yu, I .......................................................1454*Yu, K ..................................................41*, 785Yu, K O ..................................................... 786Yu, L ........................................................1114Yu, L C .........................................1600*, 1601Yu, M ...................................................... 1014Yu, S ............................................................ 77Yu, T Z .....................................................107*Yu, W W ................................................. 2185Yu, X .................................. 1155*, 1655, 2257

Yu, Z ......................................................1499*Yuan, G .................................................... 537Yuan, W ................................................1564*Yuan, Y ........................................1059*, 1905Yuce, N ................................................... 1273Yunomae, K ............................................. 826Yvon, A ....................................................830*

ZZablotny, C L ........................................... 282Zacharewki, T R ................................... 1759Zacharewski, T ....................................1970*Zacharewski, T R ............................. 35, 101, ............................................. 1363, 1382, 1383, .............................................. 1760, 1771, 1772Zacharias, W ........................................... 689Zacur, H ................................................... 422Zafar, K S ................................................... 47Zaffuto, K ...............................................894*Zager, M G ............................................1296*Zaharia, A ................................................ 218Zahnow, C A ..........................................1811Zairov, G B ............................................. 1040Zaja-Milatovic, S ..................................... 215Zajicek, J L ............................................. 1289Zakharyan, R A ............................. 153, 1329Zalups, R K ................................. 1138, 1604*Zang, Y ..................................................1267*Zangar, R C .............................. 1002*, 1003*Zaroogian, G E ...................................... 1745Zavala, F .................................................. 879Zawada, M .............................................343*Zawia, N H ........................ 1062, 1063, 1532Zayed, J ......................................1127*, 1128*Zeevalk, G ............................................. 1965Zeiger, E ................................................... 398Zeise, L ........................................... 396, 1521Zelcer, N ................................................ 1051Zelikoff, J ................................................... 18Zelikoff, J T ..................... 22*, 880, 881, 893*Zeng, Y ................................................... 1471Zenick, H ............................................... 1291Zepeda-Rodriguez, A ............................ 608Zerouala, C A ........................................ 1935Zervos, P ................................................ 1386Zewdie, T ..............................................2106*Zhang, F ............................1041, 1563, 1767*Zhang, G G ............................................ 1556Zhang, H .................................................. 658Zhang, J .....................263, 1513, 1554, 1842*Zhang, J G ................................................ 719Zhang, L ....................723, 1301, 1567, 2124*Zhang, Q ...................... 344, 723, 1567, 2071Zhang, W ............................................... 2124Zhang, X ..............................414, 415, 1279*, ................................. 1543*, 1572, 2150, 2262*Zhang, Y .................................................. 288Zhang, Z ................................................ 1969Zhang, l .................................................2279*Zhao, B ............................................. 106, 353Zhao, H W ............................................... 212Zhao, J ...........................................748*, 1934Zhao, J Q .................................................. 847Zhao, M .......................64, 1005, 1900, 2056*Zhao, Q .................................................. 2294Zhao, Q J ...............................................2094*Zhao, S ................................................... 1267Zhao, X ........................................1962, 1963*Zhao, Y ................................... 574, 941, 1603Zheng, J ...............................228, 1564, 1571*Zheng, N ....................................... 376, 1126*Zheng, Q .................................896, 897, 900*Zheng, W ........................ 590, 591, 593, 594, ....................... 1533, 1534, 1624, 1659*, 1663*Zheng, X ............................................... 1161*Zheng, X H ...................................... 146, 147Zheng, Y ........................................... 344, 614Zhong, C ...............................................1221*Zhong, Z ...............................................2133*Zhou, G ...................... 524, 1290, 1593, 2270Zhou, J .................................... 64, 1005, 1900Zhou, T ................................................... 119*Zhou, Y ............................... 119, 1124*, 1221Zhu, H .......................748, 1827, 1833, 1834*Zhu, S ....................................................1280*Zhu, Y ......................................................1129

Zhuo, X .................................................... 723Ziccardi, M .............................................. 106Zieziulewicz, T ....................................... 196Zieziulewicz, T J ..................................... 189Zijverden van, M .................................... 953Zimmerman, A J ..................................... 576Zimmerman, K ............................... 161, 884Zimniak, P ............................................. 2217Zodrow, J M .......................................... 2242Zoeller, R ............................ 1086, 1741, 1775Zou, M ................................................... 2294Zuang, V .......................................... 664, 665Zuch, C L ................................................804*Zuckerman, L A ...................................... 800Zuehlke, U ............................................. 2025Zuscik, M ................................................. 695Zwick, L ................................................. 1916

REF

EREN

CE


SOT Affiliates for 200544th Annual Meeting

and ToxExpo(James E. Klaunig, Council Liaison)

Abbott Laboratories Abbott Park, Illinois

Agilent Technologies Wilmington, Delaware

Alcon Research, Ltd. Fort Worth, Texas

American Chemistry Council Arlington, Virginia

ANI LYTICS, INC. Gaithersburg, Maryland

AstraZeneca R&D Södertälje, Sweden

BAS Evansville Mount Vernon, Indiana

Bayer Stilwell, Kansas

Berlex Laboratories, Inc. Montville, New Jersey

Biogen Idec Cambridge, Massachusetts

Boehringer Ingelheim Pharmaceuticals, Inc. Ridgefield, Connecticut

Bristol Myers Squibb Company New Brunswick, New Jersey

CANTOX Mississauga, Ontario

Charles River Laboratories Wilmington, Massachusetts

Chevron Phillips Chemical Company LP The Woodlands, Texas

ChevronTexaco Energy Research & Technology Company Richmond, California

Chlorine Chemistry Council Arlington, Virginia

CIIT Centers for Health Research Research Triangle Park, North Carolina

Coca-Cola Company Atlanta, Georgia

Colgate Palmolive Company Piscataway, New Jersey

Covance Laboratories, Inc. Madison, Wisconsin

Dial Corporation Scottsdale, Arizona

Dow Chemical Company Midland, Michigan

Dow Corning Corporation Midland, Michigan

E. I. Du Pont de Nemours & Co. Newark, Delaware

Eastman Chemical Company Kingsport, Tennessee

Eastman Kodak Company Rochester, New York

Eli Lilly & Company Indianapolis, Indiana

ExxonMobil Biomedical Sciences Inc Annandale, New Jersey

Genentech South San Francisco, California

Gillette Company Needham, Massachusetts

GlaxoSmithkline King of Prussia, Pennsylvania

Hoffmann-La Roche, Inc. Nutley, New Jersey

Honeywell International, Inc. Morristown, New Jersey

Johnson & Johnson Corporation New Brunswick, New Jersey

Johnson & Johnson Pharmaceutical R & D Raritan, New Jersey

McNeil Consumer Healthcare Fort Washington, Pennsylvania

Millennium Pharmaceuticals, Inc. Cambridge, Massachusetts

Novartis Pharmaceuticals Corporation East Hanover, New Jersey

Pfizer, Inc. New London, Connecticut

Procter & Gamble Company Cincinnati, Ohio

Sankyo Company, Ltd. Shizuoka, Japan

Sanofi-Aventis Malvern, Pennsylvania

Schering Plough Research Institute Kenilworth, New Jersey

Sequani Limited Ledbury, Herefordshire

Southern Research Institute Birmingham, Alabama

WIL Research Laboratories, Inc. Ashland, Ohio

Wyeth Ayerst Research Chazy, New York


2004–2005 Council

246

REFER

ENC

E


Linda S. Birnbaum Kendall B. Wallace James A. Popp

James E. Klaunig

• Council Subcommittee for Non-SOT and Contemporary Concepts in Toxicology (CCT) Meetings, Member

• Exhibits Committee, Liaison

• Finance Committee, Chairperson, Liaison

• SOT Affiliates, Liaison

• Council Subcommittee for Regional Chapter Funding, Member

• Finance Committee, Member

• Task Force for NIH Funding, Liaison

• World Wide Web Advisory Committee, Liaison

Gary P. Carlson

• Communique, Editor

• Council Subcommittee for Regional Chapter Funding, Member

• Historian, Liaison

• Regulatory Affairs and Legislative Assistance Committee, Liaison


• IUTOX Councilor

• Program Committee Chairperson, Liaison

Vice President-electVice PresidentPresident

Treasurer Treasurer-elect Secretary

• Board of Publications, Auditor

• Nominating Committee, Liaison

• Program Committee, Co-Chairperson

• Board of Publications, Member, Liaison


• IUTOX Councilor

Norbert E. Kaminski


REF

EREN

CE

2004–2005 Council (Continued)


Marion F. Ehrich

Past President

• Animals in Research Committee (AIR), Liaison

• Awards Committee, Liaison

• IUTOX Councilors, Liaison

• Liaison Task Force, Liaison

• Student Advisory Committee (SAC), Liaison

Ann de Peyster

• Communications Task Force, Liaison

• Council Subcommittee for Regional Chapter Funding, Chairperson, Liaison

• Education Subcommittee for K–12 Education, Liaison

• Regional Chapters, Liaison

Yvonne P. Dragan

• Continuing Education Committee, Liaison

• Education Committee, Liaison

Elaine M. Faustman

• Career Resource and Development Committee, Liaison

• Council Subcommittee for Non-SOT and Contemporary Concepts in Toxicology (CCT) Meetings, Chairperson, Liaison

• Membership Committee, Liaison

Jose E. Manautou

• Council Subcommittee for Non-SOT and Contemporary Concepts in Toxicology (CCT) Meetings, Member

• Education Subcommittee for Minority Initiatives, Liaison

• Specialty Sections, Liaison

• Task Force for NIH Funding, Co-Liaison

Shawn Douglas Lamb

• Board of Publications, Staff Liaison

• Communications Task Force, Staff Liaison

• Finance Committee, Staff Liaison

• IUTOX Councilors, Staff Liaison

• Nominating Committee, Staff Liaison

Councilor Councilor Executive Director

Councilor Councilor

248

REFER

ENC

E



1961–1962 Harold C. Hodge*

1962–1963 C. Boyd Shaffer

1963–1964 Paul S. Larson*

1964–1965 Harry W. Hays*

1965–1966 Frederick Coulston*

1966–1967 Verald K. Rowe*

1967–1968 John A. Zapp, Jr.*

1968–1969 Carrol S. Weil*

1969–1970 Ted A. Loomis

1970–1971 Robert L. Roudabush*

1971–1972 Wayland J. Hayes, Jr.*

1972–1973 Victor A. Drill*

1973–1974 Joseph F. Borzelleca

1974–1975 Sheldon D.Murphy*

1975–1976 Seymour L. Friess

1976–1977 Robert A. Scala

1977–1978 Harold M. Peck

1978–1979 Leon Golberg*

1979–1980 Tom S. Miya

1980–1981 Perry J. Gehring*

1981–1982 Robert B. Forney*

1982–1983 Robert L. Dixon*

1983–1984 Gabriel L. Plaa

1984–1985 Frederick W. Oehme

1985–1986 Emil A. Pfitzer

1986–1987 John Doull

1987–1988 Jerry B. Hook

1988–1989 James E. Gibson

1989–1990 Roger O. McClellan

1990–1991 Curtis D. Klaassen

1991–1992 Donald J. Reed

1992–1993 John L. Emmerson

1993–1994 I.Glenn Sipes

1994–1995 Meryl H. Karol

1995–1996 Jack H. Dean

1996–1997 James S. Bus

1997–1998 R. Michael McClain

1998–1999 Steven D. Cohen

1999–2000 Jay I. Goodman

2000–2001 Daniel Acosta, Jr.

2001–2002 David L. Eaton

2002–2003 William F. Greenlee

2003–2004 Marion F. Ehrich

*Deceased

Linda S. Birnbaum President (2004–2005) T: (919) 541–2655 F: (919) 541–4284 [email protected]

Kendall B. Wallace Vice President (2004–2005) T: (218) 726–8899 F: (218) 726–8014 [email protected]

James A. Popp Vice President-elect (2004–2005) T: (914) 709–2456 F: (914) 709–2516 [email protected]

James E. Klaunig Treasurer (2003–2005) T: (317) 274–7824 F: (317) 274–7787 [email protected]

Norbert E. Kaminski Treasurer-elect (2004–2005) T: (517) 353–3786 F: (517) 432–3218 [email protected]

Gary P. Carlson Secretary (2004–2004) T: (765) 494–1412 F: (765) 494–1414 [email protected]

Marion F. Ehrich Past President (2004–2005) T: (540) 231–4938 F: (540) 231–6033 [email protected]

Ann de Peyster Councilor (2003–2005) T: (619) 594–3690 F: (619) 594–6112 [email protected]

Yvonne P. Dragan Councilor (2004–2006) T: (870) 543–7689 F: (870) 543–7576 [email protected]

Elaine M. Faustman Councilor (2004–2006) T: (206) 685-2269 F: (206) 685-4696 [email protected]

Jose E. Manautou Councilor (2003–2005) T: (860) 486-3852 F: (860) 486-4998 [email protected]

Officers and Councilors

Past Presidents

REF

EREN

CE



Headquarters StaffStaff Contact Extension E-Mail Activity

Shawn Douglas Lamb Extension 1444 [email protected] Executive Director

Clarissa Russell Wilson Extension 1455 [email protected] Deputy Executive Director

Rosibel Alvarenga Extension 1432 [email protected] Membership

Jessica Canning Extension 1443 [email protected] Administration

Mia Delaney Extension 1440 [email protected] Accounting

Betty Eidemiller Extension 1430 [email protected] Animals in Research Education Programs Student Advisory Committee Student Awards

Veronica Fisher Extension 1450 [email protected] Accounting

Libby Jones Extension 1454 [email protected] Exhibits

Michele Layton Extension 1423 [email protected] Administration

Tonia Masson Extension 1433 [email protected] Administration

Deborah O’Keefe Extension 1441 [email protected] Publications World Wide Web

Sue Pitsch Extension 1442 [email protected] Publications World Wide Web Membership

Heidi Prange Extension 1424 [email protected] Meetings

Lilly Richards Extension 1454 [email protected] Media

Becca Rhame Extension 1447 [email protected] Administration

Rita Rose Extension 1434 [email protected] Historian Regional Chapters Registration Specialty Sections

Nichelle Sankey Extension 1431 [email protected] Program Committee Career Resource and Development Continuing Education

Elisa Turner Extension 1445 [email protected] Publications World Wide Web

Karen Wareham Extension 1446 [email protected] Administration

Society of Toxicology Headquarters 1821 Michael Faraday Drive, Suite 300, Reston, Virgina 20190

Tel: (703) 438–3115; Fax: (703) 438-3113 E-Mail: [email protected]; Web site: www.toxicology.org

250

REFER

ENC

E



Elected Committees

Animals in Research (AIR)(Marion F. Ehrich*)Stephen M. Lasley, Chairperson (2004–2005),

Member (2002–2005)Charles C. Barton (2002–2005)Brian R. Marable (2003–2006)Rebecca Rice (2003–2006)Harihara M. Mehendale (2004–2007)Jan Oberdoerster (2004–2007)Christina Wilson, Student Representative ad hoc (2004–2005)(Betty Eidemiller**)

Board of Publications (BOP)Linda S. Birnbaum*, President, Member (2004–2005)Richard E. Peterson, Chairperson (2003–2005),

Member (2001–2005) Brian J. Day (2002–2006)William R. Kelce (2004–2008)Lois D. Lehman-McKeeman, ToxSci Editor, AuditorNancy Ann Monteiro-Riviere (2003–2007)James A. Popp, Auditor (2004–2005)(Shawn D. Lamb**)

Career Resource and Development Committee(Elaine M. Faustman*)Tracy M. Williams, Chairperson (2004–2005),

Member (2002–2005)Yolanda Banks Anderson (2003–2006) Michel Charbonneau (2003–2006)Charles D. Hebert (2004–2007)Julia S. Kimbell (2003–2006)Willie J. McKinney (2004–2007)Virginia C. Moser (2004–2007)Mitzi Nagarkatti (2002–2005)William A. Toscano (2002–2005)Jonathan M. Maher, Student Representative

ad hoc (2004–2005)(Nichelle Sankey**)

Appointed Committees

Awards(Marion F. Ehrich*)Deborah A. Cory-Slecta, Chairperson (2004–2005)

Member (2004–2006)Kim Boekelheide (2004–2006)Annie M. Jarabek (2004–2006)Stephen H. Safe (2003–2005) Bernard A. Schwetz (2003–2005)(Shawn D. Lamb**)

Education(Yvonne P. Dragan*)Judith T. Zelikoff, Chairperson (2004–2005),

Member (2002–2005)Darlene Dixon (2002–2005)Michelle J. Hooth (2004–2007)B. Paige Lawrence (2004–2007)Mark J. Reasor (2003–2006)Rosita Rodriguez Proteau (2003–2006)Wendy N. Jefferson, Student Representative

ad hoc (2004–2005)(Betty Eidemiller**)

Membership(Elaine M. Faustman*)William Slikker, Jr., Chairperson (2004–2005)

Member (2003–2006) Jeanine L. Bussiere (2004–2007)Rory B. Conolly (2002–2005)Jack R. Harkema (2004–2007)Alvaro Puga (2003–2006) Denise E. Robinson (2002–2005)Castle J. Funatake, Student Representative

ad hoc (2004–2005)(Sue Pitsch**)

Nominating(James A. Popp*)William F. Greenlee, Chairperson (2004–2005),

Member (2004–2005)Daniel Acosta, Jr. (2004–2005)Matthew S. Bogdanffy (2004–2006)Myrtle A. Davis (2004–2006)Peter L. Goering (2004–2005)(Shawn D. Lamb**)

* Council Liaison ** Staff Liaison

REF

EREN

CE



Appointed Committees (Continued)

Continuing Education (CE)(Yvonne P. Dragan*)Betty Ann Pettersen, Chairperson (2004–2005),

Member (2002–2005)Laurie Couture Haws (2004–2007)Mary Jane Cunningham (2001–2005)Braulio D. Jimenez-Velez (2004–2007)Douglas Alan Keller (2003–2006)Jeffrey Maurice Peters (2003–2006)Jack P. Vanden Heuvel (2002–2005)Douglas C. Wolf (2004–2007)Jennifer Orme Zavaleta (2003–2006)Andrew Annalora, Student Representative ad hoc (2004–2005)(Nichelle Sankey**)

FinanceJames E. Klaunig*, Treasurer, Chairperson (2003–2005)Linda S. Birnbaum, President, Member (2004–2005)Matthew S. Bogdanffy (2002–2005)William J. Brock (2004–2007)Erik Dybing (2003–2006)Norbert E. Kaminski, Treasurer-elect,

Member (2004–2005)Kendall B. Wallace, Vice President, Member (2004–2005)(Shawn D. Lamb**)

Historian(Gary P. Carlson*)Ernest Hodgson, Chairperson (2004–2005)(Rita Rose**)

IUTOX CouncilorsMarion F. Ehrich*, Member (2004–2007)Daniel Acosta, Jr. (2004–2007)Linda S. Birnbaum (2004–2007)George B. Corcoran (2004–2007)Kendall B. Wallace (2004–2007)(Shawn D. Lamb**)

ProgramKendall B. Wallace*, Vice President,

Chairperson (2004–2005)James A. Popp, Vice President-Elect, Co-Chairperson

(2004–2005)Barbara D. Beck (2002–2005)Rakesh Dixit (2002–2005)Lori A. Dostal (2003–2006)Michael R. Franklin (2004–2007)Dori R. Germolec (2003–2006)Terry Gordon (2003–2005)Bruce J. Kelman (2004–2007)Thomas W. Kensler (2002–2005)Kannan Krishnan (2003–2006) Gary H. Perdew (2003–2006)Larry P. Sheets (2003–2005)Martin Vandenberg (2004–2007)Philip J. Bushnell (2004–2007) (Nichelle Sankey**)

Regulatory Affairs and Legislative Assistance Committee (RALA) (Gary P. Carlson*)Peter L. Goering, Chairperson (2004–2005),

Member (2003–2006)Kulbir S. Bakshi (2003–2006)Mike Bolger (2004–2007)Janis E. Hulla (2002–2005)Leslie J. Hushka (2002–2005)RuthAnn Rudel (2004–2007)Melinda Pomeroy, Student Representative ad hoc (2004–2005)(Clarissa Russell Wilson**)


252

REFER

ENC

E



Student Advisory Committee (SAC)(Marion Ehrich*)Christina Wilson, Chairperson, Animals in Research Tracy Pickering, Co-Chairperson (Michigan)Jessica E. Duffy, Secretary (Mid-Atlantic)Andrew Annalora (Mountain West), Continuing Education Jessica Berthiaume (Northland)Cary Coburn, Southern CaliforniaCastle Funatake (Pacific Northwest), MembershipWendy N. Jefferson (North Carolina), EducationTisha King-Deiden (Midwest)Joseph P. Lynch (Northeast), WWWAC, K–12 SCJonathan M. Maher (Central States), Career Resource and

Development CommitteeAshley R. Murray (Allegheny-Erie), WIT Melinda Pomeroy-Black (National Capital), RALAKaren Riveles (Southern California), Specialty SectionsSharmilee Sawant (South Central), Specialty SectionsVince Seaman (Northern California)Yang Ye (Gulf Coast)Lonnie D. Williams (Southeastern)Yu Zang (Ohio Valley), SCMIJohn Norman (Lake Ontario)(Betty Eidemiller**)

World Wide Web Advisory Committee (WWWAC)(Norbert E. Kaminski*)Michael L. Dourson, Chairperson (2004–2005),

Member (2003–2006)Christpher P. Chengelis (2004–2007)Howard Perry Glauert (2004–2007)James P. Kehrer (2001–2005)Allan R. Parrish (2002–2005)Ruth A. Roberts (2003–2006) Joseph P. Lynch, Student Representative ad hoc (2004–2005)(Deborah O’Keefe**)

Council Subcommittee for Non-SOT Funding and Contemporary Concepts in Toxicology (CCT) Meetings Elaine M. Faustman, Chairperson (2004–2005),

Member (2004–2005)James E. Klaunig*, Member (2004–2005)Jose E. Manautou (2004–2005)(Rita Rose**)

Council Subcommittee for Regional Chapter FundingAnn de Peyster*, Chairperson (2004–2005),

Member (2003–2005)Gary P. Carlson (2003–2005)Norbert E. Kaminski (2004–2005) (Rita Rose**)

Education Subcommittee for K–12 Education(Ann de Peyster*)Mark J. Reasor, Chairperson (2004–2005),

Member (2003–2006)B. Paige Lawrence, Co-Chairperson (2004–2005),

Member (2004–2007)David William Cragin (2002–2005)Darlene Dixon (2002–2005)Suzanne Fitzpatrick (2004–2006)Kenneth McMartin (2003–2006)Marion G. Miller (2002–2005)Joanne Zurlo (2002–2005)Elaine Knight, ad hoc (2003–2005)Carrie Markgraf, ad hoc (2004–2006)Liam O’Fallon, ad hoc (2004–2005)John Pierce Wise, ad hoc (2004–2005)Judith T. Zelikoff, ad hoc (2004–2005)Joseph P. Lynch, Student Representative ad hoc (2004–2005)(Betty Eidemiller**)

Education Subcommittee for Minority Initiatives(Jose E. Manautou*)Rosita Rodriguez Proteau, Chairperson (2004–2005),

Member (2003–2006)Michelle Hooth, Co-Chairperson (2004–2005),

Member (2004–2007)Marquea D. King (2003–2006)Chudy I. Nduaka (2002–2005)Peter T. Thomas (2003–2006)Alice R. Villalobos (2002–2005)Charles Azuka, ad hoc (2004–2005)Vicente Santa Cruz, ad hoc (2004–2005)Myrtle A. Davis, ad hoc (2004–2005)Heather Kleiner, ad hoc (2004–2005)Judith T. Zelikoff, ad hoc (2004–2005)Yu Zang, Student Representative ad hoc (2004–2005)(Betty Eidemiller**)

Appointed Committees (Continued)


REF

EREN

CE



Officers—Specialty SectionsBiological Modeling (79)*John M. Frazier, PresidentAlan G.E. Wilson, Vice PresidentCharles Timchalk, Vice President-electElaina Kenyon, Secretary/TreasurerJeffrey W. Fisher (Past President), Torka S. Poet,

and Lisa M. Sweeney, Councilors

Carcinogenesis (197)Ruth A. Roberts, PresidentJohn E. French, Vice PresidentMichael L. Cunningham, Vice President-electKyle J. Kolaja, Secretary/TreasurerJon C. Cook (Past President), Richard J. Bull,

Michel Charbonneau, and Lisa M. Kamendulis, Councilors

Leanne L. Berdard, Student Representative

Comparative and Veterinary (82)

William Valentine, PresidentMyrtle Davis, Vice PresidentWilson Rumbeiha, Vice President-electJames Deyo, Secretary/TreasurerStephen B. Hooser (Past President), Jay Albretsen

and Charles Capen, Councilors

Dermal Toxicology (97)Nancy A. Monteiro-Riviere, PresidentRobert L. Bronaugh, Vice PresidentJames N. McDougal, Vice President-electCynthia A. Ryan, Secretary/TreasurerIan Kimber (Past President), Carol S. Auletta, and

Debra L. Laskin, CouncilorsEthical, Legal, and Social Issues (New Section)Steven Gilbert, PresidentJacques Maurissen, Vice PresidentSpencer R. Mortensen, Secretary/TreasurerTBE, (Past President), Bruce Kelman and Bernard

Weiss, Councilor

Drug Discovery Toxicology (New Section)

Ethical, Legal, and Social Issues (New Section)

Steven Gilbert, PresidentJacques Maurissen, Vice PresidentSpencer R. Mortensen, Secretary/TreasurerTBE, (Past President), Bruce Kelman and Bernard

Weiss, Councilors

Food Safety (104)Ronald T. Riley, PresidentBryan Delaney, Vice PresidentGeorge A. Burdock, Vice President-electKenneth A. Voss, Secretary/TreasurerJoel L. Mattsson (Past President), Michael Bolger,

George E. Dunaif, Bruce G. Hammond, and Craig Llewellyn, Councilors

Immunotoxicology (261)Robert Luebke, PresidentKen Hastings, Vice PresidentMitchel Cohen, Vice President-electSteve Pruett, Secretary/TreasurerThomas T. Kawabata (Past President), Jeanine

Bussiere and Michael McCabe, CouncilorsBeatrice Seguin, Student Representative

In Vitro (106)Julio C. Davila, PresidentSidney Green, Vice PresidentGeorge DeGeorge, Vice President-electPeter T. Harvison, Secretary/TreasurerBruce A. Fowler (Past President), Mark E. Blazka,

Robert T. Dunn, Rosita Proteau, and Joan B. Tarloff, Councilors

Inhalation (191)Charles Plopper, PresidentMaryJane Selgrade, Vice PresidentMichael Foster, Vice President-electMatthew Reed, Secretary/TreasurerSteve R. Kleeberger (Past President), Lung Chi

Chen, Ian Gilmour, Ermila Kodavanti, and Michael Madden, Councilors

Mechanisms (255)Serrine S. Lau, PresidentDaniel C. Liebler, Vice PresidentKenneth S. Ramos, Vice President-electMonica A. Valentonic, Secretary/TreasurerRobin S. Goldstein (Past President), Tiffany G.

Bredfeldt, Dennis Peterson, and John H. Richburg, Councilors

Metals (106)Maryka H. Bhattacharyya, PresidentDonald R. Smith, Vice PresidentMichael J. McCabe, Vice President-electWilliam E. Achanzar, Secretary/TreasurerJudith T. Zelikoff (Past President), Kirk T. Kitchin,

and Toby G. Rossman, CouncilorsElena S. Craft, Student Representative

Molecular Biology (137)Jack P. Vanden Heuvel, PresidentMelissa A. Runge-Morris, Vice PresidentCraig Marcus, Vice President-electElizabeth V. Wattenberg, Secretary/TreasurerWilliam B. Mattes (Past President), Richard S.

Pollenz and Thomas R. Sutter, CouncilorsHeather S. Floyd, Student Representative

Neurotoxicology (219)Carey N. Pope, PresidentRichard F. Seegal, Vice PresidentRobert C. MacPhail, Vice President-electMary E. Gilbert, Secretary/TreasurerStephanie Padilla (Past President), Stephen M.

Lasley, and Lisa A. Opanashuk, Councilors

Occupational and Public Health (119)

David A. Morgott, PresidentHeather D. Burleigh-Flayer, Vice PresidentHarold Zenick, Vice President-electMarth M. Moore, Secretary/TreasurerVincent Castranova (Past President), Bryan D.

Hardin, and geary W. Olsen, Councilors

Regulatory and Safety Evaluation (359)

Ronald J. Gerson, PresidentRonald S. Slesinski, Vice PresidentJames T. MacGregor, Vice President-electFrank D. Sistare, Secretary/TreasurerCarol S. Auletta (Past President) Andrea B. Weir

and Vijayapal Reddy, Councilors

Reproductive and Developmental (227)

John M. Rogers, PresidentDana L. Shuey, Vice PresidentJerrold J. Heindel, Vice President-electGeorge L. Foley, Secretary/TreasurerCarole A. Kimmel (Past President), Kim

Boekelheide and Eve Mylchreest, Councilors

Risk Assessment (311)Annie M. Jarabek, PresidentKannan Krishnan, Vice PresidentMichael L. Gargas, Vice President-electStephen M. DiZio, Secretary/TreasurerEdward V. Sargent (Past President), Deborah M.

Proctor and Lorenz R. Rhomberg, Councilors

Toxicologic and Exploratory Pathology (88)

Brian G. Short, PresidentJack R. Harkema, Vice PresidentSusan G. Emeigh Hart, Secretary/TreasurerBruce McCullough (Past President), Thomas M.

Monticello, and Gail L. Walter, Councilors

Women in Toxicology (WIT) (141)

Eva Oberdorster, PresidentMary Ellen Cosenza, Vice PresidentMaryka H. Bhattacharyya, Secretary/TreasurerVirginia C. Moser (Past President), Janet M. Benson and Rita M. Turkall, CouncilorsAshley R. Murray, Student Representative ad hoc

254

REFER

ENC

E



Allegheny-Erie Lawrence Milchak, PresidentMark Weisberg, Vice PresidentMelanie Flint, Vice President-electRobin Gandley, SecretaryWilliam McKay, Treasurer A. Phil Leber (Past President), Elaine L. Freeman

and Jim Scabilloni, CouncilorsAshley Murray, Student Representative

Central StatesSam Cohen, PresidentCharles Barton, Vice PresidentLora Arnold, Secretary/TreasurerGeorge Casale (Past President) Bill Berndt, Dianne

Brit, Greg Reed, and Yvonne Wong, CouncilorsJonathan Maher, Student Representative

Gulf CoastDavid J. McConkey, PresidentSusan Fischer, Vice PresidentBryan Brooks, Vice President-electMary F. Kanz, TreasurerYunan Tian, SecretaryMary F. Kanz (Past President), Shawn B. Bratton

and M. Firoze Khan, CouncilorsDanyel Tacker, Student Representative

Lake Ontario TBE, PresidentTBE, Vice PresidentTBE, Treasurer/SecretaryHarish C. Sikka (Past President), and TBE,

Councilors

MichiganStephen W. Frantz, PresidentJames McKim, Vice PresidentPaul Stemmer, Treasurer/SecretaryRobert G. Meeks (Past President), Yvonne Frater,

Paul A. Jean, and John J. LaPres CouncilorTracy Pickering, Student Representative

Mid-AtlanticDavid W. Cragin, PresidentMichael F. Kelley, Vice PresidentAngelique Braen, Vice President-electDiann L. Blanset, Secretary/TreasurerPeter J. Harvison (Past President), Anne

Chappelle, Anthony R. Schatz, and Margaret A. Wojke, Councilors

Jessica Duffy, Student Representative

MidwestBruce A. Trela, PresidentKevin Williams, President-electBarbara Struthers, SecretaryLinda L. Tam, TreasurerD. Reid Patterson (Past President), Bill Johnson,

Chuck Mattis, Daniel E. McLain, and Susan L. Schantz, Councilors

Tisha King-Deiden, Student Representative

Mountain WestRobert Clark Lantz, PresidentLinda Quattrochi, Vice PresidentChris Reilly, Vice President-electNathan Cherrington, Secretary/TreasurerMary Walker (Past President), Michael Franklin

and Jim Lu, CouncilorsAndrew Annalora, Student Representative

National Capital Area ChapterDavid Jacobson-Kram, PresidentHarry Milman, Vice PresidentPamela L. Chamberlain, SecretaryLaurie Roszell, TreasurerSidney Green (Past President), Gary Burin, Lynn

Flowers and Thomas Flynn, CouncilorsMelinda Pomeroy-Black, Student RepresentativeMashael Al-Namaeh, Student Vice Representative

North CarolinaDave Dorman, PresidentMichael Waalkes, Vice PresidentNigel J. Walker, Vice President-electElaina Kenyon, Secretary/TreasurerLouise M. Ball (Past President), Kevin Crofton and

Michelle J. Hooth, CouncilorsWendy Jefferson, Student Representative

NortheastJatinder Singh, PresidentJames Blank, President-electTBE, Vice PresidentDoug Bill, Secretary/TreasurerCharles Giardina (Past President), Brian

Aneskievich, CouncilorsJoe Lynch, Student Representative

Northern CaliforniaSusan A. Rice, PresidentLinval R. DePass, President-electGeorge V. Alexeeff, Vice PresidentSanjay Chanda, SecretaryCarol E. Green, TreasurerRobert A. Howd (Past President), George R.

Clemens and Kyle L. Kolaja, CouncilorsVince Seaman, Student Representative

NorthlandElizabeth V. Wattenberg, PresidentThomas P. Brunshidle, Secretary/TreasurerHilary Carpenter (Past President), Teri K. Fick, and

Pamela J. Shubat, CouncilorsJessica Barthiaume, Student Representative

Ohio ValleyHollie I. Swanson, President James Kang, President-electCharles V. Smith, Vice PresidentGavin E. Arteel, Secretary/TreasurerJohn C. Lipscomb (Past President), Gina Grossi,

Jay Harriman, and Amy L. Roe, CouncilorsJanet Zang, Student Representative

Pacific NorthwestPeter S. Spencer, PresidentRosita Proteau, Vice PresidentAndrij Holian, Vice President-electCarin Thomas, Secretary/TreasurerMarc W. Fariss (Past President), David Shepherd,

and Cecile Krejsa, CouncilorCastle J. Funatake, Student Representative

South CentralKenneth E. McMartin, PresidentSharon Meyer, Vice PresidentMartin J. Ronis, Vice President-electTammy Dugas, SecretaryKristie Willett, TreasurerDeborah Hansen (Past President), Russell Carr and

Heather Kleiner, CouncilorsSharmilee Sawant, Student Representative

SoutheasternEssam Enan, PresidentCarol Wood, Secretary/TreasurerJames A. Deyo (Past President), Julie Coffield and

Markus Day, CouncilorsLonnie Williams, Student Representative

Southern CaliforniaJohn Wisler, PresidentDrew Badger, Vice President Julie Doerr-Stevens, SecretaryTina Leakakos, TreasurerStacie L. Wild (Past President), Anthony Ndifor,

CouncilorsCary Coburn, Student Representative

Officers—Regional Chapters

REF

EREN

CE



In recognition of distinguished toxicologists and students, SOT presents several prestigious awards each year. In addition to receiving the award stipend and plaque, recipients are honored at a special Awards Ceremony at the SOT Annual Meeting and their names are listed in SOT publications. The deadline for 2006 award nominations is October 9, 2005.

The Awards Committee reviews applications for SOT Awards and Sponsored Awards for scientists. Nominations for most of these awards must be submitted by a sponsor and a seconder who are Full members of SOT using the On-Line Award Nomination Form. The supporting documentation must indicate the candidate’s achievements in toxicology and is critical in the review of each application. See the award description for the additional requirements for some of the awards, including the Sponsored Awards. The Best Paper Awards are reviewed by the Board of Publications.

Student awards, both SOT and Sponsored awards, are reviewed by the Education Committee, and application procedures are specific for each award. Other student awards are available through Regional Chapters and Specialty Sections. A student may apply for any award for which he or she is eligible and may apply for and receive multiple awards, whether SOT, Regional Chapters, or Specialty Sections sponsor the awards. Policies related to travel awards are determined by the sponsor (SOT, Regional Chapter, or Specialty Section).

Full descriptions of each award, application procedures, and names of past recipients may be found on the SOT Web site at www.toxicology.org.

Award Descriptions

Indicates an SOT Sponsored Award

Achievement AwardThe Achievement Award is presented to a member of the Society of Toxicology who has less than 15 years experience since obtaining his/her highest earned degree (in the year of the Annual Meeting of the Society of Toxicology) and who has made significant contributions to toxicology. This award consists of a plaque and a cash stipend.

Award Recipients 1967 ..................................................................... Gabriel L. Plaa 1968 ................................................................. Allan H. Conney 1969 ................................................................Samuel S. Epstein 1970 ............................................................ Sheldon D. Murphy 1971 ............................................................................Yves Alarie 1972 ................................................................... Robert L. Dixon 1973 .......................................................................... (No Award) 1974 ...............................................................Morris F. Cranmer 1975 ........................................................................Ian C. Munro 1976 ...............................................................Curtis D. Klaassen 1977 ...................................................................James E. Gibson 1978 ....................................................... Raymond D. Harbison 1979 .................................................................. Michael R. Boyd 1980 ............................................................. Philip G. Watanabe 1981 .......................................................................... (No Award) 1982 ..................................................... Frederick P. Guengerich 1983 .......................................................................... (No Award) 1984 ............................................................ Melvin E. Andersen 1985................................................................... Alan R. Buckpitt

1986 ...........................................................................Sam Kacew 1987 ......................................................................... James S. Bus 1988 .............................................................. Jeanne M. Manson 1989 .................................................................... James P. Kehrer 1990 ..............................................................Michael P. Waalkes 1991 ..............................................................Debra Lynn Laskin 1992 .......................................................... Michael P. Holsapple 1993 .....................................................................David L. Eaton 1994 .................................................................. James L. Stevens 1995 ..................................................................... Lucio G. Costa 1996 ................................................................... Kenneth Ramos 1997 ..................................................................Kevin E. Driscoll 1998 ...........................................................Rick G. Schnellmann 1999 .......................................................... Michel Charbonneau 2000 ...........................................................Christpher Bradfield 2001 .................................................................... Martin Philbert2002.......................................................................... Ruth Roberts2003................................................Lois D. Lehman-McKeeman2004.......................................................................David Dorman

Society of Toxicology Awards

256

REFER

ENC

E



Arnold J. Lehman Award The Arnold J. Lehman Award is presented to recognize an indi-vidual who has made a major contribution to risk assessment and/or the regulation of chemical agents, including pharmaceu-ticals. The contribution may have resulted from the application of sound scientific principles to regulation and/or from research activities that have significantly influenced the regulatory process. The nominee may be employed in academia, government, or industry and must be a SOT member. This award consists of a plaque and a cash stipend.

Award Recipients 1980 ................................................................. Allan H. Conney 1981 ..................................................................... Gabriel L. Plaa 1982 ................................................................ Gary M. Williams 1983 .........................................................................David P. Rall 1984 ..........................................................................Tibor Balasz 1985 ............................................................ Frederick Coulston*1986 .................................................. Gerrit Johannes Van Esch 1987 .................................................................... John P. Frawley 1988 ................................................................Kundan S. Khera*1989 .......................................................... Richard H. Adamson 1990 ................................................................... Harold C. Grice 1991 ........................................................... Bernard A. Schwetz 1992 .............................................................Roger O. McClellan 1993 ...........................................................Thomas W. Clarkson 1994 .......................................................................... Bruce Ames 1995 ..................................................................... Emil A. Pfitzer 1996 ........................................................................John F. Rosen 1997 .......................................................................... (No Award) 1998 ......................................................... Helmut Alfred Greim 1999 .......................................................................... (No Award) 2000 .....................Carole A. Kimmel and Janardan K. Reddy 2001 ................................................................Samuel M. Cohen 2002 ............................................................Dennis Paustenbach2003 ............................................................ Michael L. Dourson2004 ............................................................ Melvin E. Andersen2005 ........................................................................Rory Conolly

AstraZeneca SOT/IUTOX Fellowship The AstraZeneca company sponsors a travel fellowship award annually through SOT and IUTOX. Awards will be available to senior scientists from a country where toxicology is underrep-resented to assist with travel to attend the Society of Toxicology Annual Meeting.

Award Recipients 2002 ................................... Christophor Dishovsky (Bulgaria)............................................................ Zoltan Gregus (Hungary)............................................ Maritza Rojas Martini (Venezuela)..................................................... Choon-Nam Ong (Singapore) ..................................................................W. Wasowicz (Poland)

................................................................ Ping-kun Zhou (China)2003 .......................................................Jian-Hui Liang (China)........................................................Marjan G. Vracko (Slovenia).................................................................... Eman A. Seif (Egypt)2004 ............................................ Cristina Bolaton (Phillipines)......................................................................... P.K. Gupta (India).......................................... Salmaan Inayat-Hussain (Malaysia)..................................................................Xianping Ying (China)

AstraZeneca Traveling Lectureship AwardsThe AstraZeneca Traveling Lectureship Awards are presented through the Society of Toxicology to recognize excellence in research and service in toxicology. AstraZeneca, Ltd., provides one or two awards annually to promote greater collaboration between European and North American toxicologists and to enable North American toxicologists to undertake a three-four week lecture tour of Europe. The awards are intended to famil-iarize recipients with research and regulatory issues in Europe as well as bring a North American perspective to these issues. Candidates for these awards should be established, mid-career North American scientists who are members of the Society and who demonstrate the ability to develop collaborative relation-ships with European colleagues. The awards are given each year in the amount of $6,000 each.

Award Recipients 1990 ............................. Robert I. Krieger, Joseph R. Landolph1991 ...........................................................................Sam Kacew1992 ........................................Charles V. Smith, Jerold A. Last1993 ........... Terrence James Monks, Harihara H. Mehendale1995 ............................. David L. Eaton, Hanspeter R. Witschi1996 .............................Rick G. Schnellmann, James P. Kehrer1997 .....................................Lucio G. Costa, Durisala Desaiah1998 .......................................Syed F. Ali, Curtis J. Omiecinski1999 ......................................................................... Alvaro Pugo2000 ............................................ Kenneth Ramos, Garold Yost2001 ...........................................Ronald Hines, Richard Seegal2003 ............................................................William D. Atchison2004 ........................................................ Charlene A. McQueen2005 ...................................................................... Kevin Crofton

Society of Toxicology Awards (Continued)

REF

EREN

CE



Board of Publications AwardThe Board of Publications Award for the Best Paper in Toxicological Sciences is presented to the author(s) of the best paper published in this official SOT publication during a 12-month period, termi-nating with the June issue of the calendar year preceding the Annual Meeting at which the award is presented. The author(s) need not be a member of the Society of Toxicology. Submissions should include a one-page summary of the paper’s contribution to the science of toxicology and a copy of the article for which the nomination is being made. Any member of the Society may submit one title for consideration. In addition, the titles of no more than six papers to be considered are submitted by the editor of Toxicological Sciences. All papers submitted will be evaluated by the Board of Publications. This award consists of a plaque and a cash stipend. (This award was formerly known as the Frank R. Blood Award.)

Best Paper in Fundamental and Applied Toxicology and Toxicological Sciences

Award Recipients 1995 ...................... J. L. Larson, D. C. Wolf, B. E. Butterworth 1995 ........M. I. Luster, C. Portier, D. G. Pait, G. J. Rosenthal, ................................D. R. Germolec, E. Corsini, B. L. Blaylock, ............................ P. Pollock, Y. Kouchi, W. Craig, K. L. White,................................................... A. E. Munson, C. E. Comment 1996 ....................... B. C. Allen, R. J. Kavlock, C. A. Kimmel,............................................................................. E. M. Faustman 1997 ................F. L. Fort, H. Ando, T. Suzuki, M. Yamamoto,........................................... T. Hamashima, S. Sato, T. Kitazaki,.......................................................M. C. Matony, G. D. Hodgen 1998 .............. D. D. Parrish, M. J. Schlosser, J. C. Kapeghian,................................................................................... V. M. Traina 1999 .................. C. A. Franklin, M. J. Inskip, C. L. Baccanale,.............................. C. M. Edwards, W. I. Manton, E. Edwards,.............................................................................. E. J. O’Flaherty 2000 .......................H.A Boulares, C. Giardina, C.L. Navarro,....................................................... E.A. Khairallah, S.D. Cohen 2001 .................. Jinqiang Chen, Yunbo Li, Jackie A. Lavigne,............................................. Michael A. Trush, James D. Yager 2002 ........................ M.J. Bajt, J.A. Lawson, S.L. Vonderfecht, ................................................................. J.S. Gujral, H. Jaeschke2003 .............S. Haddad, M. Beliveau, R. Tardif, K. Krishnan2004 ..................................Urmila Kodavanti, Carolyn Moyer, .................Allen Ledbetter, Mette Schlasweiler, Daniel Costa, .................... Russ Hauser, David Christiani, Abraham Nyska2005 ....................................Nicole V. Soucy, Michael A. Ihnat, ...................................Chandrashekhar D. Kamat, Linda Hess, ......................................................... Mark J. Post, Linda R. Klei, .................................................Callie Clark, Aaron Barchowsky

Best Paper in Toxicology and Applied Pharmacology

Award Recipients 1995 .........................M. F. Denny, M. F. Ware, W. D. Atchison 1996 ........... T. A. Slotkin, C. Lau, E. C. McCook, S. E. Lappi,..................................................................................... F. J. Seidler 1997 ..............P. R. S. Kodavanti, T. R. Ward, J. D. McKinney,............................................................ C. L. Waller, H. A. Tilson 1998 ......................J. S. Landin, S. D. Cohen, E. A. Khairallah 1999 .............................. S. K. Ramaiah, M G. Soni, T. J. Bucci,........................................................................ H. M. Mehendale, 1999 ................. C. L. Zuch, D. J. O’Mara, D. A. Cory-Slechta 2000 .......................... J.E. Staples, N.C. Fiore, D.E. Frazier, Jr.,................................................ T.A. Gasiewicz, A.E. Silverstone 2001 ................................. Barbara J. Mounho, Brian D. Thrall 2002 ................................. G.S. Ratra, S.G. Kamita, J.E. Casida2003 ............................ J. Doorn, M. Schall, D. Gage, T. Talley, .......................................................C. Thompson, R. Richardson

Award Recipients (Frank R. Blood Award)1974 ............................................................................Yves Alarie1975 ......Donald J. Ecobichon, G. J. Johnstone, O. Hutzinger1976 ................................................................Richard D. Brown1977 ............ J. Dedinas, George D. DiVincenzo, C. J. Kaplan1978 ..........Perry J. Gehring, E. O. Madrid, G. R. McGowan,....................................................................... Philip G. Watanabe1979 ...... R. Fradkin, E. J. Ritter, W. J. Scott, James G. Wilson1980 ............... Jerold A. Last, Peter F. Moore, Otto G. Raabe,..................................................................... Brian K. Tarkington 1981 .................................................Yves Alarie, Martin Brady, ......................................................Christine Dixon, Meryl Karol 1982 .........................Melvin E. Andersen, Michael L. Gargas,....................................Lawrence J. Jenkins, Jr., Robert A. Jones 1983 .....................................................................Henry D. Heck 1984 ................Erik Dybing, Sidney Nelson, Erik Soderlund,..........................................................................Christer Von Bahr 1985 ........ Nobumasa Imura, Masae Inokawa, Kyoko Miura 1986 .............Calvin C. Wilhite, M. I. Dawson, K. J. Williams 1987 ..................... John Kao, Frances K. Patterson, Jerry Hall 1988 ................Debra L. Laskin, Sungchul Ji, Anne M. Pilaro 1989 ........................................... R. G. Cuddihy, W. C. Griffith, .................................... Rogene F. Henderson, Joe L. Mauderly, ............... Roger O. McClellan, M. D. Snipes, Ronald K. Wolff 1990 ........................William P. Beierschmitt, Joseph T. Brady,..........................................John B. Bartolone, D. Stuart Wyand,...................................Edward A. Khairallah, Steven D. Cohen 1991 ...............................Jay Babcock Silkworth, Daryl Cutler, ............... LuAnn Antrim, Don Houston, Casimir Tumasonis, ..................................................................Laurence S. Kaminsky 1992 .........Donald A. Fox, Steve D. Rubinstein, Pauline Hsu1993 ........ Thomas Mably, Robert W. Moore, Robert W. Goy,.......................................................................Richard E. Peterson 1994 ............................Susan J. Borghoff, William H. Lagarde


258

REFER

ENC

E



Colgate-Palmolive Post-Doctoral Fellowship Award in In Vitro ToxicologyThe Colgate-Palmolive Company sponsors the Colgate-Palmolive Post-Doctoral Fellowship Award in In Vitro Toxicology through the Society of Toxicology to advance the development of alter-natives to animal testing in toxicological research. The award is given in alternate years and includes stipend and research-related costs (up to $33,500) for one year. The award may be extended for an additional year upon agreement between Colgate-Palmolive and the post-doctoral fellow. Post-doctoral trainees in their first year of study beyond the Ph.D., M.D. or D.V.M. degree who are employed by academic institutions, federal/national laborato-ries or research institutes worldwide may apply. The Education Committee reviews applications, which are due in even calendar years, and the fellowship is awarded for the following year. The next application deadline: October 9, 2005.

Award Recipients1988 ........................................................................Ernest Bloom 1989 ..............................................................................Gin Hsieh 1990 ............................................................Dennis E. Chapman 1991 ..........................................................................Anne Walsh 1992 .............................................................................. Qin Chen 1993 ........................................................................Erika Cretton 1994 ....................................................................... William Chan 1995 ................................................................Bob Van de Water 1997 ......................................................................... Alan Parrish1999 ....................................................................Russell Thomas2001 .....................................Kevin Kerzee, Christopher Reilly2002 ........................................................................Kevin Kerzee2003 ................................................................... Kimberly Miller2004 ................................................................... Kimberly Miller

Colgate-Palmolive/SOT Awards for Student Research Training in Alternative MethodsThe purpose of the Colgate-Palmolive/SOT Awards for Student Research Training in Alternative Methods is to enhance student research training using in vitro methods or alternative techniques to reduce, replace or refine use of animals in toxicological research. The Education Committee will present the awards to graduate students or to institutions that provide research internships. Up to six awards, at $2,500 each, are available. Applications received after October 9 will be accepted until all funds are committed.

Graduate Students: The award will help to defray expenses for graduate students in toxicology to visit an off-site laboratory for the purpose of gaining knowledge about and developing in vitro or alternative toxicology techniques that will support the student’s dissertation research. The overall goal of this program is to support the replacement, reduction or refinement of currently used animal models in toxicology research and testing.

Institutions: Awards will also be made to institutions that propose a 10-week research experience for students (at any level) involving in vitro toxicology or alternative methods to reduce, replace, or refine, the use of animals in toxicology research.

Award Recipients2000 ...........................................................................Jason Gross 2001 ...........................................Jason Biggs, Victoria Richards 2002 ...... Kartik Shankar, Chad M. Vezina, Ryan L. Williams2003 ...........Sachin Devi, Midhun Korrapati, Pallavi Limaye2004 ..............................Jaya Chilakapati, Ankur Dnyanmote, ...........................................................................Johnathan Maher


REF

EREN

CE



Colgate-Palmolive Traveling Lectureship in Alternative Methods in Toxicology AwardThe Colgate-Palmolive Company sponsors the Colgate-Palmolive Traveling Lectureship in Alternative Methods in Toxicology Award annually through the Society of Toxicology. This award covers expenses for an individual scholar to visit institution(s) for the dissemination of knowledge and for stimulating research that takes advantage of modern in vitro toxicology approaches. The overall goal of this program is to make scientists aware of the benefits of modern in vitro toxicology approaches and to stimulate research for the replacement, reduction or refinement of currently used animal models. The scholar may be asked to make a special presentation at the SOT Annual Meeting.

Lecturing scholars should be established, mid-career through late-career scientists who are members of SOT and who are developing collaborative relationships with scientists at other institutions.

Requests for funds can be made by the individual scholar or by organizations such as universities, colleges, SOT Specialty Sections and SOT Regional Chapters, and other toxicology orga-nizations that are interested in inviting the scholar. Up to $15,000 is available. The Awards Committee reviews the applications, which must be accompanied by a statement of the applicant’s experience, a brief overview of the techniques to be discussed in the lecture, and a letter from the hosting institution(s) indicating their interest in serving as host and the potential benefits to the institution.

Award Recipients1996 .......................University of Mississippi Medical Center Visiting Professor: .................................................Tetsuo Satoh 1996 ........................................ University of Illinois at UrbanaVisiting Professor: ...................................................Julio Davila 1996 ..............................................Mississippi State University Visiting Professor: ...................................... Michael Holsapple 1996 .............................................Washington State University Visiting Professor: ...............................................Daniel Acosta 1997 ........................... Indiana University School of MedicineVisiting Professor: ............................................ A. Jay Gandolfi 1997 .................University of Arizona Health Science Center Visiting Professor: ..........................................Kevin E. Driscoll 1997 .......University of New Mexico Health Sciences Center Visiting Professor: ...................................................Sam Kacew 1997 ...........................................................University of IllinoisVisiting Professor: ..........................................Michael Denison 1998 ..................................................University of Washington Visiting Professor: ................................................Bruce Fowler 1998 ................................................San Diego State University Visiting Professor: ............................... Leigh Ann Burns Naas

1999 ................................................San Diego State UniversityVisiting Professor: ..............................................Robert Chapin 2000 .................................Yale University, School of MedicineVisiting Professor: ........................................... Narendre Singh2001 ...........................................Medical College of Wisconsin Visiting Professor: ...................................................Garold Yost2003 .............................................Washington State UniversityVisiting Professor: ............................................. Marc W. Fariss2004 ........................................................ Snorri S. ThorgeirssonInstitution to be Visited: ....................................... University of .....................................................................Louisiana at Monroe

Contributions to Public Awareness of the Importance of Animals in Toxicology Research AwardThe Contributions to Public Awareness of the Importance of Animals in Toxicology Research Award is presented annually to an individual (or organization) in recognition of the contributions made to the public understanding of the role and importance of experimental animals in toxicological science. This award may be for either a single seminal piece of work or a longer-term contribution to public understanding of the necessity of the use of animals in toxicological research both to ensure and enhance the quality of human and animal health and the environment. The award consists of a plaque and a cash stipend.

Award Recipients 2000 ..................................................... Allegheny-Erie Chapter 2001 ..................Massachusetts Society for Medical Research 2002 ...............................................................George Nethercutt2003 .............................................................. Michael Derelanko2004 .........................................North Carolina Association for ..................................................Biomedical Research (NCABR), ....................................Americans for Medical Progress (AMP)2005 ........................................Orrin G. Hatch, Foundation for .....................................................................Biomedical Research


260

REFER

ENC

E



Distinguished Lifetime Toxicology Scholar Award The Distinguished Toxicology Scholar Award is presented to a member of SOT who has made substantial and seminal scientific contributions to the discipline of toxicology. The prime consid-eration for this award is scientific accomplishments and not necessarily service to the Society. This award consists of a plaque and a cash stipend. (This award was formerly known as the Scientific Achievement Award.)

Award Recipients (Scientific Achievement Award)2001 ....................................................................James E. Troska

Award Recipients 2003 ......................................................................Henry C. Pitot2004 .................................................................Gerald N. Wogan2005 .......................................................................Daniel Nebert

Education Award The Education Award is presented to an individual who is distinguished by the teaching and training of toxicologists and who has made significant contributions to education in the broad field of toxicology. This award consists of a plaque and a cash stipend.

Award Recipients 1975 .................................................................Harold C. Hodge 1976 ......................................................................Ted A. Loomis 1977 ..................................................................Robert B. Forney 1979 ............................................................ Sheldon D. Murphy 1980 ............................................................. Herbert H. Cornish 1981 ...............................................................Frederick Sperling 1982 .............................................................. Lloyd W. Hazleton 1983 ..................................................................... Julius M. Coon 1984 ........................................Frank Guthrie, Ernest Hodgson 1985 ................................................................... William B. Buck 1986 ..................................................................Robert I. Krieger 1987 ..................................................................... Gabriel L. Plaa 1988 .......................................................................... John Autian 1989 ........................................................................ Tom S. Miya 1990 ...................................................................Charles H. Hine 1991 .......................................................... Hanspeter R. Witschi 1992 ..................................................................... Dean E. Carter 1993 ...............................................................Curtis D. Klaassen 1994 ..................................................................... Robert A. Neal 1995 ................................................................... William Carlton 1996 ...................................................................... Robert Snyder 1997 ................................................................Albert E. Munson 1998 ............................................................... David J. Holbrook

1999 ....................................................................... Jules Brodeur 2000 ........................................................................Gary Carlson 2001 ...........................................................Harihara Mehendale 2002 ................................................................ Joseph Borzelleca2003 ........................................................... Frederick W. Oehme2004 .................................................................... A. Jay Gandolfi2005 ....................................................................... Nobuyuki Ito

Enhancement of Animal Welfare AwardThe Enhancement of Animal Welfare Award is presented annu-ally to a member of the Society in recognition of the contribution made to the advancement of toxicological science through the development and application of methods that replace, refine, or reduce the need for experimental animals. This award recognizes outstanding/significant contributions made by members of the Society of Toxicology to the scientifically sound and responsible use of animals in research. The achievement recognized may be either a seminal piece of work or a long-term contribution to toxicological science and animal welfare. The award consists of a plaque and a cash stipend.

Award Recipients 2000 ............................................................................Yves Alarie 2001 ..................................................................... Alan Goldberg 2002 ......................................................................Gary Williams2003 ....................................... G. Frank Gerberick, Ian Kimber 2005 .......................................................................Daniel Acosta

Graduate Student Fellowship AwardsThe Graduate Student Fellowship Awards are provided by generous sponsors and are open to student members of the SOT engaged in full-time graduate study towards a Ph.D. degree in toxicology. The major professor must be a SOT member. The Education Committee’s evaluation is based primarily on originality of the dissertation research, research productivity, relevance to toxicology, scholastic achievement, and letters of recommendation. Finalists are interviewed at the Annual Meeting and receive travel support.

Novartis Corporation Graduate Fellowship

Award Recipients1989 .........................................................Timothy Zacharewski1990 .................................................... Mary Suzanne Stefaniak1991 ...................................................................... Donald Bjerke1992 ..................................................... Lhanoo Gunawardhana


REF

EREN

CE



1993 ...................................................... Christopher Martenson1994 .........................................................................Nyla Harper1995 ...............................................................Heather E. Kleiner1996 ....................................................................Russell Thomas1997 .............................................................Melva Rios-Blancos1998 ........................................................................ Kent Carlson1999 .....................................................................Mark Hickman2000 ....................................................................... Jeffrey Moran2001 ....................................................................... Vishal Vaidya2002 .....................................................................Kartik Shankar2003 .......................................................................... Sachin Devi2004 ..................................................................James Luyendyk

(Recipients of Graduate Fellowship Awards no longer offered may be found on the SOT Web site at www. toxicology.org.)

Graduate Student Travel AwardsGraduate Student Travel Awards defray expenses for students presenting platform talks or posters at the SOT Annual Meeting. To be eligible, the student must be a SOT member (or have submitted a membership application) who has not previously received a graduate student travel award. Each institution may rank and submit applications from up to three students.

Honorary MembershipThe Society of Toxicology recognizes non-members who embody outstanding and sustained achievements in the field of toxicology with the Honorary Member Award. Candidates are nominated by two voting or associate members of the Society. Seconding letters and information regarding career achievements in toxi-cology should accompany the nomination. A two-thirds vote of Council determines recipients, with not more than two Honorary Members elected during any one term of Council. Nominations should be sent to SOT Headquarters.

Inductees1962 .........................................................Eugene M.K. Geiling*1962 ...........................................................W. F. Von Oettingen*1962 ..............................................................Torald H. Sollman*1963 .................................................................. Ethel Browning*1966 ...........................................................R. Tecwyn Williams*1976 ................................................................... Norton Nelson*1982 ......................................................... George H. Hitchings*1986 .............................................................. Bernard B. Brodie*1986 ................................................................. Herbert Remmer1991 ......................................................Hyman J. Zimmerman*1994 .......................................................... Ronald W. Estabrook1994 ...............................................................Wendell W. Weber1995 ...............................................................Gertrude B. Elion*1995 ..................................................................Charles S. Lieber 1996 ..................................................................Sten G. Orrenius1996 ........................................................................Dennis Parke

1997 ......................................................................John E. Casida1997 ................................................................Roger W. Russell*1998 ...............................................................................Jud Coon1998 .....................................................................Michel Mercier1999 ......................................................... William O. Robertson1999 ................................................................Takashi Sugimura2000 .................................................................... Findlay Russell2001 ............................................................ Herbert Needleman

Merit Award The Merit Award is presented to a member of the Society of Toxicology in recognition of a distinguished career in toxicology. This award consists of a plaque and a cash stipend.

Award Recipients1966 ..............................................................Henry F. Smyth, Jr.1967 ................................................................Arnold J. Lehman1968 .......................................................................R. T. Williams1969 .................................................................Harold C. Hodge1970 ..........................................................................Don D. Irish1971 .............................................................. Kenneth P. DuBois1972 ...............................................................O. Garth Fitzhugh1973 ........................................................... Herbert E. Stokinger1974 ........................................................William B. Deichmann1975 ............................................................ Frederick Coulston*1976 .................................................................. Verald K. Rowe*1977 .....................................................................Harry W. Hays1978 ..................................................................... Julius M. Coon1979 ..................................................................David W. Fassett1980 ................................................................... Bernard L. Oser1981 .............................................................John H. Weisburger1982 ....................................................................Harold M. Peck1983 ................................................................. Perry J. Gehring*1984 ......................................................................... Tom S. Miya1985 ....................................................................... Carrol S. Weil1986 ......................................................................Ted A. Loomis 1987 .......................................................................Bo Holmstedt1988 ................................................................Seymour L. Friess1989 .........................................................Wayland J. Hayes, Jr.*1990 ............................................................ Sheldon D. Murphy1991 ............................................................... Toshio Narahashi1992 ..........................................................W. Norman Aldridge1993 ............................................................................ John Doull1994 ...................................................................Ernest Hodgson1995 .....................................................................Robert A. Scala1996 ..................................................................... Gabriel L. Plaa1997 ...................................................................Mary O. Amdur1998 ................................................................... John A. Thomas1999 ................................................................ Thomas Clarkson2000 ................................................................... Philippe Shubik2001 ........................................................................ Donald Reed2002 ................................................................. Bernard Schwetz2003 ........................................................................ M.W. Anders2004 ........................................................................Robert Goyer2005 ..................................................................Roger McClellan


262

REFER

ENC

E



Minority Undergraduate Student and Advisor AwardsThe Minority Undergraduate Student and Advisor Awards provide support for awardees to participate in the Undergraduate Education Program at the SOT Annual Meeting. This program is an introduction to the discipline of toxicology for under-graduate science majors and includes an orientation, a special poster session with scientists, and activities with a SOT mentor. The travel awards are for those from races and ethnic groups under-represented in the sciences (African American, American Indian or Hispanic American) and for their advisors. Advisors are eligible regardless of racial or ethnic background. Meeting regis-tration and support for travel, lodging, and meals are provided for students and advisors who are not local to the meeting site. Students and advisors from local institutions receive meeting and program registration and meals. In the past, the program has been supported in part by NIH-MARC, Pfizer, and Johnson & Johnson.

Public Communications AwardThe Public Communications Award is presented by the Society of Toxicology to recognize an individual who has made a major contribution to broadening the awareness of the general public on toxicological issues through any aspect of public communi-cations. The award should reflect accomplishments made over a significant period of time. Examples of qualifying media in which the nominated communication may appear are: books, brochures, continuing education courses, data bases, extension bulletins, magazines, newspapers (local or national), public presentations, public forums, radio and television scripts, and workshops. The award consists of a plaque and a cash stipend.

Awards Recipients 1994 ..............................................................Michael A. Kamrin1995 ..................................................................... Philip Abelson1996 .....................................................................Bruce N. Ames1997 .....................................................................Audrey Gotsch1999 .................................................................... Ann de Peyster2001 ................................................................... Anna Shvedova2002 ...........................................................................Sam Kacew2003 ........................................................ Charlene A. McQueen2004 .................................................................... Kenneth Olden2005 ..................................................................... Robert Kreiger

Regional Chapter AwardsMost SOT Regional Chapters provide awards to recognize outstanding students or scientists. Application requirements and deadlines vary. Visit the Regional Chapter or Awards and Fellowship sections on the SOT Web site for full details.

Society of Toxicology/American Chemistry Council Early Career AwardThe American Chemistry Council offers an Early Career Award through the Society of Toxicology. The award is up to $100,000 and is designed to encourage persons beginning their profes-sional careers to conduct research that will improve the scientific basis for risk assessment and decision making with respect to a particular specialty area of potential toxicity of chemicals. Awards have been offered in Inhalation and Neurotoxicology. Full details are available on the SOT Web site.

Award Recipients2002 ................................ Ronald Tjalkens (Neurotoxicololgy)2003 ................................................... Ilona Jaspers (Inhalation)2004 .................................Nikolay Filipov (Neurotoxicololgy)

Specialty Section Student AwardsMost SOT Specialty Sections provide awards to recognize outstanding student presentations at the SOT Annual Meeting. Application requirements and deadlines vary. For more details refer to the Award descriptions on the SOT Web site at www.toxicology.org, under Specialty Sections or the Awards and Fellowships sections


264

REFER

ENC

E



The Society of Toxicology has established a Toxicology Specialists Program to assist journalists and members of the public in iden-tifying or locating expert toxicologists who can provide factual information on issues of public concern. The Toxicology Specialists provide information based on their own credentials and do not represent the views of the Society of Toxicology. Nominations are accepted throughout the year. Applications may be found on the SOT Web site (www.toxicology.org). For further information, please contact SOT Headquarters at (703) 438-3115, or e-mail [email protected].

Toxicology Specialists

Specialties:

CarcinogenesisJane A. S. AllenJames BondRichard BullYvonne DraganDavid L EatonJames E. KlaunigMichael McClainCharlene A. McQueenHenry PitotJames PoppRobert RubinJacqueline H. SmithCheryl Lyn Walker

Comparative and VeterinaryRoger McClellan

EpidemiologyEllen Silbergeld

General ToxicologyJane A. S. AllenLinda BirnbaumYvonne DraganDavid L. EatonSidney GreenJames E. KlaunigRobert KriegerMichael McClainKendall B. Wallace

Genetic ToxicologyJane A. S. AllenSidney GreenJames E. KlaunigCharlene A. McQueen

(environmental) Cheryl Lyn Walker

ImmunotoxicologyScott BurchielJack DeanJay Gandolfi (hypersensitivity)Norbert KaminskiNancy KerkvlietKathleen RodgersMary Jane Selgrade

In VitroDaniel Acosta, Jr.Yvonne DraganElaine M. FaustmanJay GandolfiKenneth S. RamosRick SchnellmannJacqueline H. Smith

Inhalation/PulmonaryBarbara BeckJames BondGary Boorman (pulmonary

pathology)Robert DrewRoger McClellanJohn MorrisRobert PhalenGary Yost

Kidney ToxicityWilliam BerndtSteven D. CohenMary DavisErnest FoulkesJay GandolfiRobin GoldsteinLois D. Lehman-McKeemanRick Schnellmann

Liver ToxicitySteven D. CohenGeorge B. CorcoranMary DavisYvonne DraganJay GandolfiRobin GoldsteinJames E. KlaunigJose E. ManautouHari MehendaleJames Popp

MechanismsDaniel Acosta, Jr.Jane A. S. AllenWilliam BerndtLinda BirnbaumGary P. CarlsonGeorge B. CorcoranAnn de PeysterYvonne DraganElaine M. FaustmanJay GandolfiJames E. KlaunigLois D. Lehman-McKeemanJose E. ManautouHari MehendaleJames PoppKenneth S. RamosStephen SafeRick SchnellmannEllen SilbergeldKendall B. WallaceGary Yost

Metabolism/ToxicokineticsLinda BirnbaumGeorge B. CorcoranLois D. Lehman-McKeemanRaymond Novak

MolecularElaine M. FaustmanWilliam GreenleeNorbert KaminskiHenry PitotKenneth S. RamosRobert RubinRaymond Novak (cell signaling,

gene expression)Kendall B. WallaceGary Yost

NeurotoxicityMarion F. EhrichRobert KriegerJoel MattssonEllen SilbergeldWilliam SlikkerHugh Tilson

Regulatory Toxicology/Regulatory Affairs/Safety EvaluationDaniel Acosta, Jr. (drugs/addictive

agents)Jane A. S. AllenGregory AllgoodRichard BullJack Dean (drugs)Michael Dourson Robin Goldstein (drugs)Robert A. KunaJames Lamb (pesticides and

industrial chemicals)Michael McClain (drugs)Kathleen Rodgers (drugs)Robert Rubin

Reproductive/DevelopmentalRobert ChapinGeorge DastonAnn de PeysterElaine M. FaustmanCarole A. KimmelJames LambHugh Tilson (developmental

neurotoxicology)

Risk AssessmentBarbara BeckMichael BolgerJames BondRichard BullJohn ChristopherRory ConollyMichael DoursonElaine M. FaustmanJay I. GoodmanCarole A. KimmelRobert A. KunaJames LambRoger McClellanRobert RubinJacqueline H. Smith

REF

EREN

CE



Toxicology Specialists (Continued)

ISSUES:

Air PollutionJames BondRobert Drew (air quality standards)Roger McClellan (air quality

standards-environmental and occupational)

John MorrisRobert PhalenMary Jane Selgrade

Animal Studies/Animals in ResearchGary BoormanStephen DiZioRobert Phalen

Biotechnology/Biopharmaceutical ToxicologyScott Burchiel

Chemical-Chemical InteractionsSteven D. CohenJay Gandolfi

Chlorine-Based CompoundsRichard BullRory ConollyJay Gandolfi (also fluorine

compounds)James E. KlaunigH. B. MatthewsHugh Tilson (PCBs)

Dioxins/PCBsLinda BirnbaumMichael BolgerRory ConollyDavid L. EatonWilliam GreenleeNorbert KaminskiNancy KerkvlietKenneth S. RamosEllen SilbergeldHugh Tilson

Endocrine DisruptersLinda BirnbaumMichael BolgerJames S. BusRobert ChapinRory ConollyMichael GalloNancy Kerkvliet

James LambCheryl Lyn Walker

Food Additives/Food Safety/Food ToxinsGregory AllgoodMichael DoursonDavid L. Eaton (especially

aflatoxins)Robert A. KunaRobert Rubin

Free Radicals/Oxidative Stress/AntioxidantsGregory AllgoodJames KehrerJames E. KlaunigKendall B. Wallace

Industrial Chemical ToxicologyJames S. BusRobert A. KunaKendall B. Wallace

Medical DevicesScott BurchielKathleen RodgersStephen Safe

MetalsBarbara BeckWilliam BerndtMichael BolgerErnest FoulkesJay GandolfiHugh Tilson (lead, methyl mercury)

Natural ToxinsMichael BolgerJoel Mattsson

PesticidesJames S. BusMarion F. EhrichRobert KriegerJames LambH. B. MatthewsKathleen RodgersStephen Safe

RadiationGary Boorman (EMF exposure)Mary Jane Selgrade

SolventsMary DavisKendall B. Wallace

Validation of Alternative MethodsSidney Green

Water PollutionRichard Bull

Regional Distribution:

Central StatesWilliam Berndt (NE)Kendall B. Wallace (MN)

Gulf Coast (Texas)James Kehrer Kenneth S. RamosStephen Safe William SlikkerCheryl Lyn Walker

MichiganJames S. BusGeorge B. CorcoranJay I. GoodmanNorbert KaminskiJoel MattssonRaymond Novak

Mid-AtlanticJack Dean (PA)Michael Gallo (NJ)Robin Goldstein (NJ)Robert A. Kuna (NJ)Michael McClain (NJ)James Popp (PA)Jacqueline H. Smith (NJ)

MidwestJames E. Klaunig (K)Henry Pitot (WI)

Mountain WestScott Burchiel (NM)Jay Gandolfi (AZ)Roger McClellan (NM)Charlene A. McQueen (AZ)Gary Yost (UT)

National CapitalMichael Bolger (DC)Robert Drew (DC)Sidney Green (DC)Marion F. Ehrich Carole A. Kimmel (DC)James Lamb (VA)Robert Rubin (MD)Ellen Silbergeld (MD)

North CarolinaJames A. S. AllenLinda Birnbaum James Bond Gary Boorman Rory Conolly William GreenleeH. B. MatthewsMary Jane SelgradeHugh Tilson

NortheastBarbara Beck (MA)Robert Chapin (CT)Steven D. Cohen (CT)Lois D. Lehman-McKeeman (NJ)Jose E. Manautou (CT)John Morris (CT)James A. Popp (CT)

Northern CaliforniaJohn ChristopherAnn de PeysterStephen DiZio

Ohio Valley/Allegheny-ErieDaniel Acosta, Jr. (OH)Gregory Allgood (OH)George Daston (OH)Mary Davis (WV)Michael Dourson (OH)Ernest Foulkes (OH)

Pacific NorthwestRichard Bull (WA)David L. Eaton (WA)Elaine M. Faustman (WA)Nancy Kerkvliet (OR)

South CentralYvonne Dragan (AR)Hari Mehendale (LA)

Southeastern Rick Schnellmann (SC)

Southern CaliforniaRobert KriegerRobert PhalenKathleen Rodgers

266 SOT's 44th Annual Meeting

Stay connected at www.toxicology.orgAccess the members-only section of the SOT Web site. Keep informed of breaking news in toxicology, updated meeting and program information, and resources.

Receive SOT PublicationsMembers receive the electronic publications The Toxicologist on CD ROM, Communique, and Toxicological Sciences. Members are eligible for the reduced-rate subscriptions to the print version of Toxicological Sciences and other toxicology journals. Members also receive other printed publications of the Society including the Annual Meeting Program and the Membership Directory.

Utilize the On-Line DirectoryMembers have said this is one of their most-used resources. You can search by city, state, country, specialty section, or regional chapter as well as member name.

Join a Specialty SectionChoose from 20 SOT Specialty Sections, which provide forums for networking and exchanging information with peers who share an interest in your area of toxicology. The annual receptions and meetings of the Specialty Sections at the Annual Meeting are ideal opportunities to network with colleagues. Dues for Specialty Section membership are $15.

Participate in Your Regional SOT ChapterJoin one of eighteen Regional Chapters that foster scientific exchange at a local level, organize regular local meetings throughout the year, and sponsor awards. Each chapter has a Web site, which is accessible at www.toxicology.org.

Utilize Career Resource and Development ServicesTake advantage of SOT’s on-line service that provides a year-round mechanism for linking job candidates with employment positions in toxicology and related biological sciences.

Nominate for AwardsConsider nominating a fellow toxicologist or student for an award. SOT has simplified the process of nominating candidates for SOT Sponsored Awards through the Awards Nomination On-Line system.

Participate on an SOT Committee or ActivityVolunteer to serve on an SOT Committee. Nominations for SOT Councilors and Officers come from those who have served on committees.

Find Products and ServicesVisit toxexpo.com, the year-round resource for all your scientific product and service needs.

Receive Reduced Registration Costs for Future Annual Meetings You will be able to register at reduced rates for future years. The 2006 SOT Annual Meeting will be in San Diego, CA.

Visit the SOT Membership Booth across from the Exhibit Hall entrance

Be a part of the leading global force and resource for advancing toxicology!

As an SOT Member you can . . .

SPECIAL OFFER to non-member SOT 2005 Annual Meeting attendees: Apply by May 1, 2005 for membership and SOT will waive your 2005 dues.

We’ll see you at the Annual Meeting in New Orleans!

For complete information about membership in the Society of Toxicology, visit the Membership Booth at the Annual Meeting or go to the SOT Web site, www.toxicology.org, and select Member Services. Look for the link to Membership Information.

Easy on-line membership application takes approximately 15 minutes to complete.

www.toxicology.org


M a r c h 6 – 1 0 , 2 0 0 5

new orleans - society of toxicology · new orleans, louisiana from march 6–10, 2005 for our 44th...

Documents